
@article{ ISI:000320194400020,
Author = {Tang, Deliang and Kryvenko, Oleksandr N. and Wang, Yun and Trudeau,
   Sheri and Rundle, Andrew and Takahashi, Satoru and Shirai, Tomoyuki and
   Rybicki, Benjamin A.},
Title = {{2-Amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP)-DNA adducts in
   benign prostate and subsequent risk for prostate cancer}},
Journal = {{INTERNATIONAL JOURNAL OF CANCER}},
Year = {{2013}},
Volume = {{133}},
Number = {{4}},
Pages = {{961-971}},
Month = {{AUG 15}},
Abstract = {{Despite convincing evidence that
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP)a heterocyclic
   amine generated by cooking meats at high temperaturesis carcinogenic in
   animal models, it remains unclear whether PhIP exposure leads to
   increased cancer risk in humans. PhIP-DNA adduct levels were measured in
   specimens from 534 prostate cancer case-control pairs nested within a
   historical cohort of men with histopathologically benign prostate
   specimens. We estimated the overall and race-stratified risk of
   subsequent prostate cancer associated with higher adduct levels.
   PhIP-DNA adduct levels in benign prostate were significantly higher in
   Whites than African Americans (0.274 optical density units (OD) +/-
   0.059 vs. 0.256 OD +/- 0.054; p<0.0001). Prostate cancer risk for men in
   the highest quartile of PhIP-DNA adduct levels was modestly increased
   {[}odds ratio (OR)=1.25; 95\% confidence interval (CI)=0.76-2.07]. In
   subset analyses, the highest risk estimates were observed in White
   patients diagnosed more than 4 years after cohort entry (OR=2.74; 95\%
   CI=1.01-7.42) or under age 65 (OR=2.80; 95\% CI=0.87-8.97). In Whites,
   cancer risk associated with high-grade prostatic intraepithelial
   neoplasia combined with elevated PhIP-DNA adduct levels (OR=3.89; 95\%
   CI=1.56-9.73) was greater than risk associated with either factor alone.
   Overall, elevated levels of PhIP-DNA adducts do not significantly
   increase prostate cancer risk. However, our data show that White men
   have higher PhIP-DNA adduct levels in benign prostate tissue than
   African American men, and suggest that in certain subgroups of White men
   high PhIP-DNA adduct levels may predispose to an increased risk for
   prostate cancer.}},
Publisher = {{WILEY-BLACKWELL}},
Address = {{111 RIVER ST, HOBOKEN 07030-5774, NJ USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Rybicki, BA (Reprint Author), 1 Ford Pl 3E, Detroit, MI 48202 USA.
   Tang, Deliang, Columbia Univ, Dept Environm Hlth Sci, New York, NY USA.
   Kryvenko, Oleksandr N., Henry Ford Hlth Syst, Dept Pathol, Detroit, MI USA.
   Wang, Yun; Trudeau, Sheri; Rybicki, Benjamin A., Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA.
   Rundle, Andrew, Columbia Univ, Dept Epidemiol, New York, NY USA.
   Takahashi, Satoru; Shirai, Tomoyuki, Nagoya City Univ, Sch Med, Dept Pathol, Nagoya, Aichi 467, Japan.}},
DOI = {{10.1002/ijc.28092}},
ISSN = {{0020-7136}},
Keywords = {{dNA adducts; nested case-control study; immunohistochemistry;
   carcinogens; imidazoles; biopsy; needle}},
Keywords-Plus = {{HYDROCARBON-DNA ADDUCTS; HETEROCYCLIC AMINE CONTENT; N-HYDROXY-PHIP;
   DIETARY CARCINOGEN; AFRICAN-AMERICANS; MEAT MUTAGENS; INTRAEPITHELIAL
   NEOPLASIA; CYTOCHROMES P450; BREAST-CANCER; EXPRESSION}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Author-Email = {{brybick1@hfhs.org}},
ResearcherID-Numbers = {{Rundle, Andrew/A-5282-2009}},
ORCID-Numbers = {{Rundle, Andrew/0000-0003-0211-7707}},
Funding-Acknowledgement = {{National Institutes of Health {[}5R01-ES011126]}},
Funding-Text = {{Grant sponsor: National Institutes of Health; Grant number:
   5R01-ES011126}},
Cited-References = {{ABDELRAZZAK Z, 1993, MOL PHARMACOL, V44, P707.
   Bogen KT, 2001, J EXPO ANAL ENV EPID, V11, P155, DOI 10.1038/sj.jea.7500158.
   Cross AJ, 2005, CANCER RES, V65, P11779, DOI 10.1158/0008-5472CAN-05-2191.
   Cui L, 2000, JPN J CANCER RES, V91, P52.
   Di Paolo OA, 2005, INT J CANCER, V117, P8, DOI 10.1002/ijc.21152.
   El-Zein R, 2006, MUTAT RES-FUND MOL M, V601, P1, DOI 10.1016/j.mrfmmm.2006.05.023.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   Gammon MD, 2002, CANCER EPIDEM BIOMAR, V11, P677.
   Girard H, 2005, HEPATOLOGY, V42, P448, DOI 10.1002/hep.20770.
   Girard H, 2008, MUTAT RES-FUND MOL M, V644, P56, DOI 10.1016/j.mrfmmm.2008.07.002.
   Gu D, 2012, CARCINOGENESIS, V33, P124, DOI 10.1093/carcin/bgr252.
   John EM, 2011, NUTR CANCER, V63, P525, DOI 10.1080/01635581.2011.539311.
   Keating GA, 2004, J CHROMATOGR B, V802, P127, DOI 10.1016/j.jchromb.2003.10.047.
   Keating GA, 2001, FOOD CHEM TOXICOL, V39, P29, DOI 10.1016/S0278-6915(00)00115-0.
   Kidd LCR, 1999, CANCER EPIDEM BIOMAR, V8, P439.
   Knize MG, 2002, MUTAT RES-FUND MOL M, V506, P153, DOI 10.1016/S0027-5107(02)00162-8.
   Kooiman GG, 2000, PROSTATE CANCER P D, V3, P256, DOI 10.1038/sj.pcan.4500489.
   Koutros S, 2008, CANCER EPIDEM BIOMAR, V17, P80, DOI 10.1158/1055-9965.EPI-07-0392.
   Kriek E, 1998, MUTAT RES-FUND MOL M, V400, P215, DOI 10.1016/S0027-5107(98)00065-7.
   Kryvenko ON, 2012, MODERN PATHOL, V25, P1023, DOI 10.1038/modpathol.2012.51.
   Li GX, 2012, CANCER PREV RES, V5, P963, DOI 10.1158/1940-6207.CAPR-12-0023.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   Magagnotti C, 2003, INT J CANCER, V107, P878, DOI 10.1002/ijc.11492.
   Major JM, 2011, CANCER CAUSE CONTROL, V22, P1691, DOI 10.1007/s10552-011-9845-1.
   Malfatti MA, 2001, CARCINOGENESIS, V22, P1087, DOI 10.1093/carcin/22.7.1087.
   Malfatti MA, 2006, CANCER RES, V66, P10541, DOI 10.1158/0008-5472.CAN-06-1573.
   Malfatti MA, 2004, CHEM RES TOXICOL, V17, P1137, DOI 10.1021/tx049898m.
   Martin FL, 2002, PROSTATE CANCER P D, V5, P96, DOI 10.1038/sj.pcan.4500579.
   MURRAY GI, 1995, J PATHOL, V177, P147, DOI 10.1002/path.1711770208.
   Nakai Y, 2007, CANCER RES, V67, P1378, DOI 10.1158/0008-5472.CAN-06-1336.
   Nonn L, 2009, PROSTATE, V69, P1470, DOI 10.1002/pros.20983.
   Norrish AE, 1999, J NATL CANCER I, V91, P2038, DOI 10.1093/jnci/91.23.2038.
   Nowell S, 2004, CANCER EPIDEM BIOMAR, V13, P270, DOI 10.1158/1055-9965.EPI-03-0047.
   Punnen S, 2011, PLOS ONE, V6.
   RELLING MV, 1992, CLIN PHARMACOL THER, V52, P643.
   Rybicki BA, 2011, CANCER PREV RES, V4, P1636, DOI 10.1158/1940-6207.CAPR-11-0100.
   SAKR WA, 1994, IN VIVO, V8, P439.
   Sander A, 2011, CANCER CAUSE CONTROL, V22, P109, DOI 10.1007/s10552-010-9680-9.
   Sfanos KS, 2012, HISTOPATHOLOGY, V60, P199, DOI 10.1111/j.1365-2559.2011.04033.x.
   Shirai T, 1997, CANCER RES, V57, P195.
   Shirai T, 2002, MUTAT RES-FUND MOL M, V506, P129, DOI 10.1016/S0027-5107(02)00159-8.
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P279, DOI 10.1016/S0278-6915(97)00162-2.
   Sinha R, 2002, MUTAT RES-FUND MOL M, V506, P197, DOI 10.1016/S0027-5107(02)00166-5.
   Sterling KM, 2004, J CELL BIOCHEM, V91, P423, DOI 10.1002/jcb.10753.
   Takahashi S, 1998, CANCER RES, V58, P4307.
   Takahashi S, 1994, J TOXICOL PATHOL, V7, P423.
   Tang D, 2007, INT J CANCER, V121, P1319, DOI 10.1002/ijc.22806.
   Tang DL, 2007, CANCER EPIDEM BIOMAR, V16, P803, DOI 10.1158/1055-9965.EPI-06-0973.
   VANSCHOOTEN FJ, 1992, CARCINOGENESIS, V13, P987, DOI 10.1093/carcin/13.6.987.
   Wang CY, 1999, CARCINOGENESIS, V20, P1591, DOI 10.1093/carcin/20.8.1591.
   Wang WZ, 2009, PROSTATE, V69, P1378, DOI 10.1002/pros.20992.
   WIENCKE JK, 1995, CANCER RES, V55, P4910.
   Williams JA, 2000, CARCINOGENESIS, V21, P1683, DOI 10.1093/carcin/21.9.1683.
   Zhu J, 2006, BIOMARKERS, V11, P319, DOI 10.1080/13547500600667911.
   Zhu JJ, 2003, CANCER EPIDEM BIOMAR, V12, P830.}},
Number-of-Cited-References = {{55}},
Times-Cited = {{0}},
Journal-ISO = {{Int. J. Cancer}},
Doc-Delivery-Number = {{161LM}},
Wos-Id = {{ISI:000320194400020}},
}

@article{ ISI:000315761000006,
Author = {Khan, Jehan A. and Jalal, Jalaluddin A. and Ioanndes, C. and Moselhy,
   Said S.},
Title = {{Impact of aqueous doash extract on urinary mutagenicity in rats exposed
   to heterocyclic amines}},
Journal = {{TOXICOLOGY AND INDUSTRIAL HEALTH}},
Year = {{2013}},
Volume = {{29}},
Number = {{2}},
Pages = {{142-148}},
Month = {{MAR}},
Abstract = {{Doash (Origanum majorana) is an herbaceous plant found commonly in Saudi
   Arabia. It is used as a food flavor and a folk remedy to treat a number
   of diseases. The 2-amino-3-methylimidazo{[}4,5-f] quinoline (IQ) and
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) are the most
   abundant of the heterocyclic amine carcinogens present in cooked food.
   In the present study, the potential of doash tea to influence carcinogen
   metabolism was investigated indirectly using heterocyclic amines as
   model mutagens, IQ and PhIP. Results obtained showed that doash tea had
   no influence on body weight in both the studies. Rats were treated with
   different doses of IQ (I, 3, 5 and 10 mg/kg) or PhIP (I, 5, 10 and 20
   mg/kg). The selected dosage was 5 mg/kg for both heterocyclic amines.
   Results obtained revealed that rats treated with doash tea and given a
   single dose of the heterocyclic amines, whether for I day (short-term)
   or for I month (long term), showed a statistically significant decrease
   in their excretion of indirect mutagens (IQ or PhIP). Following
   treatment of the rats with a single oral dose of IQ or PhIP, the highest
   mutagenic activity determined in the presence of an activation system
   was excreted in the urine after 24 h, with much lower levels of
   mutagencity being excreted during subsequent elimination from the body.
   No mutagenicity was observed in the absence of an activation system that
   is direct-acting mutagenicity using (IQ and PhIP). Statistical analysis
   revealed that, in comparison with the control group, the aqueous doash
   extract significantly reduced the mutagenic response after 24 h. It was
   concluded that doash extract significantly decreased the excretion of
   mutagens in comparison with the control group (water only).}},
Publisher = {{SAGE PUBLICATIONS INC}},
Address = {{2455 TELLER RD, THOUSAND OAKS, CA 91320 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Moselhy, SS (Reprint Author), King Abdulaziz Univ, Dept Biochem, Jeddah 21413, Saudi Arabia.
   Khan, Jehan A., King Abdulaziz Univ, Dept Biol, Jeddah 21413, Saudi Arabia.
   Jalal, Jalaluddin A.; Moselhy, Said S., King Abdulaziz Univ, Dept Biochem, Jeddah 21413, Saudi Arabia.
   Ioanndes, C., Univ Surrey, Sch Biol Sci, Div Toxicol, Guildford GU2 5XH, Surrey, England.}},
DOI = {{10.1177/0748233711427053}},
ISSN = {{0748-2337}},
Keywords = {{Doash tea; heterocyclic amines; antimutagencity}},
Keywords-Plus = {{GREEN TEA; BLACK TEA; CARCINOGENESIS; EXCRETION; MICE; INHIBITION;
   METABOLISM; IQ}},
Research-Areas = {{Public, Environmental \& Occupational Health; Toxicology}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Toxicology}},
Author-Email = {{moselhy6@hotmail.com}},
ResearcherID-Numbers = {{moselhy, said/I-1446-2012}},
Cited-References = {{AOYAMA T, 1989, J BIOL CHEM, V264, P10388.
   BATTULA N, 1987, P NATL ACAD SCI USA, V84, P4073, DOI 10.1073/pnas.84.12.4073.
   BuAbbas A, 1997, J SCI FOOD AGR, V75, P453, DOI 10.1002/(SICI)1097-0010(199712)75:4<453::AID-JSFA897>3.0.CO;2-3.
   Chung DH, 2001, MOL CELLS, V11, P137.
   Embola CW, 2001, CARCINOGENESIS, V22, P1095, DOI 10.1093/carcin/22.7.1095.
   Gupta S, 2001, P NATL ACAD SCI USA, V98, P10350, DOI 10.1073/pnas.171326098.
   Jun WJ, 2001, FOOD CHEM, V75, P439, DOI 10.1016/S0308-8146(01)00233-3.
   KATIYAR SK, 1993, CARCINOGENESIS, V14, P849, DOI 10.1093/carcin/14.5.849.
   Kleman MI, 1995, DRUGS DIET DIS, V1, P66.
   Li N, 2002, CARCINOGENESIS, V23, P1307, DOI 10.1093/carcin/23.8.1307.
   MARON DM, 1983, MUTAT RES, V113, P173, DOI 10.1016/0165-1161(83)90010-9.
   McArdle NJ, 1999, MUTAT RES-GEN TOX EN, V441, P191, DOI 10.1016/S1383-5718(99)00047-9.
   Mossa JS, 2000, MED PLANTS SAUDI ARA, P1.
   Qari SH, 2008, SAUDI J BIOL SCI, V15, P207.
   Samy PR, 2007, NATURE PRECEDINGS, DOI hdl:10101/npre.2007.1176.1.
   Skog K, 1998, J CHROMATOGR A, V803, P227, DOI 10.1016/S0021-9673(97)01266-1.
   Sung L, 2003, NUTR CANCER, V46, P1, DOI 10.1207/S15327914NC4601\_01.
   Turesky RJ, 2002, DRUG METAB REV, V34, P625, DOI 10.1081/DMR-120005665.
   Wang ZA, 1992, CANCER RES, V52, P1527.
   WANG ZY, 1994, CANCER RES, V54, P3428.
   Yoxall VR, 2004, ARCH TOXICOL, V78, P477, DOI 10.1007/s00204-004-0562-3.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{0}},
Journal-ISO = {{Toxicol. Ind. Health}},
Doc-Delivery-Number = {{101FQ}},
Wos-Id = {{ISI:000315761000006}},
}

@article{ ISI:000315255400005,
Author = {Busquets, Rosa and Frandsen, Henrik and Jonsson, Jan Ake and Puignou,
   Lluis and Teresa Galceran, Maria and Skog, Kerstin},
Title = {{Biomonitoring of Dietary Heterocyclic Amines and Metabolites in Urine by
   Liquid Phase Microextraction:
   2-Amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP), a Possible
   Biomarker of Exposure to Dietary PhIP}},
Journal = {{CHEMICAL RESEARCH IN TOXICOLOGY}},
Year = {{2013}},
Volume = {{26}},
Number = {{2}},
Pages = {{233-240}},
Month = {{FEB}},
Abstract = {{Heterocyclic amines (HCAs) are mutagenic/carcinogenic compounds formed
   at ng/g levels during frying meat or fish. The effect of the normal
   intake of dietary HCAs in humans and their involvement in the etiology
   of cancer are currently unknown. In this work, a new extraction method,
   liquid phase microextraction (LPME) with hollow fibers, and LC-MS/MS
   have been used for the first time to determine HCAs and metabolites in
   nonspiked human urine following a single meal of chicken cooked at 180
   degrees C for 6 min. The total intake of HCAs was estimated to be 6 mu
   g, of which 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP)
   accounted for about 1 mu g. The concentrations of PhIP in nonhydrolyzed
   urine samples ranged from 11.7 to 59.4 pg/g. The total amount of PhIP in
   urine ranged between 9.3 and 21.1 ng, which corresponds to 0.91-2.1\% of
   the ingested PhIP. In addition, the urine levels of 4'-OH-PhIP
   (2-amino-1-methyl-6-(4'-hydroxy)phenylimidazo{[}4,5-b]pyridine) and
   5-OH-PhIP (2-amino-1-methyl-6-(5-hydroxy)phenylimidazo{[}4,5-b]pyridine)
   also showed a narrow variation between the samples. The analysis of
   urine samples after acid hydrolysis did not give additional information
   but showed a notable increase in norharman in some cases. The obtained
   results suggest PhIP in urine as a possible biomarker of exposure to
   HCAs and the LPME and LC-MS/MS method as an appropriate strategy to
   biomonitor HCAs in urine.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Busquets, R (Reprint Author), Univ Brighton, Fac Sci \& Engn, Nanosci \& Nanotechnol Grp, Brighton BN2 4GJ, E Sussex, England.
   Busquets, Rosa, Univ Brighton, Fac Sci \& Engn, Nanosci \& Nanotechnol Grp, Brighton BN2 4GJ, E Sussex, England.
   Frandsen, Henrik, Tech Univ Denmark, Natl Food Inst, DK-2860 Soborg, Denmark.
   Busquets, Rosa; Jonsson, Jan Ake, Lund Univ, Dept Chem, Ctr Anal \& Synth, SE-22100 Lund, Sweden.
   Busquets, Rosa; Skog, Kerstin, Lund Univ, Dept Food Technol Engn \& Nutr, SE-22100 Lund, Sweden.
   Busquets, Rosa; Puignou, Lluis; Teresa Galceran, Maria, Univ Barcelona, Dept Analyt Chem, E-08028 Barcelona, Spain.}},
DOI = {{10.1021/tx3003966}},
ISSN = {{0893-228X}},
Keywords-Plus = {{AROMATIC-AMINES; MEMBRANE EXTRACTION; COOKED CHICKEN;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO(4,5-B)PYRIDINE PHIP; CONSUMPTION;
   HUMANS; MEAT; FOOD; CHROMATOGRAPHY; CARCINOGENS}},
Research-Areas = {{Pharmacology \& Pharmacy; Chemistry; Toxicology}},
Web-of-Science-Categories  = {{Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology}},
Author-Email = {{rosabs5@gmail.com}},
Funding-Acknowledgement = {{Dir A Pahlsson's Foundation}},
Funding-Text = {{This work was supported by Dir A Pahlsson's Foundation.}},
Cited-References = {{Busquets R, 2008, MOL NUTR FOOD RES, V52, P1408, DOI 10.1002/mnfr.200800048.
   Busquets R, 2007, J AGR FOOD CHEM, V55, P9318, DOI 10.1021/jf072252q.
   Busquets R, 2012, CARCINOGEN, P163.
   Busquets R, 2009, MOL NUTR FOOD RES, V53, P1496, DOI 10.1002/mnfr.200800577.
   COLLINS MA, 1992, BRAIN RES, V570, P154, DOI 10.1016/0006-8993(92)90576-U.
   Dashwood RH, 2002, MUTAT RES-REV MUTAT, V511, P89, DOI 10.1016/S1383-5742(02)00005-4.
   Frandsen H, 2002, FOOD CHEM TOXICOL, V40, P1125, DOI 10.1016/S0278-6915(02)00033-9.
   Frandsen H, 2008, FOOD CHEM TOXICOL, V46, P3200, DOI 10.1016/j.fct.2008.07.008.
   Frandsen H, 2007, FOOD CHEM TOXICOL, V45, P863, DOI 10.1016/j.fct.2006.11.006.
   Friesen MD, 2001, CANCER LETT, V173, P43, DOI 10.1016/S0304-3835(01)00672-3.
   GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B.
   Gu D, 2010, CHEM RES TOXICOL, V23, P788, DOI 10.1021/tx900436m.
   Hammons GJ, 1999, NUTR CANCER, V33, P46.
   Herraiz T, 2000, J CHROMATOGR A, V881, P483, DOI 10.1016/S0021-9673(99)01313-8.
   IARC, 1993, MON EV CARC RISK HUM, V56, P163.
   Iwasaki M, 2010, J FOOD COMPOS ANAL, V23, P61, DOI 10.1016/j.jfca.2009.07.004.
   John EM, 2011, NUTR CANCER, V63, P525, DOI 10.1080/01635581.2011.539311.
   Kidd LCR, 1999, CANCER EPIDEM BIOMAR, V8, P439.
   Knasmuller S, 2001, MUTAT RES-FUND MOL M, V480, P129, DOI 10.1016/S0027-5107(01)00176-2.
   Knize MG, 2001, J CHROMATOGR A, V914, P95, DOI 10.1016/S0021-9673(01)00522-2.
   Kulp KS, 2000, CARCINOGENESIS, V21, P2065, DOI 10.1093/carcin/21.11.2065.
   Kulp KS, 2004, J CHROMATOGR B, V802, P143, DOI 10.1016/j.jchromb.2003.09.032.
   KUROSAKA R, 1992, JPN J CANCER RES, V83, P919.
   Lezamiz J, 2008, ANAL BIOANAL CHEM, V390, P689, DOI 10.1007/s00216-007-1702-4.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   Malfatti MA, 2006, CANCER RES, V66, P10541, DOI 10.1158/0008-5472.CAN-06-1573.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   Murray S, 2001, CARCINOGENESIS, V22, P1413, DOI 10.1093/carcin/22.9.1413.
   Pettersson U., 2007, PUBLIC HEALTH NUTR, V10, P616.
   Pfau W, 2004, J CHROMATOGR B, V802, P115, DOI 10.1016/j.jchromb.2003.10.044.
   Puangsombat K, 2011, MEAT SCI, V88, P227, DOI 10.1016/j.meatsci.2010.12.025.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   Shah FU, 2008, J CHROMATOGR B, V870, P203, DOI 10.1016/j.jchromb.2008.06.006.
   Skog K, 2006, WOODHEAD PUBL FOOD S, P407, DOI 10.1533/9781845692018.3.407.
   Solyakov A, 2002, FOOD CHEM TOXICOL, V40, P1205, DOI 10.1016/S0278-6915(02)00054-6.
   Steinkellner H, 2001, MUTAT RES-FUND MOL M, V480, P285, DOI 10.1016/S0027-5107(01)00188-9.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   Strickland PT, 2002, MUTAT RES-FUND MOL M, V506, P163, DOI 10.1016/S0027-5107(02)00163-X.
   Sugimura T, 2004, CANCER SCI, V95, P290, DOI 10.1111/j.1349-7006.2004.tb03205.x.
   TAKAYAMA S, 2008, P JPN ACAD A-MATH, V84, P176, DOI DOI 10.2183/PJAB/84.176.
   Toribio F, 1999, J CHROMATOGR A, V836, P223, DOI 10.1016/S0021-9673(99)00074-6.
   Totsuka Y, 2006, WOODHEAD PUBL FOOD S, P296, DOI 10.1533/9781845692018.2.296.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P217, DOI 10.1021/tx9701891.}},
Number-of-Cited-References = {{43}},
Times-Cited = {{1}},
Journal-ISO = {{Chem. Res. Toxicol.}},
Doc-Delivery-Number = {{094IE}},
Wos-Id = {{ISI:000315255400005}},
}

@article{ ISI:000301796500007,
Author = {Kapoor, Sanjay and Sachar, Renu and Singh, Kuldeep and Gupta, Vivek K.
   and Rajnikant, Verma},
Title = {{Synthesis and Characterization of the Adducts of
   Bis(O-butyldithiocarbonato)nickel(II) with Substituted Heterocyclic
   Amines and X-ray Structure of
   Bis(O-butyldithiocarbonato)bis(4-cyanopyridine)nickel(II)}},
Journal = {{JOURNAL OF CHEMICAL CRYSTALLOGRAPHY}},
Year = {{2012}},
Volume = {{42}},
Number = {{3}},
Pages = {{222-226}},
Month = {{MAR}},
Abstract = {{We report the synthesis and study of a new series of the adducts of
   Bis(O-butyldithiocarbonato)nickel(II) with substituted heterocyclic
   amines such as amino and cyanopyridines. Analytical results show that
   the adducts have 1: 2 stoichiometry with general formula M(Xan)(2)L-2 (M
   = Ni(II), Xan = O-butyldithiocarbonate, L = 2-, 3- and 4-aminopyridines,
   3- and 4-cyanopyridines). The complexes have been characterized by
   analytical, magnetic susceptibility measurements, molar conductivity
   measurements, IR, electronic spectral data and X-ray diffraction
   analysis. One of the adducts,
   bis(O-butyldithiocarbonato)bis(4-cyanopyridine)-nickel(II), crystallizes
   in the monoclinic space group P2(1)/c with unit cell parameters : a =
   12.546(4), b = 11.495(3), c = 9.351(3) angstrom, beta =
   102.73(3)degrees, Z = 2. Crystal structure was solved by direct methods
   and refined by full matrix least squares procedures to a final R-value
   of 0.0299 for 2,788 observed reflections. The packing of layers of
   molecules is stabilized by weak C-H center dot center dot center dot N
   and C-H center dot center dot center dot pi hydrogen bonds.}},
Publisher = {{SPRINGER/PLENUM PUBLISHERS}},
Address = {{233 SPRING ST, NEW YORK, NY 10013 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Rajnikant, V (Reprint Author), Univ Jammu, Post Grad Dept Phys, Xray Crystallog Lab, Jammu 180006, India.
   Singh, Kuldeep; Gupta, Vivek K.; Rajnikant, Verma, Univ Jammu, Post Grad Dept Phys, Xray Crystallog Lab, Jammu 180006, India.
   Kapoor, Sanjay; Sachar, Renu, Univ Jammu, Dept Chem, Jammu 180006, India.}},
DOI = {{10.1007/s10870-011-0228-y}},
ISSN = {{1074-1542}},
Keywords = {{Adducts; O-alkyldithiocarbonates (Xanthates) and substituted
   heterocyclic amines; Direct methods; Crystal structure; C-H center dot
   center dot center dot N and C-H center dot center dot center dot pi
   hydrogen bonding}},
Keywords-Plus = {{COMPLEXES; XANTHATES; SALTS}},
Research-Areas = {{Crystallography; Spectroscopy}},
Web-of-Science-Categories  = {{Crystallography; Spectroscopy}},
Author-Email = {{rkvk.paper11@gmail.com}},
Cited-References = {{Allen F. H., 1993, CHEM DESIGN AUTOMATI, V8, p{[}1, 31].
   Ara I, 2003, TRANSIT METAL CHEM, V28, P908, DOI 10.1023/A:1026326404549.
   BASOLO F, 1953, J AM CHEM SOC, V75, P5663, DOI 10.1021/ja01118a057.
   COUCOUVA.D, 1967, INORG CHEM, V6, P2047, DOI 10.1021/ic50057a026.
   Farrugia LJ, 1997, J APPL CRYSTALLOGR, V30, P565, DOI DOI 10.1107/S0021889897003117.
   Furniss B S, 1989, VOGELS TXB PRACTICAL.
   GABLE RW, 1985, INORG CHIM A-ART LET, V96, P151, DOI 10.1016/S0020-1693(00)87575-1.
   Gimeno MC, 1996, INORG CHIM ACTA, V249, P69.
   Lever A. B. P., 1984, INORGANIC ELECT SPEC.
   LEVER ABP, 1965, J INORG NUCL CHEM, V27, P149, DOI 10.1016/0022-1902(65)80204-4.
   Litipova Sh. Z., 1991, UZB KHIM ZH, V2, P3.
   MARTIN RL, 1958, J CHEM SOC, P1394, DOI 10.1039/jr9580001394.
   Nardelli M, 1995, J APPL CRYSTALLOGR, V28, P659, DOI {[}10.1107/S0021889895007138, DOI 10.1107/S0021889895007138].
   Rao S. R., 1971, XANTHATES RELATED CO.
   Reddy PC, 1996, J RADIOAN NUCL CH LE, V213, P9, DOI 10.1007/BF02162481.
   Reddy PCh, 1996, J RADIOANAL NUCL CHE, V214, P159.
   Sheldrick G. M., 1997, SHELXS97 PROGRAM SOL.
   Sheldrick G. M., 1997, SHELXL97 PROGRAM REF.
   Spek AL, 1999, PLATON WINDOWS VERSI.
   Victoriano LI, 1996, J COORD CHEM, V39, P231, DOI 10.1080/00958979608024331.
   WOLF N, 1994, POLYHEDRON, V13, P2801, DOI 10.1016/S0277-5387(00)83440-3.
   Xiong RG, 1997, POLYHEDRON, V16, P2667.
   Zelmon DE, 1998, MATER RES SOC SYMP P, V519, P395.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{3}},
Journal-ISO = {{J. Chem. Crystallogr.}},
Doc-Delivery-Number = {{912KI}},
Wos-Id = {{ISI:000301796500007}},
}

@article{ ISI:000296039400038,
Author = {Kataoka, Hiroyuki and Miyake, Mina and Saito, Keita and Mitani, Kurie},
Title = {{Formation of heterocyclic amine-amino acid adducts by heating in a model
   system}},
Journal = {{FOOD CHEMISTRY}},
Year = {{2012}},
Volume = {{130}},
Number = {{3}},
Pages = {{725-729}},
Month = {{FEB 1}},
Abstract = {{Although mutagenic and carcinogenic heterocyclic amines (HCAs) are known
   to be formed in cooked meat and fish, human HCA exposure and
   carcinogenic risk have not been elucidated in sufficient detail. In this
   work, we investigated the formations of HCA-amino acid adducts in a
   model system by using a liquid chromatography-mass spectrometry to
   elucidate another source of human HCA exposure. The
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) adduct with
   glycine was formed easily by heating at 200 degrees C within 5 min,
   which is probably based on the dehydration condensation of the amino
   group of PhIP and carboxyl group of glycine. PhIP and other HCAs such as
   2-amino-3-methyl-3H-imidazo{[}4,5-f]quinolone,
   2-amino-3,8-dimethylimidazo{[}4,5-f]-quinoxaline and
   3-amino-1,4-dimethyl-5H-pyrido{[}3,4-b]indole, also bound with various
   amino acids by heating. Among these amino acids, proline tends to form
   adducts with HCAs, but serine, cysteine and lysine hardly bound with
   HCAs. These results provided a basic understanding of the formation of
   HCA adducts with amino acids during cooking. (C) 2011 Elsevier Ltd. All
   rights reserved.}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kataoka, H (Reprint Author), Shujitsu Univ, Sch Pharm, 1-6-1 Nishigawara, Okayama 7038516, Japan.
   Kataoka, Hiroyuki; Miyake, Mina; Saito, Keita; Mitani, Kurie, Shujitsu Univ, Sch Pharm, Okayama 7038516, Japan.}},
DOI = {{10.1016/j.foodchem.2011.07.094}},
ISSN = {{0308-8146}},
Keywords = {{Heterocyclic amines; Amino acids; Adduct formation; Heating; LC-MS
   analysis}},
Keywords-Plus = {{AROMATIC-AMINES; COOKED FOODS; MEAT}},
Research-Areas = {{Chemistry; Food Science \& Technology; Nutrition \& Dietetics}},
Web-of-Science-Categories  = {{Chemistry, Applied; Food Science \& Technology; Nutrition \& Dietetics}},
Author-Email = {{hkataoka@shujitsu.ac.jp}},
Funding-Acknowledgement = {{Urakami Foundation for Food and Food Culture Promotion; Japan Society
   for the Promotion of Science {[}C (2) 12672171]; Ministry of Health,
   Labour and Welfare of Japan}},
Funding-Text = {{This work was supported by grants from Urakami Foundation for Food and
   Food Culture Promotion, a Grant-in-Aid for Scientific Basic Research
   {[}C (2) 12672171] from the Japan Society for the Promotion of Science
   and a Grant-in-Aid for Cancer Research from the Ministry of Health,
   Labour and Welfare of Japan.}},
Cited-References = {{Alaejos MS, 2008, J CHROMATOGR B, V862, P15, DOI 10.1016/j.jchromb.2007.11.040.
   Cheng KW, 2006, MOL NUTR FOOD RES, V50, P1150, DOI 10.1002/mnfr.200600086.
   Felton JS, 2007, MUTAT RES-FUND MOL M, V616, P90, DOI 10.1016/j.mrfmmm.2006.11.010.
   Grover PL, 2002, CARCINOGENESIS, V23, P1095, DOI 10.1093/carcin/23.7.1095.
   Kataoka H, 2010, MOL NUTR FOOD RES, V54, P1039, DOI 10.1002/mnfr.200900066.
   Knize MG, 2005, NUTR REV, V63, P158, DOI 10.1301/nr.2005.may.158-165.
   Martin FL, 2010, PROSTATE, V70, P1586, DOI 10.1002/pros.21194.
   Martin FL, 2002, BIOCHEM BIOPH RES CO, V293, P1497, DOI 10.1016/S0006-291X(02)00414-X.
   Murkovic M, 2004, J CHROMATOGR B, V802, P3, DOI 10.1016/j.jchromb.2003.09.026.
   NAGAO M, 2000, FOOD BONE CARCINOGEN.
   Persson E, 2003, J AGR FOOD CHEM, V51, P4472, DOI 10.1021/jf021089q.
   Skog K, 2002, FOOD CHEM TOXICOL, V40, P1197, DOI 10.1016/S0278-6915(02)00052-2.
   Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1.
   Sugimura T, 2004, CANCER SCI, V95, P290, DOI 10.1111/j.1349-7006.2004.tb03205.x.
   Turesky RJ, 2007, TOXICOL LETT, V168, P219, DOI 10.1016/j.toxlet.2006.10.018.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{1}},
Journal-ISO = {{Food Chem.}},
Doc-Delivery-Number = {{835MB}},
Wos-Id = {{ISI:000296039400038}},
}

@article{ ISI:000294076200002,
Author = {Turesky, Robert J. and Le Marchand, Loic},
Title = {{Metabolism and Biomarkers of Heterocyclic Aromatic Amines in Molecular
   Epidemiology Studies: Lessons Learned from Aromatic Amines}},
Journal = {{CHEMICAL RESEARCH IN TOXICOLOGY}},
Year = {{2011}},
Volume = {{24}},
Number = {{8}},
Pages = {{1169-1214}},
Month = {{AUG}},
Abstract = {{Aromatic amines and heterocyclic aromatic amines (HAAs) are structurally
   related classes of carcinogens that are formed during the combustion of
   tobacco or during the high-temperature cooking of meats. Both classes of
   procarcinogens undergo metabolic activation by N-hydroxylation of the
   exocyclic amine group to produce a common proposed intermediate, the
   arylnitrenium ion, which is the critical metabolite implicated in
   toxicity and DNA damage. However, the biochemistry and chemical
   properties of these compounds are distinct, and different biomarkers of
   aromatic amines and HAAs have been developed for human biomonitoring
   studies. Hemoglobin adducts have been extensively used as biomarkers to
   monitor occupational and environmental exposures to a number of aromatic
   amines; however, HAAs do not form hemoglobin adducts at appreciable
   levels, and other biomarkers have been sought. A number of epidemiologic
   studies that have investigated dietary consumption of well-done meat in
   relation to various tumor sites reported a positive association between
   cancer risk and well-done meat consumption, although some studies have
   shown no associations between well-done meat and cancer risk. A major
   Limiting factor in most epidemiological studies is the uncertainty in
   quantitative estimates of chronic exposure to HAAs, and thus, the
   association of HAAs formed in cooked meat and Cancer risk has been
   difficult to establish. There is a critical need to establish long-term
   biomarkers of HAAs that can be implemented in molecular epidemiology
   studies. In this review, we highlight and contrast the biochemistry of
   several prototypical carcinogenic aromatic amines and HAAs to which
   humans are chronically exposed. The biochemical properties and the
   impact of polymorphisms of the major xenobiotic-metabolizing enzymes on
   the biological effects of these chemicals are examined. Lastly, the
   analytical approaches that have been successfully employed to biomonitor
   aromatic amines and HAAs, and emerging biomarkers of HAAs that may be
   implemented in molecular epidemiology studies are discussed.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Turesky, RJ (Reprint Author), Wadsworth Ctr, Div Environm Hlth Sci, Albany, NY 12201 USA.
   Turesky, Robert J., Wadsworth Ctr, Div Environm Hlth Sci, Albany, NY 12201 USA.
   Le Marchand, Loic, Univ Hawaii, Ctr Canc, Honolulu, HI 96813 USA.}},
DOI = {{10.1021/tx200135s}},
ISSN = {{0893-228X}},
Keywords-Plus = {{DNA ADDUCT FORMATION; CIGARETTE-SMOKE CONDENSATE; FOOD-BORNE CARCINOGEN;
   CHROMATOGRAPHY-MASS-SPECTROMETRY; PROSTAGLANDIN-H SYNTHASE;
   COLORECTAL-CANCER RISK; HUMAN LIVER-MICROSOMES; HUMAN SERUM-ALBUMIN;
   GLUTATHIONE S-TRANSFERASES; A-ALPHA-C}},
Research-Areas = {{Pharmacology \& Pharmacy; Chemistry; Toxicology}},
Web-of-Science-Categories  = {{Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology}},
Author-Email = {{Rturesky@wadsworth.org
   Loic@crch.hawaii.edu}},
ResearcherID-Numbers = {{yang, min/G-3030-2011}},
Funding-Acknowledgement = {{National Cancer Institute {[}R01 CA122320, R01 CA60987, CA72520];
   National Institute of Environmental Health Sciences {[}R21 ES014438];
   World Cancer Research Fund International {[}2007/58, RFA09/149]}},
Funding-Text = {{A portion of the data reported in this manuscript was supported by grant
   R01 CA122320 (to R.J.T.), and by R01 CA60987 and CA72520 (to L.L.M.)
   from the National Cancer Institute, by R21 ES014438 (to R.J.T.) from the
   National Institute of Environmental Health Sciences, and by grant
   numbers 2007/58 (to R.J.T.) and RFA09/149 (to L.L.M.) from the World
   Cancer Research Fund International.}},
Cited-References = {{ABUZEID M, 1992, CARCINOGENESIS, V13, P1307, DOI 10.1093/carcin/13.8.1307.
   Adamson RH, 1996, ARCH TOX S, V18, P303.
   ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   Agundez JAG, 2008, CURR DRUG METAB, V9, P520, DOI 10.2174/138920008784892083.
   Agus C, 2000, CARCINOGENESIS, V21, P1213, DOI 10.1093/carcin/21.6.1213.
   Airoldi L, 2002, CARCINOGENESIS, V23, P861, DOI 10.1093/carcin/23.5.861.
   Airoldi L, 2004, J CHROMATOGR B, V802, P175, DOI 10.1016/j.jchromb.2003.10.055.
   Akyuz M, 2008, J PHARMACEUT BIOMED, V47, P68, DOI 10.1016/j.jpba.2007.12.011.
   Alaejos MS, 2008, FOOD ADDIT CONTAM, V25, P2, DOI 10.1080/02652030701474235.
   Alaejos MS, 2011, COMPR REV FOOD SCI F, V10, P52, DOI 10.1111/j.1541-4337.2010.00141.x.
   Alexander J, 2002, FOOD CHEM TOXICOL, V40, P1131, DOI 10.1016/S0278-6915(02)00053-4.
   Alexander J., 1995, HETEROCYCLIC AMINES, P59.
   ALEXANDER J, 1991, CARCINOGENESIS, V12, P2239, DOI 10.1093/carcin/12.12.2239.
   Alguacil J, 2011, CARCINOGENESIS, V32, P843, DOI 10.1093/carcin/bgr048.
   Al-Zoughool M, 2006, J APPL TOXICOL, V26, P524, DOI 10.1002/jat.1172.
   Ambrosone CB, 2007, ARCH BIOCHEM BIOPHYS, V464, P169, DOI 10.1016/j.abb.2007.05.018.
   Anderson KE, 1997, CARCINOGENESIS, V18, P1085, DOI 10.1093/carcin/18.5.1085.
   ASHKENAZI M, 1989, J DENT RES, V68, P1256, DOI 10.1177/00220345890680080901.
   Augustsson K, 1999, LANCET, V353, P703, DOI 10.1016/S0140-6736(98)06099-1.
   Babu SR, 1995, CARCINOGENESIS, V16, P3069, DOI 10.1093/carcin/16.12.3069.
   Babu SR, 1996, BIOCHEM PHARMACOL, V51, P1679, DOI 10.1016/0006-2952(96)00165-7.
   Bamber DE, 2001, PHARMACOGENETICS, V11, P679, DOI 10.1097/00008571-200111000-00006.
   Baranczewski P, 2004, CANCER EPIDEM BIOMAR, V13, P1071.
   Barlow S, 2006, FOOD CHEM TOXICOL, V44, P1636, DOI 10.1016/j.fct.2006.06.020.
   BARNES WS, 1985, CARCINOGENESIS, V6, P441, DOI 10.1093/carcin/6.3.441.
   Barrett JH, 2003, CARCINOGENESIS, V24, P275, DOI 10.1093/carcin/24.2.275.
   BARTSCH H, 1990, J NATL CANCER I, V82, P1826, DOI 10.1093/jnci/82.23.1826.
   BECHTOLD WE, 1992, CARCINOGENESIS, V13, P1217, DOI 10.1093/carcin/13.7.1217.
   Beck JL, 2004, ANAL BIOCHEM, V325, P326, DOI 10.1016/j.ab.2003.10.041.
   Beland FA, 1999, CHEM RES TOXICOL, V12, P68, DOI 10.1021/tx980172y.
   BELAND FA, 1983, ENVIRON HEALTH PERSP, V49, P125, DOI 10.2307/3429589.
   BELAND FA, 1980, CANCER RES, V40, P834.
   BELAND FA, 1985, ENVIRON HEALTH PERSP, V62, P19, DOI 10.2307/3430089.
   Belloc C, 1996, TOXICOLOGY, V106, P207, DOI 10.1016/0300-483X(95)03178-I.
   Bendaly J, 2007, CANCER EPIDEM BIOMAR, V16, P1503, DOI 10.1158/1055-9965.EPI-07-0305.
   Bertz RJ, 1997, CLIN PHARMACOKINET, V32, P210.
   BESARATI NA, 2000, ENVIRON MOL MUTAGEN, V36, P127.
   Besaratinia A, 2000, Mutat Res, V468, P125, DOI 10.1016/S1383-5718(00)00049-8.
   Bessette EE, 2010, CHEM RES TOXICOL, V23, P1234, DOI 10.1021/tx100098f.
   Bessette EE, 2009, CHEM RES TOXICOL, V22, P1454, DOI 10.1021/tx900155f.
   Bessette EE, 2009, ANAL CHEM, V81, P809, DOI 10.1021/ac802096p.
   Beyerbach A, 2006, CARCINOGENESIS, V27, P1600, DOI 10.1093/carcin/bgi362.
   BJELDANES LF, 1991, P NATL ACAD SCI USA, V88, P9543, DOI 10.1073/pnas.88.21.9543.
   Blanchard RL, 2004, PHARMACOGENETICS, V14, P199, DOI 10.1097/00008571-200403000-00009.
   BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237.
   Bogen KT, 2001, J EXPO ANAL ENV EPID, V11, P155, DOI 10.1038/sj.jea.7500158.
   Bohm F, 2011, BIOMARKERS, V16, P120, DOI 10.3109/1354750X.2010.534556.
   Bonala R, 2006, CHEM RES TOXICOL, V19, P734, DOI 10.1021/tx0600191.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   Boobis AR, 1996, ARCH TOX S, V18, P286.
   BOYD JA, 1985, ENVIRON HEALTH PERSP, V64, P45, DOI 10.2307/3429997.
   BOYD JA, 1987, CANCER RES, V47, P4007.
   BOYLAND E, 1966, BIOCHEM J, V101, P84.
   BOYLAND E, 1957, BIOCHEM J, V65, P417.
   Brockton N, 2000, AM J EPIDEMIOL, V151, P846.
   Brown K, 2001, P NATL ACAD SCI USA, V98, P8507, DOI 10.1073/pnas.151251898.
   Broyde S, 2008, CHEM RES TOXICOL, V21, P45, DOI 10.1021/tx700193x.
   BRYANT MS, 1988, P NATL ACAD SCI USA, V85, P9788, DOI 10.1073/pnas.85.24.9788.
   BRYANT MS, 1987, CANCER RES, V47, P602.
   Burchell Brian, 2003, Am J Pharmacogenomics, V3, P37, DOI 10.2165/00129785-200303010-00006.
   Busquets R, 2008, MOL NUTR FOOD RES, V52, P1408, DOI 10.1002/mnfr.200800048.
   Butler LM, 2003, AM J EPIDEMIOL, V157, P434, DOI 10.1093/aje/kwf221.
   Butler LM, 2005, CANCER EPIDEM BIOMAR, V14, P1626, DOI 10.1158/1055-9965.EPI-04-0682.
   BUTLER MA, 1989, P NATL ACAD SCI USA, V86, P7696, DOI 10.1073/pnas.86.20.7696.
   BUTLER MA, 1989, CANCER RES, V49, P25.
   BUTLER MA, 1992, PHARMACOGENETICS, V2, P116, DOI 10.1097/00008571-199206000-00003.
   Carballal S, 2003, BIOCHEMISTRY-US, V42, P9906, DOI 10.1021/bi027434m.
   Carlini EJ, 2001, PHARMACOGENETICS, V11, P57, DOI 10.1097/00008571-200102000-00007.
   CASE RAM, 1954, BRIT J IND MED, V11, P75.
   Castelao JE, 2001, J NATL CANCER I, V93, P538, DOI 10.1093/jnci/93.7.538.
   CHACKO M, 1988, CARCINOGENESIS, V9, P2309, DOI 10.1093/carcin/9.12.2309.
   Chan AT, 2005, INT J CANCER, V115, P648, DOI 10.1002/ijc.20890.
   Chen C, 2007, CHEM RES TOXICOL, V20, P531, DOI 10.1021/tx600320w.
   Chepanoske CL, 2004, FOOD CHEM TOXICOL, V42, P1367, DOI 10.1016/j.fct.2003.11.012.
   Cheung C, 2005, CHEM RES TOXICOL, V18, P1471, DOI 10.1021/tx050136g.
   Chiang TA, 1999, FOOD CHEM TOXICOL, V37, P125.
   Cho BSP, 2004, J ENVIRON SCI HEAL C, V22, P57, DOI 10.1081/LESC-200038217.
   Choi JY, 2006, J BIOL CHEM, V281, P25297, DOI 10.1074/jbc.M605699200.
   CHOU HC, 1995, CANCER RES, V55, P525.
   Cioni F, 1999, RAPID COMMUN MASS SP, V13, P1833, DOI 10.1002/(SICI)1097-0231(19990930)13:18<1833::AID-RCM725>3.0.CO;2-R.
   Ciotti M, 1999, CARCINOGENESIS, V20, P1963, DOI 10.1093/carcin/20.10.1963.
   Clayson DB, 1981, NATL CANCER I MONOGR, V58, P15.
   CLEVELAN.JC, 1967, CANCER RES, V27, P708.
   COCKER J, 1990, BRIT J IND MED, V47, P154.
   COCKER J, 1988, BIOMED ENVIRON MASS, V17, P161, DOI 10.1002/bms.1200170303.
   Cohen SM, 2006, CRIT REV TOXICOL, V36, P803, DOI 10.1080/10408440600977651.
   Coles B, 2001, MUTAT RES-FUND MOL M, V482, P3, DOI 10.1016/S0027-5107(01)00187-7.
   Coles BF, 2003, BIOFACTORS, V17, P115.
   Coles BF, 2001, PHARMACOGENETICS, V11, P663, DOI 10.1097/00008571-200111000-00004.
   CONNEY AH, 1982, CANCER RES, V42, P4875.
   CONNEY AH, 1977, FED PROC, V36, P1647.
   Corbett JF, 1973, CUTIS, V12, P190.
   Cotterchio M, 2008, CANCER EPIDEM BIOMAR, V17, P3098, DOI 10.1158/1055-9965.EPI-08-0341.
   CRAMER JW, 1960, J BIOL CHEM, V235, P885.
   Crofts FG, 1997, CARCINOGENESIS, V18, P1793, DOI 10.1093/carcin/18.9.1793.
   Crofts FG, 1998, CARCINOGENESIS, V19, P1969, DOI 10.1093/carcin/19.11.1969.
   Crosbie SJ, 2000, J CHROMATOGR B, V744, P55, DOI 10.1016/S0378-4347(00)00227-9.
   Cross AJ, 2004, ENVIRON MOL MUTAGEN, V44, P44, DOI 10.1002/em.20030.
   Cui L, 2007, CHEM RES TOXICOL, V20, P1730, DOI 10.1021/tx700306c.
   Culp SJ, 1997, MUTAT RES-FUND MOL M, V378, P97, DOI 10.1016/S0027-5107(97)00101-2.
   Dashwood RH, 2003, J BIOCHEM MOL BIOL, V36, P35.
   DAVIS VM, 1993, J CHROMATOGR, V635, P160, DOI 10.1016/0021-9673(93)83128-F.
   Degen GH, 1998, ARCH TOXICOL, V72, P183, DOI 10.1007/s002040050485.
   Delaney JC, 2008, CHEM RES TOXICOL, V21, P232, DOI 10.1021/tx700292a.
   Dellinger RW, 2007, CARCINOGENESIS, V28, P2412, DOI 10.1093/carcin/bgm164.
   Di Paolo OA, 2005, INT J CANCER, V117, P8, DOI 10.1002/ijc.21152.
   DIAZ D, 1990, GASTROENTEROLOGY, V99, P737.
   Ding XX, 2003, ANNU REV PHARMACOL, V43, P149, DOI 10.1146/annurev.pharmtox.43.100901.140251.
   Dingley KH, 1999, CANCER EPIDEM BIOMAR, V8, P507.
   Dingley KH, 1998, CHEM RES TOXICOL, V11, P1217, DOI 10.1021/tx9801458.
   Dingley KH, 1998, DRUG METAB DISPOS, V26, P825.
   Doerge DR, 1999, CARCINOGENESIS, V20, P1055, DOI 10.1093/carcin/20.6.1055.
   Doerge DR, 2008, J AGR FOOD CHEM, V56, P6031, DOI 10.1021/jf073042g.
   DOLLE B, 1980, XENOBIOTICA, V10, P527.
   Dong LM, 2008, JAMA-J AM MED ASSOC, V299, P2423, DOI 10.1001/jama.299.20.2423.
   DOOLEY KL, 1992, CANCER LETT, V62, P205, DOI 10.1016/0304-3835(92)90097-F.
   DRAGSTED LO, 1995, CARCINOGENESIS, V16, P2785, DOI 10.1093/carcin/16.11.2785.
   DUPONT RL, 1995, FORENSIC SCI INT, V70, P63, DOI 10.1016/0379-0738(94)01625-F.
   Dybing E, 2008, TOXICOL LETT, V180, P110, DOI 10.1016/j.toxlet.2008.05.007.
   EATON DL, 1995, PHARMACOGENETICS, V5, P259, DOI 10.1097/00008571-199510000-00001.
   EDWARDS RJ, 1994, CARCINOGENESIS, V15, P829, DOI 10.1093/carcin/15.5.829.
   EHRENBER.L, 1974, MUTAT RES, V24, P83, DOI 10.1016/0165-1218(74)90200-6.
   EISENBRAND G, 1993, TOXICOLOGY, V84, P1, DOI 10.1016/0300-483X(93)90109-6.
   ELBAYOUMY K, 1986, CANCER RES, V46, P6064.
   ELLIS MK, 1992, CHEM-BIOL INTERACT, V82, P151, DOI 10.1016/0009-2797(92)90107-V.
   Elmquist CE, 2004, J AM CHEM SOC, V126, P11189, DOI 10.1021/ja0487022.
   EYER P, 1994, ENVIRON HEALTH PERSP, V102, P123, DOI 10.2307/3432165.
   Faraglia B, 2003, CARCINOGENESIS, V24, P719, DOI 10.1093/carcin/bgg013.
   Fede JM, 2009, CHEM RES TOXICOL, V22, P1096, DOI 10.1021/tx900052c.
   Felton J. S., 2000, Food borne carcinogens: heterocyclic amines., P31.
   Felton JS, 2004, TOXICOLOGY, V198, P135, DOI 10.1016/j.tox.2004.01.024.
   Felton JS, 2006, CARCINOGENESIS, V27, P2367, DOI 10.1093/carcin/bg1165.
   FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315.
   Ferguson LR, 2010, MEAT SCI, V84, P308, DOI 10.1016/j.meatsci.2009.06.032.
   Flamini G, 1998, CARCINOGENESIS, V19, P353, DOI 10.1093/carcin/19.2.353.
   FLAMMANG TJ, 1987, CARCINOGENESIS, V8, P1967, DOI 10.1093/carcin/8.12.1967.
   FLAMMANG TJ, 1989, CANCER RES, V49, P1977.
   FOILES PG, 1989, CARCINOGENESIS, V10, P1429, DOI 10.1093/carcin/10.8.1429.
   Frandsen H, 2008, FOOD CHEM TOXICOL, V46, P3200, DOI 10.1016/j.fct.2008.07.008.
   FRANDSEN H, 1994, MUTAGENESIS, V9, P59, DOI 10.1093/mutage/9.1.59.
   FRANDSEN H, 1994, CARCINOGENESIS, V15, P2553, DOI 10.1093/carcin/15.11.2553.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   Frandsen H, 2007, FOOD CHEM TOXICOL, V45, P863, DOI 10.1016/j.fct.2006.11.006.
   TURTELTAUB KW, 1992, CANCER RES, V52, P4682.
   Frederiksen H, 2004, CARCINOGENESIS, V25, P1525, DOI 10.1093/carcin/bgh156.
   Frederiksen H, 2004, FOOD CHEM TOXICOL, V42, P879, DOI 10.1016/j.fct.2004.01.011.
   Frederiksen H, 2003, PHARMACOL TOXICOL, V92, P246, DOI 10.1034/j.1600-0773.2003.920508.x.
   Frederiksen H, 2002, PHARMACOL TOXICOL, V90, P127, DOI 10.1034/j.1600-0773.2002.900303.x.
   Frederiksen H, 2005, MOL NUTR FOOD RES, V49, P263, DOI 10.1002/mnfr.200400061.
   FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   Fujita H, 1999, JPN J CANCER RES, V90, P1203.
   Fukushima S, 2004, TOXICOL SCI, V80, P109, DOI 10.1093/toxsci/kfh104.
   Funk WE, 2010, ANAL BIOCHEM, V400, P61, DOI 10.1016/j.ab.2010.01.006.
   Gamage N, 2006, TOXICOL SCI, V90, P5, DOI 10.1093/toxsci/kfj061.
   Gan JP, 2004, J NATL CANCER I, V96, P1425, DOI 10.1093/jnci/djh274.
   Gan JP, 2001, CHEM RES TOXICOL, V14, P672, DOI 10.1021/tx000181i.
   GAN LS, 1988, CARCINOGENESIS, V9, P1323, DOI 10.1093/carcin/9.7.1323.
   Gangl ET, 1999, CHEM RES TOXICOL, V12, P1019, DOI 10.1021/tx990060m.
   Garcia-Closas M, 2005, LANCET, V366, P649, DOI 10.1016/S0140-6736(05)67137-1.
   Garner RC, 1999, CANCER LETT, V143, P161, DOI 10.1016/S0304-3835(99)00118-4.
   Garrigos MC, 2002, J CHROMATOGR A, V976, P309, DOI 10.1016/S0021-9673(02)01162-7.
   GAYLOR DW, 1991, MUTAGENS FOOD DETECT, P229.
   GHOSHAL A, 1994, CARCINOGENESIS, V15, P2429, DOI 10.1093/carcin/15.11.2429.
   GHOSHAL A, 1995, CARCINOGENESIS, V16, P2725, DOI 10.1093/carcin/16.11.2725.
   Girard H, 2005, HEPATOLOGY, V42, P448, DOI 10.1002/hep.20770.
   Girard H, 2008, MUTAT RES-FUND MOL M, V644, P56, DOI 10.1016/j.mrfmmm.2008.07.002.
   Glatt H, 2006, WOODHEAD PUBL FOOD S, P358, DOI 10.1533/9781845692018.2.358.
   Goodenough AK, 2007, CHEM RES TOXICOL, V20, P263, DOI 10.1021/tx0601713.
   Gooderham NJ, 2001, DRUG METAB DISPOS, V29, P529.
   Gorlewska-Roberts K, 2002, ENVIRON MOL MUTAGEN, V39, P184, DOI 10.1002/em.10060.
   Gorlewska-Roberts KM, 2004, CHEM RES TOXICOL, V17, P1659, DOI 10.1021/tx049787n.
   GORROD JW, 1986, XENOBIOTICA, V16, P933.
   GRANATH F, 1992, MUTAT RES, V284, P297, DOI 10.1016/0027-5107(92)90014-S.
   Gratacos-Cubarsi M, 2006, J CHROMATOGR B, V834, P14, DOI 10.1016/j.jchromb.2006.03.007.
   GREEN LC, 1984, CANCER RES, V44, P4254.
   Green MD, 1996, DRUG METAB DISPOS, V24, P356.
   Green MD, 1998, DRUG METAB DISPOS, V26, P860.
   GREENBLATT MS, 1994, CANCER RES, V54, P4855.
   Grimmer G, 2000, SCI TOTAL ENVIRON, V247, P81, DOI 10.1016/S0048-9697(99)00471-4.
   Grollman AP, 2007, P NATL ACAD SCI USA, V104, P12129, DOI 10.1073/pnas.0701248104.
   GROSS GA, 1993, CARCINOGENESIS, V14, P2313, DOI 10.1093/carcin/14.11.2313.
   Gu D, 2010, CHEM RES TOXICOL, V23, P788, DOI 10.1021/tx900436m.
   GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P391, DOI 10.1021/tx00022a001.
   GUENGERICH FP, 1991, J PHARMACOL EXP THER, V256, P1189.
   Guengerich FP, 1997, CHEM-BIOL INTERACT, V106, P161, DOI 10.1016/S0009-2797(97)00068-9.
   Guillemette C, 2003, PHARMACOGENOMICS J, V3, P136, DOI 10.1038/sj.tpj.6500171.
   GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081.
   Hada N, 2001, MUTAT RES-GEN TOX EN, V493, P115, DOI 10.1016/S1383-5718(01)00168-1.
   Hammons GJ, 1997, CARCINOGENESIS, V18, P851, DOI 10.1093/carcin/18.4.851.
   HAMMONS GJ, 1991, CHEM RES TOXICOL, V4, P144, DOI 10.1021/tx00020a003.
   Hammons GJ, 2001, LIFE SCI, V69, P839, DOI 10.1016/S0024-3205(01)01175-4.
   HAMMONS GJ, 1987, MAMMALIAN CYTOCHROME, P81.
   HASEGAWA R, 1994, CARCINOGENESIS, V15, P2567, DOI 10.1093/carcin/15.11.2567.
   Hashimoto H, 2004, J CHROMATOGR B, V803, P209, DOI 10.1016/j.jchromb.2003.12.029.
   HASHIMOTO Y, 1982, MUTAT RES, V105, P9, DOI 10.1016/0165-7992(82)90200-7.
   HASHIMOTO Y, 1985, ENVIRON HEALTH PERSP, V62, P209, DOI 10.2307/3430115.
   Hatch FT, 2001, ENVIRON MOL MUTAGEN, V38, P268, DOI 10.1002/em.10028.
   Hatcher JF, 2002, ENVIRON MOL MUTAGEN, V39, P314, DOI 10.1002/em.10079.
   Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857.
   He YH, 2000, FOOD CHEM TOXICOL, V38, P15, DOI 10.1016/S0278-6915(99)00117-9.
   Hecht SS, 2002, CARCINOGENESIS, V23, P907, DOI 10.1093/carcin/23.6.907.
   Hecht SS, 2003, NAT REV CANCER, V3, P733, DOI 10.1038/nrc1190.
   Hegstad S, 2002, PHARMACOL TOXICOL, V90, P333, DOI 10.1034/j.1600-0773.2002.900607.x.
   Hegstad S, 2000, CHROMATOGRAPHIA, V52, P499, DOI 10.1007/BF02535726.
   HEIN DW, 1994, ARCH TOXICOL, V68, P129, DOI 10.1007/s002040050045.
   HEIN DW, 1993, CARCINOGENESIS, V14, P1633, DOI 10.1093/carcin/14.8.1633.
   Hein DW, 2002, MUTAT RES-FUND MOL M, V506, P65, DOI 10.1016/S0027-5107(02)00153-7.
   Hein DW, 2006, ONCOGENE, V25, P1649, DOI 10.1038/sj.onc.1209374.
   Hein DW, 2000, TOXICOL LETT, V112, P349, DOI 10.1016/S0378-4274(99)00226-X.
   Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29.
   HELLER HE, 1951, NATURE, V168, P909, DOI 10.1038/168909a0.
   Hempel N, 2007, INT J BIOCHEM CELL B, V39, P685, DOI 10.1016/j.biocel.2006.10.002.
   Himmelstein MW, 2009, CRIT REV TOXICOL, V39, P679, DOI 10.1080/10408440903164163.
   Hoffmann D., 1998, BEITR TABAKFORSCH, V18, P49.
   Hoffmann GR, 1997, CHEM RES TOXICOL, V10, P347, DOI 10.1021/tx960128n.
   HOFFMANN KJ, 1985, CHEM-BIOL INTERACT, V53, P155, DOI 10.1016/S0009-2797(85)80093-4.
   Holland RD, 2004, CHEM RES TOXICOL, V17, P1121, DOI 10.1021/tx049910a.
   HOWIE AF, 1990, CARCINOGENESIS, V11, P451, DOI 10.1093/carcin/11.3.451.
   HUEPER W. C., 1938, Journal of Industrial Hygiene, V20, P46.
   HUMPHREYS WG, 1992, P NATL ACAD SCI USA, V89, P8278, DOI 10.1073/pnas.89.17.8278.
   International Agency for Research on Cancer, 2004, IARC MON EV CARC RIS, V83.
   International Agency for Research on Cancer, 1993, IARC MON EV CARC RIS, V56.
   International Agency for Research on Cancer, 1986, IARC MON EV CARC RIS, V38.
   Irving C. C., 1981, NATL CANCER I MONOGR, V58, P109.
   Irving C. C., 1973, METAB CONJUGATION, P53.
   IRVING C C, 1971, Xenobiotica, V1, P387.
   Ishibe N, 2002, PHARMACOGENETICS, V12, P145, DOI 10.1097/00008571-200203000-00008.
   JAGERSTAD M, 1991, MUTAT RES, V259, P219, DOI 10.1016/0165-1218(91)90119-7.
   Jamin EL, 2007, J AM SOC MASS SPECTR, V18, P2107, DOI 10.1016/j.jasms.2007.09.008.
   Jarabek AM, 2009, CRIT REV TOXICOL, V39, P659, DOI 10.1080/10408440903164155.
   JI H, 1994, CANCER EPIDEM BIOMAR, V3, P407.
   Jiang ZW, 2006, PHARMACOGENET GENOM, V16, P359, DOI 10.1097/01.fpc.0000204994.99429.46.
   Jones CR, 2003, CHEM RES TOXICOL, V16, P1251, DOI 10.1021/tx020064i.
   JONES NJ, 1993, CANCER RES, V53, P1522.
   Jonsson C, 2010, MUTAGENESIS, V25, P499, DOI 10.1093/mutage/geq033.
   Josephy PD, 1996, MUTAGENESIS, V11, P3, DOI 10.1093/mutage/11.1.3.
   KADERLIK KR, 1995, PHARMACOGENETICS, V5, pS108, DOI 10.1097/00008571-199512001-00011.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1695, DOI 10.1093/carcin/15.8.1695.
   KADERLIK KR, 1993, CANCER EPIDEM BIOMAR, V2, P63.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1711, DOI 10.1093/carcin/15.8.1711.
   KADLUBAR FF, 1982, BIOCHEM BIOPH RES CO, V108, P253, DOI 10.1016/0006-291X(82)91859-9.
   KADLUBAR FF, 1992, ENVIRON HEALTH PERSP, V98, P69, DOI 10.2307/3431249.
   KADLUBAR FF, 1995, HETEROCYCLIC AMINES, P207.
   KADLUBAR FF, 1977, CANCER RES, V37, P805.
   KADLUBAR FF, 1985, POLYCYCLIC HYDROCARB, P332.
   KALOW W, 1991, CLIN PHARMACOL THER, V50, P508.
   Kampman E, 1999, CANCER EPIDEM BIOMAR, V8, P15.
   KANAI Y, 1990, CARCINOGENESIS, V11, P1001, DOI 10.1093/carcin/11.6.1001.
   Kataoka H, 1997, J CHROMATOGR A, V774, P121, DOI 10.1016/S0021-9673(97)00246-X.
   KATO R, 1987, JPN J CANCER RES, V78, P297.
   KATO R, 1986, CRIT REV TOXICOL, V16, P307, DOI 10.3109/10408448609037466.
   Kawamori T, 2004, CARCINOGENESIS, V25, P1967, DOI 10.1093/carcin/bgh189.
   KAZANIS S, 1992, J AM CHEM SOC, V114, P3052, DOI 10.1021/ja00034a043.
   Keating GA, 2004, J CHROMATOGR B, V802, P127, DOI 10.1016/j.jchromb.2003.10.047.
   Kennedy SA, 1997, J AM CHEM SOC, V119, P7654, DOI 10.1021/ja970698p.
   KENNELLY JC, 1984, CARCINOGENESIS, V5, P407.
   Kidd LCR, 1999, CANCER EPIDEM BIOMAR, V8, P439.
   KIESE M, 1966, PHARMACOL REV, V18, P1091.
   KIESE M, 1976, N-S ARCH PHARMACOL, V292, P59, DOI 10.1007/BF00506490.
   Kim DH, 2004, CHEM RES TOXICOL, V17, P529, DOI 10.1021/tx034267y.
   Kim JH, 2004, TOXICOL APPL PHARM, V199, P210, DOI 10.1016/j.taap.2003.11.015.
   Kimura S, 2003, CARCINOGENESIS, V24, P583, DOI 10.1093/carcin/24.3.583.
   Kimura S, 1999, CARCINOGENESIS, V20, P1825, DOI 10.1093/carcin/20.9.1825.
   KING CM, 1969, J BIOL CHEM, V244, P6209.
   King RS, 1999, CANCER LETT, V143, P167, DOI 10.1016/S0304-3835(99)00119-6.
   King R.S., 2000, FOOD BORNE CARCINOGE, P90.
   King RS, 2000, CARCINOGENESIS, V21, P1347, DOI 10.1093/carcin/21.7.1347.
   Klinkhamer J. M., 1963, J AM SOC PERIODONTIC, V1, P109.
   Knize MG, 2002, MUTAT RES-FUND MOL M, V506, P153, DOI 10.1016/S0027-5107(02)00162-8.
   Knize MG, 2005, NUTR REV, V63, P158, DOI 10.1301/nr.2005.may.158-165.
   KNIZE MG, 1994, FOOD CHEM TOXICOL, V32, P595, DOI 10.1016/0278-6915(94)90002-7.
   Kobayashi M, 2005, MUTAT RES-GEN TOX EN, V588, P136, DOI 10.1016/j.mrgentox.2005.09.008.
   Kobayashi M, 2007, MUTAT RES-GEN TOX EN, V630, P14, DOI 10.1016/jmrgentox.2007.02.003.
   Koc H, 2002, J CHROMATOGR B, V778, P323, DOI 10.1016/S1570-0232(02)00135-6.
   Kragelund C, 2008, ORAL DIS, V14, P533, DOI 10.1111/j.1601-0825.2007.01415.x.
   KRICK E, 1972, CANCER RES, V32, P2042.
   KRIEK E, 1965, BIOCHEM BIOPH RES CO, V20, P793, DOI 10.1016/0006-291X(65)90088-4.
   KRIEK E, 1992, J CANCER RES CLIN, V118, P481, DOI 10.1007/BF01225261.
   Kristal AR, 2005, CANCER EPIDEM BIOMAR, V14, P2826, DOI 10.1158/1055-9965.EPI-editorial.
   Kulp KS, 2000, CARCINOGENESIS, V21, P2065, DOI 10.1093/carcin/21.11.2065.
   Kulp KS, 2004, J CHROMATOGR B, V802, P143, DOI 10.1016/j.jchromb.2003.09.032.
   KUNZE KL, 1993, CHEM RES TOXICOL, V6, P649, DOI 10.1021/tx00035a009.
   Kurian JR, 2006, CHEM RES TOXICOL, V19, P1366, DOI 10.1021/tx060106t.
   Kury S, 2007, CANCER EPIDEM BIOMAR, V16, P1460, DOI 10.1158/1055-9965.EPI-07-0236.
   Lai MN, 2010, J NATL CANCER I, V102, P179, DOI 10.1093/jnci/djp467.
   Lakshman MK, 2005, CURR ORG SYNTH, V2, P83, DOI 10.2174/1570179052996955.
   Lakshmi VM, 1997, DRUG METAB DISPOS, V25, P481.
   Lakshmi VM, 2008, DRUG METAB DISPOS, V36, P1143, DOI 10.1124/dmd.107.019166.
   Lakshmi VM, 1998, CARCINOGENESIS, V19, P911, DOI 10.1093/carcin/19.5.911.
   Lakshmi VM, 2005, CHEM RES TOXICOL, V18, P528, DOI 10.1021/tx049792r.
   Lakshmi VM, 2005, FOOD CHEM TOXICOL, V43, P1607, DOI 10.1016/j.fct.2005.05.002.
   Lancaster FE, 1999, FOOD ADDIT CONTAM, V16, P381, DOI 10.1080/026520399283867.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   Langouet S, 2002, CARCINOGENESIS, V23, P115, DOI 10.1093/carcin/23.1.115.
   Langouet S, 2001, CHEM RES TOXICOL, V14, P211, DOI 10.1021/tx000176e.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LeMarchand L, 1997, PHARMACOGENETICS, V7, P11, DOI 10.1097/00008571-199702000-00002.
   Le Marchand L, 2001, CANCER EPIDEM BIOMAR, V10, P1259.
   Le Marchand L, 2002, MUTAT RES-FUND MOL M, V506, P205, DOI 10.1016/S0027-5107(02)00167-7.
   Lewis AJ, 1998, CARCINOGENESIS, V19, P2049, DOI 10.1093/carcin/19.11.2049.
   LHALIN R, 2006, ARCH BIOCHEM BIOPHYS, V445, P261.
   Lightfoot TJ, 2000, MUTAT RES-GEN TOX EN, V472, P119, DOI 10.1016/S1383-5718(00)00134-0.
   Lilla C, 2006, CANCER EPIDEM BIOMAR, V15, P99, DOI 10.1158/1055-9965.EPI-05-0618.
   LIN DX, 1995, DRUG METAB DISPOS, V23, P518.
   LIN DX, 1994, ENVIRON HEALTH PERSP, V102, P11, DOI 10.2307/3432144.
   LIN DX, 1994, CANCER RES, V54, P4920.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   Loeb LA, 2008, CANCER RES, V68, P6863, DOI 10.1158/0008-5472.CAN-08-2852.
   LORETZ LJ, 1984, CARCINOGENESIS, V5, P895, DOI 10.1093/carcin/5.7.895.
   LUKS HJ, 1989, CANCER RES, V49, P4407.
   Lumbreras B, 2008, CANCER CAUSE CONTROL, V19, P649, DOI 10.1007/s10552-008-9121-1.
   LUTZ WK, 1992, CARCINOGENESIS, V13, P2211, DOI 10.1093/carcin/13.12.2211.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   LYNCH AM, 1993, CARCINOGENESIS, V14, P191, DOI 10.1093/carcin/14.2.191.
   LYNCH AM, 1991, CARCINOGENESIS, V12, P1067, DOI 10.1093/carcin/12.6.1067.
   Ma Q, 2007, DRUG METAB DISPOS, V35, P1009, DOI 10.1124/dmd.107.015826.
   Magagnotti C, 2003, INT J CANCER, V107, P878, DOI 10.1002/ijc.11492.
   Magagnotti C, 2000, INT J CANCER, V88, P1, DOI 10.1002/1097-0215(20001001)88:1<1::AID-IJC1>3.0.CO;2-D.
   Malfatti MA, 2001, CARCINOGENESIS, V22, P1087, DOI 10.1093/carcin/22.7.1087.
   Malfatti MA, 2006, CANCER RES, V66, P10541, DOI 10.1158/0008-5472.CAN-06-1573.
   Malfatti MA, 2004, CHEM RES TOXICOL, V17, P1137, DOI 10.1021/tx049898m.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   MALFATTI MA, 1994, CHEM RES TOXICOL, V7, P139, DOI 10.1021/tx00038a005.
   Malfatti MA, 2005, MUTAT RES-FUND MOL M, V570, P205, DOI 10.1016/j.mrfmmm.2004.11.007.
   MANABE S, 1990, J CHROMATOGR-BIOMED, V529, P125, DOI 10.1016/S0378-4347(00)83813-X.
   MANABE S, 1993, ENVIRON POLLUT, V80, P281, DOI 10.1016/0269-7491(93)90049-T.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   Mannervik B, 2005, METHOD ENZYMOL, V401, P1, DOI 10.1016/S0076-6879(05)01001-3.
   Marques MM, 1996, CHEM RES TOXICOL, V9, P99, DOI 10.1021/tx950044z.
   MARTIN CN, 1982, CANCER RES, V42, P2678.
   Martin FL, 2010, PROSTATE, V70, P1586, DOI 10.1002/pros.21194.
   MATSUMOTO T, 1981, CANCER LETT, V12, P105, DOI 10.1016/0304-3835(81)90045-8.
   Mauthe RJ, 1999, INT J CANCER, V80, P539, DOI 10.1002/(SICI)1097-0215(19990209)80:4<539::AID-IJC10>3.3.CO;2-3.
   MEERMAN JHN, 1982, CHEM-BIOL INTERACT, V39, P149, DOI 10.1016/0009-2797(82)90118-1.
   MELICK WF, 1971, J UROLOGY, V106, P220.
   Messner C, 2004, J CHROMATOGR B, V802, P19, DOI 10.1016/j.jchromb.2003.11.015.
   Metry KJ, 2007, MOL CARCINOGEN, V46, P553, DOI 10.1002/mc.20302.
   Metry KJ, 2009, DRUG METAB DISPOS, V37, P2123, DOI 10.1124/dmd.109.029512.
   MILIC BL, 1993, FOOD CHEM, V46, P273, DOI 10.1016/0308-8146(93)90118-Y.
   MILLER EC, 1947, CANCER RES, V7, P468.
   MILLER EC, 1978, CANCER RES, V38, P1479.
   MILLER EC, 1949, CANCER RES, V9, P336.
   MILLER JA, 1970, CANCER RES, V30, P559.
   MILLER JA, 1969, PROG EXP TUMOR RES, V11, P273.
   MINCHIN RF, 1992, BIOCHEM BIOPH RES CO, V185, P839, DOI 10.1016/0006-291X(92)91703-S.
   MINERS JO, 1992, BRIT J CLIN PHARMACO, V34, P359.
   MOONEY LA, 1995, CANCER EPIDEM BIOMAR, V4, P627.
   Moreno V, 2005, INT J CANCER, V113, P683, DOI 10.1002/ijc.20613.
   Muckel E, 2002, FOOD CHEM TOXICOL, V40, P1063, DOI 10.1016/S0278-6915(02)00032-7.
   MULDER GJ, 1983, ENVIRON HEALTH PERSP, V49, P27, DOI 10.2307/3429577.
   MULDER GJ, 1982, CHEM-BIOL INTERACT, V39, P111, DOI 10.1016/0009-2797(82)90010-2.
   Murkovic M, 2004, J CHROMATOGR B, V802, P3, DOI 10.1016/j.jchromb.2003.09.026.
   MURRAY S, 1989, CARCINOGENESIS, V10, P763, DOI 10.1093/carcin/10.4.763.
   Murtaugh MA, 2004, J NUTR, V134, P776.
   Nagao M, 1997, MUTAT RES-FUND MOL M, V376, P161, DOI 10.1016/S0027-5107(97)00039-0.
   Nagao M., 2000, Food borne carcinogens: heterocyclic amines., P163.
   Nagar S, 2006, ONCOGENE, V25, P1659, DOI 10.1038/sj.onc.1209375.
   Nakagama H, 2005, CANCER SCI, V96, P627, DOI 10.1111/j.1349-7006.2005.00107.x.
   Nakagama H, 2002, MUTAT RES-FUND MOL M, V506, P137, DOI 10.1016/S0027-5107(02)00160-4.
   NAKAHARA Y, 1995, BIOL PHARM BULL, V18, P1223.
   Nakajima M, 1999, J BIOCHEM-TOKYO, V125, P803.
   Nakajima M, 2006, INT J CANCER, V119, P2520, DOI 10.1002/ijc.22136.
   NAVARRET.A, 1967, CANCER, V20, P1466, DOI 10.1002/1097-0142(196709)20:9<1466::AID-CNCR2820200913>3.0.CO;2-D.
   Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200.
   Nelson CP, 2001, CANCER RES, V61, P103.
   NEUMANN HG, 1984, ARCH TOXICOL, V56, P1, DOI 10.1007/BF00316343.
   NEUMANN HG, 1988, INT ARCH OCC ENV HEA, V60, P151, DOI 10.1007/BF00378690.
   Neumann HG, 2001, CHEMOSPHERE, V42, P473, DOI 10.1016/S0045-6535(00)00219-8.
   Neumann HG, 2010, FRONT BIOSCI-LANDMRK, V15, P1119, DOI 10.2741/3665.
   Ni WJ, 2008, J AGR FOOD CHEM, V56, P68, DOI 10.1021/jf072461a.
   Nishigaki R, 2007, CANCER EPIDEM BIOMAR, V16, P151, DOI 10.1158/1055-9965.EPI-06-0052.
   NIWA T, 1982, MUTAT RES, V95, P159, DOI 10.1016/0027-5107(82)90254-8.
   Noort D, 1999, CHEM RES TOXICOL, V12, P715, DOI 10.1021/tx9900369.
   Noort D, 2003, ARCH TOXICOL, V77, P543, DOI 10.1007/s00204-003-0484-5.
   Nothlings U, 2009, CANCER EPIDEM BIOMAR, V18, P2098, DOI 10.1158/1055-9965.EPI-08-1218.
   Nowell S, 2002, MUTAT RES-FUND MOL M, V506, P175, DOI 10.1016/S0027-5107(02)00164-1.
   Nowell S, 2000, PHARMACOGENETICS, V10, P789, DOI 10.1097/00008571-200012000-00004.
   Nowell S, 2006, ONCOGENE, V25, P1673, DOI 10.1038/sj.onc.1209376.
   Nowell SA, 1999, CARCINOGENESIS, V20, P1107, DOI 10.1093/carcin/20.6.1107.
   NUSSBAUM M, 1983, ENVIRON HEALTH PERSP, V49, P223, DOI 10.2307/3429601.
   Ochiai M, 2002, JPN J CANCER RES, V93, P478.
   Ochiai M, 1999, MUTAGENESIS, V14, P239, DOI 10.1093/mutage/14.2.239.
   Ochiai M, 1996, JPN J CANCER RES, V87, P1029.
   Oda Y, 2006, MUTAGENESIS, V21, P411, DOI 10.1093/mutage/gel047.
   Oh SW, 1997, DYES PIGMENTS, V33, P119, DOI 10.1016/S0143-7208(96)00038-1.
   OHGAKI H, 1986, ENVIRON HEALTH PERSP, V67, P129, DOI 10.2307/3430327.
   Okonogi H, 1997, CANCER LETT, V111, P105, DOI 10.1016/S0304-3835(96)04505-3.
   ORZECHOWSKI A, 1994, CARCINOGENESIS, V15, P1549, DOI 10.1093/carcin/15.8.1549.
   Osswald K, 2003, MUTAT RES-REV MUTAT, V544, P321, DOI 10.1016/mrrev.2003.06.008.
   OSTERMANGOLKAR S, 1976, MUTAT RES, V34, P1, DOI 10.1016/0027-5107(76)90256-6.
   OZAWA S, 1995, JPN J CANCER RES, V86, P264.
   Ozawa S, 1999, J BIOCHEM-TOKYO, V126, P271.
   OZAWA S, 1994, JPN J CANCER RES, V85, P1220.
   Ozeki H, 1996, PIGM CELL RES, V9, P265, DOI 10.1111/j.1600-0749.1996.tb00116.x.
   Paehler A, 2002, CHEM RES TOXICOL, V15, P551, DOI 10.1021/tx010178e.
   Pais P, 2000, J CHROMATOGR B, V747, P139, DOI 10.1016/S0378-4347(00)00118-3.
   PANTUCK EJ, 1979, CLIN PHARMACOL THER, V25, P88.
   PANTUCK EJ, 1976, SCIENCE, V194, P1055, DOI 10.1126/science.982059.
   Patel DJ, 1998, CHEM RES TOXICOL, V11, P391, DOI 10.1021/tx9702143.
   PATRIANAKOS C, 1979, J ANAL TOXICOL, V3, P150.
   PETERS T, 1972, J BIOL CHEM, V247, P3858.
   Peters T. Jr, 1996, ALBUMIN BIOCH GENETI.
   PFAU W, 1993, LARC SCI PUBL.
   Pfau W, 1997, CHEM RES TOXICOL, V10, P1192, DOI 10.1021/tx9701182.
   PFAU W, 1994, CARCINOGENESIS, V15, P877, DOI 10.1093/carcin/15.5.877.
   Phillips DH, 2005, MUTAT RES-FUND MOL M, V577, P284, DOI 10.1016/j.mrfmmm.2005.03.008.
   Phillips DH, 2002, CARCINOGENESIS, V23, P1979, DOI 10.1093/carcin/23.12.1979.
   Phillips DH, 1999, MUTAGENESIS, V14, P301, DOI 10.1093/mutage/14.3.301.
   Poirier MC, 2000, CARCINOGENESIS, V21, P353, DOI 10.1093/carcin/21.3.353.
   Poirier MC, 1995, CARCINOGENESIS, V16, P2917, DOI 10.1093/carcin/16.12.2917.
   POIRIER MC, 1992, CHEM RES TOXICOL, V5, P749, DOI 10.1021/tx00030a003.
   RADOMSKI JL, 1977, CANCER RES, V37, P1757.
   RADOMSKI JL, 1970, SCIENCE, V167, P992, DOI 10.1126/science.167.3920.992.
   Randall KL, 2010, J CHROMATOGR A, V1217, P4135, DOI 10.1016/j.chroma.2009.11.006.
   RANDERATH K, 1985, ENVIRON HEALTH PERSP, V62, P57, DOI 10.2307/3430093.
   RAPPAPORT SM, TOXICOL LETT IN PRES.
   Raza H, 1996, DRUG METAB DISPOS, V24, P395.
   Rehn L, 1895, ARCH KLIN CHIR, V50, P588.
   Reisch MS, 2003, CHEM ENG NEWS, V81, P25.
   REISTAD R, 1994, CARCINOGENESIS, V15, P2547, DOI 10.1093/carcin/15.11.2547.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   Reistad R, 1999, BIOMARKERS, V4, P263.
   REUTERSWARD AL, 1987, FOOD CHEM TOXICOL, V25, P747.
   RICH KJ, 1992, CARCINOGENESIS, V13, P2221, DOI 10.1093/carcin/13.12.2221.
   Richter E, 2002, J CHROMATOGR B, V778, P49, DOI 10.1016/S0378-4347(01)00466-2.
   Ricicki EM, 2005, CHEM RES TOXICOL, V18, P692, DOI 10.1021/tx0496921.
   Riedel K, 2006, J ANAL TOXICOL, V30, P187.
   Riffelmann M, 1995, INT ARCH OCC ENV HEA, V68, P36.
   RINGE D, 1988, CHEM RES TOXICOL, V1, P22, DOI 10.1021/tx00001a003.
   Romano G, 1997, ANTICANCER RES, V17, P2827.
   ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G.
   Rothman N, 1997, CANCER EPIDEM BIOMAR, V6, P1039.
   Rothman N, 1996, P NATL ACAD SCI USA, V93, P5084, DOI 10.1073/pnas.93.10.5084.
   Rundle A, 2006, MUTAT RES-FUND MOL M, V600, P23, DOI 10.1016/j.mrfmmm.2006.05.031.
   Sabbioni G, 2002, BIOMARKERS, V7, P347, DOI 10.1080/13547500210147253.
   SABBIONI G, 1987, CARCINOGENESIS, V8, P819, DOI 10.1093/carcin/8.6.819.
   Sachse C, 2003, BRIT J CLIN PHARMACO, V55, P68, DOI 10.1046/j.1365-2125.2003.01733.x.
   SAITO K, 1983, CARCINOGENESIS, V4, P1551, DOI 10.1093/carcin/4.12.1551.
   Schmeiser HH, 2009, CURR OPIN DRUG DISC, V12, P141.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   Schwab CE, 2000, CRIT REV TOXICOL, V30, P1, DOI 10.1080/1040844041696481.
   SCHWEIKL H, 1993, PHARMACOGENETICS, V3, P239, DOI 10.1097/00008571-199310000-00003.
   SCRIBNER JD, 1979, CHEM-BIOL INTERACT, V26, P11, DOI 10.1016/0009-2797(79)90090-5.
   SEGERBACK D, 1993, CARCINOGENESIS, V14, P2143, DOI 10.1093/carcin/14.10.2143.
   SEGERBACK D, 1992, CARCINOGENESIS, V13, P1587, DOI 10.1093/carcin/13.9.1587.
   Seyler TH, 2011, BIOMARKERS, V16, P212, DOI 10.3109/1354750X.2010.544755.
   Shertzer HG, 2002, TOXICOL APPL PHARM, V181, P32, DOI 10.1006/taap.2002.9398.
   Shibutani S, 1999, J BIOL CHEM, V274, P27433, DOI 10.1074/jbc.274.39.27433.
   Shibutani S, 1998, BIOCHEMISTRY-US, V37, P12034, DOI 10.1021/bi981059+.
   Shimada T, 1996, CANCER RES, V56, P2979.
   SHIMADA T, 1989, CANCER RES, V49, P3218.
   SHIMADA T, 1991, CANCER RES, V51, P5284.
   SHINOHARA A, 1986, CANCER RES, V46, P4362.
   SHINOHARA A, 1984, CARCINOGENESIS, V5, P683, DOI 10.1093/carcin/5.5.683.
   SHIOYA M, 1987, MUTAT RES, V191, P133, DOI 10.1016/0165-7992(87)90143-6.
   Shirai T, 1997, CANCER RES, V57, P195.
   Singh R, 2006, CARCINOGENESIS, V27, P178, DOI 10.1093/carcin/bgi260.
   Singh R, 2010, J CHROMATOGR B, V878, P2155, DOI 10.1016/j.jchromb.2010.06.008.
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P289, DOI 10.1016/S0278-6915(97)00159-2.
   SINHA R, 1994, CANCER RES, V54, P6154.
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P279, DOI 10.1016/S0278-6915(97)00162-2.
   SINHA R, 1995, CANCER RES, V55, P4516.
   SINHA R, 1995, CARCINOGENESIS, V16, P2859, DOI 10.1093/carcin/16.11.2859.
   Sinha R, 2001, CANCER EPIDEM BIOMAR, V10, P559.
   Sinha R, 2002, MUTAT RES-FUND MOL M, V506, P197, DOI 10.1016/S0027-5107(02)00166-5.
   SJODIN P, 1989, CARCINOGENESIS, V10, P1269, DOI 10.1093/carcin/10.7.1269.
   Skipper PL, 2010, CARCINOGENESIS, V31, P50, DOI 10.1093/carcin/bgp267.
   SKIPPER PL, 1994, METHOD ENZYMOL, V231, P643.
   SKIPPER PL, 1990, CARCINOGENESIS, V11, P507, DOI 10.1093/carcin/11.4.507.
   SKIPPER PL, 1994, DRUG METAB REV, V26, P111, DOI 10.3109/03602539409029787.
   Skipper PL, 2006, CHEM RES TOXICOL, V19, P1086, DOI 10.1021/tx060082q.
   SKIPPER PL, 1985, CANCER RES, V45, P5122.
   Skipper PL, 2003, CANCER EPIDEM BIOMAR, V12, P503.
   Skog K, 1998, J CHROMATOGR A, V803, P227, DOI 10.1016/S0021-9673(97)01266-1.
   SKOG K, 1995, CARCINOGENESIS, V16, P861, DOI 10.1093/carcin/16.4.861.
   Skog K, 2002, FOOD CHEM TOXICOL, V40, P1213, DOI 10.1016/S0278-6915(02)00062-5.
   Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1.
   Smith CJ, 2004, J CHROMATOGR A, V1046, P211, DOI 10.1016/j.chroma.2004.06.082.
   Snyderwine EG, 1997, MUTAT RES-FUND MOL M, V376, P203, DOI 10.1016/S0027-5107(97)00044-4.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V13, P2517.
   SNYDERWINE EG, 1995, CARCINOGENESIS, V16, P1377, DOI 10.1093/carcin/16.6.1377.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1061, DOI 10.1093/carcin/9.6.1061.
   Snyderwine EG, 2002, ENVIRON MOL MUTAGEN, V39, P165, DOI 10.1002/em.10053.
   SNYDERWINE EG, 1992, CHEM RES TOXICOL, V5, P843, DOI 10.1021/tx00030a018.
   Snyderwine EG, 2002, FOOD CHEM TOXICOL, V40, P1529, DOI 10.1016/S0278-6915(02)00110-2.
   Soglia JR, 2001, ANAL CHEM, V73, P2819, DOI 10.1021/ac010218j.
   Spivack SD, 2004, CANCER RES, V64, P6805, DOI 10.1158/0008-5472.CAN-04-1771.
   SQUIER CA, 1976, HUMAN ORAL MUCOSA DE, P3.
   Stabbert R, 2003, RAPID COMMUN MASS SP, V17, P2125, DOI 10.1002/rcm.1161.
   STAVRIC B, 1979, J ASSOC OFF ANA CHEM, V62, P1020.
   Steffensen IL, 2000, PHARMACOL TOXICOL, V86, P257, DOI 10.1111/j.0901-9928.2000.860603.x.
   Steiner M, 2000, ARCH TOXICOL, V74, P222, DOI 10.1007/s002040000118.
   STILLWELL WG, 1994, CANCER EPIDEM BIOMAR, V3, P399.
   Stillwell WG, 2002, CARCINOGENESIS, V23, P831, DOI 10.1093/carcin/23.5.831.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   Stillwell WG, 1999, CANCER LETT, V143, P145, DOI 10.1016/S0304-3835(99)00144-5.
   Stillwell WG, 1999, CANCER RES, V59, P5154.
   STONE JG, 1995, CANCER RES, V55, P1267.
   Stover JS, 2006, CHEM RES TOXICOL, V19, P1506, DOI 10.1021/tx0601455.
   Stover JS, 2007, CHEM RES TOXICOL, V20, P1972, DOI 10.1021/tx7002867.
   Strassburg CP, 1999, BIOCHEM J, V338, P489, DOI 10.1042/0264-6021:3380489.
   Strassburg CP, 2002, GUT, V50, P851, DOI 10.1136/gut.50.6.851.
   Strickland PT, 2002, MUTAT RES-FUND MOL M, V506, P163, DOI 10.1016/S0027-5107(02)00163-X.
   Strickland PT, 2001, BIOMARKERS, V6, P313.
   STYCZYNSKI PB, 1993, CHEM RES TOXICOL, V6, P846, DOI 10.1021/tx00036a014.
   Sugamori KS, 2006, DRUG METAB DISPOS, V34, P1697, DOI 10.1124/dmd.106.010819.
   SUGIMURA T, 1982, CANCER, V49, P1970, DOI 10.1002/1097-0142(19820515)49:10<1970::AID-CNCR2820491005>3.0.CO;2-F.
   SUGIMURA T, 1992, SCIENCE, V258, P603, DOI 10.1126/science.1411570.
   Sugimura T, 2004, CANCER SCI, V95, P290, DOI 10.1111/j.1349-7006.2004.tb03205.x.
   Sullivan MX, 1911, J AM CHEM SOC, V33, P2035, DOI 10.1021/ja02225a019.
   SUTTER TR, 1994, J BIOL CHEM, V269, P13092.
   Swaminathan S, 2002, CHEM-BIOL INTERACT, V139, P199, DOI 10.1016/S0009-2797(01)00300-3.
   Sweeney C, 2002, TOXICOLOGY, V181, P83, DOI 10.1016/S0300-483X(02)00259-7.
   TADA A, 1994, CARCINOGENESIS, V15, P1275, DOI 10.1093/carcin/15.6.1275.
   Takamura-Enya T, 2006, CHEM RES TOXICOL, V19, P770, DOI 10.1021/tx050296s.
   TAKAYAMA S, 1985, P JPN ACAD B-PHYS, V61, P277.
   Takiguchi M, 2010, TOXICOL SCI, V116, P79, DOI 10.1093/toxsci/kfq087.
   TALASKA G, 1991, CANCER EPIDEM BIOMAR, V1, P61.
   Talaska G, 2003, J ENVIRON SCI HEAL C, V21, P133, DOI 10.1081/GNC-120023534.
   TALASKA G, 1991, P NATL ACAD SCI USA, V88, P5350, DOI 10.1073/pnas.88.12.5350.
   Tang DL, 2007, CANCER EPIDEM BIOMAR, V16, P803, DOI 10.1158/1055-9965.EPI-06-0973.
   TANNENBAUM SR, 1993, ENVIRON HEALTH PERSP, V99, P51, DOI 10.2307/3431457.
   Teubner W, 2007, BIOCHEM J, V404, P207, DOI 10.1042/BJ20061431.
   Teunissen SF, 2010, J CHROMATOGR B, V878, P3199, DOI 10.1016/j.jchromb.2010.10.018.
   THIEBAUD HP, 1995, FOOD CHEM TOXICOL, V33, P821, DOI 10.1016/0278-6915(95)00057-9.
   Thompson PA, 2002, ENVIRON MOL MUTAGEN, V39, P134, DOI 10.1002/em.10067.
   Tiemersma EW, 2004, INT J CANCER, V108, P97, DOI 10.1002/ijc.11533.
   TOKIWA H, 1985, MUTAT RES, V157, P39, DOI 10.1016/0165-1218(85)90047-3.
   Tornqvist M, 2002, J CHROMATOGR B, V778, P279, DOI 10.1016/S1570-0232(02)00172-1.
   Totsuka T., 2006, ACRYLAMIDE OTHER HAZ, P296.
   Totsuka Y, 1999, CANCER LETT, V143, P139, DOI 10.1016/S0304-3835(99)00143-3.
   Totsuka Y, 1996, CARCINOGENESIS, V17, P1029, DOI 10.1093/carcin/17.5.1029.
   Tsuneoka Y, 2003, J NATL CANCER I, V95, P1227, DOI 10.1093/jnci/djg025.
   Turesky RJ, 2007, TOXICOL LETT, V168, P219, DOI 10.1016/j.toxlet.2006.10.018.
   Turesky RJ, 2003, CHEM RES TOXICOL, V16, P1162, DOI 10.1021/tx030029r.
   TURESKY RJ, 1988, CARCINOGENESIS, V9, P1043, DOI 10.1093/carcin/9.6.1043.
   TURESKY RJ, 1987, CARCINOGENESIS, V8, P1537, DOI 10.1093/carcin/8.10.1537.
   Turesky RJ, 1996, CHEM RES TOXICOL, V9, P403, DOI 10.1021/tx950132j.
   Turesky RJ, 1997, MUTAT RES-FUND MOL M, V376, P235, DOI 10.1016/S0027-5107(97)00048-1.
   TURESKY RJ, 1988, FOOD CHEM TOXICOL, V26, P105, DOI 10.1016/0278-6915(88)90106-8.
   Turesky RJ, 2004, CURR DRUG METAB, V5, P169, DOI 10.2174/1389200043489036.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P217, DOI 10.1021/tx9701891.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1847, DOI 10.1093/carcin/12.10.1847.
   TURESKY RJ, 1986, CARCINOGENESIS, V7, P1483, DOI 10.1093/carcin/7.9.1483.
   TURESKY RJ, 1995, HETEROCYCLIC AMINES, P59.
   Turesky RJ, 2006, WOODHEAD PUBL FOOD S, P247, DOI 10.1533/9781845692018.2.247.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P925, DOI 10.1021/tx980022n.
   TURESKY RJ, 1990, CHEM RES TOXICOL, V3, P524, DOI 10.1021/tx00018a006.
   TURESKY RJ, 1994, DNA ADDUCTS IDENTIFI, P217.
   Turesky RJ, 1996, CHEM RES TOXICOL, V9, P397, DOI 10.1021/tx950131r.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   Turesky RJ, 2004, J CHROMATOGR B, V802, P155, DOI 10.1016/j.jchromb.2003.10.053.
   TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005.
   TURESKY RJ, 1994, ENVIRON HEALTH PERSP, V102, P47, DOI 10.2307/3432151.
   TURESKY RJ, 1995, CARCINOGENESIS, V16, P2275, DOI 10.1093/carcin/16.9.2275.
   Turesky RJ, 2009, CHEM RES TOXICOL, V22, P726, DOI 10.1021/tx800473w.
   Turesky RJ, 2002, MUTAT RES-FUND MOL M, V506, P187, DOI 10.1016/S0027-5107(02)00165-3.
   Turesky RJ, 2005, MOL NUTR FOOD RES, V49, P101, DOI 10.1002/mnfr.200400076.
   Turesky RJ, 2007, CANCER EPIDEM BIOMAR, V16, P1554, DOI 10.1158/1055-9965.EPI-07-0132.
   Turesky RJ, 2001, CHEM RES TOXICOL, V14, P901, DOI 10.1021/tx010035s.
   Turteltaub KW, 1999, CANCER LETT, V143, P149, DOI 10.1016/S0304-3835(99)00116-0.
   Turteltaub KW, 1997, MUTAT RES-FUND MOL M, V376, P243, DOI 10.1016/S0027-5107(97)00049-3.
   TURTELTAUB KW, 1990, P NATL ACAD SCI USA, V87, P5288, DOI 10.1073/pnas.87.14.5288.
   Ubagai T, 2002, CARCINOGENESIS, V23, P197, DOI 10.1093/carcin/23.1.197.
   UMEMOTO A, 1988, CHEM-BIOL INTERACT, V68, P57, DOI 10.1016/0009-2797(88)90006-3.
   UMEMOTO A, 1988, BIOCHEM BIOPH RES CO, V151, P1326, DOI 10.1016/S0006-291X(88)80507-2.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   VANTASSELL RL, 1990, MUTAT RES, V238, P209, DOI 10.1016/0165-1110(90)90013-2.
   van der Logt EMJ, 2004, CARCINOGENESIS, V25, P2407, DOI 10.1093/carcin/bgh251.
   Vineis P, 1996, CANCER CAUSE CONTROL, V7, P479, DOI 10.1007/BF00052675.
   VISTISEN K, 1992, CARCINOGENESIS, V13, P1561, DOI 10.1093/carcin/13.9.1561.
   Vondracek M, 2001, CARCINOGENESIS, V22, P481, DOI 10.1093/carcin/22.3.481.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WALLIN H, 1989, CARCINOGENESIS, V10, P1277, DOI 10.1093/carcin/10.7.1277.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   WALPOLE AL, 1952, BRIT J IND MED, V9, P255.
   Walters DG, 2004, CARCINOGENESIS, V25, P1659, DOI 10.1093/carcin/bgh164.
   Wang F, 2006, J AM CHEM SOC, V128, P10085, DOI 10.1021/ja062004v.
   Wang HS, 2011, CARCINOGENESIS, V32, P203, DOI 10.1093/carcin/bgq237.
   Wang LY, 1998, AM J EPIDEMIOL, V147, P315.
   Ward EM, 1996, J NATL CANCER I, V88, P1046, DOI 10.1093/jnci/88.15.1046.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P2291, DOI 10.1093/carcin/12.12.2291.
   Weisburger J H, 1995, Princess Takamatsu Symp, V23, P240.
   WEISBURGER JH, 1966, CHEM ENG NEWS, V44, P124, DOI 10.1021/cen-v044n006.p124.
   WEISBURGER JH, 1964, CANCER RES, V24, P475.
   Weiss T, 2002, J CHROMATOGR B, V778, P179, DOI 10.1016/S0378-4347(01)00542-4.
   Welfare MR, 1997, CARCINOGENESIS, V18, P1351, DOI 10.1093/carcin/18.7.1351.
   WESTRA JG, 1976, CHEM-BIOL INTERACT, V15, P149, DOI 10.1016/0009-2797(76)90160-5.
   Whitlock JP, 1997, DRUG METAB REV, V29, P1107, DOI 10.3109/03602539709002245.
   Wiese FW, 2001, CARCINOGENESIS, V22, P5, DOI 10.1093/carcin/22.1.5.
   WILD CP, 1992, CANCER EPIDEM BIOMAR, V1, P229.
   WILD D, 1995, CARCINOGENESIS, V16, P643, DOI 10.1093/carcin/16.3.643.
   Williams JA, 2001, PHARMACOGENETICS, V11, P373, DOI 10.1097/00008571-200107000-00002.
   Williams JA, 2001, CARCINOGENESIS, V22, P209, DOI 10.1093/carcin/22.2.209.
   Williams JA, 1998, PHARMACOGENETICS, V8, P519, DOI 10.1097/00008571-199812000-00009.
   Williams JA, 2000, MUTAGENESIS, V15, P149, DOI 10.1093/mutage/15.2.149.
   Winsten J. A., 1977, ORIGINS HUMAN CANC, P1561.
   WISE RW, 1984, CANCER RES, V44, P1893.
   Wogan GN, 2004, SEMIN CANCER BIOL, V14, P473, DOI 10.1016/j.semcancer.2004.06.010.
   Wolz E, 2000, FOOD CHEM TOXICOL, V38, P513, DOI 10.1016/S0278-6915(00)00038-7.
   WOLZ E, 1995, ARCH TOXICOL, V69, P171, DOI 10.1007/s002040050154.
   Wu K, 2006, CANCER EPIDEM BIOMAR, V15, P1120, DOI 10.1158/1055-9965.EPI-05-0782.
   Wu RW, 1997, MUTAT RES-GEN TOX EN, V390, P93, DOI 10.1016/S0165-1218(97)00005-0.
   Wu RW, 2000, ENVIRON MOL MUTAGEN, V35, P57, DOI 10.1002/(SICI)1098-2280(2000)35:1<57::AID-EM8>3.0.CO;2-7.
   YAMASHITA M, 1986, JPN J CANCER RES, V77, P419.
   YAMAZAKI H, 1995, CARCINOGENESIS, V16, P2167, DOI 10.1093/carcin/16.9.2167.
   YAMAZOE Y, 1981, CANCER RES, V41, P4518.
   YAMAZOE Y, 1986, CARCINOGENESIS, V7, P179, DOI 10.1093/carcin/7.1.179.
   Yamazoe Y., 2000, FOOD BORNE CARCINOGE, P74.
   YAMAZOE Y, 1988, CARCINOGENESIS, V9, P105, DOI 10.1093/carcin/9.1.105.
   YAMAZOE Y, 1985, CARCINOGENESIS, V6, P1379, DOI 10.1093/carcin/6.9.1379.
   YAMAZOE Y, 1985, CANCER RES, V45, P2495.
   Yamazoe Y, 1995, Princess Takamatsu Symp, V23, P154.
   YAMAZOE Y, 1983, CANCER RES, V43, P5768.
   Yang CC, 1998, CARCINOGENESIS, V19, P359, DOI 10.1093/carcin/19.2.359.
   YOSHIDA D, 1978, BIOCHEM BIOPH RES CO, V83, P915, DOI 10.1016/0006-291X(78)91482-1.
   YOSHIDA D, 1980, CANCER LETT, V10, P141, DOI 10.1016/0304-3835(80)90037-3.
   Yu MC, 2002, MUTAT RES-FUND MOL M, V506, P21, DOI 10.1016/S0027-5107(02)00148-3.
   YU MC, 1994, J NATL CANCER I, V86, P712, DOI 10.1093/jnci/86.9.712.
   Yuan ZX, 2007, CHEM RES TOXICOL, V20, P497, DOI 10.1021/tx600303d.
   Yueh MF, 2001, CARCINOGENESIS, V22, P943, DOI 10.1093/carcin/22.6.943.
   YUN CH, 1992, CARCINOGENESIS, V13, P217, DOI 10.1093/carcin/13.2.217.
   ZAVON MR, 1973, ARCH ENVIRON HEALTH, V27, P1.
   Zayas B, 2007, CARCINOGENESIS, V28, P342, DOI 10.1093/carcin/bgl142.
   Zenser TV, 1998, DRUG METAB DISPOS, V26, P856.
   Zenser TV, 2001, DRUG METAB DISPOS, V29, P401.
   ZENSER TV, 1980, CANCER RES, V40, P2839.
   Zenser TV, 2002, MUTAT RES-FUND MOL M, V506, P29, DOI 10.1016/S0027-5107(02)00149-5.
   Zenser TV, 1996, CANCER RES, V56, P3941.
   Zenser TV, 2009, MUTAT RES-GEN TOX EN, V673, P109, DOI 10.1016/j.mrgentox.2008.12.007.
   Zenser TV, 1999, DRUG METAB DISPOS, V27, P1064.
   Zha Q, 2002, J CHROMATOGR SCI, V40, P403.
   Zhang LQ, 2011, NICOTINE TOB RES, V13, P120, DOI 10.1093/ntr/ntq219.
   Zhang XB, 1996, CARCINOGENESIS, V17, P2259, DOI 10.1093/carcin/17.10.2259.
   ZHANG YJ, 1995, CANCER EPIDEM BIOMAR, V4, P133.
   ZHAO K, 1994, CARCINOGENESIS, V15, P1285, DOI 10.1093/carcin/15.6.1285.
   Zheng W, 2009, NUTR CANCER, V61, P437, DOI 10.1080/01635580802710741.
   Zheng W, 2001, CANCER EPIDEM BIOMAR, V10, P89.
   Zhou Q, 1997, MUTAT RES-GEN TOX EN, V393, P199, DOI 10.1016/S1383-5718(97)00097-1.
   Zhu J, 2006, BIOMARKERS, V11, P319, DOI 10.1080/13547500600667911.
   Zhu JJ, 2003, CANCER EPIDEM BIOMAR, V12, P830.
   {*}AICR, 2007, FOOD NUTR PHYS ACT P.
   {*}INT AG RES CANC, 1987, IARC MON EV CARC R S, V7.
   {*}INT AG RES CANC, 2010, IARC MON EV CARC RIS, V99.
   {*}NAT TOX PROG, 2005, NAT TOX PROGR REP CA.}},
Number-of-Cited-References = {{646}},
Times-Cited = {{24}},
Journal-ISO = {{Chem. Res. Toxicol.}},
Doc-Delivery-Number = {{809SE}},
Wos-Id = {{ISI:000294076200002}},
}

@article{ ISI:000291896700016,
Author = {Nauwelaers, Gwendoline and Bessette, Erin E. and Gu, Dan and Tang, Yijin
   and Rageul, Julie and Fessard, Valerie and Yuan, Jian-Min and Yu, Mimi
   C. and Langouet, Sophie and Turesky, Robert J.},
Title = {{DNA Adduct Formation of 4-Aminobiphenyl and Heterocyclic Aromatic Amines
   in Human Hepatocytes}},
Journal = {{CHEMICAL RESEARCH IN TOXICOLOGY}},
Year = {{2011}},
Volume = {{24}},
Number = {{6}},
Pages = {{913-925}},
Month = {{JUN}},
Abstract = {{DNA adduct formation of the aromatic amine, 4-aminobiphenyl (4-ABP), a
   known human carcinogen present in tobacco smoke, and the heterocyclic
   aromatic amines (HAAs), 2-amino-9H-pyrido{[}2,3-b]indole (A alpha C),
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP),
   2-amino-3-methylimidazo{[}4,5-f]quinoline (IQ), and
   2-amino-3,8-dimethylmidazo{[}4,5-f]quinoxaline (MeIQx), potential human
   carcinogens, which are also present in tobacco smoke or formed during
   the high-temperature cooking of meats, was investigated in freshly
   cultured human hepatocytes. The carcinogens (10 mu M) were incubated
   with hepatocytes derived from eight different donors for time periods up
   to 24 h. The DNA adducts were quantified by liquid
   chromatography-electrospray ionization mass spectrometry with a linear
   quadrupole ion trap mass spectrometer. The principal DNA adducts formed
   for all of the carcinogens were N-(deoxyguanosin-8-yl) (dG-C8) adducts.
   The levels of adducts ranged from 3.4 to 140 adducts per 10(7) DNA
   bases. The highest level of adduct formation occurred with A alpha C,
   followed by 4-ABP, then by PhIP, MeIQx, and IQ Human hepatocytes formed
   dG-C8-HAA-adducts at levels that were up to 100-fold greater than the
   amounts of adducts produced in rat hepatocytes. In contrast to HAA
   adducts, the levels of dG-C8-4-ABP adduct formation were similar in
   human and rat hepatocytes. These DNA binding data demonstrate that the
   rat, an animal model that is used for carcinogenesis bioassays,
   significantly underestimates the potential hepatic genotoxicity of HAAs
   in humans. The high level of DNA adducts formed by A alpha C, a
   carcinogen produced in tobacco smoke at levels that are up to 100-fold
   higher than the amounts of 4-ABP, is noteworthy. The possible causal
   role of A alpha C in tobacco-associated cancers warrants investigation.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Langouet, S (Reprint Author), Univ Rennes 1, IFR 140, SeRAIC EA4427, Inst Rech Sante Environm Travail, 2 Ave Pr L Bernard, F-35043 Rennes, France.
   Nauwelaers, Gwendoline; Rageul, Julie; Langouet, Sophie, Univ Rennes 1, IFR 140, SeRAIC EA4427, Inst Rech Sante Environm Travail, F-35043 Rennes, France.
   Bessette, Erin E.; Gu, Dan; Tang, Yijin; Turesky, Robert J., New York State Dept Hlth, Wadsworth Ctr, Div Environm Hlth Sci, Albany, NY 12201 USA.
   Fessard, Valerie, La Haute Marche Javene, Anses Lab Fougeres, F-35302 Fougeres, France.
   Yuan, Jian-Min; Yu, Mimi C., Univ Minnesota, Mason Comprehens Canc Ctr, Minneapolis, MN 55455 USA.}},
DOI = {{10.1021/tx200091y}},
ISSN = {{0893-228X}},
Keywords-Plus = {{CIGARETTE-SMOKE CONDENSATE; A-ALPHA-C; SLOW ACETYLATOR
   N-ACETYLTRANSFERASE-2; CHROMATOGRAPHY-MASS SPECTROMETRY; DIESEL-EXHAUST
   PARTICLES; CANCER-RISK ASSESSMENT; FOOD-BORNE CARCINOGEN; IN-VITRO;
   METABOLIC-ACTIVATION; LIVER-MICROSOMES}},
Research-Areas = {{Pharmacology \& Pharmacy; Chemistry; Toxicology}},
Web-of-Science-Categories  = {{Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology}},
Author-Email = {{sophie.langouet@univ-rennes1.fr
   Rturesky@wadsworth.org}},
ResearcherID-Numbers = {{yang, min/G-3030-2011}},
Funding-Acknowledgement = {{National Cancer Institute {[}R01 CA122320, R01 CA134700, R01 CA80205,
   R01 CA98497, R01 CA144034]; Inserm, la Ligue contre le cancer; region
   Bretagne and Anses; College Doctoral International of the Universite
   Europeenne de Bretagne}},
Funding-Text = {{This work was funded by R01 CA122320 (to E.E.B., D.G, and R.J.T.) and
   R01 CA134700 (to E.E.B, Y.T., and R.J.T.) from the National Cancer
   Institute, and also partially supported by R01 CA80205 (to M.C.Y.), R01
   CA98497 (to J.-M.Y.), and R01 CA144034 (to J.-M.Y.) from the National
   Cancer Institute. We also thank Inserm, la Ligue contre le cancer, the
   region Bretagne and Anses (to G.N. and S.L.) for financial aid and
   College Doctoral International of the Universite Europeenne de Bretagne
   for travel fellowship (to G.N.).}},
Cited-References = {{Akyuz M, 2008, J PHARMACEUT BIOMED, V47, P68, DOI 10.1016/j.jpba.2007.12.011.
   Alexander J., 1995, HETEROCYCLIC AMINES, P59.
   Aninat C, 2006, DRUG METAB DISPOS, V34, P75, DOI 10.1124/dmd.105.006759.
   BEACH AC, 1992, CARCINOGENESIS, V13, P1053, DOI 10.1093/carcin/13.7.1053.
   Beland FA, 1999, CHEM RES TOXICOL, V12, P68, DOI 10.1021/tx980172y.
   BELAND FA, 1985, ENVIRON HEALTH PERSP, V62, P19, DOI 10.2307/3430089.
   Bendaly J, 2009, MUTAT RES-FUND MOL M, V671, P13, DOI 10.1016/j.mrfmmm.2009.08.003.
   Bendaly J, 2007, CANCER EPIDEM BIOMAR, V16, P1503, DOI 10.1158/1055-9965.EPI-07-0305.
   Bessette EE, 2010, CHEM RES TOXICOL, V23, P1234, DOI 10.1021/tx100098f.
   Bessette EE, 2009, ANAL CHEM, V81, P809, DOI 10.1021/ac802096p.
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999.
   BURKE MD, 1983, CHEM-BIOL INTERACT, V45, P243.
   BUTLER MA, 1989, P NATL ACAD SCI USA, V86, P7696, DOI 10.1073/pnas.86.20.7696.
   Chiang TA, 1999, FOOD CHEM TOXICOL, V37, P125.
   Cioni F, 1999, RAPID COMMUN MASS SP, V13, P1833, DOI 10.1002/(SICI)1097-0231(19990930)13:18<1833::AID-RCM725>3.0.CO;2-R.
   Clayson DB, 1981, NATL CANCER I MONOGR, V58, P15.
   DAVIS VM, 1993, J CHROMATOGR, V635, P160, DOI 10.1016/0021-9673(93)83128-F.
   Doerge DR, 1999, CARCINOGENESIS, V20, P1055, DOI 10.1093/carcin/20.6.1055.
   EUGSTER HP, 1993, DRUG METAB DISPOS, V21, P43.
   Felton J. S., 2000, Food borne carcinogens: heterocyclic amines., P31.
   Frederiksen H, 2004, CARCINOGENESIS, V25, P1525, DOI 10.1093/carcin/bgh156.
   Frederiksen H, 2004, FOOD CHEM TOXICOL, V42, P879, DOI 10.1016/j.fct.2004.01.011.
   Frederiksen H, 2003, PHARMACOL TOXICOL, V92, P246, DOI 10.1034/j.1600-0773.2003.920508.x.
   Garrigos MC, 2002, J CHROMATOGR A, V976, P309, DOI 10.1016/S0021-9673(02)01162-7.
   Glatt H, 2006, WOODHEAD PUBL FOOD S, P358, DOI 10.1533/9781845692018.2.358.
   Goodenough AK, 2007, CHEM RES TOXICOL, V20, P263, DOI 10.1021/tx0601713.
   Gu D, 2011, ANAL CHEM, V83, P1093, DOI 10.1021/ac102918b.
   Gu D, 2010, CHEM RES TOXICOL, V23, P788, DOI 10.1021/tx900436m.
   Guengerich FP, 1997, CHEM-BIOL INTERACT, V106, P161, DOI 10.1016/S0009-2797(97)00068-9.
   Guillouzo A, 1997, J HEPATOL, V26, P73, DOI 10.1016/S0168-8278(97)80499-0.
   Hecht SS, 2003, NAT REV CANCER, V3, P733, DOI 10.1038/nrc1190.
   International Agency for Research on Cancer, 2004, IARC MON EV CARC RIS, V83.
   International Agency for Research on Cancer, 1987, IARC MON EV CARC R S, V7, P1.
   International Agency for Research on Cancer, 1986, IARC MON EV CARC RIS, V38.
   Jarabek AM, 2009, CRIT REV TOXICOL, V39, P659, DOI 10.1080/10408440903164155.
   Jones CR, 2003, CHEM RES TOXICOL, V16, P1251, DOI 10.1021/tx020064i.
   KADLUBAR FF, 1985, POLYCYCLIC HYDROCARB, P332.
   KATO R, 1986, CRIT REV TOXICOL, V16, P307, DOI 10.3109/10408448609037466.
   King RS, 1999, CANCER LETT, V143, P167, DOI 10.1016/S0304-3835(99)00119-6.
   King RS, 2000, CARCINOGENESIS, V21, P1347, DOI 10.1093/carcin/21.7.1347.
   Kulp KS, 2004, J CHROMATOGR B, V802, P143, DOI 10.1016/j.jchromb.2003.09.032.
   Lancaster FE, 1999, FOOD ADDIT CONTAM, V16, P381, DOI 10.1080/026520399283867.
   Langouet S, 2002, CARCINOGENESIS, V23, P115, DOI 10.1093/carcin/23.1.115.
   LANGOUET S, 1995, CANCER RES, V55, P5574.
   Langouet S, 2001, CHEM RES TOXICOL, V14, P211, DOI 10.1021/tx000176e.
   LIN DX, 1994, CANCER RES, V54, P4920.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   LUCERI F, 1993, TOXICOL IND HEALTH, V9, P405.
   Malfatti MA, 2006, CANCER RES, V66, P10541, DOI 10.1158/0008-5472.CAN-06-1573.
   MANABE S, 1991, ENVIRON POLLUT, V70, P255, DOI 10.1016/0269-7491(91)90013-M.
   MANABE S, 1993, ENVIRON POLLUT, V80, P281, DOI 10.1016/0269-7491(93)90049-T.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   Metry KJ, 2007, MOL CARCINOGEN, V46, P553, DOI 10.1002/mc.20302.
   Nelson CP, 2001, CANCER RES, V61, P103.
   Oh SW, 1997, DYES PIGMENTS, V33, P119, DOI 10.1016/S0143-7208(96)00038-1.
   Okonogi H, 1997, CANCER LETT, V111, P105, DOI 10.1016/S0304-3835(96)04505-3.
   ORZECHOWSKI A, 1994, CARCINOGENESIS, V15, P489, DOI 10.1093/carcin/15.3.489.
   Otteneder M, 1999, MUTAT RES-FUND MOL M, V424, P237, DOI 10.1016/S0027-5107(99)00022-6.
   Paehler A, 2002, CHEM RES TOXICOL, V15, P551, DOI 10.1021/tx010178e.
   PATRIANAKOS C, 1979, J ANAL TOXICOL, V3, P150.
   POIRIER MC, 1992, CHEM RES TOXICOL, V5, P749, DOI 10.1021/tx00030a003.
   Raza H, 1996, DRUG METAB DISPOS, V24, P395.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P279, DOI 10.1016/S0278-6915(97)00162-2.
   Skipper PL, 2003, CANCER EPIDEM BIOMAR, V12, P503.
   Smith CJ, 2004, J CHROMATOGR A, V1046, P211, DOI 10.1016/j.chroma.2004.06.082.
   STAVRIC B, 1979, J ASSOC OFF ANA CHEM, V62, P1020.
   SUGIMURA T, 1982, CANCER, V49, P1970, DOI 10.1002/1097-0142(19820515)49:10<1970::AID-CNCR2820491005>3.0.CO;2-F.
   Sugimura T, 2004, CANCER SCI, V95, P290, DOI 10.1111/j.1349-7006.2004.tb03205.x.
   TANAKA T, 1985, JPN J CANCER RES, V76, P570.
   TOKIWA H, 1985, MUTAT RES, V157, P39, DOI 10.1016/0165-1218(85)90047-3.
   Turesky RJ, 2003, CHEM RES TOXICOL, V16, P1162, DOI 10.1021/tx030029r.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P925, DOI 10.1021/tx980022n.
   TURESKY RJ, 1990, CHEM RES TOXICOL, V3, P524, DOI 10.1021/tx00018a006.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   Turesky RJ, 2004, J CHROMATOGR B, V802, P155, DOI 10.1016/j.jchromb.2003.10.053.
   TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005.
   Turesky RJ, 2009, CHEM RES TOXICOL, V22, P726, DOI 10.1021/tx800473w.
   Turesky RJ, 2007, CANCER EPIDEM BIOMAR, V16, P1554, DOI 10.1158/1055-9965.EPI-07-0132.
   Turesky RJ, 2001, CHEM RES TOXICOL, V14, P901, DOI 10.1021/tx010035s.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   Winsten J. A., 1977, ORIGINS HUMAN CANC, P1561.
   YAMASHITA M, 1986, JPN J CANCER RES, V77, P419.
   YOSHIDA D, 1978, BIOCHEM BIOPH RES CO, V83, P915, DOI 10.1016/0006-291X(78)91482-1.
   YOSHIDA D, 1980, CANCER LETT, V10, P141, DOI 10.1016/0304-3835(80)90037-3.
   Yu MC, 2002, MUTAT RES-FUND MOL M, V506, P21, DOI 10.1016/S0027-5107(02)00148-3.
   Yuan ZX, 2007, CHEM RES TOXICOL, V20, P497, DOI 10.1021/tx600303d.
   Zha Q, 2002, J CHROMATOGR SCI, V40, P403.
   Zhang XB, 1996, CARCINOGENESIS, V17, P2259, DOI 10.1093/carcin/17.10.2259.}},
Number-of-Cited-References = {{89}},
Times-Cited = {{8}},
Journal-ISO = {{Chem. Res. Toxicol.}},
Doc-Delivery-Number = {{780YG}},
Wos-Id = {{ISI:000291896700016}},
}

@article{ ISI:000287110100038,
Author = {De Andres, Fernando and Zougagh, Mohammed and Castaneda, Gregorio and
   Luis Sanchez-Rojas, Jose and Rios, Angel},
Title = {{Screening of non-polar heterocyclic amines in urine by microextraction
   in packed sorbent-fluorimetric detection and confirmation by capillary
   liquid chromatography}},
Journal = {{TALANTA}},
Year = {{2011}},
Volume = {{83}},
Number = {{5}},
Pages = {{1562-1567}},
Month = {{FEB 15}},
Abstract = {{A rapid and simple procedure for the direct screening of urine samples
   is described. The method involves microextraction in a packed sorbent
   (MEPS) that is on-line coupled to a capillary liquid chromatograph with
   fluorimetric detection. The overall arrangement works as a
   screening/confirmatory system for monitoring non-polar heterocyclic
   aromatic amines (HAAs) in urine samples. This configuration allows the
   selective retention of HAAs from urine on a C(18) MEPS cartridge
   integrated in the needle of a micro-well plate autosampler. Retained
   HAAs were eluted with methanol/water (90:10, v/v) and directly injected
   into the fluorimetric detector. This screening method provides a yes/no
   binary response that may require confirmation. The samples for which the
   concentration of HAAs was close to or above the established threshold
   limit (30 ng mL(-1)) were subjected to capillary liquid chromatography
   (CLC) for confirmation purposes. A mobile phase of acetonitrile and
   triethylamine (25 mM) at pH 2.5, through a gradient of composition at a
   flow rate of 20 mu L min(-1). resulted in good separations between the
   analytes in less than 11 min. This confirmation method allowed the
   determination of the analytes in the 10-100 ng mL(-1) range for harmane
   and norharmane and from 20 to 200 ng mL(-1) for
   3-amino-1,4-dimethyl-5H-pyrido-{[}4,3-b] indole (Trp-P-1),
   3-amino-1-methyl-5H-pyrido-{[}4,3-b] indole (Trp-P-2),
   2-amino-9H-pyrido-{[}2,3-b] indole (A alpha C) and
   2-amino-3-methyl-9H-pyrido-{[}2,3-b] indole (MeA alpha C), with relative
   standard deviation (RSD) values between 2.12\% and 3.73\%, and limits of
   detection between 1.6 and 5.6 ng mL(-1) for all the HAAs. (C) 2010
   Elsevier B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Rios, A (Reprint Author), Univ Castilla La Mancha, Dept Analyt Chem \& Food Technol, E-13004 Ciudad Real, Spain.
   De Andres, Fernando; Castaneda, Gregorio; Rios, Angel, Univ Castilla La Mancha, Dept Analyt Chem \& Food Technol, E-13004 Ciudad Real, Spain.
   Zougagh, Mohammed, Sci \& Technol Pk Albacete, E-02006 Albacete, Spain.
   Zougagh, Mohammed; Rios, Angel, IRICA, Reg Inst Appl Sci Res, E-13004 Ciudad Real, Spain.
   Luis Sanchez-Rojas, Jose, ETSI, Dept Elect Elect \& Automatism Engn, E-13004 Ciudad Real, Spain.}},
DOI = {{10.1016/j.talanta.2010.11.060}},
ISSN = {{0039-9140}},
Keywords = {{Screening; Microextraction in packed sorbent; Capillary liquid
   chromatography; Fluorescence detection; Heterocyclic aromatic amines;
   Urine}},
Keywords-Plus = {{TANDEM MASS-SPECTROMETRY; COMUTAGENIC BETA-CARBOLINES; SOLID-PHASE
   EXTRACTION; AROMATIC-AMINES; MEAT-PRODUCTS; MODEL SYSTEMS; SYRINGE MEPS;
   COOKED FOODS; SAMPLES; PHIP}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Analytical}},
Author-Email = {{angel.rios@uclm.es}},
Funding-Acknowledgement = {{Ministry of Science and innovation (MICINN); JJCC Castilla-La Mancha
   {[}CTQ2010-15027, PCC08-0015-0722]}},
Funding-Text = {{The Spanish Ministry of Science and innovation (MICINN), and JJCC
   Castilla-La Mancha are gratefully acknowledged for funding this work
   with Grants CTQ2010-15027 and PCC08-0015-0722, respectively. The support
   given through a ``INCRECYT{''} research contract to M. Zougagh is also
   acknowledged.}},
Cited-References = {{Abdel-Rehim M, 2006, J LIQ CHROMATOGR R T, V29, P1725, DOI 10.1080/10826070600716843.
   Abdel-Rehim M, 2006, J LIQ CHROMATOGR R T, V29, P2537, DOI 10.1080/10826070600915023.
   Abdel-Rehim M, 2004, J MASS SPECTROM, V39, P1488, DOI 10.1002/jms.731.
   ADAMSON RH, 1991, XENOBIOTICS AND CANCER, P289.
   ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   Alaejos MS, 2008, J CHROMATOGR B, V862, P15, DOI 10.1016/j.jchromb.2007.11.040.
   Alaejos MS, 2008, FOOD ADDIT CONTAM, V25, P2, DOI 10.1080/02652030701474235.
   Altun Z, 2008, ANAL CHIM ACTA, V630, P116, DOI 10.1016/j.aca.2008.09.067.
   Altun Z, 2006, J LIQ CHROMATOGR R T, V29, P829, DOI 10.1080/10826070500530526.
   BERG I, 1990, FOOD CHEM TOXICOL, V28, P421, DOI 10.1016/0278-6915(90)90088-5.
   De Andres F, 2010, ANAL BIOANAL CHEM, V397, P223, DOI 10.1007/s00216-009-3370-z.
   DOOLEY KL, 1992, CANCER LETT, V62, P205, DOI 10.1016/0304-3835(92)90097-F.
   El-Beqqali A, 2007, J SEP SCI, V30, P2501, DOI 10.1002/jssc.200700067.
   El-Beqqali A, 2007, J SEP SCI, V30, P421, DOI 10.1002/jssc.200600369.
   FRIESEN MD, 1993, ENVIRON HEALTH PERSP, V99, P179, DOI 10.2307/3431476.
   Hegstad S, 2000, CHROMATOGRAPHIA, V52, P499, DOI 10.1007/BF02535726.
   Holland RD, 2004, CHEM RES TOXICOL, V17, P1121, DOI 10.1021/tx049910a.
   IARC, 1993, IARC MON EV CARC RIS, V56.
   JAGERSTAD M, 1991, MUTAT RES, V259, P219, DOI 10.1016/0165-1218(91)90119-7.
   KNIZE MG, 1995, FOOD CHEM TOXICOL, V33, P545, DOI 10.1016/0278-6915(95)00025-W.
   MANABE S, 1993, ENVIRON POLLUT, V80, P281, DOI 10.1016/0269-7491(93)90049-T.
   Martin-Calero A, 2007, J LIQ CHROMATOGR R T, V30, P27, DOI 10.1080/10826070601034204.
   Murkovic M, 2007, ANAL BIOANAL CHEM, V389, P139, DOI 10.1007/s00216-007-1306-z.
   Naccari C, 2009, FOOD CHEM TOXICOL, V47, P321, DOI 10.1016/j.fct.2008.11.018.
   NAGAO M, 1979, MUTAT RES, V68, P101, DOI 10.1016/0165-1218(79)90137-X.
   Nagao M, 1999, MUTAT RES-FUND MOL M, V431, P3, DOI 10.1016/S0027-5107(99)00154-2.
   Norrish AE, 1999, J NATL CANCER I, V91, P2038, DOI 10.1093/jnci/91.23.2038.
   Ohe T, 1997, MUTAT RES-GEN TOX EN, V393, P73, DOI 10.1016/S1383-5718(97)00087-9.
   Ohgaki H., 2000, Food borne carcinogens: heterocyclic amines., P197.
   Prabhu S, 2001, ANAL BIOCHEM, V298, P306, DOI 10.1006/abio.2001.5392.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   Rohrmann S, 2002, EUR J CLIN NUTR, V56, P1216, DOI 10.1038/sj.ejcn.1601494.
   Scott KA, 2007, CHEM RES TOXICOL, V20, P88, DOI 10.1021/tx0601861.
   Sentellas S, 2004, J CHROMATOGR A, V1032, P193, DOI 10.1016/j.chroma.2003.11.011.
   Shah FU, 2008, J CHROMATOGR B, V870, P203, DOI 10.1016/j.jchromb.2008.06.006.
   Sinha R, 2001, CANCER EPIDEM BIOMAR, V10, P559.
   Skog K, 1997, FOOD CHEM TOXICOL, V35, P555, DOI 10.1016/S0278-6915(97)00021-5.
   Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1.
   Stillwell WG, 1999, CANCER LETT, V143, P145, DOI 10.1016/S0304-3835(99)00144-5.
   Strickland PT, 2001, BIOMARKERS, V6, P313.
   SUGIMURA T, 1977, NUCLEIC ACIDS RES, pS41.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   Toribio F, 2000, J CHROMATOGR B, V747, P171, DOI 10.1016/S0378-4347(00)00154-7.
   Totsuka Y, 1999, CANCER LETT, V143, P139, DOI 10.1016/S0304-3835(99)00143-3.
   Tsuchiya H, 1996, CHROMATOGRAPHIA, V43, P419, DOI 10.1007/BF02271022.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   Wakabayashi K, 1997, MUTAT RES-FUND MOL M, V376, P253, DOI 10.1016/S0027-5107(97)00050-X.
   WU J, 1995, J CHROMATOGR SCI, V33, P712.}},
Number-of-Cited-References = {{49}},
Times-Cited = {{6}},
Journal-ISO = {{Talanta}},
Doc-Delivery-Number = {{718GW}},
Wos-Id = {{ISI:000287110100038}},
}

@article{ ISI:000287489900017,
Author = {Hanlon, Natalya and Konsue, Nattaya and Coldham, Nick and Sauer, Maurice
   J. and Ioannides, Costas},
Title = {{Exposure to Isothiocyanates Suppresses Urinary Mutagenicity in Rats
   Treated With Heterocyclic Amine IQ: Lack of Association With CYP1
   Activity}},
Journal = {{NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL}},
Year = {{2011}},
Volume = {{63}},
Number = {{2}},
Pages = {{300-305}},
Abstract = {{The principal objectives of this study were to evaluate whether exposure
   of rats to low doses of isothiocyanates modulates the overall metabolism
   of heterocyclic amine 2-amino-3-methylimidazo-{[}4,5-f]quinoline (IQ),
   as exemplified by urinary mutagenicity, a food carcinogen, and to relate
   any modifications in metabolism to changes in CYP1 and glutathione
   S-transferase activities. Animals were exposed to isothiocyanates either
   for 2 wk (long-term) or 1 day (short-term), and all animals were then
   treated with a single oral dose of IQ, and urine was collected daily for
   3 days; animals continued to receive the isothiocyanates during this
   period. Urinary mutagenic activity was determined using the Ames
   mutagenicity assay in the presence of an activation system from Aroclor
   1254-treated rats. At the end of the study, animals were killed and
   hepatic methoxy- and ethoxyresorufin dealkylations were determined as
   well as glutathione S-transferase activity. All isothiocyanates studied,
   namely sulforaphane, erucin, and phenethyl isothiocyanate, decreased
   urinary mutagenic activity, implying enhanced IQ metabolism, but only
   after long-term intake. Changes in mutagenic activity were not related
   to changes of any of the enzyme activities determined. It is concluded
   that long-term intake of isothiocyanates may stimulate the metabolism of
   IQ, but this effect is not linked to changes in hepatic CYP1A2 and
   glutathione S-transferase activities.}},
Publisher = {{LAWRENCE ERLBAUM ASSOC INC-TAYLOR \& FRANCIS}},
Address = {{325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ioannides, C (Reprint Author), Univ Surrey, Ctr Toxicol, Fac Hlth \& Med Sci, Surrey GU2 7XH, England.
   Hanlon, Natalya; Konsue, Nattaya; Ioannides, Costas, Univ Surrey, Ctr Toxicol, Fac Hlth \& Med Sci, Surrey GU2 7XH, England.
   Coldham, Nick; Sauer, Maurice J., Vet Labs Agcy Weybridge, Mol Pathogenesis \& Genet Dept, Surrey, England.}},
DOI = {{10.1080/01635581.2011.530735}},
ISSN = {{0163-5581}},
Keywords-Plus = {{PHENETHYL ISOTHIOCYANATE; CYTOCHROMES P450; CANCER-RISK; ADDUCT
   FORMATION; SULFORAPHANE; METABOLISM; CONSUMPTION; CHEMOPREVENTION;
   CARCINOGENESIS; MODULATION}},
Research-Areas = {{Oncology; Nutrition \& Dietetics}},
Web-of-Science-Categories  = {{Oncology; Nutrition \& Dietetics}},
Author-Email = {{c.ioannides@surrey.ac.uk}},
ResearcherID-Numbers = {{Sauer, Maurice/C-5061-2011
   Coldham, Nick/F-6151-2010
   AHVLA, publications/E-6082-2010}},
Funding-Acknowledgement = {{Association for International Cancer Research; Ministry of Science and
   Technology; Royal Thai Government}},
Funding-Text = {{The authors acknowledge with gratitude the financial support of the
   Association for International Cancer Research, and Nattaya Konsue
   gratefully acknowledges financial support from the Ministry of Science
   and Technology, Royal Thai Government.}},
Cited-References = {{Ambrosone CB, 2004, J NUTR, V134, P1134.
   Bacon JR, 2003, CARCINOGENESIS, V24, P1903, DOI 10.1093/carcin/bgg157.
   Barcelo S, 1998, MUTAT RES-FUND MOL M, V402, P111, DOI 10.1016/S0027-5107(97)00288-1.
   BARNES WS, 1985, MUTAT RES, V156, P83, DOI 10.1016/0165-1218(85)90010-2.
   Basten GP, 2002, CARCINOGENESIS, V23, P1399, DOI 10.1093/carcin/23.8.1399.
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999.
   BURKE MD, 1974, DRUG METAB DISPOS, V2, P583.
   BURKE MD, 1983, CHEM-BIOL INTERACT, V45, P243.
   Dingley KH, 2003, NUTR CANCER, V46, P212, DOI 10.1207/S15327914NC4602\_15.
   Fahey JW, 2002, P NATL ACAD SCI USA, V99, P7610, DOI 10.1073/pnas.112203099.
   Fimognari C, 2007, MUTAT RES-REV MUTAT, V635, P90, DOI 10.1016/j.mrrev.2006.10.004.
   Getahun SM, 1999, CANCER EPIDEM BIOMAR, V8, P447.
   GUO ZY, 1992, CARCINOGENESIS, V13, P2205, DOI 10.1093/carcin/13.12.2205.
   HABIG WH, 1974, J BIOL CHEM, V249, P7130.
   Hanlon N, 2008, J AGR FOOD CHEM, V56, P7866, DOI 10.1021/jf801456h.
   HECHT SS, 1995, CANCER EPIDEM BIOMAR, V4, P877.
   Hecht SS, 2000, DRUG METAB REV, V32, P395, DOI 10.1081/DMR-100102342.
   Higdon JV, 2007, PHARMACOL RES, V55, P224, DOI 10.1016/j.phrs.2007.01.009.
   IOANNIDES C, 1989, CARCINOGENESIS, V10, P1403, DOI 10.1093/carcin/10.8.1403.
   Juge N, 2007, CELL MOL LIFE SCI, V64, P1105, DOI 10.1007/s00018-007-6484-5.
   Kim D, 2005, ANNU REV PHARMACOL, V45, P27, DOI 10.1146/annurev.pharmtox.45.120403.100010.
   Konsue N, 2008, FOOD CHEM TOXICOL, V46, P3677, DOI 10.1016/j.fct.2008.09.046.
   Maron M., 1983, MUTAT RES, V113, P173.
   McArdle NJ, 1999, MUTAT RES-GEN TOX EN, V441, P191, DOI 10.1016/S1383-5718(99)00047-9.
   Murray S, 2001, CARCINOGENESIS, V22, P1413, DOI 10.1093/carcin/22.9.1413.
   NAMKUNG MJ, 1988, MOL PHARMACOL, V34, P628.
   RODRIGUES AD, 1989, EUR J BIOCHEM, V181, P627, DOI 10.1111/j.1432-1033.1989.tb14769.x.
   Shen G, 2007, CANCER RES, V67, P9937, DOI 10.1158/0008-5472.CAN-07-1112.
   Solt DB, 2003, CANCER LETT, V202, P147, DOI 10.1016/j.canlet.2003.08.021.
   TONG S, 1986, ANTICANCER RES, V6, P1107.
   TURESKY RJ, 1986, CARCINOGENESIS, V7, P1483, DOI 10.1093/carcin/7.9.1483.
   Turesky RJ, 2005, MOL NUTR FOOD RES, V49, P101, DOI 10.1002/mnfr.200400076.
   WATERS DG, 2004, CARCINOGENESIS, V25, P1659.
   Yoxall V, 2005, INT J CANCER, V117, P356, DOI 10.1002/ijc.21191.
   Yoxall VR, 2004, ARCH TOXICOL, V78, P477, DOI 10.1007/s00204-004-0562-3.
   Zhang YS, 2004, MUTAT RES-FUND MOL M, V555, P173, DOI 10.1016/j.mrfmmm.2004.04.017.
   Zhao H, 2007, INT J CANCER, V120, P2208, DOI 10.1002/ijc.22549.}},
Number-of-Cited-References = {{37}},
Times-Cited = {{0}},
Journal-ISO = {{Nutr. Cancer}},
Doc-Delivery-Number = {{723ET}},
Wos-Id = {{ISI:000287489900017}},
}

@article{ ISI:000281984500009,
Author = {Teunissen, S. F. and Vlaming, M. L. H. and Rosing, H. and Schellens, J.
   H. M. and Schinkel, A. H. and Beijnen, J. H.},
Title = {{Development and validation of a liquid chromatography-tandem mass
   spectrometry assay for the analysis of
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) and its
   metabolite 2-hydroxyamino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine
   (N-OH-PhIP) in plasma, urine, bile, intestinal contents, faeces and
   eight selected tissues from mice}},
Journal = {{JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
   AND LIFE SCIENCES}},
Year = {{2010}},
Volume = {{878}},
Number = {{25}},
Pages = {{2353-2362}},
Month = {{SEP 1}},
Abstract = {{The development and validation of a bioanalytical assay is described for
   the simultaneous analysis of
   2-amino-1-methyl-6-phenylimidazol{[}4-5-b]pyridine (PhIP) and its main
   metabolite 2-hydroxyamino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine
   (N-OH-PhIP) in plasma, urine, faeces, bile, liver, kidney, testis,
   spleen, brain, as well as colon-, cecum- and small intestinal tissue and
   contents from mice. The effect of the matrix on the accuracy of the
   method was extensively investigated. The bioanalytical assay is based on
   reversed phase liquid chromatography coupled with tandem mass
   spectrometry in the positive ion mode using multiple reaction monitoring
   for analyte quantification. The assay is validated from 1 to 250 ng/mL
   and the sample pretreatment consists of protein precipitation with
   acetonitrile using only 100 pi matrix (plasma, bile diluted in 4\% (m/v)
   BSA, intestinal contents, faeces and tissue samples homogenized in 4\%
   (m/v) BSA). The measured concentrations of PhIP and N-OH-PhIP in
   homogenates were expressed in ng/mL. Based on the weight of the isolated
   intestinal contents, faeces or tissue the amount of PhIP and N-OH-PhIP
   per mass unit intestinal content, faeces or tissue was calculated. The
   validated range for PhIP in urine is from 10 to 1000 ng/mL using 20 mu L
   urine. For N-OH-PhIP quantification, mouse urine was diluted 100x in
   blank human urine to compensate for matrix effects. The developed method
   is simple, robust and reproducible. The applicability of the method was
   demonstrated and the assay could be successfully used to support in vivo
   toxicokinetics studies of PhIP and N-OH-PhIP in mice. (C) 2010 Elsevier
   B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Teunissen, SF (Reprint Author), Slotervaart Hosp, Netherlands Canc Inst, Dept Pharm \& Pharmacol, Louwesweg 6, NL-1066 EC Amsterdam, Netherlands.
   Teunissen, S. F.; Rosing, H.; Beijnen, J. H., Slotervaart Hosp, Netherlands Canc Inst, Dept Pharm \& Pharmacol, NL-1066 EC Amsterdam, Netherlands.
   Vlaming, M. L. H.; Schinkel, A. H., Netherlands Canc Inst, Dept Mol Biol, NL-1066 CX Amsterdam, Netherlands.
   Schellens, J. H. M., Netherlands Canc Inst, Dept Med Oncol, NL-1066 CX Amsterdam, Netherlands.}},
DOI = {{10.1016/j.jchromb.2010.07.012}},
ISSN = {{1570-0232}},
Keywords = {{Heterocyclic amines; Liquid chromatography; Mice; Matrix effects;
   Metabolites; N-OH-PhIP; PhIP; Tandem mass spectrometry; Tissue}},
Keywords-Plus = {{HETEROCYCLIC AROMATIC-AMINES; FOOD-BORNE CARCINOGEN;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; IN-VITRO;
   GLUCURONIDATION; MUTAGEN; SULFOTRANSFERASES; BIOACTIVATION; ACETYLATION;
   ACTIVATION}},
Research-Areas = {{Biochemistry \& Molecular Biology; Chemistry}},
Web-of-Science-Categories  = {{Biochemical Research Methods; Chemistry, Analytical}},
Author-Email = {{Bas.Teunissen@slz.nl}},
Cited-References = {{Chen C, 2007, CHEM RES TOXICOL, V20, P531, DOI 10.1021/tx600320w.
   Cheung C, 2005, CHEM RES TOXICOL, V18, P1471, DOI 10.1021/tx050136g.
   CHOU HC, 1995, CANCER RES, V55, P525.
   Crofts FG, 1998, CARCINOGENESIS, V19, P1969, DOI 10.1093/carcin/19.11.1969.
   Dellinger RW, 2007, CARCINOGENESIS, V28, P2412, DOI 10.1093/carcin/bgm164.
   Frandsen H, 2007, FOOD CHEM TOXICOL, V45, P863, DOI 10.1016/j.fct.2006.11.006.
   Glatt H, 2000, CHEM-BIOL INTERACT, V129, P141, DOI 10.1016/S0009-2797(00)00202-7.
   Glatt H, 1997, FASEB J, V11, P314.
   Gooderham NJ, 2001, DRUG METAB DISPOS, V29, P529.
   Gooderham NJ, 2007, TOXICOL LETT, V168, P269, DOI 10.1016/j.toxlet.2006.10.022.
   Jamin EL, 2007, J AM SOC MASS SPECTR, V18, P2107, DOI 10.1016/j.jasms.2007.09.008.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   Ma XC, 2007, CARCINOGENESIS, V28, P732, DOI 10.1093/carcin/bgl184.
   Malfatti MA, 2004, CHEM RES TOXICOL, V17, P1137, DOI 10.1021/tx049898m.
   MALFATTI MA, 1994, CHEM RES TOXICOL, V7, P139, DOI 10.1021/tx00038a005.
   MINCHIN RF, 1992, BIOCHEM BIOPH RES CO, V185, P839, DOI 10.1016/0006-291X(92)91703-S.
   Murkovic M, 2004, J CHROMATOGR B, V802, P3, DOI 10.1016/j.jchromb.2003.09.026.
   Prabhu S, 2001, ANAL BIOCHEM, V298, P306, DOI 10.1006/abio.2001.5392.
   REISTAD R, 1994, CARCINOGENESIS, V15, P2547, DOI 10.1093/carcin/15.11.2547.
   SANZ AM, 2008, J CHROMATOGR B, V862, P15.
   SHIOYA M, 1987, MUTAT RES, V191, P133, DOI 10.1016/0165-7992(87)90143-6.
   Shirai T, 1997, CANCER RES, V57, P195.
   STYCZYNSKI PB, 1993, CHEM RES TOXICOL, V6, P846, DOI 10.1021/tx00036a014.
   Suzuki H, 2008, CARCINOGENESIS, V29, P1184, DOI 10.1093/carcin/bgn085.
   VAN HERWAARDEN AE, 2003, CANCER RES, V63, P6447.
   Vanhaecke L, 2008, FOOD CHEM TOXICOL, V46, P140, DOI 10.1016/j.fct.2007.07.008.
   Vanhaecke L, 2006, J AGR FOOD CHEM, V54, P3454, DOI 10.1021/jf053170+.
   Zheng W, 1998, J NATL CANCER I, V90, P1724, DOI 10.1093/jnci/90.22.1724.
   {*}US FDA, 2008, GUID IND BIOAN METH.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{3}},
Journal-ISO = {{J. Chromatogr. B}},
Doc-Delivery-Number = {{652EL}},
Wos-Id = {{ISI:000281984500009}},
}

@article{ ISI:000281700100038,
Author = {Cha, Hyun-Jeong and Kim, Nam-Hee and Jeong, Eun-Kyung and Na, Yun-Cheol},
Title = {{Analysis of Heterocyclic Amines in Human Urine Using Multiple
   Solid-Phase Extraction by Liquid Chromatography/Mass Spectrometry}},
Journal = {{BULLETIN OF THE KOREAN CHEMICAL SOCIETY}},
Year = {{2010}},
Volume = {{31}},
Number = {{8}},
Pages = {{2322-2328}},
Month = {{AUG 20}},
Abstract = {{A multiple solid-phase extraction (SPE) method was used with liquid
   chromatography, coupled with mass spectrometry (LC/MS), for the analysis
   of heterocyclic amines (HCAs) in human urine. Separation efficiencies
   based on the pH of the mobile phase and the types of columns were
   compared. An amide column showed better baseline separation and narrower
   HCA peak widths at pH 5.0 for the mobile phase than a C(8) column. Each
   SPE step, HLB, MCX, and HybridSPE, was optimized by controlling the pH
   conditions. The combined method with the three SPEs effectively removed
   interfering species that cause ion-suppression during HCA detection.
   Validation of the method, performed with SIM and SRM detection, showed
   correlation coefficients above 0.991 in the range 0.3 - 16.7 ng/mL.
   Recovery rates were 45.4 - 97.3\% on the C(8) column and 71.8 - 101.4\%
   on the amide column, and method detection limits were 0.11 - 0.65 ng/mL
   on the C(8) column and 0.12 - 0.48 ng/mL on the amide column. This
   method using multiple SPEs offers significant benefits for
   high-throughput determination of HCAs in urine.}},
Publisher = {{KOREAN CHEMICAL SOC}},
Address = {{635-4 YEOGSAM-DONG, KANGNAM-GU, SEOUL 135-703, SOUTH KOREA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Na, YC (Reprint Author), Korea Basic Sci Inst, Seoul Ctr, Seoul 136713, South Korea.
   Cha, Hyun-Jeong; Kim, Nam-Hee; Jeong, Eun-Kyung; Na, Yun-Cheol, Korea Basic Sci Inst, Seoul Ctr, Seoul 136713, South Korea.
   Jeong, Eun-Kyung, Kyung Hee Univ, Coll Pharm, Seoul 130701, South Korea.}},
DOI = {{10.5012/bkcs.2010.31.8.2322}},
ISSN = {{0253-2964}},
Keywords = {{Heterocyclic amines; Urine; LC/MS; Solid-phase extraction}},
Keywords-Plus = {{IONIZATION MASS-SPECTROMETRY; BLUE CHITIN COLUMNS; AROMATIC-AMINES;
   COOKED MEAT; QUANTITATIVE-ANALYSIS; CLEANUP PROCEDURE; GRILL SCRAPINGS;
   MODEL SYSTEMS; PAN RESIDUES; FOOD MUTAGEN}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Multidisciplinary}},
Author-Email = {{nyc@kbsi.re.kr}},
Funding-Acknowledgement = {{Korea Food \& Drug Administration {[}09182KFDA608]}},
Funding-Text = {{This research was supported by a grant (09182KFDA608) from Korea Food \&
   Drug Administration in 2009.}},
Cited-References = {{ADAMSON RH, 1994, ENVIRON HEALTH PERSP, V102, P190, DOI 10.2307/3431610.
   Alaejos MS, 2008, FOOD ADDIT CONTAM, V25, P2, DOI 10.1080/02652030701474235.
   ARDVISSON P, 1997, J FOOD SCI, V62, P911.
   Bang J, 2004, CHROMATOGRAPHIA, V60, P651, DOI 10.1365/s10337-004-0431.
   Bang J, 2002, J CHROMATOGR A, V977, P97, DOI 10.1016/S0021-9673(02)01351-1.
   Barcelo-Barrachina E, 2004, J CHROMATOGR B, V802, P45, DOI 10.1016/j.jchromb.2003.09.023.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   Busquets R, 2004, J CHROMATOGR B, V802, P79, DOI 10.1016/j.jchromb.2003.09.033.
   Felton J.S., 1990, HDB EXPT PHARM, P471.
   FRANDSEN H, 1994, MUTAGENESIS, V9, P59, DOI 10.1093/mutage/9.1.59.
   Galceran MT, 1996, J CHROMATOGR A, V730, P185, DOI 10.1016/0021-9673(95)01084-X.
   GROSS GA, 1993, CARCINOGENESIS, V14, P2313, DOI 10.1093/carcin/14.11.2313.
   GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B.
   Guy PA, 2000, J CHROMATOGR A, V883, P89, DOI 10.1016/S0021-9673(00)00361-7.
   Holland RD, 2004, CHEM RES TOXICOL, V17, P1121, DOI 10.1021/tx049910a.
   Inbaraj BS, 2006, J AGR FOOD CHEM, V54, P6452, DOI 10.1021/jf061300o.
   International Agency for Research on Cancer (IARC), 1993, MON EV CARC RISK HUM, V56.
   Iwasaki M, 2010, J FOOD COMPOS ANAL, V23, P61, DOI 10.1016/j.jfca.2009.07.004.
   Janoszka B, 2001, J CHROMATOGR A, V938, P155, DOI 10.1016/S0021-9673(01)01364-4.
   JOHANSSON MAE, 1994, CARCINOGENESIS, V15, P1511, DOI 10.1093/carcin/15.8.1511.
   Karamanos NK, 1996, J LIQ CHROMATOGR R T, V19, P2247, DOI 10.1080/10826079608017154.
   Kataoka H, 1998, B ENVIRON CONTAM TOX, V60, P60.
   Kataoka H, 1999, CHROMATOGRAPHIA, V50, P532, DOI 10.1007/BF02493657.
   KNIZE MG, 1994, FOOD CHEM TOXICOL, V32, P595, DOI 10.1016/0278-6915(94)90002-7.
   Kondjoyan A, 2010, FOOD CHEM, V119, P19, DOI 10.1016/j.foodchem.2009.02.081.
   LIN DX, 1994, CANCER RES, V54, P4920.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   MASAHIKO T, 2001, J CHROMATOGR A, V928, P53.
   Murkovic M, 1997, Z LEBENSM UNTERS F A, V205, P347, DOI 10.1007/s002170050178.
   MURRAY S, 1988, CARCINOGENESIS, V9, P321, DOI 10.1093/carcin/9.2.321.
   MURRAY S, 1993, J CHROMATOGR-BIOMED, V616, P211, DOI 10.1016/0378-4347(93)80388-K.
   Ni WJ, 2008, J AGR FOOD CHEM, V56, P68, DOI 10.1021/jf072461a.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   Oz F, 2007, FOOD CHEM, V104, P67, DOI 10.1016/j.foodchem.2006.10.075.
   Pais P, 1999, J AGR FOOD CHEM, V47, P1098, DOI 10.1021/jf980644e.
   Pais P, 2000, J CHROMATOGR B, V747, P139, DOI 10.1016/S0378-4347(00)00118-3.
   PERSSON E, 2007, INT J FOOD SCI TECH, V43, P62.
   Prabhu S, 2001, ANAL BIOCHEM, V298, P306, DOI 10.1006/abio.2001.5392.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   RICH KJ, 1992, CARCINOGENESIS, V13, P2221, DOI 10.1093/carcin/13.12.2221.
   Ristic A, 2004, J CHROMATOGR B, V802, P87, DOI 10.1016/j.jchromb.2003.09.028.
   Sanz Alaejos M, 2008, J Chromatogr B Analyt Technol Biomed Life Sci, V862, P15, DOI 10.1016/j.jchromb.2007.11.040.
   Sentellas S, 2004, J CHROMATOGR A, V1032, P193, DOI 10.1016/j.chroma.2003.11.011.
   Shah FU, 2008, J CHROMATOGR B, V870, P203, DOI 10.1016/j.jchromb.2008.06.006.
   Skog K, 2004, J CHROMATOGR B, V802, P39, DOI 10.1016/j.jchromb.2003.11.016.
   Skog K, 1998, J CHROMATOGR A, V803, P227, DOI 10.1016/S0021-9673(97)01266-1.
   SKOG K, 1995, CARCINOGENESIS, V16, P861, DOI 10.1093/carcin/16.4.861.
   Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1.
   Sugimura T, 2000, CARCINOGENESIS, V21, P387, DOI 10.1093/carcin/21.3.387.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   THIEBAUD HP, 1994, J AGR FOOD CHEM, V42, P1502, DOI 10.1021/jf00043a021.
   Tikkanen LM, 1996, FOOD CHEM TOXICOL, V34, P725, DOI 10.1016/0278-6915(96)00036-1.
   Toribio F, 2007, FOOD CHEM TOXICOL, V45, P667, DOI 10.1016/j.fct.2006.10.016.
   Toribio F, 2002, J MASS SPECTROM, V37, P812, DOI 10.1002/jms.340.
   Toribio F, 2000, J CHROMATOGR A, V869, P307, DOI 10.1016/S0021-9673(99)01091-2.
   Turesky RJ, 2007, CHEM RES TOXICOL, V20, P520, DOI 10.1021/tx600317r.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P217, DOI 10.1021/tx9701891.
   Turesky RJ, 2005, J AGR FOOD CHEM, V53, P3248, DOI 10.1021/jf048290g.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   Viberg P, 2006, J CHROMATOGR A, V1133, P347, DOI 10.1016/j.chroma.2006.08.034.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   WU J, 1995, J CHROMATOGR SCI, V33, P712.
   YASUYOSHI SKN, 1993, MUTAT RES, V300, P207.
   ZHOU H, 2004, BIOCHEMISTRY-US, V43, P981.
   Zimmerli B, 2001, FOOD ADDIT CONTAM, V18, P533, DOI 10.1080/02652030110035084.}},
Number-of-Cited-References = {{66}},
Times-Cited = {{1}},
Journal-ISO = {{Bull. Korean Chem. Soc.}},
Doc-Delivery-Number = {{648NB}},
Wos-Id = {{ISI:000281700100038}},
}

@article{ ISI:000276738800025,
Author = {De Andres, Fernando and Zougagh, Mohammed and Castaneda, Gregorio and
   Rios, Angel},
Title = {{Determination of heterocyclic amines in urine samples by capillary
   liquid chromatography with evaporated light-scattering detection}},
Journal = {{ANALYTICAL AND BIOANALYTICAL CHEMISTRY}},
Year = {{2010}},
Volume = {{397}},
Number = {{1}},
Pages = {{223-231}},
Month = {{MAY}},
Abstract = {{A rapid and simple method for separation and detection of six
   heterocyclic aromatic amines (2-amino-1-methyl-6-phenylimidazo
   {[}4,5-b]-pyridine, 2-amino-1-methyl-imidazo {[}4,5-f]-quinoline,
   2-amino-3,8-dimethyl-imidazo {[}4,5-f]-quinoxaline,
   2-amino-3,7,8-trimethyl-imidazo {[}4,5-f]-quinoxaline,
   2-amino-3,4,8-trimethyl-imidazo {[}4,5-f]-quinoxaline, and
   2-amino-3,4-dimethyl-imidazo {[}4,5-f]-quinoline) in human urine samples
   is proposed to reflect daily intake and recent HAAs exposure. This
   method comprises previous clean-up and preconcentration of the analytes
   on Strata-X reversed phase extraction cartridges followed by capillary
   liquid chromatography (CLC) and evaporative light-scattering detection
   (ELSD). A mobile phase of acetonitrile and ammonium acetate 35 mM at pH
   5.15 through a gradient of composition and a flow rate of 15 mu L
   min(-1) resulted in good separations of the analytes. Temperature and
   gas pressure were optimized for detection. The CLC-ELSD allows the
   separation and quantification of HAAs with good resolution, precision,
   and sensitivity. The usefulness of the proposed method was demonstrated
   by the analysis of synthetic and natural human urine samples spiked with
   different concentration levels of heterocyclic amines.}},
Publisher = {{SPRINGER HEIDELBERG}},
Address = {{TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Rios, A (Reprint Author), IRICA, Reg Inst Appl Chem Res, Ciudad Real 13004, Spain.
   Rios, Angel, IRICA, Reg Inst Appl Chem Res, Ciudad Real 13004, Spain.
   De Andres, Fernando; Zougagh, Mohammed; Castaneda, Gregorio; Rios, Angel, Univ Castilla La Mancha, Dept Analyt Chem \& Food Technol, Fac Chem, Ciudad Real 13004, Spain.
   Zougagh, Mohammed, Albacete Sci \& Technol Pk, Albacete 02006, Spain.}},
DOI = {{10.1007/s00216-009-3370-z}},
ISSN = {{1618-2642}},
Keywords = {{Capillary liquid chromatography-evaporative light-scattering detection;
   Strata-X cartridges; Heterocyclic aromatic amines; Human urine samples}},
Keywords-Plus = {{TANDEM MASS-SPECTROMETRY; AROMATIC-AMINES; ELECTROCHEMICAL DETECTION;
   HYDROLYZED URINE; COOKED MEAT; PHIP; EXTRACTION; FOODS; RISK;
   QUANTIFICATION}},
Research-Areas = {{Biochemistry \& Molecular Biology; Chemistry}},
Web-of-Science-Categories  = {{Biochemical Research Methods; Chemistry, Analytical}},
Author-Email = {{angel.rios@uclm.es}},
Funding-Acknowledgement = {{Spanish Ministry of Science and Innovation (MICINN); JJCC Castilla-La
   Mancha {[}CTQ2007-61830, PCC08-00150722]; INCRECYT}},
Funding-Text = {{The Spanish Ministry of Science and Innovation (MICINN) and JJCC
   Castilla-La Mancha are gratefully acknowledged for funding this work
   with Grants CTQ2007-61830 and PCC08-00150722, respectively. The support
   given through a ``INCRECYT{''} research contract to M. Zougagh is also
   acknowledged.}},
Cited-References = {{ADAMSON RH, 1991, XENOBIOTICS AND CANCER, P289.
   Bang J, 2004, CHROMATOGRAPHIA, V60, P651, DOI 10.1365/s10337-004-0431.
   Bermudo E, 2005, ANAL CHIM ACTA, V536, P83, DOI 10.1016/j.aca.2004.12.077.
   Busquets R, 2004, J CHROMATOGR B, V802, P79, DOI 10.1016/j.jchromb.2003.09.033.
   Cardenes L, 2004, J CHROMATOGR A, V1030, P87, DOI 10.1016/j.chroma.2003.10.040.
   Cardenes L, 2006, ANAL LETT, V39, P405, DOI 10.1080/00032710500477217.
   Casal S, 2004, J CHROMATOGR A, V1040, P105, DOI 10.1016/j.chroma.2004.03.054.
   CHARLESWORTH JM, 1978, ANAL CHEM, V50, P1414, DOI 10.1021/ac50033a011.
   Clarot I, 2009, J PHARMACEUT BIOMED, V50, P64, DOI 10.1016/j.jpba.2009.03.013.
   DOOLEY KL, 1992, CANCER LETT, V62, P205, DOI 10.1016/0304-3835(92)90097-F.
   DREUX M, 1990, SPECTRA 2000, V151, P16.
   FELTON JS, 2000, FOOD BORNE CARCINOGE.
   Friesen MD, 2001, CANCER LETT, V173, P43, DOI 10.1016/S0304-3835(01)00672-3.
   International Agency for Research on Cancer (IARC), 1993, MON EV CARC RISK HUM, V56.
   JAGERSTAD M, 1991, MUTAT RES, V259, P219, DOI 10.1016/0165-1218(91)90119-7.
   Kakiyama G, 2006, J CHROMATOGR A, V1125, P112, DOI 10.1016/j.chroma.2006.05.037.
   Knize MG, 1997, J CHROMATOGR A, V763, P179, DOI 10.1016/S0021-9673(96)00720-0.
   Knize MG, 2001, J CHROMATOGR A, V914, P95, DOI 10.1016/S0021-9673(01)00522-2.
   Kohler M, 1997, TRAC-TREND ANAL CHEM, V16, P475, DOI 10.1016/S0165-9936(97)00072-1.
   MANABE S, 1992, ENVIRON POLLUT, V75, P301, DOI 10.1016/0269-7491(92)90130-3.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   Martin-Calero A, 2009, TALANTA, V79, P590, DOI 10.1016/j.talanta.2009.04.032.
   Martin-Calero A, 2007, ANAL CHIM ACTA, V582, P259, DOI 10.1016/j.aca.2006.09.024.
   Miller J. N., 2000, STAT CHEMOMETRICS AN.
   MOTULSKY HJ, 1987, FASEB J, V1, P365.
   MOUREY TH, 1984, ANAL CHEM, V56, P2427, DOI 10.1021/ac00277a039.
   Nagao M, 1999, MUTAT RES-FUND MOL M, V431, P3, DOI 10.1016/S0027-5107(99)00154-2.
   Norrish AE, 1999, J NATL CANCER I, V91, P2038, DOI 10.1093/jnci/91.23.2038.
   OHGAKI H, 2000, FOOD BORNE CARCINOGE.
   Olsson JC, 1997, J CHROMATOGR A, V765, P329, DOI 10.1016/S0021-9673(96)00918-1.
   Richling E, 1997, J CHROMATOGR A, V791, P71, DOI 10.1016/S0021-9673(97)00842-X.
   SASAKI Y, 1996, ENV MUTAGEN RES, V18, P21.
   Shah FU, 2008, J CHROMATOGR B, V870, P203, DOI 10.1016/j.jchromb.2008.06.006.
   Sinha R, 2001, CANCER EPIDEM BIOMAR, V10, P559.
   Skog K, 2002, FOOD CHEM TOXICOL, V40, P1213, DOI 10.1016/S0278-6915(02)00062-5.
   Strickland PT, 2001, BIOMARKERS, V6, P313.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   THIEBAUD HP, 1995, FOOD CHEM TOXICOL, V33, P821, DOI 10.1016/0278-6915(95)00057-9.
   VANDYCK MMC, 1995, J CHROMATOGR A, V697, P377, DOI 10.1016/0021-9673(94)00837-Y.
   Viberg P, 2006, J CHROMATOGR A, V1133, P347, DOI 10.1016/j.chroma.2006.08.034.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   WU J, 1995, J CHROMATOGR SCI, V33, P712.
   Yan SK, 2006, J PHARMACEUT BIOMED, V40, P889, DOI 10.1016/j.jpba.2005.08.016.
   {*}ICH, 2007, CPMPICH38195.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{3}},
Journal-ISO = {{Anal. Bioanal. Chem.}},
Doc-Delivery-Number = {{584GI}},
Wos-Id = {{ISI:000276738800025}},
}

@article{ ISI:000275007900013,
Author = {Carthew, Philip and DiNovi, Michael and Setzer, R. Woodrow},
Title = {{Application of the Margin of Exposure (MOE) approach to substances in
   food that are genotoxic and carcinogenic Example: CAS No: 105650-23-5
   PhIP (2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine)}},
Journal = {{FOOD AND CHEMICAL TOXICOLOGY}},
Year = {{2010}},
Volume = {{48}},
Number = {{1}},
Pages = {{S98-S105}},
Month = {{JAN}},
Abstract = {{PhIP (2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine) is a
   heterocyclic amine and genotoxic carcinogen contaminant that occurs
   during the grilling and frying of meat and fish, through an interaction
   between sugars and creatine via the Maillard reaction. PhIP causes
   cancers of the prostate, mammary gland and colon in rodents.
   Dose-response modelling of the data for these three turnout types gives
   BMDL10 values of 0.48 mg/kg/day for the prostate tumours, 0.74 mg/kg/day
   for mammary tumours and 2.71 mg/kg/day for colon tumours. The lowest
   MOEs for prostate, mammary and colon tumours were 20,000, 40,000 and
   150,000, respectively. (C) 2009 ILSI Europe. Published by Elsevier Ltd.
   All rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Carthew, P (Reprint Author), ILSI Europe, Ave E Mounier 83,B6, B-1200 Brussels, Belgium.
   DiNovi, Michael, US FDA, Rockville, MD 20857 USA.}},
DOI = {{10.1016/j.fct.2009.10.035}},
ISSN = {{0278-6915}},
Keywords = {{PhIP; 2-Amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine; Margin of
   exposure; MoE}},
Keywords-Plus = {{SPRAGUE-DAWLEY RATS; DNA-ADDUCT LEVELS; HETEROCYCLIC AMINES;
   COOKED-FOOD; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP;
   CANCER-RISK; MUTAGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE;
   PROSTATE-CANCER; BREAST-CANCER; MEAT MUTAGENS}},
Research-Areas = {{Food Science \& Technology; Toxicology}},
Web-of-Science-Categories  = {{Food Science \& Technology; Toxicology}},
Author-Email = {{publications@ilsieurope.be}},
Cited-References = {{Beamand JA, 1998, FOOD CHEM TOXICOL, V36, P455, DOI 10.1016/S0278-6915(98)00006-4.
   Bogen KT, 2001, J EXPO ANAL ENV EPID, V11, P155, DOI 10.1038/sj.jea.7500158.
   Butler LM, 2003, AM J EPIDEMIOL, V157, P434, DOI 10.1093/aje/kwf221.
   Cross AJ, 2005, CANCER RES, V65, P11779, DOI 10.1158/0008-5472CAN-05-2191.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P61, DOI 10.1093/carcin/14.1.61.
   DOOLEY KL, 1992, CANCER LETT, V62, P205, DOI 10.1016/0304-3835(92)90097-F.
   ECHA, 2008, GUID INF REQ CHEM SA.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   Gooderham NJ, 2007, TOXICOL LETT, V168, P269, DOI 10.1016/j.toxlet.2006.10.022.
   HASEGAWA R, 1995, CANCER RES, V55, P4333.
   HASEGAWA R, 1992, CARCINOGENESIS, V13, P1427, DOI 10.1093/carcin/13.8.1427.
   HASEGAWA R, 1993, CARCINOGENESIS, V14, P2553, DOI 10.1093/carcin/14.12.2553.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   Imaida K, 1996, JPN J CANCER RES, V87, P1116.
   Imaida K, 2001, CARCINOGENESIS, V22, P1295, DOI 10.1093/carcin/22.8.1295.
   International Agency for Research on Cancer (IARC), 1993, SUMM EV PHIP 2 AM 1, V56.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   Knasmuller S, 1996, MUTAT RES-FUND MOL M, V350, P93, DOI 10.1016/0027-5107(95)00095-X.
   LAWSON T, 1994, MUTAT RES LETT, V325, P125, DOI 10.1016/0165-7992(94)90074-4.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   MALFATTI MA, 1995, MUTAGENESIS, V10, P425, DOI 10.1093/mutage/10.5.425.
   Malfatti MA, 1996, CANCER RES, V56, P2550.
   Nagao M, 2001, MUTAT RES-FUND MOL M, V477, P119, DOI 10.1016/S0027-5107(01)00113-0.
   Norrish AE, 1999, J NATL CANCER I, V91, P2038, DOI 10.1093/jnci/91.23.2038.
   O'Brien J, 2006, FOOD CHEM TOXICOL, V44, P1613, DOI 10.1016/j.fct.2006.07.004.
   Otsuka C, 1996, MUTAT RES-GENET TOX, V367, P115, DOI 10.1016/0165-1218(95)00082-8.
   Rohrmann S, 2009, AM J CLIN NUTR, V89, P1418, DOI 10.3945/ajcn.2008.26658.
   Shirai T, 1997, CANCER RES, V57, P195.
   SHIRAI T, 1995, P 23 INT S PRINC TAK, P232.
   Sinha R, 2000, J NATL CANCER I, V92, P1352, DOI 10.1093/jnci/92.16.1352.
   Sinha R, 2001, CANCER EPIDEM BIOMAR, V10, P559.
   SMITH C, 1992, MUTAT RES, V279, P61, DOI 10.1016/0165-1218(92)90267-4.
   Stephanou G, 1997, MUTAGENESIS, V12, P425, DOI 10.1093/mutage/12.6.425.
   WILD D, 1991, CARCINOGENESIS, V12, P1091, DOI 10.1093/carcin/12.6.1091.
   Wu K, 2006, CANCER EPIDEM BIOMAR, V15, P1120, DOI 10.1158/1055-9965.EPI-05-0782.
   YadollahiFarsani M, 1996, CARCINOGENESIS, V17, P617, DOI 10.1093/carcin/17.4.617.
   Zhu JJ, 2003, CANCER EPIDEM BIOMAR, V12, P830.
   {*}US NAT TOX PROGR, 2002, RG2 US NAT TOX PROGR.}},
Number-of-Cited-References = {{38}},
Times-Cited = {{5}},
Journal-ISO = {{Food Chem. Toxicol.}},
Doc-Delivery-Number = {{561VM}},
Wos-Id = {{ISI:000275007900013}},
}

@article{ ISI:000273183800003,
Author = {Busquets, Rosa and Jonsson, Jan Ake and Frandsen, Henrik and Puignou,
   Lluis and Teresa Galceran, Maria and Skog, Kerstin},
Title = {{Hollow fibre-supported liquid membrane extraction and LC-MS/MS detection
   for the analysis of heterocyclic amines in urine samples}},
Journal = {{MOLECULAR NUTRITION \& FOOD RESEARCH}},
Year = {{2009}},
Volume = {{53}},
Number = {{12}},
Pages = {{1496-1504}},
Month = {{DEC}},
Abstract = {{Heterocyclic amines (HCAs) are potent mutagens/carcinogens to which
   humans are frequently exposed through the consumption of cooked meat and
   fish food. The effect of normal intake of HCAs and their role in the
   aetiology of human cancer is unknown. To some extent, limitations of the
   existing analytical methods in monitoring the low levels of HCAs in
   biological samples have hindered obtaining conclusive results. In this
   study, a method for the analysis of HCAs in human urine has been studied
   to detect HCAs and metabolites at levels resulting from consumption of
   food cooked at ordinary conditions. The analytical method consisted of
   extraction and clean-Lip by the novel technique liquid-phase
   microextraction combined with LC-MS/MS. The effect of pH during the
   extraction and hydrolysis step was examined. High sensitivity was
   achieved when the extraction was performed in raw urine adjusted to pH
   5.5, 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine being detected
   from 2 pg/g urine, levels comparable with a normal exposure. Good
   reproducibility and repeat-ability was obtained for
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine and
   2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline, below 9\% using
   isotopic dilution. The performance of the method on
   9H-pyrido{[}3,4-b]indole,
   2-amino-1-methyl-6-(4'-hydroxyphenyl)imidazo{[}4,5-b]pyridine and
   2-amino-1-methyl-6-(5-hydroxy)phenylimidazo{[}4,5-b]pyridine was also
   studied.}},
Publisher = {{WILEY-V C H VERLAG GMBH}},
Address = {{PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Busquets, R (Reprint Author), Univ Barcelona, Dept Analyt Chem, Fac Chem, C Marti Franques 1-11, E-08028 Barcelona, Spain.
   Busquets, Rosa, Univ Barcelona, Dept Analyt Chem, Fac Chem, E-08028 Barcelona, Spain.
   Jonsson, Jan Ake, Lund Univ, Dept Analyt Chem, S-22100 Lund, Sweden.
   Skog, Kerstin, Lund Univ, Dept Food Technol Engn \& Nutr, S-22100 Lund, Sweden.
   Frandsen, Henrik, Tech Univ Denmark, Natl Food Inst, Soborg, Denmark.}},
DOI = {{10.1002/mnfr.200800577}},
ISSN = {{1613-4125}},
Keywords = {{2-Amino-1-methyl-6-(4 `-hydroxyphenyl)imidazo{[}4,5-b]pyridine;
   2-Amino-1-methyl-6-(5-hydroxy)phenylimidazo{[}4,5-b]pyridine;
   Heterocyclic amines; Liquid-phase microextraction; Urine}},
Keywords-Plus = {{AROMATIC-AMINES; MASS-SPECTROMETRY; MEAT INTAKE;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO(4,5-B)PYRIDINE PHIP; COLORECTAL
   ADENOMA; COOKED CHICKEN; FRIED BEEF; METABOLITES; CONSUMPTION; EXPOSURE}},
Research-Areas = {{Food Science \& Technology}},
Web-of-Science-Categories  = {{Food Science \& Technology}},
Author-Email = {{rosabs5@gmail.com}},
Funding-Acknowledgement = {{Dir A Pahlsson foundation}},
Funding-Text = {{The authors thank Thaer Barri and Faiz Ullah Shah for valuable
   suggestions and training in LPME. They wish to express their thanks to
   Dir A Pahlsson foundation for financial support. This work was performed
   under the auspices of Lund University.}},
Cited-References = {{Alexander J, 2002, FOOD CHEM TOXICOL, V40, P1131, DOI 10.1016/S0278-6915(02)00053-4.
   Augustsson K, 1999, LANCET, V353, P703, DOI 10.1016/S0140-6736(98)06099-1.
   Bang J, 2004, CHROMATOGRAPHIA, V60, P651, DOI 10.1365/s10337-004-0431.
   Busquets R, 2006, J AGR FOOD CHEM, V54, P8376, DOI 10.1021/jf0616311.
   Busquets R, 2008, MOL NUTR FOOD RES, V52, P1408, DOI 10.1002/mnfr.200800048.
   Busquets R, 2007, J AGR FOOD CHEM, V55, P9318, DOI 10.1021/jf072252q.
   Busquets R, 2004, J CHROMATOGR B, V802, P79, DOI 10.1016/j.jchromb.2003.09.033.
   De Stefani E, 1998, NUTR CANCER, V32, P43.
   DeStefani E, 1997, CANCER EPIDEM BIOMAR, V6, P573.
   Felton J. S., 2000, Food borne carcinogens: heterocyclic amines., P31.
   Frandsen H, 2000, CARCINOGENESIS, V21, P1197, DOI 10.1093/carcin/21.6.1197.
   Frandsen H, 2002, FOOD CHEM TOXICOL, V40, P1125, DOI 10.1016/S0278-6915(02)00033-9.
   Frandsen H, 2008, FOOD CHEM TOXICOL, V46, P3200, DOI 10.1016/j.fct.2008.07.008.
   Frandsen H, 2007, FOOD CHEM TOXICOL, V45, P863, DOI 10.1016/j.fct.2006.11.006.
   Friesen MD, 2001, CANCER LETT, V173, P43, DOI 10.1016/S0304-3835(01)00672-3.
   Gunter MJ, 2005, CARCINOGENESIS, V26, P637, DOI 10.1093/carcin/bgh350.
   International Agency for Research on Cancer, 1993, IARC MON EV CARC RIS, V56.
   JAGERSTAD M, 1983, ACS SYM SER, V215, P507.
   Kidd LCR, 1999, CANCER EPIDEM BIOMAR, V8, P439.
   King R.S., 2000, FOOD BORNE CARCINOGE, P90.
   Knize MG, 2001, J CHROMATOGR A, V914, P95, DOI 10.1016/S0021-9673(01)00522-2.
   Knize MG, 2006, WOODHEAD PUBL FOOD S, P231, DOI 10.1533/9781845692018.2.231.
   Kulp KS, 2004, J CHROMATOGR B, V802, P143, DOI 10.1016/j.jchromb.2003.09.032.
   Lezamiz J, 2008, ANAL BIOANAL CHEM, V390, P689, DOI 10.1007/s00216-007-1702-4.
   Malfatti MA, 2006, CANCER RES, V66, P10541, DOI 10.1158/0008-5472.CAN-06-1573.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   Manisali I, 2006, TRAC-TREND ANAL CHEM, V25, P243, DOI 10.1016/j.trac.2005.07.007.
   Martinez ME, 2007, CARCINOGENESIS, V28, P2019, DOI 10.1093/carcin/bgm179.
   Mendonsa SD, 1999, J CHROMATOGR A, V841, P239, DOI 10.1016/S0021-9673(99)00279-4.
   Murray S, 2001, CARCINOGENESIS, V22, P1413, DOI 10.1093/carcin/22.9.1413.
   Pedersen-Bjergaard S, 2008, J CHROMATOGR A, V1184, P132, DOI 10.1016/j.chroma.2007.08.088.
   Pfau W, 2004, J CHROMATOGR B, V802, P115, DOI 10.1016/j.jchromb.2003.10.044.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   Sentellas S, 2004, J CHROMATOGR A, V1032, P193, DOI 10.1016/j.chroma.2003.11.011.
   Shah FU, 2008, J CHROMATOGR B, V870, P203, DOI 10.1016/j.jchromb.2008.06.006.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   Strickland PT, 2002, MUTAT RES-FUND MOL M, V506, P163, DOI 10.1016/S0027-5107(02)00163-X.
   Viberg P, 2004, ANAL BIOANAL CHEM, V378, P1729, DOI 10.1007/s00216-003-2480-2.
   Viberg P, 2006, J CHROMATOGR A, V1133, P347, DOI 10.1016/j.chroma.2006.08.034.
   Winsten J. A., 1977, ORIGINS HUMAN CANC, P1561.}},
Number-of-Cited-References = {{40}},
Times-Cited = {{5}},
Journal-ISO = {{Mol. Nutr. Food Res.}},
Doc-Delivery-Number = {{538KQ}},
Wos-Id = {{ISI:000273183800003}},
}

@article{ ISI:000269738000016,
Author = {Fukuda, Hirokazu and Takamura-Enya, Takeji and Masuda, Yuji and Nohmi,
   Takehiko and Seki, Chiho and Kamiya, Kenji and Sugimura, Takashi and
   Masutani, Chikahide and Hanaoka, Fumio and Nakagama, Hitoshi},
Title = {{Translesional DNA Synthesis through a C8-Guanyl Adduct of
   2-Amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) in Vitro REV1
   INSERTS dC OPPOSITE THE LESION, AND DNA POLYMERASE kappa POTENTIALLY
   CATALYZES EXTENSION REACTION FROM THE 3 `-dC TERMINUS}},
Journal = {{JOURNAL OF BIOLOGICAL CHEMISTRY}},
Year = {{2009}},
Volume = {{284}},
Number = {{38}},
Pages = {{25585-25592}},
Month = {{SEP 18}},
Abstract = {{2-Amino-1-methyl-6-phenylimidazo{[}4,5-b] pyridine ( PhIP) is the most
   abundant heterocyclic amine in cooked foods, and is both mutagenic and
   carcinogenic. It has been suspected that the carcinogenicity of PhIP is
   derived from its ability to form DNA adducts, principally dG-C8-PhIP. To
   shed further light on the molecular mechanisms underlying the induction
   of mutations by PhIP, in vitro DNA synthesis analyses were carried out
   using a dG-C8-PhIP-modified oligonucleotide template. In this template,
   the dG-C8-PhIP adduct was introduced into the second G of the TCC GGG
   AAC sequence located in the 5' region. This represents one of the
   mutation hot spots in the rat Apc gene that is targeted by PhIP. Guanine
   deletions at this site in the Apc gene have been found to be
   preferentially induced by PhIP in rat colon tumors. DNA synthesis with
   A- or B-family DNA polymerases, such as Escherichia coli polymerase
   (pol) I and human pol delta, was completely blocked at the adducted
   guanine base. Translesional synthesis polymerases of the Y-family, pol
   eta, pol iota, pol kappa, and REV1, were also used for in vitro DNA
   synthesis analyses with the same templates. REV1, pol eta, and pol kappa
   were able to insert dCTP opposite dG-C8-PhIP, although the efficiencies
   for pol eta and pol kappa were low. pol kappa was also able to catalyze
   the extension reaction from the dC opposite dG-C8-PhIP, during which it
   often skipped over one dG of the triple dG sequence on the template.
   This slippage probably leads to the single dG base deletion in colon
   tumors.}},
Publisher = {{AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Nakagama, H (Reprint Author), Natl Canc Ctr, Res Inst, Div Biochem, Chuo Ku, 1-1 Tsukiji 5, Tokyo 1040045, Japan.
   Fukuda, Hirokazu; Seki, Chiho; Sugimura, Takashi; Nakagama, Hitoshi, Natl Canc Ctr, Res Inst, Div Biochem, Chuo Ku, Tokyo 1040045, Japan.
   Takamura-Enya, Takeji, Kanagawa Inst Technol, Fac Engn, Dept Appl Chem, Kanagawa 2430292, Japan.
   Masuda, Yuji; Kamiya, Kenji, Hiroshima Univ, Res Inst Radiat Biol \& Med, Dept Expt Oncol, Minami Ku, Hiroshima 7348553, Japan.
   Nohmi, Takehiko, Natl Inst Hlth Sci, Div Genet \& Mutagenesis, Setagaya Ku, Tokyo 1588501, Japan.
   Masutani, Chikahide; Hanaoka, Fumio, Osaka Univ, Cellular Biol Lab, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan.}},
DOI = {{10.1074/jbc.M109.037259}},
ISSN = {{0021-9258}},
Keywords-Plus = {{YEAST REV1 PROTEIN; HETEROCYCLIC AMINES;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; ESCHERICHIA-COLI;
   COOKED FOOD; IDENTIFICATION; MUTATIONS; RAT; MUTAGENESIS; CARCINOGEN}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{hnakagam@ncc.go.jp}},
Funding-Acknowledgement = {{Kakenhi {[}19570144]}},
Funding-Text = {{This work was supported by Kakenhi Grant 19570144.}},
Cited-References = {{Choi JY, 2006, J BIOL CHEM, V281, P25297, DOI 10.1074/jbc.M605699200.
   Dashwood RH, 1998, CANCER RES, V58, P1127.
   ENDO H, 1994, CANCER RES, V54, P3745.
   Felton J. S., 2000, Food borne carcinogens: heterocyclic amines., P31.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   Fukuda H, 2002, P NATL ACAD SCI USA, V99, P12685, DOI 10.1073/pnas.152456899.
   Fukuda H, 1997, GENES CELLS, V2, P735, DOI 10.1046/j.1365-2443.1997.1580356.x.
   Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301.
   Haracska L, 2002, J BIOL CHEM, V277, P15546, DOI 10.1074/jbc.M112146200.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   Imaida K, 1996, JPN J CANCER RES, V87, P1116.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   Johnson RE, 2000, NATURE, V406, P1015.
   KAKIUCHI H, 1995, P NATL ACAD SCI USA, V92, P910, DOI 10.1073/pnas.92.3.910.
   Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792.
   Kobayashi S, 2002, J BIOL CHEM, V277, P34198, DOI 10.1074/jbc.M204826200.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3.
   Lynch AM, 1998, MUTAGENESIS, V13, P601, DOI 10.1093/mutage/13.6.601.
   Masuda Y, 2003, J BIOL CHEM, V278, P12356, DOI 10.1074/jbc.M211765200.
   Masuda Y, 2007, NUCLEIC ACIDS RES, V35, P6904, DOI 10.1093/nar/gkm822.
   Masuda Y, 2002, FEBS LETT, V520, P88, DOI 10.1016/S0014-5793(02)02773-4.
   Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100.
   MORGENTHALER PML, 1995, CARCINOGENESIS, V16, P713, DOI 10.1093/carcin/16.4.713.
   Mozzherin DJ, 1997, P NATL ACAD SCI USA, V94, P6126, DOI 10.1073/pnas.94.12.6126.
   Nagao M, 1999, MUTAT RES-FUND MOL M, V431, P3, DOI 10.1016/S0027-5107(99)00154-2.
   Nagao M, 1997, MUTAT RES-FUND MOL M, V376, P161, DOI 10.1016/S0027-5107(97)00039-0.
   Nagao M., 2000, Food borne carcinogens: heterocyclic amines., P163.
   Nakagama H, 2002, MUTAT RES-FUND MOL M, V506, P137, DOI 10.1016/S0027-5107(02)00160-4.
   Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0.
   NIIMI N, 2009, BIOCHEMISTRY-US, V48.
   Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x.
   Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   Okochi E, 1999, CARCINOGENESIS, V20, P1933, DOI 10.1093/carcin/20.10.1933.
   Okonogi H, 1997, MUTAT RES-GEN TOX EN, V395, P93, DOI 10.1016/S1383-5718(97)00146-0.
   Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250.
   Sambrook J., 1989, MOL CLONING LAB MANU.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   SUGIMURA T., 2000, Introduction. In Food Borne Carcinogens, P1.
   Sugimura T, 2004, CANCER SCI, V95, P290, DOI 10.1111/j.1349-7006.2004.tb03205.x.
   Sugiyama H, 1996, J AM CHEM SOC, V118, P7063, DOI 10.1021/ja9609821.
   Takamura-Enya T, 2006, CHEM RES TOXICOL, V19, P770, DOI 10.1021/tx050296s.
   YadollahiFarsani M, 1996, CARCINOGENESIS, V17, P617, DOI 10.1093/carcin/17.4.617.}},
Number-of-Cited-References = {{48}},
Times-Cited = {{2}},
Journal-ISO = {{J. Biol. Chem.}},
Doc-Delivery-Number = {{493LK}},
Wos-Id = {{ISI:000269738000016}},
}

@article{ ISI:000267020500015,
Author = {Fede, Jean-Marie and Thakur, Anup P. and Gooderham, Nigel J. and
   Turesky, Robert J.},
Title = {{Biomonitoring of 2-Amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine
   (PhIP) and Its Carcinogenic Metabolites in Urine}},
Journal = {{CHEMICAL RESEARCH IN TOXICOLOGY}},
Year = {{2009}},
Volume = {{22}},
Number = {{6}},
Pages = {{1096-1105}},
Month = {{JUN}},
Abstract = {{2-Amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) is a
   carcinogenic heterocyclic aromatic amine that is produced in cooked
   meats. The simultaneous analysis of PhIP and its metabolites in human
   urine is a challenge, because these biomarkers only occur in urine at
   parts per billion or lower concentrations and must be selectively
   purifed from thousands of other urinary constituents. We have developed
   a facile solid-phase extraction method, employing a mixed-mode
   reverse-phase cation exchange resin, to simultaneously isolate PhIP, its
   glucuronide conjugates, and the glucuronide conjugates of the genotoxic
   metabolite 2-hydroxyamino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine from
   the urine of meat eaters. PhIP and its metabolites were quantified by
   liquid chromatography-electrospray ionization/tandem mass spectrometry
   (LC-ESI/MS/MS), using a triple stage quadrupole mass spectrometer in the
   selected reaction monitoring scan mode. The lower limit of
   quantification (LOQ) of PhIP is 5 parts per trillion (ppt), and the LOQ
   values for the glucuronide conjugates are 50 ppt, when 25 mu L of urine
   is employed for assay. The extraction scheme is versatile and has been
   employed to isolate other ring-hydroxylated and glucuronidated
   metabolites of PhIP, for characterization by LC-ESI/MS/MS.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Turesky, RJ (Reprint Author), New York State Dept Hlth, Wadsworth Ctr, Div Environm Hlth Sci, Albany, NY 12201 USA.
   Fede, Jean-Marie; Thakur, Anup P.; Turesky, Robert J., New York State Dept Hlth, Wadsworth Ctr, Div Environm Hlth Sci, Albany, NY 12201 USA.
   Gooderham, Nigel J., Univ London Imperial Coll Sci Technol \& Med, London SW7 2AZ, England.}},
DOI = {{10.1021/tx900052c}},
ISSN = {{0893-228X}},
Keywords-Plus = {{HETEROCYCLIC AROMATIC-AMINES; CRUCIFEROUS VEGETABLE CONSUMPTION; HUMAN
   LIVER-MICROSOMES; MASS-SPECTROMETRY; DNA-ADDUCTS; DIETARY CARCINOGEN;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO(4,5-B)PYRIDINE PHIP; CYTOCHROME-P450
   ENZYMES; HUMAN HEPATOCYTES; COOKED CHICKEN}},
Research-Areas = {{Pharmacology \& Pharmacy; Chemistry; Toxicology}},
Web-of-Science-Categories  = {{Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology}},
Author-Email = {{Rturesky@wadsworth.org}},
ResearcherID-Numbers = {{yang, min/G-3030-2011}},
Funding-Acknowledgement = {{National Cancer Institute {[}R01CA-122320]}},
Funding-Text = {{The project was supported by Grant R01CA-122320 from the National Cancer
   Institute (J.-M.F., A.P.T., and R.J.T.).}},
Cited-References = {{Alexander J, 2002, FOOD CHEM TOXICOL, V40, P1131, DOI 10.1016/S0278-6915(02)00053-4.
   Alexander J., 1995, HETEROCYCLIC AMINES, P59.
   ALEXANDER J, 1991, CARCINOGENESIS, V12, P2239, DOI 10.1093/carcin/12.12.2239.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   Chen Yi-tai, 2007, Forest Research, V20, P542.
   Crofts FG, 1998, CARCINOGENESIS, V19, P1969, DOI 10.1093/carcin/19.11.1969.
   Dellinger RW, 2007, CARCINOGENESIS, V28, P2412, DOI 10.1093/carcin/bgm164.
   Felton JS, 2004, TOXICOLOGY, V198, P135, DOI 10.1016/j.tox.2004.01.024.
   Frandsen H, 2002, FOOD CHEM TOXICOL, V40, P1125, DOI 10.1016/S0278-6915(02)00033-9.
   Frandsen H, 2008, FOOD CHEM TOXICOL, V46, P3200, DOI 10.1016/j.fct.2008.07.008.
   Frandsen H, 2007, FOOD CHEM TOXICOL, V45, P863, DOI 10.1016/j.fct.2006.11.006.
   FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   Girard H, 2005, HEPATOLOGY, V42, P448, DOI 10.1002/hep.20770.
   Glatt H, 2006, WOODHEAD PUBL FOOD S, P358, DOI 10.1533/9781845692018.2.358.
   Hammons GJ, 1997, CARCINOGENESIS, V18, P851, DOI 10.1093/carcin/18.4.851.
   Hecht SS, 2002, CARCINOGENESIS, V23, P907, DOI 10.1093/carcin/23.6.907.
   Holland RD, 2004, CHEM RES TOXICOL, V17, P1121, DOI 10.1021/tx049910a.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   King R.S., 2000, FOOD BORNE CARCINOGE, P90.
   Kulp KS, 2004, J CHROMATOGR B, V802, P143, DOI 10.1016/j.jchromb.2003.09.032.
   Langouet S, 2002, CARCINOGENESIS, V23, P115, DOI 10.1093/carcin/23.1.115.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   Magagnotti C, 2003, INT J CANCER, V107, P878, DOI 10.1002/ijc.11492.
   Malfatti MA, 2006, CANCER RES, V66, P10541, DOI 10.1158/0008-5472.CAN-06-1573.
   Malfatti MA, 2004, CHEM RES TOXICOL, V17, P1137, DOI 10.1021/tx049898m.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   MINCHIN RF, 1992, BIOCHEM BIOPH RES CO, V185, P839, DOI 10.1016/0006-291X(92)91703-S.
   Mottier P, 2008, J AGR FOOD CHEM, V56, P35, DOI 10.1021/jf072934d.
   Murray S, 2001, CARCINOGENESIS, V22, P1413, DOI 10.1093/carcin/22.9.1413.
   Ni WJ, 2008, J AGR FOOD CHEM, V56, P68, DOI 10.1021/jf072461a.
   Nowell S, 2000, PHARMACOGENETICS, V10, P789, DOI 10.1097/00008571-200012000-00004.
   Nowell SA, 1999, CARCINOGENESIS, V20, P1107, DOI 10.1093/carcin/20.6.1107.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   Snyderwine EG, 1997, MUTAT RES-FUND MOL M, V376, P203, DOI 10.1016/S0027-5107(97)00044-4.
   Stillwell WG, 2002, CARCINOGENESIS, V23, P831, DOI 10.1093/carcin/23.5.831.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   Stillwell WG, 1999, CANCER LETT, V143, P145, DOI 10.1016/S0304-3835(99)00144-5.
   Strassburg CP, 2002, GUT, V50, P851, DOI 10.1136/gut.50.6.851.
   Strickland PT, 2002, MUTAT RES-FUND MOL M, V506, P163, DOI 10.1016/S0027-5107(02)00163-X.
   STYCZYNSKI PB, 1993, CHEM RES TOXICOL, V6, P846, DOI 10.1021/tx00036a014.
   Sugimura T, 2004, CANCER SCI, V95, P290, DOI 10.1111/j.1349-7006.2004.tb03205.x.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P925, DOI 10.1021/tx980022n.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   Turesky RJ, 2002, MUTAT RES-FUND MOL M, V506, P187, DOI 10.1016/S0027-5107(02)00165-3.
   Turesky RJ, 2001, CHEM RES TOXICOL, V14, P901, DOI 10.1021/tx010035s.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   Walters DG, 2004, CARCINOGENESIS, V25, P1659, DOI 10.1093/carcin/bgh164.
   WESTRA JG, 1981, CARCINOGENESIS, V2, P355, DOI 10.1093/carcin/2.4.355.
   Wishart DS, 2007, NUCLEIC ACIDS RES, V35, pD521, DOI 10.1093/nar/gkl923.
   ZHAO K, 1994, CARCINOGENESIS, V15, P1285, DOI 10.1093/carcin/15.6.1285.
   {*}NAT TOX PROGR, 2005, REP CARC US DEP HLTH.}},
Number-of-Cited-References = {{51}},
Times-Cited = {{10}},
Journal-ISO = {{Chem. Res. Toxicol.}},
Doc-Delivery-Number = {{458KX}},
Wos-Id = {{ISI:000267020500015}},
}

@article{ ISI:000263831300002,
Author = {Rohrmann, Sabine and Jung, Sea-Uck Lukas and Linseisen, Jakob and Pfau,
   Wolfgang},
Title = {{Dietary intake of meat and meat-derived heterocyclic aromatic amines and
   their correlation with DNA adducts in female breast tissue}},
Journal = {{MUTAGENESIS}},
Year = {{2009}},
Volume = {{24}},
Number = {{2}},
Pages = {{127-132}},
Month = {{MAR}},
Abstract = {{It was the aim of this study to examine the association of the
   consumption of meat in general, meat prepared by different cooking
   methods and the dietary intake of heterocyclic aromatic amines (HCA)
   with the level of DNA adducts in the breast tissue of women undergoing
   reduction mammoplasty. Dietary intake of meat and HCA were assessed via
   questionnaire in 44 women undergoing reduction mammoplasty. DNA adduct
   analysis in breast tissue was performed by (32)P-postlabelling analysis.
   Spearman rank correlation coefficients (r) were calculated to examine
   the association of meat consumption and dietary HCA intake with tissue
   DNA adduct levels. A median DNA adduct level of 18.45 (interquartile
   range 12.81-25.65) per 10(9) nucleotides in breast tissue was observed;
   median HCA intake was 40.43 ng/day (interquartile range 19.55-102.33
   ng/day). Total HCA intake (r = 0.33, P = 0.03), consumption of fried
   meat (r = 0.39, P = 0.01), beef (r = 0.32, P = 0.03) and processed meat
   (r = 0.51, P = 0.0004) were statistically significantly correlated with
   the level of DNA adducts in breast tissue. The detected DNA adducts
   could not be confirmed to be specific HCA-derived DNA adducts by
   comparison with external standards, using the (32)P-postlabelling assay.
   We observed strong correlations of dietary HCA intake and consumption of
   fried and processed meat with DNA adduct levels in breast tissue of 44
   women. Since the detected DNA adducts were not necessarily specific only
   for HCA, it is possible that HCA intake is a surrogate of other
   genotoxic substances, such as polycyclic aromatic hydrocarbons, in meat
   prepared at high temperatures.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Rohrmann, S (Reprint Author), German Canc Res Ctr, Div Clin Epidemiol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
   Rohrmann, Sabine; Linseisen, Jakob, German Canc Res Ctr, Div Clin Epidemiol, D-69120 Heidelberg, Germany.
   Jung, Sea-Uck Lukas; Pfau, Wolfgang, Univ Hamburg, Fac Med, Dept Expt \& Clin Pharmacol \& Toxicol, Hamburg, Germany.
   Pfau, Wolfgang, Umweltmed Hamburg eV, Hamburg, Germany.}},
DOI = {{10.1093/mutage/gen058}},
ISSN = {{0267-8357}},
Keywords-Plus = {{FOOD FREQUENCY QUESTIONNAIRE; MAMMARY EPITHELIAL-CELLS; N-NITROSO
   COMPOUNDS; BODY-MASS INDEX; CANCER-RISK; RELATIVE VALIDITY; SULT1A1
   POLYMORPHISM; METABOLIC-ACTIVATION; EPIC PROJECT; PAN RESIDUES}},
Research-Areas = {{Genetics \& Heredity; Toxicology}},
Web-of-Science-Categories  = {{Genetics \& Heredity; Toxicology}},
Author-Email = {{s.rohrmann@dkfz.de}},
ResearcherID-Numbers = {{Rohrmann, Sabine/D-2113-2012}},
Funding-Acknowledgement = {{European Union {[}513943]}},
Funding-Text = {{Environmental Cancer Risk, Nutrition and Individual Susceptibility, a
   network of excellence operating within the European Union 6th Framework
   Program, Priority 5: `Food Quality and Safety' ( Contract No 513943).}},
Cited-References = {{ADAMS ME, 1990, COCKROACHES MODELS N, V2, P3.
   ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   Ambrosone CB, 1998, INT J CANCER, V75, P825, DOI 10.1002/(SICI)1097-0215(19980316)75:6<825::AID-IJC2>3.0.CO;2-X.
   Augustsson K, 1999, LANCET, V353, P703, DOI 10.1016/S0140-6736(98)06099-1.
   Bingham SA, 2002, J NUTR, V132, p3522S.
   BohlscheidThomas S, 1997, INT J EPIDEMIOL, V26, pS59, DOI 10.1093/ije/26.suppl\_1.S59.
   BohlscheidThomas S, 1997, INT J EPIDEMIOL, V26, pS71, DOI 10.1093/ije/26.suppl\_1.S71.
   Cantwell M, 2004, CANCER EPIDEM BIOMAR, V13, P293, DOI 10.1158/1055-9965.EPI-270-2.
   Carmichael PL, 1996, CARCINOGENESIS, V17, P1769, DOI 10.1093/carcin/17.8.1769.
   Cho EY, 2006, ARCH INTERN MED, V166, P2253, DOI 10.1001/archinte.166.20.2253.
   Delfino RJ, 2000, CARCINOGENESIS, V21, P607, DOI 10.1093/carcin/21.4.607.
   DeStefani E, 1997, CANCER EPIDEM BIOMAR, V6, P573.
   EASTY GC, 1980, INT J CANCER, V26, P577, DOI 10.1002/ijc.2910260509.
   Gertig DM, 1999, INT J CANCER, V80, P13, DOI 10.1002/(SICI)1097-0215(19990105)80:1<13::AID-IJC3>3.0.CO;2-W.
   Godschalk RWL, 2002, CANCER EPIDEM BIOMAR, V11, P790.
   Gorlewska-Roberts K, 2002, ENVIRON MOL MUTAGEN, V39, P184, DOI 10.1002/em.10060.
   GUPTA RC, 1985, CANCER RES, V45, P5656.
   Han DF, 2004, TOXICOL LETT, V150, P167, DOI 10.1016/j.toxlet.2004.01.012.
   Hermann S, 2002, NUTR CANCER, V44, P23, DOI 10.1207/S15327914NC441\_4.
   Jakszyn P, 2006, CARCINOGENESIS, V27, P1497, DOI 10.1093/carcin/bcl019.
   Jakszyn P, 2006, WORLD J GASTROENTERO, V12, P4296.
   Knize M G, 1999, Adv Exp Med Biol, V459, P179.
   Li DH, 1996, CANCER RES, V56, P287.
   Lightfoot TJ, 2000, MUTAT RES-GEN TOX EN, V472, P119, DOI 10.1016/S1383-5718(00)00134-0.
   Lijinsky W, 1999, MUTAT RES-GEN TOX EN, V443, P129, DOI 10.1016/S1383-5742(99)00015-0.
   Linseisen J, 2002, PUBLIC HEALTH NUTR, V5, P1243, DOI 10.1079/PHN2002402.
   Linseisen J, 2006, PUBLIC HEALTH NUTR, V9, P449, DOI 10.1079/PHN2005861.
   Martin FL, 1996, CANCER RES, V56, P5342.
   Missmer SA, 2002, INT J EPIDEMIOL, V31, P78, DOI 10.1093/ije/31.1.78.
   PERERA FP, 1995, CANCER EPIDEM BIOMAR, V4, P233.
   Pfau W, 1998, CANCER EPIDEM BIOMAR, V7, P1019.
   PFAU W, 1992, CARCINOGENESIS, V13, P907, DOI 10.1093/carcin/13.5.907.
   PFAU W, 1994, CARCINOGENESIS, V15, P877, DOI 10.1093/carcin/15.5.877.
   Phillips DH, 1999, MUTAT RES-GEN TOX EN, V443, P139, DOI 10.1016/S1383-5742(99)00016-2.
   Phillips DH, 2000, ENVIRON MOL MUTAGEN, V35, P222, DOI 10.1002/(SICI)1098-2280(2000)35:3<222::AID-EM9>3.0.CO;2-E.
   Rohrmann S, 2001, ERNAHRUNGS-UMSCHAU, V48, P447.
   Rohrmann S, 2002, PUBLIC HEALTH NUTR, V5, P699, DOI 10.1079/PHN2002331.
   ROHRMANN S, 2007, BR J NUTR, V28, P1112.
   Rundle A, 2003, CANCER EPIDEM BIOMAR, V12, P911.
   Rundle A, 2000, CARCINOGENESIS, V21, P1281, DOI 10.1093/carcin/21.7.1281.
   Rundle A, 2007, BIOMARKERS, V12, P123, DOI 10.1080/13547500601010418.
   Shirai T, 1995, Princess Takamatsu Symp, V23, P232.
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P279, DOI 10.1016/S0278-6915(97)00162-2.
   SINHA R, 1995, CANCER RES, V55, P4516.
   Sinha R, 2000, J NATL CANCER I, V92, P1352, DOI 10.1093/jnci/92.16.1352.
   Skog K, 2002, FOOD CHEM TOXICOL, V40, P1197, DOI 10.1016/S0278-6915(02)00052-2.
   Skog K, 1997, FOOD CHEM TOXICOL, V35, P555, DOI 10.1016/S0278-6915(97)00021-5.
   SKOG K, 1995, CARCINOGENESIS, V16, P861, DOI 10.1093/carcin/16.4.861.
   Snyderwine EG, 1998, RECENT RES CANCER, V152, P3.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   Tang DL, 2003, BREAST CANCER RES TR, V78, P217, DOI 10.1023/A:1022968303118.
   Taylor EF, 2007, BRIT J CANCER, V96, P1139, DOI 10.1038/sj.bjc.6603689.
   Thompson PA, 2002, ENVIRON MOL MUTAGEN, V39, P134, DOI 10.1002/em.10067.
   Wang MY, 1998, CANCER RES, V58, P38.
   Williams JA, 2001, PHARMACOGENETICS, V11, P373, DOI 10.1097/00008571-200107000-00002.
   Zheng W, 1998, J NATL CANCER I, V90, P1724, DOI 10.1093/jnci/90.22.1724.
   Zhu JJ, 2003, CANCER EPIDEM BIOMAR, V12, P830.}},
Number-of-Cited-References = {{57}},
Times-Cited = {{5}},
Journal-ISO = {{Mutagenesis}},
Doc-Delivery-Number = {{413YO}},
Wos-Id = {{ISI:000263831300002}},
}

@article{ ISI:000268737300003,
Author = {Zheng, Wei and Lee, Sang-Ah},
Title = {{Well-Done Meat Intake, Heterocyclic Amine Exposure, and Cancer Risk}},
Journal = {{NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL}},
Year = {{2009}},
Volume = {{61}},
Number = {{4}},
Pages = {{437-446}},
Abstract = {{High intake of meat, particularly red and processed meat, has been
   associated with an increased risk of a number of common cancers such as
   breast, colorectum, and prostate in many epidemiological studies.
   Heterocyclic amines (HCAs) are a group of mutagenic compounds found in
   cooked meats, particularly well-done meats. HCAs are some of most potent
   mutagens detected using the Ames/salmonella tests and have been clearly
   shown to induce tumors in experimental animal models. Over the past 10
   years, an increasing number of epidemiological studies have evaluated
   the association of well-done meat intake and meat carcinogen exposure
   with cancer risk. The results from these epidemiologic studies were
   evaluated and summarized in this review. The majority of these studies
   have shown that high intake of well-done meat and high exposure to meat
   carcinogens, particularly HCAs, may increase the risk of human cancer.}},
Publisher = {{LAWRENCE ERLBAUM ASSOC INC-TAYLOR \& FRANCIS}},
Address = {{325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Zheng, W (Reprint Author), Vanderbilt Univ, Sch Med, Inst Med \& Publ Hlth, Vanderbilt Epidemiol Ctr,Div Epidemiol,Dept Med, 2525 W End Ave,8th Floor,Suite 800, Nashville, TN 37203 USA.
   Zheng, Wei; Lee, Sang-Ah, Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37203 USA.}},
DOI = {{10.1080/01635580802710741}},
ISSN = {{0163-5581}},
Keywords-Plus = {{PHIP-DNA ADDUCTS; BREAST-CANCER; COLORECTAL-CANCER; PANCREATIC-CANCER;
   PROSTATE-CANCER; RED MEAT; DIETARY-INTAKE; UNITED-STATES; COLON-CANCER;
   GENETIC SUSCEPTIBILITY}},
Research-Areas = {{Oncology; Nutrition \& Dietetics}},
Web-of-Science-Categories  = {{Oncology; Nutrition \& Dietetics}},
Author-Email = {{wei.zheng@vanderbilt.edu}},
Funding-Acknowledgement = {{NIH {[}R01CA100374]; Physicians Committee for Responsible Medicine}},
Funding-Text = {{This work is supported in part by NIH grant R01CA100374 and the
   Physicians Committee for Responsible Medicine. The authors would like to
   thank Brandy Sue Venuti for technical assistance in the preparation of
   this review.}},
Cited-References = {{Adamson R. H., 1995, HETEROCYCLIC AMINES.
   Anderson KE, 2002, MUTAT RES-FUND MOL M, V506, P225, DOI 10.1016/S0027-5107(02)00169-0.
   Anderson KE, 2005, CANCER EPIDEM BIOMAR, V14, P2261, DOI 10.1158/1055-9965.EPI-04-0514.
   Augustsson K, 1999, LANCET, V353, P703, DOI 10.1016/S0140-6736(98)06099-1.
   Butler LM, 2003, AM J EPIDEMIOL, V157, P434, DOI 10.1093/aje/kwf221.
   Butler LM, 2005, CANCER EPIDEM BIOMAR, V14, P1626, DOI 10.1158/1055-9965.EPI-04-0682.
   Chao A, 2005, JAMA-J AM MED ASSOC, V293, P172, DOI 10.1001/jama.293.2.172.
   Cho EY, 2006, ARCH INTERN MED, V166, P2253, DOI 10.1001/archinte.166.20.2253.
   Cross AJ, 2004, ENVIRON MOL MUTAGEN, V44, P44, DOI 10.1002/em.20030.
   Cross AJ, 2005, CANCER RES, V65, P11779, DOI 10.1158/0008-5472CAN-05-2191.
   Deitz AC, 2000, CANCER EPIDEM BIOMAR, V9, P905.
   Delfino RJ, 2000, CARCINOGENESIS, V21, P607, DOI 10.1093/carcin/21.4.607.
   De Stefani E, 1998, NUTR CANCER, V32, P43.
   DeStefani E, 1997, CANCER EPIDEM BIOMAR, V6, P573.
   De Stefani E, 2001, NUTR CANCER, V40, P103, DOI 10.1207/S15327914NC402\_5.
   Felton JS, 2007, MUTAT RES-FUND MOL M, V616, P90, DOI 10.1016/j.mrfmmm.2006.11.010.
   Gunter MJ, 2005, CARCINOGENESIS, V26, P637, DOI 10.1093/carcin/bgh350.
   Hunter DJ, 1996, NEW ENGL J MED, V334, P356, DOI 10.1056/NEJM199602083340603.
   Ishibe N, 2002, PHARMACOGENETICS, V12, P145, DOI 10.1097/00008571-200203000-00008.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   Kampman E, 1999, CANCER EPIDEM BIOMAR, V8, P15.
   Key TJ, 2002, LANCET, V360, P861, DOI 10.1016/S0140-6736(02)09958-0.
   Knize MG, 2005, NUTR REV, V63, P158, DOI 10.1301/nr.2005.may.158-165.
   Kobayashi M, 2007, MUTAT RES-GEN TOX EN, V630, P14, DOI 10.1016/jmrgentox.2007.02.003.
   Koutros S, 2008, CANCER EPIDEM BIOMAR, V17, P80, DOI 10.1158/1055-9965.EPI-07-0392.
   Larsson SC, 2006, INT J CANCER, V119, P2657, DOI 10.1002/ijc.22170.
   Le Marchand L, 2001, CANCER EPIDEM BIOMAR, V10, P1259.
   Li DH, 2007, CANCER EPIDEM BIOMAR, V16, P655, DOI 10.1158/1055-9965.EPI-06-0993.
   Malfatti MA, 2006, CANCER RES, V66, P10541, DOI 10.1158/0008-5472.CAN-06-1573.
   Murtaugh MA, 2005, J NUTR, V135, P179.
   Murtaugh MA, 2004, J NUTR, V134, P776.
   Navarro A, 2004, NUTRITION, V20, P873, DOI 10.1016/j.nut.2004.06.008.
   Norat T, 2005, J NATL CANCER I, V97, P906, DOI 10.1093/jnci/dji164.
   Norrish AE, 1999, J NATL CANCER I, V91, P2038, DOI 10.1093/jnci/91.23.2038.
   Nowell S, 2002, MUTAT RES-FUND MOL M, V506, P175, DOI 10.1016/S0027-5107(02)00164-1.
   ProbstHensch NM, 1997, CANCER CAUSE CONTROL, V8, P175, DOI 10.1023/A:1018416128894.
   Rovito PM, 2005, PROSTATE CANCER P D, V8, P69, DOI 10.1038/sj.pcan.4500780.
   SHIN A, 2007, CANCER EPIDEM BIOMAR, V17, P320.
   Shin A, 2007, INT J CANCER, V121, P136, DOI 10.1002/ijc.22664.
   SHIRAI T, 1995, HETEROCYCLIC AMINES, P232.
   Sinha R, 2000, CANCER RES, V60, P3753.
   Sinha R, 2000, J NATL CANCER I, V92, P1352, DOI 10.1093/jnci/92.16.1352.
   Sinha R, 1998, CANCER CAUSE CONTROL, V9, P621, DOI 10.1023/A:1008805525525.
   Sinha R, 2001, CANCER EPIDEM BIOMAR, V10, P559.
   Sinha R, 2002, MUTAT RES-FUND MOL M, V506, P197, DOI 10.1016/S0027-5107(02)00166-5.
   Sinha R, 1999, CANCER RES, V59, P4320.
   Sinha R, 2005, CANCER RES, V65, P8034, DOI 10.1158/0008-5472.CAN-04-3429.
   Stolzenberg-Solomon RZ, 2007, CANCER EPIDEM BIOMAR, V16, P2664, DOI 10.1158/1055-9965.EPI-07-0378.
   Tang D, 2007, INT J CANCER, V121, P1319, DOI 10.1002/ijc.22806.
   Tang DL, 2007, CANCER EPIDEM BIOMAR, V16, P803, DOI 10.1158/1055-9965.EPI-06-0973.
   Terry PD, 2003, CANCER EPIDEM BIOMAR, V12, P940.
   Tiemersma EW, 2004, CANCER CAUSE CONTROL, V15, P225, DOI 10.1023/B:CACO.0000024263.44973.92.
   Turesky RJ, 2004, J CHROMATOGR B, V802, P155, DOI 10.1016/j.jchromb.2003.10.053.
   Ward MH, 1997, INT J CANCER, V71, P14, DOI 10.1002/(SICI)1097-0215(19970328)71:1<14::AID-IJC4>3.0.CO;2-6.
   Willett WC, 2005, JAMA-J AM MED ASSOC, V293, P233, DOI 10.1001/jama.293.2.233.
   Wu K, 2006, CANCER EPIDEM BIOMAR, V15, P1120, DOI 10.1158/1055-9965.EPI-05-0782.
   Zheng W, 1998, J NATL CANCER I, V90, P1724, DOI 10.1093/jnci/90.22.1724.
   Zheng W, 1999, CANCER EPIDEM BIOMAR, V8, P233.
   Zheng W, 2001, CANCER EPIDEM BIOMAR, V10, P89.
   Zheng W, 2002, BREAST CANCER RES TR, V74, P9, DOI 10.1023/A:1016005100958.
   Zhu J, 2006, BIOMARKERS, V11, P319, DOI 10.1080/13547500600667911.}},
Number-of-Cited-References = {{61}},
Times-Cited = {{51}},
Journal-ISO = {{Nutr. Cancer}},
Doc-Delivery-Number = {{480LW}},
Wos-Id = {{ISI:000268737300003}},
}

@article{ ISI:000260420800002,
Author = {Jamin, Emilien L. and Arquier, Delphine and Tulliez, Jacques and
   Debrauwer, Laurent},
Title = {{Mass spectrometric investigation of the sequence selectivity for
   adduction of heterocyclic aromatic amines on single-strand
   oligonucleotides}},
Journal = {{RAPID COMMUNICATIONS IN MASS SPECTROMETRY}},
Year = {{2008}},
Volume = {{22}},
Number = {{20}},
Pages = {{3100-3110}},
Month = {{OCT}},
Abstract = {{Heterocyclic aromatic amines (HAAs) generated during the cooking of
   meats are known to be genotoxic substances able to form covalent bonds
   with DNA bases after metabolic activation. This work aimed at the
   investigation of the influence of the local environment of nucleobases
   along the nucleotidic sequence on its modification induced by two
   different HAAs, namely 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine
   (PhIP) and 2-amino-3-methylimidazo{[}4,5-flquinoline (IQ), in order to
   identify possible sequences more susceptible to modification. A
   systematic study of the neighbouring base effect on the adduction was
   emphasized. Thus, PhIP and IQ adducts have been synthesized with various
   T-rich model single-strand oligonucleotides displaying different
   flanking bases (A, G, C or T) at the 3' or the 5' side of the targeted
   guanine, which allowed a comparison of the flanking base effects on
   adduction.. Modified oligonucleotides were then analyzed by
   high-performance liquid chromatography (HPLC) coupled to electrospray
   ionization mass spectrometry. The localization of the modifications
   induced by PhIP or IQ along the oligonucleotide sequence was achieved by
   tandem mass spectrometry, and modification yields of the various model
   sequences were compared. Results indicate a favouring sequence context
   effect on the G-C8-IQ adduct formation with the sequence (5')GGG(3').
   Although higher than IQ, modification yields observed with PhIP showed a
   less obvious effect of the neighbouring base on the G-C8-PhIP adduct
   formation, with a preferential sequence (5')GGA/G/T-3'. Copyright (C)
   2008 John Wiley \& Sons, Ltd.}},
Publisher = {{JOHN WILEY \& SONS LTD}},
Address = {{THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Jamin, EL (Reprint Author), INRA, UMR Xenobiot 1089, 180 Chem Tournefeuille, F-31931 Toulouse 9, France.
   Jamin, Emilien L.; Arquier, Delphine; Tulliez, Jacques; Debrauwer, Laurent, INRA, UMR Xenobiot 1089, F-31000 Toulouse, France.}},
DOI = {{10.1002/rcm.3707}},
ISSN = {{0951-4198}},
Keywords-Plus = {{MULTIPLY-CHARGED OLIGONUCLEOTIDES; DNA ADDUCT;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; TRUNCATION
   MUTATIONS; INHIBITION ASSAYS; BINDING-SITES; DIOL EPOXIDE; DUPLEX DNA;
   APC GENE; IN-VITRO}},
Research-Areas = {{Chemistry; Spectroscopy}},
Web-of-Science-Categories  = {{Chemistry, Analytical; Spectroscopy}},
Author-Email = {{jamin@toulouse.inra.fr}},
ResearcherID-Numbers = {{Jamin, Emilien/B-7407-2009
   Debrauwer, Laurent/H-7807-2013}},
Funding-Acknowledgement = {{INP}},
Funding-Text = {{Financial Support (EL Jamin, PhD grant) was provided by INP (Institut
   National Polytechnique de Toulouse, France) which is greatly
   acknowledged. The authors would also like to especially thank Alexia
   Carrere for her contribution during the development of syntheses of
   adducts. Estelle Rathahao and Isabelle Jouanin (INRA, Toulouse, France)
   are thanked for helpful advice concerning the oligonucleotides adduct
   syntheses and LC/MS/MS analyses.}},
Cited-References = {{ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   Andreassen A, 2002, MUTAT RES-GEN TOX EN, V517, P157, DOI 10.1016/S1383-5718(02)00065-7.
   Andrews CL, 2004, INT J MASS SPECTROM, V231, P169, DOI {[}10.1016/j.ijms.2003.10.005, 10.1016/j.ijins.2003.10.005].
   Bol SAM, 2000, CARCINOGENESIS, V21, P1, DOI 10.1093/carcin/21.1.1.
   Brown K, 2003, J MASS SPECTROM, V38, P68, DOI 10.1002/jms.401.
   Brown K, 2001, P NATL ACAD SCI USA, V98, P8507, DOI 10.1073/pnas.151251898.
   COMBATES NJ, 1992, J BIOMOL STRUCT DYN, V10, P63.
   Debrauwer L, 2002, J CHROMATOGR A, V976, P123, DOI 10.1016/S0021-9673(02)00940-8.
   de Kok TMCM, 2002, J CHROMATOGR B, V778, P345, DOI 10.1016/S0378-4347(01)00543-6.
   Goodenough AK, 2007, CHEM RES TOXICOL, V20, P263, DOI 10.1021/tx0601713.
   Harsch A, 1998, ANAL CHEM, V70, P3021, DOI 10.1021/ac9713823.
   Harsch A, 2000, CHEM RES TOXICOL, V13, P1342, DOI 10.1021/tx000140m.
   IARC, 1993, IARC MON EV CARC RIS, V56, P165.
   Jamin EL, 2007, J AM SOC MASS SPECTR, V18, P2107, DOI 10.1016/j.jasms.2007.09.008.
   KAKIUCHI H, 1995, P NATL ACAD SCI USA, V92, P910, DOI 10.1073/pnas.92.3.910.
   Leong-Morgenthaler PM, 1998, CARCINOGENESIS, V19, P1749, DOI 10.1093/carcin/19.10.1749.
   LOBANENKOV VV, 1986, CARCINOGENESIS, V7, P1689, DOI 10.1093/carcin/7.10.1689.
   MALLAMACI MA, 1992, J BIOMOL STRUCT DYN, V10, P83.
   Marzilli LA, 1998, J AM SOC MASS SPECTR, V9, P676, DOI 10.1016/S1044-0305(98)00039-7.
   MCLUCKEY SA, 1994, J AM SOC MASS SPECTR, V5, P740, DOI 10.1016/1044-0305(94)80006-5.
   MCLUCKEY SA, 1992, J AM SOC MASS SPECTR, V3, P60, DOI 10.1016/1044-0305(92)85019-G.
   Mollersen L, 2004, MUTAT RES-GEN TOX EN, V557, P29, DOI 10.1016/j.mrgentox.2003.09.008.
   Murkovic M, 2004, J CHROMATOGR B, V802, P3, DOI 10.1016/j.jchromb.2003.09.026.
   Nagao M, 1999, MUTAT RES-FUND MOL M, V431, P3, DOI 10.1016/S0027-5107(99)00154-2.
   Novak M, 2004, J PHYS ORG CHEM, V17, P615, DOI 10.1002/poc.765.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   Okochi E, 1999, CARCINOGENESIS, V20, P1933, DOI 10.1093/carcin/20.10.1933.
   Okonogi H, 1997, MUTAT RES-GEN TOX EN, V395, P93, DOI 10.1016/S1383-5718(97)00146-0.
   Okonogi H, 1997, CARCINOGENESIS, V18, P745, DOI 10.1093/carcin/18.4.745.
   RILL RL, 1990, BIOCHEMISTRY-US, V29, P6050, DOI 10.1021/bi00477a024.
   Shibutani S, 1998, Z LEBENSM UNTERS F A, V207, P459, DOI 10.1007/s002170050361.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   Turesky RJ, 2004, J CHROMATOGR B, V802, P155, DOI 10.1016/j.jchromb.2003.10.053.
   Turesky RJ, 2005, MOL NUTR FOOD RES, V49, P101, DOI 10.1002/mnfr.200400076.
   Vanhoutte K, 1997, ANAL CHEM, V69, P3161, DOI 10.1021/ac970121q.
   Wan KX, 2001, J AM SOC MASS SPECTR, V12, P580, DOI 10.1016/S1044-0305(01)00223-9.
   Winsten J. A., 1977, ORIGINS HUMAN CANC, P1561.
   Wu J, 2004, INT J MASS SPECTROM, V237, P197, DOI 10.1016/j.ijms.2004.06.014.
   Wu XY, 1999, CHEM RES TOXICOL, V12, P895, DOI 10.1021/tx990108w.
   Yu MS, 2002, CARCINOGENESIS, V23, P877, DOI 10.1093/carcin/23.5.877.
   {*}IARC, 1987, IARC MON EV CARC RIS, V40, P222.
   {*}IARC, 1987, IARC MON EV CARC RIS, V31, P247.}},
Number-of-Cited-References = {{42}},
Times-Cited = {{4}},
Journal-ISO = {{Rapid Commun. Mass Spectrom.}},
Doc-Delivery-Number = {{365PX}},
Wos-Id = {{ISI:000260420800002}},
}

@article{ ISI:000259762100035,
Author = {Frandsen, H.},
Title = {{Biomonitoring of urinary metabolites of 2-amino-1-methyl-6-phenylimidazo
   {[}4,5-b]pyridine (PhIP) following human consumption of cooked chicken}},
Journal = {{FOOD AND CHEMICAL TOXICOLOGY}},
Year = {{2008}},
Volume = {{46}},
Number = {{9}},
Pages = {{3200-3205}},
Month = {{SEP}},
Abstract = {{Human risk assessment of exposure to
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) through the
   diet may be improved by conducting biomonitoring studies comparing
   metabolism in humans and rodents. Eleven volunteers ingested a meal of
   cooked chicken containing 4-OH-PhIP and PhIP in amounts of 0.6 and 0.8
   mu g/kg, respectively and urine was collected for the next 16 h. The
   large number of PhIP metabolites was by treatment of the urine samples
   with hydrazine hydrate and hydrolytic enzymes reduced to three
   substances, 4'-OH-PhIP, PhIP and 5-OH-PhIP of which the first is a
   biomarker for detoxification and the last a biomarker for activation.
   The eleven volunteers eliminated large amounts of 4'-OH-PhiP in the
   urine. The majority of which Could be accounted for by the presence of
   4'-OH-PhIP in the fried chicken, showing that PhIP only to a small
   extent (11\%) was metabolised to 4'-OH-PhIP. A larger fraction of the
   PhIP exposure, 38\%, was recovered as PhIP and the largest fraction
   (51\%) was recovered as 5-OH-PhIP Suggesting that PhIP in humans to a
   large extent is metabolised to reactive Substances. In rats, less than
   1\% of the dose of PhIP was eliminated as 5-OH-PhIP, Suggesting that
   human cancer risk from exposure to PhIP is considerable higher than risk
   estimations based on extrapolation from rodent bioassays. (C) 2008
   Elsevier Ltd. All rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Frandsen, H (Reprint Author), Tech Univ Denmark, Natl Food Inst, Morkhoj Bygade 19, DK-2860 Soborg, Denmark.
   Tech Univ Denmark, Natl Food Inst, DK-2860 Soborg, Denmark.}},
DOI = {{10.1016/j.fct.2008.07.008}},
ISSN = {{0278-6915}},
Keywords = {{biomonitoring; PhIP; metabolites; human}},
Keywords-Plus = {{HETEROCYCLIC AMINES; ADDUCT FORMATION; FOOD MUTAGEN; IDENTIFICATION;
   DNA; EXPOSURE; 2'-DEOXYGUANOSINE; ACTIVATION; CARCINOGEN; BIOMARKER}},
Research-Areas = {{Food Science \& Technology; Toxicology}},
Web-of-Science-Categories  = {{Food Science \& Technology; Toxicology}},
Author-Email = {{hlafr@food.dtu.dk}},
Cited-References = {{Alexander J, 2002, FOOD CHEM TOXICOL, V40, P1131, DOI 10.1016/S0278-6915(02)00053-4.
   Alexander J, 1997, MUTAT RES-FUND MOL M, V376, P7, DOI 10.1016/S0027-5107(97)00019-5.
   Busquets R, 2007, J AGR FOOD CHEM, V55, P9318, DOI 10.1021/jf072252q.
   CHEN C, 2007, CHEM RES TOXICOL, P531.
   Dingley KH, 1999, CANCER EPIDEM BIOMAR, V8, P507.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312.
   Frandsen H, 2000, CARCINOGENESIS, V21, P1197, DOI 10.1093/carcin/21.6.1197.
   Frandsen H, 2002, FOOD CHEM TOXICOL, V40, P1125, DOI 10.1016/S0278-6915(02)00033-9.
   FRANDSEN H, 1991, MUTAGENESIS, V6, P93, DOI 10.1093/mutage/6.1.93.
   FRANDSEN H, 2006, FOOD CHEM TOXICOL, V45, P863.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   Ito N, 1997, MUTAT RES-FUND MOL M, V376, P107, DOI 10.1016/S0027-5107(97)00032-8.
   Knize MG, 2005, NUTR REV, V63, P158, DOI 10.1301/nr.2005.may.158-165.
   Lake B. G., 1987, BIOCH TOXICOLOGY PRA, P183.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MacLeod S, 1997, MUTAT RES-FUND MOL M, V376, P135, DOI 10.1016/S0027-5107(97)00036-5.
   Malfatti MA, 2006, CANCER RES, V66, P10541, DOI 10.1158/0008-5472.CAN-06-1573.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   NAGAOKA H, 1992, JPN J CANCER RES, V83, P1025.
   REISTAD R, 1994, CARCINOGENESIS, V15, P2547, DOI 10.1093/carcin/15.11.2547.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P217, DOI 10.1021/tx9701891.
   Turteltaub KW, 1999, CANCER LETT, V143, P149, DOI 10.1016/S0304-3835(99)00116-0.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{14}},
Journal-ISO = {{Food Chem. Toxicol.}},
Doc-Delivery-Number = {{356ES}},
Wos-Id = {{ISI:000259762100035}},
}

@article{ ISI:000258388600011,
Author = {Shah, Faiz Ullah and Barri, Thaer and Jonsson, Jan Ake and Skog, Kerstin},
Title = {{Determination of heterocyclic aromatic amines in human urine by using
   hollow-fibre supported liquid membrane extraction and liquid
   chromatography-ultraviolet detection system}},
Journal = {{JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
   AND LIFE SCIENCES}},
Year = {{2008}},
Volume = {{870}},
Number = {{2}},
Pages = {{203-208}},
Month = {{JUL 15}},
Abstract = {{A hollow-fibre supported liquid membrane (HF-SLM) extraction method has
   been developed for determination of 11 heterocyclic aromatic amines
   (HCAs) in human urine samples by using high performance liquid
   chromatography (HPLC) equipped with an ultraviolet (UV) absorbance
   detector. These compounds were extracted from an alkaline urine sample
   (donor phase) into the organic solvent residing in the pores of a
   polypropylene hollow fibre and then back extracted into an acidic
   solution (acceptor phase) inside the lumen of the hollow fibre. After
   extraction, HCAs were analyzed by injecting the analyte enriched
   acceptor phase into the HPLC. The analyte enrichment factors ranged
   between 241 and 339 obtained in a 90 min extraction time, and method
   detection limits (MDL) ranged between 0.1 and 0.5 mu g L-1 with relative
   standard deviation (RSD) values between 3.4\% and 11\%. The extraction
   technique employed in this work is easy to use and rapid as it involves
   only a few minutes manipulation of each sample. It is the most
   economical sample preparation/preconcentration technique to our
   knowledge as compared to other microextraction techniques. (C) 2008
   Elsevier B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Jonsson, JA (Reprint Author), Lund Univ, Dept Analyt Chem, POB 124, SE-22100 Lund, Sweden.
   Shah, Faiz Ullah; Barri, Thaer; Jonsson, Jan Ake, Lund Univ, Dept Analyt Chem, SE-22100 Lund, Sweden.
   Skog, Kerstin, Lund Univ, Dept Food Engn Technol \& Nutr, SE-22100 Lund, Sweden.}},
DOI = {{10.1016/j.jchromb.2008.06.006}},
ISSN = {{1570-0232}},
Keywords = {{heterocyclic aromatic amines; urine sample; hollow-fibre supported
   liquid membrane; high performance liquid chromatography with ultraviolet
   detector}},
Keywords-Plus = {{IONIZATION MASS-SPECTROMETRY;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO(4,5-B)PYRIDINE PHIP; MUTAGENIC AMINES;
   BEEF EXTRACTS; MEAT EXTRACTS; MODEL SYSTEMS; FRIED BEEF; CARCINOGEN;
   SAMPLES; IDENTIFICATION}},
Research-Areas = {{Biochemistry \& Molecular Biology; Chemistry}},
Web-of-Science-Categories  = {{Biochemical Research Methods; Chemistry, Analytical}},
Author-Email = {{jan\_ake.jonsson@analykem.lu.se}},
ResearcherID-Numbers = {{Shah, Faiz Ullah/I-3891-2012}},
ORCID-Numbers = {{Shah, Faiz Ullah/0000-0003-3652-7798}},
Cited-References = {{Britt C, 1998, J AGR FOOD CHEM, V46, P4891, DOI 10.1021/jf980233y.
   Busquets R, 2004, J CHROMATOGR B, V802, P79, DOI 10.1016/j.jchromb.2003.09.033.
   Cardenes L, 2004, J CHROMATOGR A, V1030, P87, DOI 10.1016/j.chroma.2003.10.040.
   FELTON JS, 2000, FOOD BORNE CARCINOGE.
   Friesen MD, 2001, CANCER LETT, V173, P43, DOI 10.1016/S0304-3835(01)00672-3.
   Galceran MT, 1996, J CHROMATOGR A, V719, P203, DOI 10.1016/0021-9673(95)00420-3.
   JAGERSTAD M, 1991, MUTAT RES, V259, P219, DOI 10.1016/0165-1218(91)90119-7.
   Jonsson JA, 2000, J CHROMATOGR A, V902, P205, DOI 10.1016/S0021-9673(00)00922-5.
   Kataoka H, 1998, B ENVIRON CONTAM TOX, V60, P60.
   Kataoka H, 2000, MUTAT RES-GEN TOX EN, V466, P27, DOI 10.1016/S1383-5718(99)00235-1.
   Knize MG, 1998, J AGR FOOD CHEM, V46, P4648, DOI 10.1021/jf980639a.
   Knize MG, 2001, J CHROMATOGR A, V914, P95, DOI 10.1016/S0021-9673(01)00522-2.
   Lezamiz J, 2008, ANAL BIOANAL CHEM, V390, P689, DOI 10.1007/s00216-007-1702-4.
   Lezamiz J, 2007, J CHROMATOGR A, V1152, P226, DOI 10.1016/j.chroma.2006.11.104.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   MANABE S, 1993, ENVIRON POLLUT, V80, P281, DOI 10.1016/0269-7491(93)90049-T.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   MURRAY S, 1988, CARCINOGENESIS, V9, P321, DOI 10.1093/carcin/9.2.321.
   Pais P, 1997, J CHROMATOGR A, V778, P207, DOI 10.1016/S0021-9673(97)00219-7.
   Pais P, 2000, J AGR FOOD CHEM, V48, P1721, DOI 10.1021/jf990601d.
   Puignou L, 1997, J CHROMATOGR A, V769, P293, DOI 10.1016/S0021-9673(97)00033-2.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   Richling E, 1997, J CHROMATOGR A, V791, P71, DOI 10.1016/S0021-9673(97)00842-X.
   Skog K, 1998, J CHROMATOGR A, V803, P227, DOI 10.1016/S0021-9673(97)01266-1.
   SKOG K, 1992, MUTAT RES, V268, P191, DOI 10.1016/0027-5107(92)90224-P.
   SKOG K, 2002, FOOD CHEM TOXICOL, V40, P1212.
   Strickland PT, 2002, MUTAT RES-FUND MOL M, V506, P163, DOI 10.1016/S0027-5107(02)00163-X.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   SUGIMURA T, 1988, TRENDS PHARMACOL SCI, V9, P205.
   Toribio F, 2000, J CHROMATOGR A, V869, P307, DOI 10.1016/S0021-9673(99)01091-2.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   Viberg P, 2006, J CHROMATOGR A, V1133, P347, DOI 10.1016/j.chroma.2006.08.034.}},
Number-of-Cited-References = {{32}},
Times-Cited = {{22}},
Journal-ISO = {{J. Chromatogr. B}},
Doc-Delivery-Number = {{336TX}},
Wos-Id = {{ISI:000258388600011}},
}

@article{ ISI:000252170400025,
Author = {Lezamiz, Jon and Barri, Thaer and Jonsson, Jan Ake and Skog, Kerstin},
Title = {{A simplified hollow-fibre supported liquid membrane extraction method
   for quantification of 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine
   (PhIP) in urine and plasma samples}},
Journal = {{ANALYTICAL AND BIOANALYTICAL CHEMISTRY}},
Year = {{2008}},
Volume = {{390}},
Number = {{2}},
Pages = {{689-696}},
Month = {{JAN}},
Abstract = {{A simple and easy-to-use extraction procedure has been optimised,
   validated, and applied for extraction of
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) in urine and
   spiked plasma samples. PhIP is a carcinogenic and mutagenic heterocyclic
   aromatic amine that is formed during cooking of meat and fish. The
   novelty of the extraction procedure lies in using a short piece of
   narrow capillary-like microporous hollow-fibre (HF) membrane as
   extraction device. The HF membrane was filled with a few microlitres of
   acidic solution and the membrane pores were impregnated with an organic
   extraction solvent. Therefore, the technique was called hollow-fibre
   supported liquid membrane (HF-SLM) extraction. The HF extraction device
   was then supported by a syringe needle and directly immersed in urine
   (1.4 mL) or plasma (0.3 mL) previously made alkaline by adding 0.5 mol
   L-1 NaOH solution to give a final volume of 1.6 mL. The operation of the
   HF-SLM extraction at the optimal conditions resulted in a PhIP
   extraction efficiency of 74\% from both spiked urine and plasma,
   corresponding to enrichment factors of 126 and 27, respectively. For 90
   min extraction time, limits of detection and quantification were,
   respectively, 8 and 25 pg mL(-1) for urine and 6 and 11 pg mL(-1) for
   plasma. Within-day repeatability (n=6) and between-day reproducibility
   (n=3) were, respectively, 5\% and 13\% for urine and 6\% and 7\% for
   plasma. Analysis of urine samples collected for 12 h after a volunteer
   had eaten 250 g well-done chicken showed the PhIP concentration was 124
   +/- 21 pg mL(-1), calculated assuming an extraction efficiency of 74\%.}},
Publisher = {{SPRINGER HEIDELBERG}},
Address = {{TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Barri, T (Reprint Author), Lund Univ, Dept Analyt Chem, POB 124, S-22100 Lund, Sweden.
   Lezamiz, Jon; Barri, Thaer; Jonsson, Jan Ake, Lund Univ, Dept Analyt Chem, S-22100 Lund, Sweden.
   Skog, Kerstin, Lund Univ, Dept Food Engn Technol \& Nutr, S-22100 Lund, Sweden.}},
DOI = {{10.1007/s00216-007-1702-4}},
ISSN = {{1618-2642}},
Keywords = {{heterocyclic aromatic amines; 2-amino-1-methyl-6-phenylimidazo{[}4,
   5-b]pyridine (PhIP); plasma; urine; hollow-fibre supported liquid
   membrane extraction}},
Keywords-Plus = {{HETEROCYCLIC AROMATIC-AMINES; CHROMATOGRAPHY-MASS-SPECTROMETRY;
   SOLID-PHASE MICROEXTRACTION; BLUE CHITIN COLUMNS;
   CAPILLARY-ELECTROPHORESIS; FOOD-PRODUCTS; HUMAN HAIR; CLEANUP
   PROCEDURES; HYDROLYZED URINE; COOKED MEAT}},
Research-Areas = {{Biochemistry \& Molecular Biology; Chemistry}},
Web-of-Science-Categories  = {{Biochemical Research Methods; Chemistry, Analytical}},
Author-Email = {{thaer.barri@analykem.lu.se}},
Cited-References = {{Bang J, 2004, CHROMATOGRAPHIA, V60, P651, DOI 10.1365/s10337-004-0431.
   Bang J, 2002, J CHROMATOGR A, V977, P97, DOI 10.1016/S0021-9673(02)01351-1.
   Bermudo E, 2004, J CHROMATOGR B, V802, P61, DOI 10.1016/j.jchromb.2003.09.031.
   Bordas M, 2004, J CHROMATOGR B, V802, P11, DOI 10.1016/j.jchromb.2003.09.024.
   Busquets R, 2004, J CHROMATOGR B, V802, P79, DOI 10.1016/j.jchromb.2003.09.033.
   DeBruin LS, 2001, CHEM RES TOXICOL, V14, P1523, DOI 10.1021/tx015556u.
   Friesen MD, 2001, CANCER LETT, V173, P43, DOI 10.1016/S0304-3835(01)00672-3.
   Galceran MT, 2006, WOODHEAD PUBL FOOD S, P68, DOI 10.1533/9781845692018.1.68.
   GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B.
   Hashimoto H, 2004, J CHROMATOGR B, V803, P209, DOI 10.1016/j.jchromb.2003.12.029.
   Hegstad S, 2000, CHROMATOGRAPHIA, V52, P499, DOI 10.1007/BF02535726.
   Holland RD, 2005, CHEM RES TOXICOL, V18, P579, DOI 10.1021/tx049675w.
   Jakubowska N, 2005, CRIT REV ANAL CHEM, V35, P217, DOI 10.1080/10408340500304032.
   Janoszka B, 2001, J CHROMATOGR A, V938, P155, DOI 10.1016/S0021-9673(01)01364-4.
   Jonsson JA, 2000, J CHROMATOGR A, V902, P205, DOI 10.1016/S0021-9673(00)00922-5.
   JONSSON JA, 2001, ADV CHROMATOGRAPHY.
   Klassen RD, 2002, FOOD RES INT, V35, P837, DOI 10.1016/S0963-9969(02)00087-X.
   Knize MG, 2001, J CHROMATOGR A, V914, P95, DOI 10.1016/S0021-9673(01)00522-2.
   Kobayashi M, 2005, MUTAT RES-GEN TOX EN, V588, P136, DOI 10.1016/j.mrgentox.2005.09.008.
   Martin-Calero A, 2007, ANAL CHIM ACTA, V582, P259, DOI 10.1016/j.aca.2006.09.024.
   Mendonsa SD, 1999, J CHROMATOGR A, V841, P239, DOI 10.1016/S0021-9673(99)00279-4.
   Moonen HJJ, 2004, FOOD CHEM TOXICOL, V42, P869, DOI 10.1016/j.fct.2004.01.010.
   Pais P, 2000, J CHROMATOGR B, V747, P139, DOI 10.1016/S0378-4347(00)00118-3.
   Pedersen-Bjergaard S, 1999, ANAL CHEM, V71, P2650, DOI 10.1021/ac990055n.
   Persson E, 2004, J AGR FOOD CHEM, V52, P7561, DOI 10.1021/jf0493831.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   Santos FJ, 2004, J CHROMATOGR B, V802, P69, DOI 10.1016/j.jchromb.2003.09.030.
   Scott KA, 2007, CHEM RES TOXICOL, V20, P88, DOI 10.1021/tx0601861.
   Sentellas S, 2004, J CHROMATOGR A, V1032, P193, DOI 10.1016/j.chroma.2003.11.011.
   Sentellas S, 2003, ELECTROPHORESIS, V24, P3075, DOI 10.1002/elps.200305523.
   Skog K, 2004, J CHROMATOGR B, V802, P39, DOI 10.1016/j.jchromb.2003.11.016.
   Skog K, 2002, FOOD CHEM TOXICOL, V40, P1213, DOI 10.1016/S0278-6915(02)00062-5.
   Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1.
   Solyakov A, 2002, FOOD CHEM TOXICOL, V40, P1205, DOI 10.1016/S0278-6915(02)00054-6.
   Strickland PT, 2001, BIOMARKERS, V6, P313.
   Sugimura T, 2000, CARCINOGENESIS, V21, P387, DOI 10.1093/carcin/21.3.387.
   Toribio F, 1999, J CHROMATOGR A, V836, P223, DOI 10.1016/S0021-9673(99)00074-6.
   Toribio F, 2000, J CHROMATOGR B, V747, P171, DOI 10.1016/S0378-4347(00)00154-7.
   Viberg P, 2004, ANAL BIOANAL CHEM, V378, P1729, DOI 10.1007/s00216-003-2480-2.
   Viberg P, 2006, J CHROMATOGR A, V1133, P347, DOI 10.1016/j.chroma.2006.08.034.
   Wu JC, 2001, ANAL CHEM, V73, P55, DOI 10.1021/ac000885x.
   Zimmerli B, 2001, FOOD ADDIT CONTAM, V18, P533, DOI 10.1080/02652030110035084.}},
Number-of-Cited-References = {{42}},
Times-Cited = {{8}},
Journal-ISO = {{Anal. Bioanal. Chem.}},
Doc-Delivery-Number = {{248QW}},
Wos-Id = {{ISI:000252170400025}},
}

@article{ ISI:000252326000001,
Author = {Alaejos, M. S. and Gonzalez, V. and Afonso, A. M.},
Title = {{Exposure to heterocyclic aromatic amines from the consumption of cooked
   red meat and its effect on human cancer risk: A review}},
Journal = {{FOOD ADDITIVES AND CONTAMINANTS}},
Year = {{2008}},
Volume = {{25}},
Number = {{1}},
Pages = {{2-24}},
Abstract = {{This review covers the bibliographic data from the last 10 years on the
   possible carcinogenicity of heterocyclic aromatic amines (HAAs) in
   humans. Aspects such as red meat intake, cooking methods applied to red
   meat, and doneness of cooking are discussed from an epidemiological
   point of view. The role in the carcinogenicity of the HAAs has been
   assigned to two main factors: first, the very high frequency of
   consumption of red meat; and, second, very darkly browned meats from
   cooking. However, there are some uncertainties associated with
   epidemiological results such as the presence of other carcinogens,
   co-carcinogens and anti-carcinogens in the diet, analytical results on
   the content of HAAs in foods, food frequency questionnaires, and mainly
   genetic susceptibility to HAAs. It is concluded that there is not
   sufficient scientific evidence to support the hypothesis that human
   cancer risk is due specifically to the intake of HAAs in the diet.}},
Publisher = {{TAYLOR \& FRANCIS LTD}},
Address = {{4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Alaejos, MS (Reprint Author), Univ La Laguna, Dept Analyt Chem Nutr \& Food Sci, E-38205 San Cristobal la Laguna, Santa Cruz De T, Spain.
   Alaejos, M. S.; Gonzalez, V.; Afonso, A. M., Univ La Laguna, Dept Analyt Chem Nutr \& Food Sci, E-38205 San Cristobal la Laguna, Santa Cruz De T, Spain.}},
DOI = {{10.1080/02652030701474235}},
ISSN = {{0265-203X}},
Keywords = {{heterocyclic aromatic amines; intake; human cancer risk}},
Keywords-Plus = {{HAWAII UNITED-STATES; COLORECTAL-CANCER; COLON-CANCER; FOOD GROUPS;
   WELL-DONE; PROSTATE-CANCER; LUNG-CANCER; GENETIC SUSCEPTIBILITY;
   PANCREATIC-CANCER; URINARY-EXCRETION}},
Research-Areas = {{Chemistry; Food Science \& Technology; Toxicology}},
Web-of-Science-Categories  = {{Chemistry, Applied; Food Science \& Technology; Toxicology}},
Author-Email = {{mtsanz@ull.es}},
Cited-References = {{Adamson RH, 1996, ARCH TOX S, V18, P303.
   ALAEJOS MS, 2007, UNPUB TOXICOLOGICAL.
   ALAEJOS MS, 2007, UNPUB CHEM REV.
   ALAEJOS MS, 2007, UNPUB J CHROMATOGR B.
   Alexander J, 2002, FOOD CHEM TOXICOL, V40, P1131, DOI 10.1016/S0278-6915(02)00053-4.
   Anderson KE, 2002, MUTAT RES-FUND MOL M, V506, P225, DOI 10.1016/S0027-5107(02)00169-0.
   Anderson KE, 2005, CANCER EPIDEM BIOMAR, V14, P2261, DOI 10.1158/1055-9965.EPI-04-0514.
   Augustsson K, 1997, CARCINOGENESIS, V18, P1931, DOI 10.1093/carcin/18.10.1931.
   Augustsson K, 1999, LANCET, V353, P703, DOI 10.1016/S0140-6736(98)06099-1.
   Balbi JC, 2001, EUR J CANCER PREV, V10, P453, DOI 10.1097/00008469-200110000-00009.
   Barrett JH, 2003, CARCINOGENESIS, V24, P275, DOI 10.1093/carcin/24.2.275.
   Bogen KT, 2001, J EXPO ANAL ENV EPID, V11, P155, DOI 10.1038/sj.jea.7500158.
   BOGEN KT, 1994, FOOD CHEM TOXICOL, V32, P505, DOI 10.1016/0278-6915(94)90106-6.
   Bosetti C, 2002, INT J CANCER, V100, P355, DOI 10.1002/ijc.10485.
   Bosetti C, 2002, BRIT J CANCER, V87, P1230, DOI 10.1038/sj.bjc.6606639.
   Bosetti C, 2001, INT J CANCER, V93, P911, DOI 10.1002/ijc.1422.
   Bosetti C, 2000, INT J CANCER, V87, P289, DOI 10.1002/1097-0215(20000715)87:2<289::AID-IJC22>3.3.CO;2-0.
   Boutron-Ruault MC, 1999, EUR J CANCER PREV, V8, P229, DOI 10.1097/00008469-199906000-00011.
   Butler LM, 2003, AM J EPIDEMIOL, V157, P434, DOI 10.1093/aje/kwf221.
   Chan JM, 2005, J CLIN ONCOL, V23, P8152, DOI 10.1200/JCO.2005.03.1492.
   Chao A, 2005, JAMA-J AM MED ASSOC, V293, P172, DOI 10.1001/jama.293.2.172.
   Chiu BCH, 2003, CANCER EPIDEM BIOMAR, V12, P201.
   Dai Q, 2002, CANCER EPIDEM BIOMAR, V11, P801.
   DeneoPellegrini H, 1996, LUNG CANCER-J IASLC, V14, P195, DOI 10.1016/0169-5002(95)00546-3.
   Deneo-Pellegrini H, 1999, BRIT J CANCER, V80, P591, DOI 10.1038/sj.bjc.6690396.
   De Stefani E, 1998, NUTR CANCER, V32, P43.
   DeStefani E, 1997, CANCER EPIDEM BIOMAR, V6, P573.
   De Stefani E, 2001, NUTR CANCER, V40, P103, DOI 10.1207/S15327914NC402\_5.
   De Stefani E, 1998, BRIT J CANCER, V78, P1239, DOI 10.1038/bjc.1998.661.
   FELTON JS, 1992, CANCER RES, V52, pS2103.
   Ferguson LR, 2002, MUTAT RES-FUND MOL M, V506, P215, DOI 10.1016/S0027-5107(02)00168-9.
   Franceschi S, 1997, INT J CANCER, V72, P56, DOI 10.1002/(SICI)1097-0215(19970703)72:1<56::AID-IJC8>3.0.CO;2-3.
   Frandsen H, 2002, FOOD CHEM TOXICOL, V40, P1125, DOI 10.1016/S0278-6915(02)00033-9.
   Frantz S, 2005, NAT REV DRUG DISCOV, V4, P5, DOI 10.1038/nrd1629.
   Gaard M, 1996, EUR J CANCER PREV, V5, P445.
   Galeone C, 2005, BRIT J CANCER, V92, P2065, DOI 10.1038/sj.bjc.6602542.
   GAYLOR DW, 1991, FOMUTAGENS FOOD DETE, P229.
   Gooderham NJ, 2001, DRUG METAB DISPOS, V29, P529.
   Guengerich FP, 1997, CHEM-BIOL INTERACT, V106, P161, DOI 10.1016/S0009-2797(97)00068-9.
   Gunter MJ, 2005, CARCINOGENESIS, V26, P637, DOI 10.1093/carcin/bgh350.
   Hu JF, 1999, INT J CANCER, V81, P20, DOI 10.1002/(SICI)1097-0215(19990331)81:1<20::AID-IJC4>3.0.CO;2-2.
   International Agency for Research on Cancer, 1993, IARC MON EV CARC RIS, V56.
   Jagerstad M, 2005, MUTAT RES-FUND MOL M, V574, P156, DOI 10.1016/j.mrfmmm.2005.01.030.
   JI BT, 1995, CANCER EPIDEM BIOMAR, V4, P885.
   JI H, 1994, CANCER EPIDEM BIOMAR, V3, P407.
   KAMPMAN E, 1995, CANCER CAUSE CONTROL, V6, P225, DOI 10.1007/BF00051794.
   Kampman E, 1999, CANCER EPIDEM BIOMAR, V8, P15.
   Kato I, 1997, NUTR CANCER, V28, P276.
   Keating GA, 1999, MUTAT RES-GEN TOX EN, V443, P149, DOI 10.1016/S1383-5742(99)00017-4.
   Keating GA, 2000, CANCER CAUSE CONTROL, V11, P731, DOI 10.1023/A:1008935407971.
   Keating GA, 2004, J CHROMATOGR B, V802, P127, DOI 10.1016/j.jchromb.2003.10.047.
   Keating GA, 2001, FOOD CHEM TOXICOL, V39, P29, DOI 10.1016/S0278-6915(00)00115-0.
   Kim D, 2005, ANNU REV PHARMACOL, V45, P27, DOI 10.1146/annurev.pharmtox.45.120403.100010.
   Knize MG, 2002, MUTAT RES-FUND MOL M, V506, P153, DOI 10.1016/S0027-5107(02)00162-8.
   Kobayashi M, 2005, MUTAT RES-GEN TOX EN, V588, P136, DOI 10.1016/j.mrgentox.2005.09.008.
   Larsson SC, 2005, INT J CANCER, V113, P829, DOI 10.1002/ijc.20658.
   LaVecchia C, 1996, INT J CANCER, V66, P60, DOI 10.1002/(SICI)1097-0215(19960328)66:1<60::AID-IJC11>3.0.CO;2-F.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   Le Marchand L, 2002, MUTAT RES-FUND MOL M, V506, P205, DOI 10.1016/S0027-5107(02)00167-7.
   LeMarchand L, 1997, CANCER CAUSE CONTROL, V8, P637, DOI 10.1023/A:1018406716115.
   Levi F, 1998, INT J CANCER, V77, P705, DOI 10.1002/(SICI)1097-0215(19980831)77:5<705::AID-IJC8>3.0.CO;2-Z.
   Levi F, 1999, BRIT J CANCER, V79, P1283, DOI 10.1038/sj.bjc.6690206.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   Matos E, 2002, MUTAT RES-FUND MOL M, V506, P243, DOI 10.1016/S0027-5107(02)00171-9.
   Murtaugh MA, 2004, J NUTR, V134, P776.
   Navarro A, 2003, NUTRITION, V19, P7, DOI 10.1016/S0899-9007(02)00832-8.
   Navarro A, 2004, NUTRITION, V20, P873, DOI 10.1016/j.nut.2004.06.008.
   Nomura AMY, 2003, CANCER CAUSE CONTROL, V14, P547, DOI 10.1023/A:1024887411846.
   Norat T, 2001, NUTR REV, V59, P37.
   Norrish AE, 1999, J NATL CANCER I, V91, P2038, DOI 10.1093/jnci/91.23.2038.
   Nowell S, 2004, CANCER EPIDEM BIOMAR, V13, P270, DOI 10.1158/1055-9965.EPI-03-0047.
   Nowell S, 2002, MUTAT RES-FUND MOL M, V506, P175, DOI 10.1016/S0027-5107(02)00164-1.
   Olsson V, 2005, FOOD QUAL PREFER, V16, P91, DOI 10.1016/j.foodqual.2004.02.003.
   Oreggia F, 2001, ORAL ONCOL, V37, P141, DOI 10.1016/S1368-8375(00)00074-9.
   Peters U, 2003, CANCER EPIDEM BIOMAR, V12, P1253.
   Pietinen P, 1999, CANCER CAUSE CONTROL, V10, P387, DOI 10.1023/A:1008962219408.
   ProbstHensch NM, 1997, CANCER CAUSE CONTROL, V8, P175, DOI 10.1023/A:1018416128894.
   Seow A, 2000, CANCER EPIDEM BIOMAR, V9, P1215.
   Shannon J, 1996, CANCER EPIDEM BIOMAR, V5, P495.
   Singh PN, 1998, AM J EPIDEMIOL, V148, P761.
   Sinha R, 1999, CANCER LETT, V143, P189, DOI 10.1016/S0304-3835(99)00123-8.
   Sinha R, 2000, CANCER RES, V60, P3753.
   SINHA R, 1995, CARCINOGENESIS, V16, P2859, DOI 10.1093/carcin/16.11.2859.
   Sinha R, 1998, CANCER CAUSE CONTROL, V9, P621, DOI 10.1023/A:1008805525525.
   Sinha R, 2001, CANCER EPIDEM BIOMAR, V10, P559.
   Sinha R, 2002, MUTAT RES-FUND MOL M, V506, P197, DOI 10.1016/S0027-5107(02)00166-5.
   Sinha R, 1999, CANCER RES, V59, P4320.
   Sinha R, 2005, CANCER RES, V65, P8034, DOI 10.1158/0008-5472.CAN-04-3429.
   Sinha R, 1997, MUTAT RES-FUND MOL M, V376, P195, DOI 10.1016/S0027-5107(97)00043-2.
   Skog K, 2002, FOOD CHEM TOXICOL, V40, P1197, DOI 10.1016/S0278-6915(02)00052-2.
   Slattery ML, 1997, CANCER CAUSE CONTROL, V8, P872, DOI 10.1023/A:1018416412906.
   STILLWELL WG, 1994, CANCER EPIDEM BIOMAR, V3, P399.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   Stillwell WG, 1999, CANCER LETT, V143, P145, DOI 10.1016/S0304-3835(99)00144-5.
   Stillwell WG, 1999, CANCER RES, V59, P5154.
   Strickland PT, 2001, BIOMARKERS, V6, P313.
   Sugimura T, 1996, ENVIRON HEALTH PERSP, V104, P429, DOI 10.2307/3432798.
   Tavani A, 2000, INT J CANCER, V86, P425, DOI 10.1002/(SICI)1097-0215(20000501)86:3<425::AID-IJC19>3.3.CO;2-J.
   Terry PD, 2003, CANCER EPIDEM BIOMAR, V12, P940.
   Tiemersma EW, 2004, CANCER CAUSE CONTROL, V15, P225, DOI 10.1023/B:CACO.0000024263.44973.92.
   Tiemersma EW, 2002, CANCER CAUSE CONTROL, V13, P383, DOI 10.1023/A:1015236701054.
   Truswell AS, 2002, EUR J CLIN NUTR, V56, pS19, DOI 10.1038/sj.ejcn.1601349.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P217, DOI 10.1021/tx9701891.
   Turesky RJ, 1999, CANCER LETT, V143, P109, DOI 10.1016/S0304-3835(99)00137-8.
   Turesky RJ, 2001, CHEM RES TOXICOL, V14, P901, DOI 10.1021/tx010035s.
   VECCHIA CL, 1996, INT J CANCER, V66, P60.
   Wakabayashi K, 1997, MUTAT RES-FUND MOL M, V376, P253, DOI 10.1016/S0027-5107(97)00050-X.
   Ward MH, 1997, INT J CANCER, V71, P14, DOI 10.1002/(SICI)1097-0215(19970328)71:1<14::AID-IJC4>3.0.CO;2-6.
   Wild CP, 2001, BRIT J NUTR, V86, pS37, DOI 10.1079/BJN2001338.
   World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR), 1997, FOOD NUTR PREV CANC.
   Zhang SM, 1999, J NATL CANCER I, V91, P1751, DOI 10.1093/jnci/91.20.1751.
   Zheng W, 1998, J NATL CANCER I, V90, P1724, DOI 10.1093/jnci/90.22.1724.
   Zimmerli B, 2001, FOOD ADDIT CONTAM, V18, P533, DOI 10.1080/02652030110035084.
   {*}US DEP HHS, 2002, NTP REP CARC.
   {*}US DEP HHS, 2004, NTP REP CARC, P135.}},
Number-of-Cited-References = {{115}},
Times-Cited = {{25}},
Journal-ISO = {{Food Addit. Contam.}},
Doc-Delivery-Number = {{250UH}},
Wos-Id = {{ISI:000252326000001}},
}

@article{ ISI:000261089100014,
Author = {Neale, Jason R. and Smith, Ned B. and Pierce, Jr., William M. and Hein,
   David W.},
Title = {{METHODS FOR AROMATIC AND HETEROCYCLIC AMINE CARCINOGEN-DNA ADDUCT
   ANALYSIS BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY}},
Journal = {{POLYCYCLIC AROMATIC COMPOUNDS}},
Year = {{2008}},
Volume = {{28}},
Number = {{4-5}},
Pages = {{402-417}},
Note = {{21st International Symposium for Polycyclic Aromatic Compounds,
   Trondheim, NORWAY, AUG 05-10, 2007}},
Abstract = {{Xenobiotic-DNA adducts are used as biomarkers to assess the genotoxic
   effects of carcinogens. Rats were dosed with 4-aminobiphenyl (4-ABP),
   2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline (MeIQx), or
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP). DNA was
   isolated from the colons of vehicle and carcinogen-treated rats and
   digested using different nucleases and alkaline phosphatase.
   Deoxyribonucleoside adducts were quantified by capillary liquid
   chromatography-tandem mass spectrometry (LC-MS/MS) using isotope
   dilution methods with deuterated internal standards. Major adducts were
   those bound to the C8 position of deoxyguanosine. 3'- and 5'-
   Exonucleases were the most efficient nucleases at isolating dG-C8-ABP
   adducts. However, bulky adducts such as dG-C8-MeIQx and dG-C8-PhIP were
   better isolated using nuclease P1 rather than a combination of
   micrococcal nuclease and spleen phosphodiesterase. The use of DNase I
   enhanced the detection of all three adducts. We describe LC-MS/MS
   methods for DNA adduct detection and support the testing of different
   nucleases that increase DNA digestion efficiency and make available more
   DNA adducts for detection.}},
Publisher = {{TAYLOR \& FRANCIS LTD}},
Address = {{4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Hein, DW (Reprint Author), Univ Louisville, Sch Med, Dept Pharmacol \& Toxicol, Louisville, KY 40292 USA.
   Hein, David W., Univ Louisville, Sch Med, Dept Pharmacol \& Toxicol, Louisville, KY 40292 USA.
   Univ Louisville, Sch Med, James Graham Brown Canc Ctr, Louisville, KY 40292 USA.}},
DOI = {{10.1080/10406630802377773}},
ISSN = {{1040-6638}},
Keywords = {{4-aminobiphenyl; 2-amino-3; 8-dimethylimidazo{[}4; 5-f]quinoxaline;
   MeIQx; 2-amino-1-methyl-6-phenylimidazo{[}4; 5-b]pyridine; PhIP}},
Keywords-Plus = {{SLOW ACETYLATOR N-ACETYLTRANSFERASE-2; RAS PROTOONCOGENE; IN-VITRO;
   QUANTIFICATION; GENOTOXICITY; SENSITIVITY; MUTAGENESIS; METABOLISM;
   DUPLEX}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Organic}},
Author-Email = {{d.hein@louisville.edu}},
ResearcherID-Numbers = {{Hein, David/A-9707-2008}},
Cited-References = {{Beland FA, 1999, CHEM RES TOXICOL, V12, P68, DOI 10.1021/tx980172y.
   Bendaly J, 2007, CANCER EPIDEM BIOMAR, V16, P1503, DOI 10.1158/1055-9965.EPI-07-0305.
   Brown K, 2001, NUCLEIC ACIDS RES, V29, P1951, DOI 10.1093/nar/29.9.1951.
   Brown K, 2001, P NATL ACAD SCI USA, V98, P8507, DOI 10.1073/pnas.151251898.
   CHO BP, 1994, BIOCHEMISTRY-US, V33, P1373, DOI 10.1021/bi00172a013.
   CHO BP, 1992, BIOCHEMISTRY-US, V31, P9587, DOI 10.1021/bi00155a011.
   Crosbie SJ, 2000, J CHROMATOGR B, V744, P55, DOI 10.1016/S0378-4347(00)00227-9.
   Doerge DR, 1999, CARCINOGENESIS, V20, P1055, DOI 10.1093/carcin/20.6.1055.
   Gauvin J, 2001, CHEM RES TOXICOL, V14, P476, DOI 10.1021/tx000144r.
   GUPTA RC, 1985, CANCER RES, V45, P5656.
   HEIN DW, 1988, BIOCHIM BIOPHYS ACTA, V948, P37, DOI 10.1016/0304-419X(88)90004-2.
   Hein DW, 2002, MUTAT RES-FUND MOL M, V506, P65, DOI 10.1016/S0027-5107(02)00153-7.
   HEIN DW, 1991, J PHARMACOL EXP THER, V258, P232.
   Landi MT, 1999, IARC SCI PUBL, V148, P173.
   Metry KJ, 2007, MOL CARCINOGEN, V46, P553, DOI 10.1002/mc.20302.
   Opiteck GJ, 1997, ANAL CHEM, V69, P1518, DOI 10.1021/ac961155l.
   Paehler A, 2002, CHEM RES TOXICOL, V15, P551, DOI 10.1021/tx010178e.
   Phillips DH, 2000, ENVIRON MOL MUTAGEN, V35, P222, DOI 10.1002/(SICI)1098-2280(2000)35:3<222::AID-EM9>3.0.CO;2-E.
   RANDERATH K, 1981, P NATL ACAD SCI-BIOL, V78, P6126, DOI 10.1073/pnas.78.10.6126.
   REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543.
   Ricicki EM, 2005, CHEM RES TOXICOL, V18, P692, DOI 10.1021/tx0496921.
   RINDGEN D, 1995, CHEM RES TOXICOL, V8, P1005, DOI 10.1021/tx00050a003.
   Sharma RA, 2004, CLIN CANCER RES, V10, P4901, DOI 10.1158/1078-0432.CCR-04-0098.
   Turesky RJ, 2002, DRUG METAB REV, V34, P625, DOI 10.1081/DMR-120005665.
   {[}Anonymous], 2005, NAT TOX PROGR REP CA.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{8}},
Journal-ISO = {{Polycycl. Aromat. Compd.}},
Doc-Delivery-Number = {{375BX}},
Wos-Id = {{ISI:000261089100014}},
}

@article{ ISI:000251589100004,
Author = {Jamin, Emilien L. and Arquier, Delphine and Canlet, Ceicle and Rathahao,
   Estelle and Tulliez, Jacques and Debrauwer, Laurent},
Title = {{New insights in deoxynucleoside the formation of adducts with the
   heterocyclic aromatic amines PhIP and IQ by means of ion trap MS(n) and
   accurate mass measurement of fragment ions}},
Journal = {{JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY}},
Year = {{2007}},
Volume = {{18}},
Number = {{12}},
Pages = {{2107-2118}},
Month = {{DEC}},
Abstract = {{The formation of adducts by reaction of active metabolites of two
   heterocyclic aromatic amines (NHOH-PhIP and NHOH-IQ) at nucleophilic
   sites of deoxynucleosides has been studied by LC-MS(n) analyses of the
   obtained reaction mixtures. Sequential MS(3) experiments were carried
   out on an ion trap mass spectrometer to gain extensive structural
   information on each adduct detected in the first MS step. Attribution of
   ions was supported by accurate mass measurements performed on an
   Orbitrap mass analyzer. Particular attention was given to ions
   diagnostic of the linking between the heterocyclic aromatic amine (HAA)
   and the deoxynucleoside. By this way, the structures of five adducts
   have been characterized in this study, among which two are new
   compounds: dG-N7-IQ and dA-N(6)-IQ. No de urinating adduct was found in
   the reactions investigated therein. As expected, the C8 and N(2) atoms
   of dG were found as the most reactive sites of deoxynucleosides,
   resulting in the formation of two different adducts with IQ and one
   adduct with PhIP. An unusual non-depurinating dG-N7-IQ adduct has been
   characterized and a mechanism is proposed for its formation on the basis
   of the reactivity of arylamines. A dA-N(6)-IQ adduct has been identified
   for the first time in this work, showing that HAAs can generate DNA
   adducts with bases other than dG.}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING ST, NEW YORK, NY 10013 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Debrauwer, L (Reprint Author), INRA, Lab Xenobiot, ENVT, UMR 1089, BP 3,180 Chem Tournefeuille, F-31931 Toulouse, France.
   Jamin, Emilien L.; Arquier, Delphine; Canlet, Ceicle; Tulliez, Jacques; Debrauwer, Laurent, INRA, Lab Xenobiot, ENVT, UMR 1089, F-31931 Toulouse, France.
   Rathahao, Estelle, AgroParis Tech, Chim Analyt Lab, INRA, INA PG,UMR 0214 AQA, Paris, France.}},
DOI = {{10.1016/j.jasms.2007.09.008}},
ISSN = {{1044-0305}},
Keywords-Plus = {{FORMED DNA-ADDUCTS; ELECTROSPRAY-IONIZATION; CHEMICAL CARCINOGENESIS;
   MODEL SYSTEMS; COOKED FOODS; IN-VITRO; SPECTROMETRY; QUANTIFICATION;
   GUANINE; IDENTIFICATION}},
Research-Areas = {{Biochemistry \& Molecular Biology; Chemistry; Spectroscopy}},
Web-of-Science-Categories  = {{Biochemical Research Methods; Chemistry, Analytical; Chemistry,
   Physical; Spectroscopy}},
Author-Email = {{laurent.debrauwer@toulouse.inra.fr}},
ResearcherID-Numbers = {{Jamin, Emilien/B-7407-2009
   Debrauwer, Laurent/H-7807-2013}},
Cited-References = {{Brown K, 2001, NUCLEIC ACIDS RES, V29, P1951, DOI 10.1093/nar/29.9.1951.
   Crosbie SJ, 2000, J CHROMATOGR B, V744, P55, DOI 10.1016/S0378-4347(00)00227-9.
   de Kok TMCM, 2002, J CHROMATOGR B, V778, P345, DOI 10.1016/S0378-4347(01)00543-6.
   DIPPLE A, 1995, CARCINOGENESIS, V16, P437, DOI 10.1093/carcin/16.3.437.
   Gangl ET, 1999, CHEM RES TOXICOL, V12, P1019, DOI 10.1021/tx990060m.
   Garner RC, 1998, MUTAT RES-FUND MOL M, V402, P67.
   Gates KS, 2004, CHEM RES TOXICOL, V17, P839, DOI 10.1021/tx049965c.
   Goodenough AK, 2007, CHEM RES TOXICOL, V20, P263, DOI 10.1021/tx0601713.
   Guengerich FP, 1999, CHEM RES TOXICOL, V12, P906, DOI 10.1021/tx990094u.
   Hu QZ, 2005, J MASS SPECTROM, V40, P430, DOI 10.1002/jms.856.
   HUMPHREYS WG, 1992, P NATL ACAD SCI USA, V89, P8278, DOI 10.1073/pnas.89.17.8278.
   Jouanin I, 2002, STEROIDS, V67, P1091, DOI 10.1016/S0039-128X(02)00070-3.
   Kaiya T, 2000, CHEM RES TOXICOL, V13, P993, DOI 10.1021/tx0000724.
   KAKIUCHI H, 1995, P NATL ACAD SCI USA, V92, P910, DOI 10.1073/pnas.92.3.910.
   Kennedy SA, 1997, J AM CHEM SOC, V119, P7654, DOI 10.1021/ja970698p.
   Khalili H, 2000, MUTAT RES-GEN TOX EN, V465, P39, DOI 10.1016/S1383-5718(99)00203-X.
   Koc H, 2002, J CHROMATOGR B, V778, P323, DOI 10.1016/S1570-0232(02)00135-6.
   Li L, 2003, J AM SOC MASS SPECTR, V14, P1488, DOI 10.1016/j.jasms.2003.08.009.
   Murkovic M, 2004, J CHROMATOGR B, V802, P3, DOI 10.1016/j.jchromb.2003.09.026.
   Novak M, 2004, J PHYS ORG CHEM, V17, P615, DOI 10.1002/poc.765.
   Paehler A, 2002, CHEM RES TOXICOL, V15, P551, DOI 10.1021/tx010178e.
   PULLMAN A, 1981, Q REV BIOPHYS, V14, P289.
   RINDGEN D, 1995, CHEM RES TOXICOL, V8, P1005, DOI 10.1021/tx00050a003.
   Roberts KP, 1999, J CHROMATOGR A, V853, P159, DOI 10.1016/S0021-9673(99)00507-5.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   Skog K, 2002, FOOD CHEM TOXICOL, V40, P1197, DOI 10.1016/S0278-6915(02)00052-2.
   Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1.
   Snyderwine EG, 2002, MUTAT RES-FUND MOL M, V506, P145, DOI 10.1016/S0027-5107(02)00161-6.
   Soglia JR, 2001, ANAL CHEM, V73, P2819, DOI 10.1021/ac010218j.
   Tanga MJ, 2001, J LABELLED COMPD RAD, V44, P405, DOI 10.1002/jlcr.468.
   Turesky RJ, 2004, J CHROMATOGR B, V802, P155, DOI 10.1016/j.jchromb.2003.10.053.
   TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005.
   Turesky RJ, 2005, MOL NUTR FOOD RES, V49, P101, DOI 10.1002/mnfr.200400076.
   Wogan GN, 2004, SEMIN CANCER BIOL, V14, P473, DOI 10.1016/j.semcancer.2004.06.010.
   Zhou SF, 2004, LIFE SCI, V74, P935, DOI 10.1016/j.lfs.2003.09.035.
   Zochling S, 2002, FOOD CHEM, V79, P125, DOI 10.1016/S0308-8146(02)00214-5.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{12}},
Journal-ISO = {{J. Am. Soc. Mass Spectrom.}},
Doc-Delivery-Number = {{240LM}},
Wos-Id = {{ISI:000251589100004}},
}

@article{ ISI:000248976800020,
Author = {Tang, Deliang and Liu, Jason J. and Bock, Cathryn H. and Neslund-Dudas,
   Christine and Rundle, Andrew and Savera, Adnan T. and Yang, James J. and
   Nock, Nora L. and Rybicki, Benjamin A.},
Title = {{Racial differences in clinical and pathological associations with
   PhIP-DNA adducts in prostate}},
Journal = {{INTERNATIONAL JOURNAL OF CANCER}},
Year = {{2007}},
Volume = {{121}},
Number = {{6}},
Pages = {{1319-1324}},
Month = {{SEP 15}},
Abstract = {{African-American men have a higher dietary intake of
   2-amino1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP), which is the
   most abundant heterocyclic amine in cooked meats and is carcinogenic in
   rat prostate through the formation of DNA adducts. To determine the
   clinical and demographic factors associated with PhIP-DNA adduct levels,
   the biologically effective dose of PhIP in human prostate, we
   inummohistochemically measured PhIP-DNA adducts in a study of 162
   Caucasian and 102 African-American men who underwent radical
   prostatectomy for prostate cancer. A strong correlation between PhIP-DNA
   adduct levels in prostate tumor and adjacent non-tumor cells was
   observed (p = 0.62; p < 0.0001); however, non-tumor cells had
   significantly higher adduct levels compared with tumor (0.167 optical
   density (OD) units 0.043 vs. 0.104 OD 0.027; p < 0.0001). Race was not
   associated with PhIP-DNA adduct levels in either tumor or non-tumor
   cells, but race-specific associations were observed. In prostate tumor
   and non-tumor cells, tumor volume had the strongest association with
   PhIP-DNA adducts in Caucasians, whereas in African-Americans prostate
   volume was most strongly associated with adduct levels in tumor cells
   and advanced Gleason grade had the strongest association in non-tumor
   cells. In race interaction models, while the only statistically
   significant interaction was between African-American race and advanced
   Gleason grade in non-tumor cells (P = 0.029; p = 0.02), in tumor cells
   we observed opposite effects by race (positive for African-Americans,
   negative for Caucasians) for older age and high PSA levels at diagnosis.
   In conclusion, while PhIP-DNA adduct levels in prostate cells do not
   vary significantly by race, our results suggest that PhIP exposure may
   have stronger effects on prostate tumor differentiation in
   African-American men. (c) 2007 Wiley-Liss, Inc.}},
Publisher = {{WILEY-BLACKWELL}},
Address = {{COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Rybicki, BA (Reprint Author), Henry Ford Hlth Syst, Dept Biostat \& Res Epidemiol, 1 Ford Pl,3E, Detroit, MI 48202 USA.
   Henry Ford Hlth Syst, Dept Biostat \& Res Epidemiol, Detroit, MI 48202 USA.
   Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA.
   Wayne State Univ, Karmanos Canc Inst, Populat Studies \& Prevent Program, Detroit, MI USA.
   Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
   Henry Ford hlth Syst, Dept Surg Pathol, Detroit, MI USA.
   Case Western Reserve Univ, Dept Epidemiol, Cleveland, OH 44106 USA.}},
DOI = {{10.1002/ijc.22806}},
ISSN = {{0020-7136}},
Keywords = {{2-amino-1-methyl-6-phenylimidazo(4,5-b)pyri dine; African-Americans;
   immunohistochemistry; neoplasms; DNA damage}},
Keywords-Plus = {{HETEROCYCLIC AMINE CARCINOGENS; AFRICAN-AMERICAN MEN;
   LOS-ANGELES-COUNTY; CANCER RISK; RADICAL PROSTATECTOMY;
   METABOLIC-ACTIVATION; N-ACETYLTRANSFERASE; URINARY-EXCRETION;
   CYTOCHROMES P450; EXPRESSION}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Author-Email = {{brybickl@hfhs.org}},
ResearcherID-Numbers = {{Rundle, Andrew/A-5282-2009}},
ORCID-Numbers = {{Rundle, Andrew/0000-0003-0211-7707}},
Cited-References = {{Al-Buheissi SZ, 2006, PROSTATE, V66, P876, DOI 10.1002/pros.20400.
   Bogen KT, 2001, J EXPO ANAL ENV EPID, V11, P155, DOI 10.1038/sj.jea.7500158.
   BOGEN KT, IN PRESS PROSTATE CA.
   CHOU HC, 1995, CANCER RES, V55, P525.
   Cui L, 2000, JPN J CANCER RES, V91, P52.
   Di Paolo OA, 2005, INT J CANCER, V117, P8, DOI 10.1002/ijc.21152.
   Fan R, 2004, CANCER RES, V64, P8526, DOI 10.1158/0008-5472.CAN-04-1601.
   JI H, 1994, CANCER EPIDEM BIOMAR, V3, P407.
   Kang JS, 2004, BJU INT, V93, P1207, DOI 10.1111/j.1464-410X.2004.04846.x.
   Kidd LCR, 1999, CANCER EPIDEM BIOMAR, V8, P439.
   Kolonel LN, 2001, EPIDEMIOL REV, V23, P72.
   Kooiman GG, 2000, PROSTATE CANCER P D, V3, P256, DOI 10.1038/sj.pcan.4500489.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   MINCHIN RF, 1992, BIOCHEM BIOPH RES CO, V185, P839, DOI 10.1016/0006-291X(92)91703-S.
   MOUL JW, 1995, JAMA-J AM MED ASSOC, V274, P1277, DOI 10.1001/jama.274.16.1277.
   Nakai Y, 2007, CANCER RES, V67, P1378, DOI 10.1158/0008-5472.CAN-06-1336.
   Nelson CP, 2001, CANCER RES, V61, P103.
   Nowell S, 2004, CANCER EPIDEM BIOMAR, V13, P270, DOI 10.1158/1055-9965.EPI-03-0047.
   Pettaway CA, 1998, J UROLOGY, V160, P437, DOI 10.1016/S0022-5347(01)62919-7.
   Ragavan N, 2004, CANCER LETT, V215, P69, DOI 10.1016/j.canlet.2004.06.051.
   RELLING MV, 1992, CLIN PHARMACOL THER, V52, P643.
   Rybicki BA, 2004, CANCER RES, V64, P8854, DOI 10.1158/0008-5472.CAN-04-2323.
   Rybicki BA, 2006, CANCER DETECT PREV, V30, P412, DOI 10.1016/j.cdp.2006.09.004.
   Sanchez-Ortiz RF, 2006, CANCER, V107, P75, DOI 10.1002/cncr.21954.
   Shirai T, 1997, CANCER RES, V57, P195.
   Shirai T, 2002, MUTAT RES-FUND MOL M, V506, P129, DOI 10.1016/S0027-5107(02)00159-8.
   Sterling KM, 2004, J CELL BIOCHEM, V91, P423, DOI 10.1002/jcb.10753.
   Sugimura T, 2000, CARCINOGENESIS, V21, P387, DOI 10.1093/carcin/21.3.387.
   Takahashi S, 1998, CANCER RES, V58, P4307.
   Tang DL, 2007, CANCER EPIDEM BIOMAR, V16, P803, DOI 10.1158/1055-9965.EPI-06-0973.
   Tewari A, 2005, BJU INT, V96, P29, DOI 10.1111/j.1464-410X.2005.05561.x.
   Wang GJ, 1999, MACROMOL RAPID COMM, V20, P591, DOI 10.1002/(SICI)1521-3927(19991101)20:11<591::AID-MARC591>3.0.CO;2-T.
   Welsh JB, 2001, CANCER RES, V61, P5974.
   Williams JA, 2000, CARCINOGENESIS, V21, P1683, DOI 10.1093/carcin/21.9.1683.
   Zhu J, 2006, BIOMARKERS, V11, P319, DOI 10.1080/13547500600667911.
   Zhu JJ, 2003, CANCER EPIDEM BIOMAR, V12, P830.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{10}},
Journal-ISO = {{Int. J. Cancer}},
Doc-Delivery-Number = {{203LT}},
Wos-Id = {{ISI:000248976800020}},
}

@article{ ISI:000246213800019,
Author = {Frandsen, H.},
Title = {{Deconjugation of N-glucuronide conjugated metabolites with hydrazine
   hydrate - Biomarkers for exposure to the food-borne carcinogen
   2-amino-l-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP)}},
Journal = {{FOOD AND CHEMICAL TOXICOLOGY}},
Year = {{2007}},
Volume = {{45}},
Number = {{5}},
Pages = {{863-870}},
Month = {{MAY}},
Abstract = {{The metabolism of the carcinogen
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) has been
   investigated in rabbit liver S9. Two phase I metabolites, N(2)-OH-PhIP
   and 4'-OH-PhIP were identified based on UV and mass spectra and
   co-elution with reference standards. Fortification of the incubation
   with UDGPA resulted in a complete glucuronidation of PhIP and
   N(2)-OH-PhIP, while 4'-OH-PhIP was only partly glucuronidated. Also, the
   PhIP metabolite 5-OH-PhIP was completely glucuronidated by rabbit liver
   S9, while 5-OH-PhIP was a poor substrate for CYP mediated hydroxylation.
   The glucuronic acid conjugates of PhIP metabolites were unsusceptible to
   treatment with beta-glucuronidase indicating that these are
   N-glucuronides. Treatment of the conjugates with hydrazine hydrate,
   however, resulted in complete hydrolysis of the glucuronic acid
   conjugates as well as in reduction to the parent amine of metabolites
   hydroxylated in the exocyclic amino group. Urine was collected from a
   male volunteer following consumption of fried chicken. Treatment of the
   urine with beta-glucuronidase/sulfatase resulted in release of
   4'-OH-PhIP, while treatment with hydrazine hydrate in addition resulted
   in release of substantial amounts of PhIP and 5-OH-PhIP. The data show
   that hydrazine hydrate can hydrolyse N-glucuronides of metabolites of
   PhIP, glucuronides that are unsusceptible to enzymatic hydrolysis. In
   addition the data indicate that humans metabolise a large fraction of
   ingested PhIP to genotoxic metabolites. The chemical hydrolysis of
   glucuronide conjugates of PhIP metabolites with hydrazine hydrate
   observed in this study may also be a useful approach in the development
   of biomarkers for exposure and effect of other xenobiotics. (c) 2006
   Elsevier Ltd. All rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Frandsen, H (Reprint Author), Danish Inst Food \& Vet Res, Inst Food Safety, Morkhoj Bygade 19, DK-2600 Soborg, Denmark.
   Danish Inst Food \& Vet Res, Inst Food Safety, DK-2600 Soborg, Denmark.}},
DOI = {{10.1016/j.fct.2006.11.006}},
ISSN = {{0278-6915}},
Keywords = {{PhIP; glucuronides; hydrazine hydrate; biomarkers}},
Keywords-Plus = {{HETEROCYCLIC AROMATIC-AMINES;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; LIVER-MICROSOMES;
   ADDUCT FORMATION; HUMAN URINE; IN-VITRO; IDENTIFICATION; HUMANS; DNA;
   MUTAGEN}},
Research-Areas = {{Food Science \& Technology; Toxicology}},
Web-of-Science-Categories  = {{Food Science \& Technology; Toxicology}},
Author-Email = {{hf@dfvf.dk}},
Cited-References = {{Alexander J, 2002, FOOD CHEM TOXICOL, V40, P1131, DOI 10.1016/S0278-6915(02)00053-4.
   Alexander J, 1997, MUTAT RES-FUND MOL M, V376, P7, DOI 10.1016/S0027-5107(97)00019-5.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312.
   Frandsen H, 2000, CARCINOGENESIS, V21, P1197, DOI 10.1093/carcin/21.6.1197.
   Frandsen H, 2002, FOOD CHEM TOXICOL, V40, P1125, DOI 10.1016/S0278-6915(02)00033-9.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   Franks J., 2005, Review of Finance, V9, DOI 10.1007/s10679-005-2988-8.
   Holland RD, 2004, CHEM RES TOXICOL, V17, P1121, DOI 10.1021/tx049910a.
   Ito N, 1997, MUTAT RES-FUND MOL M, V376, P107, DOI 10.1016/S0027-5107(97)00032-8.
   Kulp KS, 2000, CARCINOGENESIS, V21, P2065, DOI 10.1093/carcin/21.11.2065.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MacLeod S, 1997, MUTAT RES-FUND MOL M, V376, P135, DOI 10.1016/S0027-5107(97)00036-5.
   Malfatti MA, 2004, CHEM RES TOXICOL, V17, P1137, DOI 10.1021/tx049898m.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   NAGAOKA H, 1992, JPN J CANCER RES, V83, P1025.
   REISTAD R, 1994, CARCINOGENESIS, V15, P2547, DOI 10.1093/carcin/15.11.2547.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   Scharer OD, 1997, CURR OPIN CHEM BIOL, V1, P526, DOI 10.1016/S1367-5931(97)80048-8.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   Stillwell WG, 2002, CARCINOGENESIS, V23, P831, DOI 10.1093/carcin/23.5.831.
   STYCZYNSKI PB, 1993, CHEM RES TOXICOL, V6, P846, DOI 10.1021/tx00036a014.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P217, DOI 10.1021/tx9701891.
   Turteltaub KW, 1999, CANCER LETT, V143, P149, DOI 10.1016/S0304-3835(99)00116-0.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P941, DOI 10.1093/carcin/11.6.941.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   WESTRA JG, 1981, CARCINOGENESIS, V2, P355, DOI 10.1093/carcin/2.4.355.
   Zenser TV, 1999, DRUG METAB DISPOS, V27, P1064.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{15}},
Journal-ISO = {{Food Chem. Toxicol.}},
Doc-Delivery-Number = {{164DR}},
Wos-Id = {{ISI:000246213800019}},
}

@article{ ISI:000245732600024,
Author = {Tang, Deliang and Liu, Jason J. and Rundle, Andrew and Neslund-Dudas,
   Christine and Savera, Adman T. and Bock, Cathryn H. and Nock, Nora L.
   and Yang, James J. and Rybicki, Benjamin A.},
Title = {{Grilled meat consumption and PhIP-DNA adducts in prostate carcinogenesis}},
Journal = {{CANCER EPIDEMIOLOGY BIOMARKERS \& PREVENTION}},
Year = {{2007}},
Volume = {{16}},
Number = {{4}},
Pages = {{803-808}},
Month = {{APR}},
Abstract = {{2-Amino-l-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) is the major
   heterocyclic amine generated from cooking meats at high temperatures,
   and dietary exposures have been shown to induce prostate cancer in rats.
   PhIP derives its carcinogenic potential through the formation of
   PhIP-DNA adducts. The purpose of this study was to examine whether
   self-reported consumption and preparation doneness of grilled meats were
   associated with PhIP-DNA adduct levels in prostate epithelial cells. The
   study population consisted of 268 African-American and Caucasian men who
   underwent radical prostatectomy for prostate cancer. PhIP-DNA adducts in
   tumor and adjacent nontumor cells were measured using
   immunohistochemical methods, and dietary meat intake information was
   based on food frequency questionnaires. Data were analyzed using
   multivariate linear regression models. After adjusting for age at
   prostatectomy and race, grilled meat consumption (P = 0.002) was
   significantly associated with higher adduct levels in tumor cells, but
   this association seemed to be primarily due to consumption of grilled
   red meats (P = 0.001) as opposed to grilled white meat consumption (P =
   0.15). Among the specific food items, grilled hamburger consumption had
   the most significant association with adduct level in tumor cells (P =
   0.002). Similar trends in positive associations with grilled meat
   consumption and adduct levels were observed in nontumor cells, but none
   of these associations reached statistical significance. Our results
   suggest that dietary interventions targeted at lower consumption of
   grilled red meats may reduce prostate cancer risk via the PhIP prostate
   carcinogenic pathway.}},
Publisher = {{AMER ASSOC CANCER RESEARCH}},
Address = {{615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Tang, D (Reprint Author), Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, 630 W 168th St,P\&S 19-407, New York, NY 10027 USA.
   Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10027 USA.
   Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
   Wayne State Univ, Sch Med, Karmanos Canc Inst, Populat Studies \& Prevent Program, Detroit, MI USA.
   Henry Ford Hlth Syst, Dept Biostat \& Res Epidemiol, Detroit, MI USA.
   Henry Ford Hlth Syst, Dept Surg Pathol, Detroit, MI USA.
   Case Western Reserve Univ, Dept Epidemiol \& Biostat, Cleveland, OH USA.}},
DOI = {{10.1158/1055-9965.EPI-06-0973}},
ISSN = {{1055-9965}},
Keywords-Plus = {{HETEROCYCLIC AMINE CARCINOGENS;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP;
   METABOLIC-ACTIVATION; BREAST-CANCER; UNITED-STATES; COLORECTAL ADENOMAS;
   (PHIP)-DNA ADDUCTS; CYTOCHROMES P450; VARYING DEGREES; LUNG-CANCER}},
Research-Areas = {{Oncology; Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Oncology; Public, Environmental \& Occupational Health}},
Author-Email = {{dt14@columbia.edu
   brybick1@hfhs.org}},
ResearcherID-Numbers = {{Rundle, Andrew/A-5282-2009}},
ORCID-Numbers = {{Rundle, Andrew/0000-0003-0211-7707}},
Cited-References = {{Archer CL, 2000, CANCER LETT, V155, P55, DOI 10.1016/S0304-3835(00)00413-4.
   Bogen KT, 2001, J EXPO ANAL ENV EPID, V11, P155, DOI 10.1038/sj.jea.7500158.
   Byrne C, 1998, CANCER EPIDEM BIOMAR, V7, P523.
   Cantwell M, 2004, CANCER EPIDEM BIOMAR, V13, P293, DOI 10.1158/1055-9965.EPI-270-2.
   CHOU HC, 1995, CANCER RES, V55, P525.
   Cross AJ, 2005, CANCER RES, V65, P11779, DOI 10.1158/0008-5472CAN-05-2191.
   Dai Q, 2002, CANCER EPIDEM BIOMAR, V11, P801.
   Di Paolo OA, 2005, INT J CANCER, V117, P8, DOI 10.1002/ijc.21152.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1992, CANCER RES, V52, pS2103.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   Friesen MD, 2001, CANCER LETT, V173, P43, DOI 10.1016/S0304-3835(01)00672-3.
   Hayes RB, 1999, CANCER EPIDEM BIOMAR, V8, P25.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106.
   Keating GA, 2000, CANCER CAUSE CONTROL, V11, P731, DOI 10.1023/A:1008935407971.
   Keating GA, 2004, J CHROMATOGR B, V802, P127, DOI 10.1016/j.jchromb.2003.10.047.
   Kobayashi M, 2005, MUTAT RES-GEN TOX EN, V588, P136, DOI 10.1016/j.mrgentox.2005.09.008.
   Kolonel LN, 2001, EPIDEMIOL REV, V23, P72.
   Kulp KS, 2000, CARCINOGENESIS, V21, P2065, DOI 10.1093/carcin/21.11.2065.
   Lawson T, 2002, CANCER LETT, V175, P141, DOI 10.1016/S0304-3835(01)00732-7.
   Lee WH, 1997, CANCER EPIDEM BIOMAR, V6, P443.
   Magagnotti C, 2003, INT J CANCER, V107, P878, DOI 10.1002/ijc.11492.
   MINCHIN RF, 1992, BIOCHEM BIOPH RES CO, V185, P839, DOI 10.1016/0006-291X(92)91703-S.
   NAGAOKA H, 1992, JPN J CANCER RES, V83, P1025.
   Nakai Y, 2007, CANCER RES, V67, P1378, DOI 10.1158/0008-5472.CAN-06-1336.
   Nelson CP, 2001, CANCER RES, V61, P103.
   Norrish AE, 1999, J NATL CANCER I, V91, P2038, DOI 10.1093/jnci/91.23.2038.
   Purewal M, 2000, CANCER LETT, V149, P53, DOI 10.1016/S0304-3835(99)00346-8.
   Rodriguez C, 2006, CANCER EPIDEM BIOMAR, V15, P211, DOI 10.1158/1055-9965.EPI-05-0614.
   Rybicki BA, 2004, CANCER RES, V64, P8854, DOI 10.1158/0008-5472.CAN-04-2323.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   Schut HAJ, 1997, MUTAT RES-FUND MOL M, V376, P185, DOI 10.1016/S0027-5107(97)00042-0.
   Shirai T, 1997, CANCER RES, V57, P195.
   Shirai T, 2002, MUTAT RES-FUND MOL M, V506, P129, DOI 10.1016/S0027-5107(02)00159-8.
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P289, DOI 10.1016/S0278-6915(97)00159-2.
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P279, DOI 10.1016/S0278-6915(97)00162-2.
   Sinha R, 2000, CANCER RES, V60, P3753.
   Sinha R, 2000, J NATL CANCER I, V92, P1352, DOI 10.1093/jnci/92.16.1352.
   Sinha R, 1998, CANCER CAUSE CONTROL, V9, P621, DOI 10.1023/A:1008805525525.
   Sinha R, 2001, CANCER EPIDEM BIOMAR, V10, P559.
   Sinha R, 2002, MUTAT RES-FUND MOL M, V506, P197, DOI 10.1016/S0027-5107(02)00166-5.
   Sinha R, 1999, CANCER RES, V59, P4320.
   SKOG K, 1995, CARCINOGENESIS, V16, P861, DOI 10.1093/carcin/16.4.861.
   Strickland PT, 2002, MUTAT RES-FUND MOL M, V506, P163, DOI 10.1016/S0027-5107(02)00163-X.
   Takahashi S, 1998, CANCER RES, V58, P4307.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   TURTELTAUB KW, 1993, ENVIRON HEALTH PERSP, V99, P183, DOI 10.2307/3431477.
   Wang CY, 1999, CARCINOGENESIS, V20, P1591, DOI 10.1093/carcin/20.8.1591.
   Ward MH, 1997, INT J CANCER, V71, P14, DOI 10.1002/(SICI)1097-0215(19970328)71:1<14::AID-IJC4>3.0.CO;2-6.
   Williams JA, 2000, CARCINOGENESIS, V21, P1683, DOI 10.1093/carcin/21.9.1683.
   Zhu J, 2006, BIOMARKERS, V11, P319, DOI 10.1080/13547500600667911.
   Zhu JJ, 2003, CANCER EPIDEM BIOMAR, V12, P830.}},
Number-of-Cited-References = {{53}},
Times-Cited = {{34}},
Journal-ISO = {{Cancer Epidemiol. Biomarkers Prev.}},
Doc-Delivery-Number = {{157PN}},
Wos-Id = {{ISI:000245732600024}},
}

@article{ ISI:000241772800040,
Author = {Viberg, Peter and Wahlund, Karl-Gustav and Skog, Kerstin},
Title = {{On-line capillary based quantitative analysis of a heterocyclic amine in
   human urine}},
Journal = {{JOURNAL OF CHROMATOGRAPHY A}},
Year = {{2006}},
Volume = {{1133}},
Number = {{1-2}},
Pages = {{347-352}},
Month = {{NOV 10}},
Abstract = {{A high through-put miniaturised separation-quantification method for the
   heterocyclic aromatic amine
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) in urine was
   developed. The limit of detection was of 0.65 fmol (0.14 pg) injected or
   65 pM. Heterocyclic aromatic amines are mutagenic and carcinogenic
   compounds formed at low levels in protein-rich food during cooking. Due
   to the low concentrations and the high complexity of the matrix in which
   they exist (food, blood, and urine), and the often small sample volumes
   (capillary blood; urine, blood and milk from small animals), very
   sensitive and selective analytical methods are required for their
   detection. Miniaturisation was accomplished by micro solid-phase
   extraction in capillaries with blue chitin as solid-phase, coupled
   on-line (in-capillary) to capillary electrophoresis with nanospray
   tandem mass spectrometric detection. This new technique provided a total
   analysis time of only 15 min, including extraction and separation,
   together with low sample and solvent consumption. Blue chitin showed
   high tolerance towards the urine matrix. Urine collected 12 h after
   consumption of fried chicken contained 1.8 nmol L-1 (0.40 pg mu L-1) of
   PhIP. (c) 2006 Elsevier B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Viberg, P (Reprint Author), Lund Univ, Dept Food Technol, Div Appl Nutr \& Food Chem, POB 124, SE-22100 Lund, Sweden.
   Lund Univ, Dept Food Technol, Div Appl Nutr \& Food Chem, SE-22100 Lund, Sweden.
   Lund Univ, Div Analyt Chem, Ctr Chem \& Chem Engn, SE-22100 Lund, Sweden.}},
DOI = {{10.1016/j.chroma.2006.08.034}},
ISSN = {{0021-9673}},
Keywords = {{on-line; in-capillary; nanospray; nanoelectrospray; tandem mass
   spectrometry; capillary electrophoresis; blue chitin; PhIP; Heterocyclic
   amines; food analysis}},
Keywords-Plus = {{TANDEM MASS-SPECTROMETRY; BLUE CHITIN COLUMNS; AROMATIC-AMINES; COOKED
   MEAT; COPPER-PHTHALOCYANINE; MUTAGENS CARCINOGENS; ZONE ELECTROPHORESIS;
   FOOD-PRODUCTS; RISK; EXTRACTION}},
Research-Areas = {{Biochemistry \& Molecular Biology; Chemistry}},
Web-of-Science-Categories  = {{Biochemical Research Methods; Chemistry, Analytical}},
Author-Email = {{peter.viberg@teknlk.lth.se}},
ResearcherID-Numbers = {{Wahlund, Karl-Gustav/A-1916-2013}},
Cited-References = {{Bang J, 2004, CHROMATOGRAPHIA, V60, P651, DOI 10.1365/s10337-004-0431.
   Bang J, 2002, J CHROMATOGR A, V977, P97, DOI 10.1016/S0021-9673(02)01351-1.
   Barcelo-Barrachina E, 2004, J CHROMATOGR A, V1023, P67, DOI 10.1016/j.chroma.2003.10.030.
   Busquets R, 2004, J CHROMATOGR B, V802, P79, DOI 10.1016/j.jchromb.2003.09.033.
   Felton J.S., 1990, HDB EXPT PHARM, P471.
   Frandsen H, 2002, FOOD CHEM TOXICOL, V40, P1125, DOI 10.1016/S0278-6915(02)00033-9.
   Friesen MD, 2001, CANCER LETT, V173, P43, DOI 10.1016/S0304-3835(01)00672-3.
   GROSS GA, 1989, CARCINOGENESIS, V10, P1175, DOI 10.1093/carcin/10.7.1175.
   GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B.
   HAYATSU H, 1983, MUTAT RES, V119, P233, DOI 10.1016/0165-7992(83)90166-5.
   HAYATSU H, 1992, J CHROMATOGR, V597, P37, DOI 10.1016/0021-9673(92)80095-C.
   HAYATSU H, 1987, CANCER RES, V47, P791.
   Hayatsu H, 1996, ANAL BIOCHEM, V235, P185, DOI 10.1006/abio.1996.0110.
   INAMASU T, 1988, JPN J CANCER RES, V79, P42.
   International Agency for Research on Cancer (IARC), 1993, MON EV CARC RISK HUM, V56.
   Kataoka H, 1997, J CHROMATOGR A, V774, P121, DOI 10.1016/S0021-9673(97)00246-X.
   KNIZE MG, 1992, J CHROMATOGR, V624, P253, DOI 10.1016/0021-9673(92)85683-K.
   Knize MG, 2001, J CHROMATOGR A, V914, P95, DOI 10.1016/S0021-9673(01)00522-2.
   MURRAY S, 1989, CARCINOGENESIS, V10, P763, DOI 10.1093/carcin/10.4.763.
   Nagao M, 1999, MUTAT RES-FUND MOL M, V431, P3, DOI 10.1016/S0027-5107(99)00154-2.
   Norrish AE, 1999, J NATL CANCER I, V91, P2038, DOI 10.1093/jnci/91.23.2038.
   Pais P, 2000, J CHROMATOGR B, V747, P139, DOI 10.1016/S0378-4347(00)00118-3.
   Persson E, 2003, J AGR FOOD CHEM, V51, P4472, DOI 10.1021/jf021089q.
   Puignou L, 1997, J CHROMATOGR A, V769, P293, DOI 10.1016/S0021-9673(97)00033-2.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   Santesson S, 2004, ANAL CHEM, V76, P303, DOI 10.1021/ac034951h.
   Sentellas S, 2004, J CHROMATOGR A, V1032, P193, DOI 10.1016/j.chroma.2003.11.011.
   Sentellas S, 2003, ELECTROPHORESIS, V24, P3075, DOI 10.1002/elps.200305523.
   Sinha R, 2001, CANCER EPIDEM BIOMAR, V10, P559.
   Skog K, 2004, J CHROMATOGR B, V802, P39, DOI 10.1016/j.jchromb.2003.11.016.
   Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1.
   Sugimura T, 2000, CARCINOGENESIS, V21, P387, DOI 10.1093/carcin/21.3.387.
   SUGIMURA T, 1993, FOOD NUTR CHEM TOXIC, P259.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   Toribio F, 2002, J CHROMATOGR A, V948, P267, DOI 10.1016/S0021-9673(01)01476-5.
   Toribio F, 2000, J CHROMATOGR B, V747, P171, DOI 10.1016/S0378-4347(00)00154-7.
   Toribio F, 2000, J CHROMATOGR A, V869, P307, DOI 10.1016/S0021-9673(99)01091-2.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   Viberg P, 2004, ANAL CHEM, V76, P4241, DOI 10.1021/ac049728e.
   Viberg P, 2004, ANAL BIOANAL CHEM, V378, P1729, DOI 10.1007/s00216-003-2480-2.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   WU J, 1995, J CHROMATOGR SCI, V33, P712.
   WU J, 1995, J CHROMATOGR A, V709, P351, DOI 10.1016/0021-9673(95)00459-Z.
   Zhao YI, 1998, ELECTROPHORESIS, V19, P2213, DOI 10.1002/elps.1150191228.
   Zheng W, 1998, J NATL CANCER I, V90, P1724, DOI 10.1093/jnci/90.22.1724.}},
Number-of-Cited-References = {{45}},
Times-Cited = {{15}},
Journal-ISO = {{J. Chromatogr. A}},
Doc-Delivery-Number = {{101WV}},
Wos-Id = {{ISI:000241772800040}},
}

@article{ ISI:000241704700001,
Author = {El-Zein, Randa and Etzel, Carol J. and Lopez, Mirtha S. and Gu, Yun and
   Spitz, Margaret R. and Strom, Sara S.},
Title = {{Human sensitivity to PhIP: A novel marker for prostate cancer risk}},
Journal = {{MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS}},
Year = {{2006}},
Volume = {{601}},
Number = {{1-2}},
Pages = {{1-10}},
Month = {{OCT 10}},
Abstract = {{2-Amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) has been
   implicated in the development of colon, prostate and mammary gland
   tumors in rats. In this study, we developed a modified in vitro mutagen
   sensitivity assay, with activated PhIP (N-OH-PhIP) as the challenge
   mutagen and chromosome aberrations as the endpoint, and applied it in a
   pilot prostate cancer case-control study of 81 cases and 84 age and
   ethnicity-matched controls. Our results showed significantly higher
   baseline breaks among the cases, mean +/- S.E. = 1.86 +/- 0.23 versus
   0.96 +/- 0.14 in controls; P = 0.006. Individuals with high baseline
   breaks (dichotomized at the control median) had a 36\% increased risk
   for PC (OR = 1.36; 95\% CI = 1.08-1.72). In stratified analysis, high
   baseline breaks was associated in younger participants (<= 60 years)
   with an OR of 1.71 (1.14-2.57) and in those with a positive family
   history of PC, an OR of 1.43 (0.97-2.11). PhIP treatment induced
   significantly higher breaks in cases, mean +/- S.E. = 5.07 +/- 0.39
   versus 3.83 +/- 0.24 in controls; P = 0.05. Higher PhIP-induced breaks
   was associated with an overall 17\% increased risk for PC (OR = 1.17;
   95\% CI = 1.03-1.33), a significantly increased risks (OR = 1.19; 95\%
   CI = 1.00-1.41) among younger participants, non-smokers (OR = 1.39,
   1.03-1.88) and 1.20 (1.00-1.45) among those with no family history of
   PC. Results from this pilot study demonstrate differential sensitivity
   to PhIP among subgroups and therefore, this assay have potential as a
   susceptibility marker for prostate cancer risk. (c) 2006 Elsevier B.V.
   All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{El-Zein, R (Reprint Author), Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Unit 1340,1155 Pressler St, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.}},
DOI = {{10.1016/j.mrfmmm.2006.05.023}},
ISSN = {{0027-5107}},
Keywords = {{prostate cancer; PhIP; peripheral blood lymphocytes; susceptibility}},
Keywords-Plus = {{PERIPHERAL-BLOOD LYMPHOCYTES; HETEROCYCLIC AMINES HCAS; PREDICT HUMAN
   CANCER; MUTAGEN SENSITIVITY; CHROMOSOMAL-ABERRATIONS; LUNG-CANCER;
   DNA-REPAIR; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP;
   GENETIC POLYMORPHISMS; METABOLIZING ENZYMES}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Author-Email = {{relzein@mdanderson.org}},
Cited-References = {{Abdel-Rahman SZ, 2000, CANCER LETT, V159, P63, DOI 10.1016/S0304-3835(00)00532-2.
   Affatato AA, 2004, ENVIRON MOL MUTAGEN, V44, P65, DOI 10.1002/em.20032.
   American Cancer Society, 2005, CANC FACTS FIG.
   ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411.
   BARRIOS L, 1990, CANCER GENET CYTOGEN, V49, P107, DOI 10.1016/0165-4608(90)90170-F.
   BARRIOS L, 1988, HUM GENET, V78, P320, DOI 10.1007/BF00291727.
   Bartsch H, 2000, MUTAT RES-REV MUTAT, V462, P255, DOI 10.1016/S1383-5742(00)00008-9.
   BOHR VA, 1989, LAB INVEST, V61, P143.
   Bonassi S, 2000, CANCER RES, V60, P1619.
   BONASSI S, 1995, CANCER GENET CYTOGEN, V79, P133, DOI 10.1016/0165-4608(94)00131-T.
   Bondy ML, 2001, J NATL CANCER I, V93, P1553.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   BROGGER A, 1990, CANCER GENET CYTOGEN, V45, P85, DOI 10.1016/0165-4608(90)90071-H.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   Cloos J, 1996, Eur J Cancer B Oral Oncol, V32B, P367, DOI 10.1016/S0964-1955(96)00019-X.
   Cloos J, 1999, J NATL CANCER I, V91, P1125, DOI 10.1093/jnci/91.13.1125.
   Deneo-Pellegrini H, 1999, BRIT J CANCER, V80, P591, DOI 10.1038/sj.bjc.6690396.
   Deutsch E, 2004, LANCET ONCOL, V5, P303, DOI 10.1016/S1470-2045(04)01468-8.
   Dhillon VS, 1996, CANCER GENET CYTOGEN, V86, P54, DOI 10.1016/0165-4608(95)00168-9.
   El-Zein R, 2001, MUTAT RES-GEN TOX EN, V490, P35, DOI 10.1016/S1383-5718(00)00154-6.
   El-Zein R, 1999, CARCINOGENESIS, V20, P811, DOI 10.1093/carcin/20.5.811.
   ElZein RA, 1997, CANCER LETT, V112, P71, DOI 10.1016/S0304-3835(96)04547-8.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   Felton J.S., 1990, HDB EXPT PHARM, P471.
   FELTON JS, 1984, CARCINOGENESIS, V5, P95, DOI 10.1093/carcin/5.1.95.
   Fraser GE, 1999, PREV MED, V29, pS18, DOI 10.1006/pmed.1998.0415.
   FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P1571, DOI 10.1093/jnci/85.19.1571.
   Glaab WE, 1999, CARCINOGENESIS, V20, P391, DOI 10.1093/carcin/20.3.391.
   Gooderham NJ, 2002, MUTAT RES-FUND MOL M, V506, P91, DOI 10.1016/S0027-5107(02)00155-0.
   GRAHAM S, 1983, J NATL CANCER I, V70, P687.
   Grossman L, 1997, ENVIRON HEALTH PERSP, V105, P927, DOI 10.2307/3433305.
   Hagmar L, 1998, CANCER RES, V58, P4117.
   HAGMAR L, 1994, CANCER RES, V54, P2919.
   HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079.
   HSU TC, 1989, INT J CANCER, V43, P403, DOI 10.1002/ijc.2910430310.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KEY T, 1995, CANCER SURV, V23, P63.
   KOLONEL LN, 1996, CANCER CAUSE CONTROL, V7, P44.
   Kolonel LN, 1999, J NATL CANCER I, V91, P414, DOI 10.1093/jnci/91.5.414.
   Landi S, 1998, PHARMACOGENETICS, V8, P461, DOI 10.1097/00008571-199812000-00002.
   Lee JJ, 1996, CANCER EPIDEM BIOMAR, V5, P191.
   MADHAVI R, 1990, CANCER GENET CYTOGEN, V44, P203, DOI 10.1016/0165-4608(90)90048-F.
   Magagnotti C, 2003, INT J CANCER, V107, P878, DOI 10.1002/ijc.11492.
   Martin Francis L., 2000, Mutagenesis, V15, P447.
   Miller DG, 1998, CANCER EPIDEM BIOMAR, V7, P321.
   MURTY VVVS, 1985, CANCER GENET CYTOGEN, V17, P347, DOI 10.1016/0165-4608(85)90118-9.
   NORDENSON I, 1984, HUM HERED, V34, P76, DOI 10.1159/000153440.
   NORPPA H, 2004, MECH CARCINOGENESIS, P179.
   Norppa H, 1997, ENVIRON HEALTH PERSP, V105, P829, DOI 10.2307/3433290.
   Otsuka C, 1996, MUTAT RES-GENET TOX, V367, P115, DOI 10.1016/0165-1218(95)00082-8.
   Parnes HL, 2005, J CLIN ONCOL, V23, P368, DOI 10.1200/JCO.2005.08.027.
   POTTER JD, 1993, EPIDEMIOL REV, V15, P499.
   SANDBERG AA, 1991, MUTAT RES, V247, P231, DOI 10.1016/0027-5107(91)90019-K.
   SCHANTZ SP, 1990, J NATL CANCER I, V82, P1773, DOI 10.1093/jnci/82.22.1773.
   Shirai T, 1997, CANCER RES, V57, P195.
   Sinha R, 1999, CANCER LETT, V143, P189, DOI 10.1016/S0304-3835(99)00123-8.
   Sinha R, 1997, MUTAT RES-FUND MOL M, V376, P195, DOI 10.1016/S0027-5107(97)00043-2.
   SNOWDON DA, 1984, AM J EPIDEMIOL, V120, P244.
   SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167.
   SORSA M, 1992, HUMAN CYTOGENETIC DA, P543.
   SPITZ MR, 1995, CANCER EPIDEM BIOMAR, V4, P99.
   SPITZ MR, 1993, CANCER EPIDEM BIOMAR, V2, P329.
   SPITZ MR, 1989, CANCER RES, V49, P4626.
   Srivastava DSL, 2005, BJU INT, V95, P170, DOI 10.1111/j.1464-410X.2005.05271.x.
   Stephens FO, 1999, ONCOL REP, V6, P865.
   STROM SS, 1995, J NATL CANC I MONOGR, V18, P29.
   Stuart GR, 2000, CANCER RES, V60, P266.
   SUGIMURA T, 1983, CANCER RES, V43, P2415.
   SUGIMURA T, 1997, ORIGINS HUMAN CANC, P1561.
   TALAMINI R, 1992, NUTR CANCER, V18, P277.
   Tigli Hulya, 2003, Research Communications in Molecular Pathology and Pharmacology, V113, P307.
   Tuimala J, 2002, CARCINOGENESIS, V23, P1003, DOI 10.1093/carcin/23.6.1003.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P925, DOI 10.1021/tx980022n.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   Wei Q, 1998, J Investig Dermatol Symp Proc, V3, P19.
   Wei QY, 1996, CANCER RES, V56, P3975.
   Williams JA, 2000, CARCINOGENESIS, V21, P1683, DOI 10.1093/carcin/21.9.1683.
   Wu XF, 1998, CANCER-AM CANCER SOC, V83, P1118, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1118::AID-CNCR10>3.0.CO;2-8.
   WU XF, 1995, CANCER EPIDEM BIOMAR, V4, P583.
   Zheng YL, 2003, CARCINOGENESIS, V24, P269, DOI 10.1093/carcin/24.2.269.}},
Number-of-Cited-References = {{81}},
Times-Cited = {{7}},
Journal-ISO = {{Mutat. Res.-Fundam. Mol. Mech. Mutagen.}},
Doc-Delivery-Number = {{100XY}},
Wos-Id = {{ISI:000241704700001}},
}

@article{ ISI:000240494300003,
Author = {Zhu, J. and Rashid, A. and Cleary, K. and Abbruzzese, J. L. and Friess,
   H. and Takahashi, S. and Shirai, T. and Li, D.},
Title = {{Detection of 2-amino-1-methyl-6-phenylimidazo {[}4,5-b]-pyridine
   (PhIP)-DNA adducts in human pancreatic tissues}},
Journal = {{BIOMARKERS}},
Year = {{2006}},
Volume = {{11}},
Number = {{4}},
Pages = {{319-328}},
Month = {{JUL-AUG}},
Abstract = {{Recent epidemiological investigations have observed an association
   between the consumption of grilled or barbecued meat and an increased
   risk of pancreatic cancer, suggesting that dietary exposure to
   heterocyclic aromatic amines (HCA) may contribute to the development of
   this disease. 2-Amino-1-methyl-6-phenylimidazo {[}4,5-b]-pyridine (PhIP)
   is the most abundant HCA found in well-done and grilled meats. To
   determine whether HCA-induced DNA damage is present in the human
   pancreas, immunohistochemistry and computer-assisted image analysis were
   used to measure PhIP-DNA adducts in 54 normal pancreatic tissues (N)
   from persons without pancreatic cancer and in 38 normal adjacent
   pancreatic tissues (A) and in 39 cancer tissues (T) from 68 patients
   with pancreatic adenocarcinoma. PhIP-DNA adducts were detected in 53 N,
   34 A and 39 T samples. Mean values (+/- SD) of the absorbency for PhIP
   staining were 0.22 +/- 0.04, 0.24 +/- 0.04, and 0.24 +/- 0.03 for N, A,
   and T samples, respectively (p = 0.004). Using the median absorbency
   (0.21) of the samples from normal controls as the cut-off, 71\% of A and
   77\% of T tissues, compared with 48\% of N tissues, were distributed in
   the higher range (p = 0.009). The odds ratio of pancreatic cancer was
   3.4 (95\% confidence interval 1.5-7.5, p = 0.002) for individuals with a
   higher level of PhIP-DNA adducts. This is the first report of the
   detection of PhIP-DNA adducts in human pancreatic tissue samples
   obtained from patients with unknown exposure to HCA. Although limited by
   the small sample size, these preliminary results suggest that PhIP
   exposure may contribute to human pancreatic cancer development.}},
Publisher = {{TAYLOR \& FRANCIS LTD}},
Address = {{4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Li, D (Reprint Author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   Univ Bern, Inselspital, Bern, Switzerland.
   Nagoya City Univ, Sch Med, Nagoya, Aichi 467, Japan.}},
DOI = {{10.1080/13547500600667911}},
ISSN = {{1354-750X}},
Keywords = {{DNA adduct; 2-amino-1-methyl-6 phenylimidazo {[}4,5b]-pyridine ( PhIP);
   pancreatic cancer; immunohistochemistry}},
Keywords-Plus = {{SPRAGUE-DAWLEY RATS; DNA-ADDUCTS; HETEROCYCLIC AMINES; BREAST-CANCER;
   MEAT INTAKE; MASS-SPECTROMETRY; PHIP; CARCINOGEN; RISK; FOOD}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Toxicology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Toxicology}},
Author-Email = {{dli@mdanderson.org}},
Cited-References = {{American Cancer Society, 2005, CANC FACTS FIG.
   Anderson KE, 2002, MUTAT RES-FUND MOL M, V506, P225, DOI 10.1016/S0027-5107(02)00169-0.
   Butler LM, 2003, AM J EPIDEMIOL, V157, P434, DOI 10.1093/aje/kwf221.
   DeBruin LS, 2001, CHEM RES TOXICOL, V14, P1523, DOI 10.1021/tx015556u.
   FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   Friesen MD, 1996, CARCINOGENESIS, V17, P67, DOI 10.1093/carcin/17.1.67.
   GHADIRIAN P, 1995, CANCER EPIDEM BIOMAR, V4, P895.
   Gold E B, 1998, Surg Oncol Clin N Am, V7, P67.
   Hirose M, 2000, CANCER LETT, V155, P79, DOI 10.1016/S0304-3835(00)00411-0.
   Imaida K, 1996, JPN J CANCER RES, V87, P1116.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   JAGERSTAD M, 1991, MUTAT RES, V259, P219, DOI 10.1016/0165-1218(91)90119-7.
   JI BT, 1995, CANCER EPIDEM BIOMAR, V4, P885.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   Kidd LCR, 1999, CANCER EPIDEM BIOMAR, V8, P439.
   Kulp KS, 2000, CARCINOGENESIS, V21, P2065, DOI 10.1093/carcin/21.11.2065.
   Lightfoot TJ, 2000, MUTAT RES-GEN TOX EN, V472, P119, DOI 10.1016/S1383-5718(00)00134-0.
   LYON JL, 1993, CANCER EPIDEM BIOMAR, V2, P513.
   MANABE S, 1993, CARCINOGENESIS, V14, P899, DOI 10.1093/carcin/14.5.899.
   MANABE S, 1993, ENVIRON POLLUT, V80, P281, DOI 10.1016/0269-7491(93)90049-T.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   NIEDERHUBER JE, 1995, CANCER, V76, P1671, DOI 10.1002/1097-0142(19951101)76:9<1671::AID-CNCR2820760926>3.0.CO;2-R.
   Ohba S, 1996, INT J PANCREATOL, V20, P37.
   Prokopczyk B, 2002, CHEM RES TOXICOL, V15, P677, DOI 10.1021/tx0101088.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   Sinha R, 2000, J NATL CANCER I, V92, P1352, DOI 10.1093/jnci/92.16.1352.
   SKOG K, 1995, CARCINOGENESIS, V16, P861, DOI 10.1093/carcin/16.4.861.
   Takahashi S, 1998, CANCER RES, V58, P4307.
   Thompson PA, 1999, MUTAT RES-FUND MOL M, V424, P263, DOI 10.1016/S0027-5107(99)00024-X.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   Wang MY, 1998, CANCER RES, V58, P38.
   Washaw AL, 1992, NEW ENGL J MED, V326, P455.
   Yoshimoto M, 1999, CANCER LETT, V143, P235, DOI 10.1016/S0304-3835(99)00131-7.
   Zheng W, 1998, J NATL CANCER I, V90, P1724, DOI 10.1093/jnci/90.22.1724.
   Zhu JJ, 2003, CANCER EPIDEM BIOMAR, V12, P830.}},
Number-of-Cited-References = {{35}},
Times-Cited = {{16}},
Journal-ISO = {{Biomarkers}},
Doc-Delivery-Number = {{083YD}},
Wos-Id = {{ISI:000240494300003}},
}

@article{ ISI:000238323200002,
Author = {Bonala, R and Torres, MC and Iden, CR and Johnson, F},
Title = {{Synthesis of the PhIP adduct of 2 `-deoxyguanosine and its incorporation
   into oligomeric DNA}},
Journal = {{CHEMICAL RESEARCH IN TOXICOLOGY}},
Year = {{2006}},
Volume = {{19}},
Number = {{6}},
Pages = {{734-738}},
Month = {{JUN 19}},
Abstract = {{The 2'-deoxyguanosine adduct of the dietary mutagen
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b] pyridine (PhIP) has been
   synthesized and incorporated into DNA using solid state synthesis
   technology. The key step to obtaining the C8-dG adduct is a palladium
   (Xantphos-chelated)-catalyzed-N-arylation (Buchwald-Hartwig reaction) of
   PhIP by a suitably protected 8-bromo-2'-deoxyguanosine derivative. The
   reaction proceeded in good yield without complicating side products, and
   the adduct was converted to the required 5'-O-DMT-3'-O-phosphoramidite
   by standard methods. This modified deoxynucleoside was used to
   synthesize three oligodeoxynucleotides in which the C8-PhIP-dG adduct
   was incorporated at a single site. The oligomers were purified by
   reverse phase HPLC and characterized by mass spectrometry.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Johnson, F (Reprint Author), SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.
   SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.}},
DOI = {{10.1021/tx0600191}},
ISSN = {{0893-228X}},
Keywords-Plus = {{TRYPTOPHAN PYROLYSIS PRODUCTS; CIGARETTE-SMOKE CONDENSATE;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; COOKED FOOD;
   CARCINOGEN; MUTAGENS}},
Research-Areas = {{Pharmacology \& Pharmacy; Chemistry; Toxicology}},
Web-of-Science-Categories  = {{Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology}},
Author-Email = {{francis@pharm.sunysb.edu}},
Cited-References = {{FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   Garner RC, 1998, MUTAT RES-FUND MOL M, V402, P67.
   Huang YH, 2003, BIOORG CHEM, V31, P136, DOI 10.1016/S0045-2068(02)00525-4.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   Johnson F, 2002, CHEM RES TOXICOL, V15, P1489, DOI 10.1021/tx0256174.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MANABE S, 1989, MUTAT RES, V226, P215, DOI 10.1016/0165-7992(89)90072-9.
   MANABE S, 1990, ENVIRON POLLUT, V64, P121, DOI 10.1016/0269-7491(90)90109-P.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   PELUSO M, 1991, CARCINOGENESIS, V12, P713, DOI 10.1093/carcin/12.4.713.
   Shibutani S, 1999, J BIOL CHEM, V274, P27433, DOI 10.1074/jbc.274.39.27433.
   Sugimura T, 2000, MUTAT RES-FUND MOL M, V447, P15, DOI 10.1016/S0027-5107(99)00196-7.
   WANG ZW, 1991, ORG LETT, V3, P565.
   Yin JJ, 2002, ORG LETT, V4, P3481, DOI 10.1021/ol0265923.
   2004, 228 ACS NAT M DIV CH.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{11}},
Journal-ISO = {{Chem. Res. Toxicol.}},
Doc-Delivery-Number = {{053RR}},
Wos-Id = {{ISI:000238323200002}},
}

@article{ ISI:000238323200007,
Author = {Takamura-Enya, T and Ishikawa, S and Mochizuki, M and Wakabayashi, K},
Title = {{Chemical synthesis of 2 `-deoxyguanosine - C8 adducts with heterocyclic
   amines: An application to synthesis of oligonucleotides
   site-specifically adducted with
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b] pyridine}},
Journal = {{CHEMICAL RESEARCH IN TOXICOLOGY}},
Year = {{2006}},
Volume = {{19}},
Number = {{6}},
Pages = {{770-778}},
Month = {{JUN 19}},
Abstract = {{Synthesis of 2'-deoxyguanosine-C8 adducts (dG-C8 adducts) with
   mutagenic/carcinogenic heterocyclic amines (HCAs) was achieved via the
   Buchwald-Hartwig arylamination reaction. By using
   tris-(dibenzylideneacetone) dipalladium (Pd(2)dba(3)) and
   9,9-dimethyl-4,5-bis(diphenylphosphino) xanthene (xantphos) with a
   cesium carbonate (Cs2CO3) base at a reaction temperature of 100 similar
   to 120 degrees C, we obtained derivatives of dG-C8 adducts with
   2-amino-3-methylimidazo{[}4,5-f] quinoline (IQ),
   2-amino-6-methyldipyrido{[}1,2-a:3',2'-d]imidazole (Glu-P-1),
   3-amino-1,4-dimethyl-5H-pyrido{[}4,3-b] indole (Trp-P-1),
   2-amino-3,8-dimethylimidazo{[}4,5-f] quinoxaline (MeIQx), and
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b] pyridine (PhIP) in 69\%similar
   to 97\% yield from the cross-coupling of an 8-bromodeoxyguanosine
   derivative. In the case of PhIP, it was found that dimethyl sulfoxide (
   DMSO) was the critical solvent for the arylamination reaction.
   Subsequent deprotection of the resulting dG-C8 adduct derivatives
   yielded authentic samples of dG-C8 adducts with HCAs. The dG-C8-PhIP
   adduct was further converted into a suitably protected phosphoramidite
   derivative for automated DNA synthesis. Synthesis of oligonucleotides
   wherein PhIP adducted on each G within a triple G sequence in codon 869
   (TCC GGG AAC) of rat Apc genes was performed with a modification in the
   coupling time and deprotection procedures.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Takamura-Enya, T (Reprint Author), Natl Canc Ctr, Res Inst, Canc Prevent Basic Res Project, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.
   Natl Canc Ctr, Res Inst, Canc Prevent Basic Res Project, Chuo Ku, Tokyo 1040045, Japan.
   Kyoritsu Univ Pharm, Minato Ku, Tokyo 1058512, Japan.}},
DOI = {{10.1021/tx050296s}},
ISSN = {{0893-228X}},
Keywords-Plus = {{PALLADIUM-CATALYZED AMINATION; DNA-ADDUCTS; C8-DEOXYGUANOSINE ADDUCTS;
   GENERAL-METHOD; MUTAGEN IQ;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE; IDENTIFICATION; ACID;
   CARCINOGEN; INVITRO}},
Research-Areas = {{Pharmacology \& Pharmacy; Chemistry; Toxicology}},
Web-of-Science-Categories  = {{Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology}},
Author-Email = {{tenya@gan2.res.ncc.go.jp}},
Cited-References = {{Bonala RR, 2004, CHEM RES TOXICOL, V17, P1780.
   BONALA RR, COMMUNICATION.
   BONALA RR, 2004, AM CHEM SOC DIV CHEM.
   Brown K, 2001, NUCLEIC ACIDS RES, V29, P1951, DOI 10.1093/nar/29.9.1951.
   Brown K, 2003, J MASS SPECTROM, V38, P68, DOI 10.1002/jms.401.
   Brown K, 2001, P NATL ACAD SCI USA, V98, P8507, DOI 10.1073/pnas.151251898.
   Dashwood RH, 2002, MUTAT RES-REV MUTAT, V511, P89, DOI 10.1016/S1383-5742(02)00005-4.
   De Riccardis F, 1999, J AM CHEM SOC, V121, P10453, DOI 10.1021/ja991328z.
   Elmquist CE, 2004, J AM CHEM SOC, V126, P11189, DOI 10.1021/ja0487022.
   Enya T, 1998, CHEM RES TOXICOL, V11, P1460, DOI 10.1021/tx980104b.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   Frederiksen H, 2004, CARCINOGENESIS, V25, P1525, DOI 10.1093/carcin/bgh156.
   Gillet LCJ, 2002, ORG LETT, V4, P4205, DOI 10.1021/ol026474f.
   Gillet LCJ, 2005, NUCLEIC ACIDS RES, V33, P1961, DOI 10.1093/nar/gki335.
   Guengerich FP, 2002, DRUG METAB REV, V34, P607, DOI 10.1081/DMR-120005663.
   Hartwig JF, 1997, SYNLETT, P329, DOI 10.1055/s-1997-789.
   Harwood EA, 2000, J ORG CHEM, V65, P2959, DOI 10.1021/jo991501+.
   HASHIMOTO Y, 1982, J AM CHEM SOC, V104, P7636, DOI 10.1021/ja00390a040.
   KAKIUCHI H, 1995, P NATL ACAD SCI USA, V92, P910, DOI 10.1073/pnas.92.3.910.
   Kennedy SA, 1997, J AM CHEM SOC, V119, P7654, DOI 10.1021/ja970698p.
   Lakshman MK, 2005, CURR ORG SYNTH, V2, P83, DOI 10.2174/1570179052996955.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   Maruenda H, 1998, J ORG CHEM, V63, P4385, DOI 10.1021/jo980170i.
   Meier C, 2005, NUCLEOS NUCLEOT NUCL, V24, P691, DOI 10.1081/NCN-200060267.
   Meier C, 2002, SYNLETT, P802.
   Nagao M., 2000, FOOD BORNE CARCINOGE.
   Novak M, 2002, J AM CHEM SOC, V124, P7972, DOI 10.1021/ja0121944.
   Novak M, 2003, J ORG CHEM, V68, P9875, DOI 10.1021/jo034505u.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   Shibutani S, 1999, J BIOL CHEM, V274, P27433, DOI 10.1074/jbc.274.39.27433.
   SHIBUTANI S, 1991, CARCINOGENESIS, V12, P813, DOI 10.1093/carcin/12.5.813.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P411, DOI 10.1093/carcin/9.3.411.
   TAKAMURAENYA T, 2003, NUCL ACID RES S, V3, P23.
   Takamura-Enya T, 2003, TETRAHEDRON LETT, V44, P5969, DOI 10.1016/S0040-4039(03)01484-9.
   TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005.
   Wang ZW, 2001, ORG LETT, V3, P565, DOI 10.1021/ol006968h.
   Wolfe JP, 2000, J ORG CHEM, V65, P1158, DOI 10.1021/jo991699y.}},
Number-of-Cited-References = {{37}},
Times-Cited = {{10}},
Journal-ISO = {{Chem. Res. Toxicol.}},
Doc-Delivery-Number = {{053RR}},
Wos-Id = {{ISI:000238323200007}},
}

@article{ ISI:000234760200014,
Author = {Arimoto-Kobayashi, S and Ishida, R and Nakai, Y and Idei, C and Takata,
   J and Takahashi, E and Okamoto, K and Negishi, T and Konuma, T},
Title = {{Inhibitory effects of beer on mutation in the Ames test and DNA adduct
   formation in mouse organs induced by
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP)}},
Journal = {{BIOLOGICAL \& PHARMACEUTICAL BULLETIN}},
Year = {{2006}},
Volume = {{29}},
Number = {{1}},
Pages = {{67-70}},
Month = {{JAN}},
Abstract = {{An evaluation of the antigenotoxic potential of beer components against
   carcinogens contained in the human diet, namely heterocyclic amines
   (HCAs) including 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine
   (PhIP), was determined. The protective mechanism involved was also
   investigated. Beer samples were found to inhibit the mutagenicity of
   HCAs in the Ames test. Beer solution, consisting of a freeze-dried and
   dissolved sample, given as drink-water significantly reduced the
   formation of PhIP-DNA adducts in mouse colon and lung compared to
   control mice fed with PhIP in the absence of beer solution. Furthermore,
   beer solution added in the diet as a food additive mimic significantly
   reduced the amount of DNA adducts present in the liver and lung of mice
   fed with PhIP. In an effort to investigate the mechanism responsible for
   the observed protective effect, the effect of beer solutions on HCA
   metabolizing enzymes was investigated. Beer solutions inhibited the
   activity of CYP1A1 and CYP1A2, as determined from deethylation and
   demethylation assays using 7-ethoxy- and 7-methoxyresolufin,
   respectively. Considering the overall suppression of PhIP genotoxicity
   by beer, this study confirmed that beer components can interfere with
   the enzyme activity involved in the metabolism of HCAs and subsequently
   suppress the observed genotoxicity. The results of this study showed
   that beer components act in a protective capacity against the genotoxic
   effects of heterocyclic amines in vivo.}},
Publisher = {{PHARMACEUTICAL SOC JAPAN}},
Address = {{2-12-15-201 SHIBUYA, SHIBUYA-KU, TOKYO, 150, JAPAN}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Arimoto-Kobayashi, S (Reprint Author), Okayama Univ, Div Pharmaceut Sci, Grad Sch Med Dent \& Pharmaceut Sci, Okayama 7008530, Japan.
   Okayama Univ, Div Pharmaceut Sci, Grad Sch Med Dent \& Pharmaceut Sci, Okayama 7008530, Japan.}},
DOI = {{10.1248/bpb.29.67}},
ISSN = {{0918-6158}},
Keywords = {{2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP); beer; DNA
   adduct; in vivo effect; antigenotoxicity; antimutagenicity}},
Keywords-Plus = {{HETEROCYCLIC AMINE; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE
   PHIP; ANTIMUTAGENIC SUBSTANCE; METABOLISM; CARCINOGENS; PSEUDOURIDINE;
   PROTECTION; BEVERAGES; HUMANS; LIVER}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Author-Email = {{arimoto@cc.okayama-u.ac.jp}},
ResearcherID-Numbers = {{TAKAHASHI, Eizo/B-2282-2011}},
Cited-References = {{Arimoto-Kobayashi S, 1999, J AGR FOOD CHEM, V47, P221, DOI 10.1021/jf980685a.
   Arimoto-Kobayashi S, 2005, J AGR FOOD CHEM, V53, P812, DOI 10.1021/jf049208k.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   BUONARATI MH, 1992, CARCINOGENESIS, V13, P621, DOI 10.1093/carcin/13.4.621.
   Dashwood RH, 2002, MUTAT RES-REV MUTAT, V511, P89, DOI 10.1016/S1383-5742(02)00005-4.
   Edenharder R, 2002, MUTAT RES-GEN TOX EN, V521, P57, DOI 10.1016/S1383-5718(02)00212-7.
   FELTON JS, 2000, FOOD BORN CARCINOGEN, P198.
   FUKUTOME K, 1994, JPN J CANCER RES, V85, P113.
   Hammons GJ, 1997, CARCINOGENESIS, V18, P851, DOI 10.1093/carcin/18.4.851.
   IARC, 1993, IARC MON EV CARC RIS, V56, P229.
   Kimura S, 1999, MUTAT RES-GEN TOX EN, V439, P267, DOI 10.1016/S1383-5718(99)00004-2.
   Knasmuller S, 2002, FOOD CHEM TOXICOL, V40, P1051, DOI 10.1016/S0278-6915(02)00101-1.
   MAJOR BJ, 2005, FOOD CHEM TOXICOL, V43, P433.
   MARON DM, 1984, HDB MUTAGENICITY TES, P93.
   Miranda CL, 2000, DRUG METAB DISPOS, V28, P1297.
   Monobe M, 2003, MUTAT RES-GEN TOX EN, V538, P93, DOI 10.1016/S1383-5718(03)00094-9.
   Nagao M, 2001, MUTAT RES-FUND MOL M, V477, P119, DOI 10.1016/S0027-5107(01)00113-0.
   Nelson CP, 2001, CANCER RES, V61, P103.
   OHGAKI H., 2000, FOOD BORNE CARCINOGE, P198.
   Sugimura T, 2000, CARCINOGENESIS, V21, P387, DOI 10.1093/carcin/21.3.387.
   Takahashi E, 2002, MUTAT RES-FUND MOL M, V508, P147, DOI 10.1016/S0027-5107(02)00212-9.
   Walters DG, 2004, CARCINOGENESIS, V25, P1659, DOI 10.1093/carcin/bgh164.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P1073, DOI 10.1093/carcin/12.6.1073.
   YAHAGI T, 1977, MUTAT RES, V48, P121, DOI 10.1016/0027-5107(77)90151-8.
   Yoshikawa T, 2002, FOOD CHEM TOXICOL, V40, P1165, DOI 10.1016/S0278-6915(02)00060-1.
   Zsivkovits M, 2003, CARCINOGENESIS, V24, P1913, DOI 10.1093/carcin/bgg167.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{5}},
Journal-ISO = {{Biol. Pharm. Bull.}},
Doc-Delivery-Number = {{004NT}},
Wos-Id = {{ISI:000234760200014}},
}

@article{ ISI:000233147000010,
Author = {Steffensen, IL and Schut, HAJ and Alexander, J},
Title = {{Age at exposure and Apc status influence the levels of
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP)-DNA adducts in
   mouse intestine and liver}},
Journal = {{MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS}},
Year = {{2005}},
Volume = {{587}},
Number = {{1-2}},
Pages = {{73-89}},
Month = {{NOV 10}},
Abstract = {{We have previously shown that C57BL/6J-Min/+ (multiple intestinal
   neoplasia) mice, heterozygous for the Min mutation in the adenomatous
   polyposis coli gene, were more susceptible to intestinal tumorigenesis
   and had higher intestinal PhIP-DNA adduct levels after exposure to the
   food mutagen 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) on
   day 12 than on day 36 after birth {[}I.-L. Steffensen, H.A.J. Schut,
   J.E. Paulsen, angstrom. Andreassen, J. Alexander, Intestinal
   tumorigenesis in multiple intestinal neoplasia mice induced by the food
   mutagen 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine: perinatal
   susceptibility, regional variation, and correlation with DNA adducts,
   Cancer Res. 61 (2001) 8689-8696]. In the present study, we have
   evaluated further whether this difference in susceptibility is related
   to adduct formation/removal, cell proliferation, apoptosis or expression
   of the nucleotide excision repair protein Xeroderma pigmentosum group A
   (XPA) in the intestines. Min/+ and +/+ (wild-type) mice were given a
   subcutaneous injection of 50 mg/kg bw PhIP on day 12 or 36, and the
   levels of PhIP-DNA adducts after 8, 12, 24 h, 3 or 7 days were
   quantified by use of P-32-postlabelling. In Min/+ mice, adduct levels
   were significantly higher after exposure on day 12 than on day 36 in the
   middle (1.5- to 8.5-fold) and distal (1.3- to 6.5-fold) small intestine
   from 8 It to 3 days after administration of PhIP, but not in the colon
   and proximal small intestine. In the liver - a non-target organ for PhIP
   adduct levels were 2.0- to 7.5-fold higher after exposure on day 12 than
   on day 36 from 8 to 24 h after exposure. Adduct levels were generally
   higher in the middle (1.1- to 1.8-fold) and distal (1.1- to 2.0-fold)
   small intestines of Min/+ compared with +/+ mice after PhIP exposure on
   day 12, i.e. in the area of the intestines previously found also to have
   the highest number of tumors in Min/+ mice. PhIP increased cell
   proliferation and the number of apoptotic cells in the intestine and
   liver. However, the higher susceptibility to intestinal tumorigenesis in
   Min/+ mice exposed to PhIP at early age, or in Min/+ mice compared with
   +/+ mice, could not be explained by differences in cell proliferation,
   apoptosis or expression of the XPA repair protein. (c) 2005 Elsevier
   B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Steffensen, IL (Reprint Author), Norwegian Inst Publ Hlth, Div Environm Med, Dept Food Toxicol, POB 4404, NO-0403 Oslo, Norway.
   Norwegian Inst Publ Hlth, Div Environm Med, Dept Food Toxicol, NO-0403 Oslo, Norway.
   Med Univ Ohio, Dept Biochem \& Canc Biol, Toledo, OH 43614 USA.}},
DOI = {{10.1016/j.mrgentox.2005.07.004}},
ISSN = {{1383-5718}},
Keywords = {{PhIP; Min/ plus mouse; DNA adducts; cell proliferation; apoptosis;
   nucleotide excision repair; Xeroderma pigmentosum group A}},
Keywords-Plus = {{FOOD MUTAGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE; NUCLEOTIDE
   EXCISION-REPAIR; ABERRANT CRYPT FOCI; GROUP-A GENE; NEOPLASIA MICE;
   DNA-ADDUCTS; TRUNCATION MUTATIONS; CELL-DEATH; PHIP; TUMORS}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Author-Email = {{inger-lise.steffensen@fhi.no}},
Cited-References = {{Andreassen A, 2001, MUTAGENESIS, V16, P309, DOI 10.1093/mutage/16.4.309.
   Andreassen A, 2002, MUTAT RES-GEN TOX EN, V517, P157, DOI 10.1016/S1383-5718(02)00065-7.
   Collett GP, 2001, CARCINOGENESIS, V22, P821, DOI 10.1093/carcin/22.5.821.
   CUMMINGS DA, 1994, CARCINOGENESIS, V15, P2623, DOI 10.1093/carcin/15.11.2623.
   Damia G, 1998, EUR J CANCER, V34, P1783, DOI 10.1016/S0959-8049(98)00190-7.
   de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493.
   Gerhardsson de Verdier M, 1991, Int J Cancer, V49, P520.
   HASEGAWA R, 1993, CARCINOGENESIS, V14, P2553, DOI 10.1093/carcin/14.12.2553.
   HOEIJMAKERS JHJ, 1990, MUTAT RES, V236, P223, DOI 10.1016/0921-8777(90)90007-R.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   Imaida K, 2000, CANCER LETT, V150, P63, DOI 10.1016/S0304-3835(99)00377-8.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   Josyula S, 1999, FOOD CHEM TOXICOL, V37, P287, DOI 10.1016/S0278-6915(99)00018-6.
   KERR JFR, 1995, METHOD CELL BIOL, V46, P1.
   Klein JC, 2001, CARCINOGENESIS, V22, P619, DOI 10.1093/carcin/22.4.619.
   Mahmoud NN, 1997, CANCER RES, V57, P5045.
   Mollersen L, 2004, MUTAT RES-GEN TOX EN, V557, P29, DOI 10.1016/j.mrgentox.2003.09.008.
   MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722.
   Muotri AR, 2002, CARCINOGENESIS, V23, P1039, DOI 10.1093/carcin/23.6.1039.
   NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0.
   OCHIAI M, 1991, JPN J CANCER RES, V82, P363.
   Ochiai M, 2002, JPN J CANCER RES, V93, P478.
   Paulsen JE, 1999, CARCINOGENESIS, V20, P1277, DOI 10.1093/carcin/20.7.1277.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   Shirai T, 1997, CANCER RES, V57, P195.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   Steffensen IL, 2001, CANCER RES, V61, P8689.
   Steffensen IL, 1997, CARCINOGENESIS, V18, P1049, DOI 10.1093/carcin/18.5.1049.
   SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108.
   TAKAHASHI S, 1991, JPN J CANCER RES, V82, P135.
   THOMPSON LH, 1987, MUTAGENESIS, V2, P483, DOI 10.1093/mutage/2.6.483.
   TUDEK B, 1989, CANCER RES, V49, P1236.
   Turesky RJ, 2004, CURR DRUG METAB, V5, P169, DOI 10.2174/1389200043489036.
   Turesky RJ, 2002, DRUG METAB REV, V34, P625, DOI 10.1081/DMR-120005665.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   Watson AJM, 2004, GUT, V53, P1701, DOI 10.1136/gut.2004.052704.
   Willett WC, 1995, ENVIRON HEALTH PERSP, V103, P165, DOI 10.2307/3432305.
   Wong WM, 1999, J CLIN PATHOL, V52, P321.
   WYLLIE AH, 1980, INT REV CYTOL, V68, P25.
   Zhu HJ, 2000, CANCER RES, V60, P1283.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{4}},
Journal-ISO = {{Mutat. Res. Genet. Toxicol. Environ. Mutagen.}},
Doc-Delivery-Number = {{982GV}},
Wos-Id = {{ISI:000233147000010}},
}

@article{ ISI:000227868700018,
Author = {Holland, RD and Gehring, T and Taylor, J and Lake, BG and Gooderham, NJ
   and Turesky, RJ},
Title = {{Formation of a mutagenic heterocyclic aromatic amine from creatinine in
   urine of meat eaters and vegetarians}},
Journal = {{CHEMICAL RESEARCH IN TOXICOLOGY}},
Year = {{2005}},
Volume = {{18}},
Number = {{3}},
Pages = {{579-590}},
Month = {{MAR}},
Abstract = {{Liquid chromatography electrospray ionization mass spectrometry (MS)
   with a triple quadrupole MS was used to identify known and novel
   heterocyclic aromatic amines (HAAs) in human urine. The identities of
   2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline (8-MeIQx) and
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) were confirmed
   by their product ion spectra. The constant neutral loss scan mode was
   employed to probe for other analytes in urine that display the
   transition {[}M + H](+) -> {[}M + H - CH3 center dot](+center dot),
   which is common to HAAs containing an N-methylimidazo moiety, and led to
   the detection of a previously unreported isomer of 8-MeIQx {[}Holland,
   R., et al. (2004) Chem. Res. Toxicol. 17, 1121-1136]. We now report the
   identification of another novel HAA,
   2-amino-1-methylimidazo{[}4,5-b]quinoline (IQ{[}4,5-b]), an isomer of
   the powerful animal carcinogen 2-amino-3-methylimidazo{[}4,5-f]quinoline
   (IQ). The amounts of IQ{[}4,5-b] measured in the urine of human
   volunteers who consumed grilled beef ranged from 15 to 135\% of the
   ingested dose, while the amounts of 8-MeIQx and PhIP excreted in urine
   were on average <2\% of the ingested dose. Base treatment of urine at 70
   degrees C increased the concentrations of 8-MeIQx and PhIP by as much as
   6-fold, indicating the presence of phase II conjugates; however, the
   amount of IQ{[}4,5-b] increased by more than 100-fold. IQ{[}4,5-b] was
   also detected in the urine of vegetarians following base hydrolysis. The
   formation of IQ{[}4,5-b], but not IQ, 8-MeIQx, or PhIP, also occurred in
   urine incubated at 37 degrees C. Creatinine and 2-aminobenzaldehyde are
   likely precursors of IQ{[}4,5-b]. The detection of IQ{[}4,5-b] in the
   urine of both meat eaters and vegetarians suggests that this HAA may be
   present in nonmeat staples or that IQ {[}4,5-b] formation may occur
   endogenously within the urinary bladder or other biological fluids.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Turesky, RJ (Reprint Author), New York State Dept Hlth, Wadsworth Ctr, Div Environm Dis Prevent, Empire State Plaza,POB 509, Albany, NY 12201 USA.
   Natl Ctr Toxicol Res, Div Chem, Jefferson, AR 72079 USA.
   BIBRA Int, Carshalton SM5 4DS, Surrey, England.
   Univ London Imperial Coll Sci Technol \& Med, Div Biomed Sci, London SW7 2AZ, England.}},
DOI = {{10.1021/tx049675w}},
ISSN = {{0893-228X}},
Keywords-Plus = {{TANDEM MASS-SPECTROMETRY; COMMERCIAL BEEF EXTRACT;
   LIQUID-CHROMATOGRAPHY; COOKED FOODS; FRIED BEEF;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO(4,5-B)PYRIDINE PHIP;
   2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE IQ; COLORECTAL-CANCER;
   DNA-ADDUCTS; HUMAN LIVER}},
Research-Areas = {{Pharmacology \& Pharmacy; Chemistry; Toxicology}},
Web-of-Science-Categories  = {{Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology}},
Author-Email = {{Rturesky@wadsworth.org}},
Cited-References = {{ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   Brudnak MA, 2004, TOXICOL LETT, V150, P123, DOI 10.1016/j.toxlet.2004.01.013.
   Chen HJC, 2004, CHEM RES TOXICOL, V17, P896, DOI 10.1021/tx0342013.
   ELBAYOUMY K, 1986, CANCER RES, V46, P6064.
   Felton J. S., 2000, Food borne carcinogens: heterocyclic amines., P31.
   FELTON JS, 1994, ENVIRON HEALTH PERSP, V102, P201, DOI 10.2307/3432178.
   Friesen MD, 2001, CANCER LETT, V173, P43, DOI 10.1016/S0304-3835(01)00672-3.
   GROSE KR, 1986, J AGR FOOD CHEM, V34, P201, DOI 10.1021/jf00068a012.
   GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B.
   GROSS GG, 1969, EUR J BIOCHEM, V8, P413, DOI 10.1111/j.1432-1033.1969.tb00543.x.
   Guy PA, 2000, J CHROMATOGR A, V883, P89, DOI 10.1016/S0021-9673(00)00361-7.
   Hada N, 2001, MUTAT RES-GEN TOX EN, V493, P115, DOI 10.1016/S1383-5718(01)00168-1.
   HARGRAVES WA, 1983, CANCER RES, V43, P1467.
   Hecht SS, 2002, CARCINOGENESIS, V23, P907, DOI 10.1093/carcin/23.6.907.
   Holder CL, 1997, RAPID COMMUN MASS SP, V11, P1667, DOI 10.1002/(SICI)1097-0231(19971015)11:15<1667::AID-RCM58>3.0.CO;2-N.
   Holland RD, 2004, CHEM RES TOXICOL, V17, P1121, DOI 10.1021/tx049910a.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KATO T, 1990, MUTAT RES, V240, P259, DOI 10.1016/0165-1218(90)90076-E.
   Kawamori T, 2004, CARCINOGENESIS, V25, P1967, DOI 10.1093/carcin/bgh189.
   King R.S., 2000, FOOD BORNE CARCINOGE, P90.
   KNIZE MG, 1994, FOOD CHEM TOXICOL, V32, P595, DOI 10.1016/0278-6915(94)90002-7.
   Kulp KS, 2004, J CHROMATOGR B, V802, P143, DOI 10.1016/j.jchromb.2003.09.032.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   Le Marchand L, 2001, CANCER EPIDEM BIOMAR, V10, P1259.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   MANABE S, 1992, CARCINOGENESIS, V13, P827, DOI 10.1093/carcin/13.5.827.
   MURRAY S, 1988, CARCINOGENESIS, V9, P321, DOI 10.1093/carcin/9.2.321.
   Murray S, 2001, CARCINOGENESIS, V22, P1413, DOI 10.1093/carcin/22.9.1413.
   MURRAY S, 1993, J CHROMATOGR-BIOMED, V616, P211, DOI 10.1016/0378-4347(93)80388-K.
   NAGAO M, 1993, MUTAT RES, V290, P43, DOI 10.1016/0027-5107(93)90031-A.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   Poortmans JR, 2000, SPORTS MED, V30, P155, DOI 10.2165/00007256-200030030-00002.
   RICH KJ, 1992, CARCINOGENESIS, V13, P2221, DOI 10.1093/carcin/13.12.2221.
   RONNE E, 1994, SYNTHETIC COMMUN, V24, P1363, DOI 10.1080/00397919408011739.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P279, DOI 10.1016/S0278-6915(97)00162-2.
   SKOG K, 1995, CARCINOGENESIS, V16, P861, DOI 10.1093/carcin/16.4.861.
   Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1.
   SON OS, 1980, XENOBIOTICA, V10, P457.
   SPINGARN NE, 1980, CANCER LETT, V9, P177, DOI 10.1016/0304-3835(80)90084-1.
   Spiteller P, 2001, PHYTOCHEMISTRY, V57, P361, DOI 10.1016/S0031-9422(01)00036-X.
   STILLWELL WG, 1994, CANCER EPIDEM BIOMAR, V3, P399.
   Stillwell WG, 1999, CANCER LETT, V143, P145, DOI 10.1016/S0304-3835(99)00144-5.
   Stillwell WG, 1999, CANCER RES, V59, P5154.
   Strickland PT, 2002, MUTAT RES-FUND MOL M, V506, P163, DOI 10.1016/S0027-5107(02)00163-X.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   Sugimura T, 2004, CANCER SCI, V95, P290, DOI 10.1111/j.1349-7006.2004.tb03205.x.
   TAKAHASHI M, 1985, CARCINOGENESIS, V6, P1195, DOI 10.1093/carcin/6.8.1195.
   Toribio F, 2002, J MASS SPECTROM, V37, P812, DOI 10.1002/jms.340.
   Totsuka Y, 2002, MUTAT RES-FUND MOL M, V506, P49, DOI 10.1016/S0027-5107(02)00151-3.
   Totsuka Y, 2004, J CHROMATOGR B, V802, P135, DOI 10.1016/j.jchromb.2003.10.041.
   TURESKY RJ, 2004, IN PRESS J AGR FOOD.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P217, DOI 10.1021/tx9701891.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P925, DOI 10.1021/tx980022n.
   TURESKY RJ, 1994, DNA ADDUCTS IDENTIFI, P217.
   TURESKY RJ, 1983, CARCINOGENESIS, V4, P863, DOI 10.1093/carcin/4.7.863.
   Turesky RJ, 2004, J CHROMATOGR B, V802, P155, DOI 10.1016/j.jchromb.2003.10.053.
   UCHIDA MAKIO, 1953, MED JOUR OSAKA UNIV, V3, P487.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   VIKSE R, 1995, ENVIRON MOL MUTAGEN, V26, P79, DOI 10.1002/em.2850260112.
   vonNussbaum F, 1997, PHYTOCHEMISTRY, V46, P261, DOI 10.1016/S0031-9422(97)00304-X.
   Weimann A, 2001, FREE RADICAL BIO MED, V30, P757, DOI 10.1016/S0891-5849(01)00462-2.
   Wogan GN, 2004, SEMIN CANCER BIOL, V14, P473, DOI 10.1016/j.semcancer.2004.06.010.
   WOLF H, 1974, SCAND J CLIN LAB I S, V33, P136.
   Wyss M, 2000, PHYSIOL REV, V80, P1107.
   YAMAIZUMI Z, 1986, MUTAT RES, V173, P1, DOI 10.1016/0165-7992(86)90002-3.
   Zheng W, 1998, J NATL CANCER I, V90, P1724, DOI 10.1093/jnci/90.22.1724.
   {*}AG FRANC SEC SAN, 2001, OP FRENCH AG FOOD SA.
   2004, KEGG TRYPTOPHAN META.}},
Number-of-Cited-References = {{70}},
Times-Cited = {{8}},
Journal-ISO = {{Chem. Res. Toxicol.}},
Doc-Delivery-Number = {{909OH}},
Wos-Id = {{ISI:000227868700018}},
}

@article{ ISI:000227910400007,
Author = {Frederiksen, H},
Title = {{Two food-borne heterocyclic amines: Metabolism and DNA adduct formation
   of amino-alpha-carbolines}},
Journal = {{MOLECULAR NUTRITION \& FOOD RESEARCH}},
Year = {{2005}},
Volume = {{49}},
Number = {{3}},
Pages = {{263-273}},
Month = {{MAR}},
Abstract = {{The amino-alpha-carbolines 2-amino-9H-pyrido{[}2,3-b]indole (A alpha C)
   and 2-amino-3-methyl-9H-pyrido-{[}2,3-b]indole (MeA alpha C) are two
   mutagenic and carcinogenic heterocyclic amines formed during ordinary
   cooking. Amino-alpha-carbolines can be formed in model systems by
   pyrolyzing tryptophan or proteins of animal or vegetable origin,
   furthermore they are found in many cooked foods, such as fish, meat, and
   chicken. The specific mutagenicity of the amino-a-carbolines are lower
   in the Ames Salmonella assay than other heterocyclic amines, but in
   rodent studies the carcinogenicity of the aminoa, alpha-carbolines are
   comparable to other heterocyclic amines. The metabolic pathways of the
   amino-alpha-carbolines have been studied in vitro and in vivo, and the
   detoxified phase I and phase II metabolites characterized and
   quantified. The metabolic activation of the amino-a-carbolines and the
   formation of DNA-adducts have also been studied. Characteristic for the
   amino-a-carbolines are that relatively large amounts of these compounds
   in rat and human hepatic microsomes are activated to potent carcinogenic
   compounds compared with other heterocyclic amines, but further in vivo
   studies of the amino-a-carbolines are needed to highlight these
   indications. In this review, the main characteristics with focus on the
   metabolism and the DNA-adduct formation of the amino-a-carbolines are
   described and compared with other heterocyclic amines.}},
Publisher = {{WILEY-V C H VERLAG GMBH}},
Address = {{PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Frederiksen, H (Reprint Author), Danish Inst Food \& Vet Res, Dept Toxicol \& Risk Assessment, Morkhoj Bygade 19, DK-2860 Soborg, Denmark.
   Danish Inst Food \& Vet Res, Dept Toxicol \& Risk Assessment, DK-2860 Soborg, Denmark.}},
DOI = {{10.1002/mnfr.200400061}},
ISSN = {{1613-4125}},
Keywords = {{amino-alpha-carbolines; DNA-adducts; heterocyclic-amines; metabolism;
   review}},
Keywords-Plus = {{CIGARETTE-SMOKE CONDENSATE; PERFORMANCE LIQUID-CHROMATOGRAPHY;
   AROMATIC-AMINES; COOKED FOODS;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; LIVER-MICROSOMES;
   IN-VITRO; P-32-POSTLABELING ANALYSIS; SPECIES-DIFFERENCES; HEPATIC
   MICROSOMES}},
Research-Areas = {{Food Science \& Technology}},
Web-of-Science-Categories  = {{Food Science \& Technology}},
Author-Email = {{haf@dfvf.dk}},
Cited-References = {{Busquets R, 2004, J CHROMATOGR B, V802, P79, DOI 10.1016/j.jchromb.2003.09.033.
   DEGAWA M, 1990, JPN J CANCER RES, V81, P1253.
   DRAGSTED LO, 1995, CARCINOGENESIS, V16, P2785, DOI 10.1093/carcin/16.11.2785.
   EISENBRAND G, 1993, TOXICOLOGY, V84, P1, DOI 10.1016/0300-483X(93)90109-6.
   FELTON JS, 2002, FOOD BORNE CARCINOGE, P31.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   Frandsen H, 2002, FOOD CHEM TOXICOL, V40, P1125, DOI 10.1016/S0278-6915(02)00033-9.
   Frandsen H, 1998, MUTAGENESIS, V13, P181, DOI 10.1093/mutage/13.2.181.
   FRANDSEN H, 1994, CARCINOGENESIS, V15, P2553, DOI 10.1093/carcin/15.11.2553.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   Frederiksen H, 2004, CARCINOGENESIS, V25, P1525, DOI 10.1093/carcin/bgh156.
   Frederiksen H, 2004, FOOD CHEM TOXICOL, V42, P879, DOI 10.1016/j.fct.2004.01.011.
   Frederiksen H, 2004, DRUG METAB DISPOS, V32, P661, DOI 10.1124/dmd.32.6.661.
   Frederiksen H, 2003, PHARMACOL TOXICOL, V92, P246, DOI 10.1034/j.1600-0773.2003.920508.x.
   Frederiksen H, 2002, PHARMACOL TOXICOL, V90, P127, DOI 10.1034/j.1600-0773.2002.900303.x.
   Glatt H, 2004, CARCINOGENESIS, V25, P801, DOI 10.1093/carcin/bgh077.
   GROSS GA, 1990, CARCINOGENESIS, V11, P1597, DOI 10.1093/carcin/11.9.1597.
   GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B.
   GUPTA RC, 1985, CANCER RES, V45, P5656.
   GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081.
   HASEGAWA R, 1992, CARCINOGENESIS, V13, P1427, DOI 10.1093/carcin/13.8.1427.
   HASHIMOTO Y, 1980, BIOCHEM BIOPH RES CO, V96, P355, DOI 10.1016/0006-291X(80)91222-X.
   HIBINO S, 1991, CHEM PHARM BULL, V39, P79.
   Jagerstad M, 1998, Z LEBENSM UNTERS F A, V207, P419, DOI 10.1007/s002170050355.
   Kadlubar F, 1995, Princess Takamatsu Symp, V23, P207.
   KING RS, 2002, FOOD BORNE CARCINOGE, P90.
   King RS, 2000, CARCINOGENESIS, V21, P1347, DOI 10.1093/carcin/21.7.1347.
   Knize M. G., 1996, Journal of Muscle Foods, V7, P271, DOI 10.1111/j.1745-4573.1996.tb00603.x.
   Knize M. G., 1987, Developments in Industrial Microbiology, V28, P171.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LIN DX, 1995, DRUG METAB DISPOS, V23, P518.
   MANABE S, 1990, J CHROMATOGR-BIOMED, V529, P125, DOI 10.1016/S0378-4347(00)83813-X.
   MATSUMOTO T, 1981, CANCER LETT, V12, P105, DOI 10.1016/0304-3835(81)90045-8.
   MATSUMOTO T, 1977, MUTAT RES, V48, P279, DOI 10.1016/0027-5107(77)90170-1.
   MCMANUS ME, 1990, CANCER RES, V50, P3367.
   NIWA T, 1982, MUTAT RES, V95, P159, DOI 10.1016/0027-5107(82)90254-8.
   OHGAKI H, 1984, CARCINOGENESIS, V5, P815, DOI 10.1093/carcin/5.6.815.
   Okonogi H, 1997, CANCER LETT, V111, P105, DOI 10.1016/S0304-3835(96)04505-3.
   Pais P, 2000, J CHROMATOGR B, V747, P139, DOI 10.1016/S0378-4347(00)00118-3.
   Pfau W, 1996, CARCINOGENESIS, V17, P2727, DOI 10.1093/carcin/17.12.2727.
   Pfau W, 1999, CARCINOGENESIS, V20, P545, DOI 10.1093/carcin/20.4.545.
   Pfau W, 1997, CHEM RES TOXICOL, V10, P1192, DOI 10.1021/tx9701182.
   Poirier MC, 2000, CARCINOGENESIS, V21, P353, DOI 10.1093/carcin/21.3.353.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   Raza H, 1996, DRUG METAB DISPOS, V24, P395.
   Richling E, 1997, J CHROMATOGR A, V791, P71, DOI 10.1016/S0021-9673(97)00842-X.
   Ristic A, 2004, J CHROMATOGR B, V802, P87, DOI 10.1016/j.jchromb.2003.09.028.
   SHIMADA T, 1991, CANCER RES, V51, P5284.
   Skog K, 1998, J CHROMATOGR A, V803, P227, DOI 10.1016/S0021-9673(97)01266-1.
   Skog K, 2002, FOOD CHEM TOXICOL, V40, P1197, DOI 10.1016/S0278-6915(02)00052-2.
   Snyderwine EG, 1998, FOOD CHEM TOXICOL, V36, P1033, DOI 10.1016/S0278-6915(98)00088-X.
   Steffensen IL, 2002, CARCINOGENESIS, V23, P1373, DOI 10.1093/carcin/23.8.1373.
   SUGIMURA T, 2002, FOOD BORNE CARCINOGE, P1.
   SUGIMURA T, 1985, MUTAT RES, V150, P33, DOI 10.1016/0027-5107(85)90098-3.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   SUGIMURA T, 1990, PROG CLIN BIOL RES, V347, P1.
   SYNDERWINE EG, 2002, FOOD BORNE CARCINOGE, P131.
   TURESKY RJ, 1994, ENVIRON HEALTH PERSP, V102, P47, DOI 10.2307/3432151.
   Wakabayashi K, 1995, Princess Takamatsu Symp, V23, P39.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   YAMASHITA K, 1986, P JPN ACAD B-PHYS, V62, P45, DOI 10.2183/pjab.62.45.
   YANAZOE Y, 2002, FOOD BORNE CARCINOGE, P74.
   YOSHIDA D, 1978, BIOCHEM BIOPH RES CO, V83, P915, DOI 10.1016/0006-291X(78)91482-1.
   YOSHIDA D, 1980, CANCER LETT, V10, P141, DOI 10.1016/0304-3835(80)90037-3.
   Zhang XB, 1996, CARCINOGENESIS, V17, P2259, DOI 10.1093/carcin/17.10.2259.}},
Number-of-Cited-References = {{66}},
Times-Cited = {{5}},
Journal-ISO = {{Mol. Nutr. Food Res.}},
Doc-Delivery-Number = {{910DL}},
Wos-Id = {{ISI:000227910400007}},
}

@article{ ISI:000226782900047,
Author = {Arimoto-Kobayashi, S and Takata, J and Nakandakari, N and Fujioka, R and
   Okamoto, K and Konuma, T},
Title = {{Inhibitory effects of heterocyclic amine-induced DNA adduct formation in
   mouse liver and lungs by beer}},
Journal = {{JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY}},
Year = {{2005}},
Volume = {{53}},
Number = {{3}},
Pages = {{812-815}},
Month = {{FEB 9}},
Abstract = {{An evaluation of the in vivo antigenotoxic potential of beer components
   on heterocyclic amines including
   2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline (MelQx) and
   3-amino-1-methyl-5H-pyrido-{[}4.3-b]indole (Trp-P-2) was determined with
   particular focus on the target organs of tumorigenesis, and the
   protective mechanisms involved were investigated. Beer-solution,
   consisting of a freeze-dried and dissolved sample, given as drinking
   water, reduced the formation of MelQx-DNA adducts in mouse liver and
   lungs. Beer-solution added in the diet as a mimic of food additives also
   significantly reduced the amount of DNA adducts present in the liver,
   lung, and kidney DNA of mice fed with MelQx compared to control mice fed
   with MelQx in the absence of beer-solution. The amount of adducts
   present in the liver of mice with single or continuous administration of
   Trp-P-2 was significantly reduced when beer-solution was given as part
   of the diet compared to control mice given Trp-P-2 without
   beer-solution. Protective effects were observed both with lager- and
   stout-type samples. In an effort to investigate the mechanisms
   responsible for the observed protective effects, the effects of
   beer-solution on metabolizing enzymes for heterocyclic amines were
   examined. Beer-solutions inhibited the metabolic activation of Trp-P-2
   to Trp-P-2(NHOH), as demonstrated by HPLC analysis. Considering the
   overall suppression of the genotoxicity of MelQx and Trp-P-2 by beer, we
   have shown that beer components can inhibit the metabolic activation of
   heterocyclic amines and subsequently suppress the observed genotoxicity.
   The results of this study show that beer components are protective
   against the genotoxic effects of heterocyclic amines on target organs
   associated with tumorigenesis in vivo.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Arimoto-Kobayashi, S (Reprint Author), Okayama Univ, Fac Pharmaceut Sci, Okayama 7008530, Japan.
   Okayama Univ, Fac Pharmaceut Sci, Okayama 7008530, Japan.}},
DOI = {{10.1021/jf049208k}},
ISSN = {{0021-8561}},
Keywords = {{antimutagenicity; beer; DNA adduct; heterocyclic amines; metabolic
   activation}},
Keywords-Plus = {{ANTIMUTAGENIC SUBSTANCE; PSEUDOURIDINE; CARCINOGENS; PROTECTION;
   ACTIVATION; BEVERAGES; ACID; P1}},
Research-Areas = {{Agriculture; Chemistry; Food Science \& Technology}},
Web-of-Science-Categories  = {{Agriculture, Multidisciplinary; Chemistry, Applied; Food Science \&
   Technology}},
Author-Email = {{arimoto@cc.okayama-u.ac.jp}},
Cited-References = {{Arimoto-Kobayashi S, 1999, J AGR FOOD CHEM, V47, P221, DOI 10.1021/jf980685a.
   Arimoto-Kobayashi S, 2003, ENV MUTAGEN RES, V25, P77, DOI 10.3123/jems.25.77.
   Arimoto-Kobayashi S, 2003, J AGR FOOD CHEM, V51, P5150, DOI 10.1021/jf0302761.
   Dashwood RH, 2002, MUTAT RES-REV MUTAT, V511, P89, DOI 10.1016/S1383-5742(02)00005-4.
   Edenharder R, 2002, MUTAT RES-GEN TOX EN, V521, P57, DOI 10.1016/S1383-5718(02)00212-7.
   FELTON JS, 2000, FOOD BORN CARCINOGEN, P198.
   Kimura S, 1999, MUTAT RES-GEN TOX EN, V439, P267, DOI 10.1016/S1383-5718(99)00004-2.
   Knasmuller S, 2002, FOOD CHEM TOXICOL, V40, P1051, DOI 10.1016/S0278-6915(02)00101-1.
   Miranda CL, 2000, DRUG METAB DISPOS, V28, P1297.
   Monobe M, 2003, MUTAT RES-GEN TOX EN, V538, P93, DOI 10.1016/S1383-5718(03)00094-9.
   Nagao M, 2001, MUTAT RES-FUND MOL M, V477, P119, DOI 10.1016/S0027-5107(01)00113-0.
   Nelson CP, 2001, CANCER RES, V61, P103.
   OCHIAI M, 1993, CARCINOGENESIS, V14, P2165, DOI 10.1093/carcin/14.10.2165.
   OHGAKI H., 2000, FOOD BORNE CARCINOGE, P198.
   SAITO K, 1983, CARCINOGENESIS, V4, P1547, DOI 10.1093/carcin/4.12.1547.
   Sugimura T, 2000, CARCINOGENESIS, V21, P387, DOI 10.1093/carcin/21.3.387.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P925, DOI 10.1021/tx980022n.
   Xu MR, 1999, CANCER LETT, V143, P179, DOI 10.1016/S0304-3835(99)00121-4.
   Yamazoe Y., 2000, FOOD BORNE CARCINOGE, P74.
   Yoshikawa T, 2002, FOOD CHEM TOXICOL, V40, P1165, DOI 10.1016/S0278-6915(02)00060-1.
   YOXALL VR, 2004, IN PRESS ARCH TOXICO.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{7}},
Journal-ISO = {{J. Agric. Food Chem.}},
Doc-Delivery-Number = {{894HX}},
Wos-Id = {{ISI:000226782900047}},
}

@article{ ISI:000225815500008,
Author = {Bang, J and Frandsen, H and Skog, K},
Title = {{Blue Chitin columns for the extraction of heterocyclic amines from urine
   samples}},
Journal = {{CHROMATOGRAPHIA}},
Year = {{2004}},
Volume = {{60}},
Number = {{11-12}},
Pages = {{651-655}},
Month = {{DEC}},
Abstract = {{During normal cooking of meat, a class of mutagenic/carcinogenic
   compounds called heterocyclic amines is formed. Heterocyclic amines are
   rapidly absorbed and metabolised in the human body, and for estimation
   of the intake of heterocyclic amines, it is useful to determinate their
   levels in the urine. Blue Chitin columns were used for the extraction
   and purification of heterocyclic amines from urine samples spiked with
   14 different heterocyclic amines. The samples were analysed using LC-MS.
   The results show that Blue Chitin columns provide a straightforward and
   rapid means of extracting heterocyclic amines from urine samples, and
   that Blue Chitin column are also useful in the purification of urinary
   metabolites.}},
Publisher = {{VIEWEG}},
Address = {{ABRAHAM-LINCOLN-STRABE 46, POSTFACH 15 47, D-65005 WIESBADEN, GERMANY}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Skog, K (Reprint Author), Lund Univ, Dept Food Technol Engn \& Nutr, Div Appl Nutr \& Food Chem, POB 124, S-22100 Lund, Sweden.
   Lund Univ, Dept Food Technol Engn \& Nutr, Div Appl Nutr \& Food Chem, S-22100 Lund, Sweden.
   Danish Inst Food \& Vet Res, DK-2860 Soborg, Denmark.}},
DOI = {{10.1365/s10337-004-0431}},
ISSN = {{0009-5893}},
Keywords = {{column liquid chromatography - mass spectrometry; Blue Chitin columns;
   heterocyclic amines; urine samples}},
Keywords-Plus = {{CHROMATOGRAPHY-MASS-SPECTROMETRY; COOKED MEAT; CONCENTRATING MUTAGENS;
   PAN RESIDUES; CANCER; PHIP; METABOLITES; EXPOSURE; HUMANS; FOODS}},
Research-Areas = {{Biochemistry \& Molecular Biology; Chemistry}},
Web-of-Science-Categories  = {{Biochemical Research Methods; Chemistry, Analytical}},
Author-Email = {{Kerstin.Skog@inl.lth.se}},
Cited-References = {{ADAMSON RH, 1990, INT S PRINCESS TAKAM, V21, P289.
   Augustsson K, 1997, CARCINOGENESIS, V18, P1931, DOI 10.1093/carcin/18.10.1931.
   Augustsson K, 1999, LANCET, V353, P703, DOI 10.1016/S0140-6736(98)06099-1.
   Bang J, 2002, J CHROMATOGR A, V977, P97, DOI 10.1016/S0021-9673(02)01351-1.
   Bogen KT, 2001, J EXPO ANAL ENV EPID, V11, P155, DOI 10.1038/sj.jea.7500158.
   DeStefani E, 1997, CANCER EPIDEM BIOMAR, V6, P573.
   DOOLEY KL, 1992, CANCER LETT, V62, P205, DOI 10.1016/0304-3835(92)90097-F.
   Felton JS, 1997, MUTAT RES-FUND MOL M, V376, P37, DOI 10.1016/S0027-5107(97)00023-7.
   FELTON JS, 1990, HDB EXPT PHARM.
   FELTON JS, 2000, FOOD BORNE CARCINOGE.
   Frandsen H, 2000, CARCINOGENESIS, V21, P1197, DOI 10.1093/carcin/21.6.1197.
   Frandsen H, 2002, FOOD CHEM TOXICOL, V40, P1125, DOI 10.1016/S0278-6915(02)00033-9.
   Friesen MD, 2001, CANCER LETT, V173, P43, DOI 10.1016/S0304-3835(01)00672-3.
   Gerhardsson de Verdier M, 1991, Int J Cancer, V49, P520.
   HAYATSU H, 1983, MUTAT RES, V119, P233, DOI 10.1016/0165-7992(83)90166-5.
   HAYATSU H, 1987, CANCER RES, V47, P791.
   Hayatsu H, 1996, ANAL BIOCHEM, V235, P185, DOI 10.1006/abio.1996.0110.
   INAMASU T, 1988, JPN J CANCER RES, V79, P42.
   Kataoka H, 1997, J CHROMATOGR A, V774, P121, DOI 10.1016/S0021-9673(97)00246-X.
   KING RS, 2000, FOOD BORNE CARCINOGE.
   Knize MG, 2001, J CHROMATOGR A, V914, P95, DOI 10.1016/S0021-9673(01)00522-2.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   MURRAY S, 1989, CARCINOGENESIS, V10, P763, DOI 10.1093/carcin/10.4.763.
   MUSCAT JE, 1994, AM J PUBLIC HEALTH, V84, P856, DOI 10.2105/AJPH.84.5.856.
   OHGAKI H, 2000, FOOD BORNE CARCINOGE.
   Pais P, 2000, J CHROMATOGR B, V747, P139, DOI 10.1016/S0378-4347(00)00118-3.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   Sakamoto H, 1996, MUTAT RES-GENET TOX, V371, P79, DOI 10.1016/S0165-1218(96)90097-X.
   SINHA R, 1995, CANCER RES, V55, P4516.
   Skog K, 1998, J CHROMATOGR A, V803, P227, DOI 10.1016/S0021-9673(97)01266-1.
   Skog K, 1997, FOOD CHEM TOXICOL, V35, P555, DOI 10.1016/S0278-6915(97)00021-5.
   SKOG K, 1995, CARCINOGENESIS, V16, P861, DOI 10.1093/carcin/16.4.861.
   Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1.
   SUGIMURA T, 1993, FOOD NUTR CHEM TOXIC.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P217, DOI 10.1021/tx9701891.
   Unger M, 2002, J CHROMATOGR B, V767, P245, DOI 10.1016/S0378-4347(01)00538-2.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   Wolk A, 1996, INT J CANCER, V65, P67, DOI 10.1002/(SICI)1097-0215(19960103)65:1<67::AID-IJC12>3.0.CO;2-F.}},
Number-of-Cited-References = {{41}},
Times-Cited = {{7}},
Journal-ISO = {{Chromatographia}},
Doc-Delivery-Number = {{880UQ}},
Wos-Id = {{ISI:000225815500008}},
}

@article{ ISI:000223142700025,
Author = {Frederiksen, H and Frandsen, H and Pfau, W},
Title = {{Syntheses of DNA adducts of two heterocyclic amines,
   2-amino-3-methyl-9H-pyrido{[}2,3-b]indole (MeA alpha C) and
   2-amino-9H-pyrido{[}2,3-b]indole (A alpha C) and identification of DNA
   adducts in organs from rats dosed with MeA alpha C}},
Journal = {{CARCINOGENESIS}},
Year = {{2004}},
Volume = {{25}},
Number = {{8}},
Pages = {{1525-1533}},
Month = {{AUG}},
Abstract = {{2-Amino-3-methyl-9H-pyrido{[}2,3-b]indole (MeAalphaC) and
   2-amino-3-methyl-9H-pyrido{[}2,3-b]indole (AalphaC) are mutagenic and
   carcinogenic heterocyclic amines formed during ordinary cooking.
   MeAalphaC and AalphaC are activated to mutagenic metabolites by
   cytochrome P450-mediated N-oxidation to the corresponding N-2-OH
   derivatives. The proximate mutagenic N-2-OH derivatives of MeAalphaC and
   AalphaC did not react with deoxynucleosides or DNA. However, upon
   acetylation with acetic anhydride both reacted with 2'-deoxyguannosine
   and 3'-phospho-2'-deoxyguanosine, resulting in one adduct each, but not
   with other nucleosides or nucleotides. The adducts were identified as
   N-2-(2'-deoxyguanosin-8-yl)-MeAalphaC,
   N-2-(2'-deoxyguanosin-8-yl)-AalphaC,
   N-2-(3'-phospho-2'-deoxyguanosin-8-yl)-MeAalphaC and
   N-2-(3'-phospho-2'-deoxyguanosin-8-yl)-AalphaC by comparison with
   adducts of known structure obtained by reaction of the parent amines
   with acetylated guanine N3-oxide. N-2-OH-MeAalphaC and N-2-OH-AalphaC
   reacted with calf thymus DNA after addition of acetic anhydride.
   P-32-postlabelling analysis of modified DNA showed one major adduct
   co-migrating with N-2-(3',5'-diphospho-2'-deoxyguanosin-8-yl)-MeAalphaC
   and N-2-(3',5'-diphospho-2'-deoxyguanosin-8-yl)-AalphaC, respectively.
   Some minor adducts presumed to be undigested oligomers were also
   detected. P-32-postlabelling analysis of DNA from several organs of rats
   dosed orally with MeAalphaC showed that in vivo
   N-2-(2'-deoxyguanosin-8-yl)-MeAalphaC also was the major adduct formed.
   Relative adduct level in DNA isolated from the liver of the rats was
   about 50.40 adducts/10(9) nt. The adduct levels were similar to4-fold
   lower in the colon and the heart and similar to12-fold lower in the
   kidney of the rats.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Frederiksen, H (Reprint Author), Danish Vet \& Food Adm, Inst Food Safety \& Nutr, Morkhoj Bygade 19, DK-2860 Soborg, Denmark.
   Danish Vet \& Food Adm, Inst Food Safety \& Nutr, DK-2860 Soborg, Denmark.
   Univ Hamburg, Sch Med, Inst Clin \& Expt Toxicol, D-22527 Hamburg, Germany.}},
DOI = {{10.1093/carcin/bgh156}},
ISSN = {{0143-3334}},
Keywords-Plus = {{CIGARETTE-SMOKE CONDENSATE; PERFORMANCE LIQUID-CHROMATOGRAPHY;
   POST-LABELING ANALYSIS; FOOD MUTAGEN; AROMATIC-AMINES;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; P-32-POSTLABELING
   ANALYSIS; MICROSOMAL METABOLISM; MASS-SPECTROMETRY; SOYBEAN GLOBULIN}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Author-Email = {{haf@fdir.dk}},
Cited-References = {{DRAGSTED LO, 1995, CARCINOGENESIS, V16, P2785, DOI 10.1093/carcin/16.11.2785.
   EISENBRAND G, 1993, TOXICOLOGY, V84, P1, DOI 10.1016/0300-483X(93)90109-6.
   Frandsen H, 1998, MUTAGENESIS, V13, P181, DOI 10.1093/mutage/13.2.181.
   FRANDSEN H, 1994, MUTAGENESIS, V9, P59, DOI 10.1093/mutage/9.1.59.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   Frederiksen H, 2002, PHARMACOL TOXICOL, V90, P127, DOI 10.1034/j.1600-0773.2002.900303.x.
   GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B.
   GUPTA RC, 1985, CANCER RES, V45, P5656.
   GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943.
   GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081.
   HALL M, 1990, CARCINOGENESIS, V11, P1005, DOI 10.1093/carcin/11.6.1005.
   HASEMANN JK, 1992, BEHAV GENET, V2, P3.
   HASHIMOTO Y, 1980, BIOCHEM BIOPH RES CO, V96, P355, DOI 10.1016/0006-291X(80)91222-X.
   King RS, 2000, CARCINOGENESIS, V21, P1347, DOI 10.1093/carcin/21.7.1347.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   MANABE S, 1990, J CHROMATOGR-BIOMED, V529, P125, DOI 10.1016/S0378-4347(00)83813-X.
   MATSUMOTO T, 1981, CANCER LETT, V12, P105, DOI 10.1016/0304-3835(81)90045-8.
   Mendonsa SD, 1999, J CHROMATOGR A, V841, P239, DOI 10.1016/S0021-9673(99)00279-4.
   OHGAKI H, 1984, CARCINOGENESIS, V5, P815, DOI 10.1093/carcin/5.6.815.
   PALMGREN G, 1990, BIOCHIM BIOPHYS ACTA, V1049, P293, DOI 10.1016/0167-4781(90)90100-G.
   Pfau W, 1996, CARCINOGENESIS, V17, P2727, DOI 10.1093/carcin/17.12.2727.
   Pfau W, 1997, CHEM RES TOXICOL, V10, P1192, DOI 10.1021/tx9701182.
   PFAU W, 1994, CARCINOGENESIS, V15, P877, DOI 10.1093/carcin/15.5.877.
   Phillips DH, 1999, MUTAGENESIS, V14, P301, DOI 10.1093/mutage/14.3.301.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   Raza H, 1996, DRUG METAB DISPOS, V24, P395.
   REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543.
   Richling E, 1997, J CHROMATOGR A, V791, P71, DOI 10.1016/S0021-9673(97)00842-X.
   Skog K, 1998, J CHROMATOGR A, V803, P227, DOI 10.1016/S0021-9673(97)01266-1.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1061, DOI 10.1093/carcin/9.6.1061.
   SNYDERWINE EG, 2002, FOOD BORNE CARCINOGE, P131.
   Snyderwine EG, 1998, FOOD CHEM TOXICOL, V36, P1033, DOI 10.1016/S0278-6915(98)00088-X.
   Solyakov A, 1999, FOOD CHEM TOXICOL, V37, P1, DOI 10.1016/S0278-6915(98)00098-2.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   SUGIMURA T, 1990, PROG CLIN BIOL RES, V347, P1.
   TAMANO S, 1994, CARCINOGENESIS, V15, P2009, DOI 10.1093/carcin/15.9.2009.
   TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   Wolz E, 2000, FOOD CHEM TOXICOL, V38, P513, DOI 10.1016/S0278-6915(00)00038-7.
   YAMASHITA K, 1986, P JPN ACAD B-PHYS, V62, P45, DOI 10.2183/pjab.62.45.
   YOSHIDA D, 1978, BIOCHEM BIOPH RES CO, V83, P915, DOI 10.1016/0006-291X(78)91482-1.
   YOSHIDA D, 1980, CANCER LETT, V10, P141, DOI 10.1016/0304-3835(80)90037-3.}},
Number-of-Cited-References = {{43}},
Times-Cited = {{11}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{844FJ}},
Wos-Id = {{ISI:000223142700025}},
}

@article{ ISI:000223412000014,
Author = {Holland, RD and Taylor, J and Schoenbachler, L and Jones, RC and
   Freeman, JP and Miller, TW and Lake, BG and Gooderham, NJ and Turesky,
   RJ},
Title = {{Rapid biomonitoring of heterocyclic aromatic amines in human urine by
   tandem solvent solid phase extraction liquid chromatography electrospray
   ionization mass spectrometry}},
Journal = {{CHEMICAL RESEARCH IN TOXICOLOGY}},
Year = {{2004}},
Volume = {{17}},
Number = {{8}},
Pages = {{1121-1136}},
Month = {{AUG}},
Abstract = {{A rapid and facile tandem solvent solid phase extraction method was
   established to isolate the heterocyclic aromatic amines (HAAs)
   2-amino-3,8-dimethylimidazo{[}4,5-f] quinoxaline (8-MeIQx),
   2-amino-3,4,8-trimethylimidazo{[}4,5-f] quinoxaline,
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine, and
   2-amino-9H-pyrido{[}2,3-b]indole from urine. The HAAs were separated by
   reversed phase liquid chromatography and quantified by electrospray
   ionization tandem mass spectrometry (ESI/MS/MS) using selected reaction
   monitoring. The limits of detection and quantitation of these HAAs
   approached 1-3 and 2-8 pg/mL, respectively, using only 0.3 mL of urine
   for analysis. Full product ion spectra were acquired to corroborate
   analyte identities. The pretreatment of urine from human volunteers that
   had consumed a grilled beef meal with acid or base at 70 degreesC
   increased the concentration of HAAs by as much as 6-fold, indicating the
   presence of phase II conjugates of the parent compounds. HAAs containing
   an N-methylimidazole moiety undergo facile cleavage of the N-methyl
   group under collision-induced dissociation conditions, and MS/MS
   analysis in the constant neutral loss scan mode monitoring the
   transition {[}M + H](+) --> {[}M + H - CH3.](+) revealed the presence of
   two other HAAs. 2-Amino-3-methylimidazo {[}4,5-f] quinoxaline (IQx) was
   identified by coelution of the analyte with synthetic IQx and by
   acquisition of the product ion spectrum. The second HAA was present in a
   relatively high abundance in urine. The molecule had the same nominal
   mass as 8-MeIQx (MH+ at m/z 214), and the product ion spectrum was
   similar to that of 8-MeIQx. This novel HAA was also found in the grilled
   meat consumed by the volunteers at a concentration of 8 parts per
   billion. The accurate mass measurement and product ion spectrum of this
   molecule by ESI quadrupole time-of-flight mass spectrometry revealed
   that it was an isomer of 8-MeIQx. This tandem solvent solid phase
   extraction LC/ESI/MS/MS procedure may be used to rapidly assess the
   daily exposure to a variety of HAAs in urine.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Turesky, RJ (Reprint Author), Natl Ctr Toxicol Res, Div Chem, 3900 NCTR Rd, Jefferson, AR 72079 USA.
   Natl Ctr Toxicol Res, Div Chem, Jefferson, AR 72079 USA.
   BIBRA Int, Carshalton SM5 4DS, Surrey, England.
   Univ London Imperial Coll Sci Technol \& Med, Div Biomed Sci, London SW7 2AZ, England.}},
DOI = {{10.1021/tx049910a}},
ISSN = {{0893-228X}},
Keywords-Plus = {{COLORECTAL-CANCER; COOKED FOODS;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO(4,5-B)PYRIDINE PHIP; CYTOCHROME
   P4501A2; HYDROLYZED URINE; MODEL SYSTEMS; BREAST-CANCER; METABOLISM;
   MEAT; RISK}},
Research-Areas = {{Pharmacology \& Pharmacy; Chemistry; Toxicology}},
Web-of-Science-Categories  = {{Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology}},
Author-Email = {{Rturesky@nctr.fda.gov}},
Cited-References = {{Barcelo-Barrachina E, 2004, J CHROMATOGR A, V1023, P67, DOI 10.1016/j.chroma.2003.10.030.
   Barrett JH, 2003, CARCINOGENESIS, V24, P275, DOI 10.1093/carcin/24.2.275.
   BECHER G, 1988, CARCINOGENESIS, V9, P247, DOI 10.1093/carcin/9.2.247.
   Boobis AR, 1996, ARCH TOX S, V18, P286.
   BUTLER MA, 1989, P NATL ACAD SCI USA, V86, P7696, DOI 10.1073/pnas.86.20.7696.
   Chen Y, 2002, J AGR FOOD CHEM, V50, P2372, DOI 10.1021/fj011244.
   Fay LB, 1997, MUTAT RES-FUND MOL M, V376, P29, DOI 10.1016/S0027-5107(97)00022-5.
   Felton J. S., 2000, Food borne carcinogens: heterocyclic amines., P31.
   Felton JS, 2002, ENVIRON MOL MUTAGEN, V39, P112, DOI 10.1002/em.10070.
   FELTON JS, 1994, ENVIRON HEALTH PERSP, V102, P201, DOI 10.2307/3432178.
   Friesen MD, 2001, CANCER LETT, V173, P43, DOI 10.1016/S0304-3835(01)00672-3.
   Grimmer G, 2000, SCI TOTAL ENVIRON, V247, P81, DOI 10.1016/S0048-9697(99)00471-4.
   GRIVAS S, 1985, ACTA CHEM SCAND B, V39, P31, DOI 10.3891/acta.chem.scand.39b-0031.
   GRIVAS S, 1995, HETEROCYCLIC AMINES, P1.
   GROSS GA, 1993, CARCINOGENESIS, V14, P2313, DOI 10.1093/carcin/14.11.2313.
   Guy PA, 2000, J CHROMATOGR A, V883, P89, DOI 10.1016/S0021-9673(00)00361-7.
   Hecht SS, 2002, CARCINOGENESIS, V23, P907, DOI 10.1093/carcin/23.6.907.
   Hein DW, 2000, TOXICOL LETT, V112, P349, DOI 10.1016/S0378-4274(99)00226-X.
   Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29.
   Holder CL, 1997, RAPID COMMUN MASS SP, V11, P1667, DOI 10.1002/(SICI)1097-0231(19971015)11:15<1667::AID-RCM58>3.0.CO;2-N.
   King R.S., 2000, FOOD BORNE CARCINOGE, P90.
   Knize MG, 2002, MUTAT RES-FUND MOL M, V506, P153, DOI 10.1016/S0027-5107(02)00162-8.
   Knize M. G., 1996, Journal of Muscle Foods, V7, P271, DOI 10.1111/j.1745-4573.1996.tb00603.x.
   Kulp KS, 2000, CARCINOGENESIS, V21, P2065, DOI 10.1093/carcin/21.11.2065.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   Langouet S, 2002, CARCINOGENESIS, V23, P115, DOI 10.1093/carcin/23.1.115.
   Le Marchand L, 2001, CANCER EPIDEM BIOMAR, V10, P1259.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   MacDougall D, 1980, ANAL CHEM, V52, P2242, DOI DOI 10.1021/AC50064A004.
   MATSUMOTO T, 1981, CANCER LETT, V12, P105, DOI 10.1016/0304-3835(81)90045-8.
   Murray S, 2001, CARCINOGENESIS, V22, P1413, DOI 10.1093/carcin/22.9.1413.
   MURRAY S, 1993, J CHROMATOGR-BIOMED, V616, P211, DOI 10.1016/0378-4347(93)80388-K.
   NUKAYA H, 1994, CARCINOGENESIS, V15, P1151, DOI 10.1093/carcin/15.6.1151.
   NYHAMMAR T, 1986, ACTA CHEM SCAND B, V40, P583, DOI 10.3891/acta.chem.scand.40b-0583.
   Pais P, 1999, J AGR FOOD CHEM, V47, P1098, DOI 10.1021/jf980644e.
   Peters U, 2003, CANCER EPIDEM BIOMAR, V12, P1253.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   Sachse C, 2003, BRIT J CLIN PHARMACO, V55, P68, DOI 10.1046/j.1365-2125.2003.01733.x.
   Shirai T, 1997, CANCER RES, V57, P195.
   SINHA R, 1995, CARCINOGENESIS, V16, P2859, DOI 10.1093/carcin/16.11.2859.
   Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1.
   STILLWELL WG, 1994, CANCER EPIDEM BIOMAR, V3, P399.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   Strickland PT, 2002, MUTAT RES-FUND MOL M, V506, P163, DOI 10.1016/S0027-5107(02)00163-X.
   Strickland PT, 2001, BIOMARKERS, V6, P313.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   TIAN W, 1992, J HETEROCYCLIC CHEM, V29, P1305.
   Toribio F, 2002, J MASS SPECTROM, V37, P812, DOI 10.1002/jms.340.
   Turesky RJ, 2003, CHEM RES TOXICOL, V16, P1162, DOI 10.1021/tx030029r.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P217, DOI 10.1021/tx9701891.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P925, DOI 10.1021/tx980022n.
   TURESKY RJ, 1988, FOOD CHEM TOXICOL, V26, P501, DOI 10.1016/0278-6915(88)90002-6.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WAKABAYASHI K, 1995, HETEROCYCLIC AMINES, P39.
   WATKINS BE, 1987, HETEROCYCLES, V26, P2069.
   Winsten J. A., 1977, ORIGINS HUMAN CANC, P1561.
   YAMAIZUMI Z, 1986, MUTAT RES, V173, P1, DOI 10.1016/0165-7992(86)90002-3.
   Zheng W, 2001, CANCER EPIDEM BIOMAR, V10, P89.}},
Number-of-Cited-References = {{58}},
Times-Cited = {{26}},
Journal-ISO = {{Chem. Res. Toxicol.}},
Doc-Delivery-Number = {{847RG}},
Wos-Id = {{ISI:000223412000014}},
}

@article{ ISI:000222549400020,
Author = {Chepanoske, CL and Brown, K and Turteltaub, KW and Dingley, KH},
Title = {{Characterization of a peptide adduct formed by
   N-acetoxy-2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP), a
   reactive intermediate of the food carcinogen PhIP}},
Journal = {{FOOD AND CHEMICAL TOXICOLOGY}},
Year = {{2004}},
Volume = {{42}},
Number = {{8}},
Pages = {{1367-1372}},
Month = {{AUG}},
Abstract = {{2-Amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) is a member of
   a class of compounds known as the heterocyclic amines (HCAs) that are
   formed in meat during cooking. It is a multi-organ carcinogen in rodents
   forms adducts and with DNA and protein. Although protein adducts are not
   thought to be involved in cancer development, they may be useful as
   internal dosimeters of PhIP exposure and bioactivation. Towards the
   goals of characterizing the adducts formed in humans and the development
   of an assay for quantitation of adduct levels, we have characterized a
   peptide adduct formed by the putative genotoxic metabolite,
   N-acetoxy-PhIP. A model peptide with the internal sequence
   Leu-Gin-Lys-Cys-Pro-Tyr, which is homologous to a potential target
   sequence for HCAs in human serum albumin, was reacted with
   N-acetoxy-PhIP and an adduct was identified and further characterized by
   LC-ESI-MS/MS. N-acetoxy-PhIP is covalently bound to the peptide via
   cysteine and the exocyclic amino group of PhIP. Future work is needed to
   establish if this adduct is formed and is stable in vivo in humans
   following exposure to PhIP. (C) 2004 Elsevier Ltd. All rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Dingley, KH (Reprint Author), Lawrence Livermore Natl Lab, Biol \& Biotechnol Res Program, 7000 E Ave, Livermore, CA 94550 USA.
   Lawrence Livermore Natl Lab, Biol \& Biotechnol Res Program, Livermore, CA 94550 USA.}},
DOI = {{10.1016/j.fct.2003.11.012}},
ISSN = {{0278-6915}},
Keywords = {{heterocyclic amine; PhIP; protein; adduct; structure; mass spectrometry}},
Keywords-Plus = {{2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; HETEROCYCLIC
   AMINES; PROTEIN ADDUCTS; COOKED FOODS; EXPOSURE; ALBUMIN; HUMANS; COLON;
   RAT}},
Research-Areas = {{Food Science \& Technology; Toxicology}},
Web-of-Science-Categories  = {{Food Science \& Technology; Toxicology}},
Author-Email = {{dingley1@llnl.gov}},
Cited-References = {{BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   BROWN K, 2001, NUCLEIC ACIDS RES, V29, P1.
   BUONARATI MH, 1990, MUTAT RES, V140, P61.
   Dingley KH, 1999, CANCER EPIDEM BIOMAR, V8, P507.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   REISTAD R, 1994, CARCINOGENESIS, V15, P2547, DOI 10.1093/carcin/15.11.2547.
   Shirai T, 1997, CANCER RES, V57, P195.
   Sinha R, 2002, MUTAT RES-FUND MOL M, V506, P197, DOI 10.1016/S0027-5107(02)00166-5.
   SKIPPER PL, 1994, DRUG METAB REV, V26, P111, DOI 10.3109/03602539409029787.
   Sugio S, 1999, PROTEIN ENG, V12, P439, DOI 10.1093/protein/12.6.439.
   THOMPSON LH, 1987, MUTAGENESIS, V2, P483, DOI 10.1093/mutage/2.6.483.
   TURESKY RJ, 1987, CARCINOGENESIS, V8, P1537, DOI 10.1093/carcin/8.10.1537.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P925, DOI 10.1021/tx980022n.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{11}},
Journal-ISO = {{Food Chem. Toxicol.}},
Doc-Delivery-Number = {{836IP}},
Wos-Id = {{ISI:000222549400020}},
}

@article{ ISI:000222585800006,
Author = {Moonen, HJJ and Dommels, YEM and van Zwam, M and van Herwijnen, MHM and
   Kleinjans, JCS and Alink, GM and de Kok, TMCM},
Title = {{Effects of polyunsaturated fatty acids on prostaglandin synthesis and
   cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic
   amines in human adenocarcinoma colon cells}},
Journal = {{MOLECULAR CARCINOGENESIS}},
Year = {{2004}},
Volume = {{40}},
Number = {{3}},
Pages = {{180-188}},
Month = {{JUL}},
Abstract = {{Dietary heterocyclic aromatic amines (HCA) and polyunsaturated fatty
   acids (PUFA) are both believed to play a role in colon carcinogenesis,
   and are both substrate for the enzyme cyclooxygenase (COX). In HCA-7
   cells, highly expressing isoform COX-2, we investigated the effects of
   PUFA on prostaglandin synthesis and DNA adduct formation by the HCA
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) and
   2-amino-3-methylimidazo{[}4,5-f]quinoline (IQ). Furthermore, we studied
   the role of COX, COX-2 in particular, and cytochrome P4501A2 (CYP1A2) by
   using the enzyme inhibitors indomethacin (IM), NS-398, and phenethyl
   isothiocyanate (PEITC), respectively. COX-mediated formation of
   prostaglandin E-2 (PGE(2)) from linoleic acid (LA) showed that HCA-7
   cells can convert LA into arachidonic acid (AA). Alternatively,
   eicosapentaenoic acid (EPA) was found to compete with AA for COX.
   Strongly decreased PGE2 levels by addition of IM demonstrated
   involvement of COX in PUFA metabolism. Both IM and NS-398 inhibited
   adduct formation by HCA to nearly the same extent, indicating
   involvement of COX-2 rather than COX-1, while CYP1A2 activity in HCA-7
   cells was demonstrated by addition of PEITC. Overall, inhibiting effects
   were stronger for PhIP than for IQ. HCA-DNA adduct formation was
   stimulated by addition of PUFA, although high PUFA concentrations partly
   reduced this stimulating effect. Finally, similar effects for n-3 and
   n-6 fatty acids suggested that adduct formation may not be the crucial
   mechanism behind the differential effects of PUFA on colon
   carcinogenesis that have been described. These results show that COX,
   and COX-2 in particular, can play a substantial role in HCA activation,
   especially in extrahepatic tissues like the colon. Furthermore, the
   obvious interactions between PUFA and HCA in COX-2 expressing cancer
   cells may be important in modulating colorectal cancer risk. (C) 2004
   Wiley-Liss, Inc.}},
Publisher = {{WILEY-LISS}},
Address = {{DIV JOHN WILEY \& SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Moonen, HJJ (Reprint Author), Univ Maastricht, Dept Hlth Risk Anal \& Toxicol, POB 616, NL-6200 MD Maastricht, Netherlands.
   Univ Maastricht, Dept Hlth Risk Anal \& Toxicol, NL-6200 MD Maastricht, Netherlands.
   Wageningen Univ, Dept Toxicol, Wageningen, Netherlands.}},
DOI = {{10.1002/mc.20032}},
ISSN = {{0899-1987}},
Keywords = {{COX; HCA; PUFA; HCA-7; P-32-postlabeling}},
Keywords-Plus = {{NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HUMAN COLORECTAL-CANCER;
   DOCOSAHEXAENOIC ACID; LIVER-MICROSOMES;
   2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE IQ; CYTOCHROME-P450 ISOZYMES;
   ARACHIDONIC-ACID; LINOLEIC ACIDS; DIETARY-FAT; IN-VITRO}},
Research-Areas = {{Biochemistry \& Molecular Biology; Oncology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Oncology}},
Cited-References = {{ANDERSON KE, 1991, ANNU REV NUTR, V11, P141, DOI 10.1146/annurev.nutr.11.1.141.
   BLOT WJ, 1975, J NATL CANCER I, V55, P546.
   Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   Bylund J, 1998, J PHARMACOL EXP THER, V284, P51.
   Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657.
   COREY EJ, 1983, P NATL ACAD SCI-BIOL, V80, P3581, DOI 10.1073/pnas.80.12.3581.
   CROFT KD, 1984, BIOCHIM BIOPHYS ACTA, V795, P196, DOI 10.1016/0005-2760(84)90066-3.
   de Kok TMCM, 2002, J CHROMATOGR B, V778, P345, DOI 10.1016/S0378-4347(01)00543-6.
   DIANA GC, 1987, J AM SOC HORTIC SCI, V112, P173.
   DOMMELS YEM, 2002, ENVIRON TOXICOL PHAR, V12, P233, DOI 10.1016/S1382-6689(02)00095-9.
   DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017.
   Elder DJE, 1997, CLIN CANCER RES, V3, P1679.
   FISCHER SM, 1997, FRONT BIOSCI, V2, P482.
   GIOVANNUCCI E, 1994, ANN MED, V26, P443, DOI 10.3109/07853899409148367.
   GURR M, 1993, HUMAN NUTR DIETETICS, P77.
   HAYATSU H, 1988, MUTAT RES, V202, P429, DOI 10.1016/0027-5107(88)90204-7.
   HAYATSU H, 1981, MUTAT RES, V81, P287, DOI 10.1016/0027-5107(81)90117-2.
   HENDERSON RM, 1992, BRIT J PHARMACOL, V106, P109.
   HO TA, 1992, FOOD CHEM TOXICOL, V30, P853, DOI 10.1016/0278-6915(92)90050-U.
   HO TA, 1992, MUTAT RES, V269, P279, DOI 10.1016/0027-5107(92)90210-S.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   INNIS SM, 1994, PRESENT KNOWLEDGE NU, P58.
   Josyula S, 1999, FOOD CHEM TOXICOL, V37, P287, DOI 10.1016/S0278-6915(99)00018-6.
   KARGMAN SL, 1995, CANCER RES, V55, P2556.
   KIRKLAND SC, 1985, CANCER RES, V45, P3790.
   KIRKLAND SC, 1995, INT J CANCER, V60, P877, DOI 10.1002/ijc.2910600626.
   KUPFER D, 1982, HEPATIC CYTOCHROME P, P157.
   Lands William E. M., 1972, ADV BIOSCI, V9, P15.
   LEE JAH, 1976, INT J EPIDEMIOL, V5, P187, DOI 10.1093/ije/5.2.187.
   Lehmann JM, 1997, J BIOL CHEM, V272, P3406.
   MILLER AB, 1983, INT J CANCER, V32, P155, DOI 10.1002/ijc.2910320204.
   Mitchell DB, 1981, J TISSUE CULTURE MET, P113, DOI 10.1007/BF02082861.
   Moonen HJJ, 2002, MOL CARCINOGEN, V35, P196, DOI 10.1002/mc.10089.
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4.
   Mutoh M, 2002, CANCER RES, V62, P28.
   NEEDLEMAN P, 1979, P NATL ACAD SCI USA, V76, P944, DOI 10.1073/pnas.76.2.944.
   NEMOTO N, 1983, CARCINOGENESIS, V4, P1253, DOI 10.1093/carcin/4.10.1253.
   ONEILL GP, 1995, AGENT ACTION SUPPL, V46, P159.
   OSHIMA M, 1995, CARCINOGENESIS, V16, P2605, DOI 10.1093/carcin/16.11.2605.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   REDDY BS, 1991, CANCER RES, V51, P487.
   REICHERT WL, 1992, CARCINOGENESIS, V13, P1474.
   SANO H, 1995, CANCER RES, V55, P3785.
   Schut HAJ, 1997, MUTAT RES-FUND MOL M, V378, P23, DOI 10.1016/S0027-5107(97)00094-8.
   Schut HAJ, 1997, MUTAT RES-FUND MOL M, V376, P185, DOI 10.1016/S0027-5107(97)00042-0.
   SCHUT HAJ, 1994, ENVIRON HEALTH PERSP, V102, P57, DOI 10.2307/3432153.
   Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200.
   Sheng HM, 1998, CANCER RES, V58, P362.
   SHIMADA T, 1991, CANCER RES, V51, P5284.
   Singh J, 1997, CANCER RES, V57, P3465.
   Skog K, 1997, FOOD CHEM TOXICOL, V35, P555, DOI 10.1016/S0278-6915(97)00021-5.
   Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1.
   Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0.
   Takahashi M, 1997, CARCINOGENESIS, V18, P1337, DOI 10.1093/carcin/18.7.1337.
   Tapiero H, 2002, BIOMED PHARMACOTHER, V56, P215, DOI 10.1016/S0753-3322(02)00193-2.
   Thapliyal R, 2001, FOOD CHEM TOXICOL, V39, P541, DOI 10.1016/S0278-6915(00)00165-4.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P941, DOI 10.1093/carcin/11.6.941.
   Wiese F. W., 2001, CARCINOGENESIS, V21, P5.
   WOLZ E, 1995, ARCH TOXICOL, V69, P171, DOI 10.1007/s002040050154.
   WYNDER EL, 1969, CANCER, V23, P1210, DOI 10.1002/1097-0142(196905)23:5<1210::AID-CNCR2820230530>3.0.CO;2-M.
   YANG CS, 1992, FASEB J, V6, P737.
   Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451.}},
Number-of-Cited-References = {{63}},
Times-Cited = {{9}},
Journal-ISO = {{Mol. Carcinog.}},
Doc-Delivery-Number = {{836WD}},
Wos-Id = {{ISI:000222585800006}},
}

@article{ ISI:000221867900026,
Author = {Baranczewski, P and Moller, L},
Title = {{Relationship between content and activity of cytochrome P450 and
   induction of heterocyclic amine DNA adducts in human liver samples In
   vivo and In vitro}},
Journal = {{CANCER EPIDEMIOLOGY BIOMARKERS \& PREVENTION}},
Year = {{2004}},
Volume = {{13}},
Number = {{6}},
Pages = {{1071-1078}},
Month = {{JUN}},
Abstract = {{This study was designed to estimate a correlation between metabolic
   activation phenotypes and formation of DNA adducts by heterocyclic
   amines (HCA) in 15 liver samples from healthy donors. The correlation
   between the amount of endogenous DNA adducts and the content of
   cytochrome P450 in human liver samples in vivo was statistically
   significant at r(2) = 0.71 and P < 0.005. Furthermore, the isolated
   human liver microsomes were treated in vitro with two HCAs,
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) and
   2-amino-9H-pyrido{[}2,3-b]indole (AalphaC), which have been recognized
   to induce two DNA adducts:
   3'5'-diphosphate-N-(2'-deoxyguanosin-8-yl)-PhIP (3',5'-pdGp-C8-PhIP) and
   3',5'-diphosphate-N-(2'-deoxyguanosin-8-yl)-AalphaC
   (3',5'-pdGp-C8-AalphaC). The correlations between the amount of DNA
   adducts induced by both compounds in vitro and the content of cytochrome
   P450 in human microsomes are statistically significant at r(2) = 0.69
   and r(2) = 0.62 (P < 0.001), respectively. Furthermore, the level of DNA
   adducts after treatment withPhIP and AalphaC correlated with the
   activities of three isozymes of cytochrome P450: CYP1A1, CYP1A2, and
   CYP3A4. Therefore, three chemical inhibitors were used in the
   experiments: ellipticine against CYP1A1, furafylline against CYP1A2, and
   troleandomycin against CYP3A4. The highest inhibition levels in the
   formation of 3',5'-pdGp-C8-PhIP and 3',5'-pdGp-C8-AalphaC adducts were
   estimated to occur in the presence of furafylline at 56\% and 69\%,
   respectively. Ellipticine was involved in the inhibition of 40\% of
   3,5'-pdG-C8-PhIP adducts and in only 18\% of the inhibition of
   3',5'-pdGp-C8-AalphaC adducts. Troleandomycin did not significantly
   inhibit the formation of 3',5'-pdGp-C8-PhIP adducts under these
   conditions, but it inhibited the formation of 31\% of the
   3',5'-pdGpC8-AalphaC adducts. We conclude that the formation of DNA
   adducts can be used as a relevant marker of interindividual variability
   in the metabolic activation of HCAs in humans.}},
Publisher = {{AMER ASSOC CANCER RESEARCH}},
Address = {{615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Moller, L (Reprint Author), Karolinska Inst, Novum, CNT, Lab Analyt Toxicol,Dept Biosci, S-14157 Huddinge, Sweden.
   Karolinska Inst, Novum, CNT, Lab Analyt Toxicol,Dept Biosci, S-14157 Huddinge, Sweden.}},
ISSN = {{1055-9965}},
Keywords-Plus = {{HUMAN TISSUES; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP;
   METABOLISM; CANCER; IDENTIFICATION; CARCINOGENS; MICROSOMES; ACTIVATION;
   P4501A2; MUTAGEN}},
Research-Areas = {{Oncology; Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Oncology; Public, Environmental \& Occupational Health}},
Author-Email = {{lennart.moller@cnt.ki.se}},
Cited-References = {{BOOBIS AR, 1994, CANCER RES, V54, P89.
   Crofts FG, 1997, CARCINOGENESIS, V18, P1793, DOI 10.1093/carcin/18.9.1793.
   CUI XS, 1995, CARCINOGENESIS, V16, P2135, DOI 10.1093/carcin/16.9.2135.
   Felton J. S., 2000, Food borne carcinogens: heterocyclic amines., P31.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   GUENGERICH FP, 1990, CHEM RES TOXICOL, V3, P363, DOI 10.1021/tx00016a015.
   HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007.
   JOHANSSON MAE, 1994, CARCINOGENESIS, V15, P1511, DOI 10.1093/carcin/15.8.1511.
   Josephy PD, 2001, ENVIRON MOL MUTAGEN, V38, P12, DOI 10.1002/em.1045.
   King RS, 2000, CARCINOGENESIS, V21, P1347, DOI 10.1093/carcin/21.7.1347.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   MILLER EC, 1981, CANCER-AM CANCER SOC, V47, P2327, DOI 10.1002/1097-0142(19810515)47:10<2327::AID-CNCR2820471003>3.0.CO;2-Z.
   MOLLER L, 1993, CARCINOGENESIS, V14, P1343, DOI 10.1093/carcin/14.7.1343.
   Pearce RE, 1996, ARCH BIOCHEM BIOPHYS, V331, P145, DOI 10.1006/abbi.1996.0294.
   Perera FP, 1997, SCIENCE, V278, P1068, DOI 10.1126/science.278.5340.1068.
   Pfau W, 1997, CHEM RES TOXICOL, V10, P1192, DOI 10.1021/tx9701182.
   Raza H, 1996, DRUG METAB DISPOS, V24, P395.
   Shimada T, 1996, CANCER RES, V56, P2979.
   Totsuka Y, 1996, CARCINOGENESIS, V17, P1029, DOI 10.1093/carcin/17.5.1029.
   Turesky RJ, 2002, DRUG METAB REV, V34, P625, DOI 10.1081/DMR-120005665.
   Turteltaub KW, 1997, MUTAT RES-FUND MOL M, V376, P243, DOI 10.1016/S0027-5107(97)00049-3.
   Wohlin P, 1996, CHEM RES TOXICOL, V9, P1050, DOI 10.1021/tx960050a.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{7}},
Journal-ISO = {{Cancer Epidemiol. Biomarkers Prev.}},
Doc-Delivery-Number = {{826ZL}},
Wos-Id = {{ISI:000221867900026}},
}

@article{ ISI:000221750400025,
Author = {Fang, M and Edwards, RJ and Bartlet-Jones, M and Taylor, GW and Murray,
   S and Boobis, AR},
Title = {{Urinary N-2-(2 `-deoxyguanosin-8-yl)PhIP as a biomarker for PhIP
   exposure}},
Journal = {{CARCINOGENESIS}},
Year = {{2004}},
Volume = {{25}},
Number = {{6}},
Pages = {{1053-1062}},
Month = {{JUN}},
Abstract = {{The food-derived, heterocyclic aromatic amine
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) is genotoxic
   and is carcinogenic in experimental animals. Studies on the role of PhIP
   in human diet-related cancer would be aided considerably by the
   availability of a readily applicable biomarker of the internal dose of
   the ultimate genotoxic species. PhIP has been shown to adduct primarily
   at C-8 of deoxyguanosine in DNA and so the DNA repair product
   N-2-(2'-deoxyguanosin-8-yl)PhIP is a potential biomarker of DNA
   adduction and repair after exposure to PhIP. An assay for
   N-2-(2'-deoxyguanosin-8-yl)PhIP in urine has been developed based on
   liquid chromatography mass spectrometry, using a deuterated analogue of
   the nucleoside as an internal standard and an antibody-mediated
   extraction procedure. Polyclonal antibodies were raised against the
   PhIP-nucleotide, PhIP-nucleoside and PhIP-guanine base adducts
   conjugated to keyhole limpet haemocyanin. Following their evaluation,
   the immobilized PhIP nucleotide antibody was used for the extraction of
   N-2-(2'-deoxyguanosin-8-yl)PhIP from urine. The limit of detection of
   the assay was 125 pg and the limit of quantification 200 pg for a 50 ml
   human urine sample. Following oral administration of PhIP (20 mg/kg body
   wt/day) to rats for 6 days, N-2-(2'-deoxyguanosin-8-yl) PhIP was readily
   detected in the urine, reaching steady state over 3 days. This is the
   first direct demonstration of the urinary elimination of this adduct
   following exposure to parent amine. The half-life of the adduct with DNA
   was estimated to be similar to20 h. The total amount of PhIP recovered
   in the urine as adduct was <0.5 x 10(-3)\% of the dose administered.
   Levels of the PhIP adduct in urine collections from human subjects
   ingesting the amine (4.9 mug) in cooked meat were below the limits of
   detection, indicating that humans are exposed to a bioactive dose of <3
   x 10(-4) of that associated with a non-carcinogenic level in rats.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Murray, S (Reprint Author), Univ London Imperial Coll Sci \& Technol, Sect Proteom, Div Med, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.
   Univ London Imperial Coll Sci \& Technol, Sect Proteom, Div Med, London W12 0NN, England.
   Univ London Imperial Coll Sci \& Technol, Sect Expt Med \& Toxicol, London W12 0NN, England.
   Canc Res UK, London WC2A 3PX, England.}},
DOI = {{10.1093/carcin/bgh084}},
ISSN = {{0143-3334}},
Keywords-Plus = {{HETEROCYCLIC AMINE CARCINOGENS; TANDEM MASS-SPECTROMETRY; FORMED
   DNA-ADDUCTS; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP;
   COOKED FOOD; IMMUNOAFFINITY CHROMATOGRAPHY; METABOLIC-ACTIVATION;
   COLORECTAL-CANCER; IN-VITRO; IDENTIFICATION}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Author-Email = {{s.murray@imperial.ac.uk}},
Cited-References = {{AESCHBACHER HU, 1991, MUTAT RES, V259, P235, DOI 10.1016/0165-1218(91)90120-B.
   ALDEEN AN, 1990, J CHROMATOGR, V512, P409, DOI 10.1016/S0021-9673(01)89507-8.
   Andreassen A, 2001, MUTAGENESIS, V16, P309, DOI 10.1093/mutage/16.4.309.
   ATKINSON T, 1984, OLIGONUCLEOTIDE SYNT, P47.
   Barrett JH, 2003, CARCINOGENESIS, V24, P275, DOI 10.1093/carcin/24.2.275.
   Bhattacharya S, 2003, CHEM RES TOXICOL, V16, P479, DOI 10.1021/tx020060d.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   Boobis AR, 1996, ARCH TOX S, V18, P286.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   Carmichael PL, 1996, CARCINOGENESIS, V17, P1769, DOI 10.1093/carcin/17.8.1769.
   Crosbie SJ, 2000, J CHROMATOGR B, V744, P55, DOI 10.1016/S0378-4347(00)00227-9.
   DRAGSTED LO, 1995, CARCINOGENESIS, V16, P2795, DOI 10.1093/carcin/16.11.2795.
   EDWARDS RJ, 1988, BIOCHEM PHARMACOL, V37, P3735, DOI 10.1016/0006-2952(88)90408-X.
   EDWARDS RJ, 1991, METHOD ENZYMOL, V206, P220.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   Felton JS, 1997, MUTAT RES-FUND MOL M, V376, P37, DOI 10.1016/S0027-5107(97)00023-7.
   FRANDSEN H, 1994, CARCINOGENESIS, V15, P2553, DOI 10.1093/carcin/15.11.2553.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   Frandsen H, 1997, CARCINOGENESIS, V18, P1555, DOI 10.1093/carcin/18.8.1555.
   GAILIT J, 1993, ANAL BIOCHEM, V214, P334, DOI 10.1006/abio.1993.1499.
   Gangl ET, 1999, CHEM RES TOXICOL, V12, P1019, DOI 10.1021/tx990060m.
   Gangl ET, 2001, ANAL CHEM, V73, P2397, DOI 10.1021/ac0100401.
   Garner RC, 1999, CANCER LETT, V143, P161, DOI 10.1016/S0304-3835(99)00118-4.
   Giovannucci E, 2003, J WOMEN HEALTH GEN-B, V12, P173, DOI 10.1089/154099903321576574.
   GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D.
   GROOPMAN JD, 1993, ENVIRON HEALTH PERSP, V99, P107, DOI 10.2307/3431465.
   HASEGAWA R, 1995, CANCER RES, V55, P4333.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   Knize MG, 2001, J CHROMATOGR A, V914, P95, DOI 10.1016/S0021-9673(01)00522-2.
   Kulp KS, 2000, CARCINOGENESIS, V21, P2065, DOI 10.1093/carcin/21.11.2065.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MAO SJT, 1989, J IMMUNOL METHODS, V120, P45, DOI 10.1016/0022-1759(89)90287-1.
   Michaud DS, 2001, CANCER CAUSE CONTROL, V12, P557, DOI 10.1023/A:1011256201044.
   Murray S, 2001, CARCINOGENESIS, V22, P1413, DOI 10.1093/carcin/22.9.1413.
   NAGAO M, 1994, CANCER, V74, P1063, DOI 10.1002/1097-0142(19940801)74:3+<1063::AID-CNCR2820741514>3.0.CO;2-2.
   NAGAOKA H, 1992, JPN J CANCER RES, V83, P1025.
   Ochiai M, 1996, CARCINOGENESIS, V17, P95, DOI 10.1093/carcin/17.1.95.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   Paehler A, 2002, CHEM RES TOXICOL, V15, P551, DOI 10.1021/tx010178e.
   RINDGEN D, 1995, CHEM RES TOXICOL, V8, P1005, DOI 10.1021/tx00050a003.
   SHIRAI T, 1995, HETEROCYCLIC AMINES, P232.
   Shirai Tomoyuki, 1998, Toxicology Letters (Shannon), V102-103, P441, DOI 10.1016/S0378-4274(98)00366-X.
   Snyderwine EG, 2002, ENVIRON MOL MUTAGEN, V39, P165, DOI 10.1002/em.10053.
   SUGIMURA T, 1982, CANCER, V49, P1970, DOI 10.1002/1097-0142(19820515)49:10<1970::AID-CNCR2820491005>3.0.CO;2-F.
   SUGIMURA T, 1983, CANCER RES, V43, P2415.
   Takahashi S, 1998, CANCER RES, V58, P4307.
   TURTELTAUB KW, 1993, ENVIRON HEALTH PERSP, V99, P183, DOI 10.2307/3431477.
   Turteltaub KW, 1999, CANCER LETT, V143, P149, DOI 10.1016/S0304-3835(99)00116-0.
   Turteltaub KW, 1997, MUTAT RES-FUND MOL M, V376, P243, DOI 10.1016/S0027-5107(97)00049-3.
   TURTELTAUB KW, 1995, HETEROCYCLIC AMINES, P93.
   TURTELTAUB KW, 1990, P NATL ACAD SCI USA, V87, P5288, DOI 10.1073/pnas.87.14.5288.
   VANDERLAAN M, 1989, CARCINOGENESIS, V10, P2215, DOI 10.1093/carcin/10.12.2215.
   VANDERLAAN M, 1993, ENVIRON HEALTH PERSP, V99, P285, DOI 10.2307/3431502.
   VANDERLAAN M, 1991, CARCINOGENESIS, V12, P349, DOI 10.1093/carcin/12.2.349.
   Vineis P, 2001, IARC Sci Publ, V154, P57.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.}},
Number-of-Cited-References = {{61}},
Times-Cited = {{5}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{825IQ}},
Wos-Id = {{ISI:000221750400025}},
}

@article{ ISI:000221541200012,
Author = {Frederiksen, H and Frandsen, H},
Title = {{Identification of metabolites in urine and feces from rats dosed with
   the heterocyclic amine, 2-amino-3-methyl-9H-pyrido{[}2,3-b]indole (MeA
   alpha C)}},
Journal = {{DRUG METABOLISM AND DISPOSITION}},
Year = {{2004}},
Volume = {{32}},
Number = {{6}},
Pages = {{661-665}},
Month = {{JUN 1}},
Abstract = {{2-Amino-3-methyl-9H-pyrido{[}2,3-b]indole (MeAalphaC) is a proximate
   mutagenic and carcinogenic heterocyclic amine formed during ordinary
   cooking. In model systems, MeAalphaC can be formed by pyrolyses of
   either tryptophan or proteins of animal or vegetable origin. In the
   present study, the in vivo metabolism of MeAalphaC in rats was
   investigated. Rats were dosed with tritium-labeled MeAalphaC, and urine
   and feces were collected over 3 days. The metabolites of MeAalphaC were
   identified by high performance liquid chromatography-mass spectrometry
   and quantified by liquid scintillation counting. Conjugated metabolites
   were characterized by enzymatic hydrolyzes with beta-glucuronidase or
   arylsulfatase. The data showed that the metabolic pattern of MeAalphaC
   was similar in all rats. About 65\% of the dose was excreted in urine
   and feces, and the major amount of MeAalphaC-metabolites was excreted
   during the first 24 h. Thirty-four percent of the dose was found in the
   rat urine samples collected to 24 h. In addition to unmetabolized
   MeAalphaC and two phase I metabolites, 6-OH-MeAalphaC and
   7-OH-MeAalphaC, the following conjugated metabolites were identified:
   MeAalphaC-N-2-glucuronide, AalphaC-3-CH2O-glucuronide, 3-carboxy-AalphaC
   and 3-carboxy-AalphaC-glucuronide, and sulfate and glucuronide
   conjugates of 6-OH-MeAalphaC and 7-OH-MeAalphaC. Also, a large amount of
   a rather unstable compound proposed to be of MeAalphaC-N1-glucuronide
   was found. About 21\% of the dose was excreted in feces during the first
   24 h, and MeAalphaC and 7-OH-MeAalphaC were the only compounds
   identified in feces. Any activated metabolites of MeAalphaC were not
   detected in rat urine or feces.}},
Publisher = {{AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Frandsen, H (Reprint Author), Danish Vet \& Food Adm, Inst Food Safety \& Nutr, Morkhoj Bygade 19, DK-2860 Soborg, Denmark.
   Danish Vet \& Food Adm, Inst Food Safety \& Nutr, DK-2860 Soborg, Denmark.}},
DOI = {{10.1124/dmd.32.6.661}},
ISSN = {{0090-9556}},
Keywords-Plus = {{PERFORMANCE LIQUID-CHROMATOGRAPHY; CIGARETTE-SMOKE CONDENSATE;
   LIVER-MICROSOMES; AROMATIC-AMINES; MASS-SPECTROMETRY; SOYBEAN GLOBULIN;
   COOKED FOODS; CARCINOGENICITY; CARBOLINES; MUTAGEN}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Author-Email = {{hf@fdir.dk}},
Cited-References = {{CALDWELL WS, 1992, CHEM RES TOXICOL, V5, P280, DOI 10.1021/tx00026a021.
   CHAUDHURI NK, 1976, DRUG METAB DISPOS, V4, P372.
   EISENBRAND G, 1993, TOXICOLOGY, V84, P1, DOI 10.1016/0300-483X(93)90109-6.
   Frandsen H, 1998, MUTAGENESIS, V13, P181, DOI 10.1093/mutage/13.2.181.
   Frederiksen H, 2003, PHARMACOL TOXICOL, V92, P246, DOI 10.1034/j.1600-0773.2003.920508.x.
   Frederiksen H, 2002, PHARMACOL TOXICOL, V90, P127, DOI 10.1034/j.1600-0773.2002.900303.x.
   GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B.
   KING RS, 2002, FOOD BORNE CARCINOGE, P90.
   King RS, 2000, CARCINOGENESIS, V21, P1347, DOI 10.1093/carcin/21.7.1347.
   Knize MG, 1997, J CHROMATOGR A, V763, P179, DOI 10.1016/S0021-9673(96)00720-0.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   MANABE S, 1990, J CHROMATOGR-BIOMED, V529, P125, DOI 10.1016/S0378-4347(00)83813-X.
   MATSUMOTO T, 1981, CANCER LETT, V12, P105, DOI 10.1016/0304-3835(81)90045-8.
   MATSUMOTO T, 1977, MUTAT RES, V48, P279, DOI 10.1016/0027-5107(77)90170-1.
   MCKILLOP D, 1990, XENOBIOTICA, V20, P401.
   NAGAO M, 1983, BIOCHEM BIOPH RES CO, V114, P626, DOI 10.1016/0006-291X(83)90826-4.
   NIWA T, 1982, MUTAT RES, V95, P159, DOI 10.1016/0027-5107(82)90254-8.
   OHGAKI H, 1984, CARCINOGENESIS, V5, P815, DOI 10.1093/carcin/5.6.815.
   Parkinson A., 1996, CASARETT DOULLS TOXI, P113.
   Pfau W, 1996, CARCINOGENESIS, V17, P2727, DOI 10.1093/carcin/17.12.2727.
   Pfau W, 1997, CHEM RES TOXICOL, V10, P1192, DOI 10.1021/tx9701182.
   Raza H, 1996, DRUG METAB DISPOS, V24, P395.
   Richling E, 1997, J CHROMATOGR A, V791, P71, DOI 10.1016/S0021-9673(97)00842-X.
   Skog K, 1998, J CHROMATOGR A, V803, P227, DOI 10.1016/S0021-9673(97)01266-1.
   Snyderwine EG, 1998, FOOD CHEM TOXICOL, V36, P1033, DOI 10.1016/S0278-6915(98)00088-X.
   Solyakov A, 1999, FOOD CHEM TOXICOL, V37, P1, DOI 10.1016/S0278-6915(98)00098-2.
   SUGIMURA T, 1985, MUTAT RES, V150, P33, DOI 10.1016/0027-5107(85)90098-3.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   TAMANO S, 1994, CARCINOGENESIS, V15, P2009, DOI 10.1093/carcin/15.9.2009.
   Turesky RJ, 2001, CHEM RES TOXICOL, V14, P901, DOI 10.1021/tx010035s.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   YAMASHITA K, 1986, P JPN ACAD B-PHYS, V62, P45, DOI 10.2183/pjab.62.45.
   YANAZOE Y, 2002, FOOD BORNE CARCINOGE, P74.
   YOSHIDA D, 1978, BIOCHEM BIOPH RES CO, V83, P915, DOI 10.1016/0006-291X(78)91482-1.
   YOSHIDA D, 1980, CANCER LETT, V10, P141, DOI 10.1016/0304-3835(80)90037-3.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{2}},
Journal-ISO = {{Drug Metab. Dispos.}},
Doc-Delivery-Number = {{822LJ}},
Wos-Id = {{ISI:000221541200012}},
}

@article{ ISI:000221448800001,
Author = {Moonen, HJJ and Moonen, EJC and Maas, L and Dallinga, JW and Kleinjans,
   JCS and De Kok, TMCM},
Title = {{CYP1A2 and NAT2 genotype/phenotype relations and urinary excretion of
   2-amino-1-methyl-6-phenylimidazo {[}4,5-b]pyridine (PhIP) in a human
   dietary intervention study}},
Journal = {{FOOD AND CHEMICAL TOXICOLOGY}},
Year = {{2004}},
Volume = {{42}},
Number = {{6}},
Pages = {{869-878}},
Month = {{JUN}},
Abstract = {{2-Amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) is a mutagenic
   and carcinogenic heterocyclic amine formed during ordinary cooking, and
   is subsequently metabolically activated by cytochrome P4501A2 (CYP1A2)
   and N-acetyltransferase 2 (NAT2). Respective genes encoding for these
   enzymes, display polymorphic distribution in the human population and
   are thus believed to cause interindividual differences in cancer risk
   susceptibility. The present study investigated the influence of dietary
   exposure and CYP1A2 and NAT2 genotypes and phenotypes on differential
   urinary PhTP excretion levels in 71 human volunteers after consumption
   of either a high (7.4 ng/g) or low (1.7 ng/g) dose of PhIP. Urinary PhIP
   excretion levels were found to reflect recent dietary exposure levels,
   with average levels of 174\% (high dose group) and 127\% (low dose
   group), as compared to pre-feed levels. Urinary caffeine metabolite
   ratios were significantly different between the two NAT2 genotypes,
   whereas for CYP1A2, the apparent difference in metabolic ratios between
   the genotypes was statistically non-significant. Significant
   correlations were firstly found between the CYP1A2-164A-->C
   (CYP1A2{*}1F) polymorphism and differential urinary PhIP excretion
   levels. Although the found correlations are driven primarily by a small
   number of subjects possessing the homozygous variant constellation, the
   strong influence of this genotype indicates that the CYP1A2{*}1F
   polymorphism could play an important role in human cancer risk
   susceptibility. (C) 2004 Elsevier Ltd. All rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Moonen, HJJ (Reprint Author), Univ Maastricht, Dept Hlth Risk Anal \& Toxicol, POB 616, NL-6200 MD Maastricht, Netherlands.
   Univ Maastricht, Dept Hlth Risk Anal \& Toxicol, NL-6200 MD Maastricht, Netherlands.}},
DOI = {{10.1016/j.fct.2004.01.010}},
ISSN = {{0278-6915}},
Keywords = {{heterocyclic aromatic amines; cytochrome P45O1A2; N-acetyltransferase;
   CYPIA2{*}1F polymorphism; genotype; phenotype; urinary PhIP excretion}},
Keywords-Plus = {{HETEROCYCLIC AROMATIC-AMINES; DONE RED MEAT; COLORECTAL-CANCER;
   N-ACETYLTRANSFERASE; CYTOCHROME P4501A2; FRIED MEAT; METABOLIC
   PHENOTYPES; COOKED FOODS; IN-VITRO; CAFFEINE}},
Research-Areas = {{Food Science \& Technology; Toxicology}},
Web-of-Science-Categories  = {{Food Science \& Technology; Toxicology}},
Author-Email = {{h.moonen@grat.unimaas.nl}},
Cited-References = {{Alexander J, 2002, FOOD CHEM TOXICOL, V40, P1131, DOI 10.1016/S0278-6915(02)00053-4.
   BELL DA, 1993, CARCINOGENESIS, V14, P1689, DOI 10.1093/carcin/14.8.1689.
   BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   BUTLER MA, 1992, PHARMACOGENETICS, V2, P116, DOI 10.1097/00008571-199206000-00003.
   CAMPBELL ME, 1987, CLIN PHARMACOL THER, V42, P157.
   Chevalier D, 2001, Hum Mutat, V17, P355, DOI 10.1002/humu.48.
   Christiansen L, 2000, HUM GENET, V107, P612, DOI 10.1007/s004390000415.
   Crofts FG, 1998, CARCINOGENESIS, V19, P1969, DOI 10.1093/carcin/19.11.1969.
   DOLL MA, 1995, ANAL BIOCHEM, V231, P413, DOI 10.1006/abio.1995.9978.
   EISENBRAND G, 1993, TOXICOLOGY, V84, P1, DOI 10.1016/0300-483X(93)90109-6.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   Friesen MD, 2001, CANCER LETT, V173, P43, DOI 10.1016/S0304-3835(01)00672-3.
   Fuhr U, 1996, PHARMACOGENETICS, V6, P159, DOI 10.1097/00008571-199604000-00003.
   GIOVANNUCCI E, 1994, ANN MED, V26, P443, DOI 10.3109/07853899409148367.
   GRANT DM, 1984, BRIT J CLIN PHARMACO, V17, P459.
   GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B.
   Gross M, 1999, CANCER EPIDEM BIOMAR, V8, P683.
   Huang JD, 1999, DRUG METAB DISPOS, V27, P98.
   KADLUBAR FF, 1992, ENVIRON HEALTH PERSP, V98, P69, DOI 10.2307/3431249.
   KADLUBAR FF, 1995, IARC SCI PUBL, V148, P173.
   Knize MG, 2002, MUTAT RES-FUND MOL M, V506, P153, DOI 10.1016/S0027-5107(02)00162-8.
   KNIZE MG, 1995, FOOD CHEM TOXICOL, V33, P545, DOI 10.1016/0278-6915(95)00025-W.
   KNIZE MG, 1994, FOOD CHEM TOXICOL, V32, P595, DOI 10.1016/0278-6915(94)90002-7.
   Krul C, 1998, J CHROMATOGR B, V709, P27, DOI 10.1016/S0378-4347(98)00016-4.
   Kulp KS, 2000, CARCINOGENESIS, V21, P2065, DOI 10.1093/carcin/21.11.2065.
   Landi MT, 1999, IARC SCI PUBL, V148, P173.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   Le Marchand L, 2001, CANCER EPIDEM BIOMAR, V10, P1259.
   Le Marchand L, 2002, MUTAT RES-FUND MOL M, V506, P205, DOI 10.1016/S0027-5107(02)00167-7.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   MacLeod S, 1997, MUTAT RES-FUND MOL M, V376, P135, DOI 10.1016/S0027-5107(97)00036-5.
   MacLeod S. L., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P396.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   Moonen HJJ, 2002, MOL CARCINOGEN, V35, P196, DOI 10.1002/mc.10089.
   Nakajima M, 1999, J BIOCHEM-TOKYO, V125, P803.
   Potter JD, 1999, J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   Sachse C, 2003, BRIT J CLIN PHARMACO, V55, P68, DOI 10.1046/j.1365-2125.2003.01733.x.
   Sachse C, 1999, BRIT J CLIN PHARMACO, V47, P445, DOI 10.1046/j.1365-2125.1999.00898.x.
   SACHSE C, CARCINOGENESIS, V23, P1839.
   Salmon CP, 1997, FOOD CHEM TOXICOL, V35, P433, DOI 10.1016/S0278-6915(97)00020-3.
   SINHA R, 1994, CANCER RES, V54, P6154.
   Sinha R, 1997, ANN EPIDEMIOL, V7, P350, DOI 10.1016/S1047-2797(97)00027-6.
   Skog K, 2002, FOOD CHEM TOXICOL, V40, P1197, DOI 10.1016/S0278-6915(02)00052-2.
   SKOG K, 1995, CARCINOGENESIS, V16, P861, DOI 10.1093/carcin/16.4.861.
   Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1.
   Smith CAD, 1997, J MED GENET, V34, P758, DOI 10.1136/jmg.34.9.758.
   Solyakov A, 2002, FOOD CHEM TOXICOL, V40, P1205, DOI 10.1016/S0278-6915(02)00054-6.
   Stillwell WG, 2002, CARCINOGENESIS, V23, P831, DOI 10.1093/carcin/23.5.831.
   TANG BK, 1994, PHARMACOGENETICS, V4, P117, DOI 10.1097/00008571-199406000-00002.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   VATSIS KP, 1995, PHARMACOGENETICS, V5, P1, DOI 10.1097/00008571-199502000-00001.
   VISTISEN K, 1991, ADV EXP MED BIOL, V283, P407.
   Winsten J. A., 1977, ORIGINS HUMAN CANC, P1561.}},
Number-of-Cited-References = {{55}},
Times-Cited = {{9}},
Journal-ISO = {{Food Chem. Toxicol.}},
Doc-Delivery-Number = {{821GQ}},
Wos-Id = {{ISI:000221448800001}},
}

@article{ ISI:000221448800002,
Author = {Frederiksen, H and Frandsen, H},
Title = {{Excretion of metabolites in urine and faeces from rats dosed with the
   heterocyclic amine, 2-amino-9H-pyrido{[}2,3-b]indole (A alpha C)}},
Journal = {{FOOD AND CHEMICAL TOXICOLOGY}},
Year = {{2004}},
Volume = {{42}},
Number = {{6}},
Pages = {{879-885}},
Month = {{JUN}},
Abstract = {{2-amino-9H-pyrido{[}2,3-b]indole (AalphaC) is a mutagenic and
   carcinogenic heterocyclic amine formed during ordinary cooking. In model
   systems AalphaC can be formed by pyrolysing either tryptophan or
   proteins of animal or vegetable origin. In the present study, the in
   vivo metabolism of AalphaC in rats was investigated. Rats were dosed
   with tritium labelled AalphaC. Urine and faeces were collected over
   three days. The metabolites of AalphaC were characterised by HPLC-MS and
   quantified by liquid scintillation counting. Conjugated metabolites were
   characterised by enzymatic hydrolyses with beta-Glucuronidase or
   arylsulfatase. The data showed that the metabolic pattern of AalphaC was
   similar in all rats. About 55\% of the dose was excreted in urine and
   faeces during 72 h and the major amount of AalphaC metabolites (31\%)
   was excreted during the first 24 h. In addition to a small amount of
   unmetabolised AalphaC seven conjugated metabolites were characterised.
   Three minor metabolites were characterised as AalphaC-N-2-glucuronide
   and glucuronic acid conjugates of 3-OH-AalphaC and 6-OH-AalphaC. Four
   metabolites were all characterised as sulphuric acid conjugates and
   accounted for the largest amount of metabolites excreted in urine. The
   two major sulphuric acid conjugates were identified as
   AalphaC-3-O-sulfate and AalphaC-6-O-sulfate, while the minor sulphuric
   acid conjugates were proposed to be other O-sulfonated metabolites. In
   faeces only AalphaC was excreted and accounted for about 12\% of dose
   during the first 24 hours. Any activated metabolites of AalphaC were not
   detected in rat urine or faeces. In future accumulation or binding of
   AalphaC to macromolecules such as DNA and proteins has to be studied.
   (C) 2004 Elsevier Ltd. All rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Frandsen, H (Reprint Author), Danish Vet \& Food Adm, Inst Food Safety \& Nutr, Morkhoj Bygade 19, DK-2860 Soborg, Denmark.
   Danish Vet \& Food Adm, Inst Food Safety \& Nutr, DK-2860 Soborg, Denmark.}},
DOI = {{10.1016/j.fct.2004.01.011}},
ISSN = {{0278-6915}},
Keywords = {{heterocyclic amines; 2-amino-9H-pyrido{[}2,3-b]indole; A alpha C;
   metabolism; excretion}},
Keywords-Plus = {{CIGARETTE-SMOKE CONDENSATE; PERFORMANCE LIQUID-CHROMATOGRAPHY;
   AROMATIC-AMINES; LIVER-MICROSOMES; SOYBEAN GLOBULIN; COOKED FOODS;
   2-AMINO-9H-PYRIDO<2,3-B>INDOLE; CARBOLINES; MUTAGEN; CARCINOGENICITY}},
Research-Areas = {{Food Science \& Technology; Toxicology}},
Web-of-Science-Categories  = {{Food Science \& Technology; Toxicology}},
Author-Email = {{hf@dfvf.dk}},
Cited-References = {{EISENBRAND G, 1993, TOXICOLOGY, V84, P1, DOI 10.1016/0300-483X(93)90109-6.
   Frederiksen H, 2003, PHARMACOL TOXICOL, V92, P246, DOI 10.1034/j.1600-0773.2003.920508.x.
   Frederiksen H, 2002, PHARMACOL TOXICOL, V90, P127, DOI 10.1034/j.1600-0773.2002.900303.x.
   GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B.
   Kadlubar F, 1995, Princess Takamatsu Symp, V23, P207.
   KING RS, 2002, FOOD BORNE CARCINOGE, P90.
   King RS, 2000, CARCINOGENESIS, V21, P1347, DOI 10.1093/carcin/21.7.1347.
   Knize MG, 1997, J CHROMATOGR A, V763, P179, DOI 10.1016/S0021-9673(96)00720-0.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   MANABE S, 1990, J CHROMATOGR-BIOMED, V529, P125, DOI 10.1016/S0378-4347(00)83813-X.
   MATSUMOTO T, 1981, CANCER LETT, V12, P105, DOI 10.1016/0304-3835(81)90045-8.
   MATSUMOTO T, 1977, MUTAT RES, V48, P279, DOI 10.1016/0027-5107(77)90170-1.
   NIWA T, 1982, MUTAT RES, V95, P159, DOI 10.1016/0027-5107(82)90254-8.
   OHGAKI H, 1984, CARCINOGENESIS, V5, P815, DOI 10.1093/carcin/5.6.815.
   Pfau W, 1997, CHEM RES TOXICOL, V10, P1192, DOI 10.1021/tx9701182.
   Raza H, 1996, DRUG METAB DISPOS, V24, P395.
   Skog K, 1998, J CHROMATOGR A, V803, P227, DOI 10.1016/S0021-9673(97)01266-1.
   Skog K, 2002, FOOD CHEM TOXICOL, V40, P1213, DOI 10.1016/S0278-6915(02)00062-5.
   Snyderwine EG, 1998, FOOD CHEM TOXICOL, V36, P1033, DOI 10.1016/S0278-6915(98)00088-X.
   Steffensen IL, 2002, CARCINOGENESIS, V23, P1373, DOI 10.1093/carcin/23.8.1373.
   SUGIMURA T, 1985, MUTAT RES, V150, P33, DOI 10.1016/0027-5107(85)90098-3.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   TURESKY RJ, 1994, ENVIRON HEALTH PERSP, V102, P47, DOI 10.2307/3432151.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   YANAZOE Y, 2002, FOOD BORNE CARCINOGE, P74.
   YOSHIDA D, 1978, BIOCHEM BIOPH RES CO, V83, P915, DOI 10.1016/0006-291X(78)91482-1.
   YOSHIDA D, 1980, CANCER LETT, V10, P141, DOI 10.1016/0304-3835(80)90037-3.
   Zhang XB, 1996, CARCINOGENESIS, V17, P2259, DOI 10.1093/carcin/17.10.2259.}},
Number-of-Cited-References = {{28}},
Times-Cited = {{8}},
Journal-ISO = {{Food Chem. Toxicol.}},
Doc-Delivery-Number = {{821GQ}},
Wos-Id = {{ISI:000221448800002}},
}

@article{ ISI:000222274200022,
Author = {Novak, M and Rajagopal, S and Xu, LL and Kazerani, S and Toth, K and
   Brooks, M and Nguyen, TM},
Title = {{Chemistry of carcinogenic and mutagenic metabolites of heterocyclic
   aromatic amines}},
Journal = {{JOURNAL OF PHYSICAL ORGANIC CHEMISTRY}},
Year = {{2004}},
Volume = {{17}},
Number = {{6-7}},
Pages = {{615-624}},
Month = {{JUN-JUL}},
Abstract = {{Ester derivatives of the hydroxylamine metabolic oxidation products of
   heterocyclic amines (HCAs) are the ultimate mutagenic and carcinogenic
   compounds derived from this ubiquitous class of chemical carcinogens
   that are produced during the cooking of protein-containing foods.
   Considerable work has been done on the mechanism of formation of the
   HCAs during cooking processes, their detection at ppb levels in food
   products, the metabolism of the HCAs and the detection and
   characterization of DNA adducts of the HCA metabolites, but until
   recently very little work had been done to characterize the chemistry of
   the carcinogenic/mutagenic metabolites themselves. This paper reviews
   our recent work on the chemistry of model carcinogens from this class.
   The kinetics of their decomposition in aqueous solution, identification
   of reaction products and the characterization of the reactivity and
   selectivity of heterocyclic nitrenium ions generated during their
   reactions are presented. The implications of these results with respect
   to mutagenicity and carcinogenicity are discussed. Copyright (C) 2004
   John Wiley Sons, Ltd.}},
Publisher = {{JOHN WILEY \& SONS LTD}},
Address = {{THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Novak, M (Reprint Author), Miami Univ, Dept Chem \& Biochem, Oxford, OH 45056 USA.
   Miami Univ, Dept Chem \& Biochem, Oxford, OH 45056 USA.}},
DOI = {{10.1002/poc.765}},
ISSN = {{0894-3230}},
Keywords = {{heterocyclic aromatic amines; decomposition kinetics; carcinogens;
   mutagens; nitrenium ions; azide clock; 2 `-deoxyguanosine adducts}},
Keywords-Plus = {{LASER FLASH-PHOTOLYSIS; N-ARYLNITRENIUM IONS; CORRESPONDING HYDROXAMIC
   ACID; AQUEOUS-SOLUTION; NITRENIUM IONS; ESTER DERIVATIVES; AZIDE ION;
   SPECTROSCOPIC CHARACTERIZATION; 1-PHENYLETHYL DERIVATIVES;
   NUCLEOPHILIC-SUBSTITUTION}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Organic; Chemistry, Physical}},
Author-Email = {{novakm@muchio.edu}},
Cited-References = {{Benigni R, 2000, CHEM REV, V100, P3697, DOI 10.1021/cr9901079.
   Bose R, 1999, J CHEM SOC PERK T 2, P1591, DOI 10.1039/a904230j.
   CHIAPPERINO D, 2002, J AM CHEM SOC, V124, P356.
   DAVIDSE PA, 1994, J AM CHEM SOC, V116, P4513, DOI 10.1021/ja00089a065.
   EISENBRAND G, 1993, TOXICOLOGY, V84, P1, DOI 10.1016/0300-483X(93)90109-6.
   Falvey DE, 1999, J PHYS ORG CHEM, V12, P589, DOI 10.1002/(SICI)1099-1395(199908)12:8<589::AID-POC170>3.0.CO;2-T.
   Felton J. S., 2000, Food borne carcinogens: heterocyclic amines., P31.
   FISHBEIN JC, 1987, J AM CHEM SOC, V109, P2824, DOI 10.1021/ja00243a045.
   Freedman H. H., 1973, CARBONIUM IONS, V4.
   GRIVAs S., 2000, FOOD BORNE CARCINOGE, P5.
   HATCH FT, 1991, ENVIRON MOL MUTAGEN, V17, P4, DOI 10.1002/em.2850170103.
   KEMP DS, 1973, J AM CHEM SOC, V95, P6670, DOI 10.1021/ja00801a024.
   Kennedy SA, 1997, J AM CHEM SOC, V119, P7654, DOI 10.1021/ja970698p.
   King R.S., 2000, FOOD BORNE CARCINOGE, P90.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LEO AJ, 1993, CHEM REV, V93, P1281, DOI 10.1021/cr00020a001.
   LOTLICAR PRABHAKAR D., 1966, LIFE SCI, V5, P1263, DOI 10.1016/0024-3205(66)90026-9.
   MCCLELLAND RA, 1989, J AM CHEM SOC, V111, P3966, DOI 10.1021/ja00193a031.
   McClelland RA, 1999, J AM CHEM SOC, V121, P3303, DOI 10.1021/ja9836702.
   MCCLELLAND RA, 2001, ARKIVOC, V12, P72.
   MCCLELLAND RA, 1991, J AM CHEM SOC, V113, P1009, DOI 10.1021/ja00003a040.
   McClelland RA, 1998, CAN J CHEM, V76, P1327, DOI 10.1139/cjc-76-10-1327.
   MCCLELLAND RA, 1995, J AM CHEM SOC, V117, P4173, DOI 10.1021/ja00119a035.
   MEERMAN JHN, 1994, CHEM-BIOL INTERACT, V92, P321, DOI 10.1016/0009-2797(94)90073-6.
   Meinl W, 2002, PHARMACOGENETICS, V12, P677, DOI 10.1097/00008571-200212000-00002.
   MILLER JA, 1970, CANCER RES, V30, P559.
   Muckel E, 2002, FOOD CHEM TOXICOL, V40, P1063, DOI 10.1016/S0278-6915(02)00032-7.
   Novak M, 1998, J AM CHEM SOC, V120, P1643, DOI 10.1021/ja974222h.
   Novak M, 2000, J AM CHEM SOC, V122, P3606, DOI 10.1021/ja993433e.
   Novak M, 2002, J AM CHEM SOC, V124, P7972, DOI 10.1021/ja0121944.
   NOVAK M, 1994, J AM CHEM SOC, V116, P11626, DOI 10.1021/ja00104a076.
   NOVAK M, 1993, J AM CHEM SOC, V115, P9453, DOI 10.1021/ja00074a010.
   NOVAK M, 1985, J ORG CHEM, V50, P4884, DOI 10.1021/jo00224a047.
   NOVAK M, 1993, J ORG CHEM, V58, P7813, DOI 10.1021/jo00079a028.
   Novak M, 2001, ADV PHYS ORG CHEM, V36, P167, DOI 10.1016/S0065-3160(01)36005-7.
   NOVAK M, 1992, J ORG CHEM, V57, P1285, DOI 10.1021/jo00030a043.
   Novak M, 2002, CHEM RES TOXICOL, V15, P1495, DOI 10.1021/tx025584s.
   NOVAK M, 1995, J AM CHEM SOC, V117, P574, DOI 10.1021/ja00106a083.
   Novak M, 1999, J ORG CHEM, V64, P6032, DOI 10.1021/jo990581e.
   Novak M, 2003, J ORG CHEM, V68, P9875, DOI 10.1021/jo034505u.
   OHGAKI H, 1984, CARCINOGENESIS, V5, P815, DOI 10.1093/carcin/5.6.815.
   Rajagopal S, 2003, TETRAHEDRON, V59, P8003, DOI 10.1016/j.tet.2003.08.005.
   Ramlall P, 1999, J CHEM SOC PERK T 2, P225, DOI 10.1039/a807567k.
   RAPPOPORT Z, 1979, TETRAHEDRON LETT, P2559.
   Ren D, 1998, CAN J CHEM, V76, P78, DOI 10.1139/cjc-76-1-78.
   RICHARD JP, 1984, J AM CHEM SOC, V106, P1383, DOI 10.1021/ja00317a033.
   RICHARD JP, 1982, J AM CHEM SOC, V104, P4689, DOI 10.1021/ja00381a037.
   RICHARD JP, 1982, J AM CHEM SOC, V104, P4691, DOI 10.1021/ja00381a038.
   RICHARD JP, 1984, J AM CHEM SOC, V106, P1361, DOI 10.1021/ja00317a031.
   RICHARD JP, 1991, J AM CHEM SOC, V113, P5871, DOI 10.1021/ja00015a056.
   SHINOHARA A, 1986, CANCER RES, V46, P4362.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P411, DOI 10.1093/carcin/9.3.411.
   Snyderwine E. G., 2000, Food borne carcinogens: heterocyclic amines., P131.
   Srivastava S, 2000, J AM CHEM SOC, V122, P8271, DOI 10.1021/ja001184k.
   SRIVASTAVA S, 1995, J AM CHEM SOC, V117, P10186, DOI 10.1021/ja00146a003.
   SUGIMURA T, 1986, ENVIRON HEALTH PERSP, V67, P5, DOI 10.2307/3430310.
   SUGIMURA T, 1985, MUTAT RES, V150, P33, DOI 10.1016/0027-5107(85)90098-3.
   TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005.
   Williams KB, 1998, J PHYS ORG CHEM, V11, P701, DOI 10.1002/(SICI)1099-1395(1998100)11:10<701::AID-POC26>3.0.CO;2-4.
   Winsten J. A., 1977, ORIGINS HUMAN CANC, P1561.
   Yamazoe Y., 2000, FOOD BORNE CARCINOGE, P74.
   Zhang XM, 1998, J ORG CHEM, V63, P4671, DOI 10.1021/jo980120d.}},
Number-of-Cited-References = {{62}},
Times-Cited = {{12}},
Journal-ISO = {{J. Phys. Org. Chem.}},
Doc-Delivery-Number = {{832NM}},
Wos-Id = {{ISI:000222274200022}},
}

@article{ ISI:000221622000016,
Author = {Felton, JS and Knize, MG and Bennett, LM and Malfatti, MA and Colvin, ME
   and Kulp, KS},
Title = {{Impact of environmental exposures on the mutagenicity/carcinogenicity of
   heterocyclic amines}},
Journal = {{TOXICOLOGY}},
Year = {{2004}},
Volume = {{198}},
Number = {{1-3}},
Pages = {{135-145}},
Month = {{MAY 20}},
Note = {{5th Congress of Toxicology in Developing Countries, GUILIN, PEOPLES R
   CHINA, OCT 10-13, 2003}},
Organization = {{Chinese Soc Toxicol; Int Union Toxicol}},
Abstract = {{Carcinogenic heterocyclic amines are produced from overcooked foods and
   are highly mutagenic in most short-term test Systems. One of the most
   abundant of these amines,
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP), induces
   breast, colon and prostate tumors in rats. Human dietary epidemiology
   studies suggest a strong correlation between either meat consumption or
   well-done muscle meat consumption and cancers of the colon, breast,
   stomach, lung and esophagus. For over 20 years our laboratory has helped
   define the human exposure to these dietary carcinogens. In this report
   we describe how various environmental exposures may modulate the risk
   from exposure to heterocyclic amines, especially PhIR To assess the
   impact of foods on PhIP metabolism in humans, we developed an LC/MS/MS
   method to analyze the four major PhIP urinary metabolites following the
   consumption of a single portion of grilled chicken. Adding broccoli to
   the volunteers' diet altered the kinetics of PhIP metabolism. At the
   cellular level we have found that PhIP itself stimulates a significant
   estrogenic response in MCF-7 cells, but even more interestingly,
   co-incubation of the cells with herbal teas appear to enhance the
   response. Numerous environmental chemicals found in food or the
   atmosphere can impact the exposure, metabolism, and cell proliferation
   response of heterocyclic amines. (C) 2004 Published by Elsevier Ireland
   Ltd.}},
Publisher = {{ELSEVIER SCI IRELAND LTD}},
Address = {{CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Felton, JS (Reprint Author), Lawrence Livermore Natl Lab, Biol \& Biotechnol Res Program, L-452, Livermore, CA 94551 USA.
   Lawrence Livermore Natl Lab, Biol \& Biotechnol Res Program, Livermore, CA 94551 USA.
   NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.}},
DOI = {{10.1016/j.tox.2004.01.024}},
ISSN = {{0300-483X}},
Keywords = {{mutagenicity; carcinogenicity; heterocyclic amines; PhIP}},
Keywords-Plus = {{DNA ADDUCT FORMATION; FRIED BEEF PATTIES; FEMALE F344 RATS;
   N-HYDROXY-PHIP; AROMATIC-AMINES;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; NONHUMAN-PRIMATES;
   PAN RESIDUES; GREEN TEA; INHIBITION}},
Research-Areas = {{Pharmacology \& Pharmacy; Toxicology}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy; Toxicology}},
Author-Email = {{feltonl@llnl.gov}},
Cited-References = {{ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   ADAMSON RH, 1994, ENVIRON HEALTH PERSP, V102, P190, DOI 10.2307/3431610.
   Breinholt V, 1999, XENOBIOTICA, V29, P1227.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   Busquets R, 2004, J CHROMATOGR B, V802, P79, DOI 10.1016/j.jchromb.2003.09.033.
   Colvin ME, 1998, MUTAT RES-FUND MOL M, V400, P479, DOI 10.1016/S0027-5107(98)00073-6.
   Dubuisson JG, 2002, CANCER LETT, V182, P27, DOI 10.1016/S0304-3835(02)00061-7.
   Ernst E, 1999, EUR J CANCER, V35, P1608, DOI 10.1016/S0959-8049(99)00198-7.
   FELTON JS, 1994, FOOD CHEM TOXICOL, V32, P897, DOI 10.1016/0278-6915(94)90087-6.
   Futakuchi M, 2002, CARCINOGENESIS, V23, P283, DOI 10.1093/carcin/23.2.283.
   Gooderham NJ, 2002, MUTAT RES-FUND MOL M, V506, P91, DOI 10.1016/S0027-5107(02)00155-0.
   Guo Dexin, 1995, Carcinogenesis (Oxford), V16, P2931, DOI 10.1093/carcin/16.12.2931.
   He YH, 2000, FOOD CHEM TOXICOL, V38, P15, DOI 10.1016/S0278-6915(99)00117-9.
   He Y H, 1997, J Cell Biochem Suppl, V27, P42.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1398.
   HORIKAWA K, 1994, MUTAGENESIS, V9, P523, DOI 10.1093/mutage/9.6.523.
   Huber WW, 2002, ARCH TOXICOL, V75, P685, DOI 10.1007/s00204-001-0295-5.
   JOHANSSON MAE, 1994, CARCINOGENESIS, V15, P1511, DOI 10.1093/carcin/15.8.1511.
   Josyula S, 1998, NUTR CANCER, V32, P132.
   KADERLIK KR, 1995, PHARMACOGENETICS, V5.
   Kaegi E, 1998, CMAJ, V158, P1161.
   Kimura S, 2003, CARCINOGENESIS, V24, P583, DOI 10.1093/carcin/24.3.583.
   Knasmuller S, 2001, MUTAT RES-FUND MOL M, V480, P129, DOI 10.1016/S0027-5107(01)00176-2.
   KNIZE MG, 1994, FOOD CHEM TOXICOL, V32, P595, DOI 10.1016/0278-6915(94)90002-7.
   Krul C, 2001, MUTAT RES-FUND MOL M, V474, P71, DOI 10.1016/S0027-5107(00)00158-5.
   Kulp KS, 2000, CARCINOGENESIS, V21, P2065, DOI 10.1093/carcin/21.11.2065.
   Kulp KS, 2003, FOOD CHEM TOXICOL, V41, P1701, DOI 10.1016/S0278-6915(03)00197-2.
   Langouet S, 2002, CARCINOGENESIS, V23, P115, DOI 10.1093/carcin/23.1.115.
   LEE H, 1991, FOOD CHEM TOXICOL, V29, P765, DOI 10.1016/0278-6915(91)90185-A.
   Lin DX, 2003, MUTAT RES-FUND MOL M, V523, P193, DOI 10.1016/S0027-5107(02)00335-4.
   Malfatti MA, 2001, CARCINOGENESIS, V22, P1087, DOI 10.1093/carcin/22.7.1087.
   MALFATTI MA, 1994, CHEM RES TOXICOL, V7, P139, DOI 10.1021/tx00038a005.
   Mori Y, 2003, MUTAGENESIS, V18, P87, DOI 10.1093/mutage/18.1.87.
   Murray S, 2001, CARCINOGENESIS, V22, P1413, DOI 10.1093/carcin/22.9.1413.
   MURRAY S, 1993, J CHROMATOGR-BIOMED, V616, P211, DOI 10.1016/0378-4347(93)80388-K.
   Muto S, 2001, MUTAT RES-FUND MOL M, V479, P197, DOI 10.1016/S0027-5107(01)00204-4.
   PERCIVAL J, 1994, ESSIAC HDB.
   Richardson MA, 2000, J CLIN ONCOL, V18, P2505.
   Salmon CP, 1997, FOOD CHEM TOXICOL, V35, P433, DOI 10.1016/S0278-6915(97)00020-3.
   Salmon CP, 2000, J NATL CANCER I, V92, P1773, DOI 10.1093/jnci/92.21.1773.
   Santana-Rios G, 2001, NUTR CANCER, V41, P98, DOI 10.1207/S15327914NC41-1\&2\_13.
   Sasaki JC, 2002, MUTAT RES-FUND MOL M, V506, P79, DOI 10.1016/S0027-5107(02)00154-9.
   Schut HAJ, 1997, MUTAT RES-FUND MOL M, V376, P185, DOI 10.1016/S0027-5107(97)00042-0.
   Schwab CE, 2000, CRIT REV TOXICOL, V30, P1, DOI 10.1080/1040844041696481.
   Shirai T, 1997, CANCER RES, V57, P195.
   SKOG K, 1997, POLAR NONPOLAR HETER.
   SKOG K, 1995, CARCINOGENESIS, V16, P861, DOI 10.1093/carcin/16.4.861.
   Smith M, 1999, PATIENT EDUC COUNS, V38, P109, DOI 10.1016/S0738-3991(99)00058-0.
   Snyderwine EG, 2002, FOOD CHEM TOXICOL, V40, P1529, DOI 10.1016/S0278-6915(02)00110-2.
   STAINSBY M, 1992, KEEPING HOPE ALIVE.
   Steinkellner H, 2001, MUTAT RES-FUND MOL M, V480, P285, DOI 10.1016/S0027-5107(01)00188-9.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   TAKAHASHI M, 1997, CARCINOGENESIS, V18, P1907.
   Takeshita F, 2003, CANCER LETT, V194, P25, DOI 10.1016/S0304-3835(03)00051-X.
   TURTELTAUB KW, 1989, FOOD CHEM TOXICOL, V27, P667, DOI 10.1016/0278-6915(89)90121-X.
   Ubagai T, 2002, CARCINOGENESIS, V23, P197, DOI 10.1093/carcin/23.1.197.
   Wagner ED, 2003, MUTAT RES-GEN TOX EN, V536, P103, DOI 10.1016/S1383-5718(03)00037-8.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   WHITAKER J, 1995, DR WHITAKERS NEWSLET, V5.
   Yu Z, 2001, FOOD CHEM TOXICOL, V39, P655, DOI 10.1016/S0278-6915(01)00012-6.
   Zimmerli B, 2001, FOOD ADDIT CONTAM, V18, P533, DOI 10.1080/02652030110035084.}},
Number-of-Cited-References = {{61}},
Times-Cited = {{34}},
Journal-ISO = {{Toxicology}},
Doc-Delivery-Number = {{823OH}},
Wos-Id = {{ISI:000221622000016}},
}

@article{ ISI:000225863700002,
Author = {Baranczewski, P and Gustafsson, JA and Moller, L},
Title = {{DNA adduct formation of 14 heterocyclic aromatic amines in mouse tissue
   after oral administration and characterization of the DNA adduct formed
   by 2-amino-9H-pyrido{[}2,3-b]indole (A alpha C), analysed by P-32-HPLC}},
Journal = {{BIOMARKERS}},
Year = {{2004}},
Volume = {{9}},
Number = {{3}},
Pages = {{243-257}},
Month = {{MAY-JUN}},
Abstract = {{Heterocyclic aromatic amines (HAAs) are produced during cooking of
   proteinaceous food such as meat and fish. Humans eating a normal diet
   are regularly exposed to these food-borne substances. HAAs have proved
   to be carcinogenic in animals and to induce early lesions in the
   development of cancer. DNA adduct levels in mouse liver have been
   measured by P-32-HPLC after oral administration each of 14 different
   HAAs. The highest DNA adduct levels were detected for
   3-amino-1-methyl-5H-pyrido{[}4,3-b]-indole (Trp-P-2),
   3-amino-1,4-dimethyl-5H-pyrido{[}4,3-b] indole (Trp-P-1) and
   2-amino-9H-pyrido{[} 2,3-b] indole (AalphaC), respectively. To assess a
   relative risk in a human population, a relative risk index was
   calculated by combining the DNA adduct levels in mouse liver with human
   daily intake of heterocyclic amines in a US and in a Swedish population.
   Such calculations suggest that AaC presents the highest risk for humans,
   e. g. nine-fold higher compared with the most abundant amines in food,
   2-amino-1-methyl-6-phenylimidazo{[} 4,5-b]-pyridine ( PhIP). Therefore,
   the distribution of DNA adducts in different tissues of mouse was
   investigated after oral administration of AalphaC. The highest AalphaC -
   DNA adduct levels were found in liver ( 137 adducts/10(8) normal
   nucleotides) followed by heart, kidney, lung, large intestine, small
   intestine, stomach and spleen, in descending order. To characterize the
   chemical structure of the major DNA adduct, chemical synthesis was
   performed. The major DNA adduct from the in vivo experiments was
   characterized by five different methods. On the basis of these results,
   the adduct was characterized as N-2(
   deoxyguanin-8-yl)-2-amino-9H-pyrido{[}2,3-b] indole. Considering the
   abundance of AalphaC not only in grilled meat, but also in other
   products like grilled chicken, vegetables and cigarette smoke and in
   light of the results of the present study, it is suggested that the
   human cancer risk for AalphaC might be underestimated.}},
Publisher = {{TAYLOR \& FRANCIS LTD}},
Address = {{4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Moller, L (Reprint Author), Karolinska Inst, Novum, Dept Biosci, Lab Analyt Toxicol, SE-14157 Stockholm, Sweden.
   Karolinska Inst, Novum, Dept Biosci, Lab Analyt Toxicol, SE-14157 Stockholm, Sweden.
   Karolinska Inst, Novum, Dept Med Nutr, SE-14157 Stockholm, Sweden.}},
DOI = {{10.1080/13547500400010056}},
ISSN = {{1354-750X}},
Keywords = {{DNA adduct; cancer; food; amine; food mutagen}},
Keywords-Plus = {{IN-VITRO; CYTOCHROME P4501A2; SOYBEAN GLOBULIN; GLUTAMIC-ACID; VIVO;
   METABOLISM; MUTAGEN; LIVER; RISK; RATS}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Toxicology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Toxicology}},
Author-Email = {{lennart.moller@cnt.ki.se}},
Cited-References = {{Augustsson K, 1997, CARCINOGENESIS, V18, P1931, DOI 10.1093/carcin/18.10.1931.
   Baranczewski P, 2004, CANCER EPIDEM BIOMAR, V13, P1071.
   Bogen KT, 2001, J EXPO ANAL ENV EPID, V11, P155, DOI 10.1038/sj.jea.7500158.
   BUTLER LM, 2003, AM J EPIDEMIOL, V57, P434.
   CUI XS, 1995, CARCINOGENESIS, V16, P2135, DOI 10.1093/carcin/16.9.2135.
   Davis CD, 1996, MUTAT RES-FUND MOL M, V356, P287, DOI 10.1016/0027-5107(96)00074-7.
   EISENBRAND G, 1993, TOXICOLOGY, V84, P1, DOI 10.1016/0300-483X(93)90109-6.
   Frederiksen H, 2004, CARCINOGENESIS, V25, P1525, DOI 10.1093/carcin/bgh156.
   Frederiksen H, 2003, PHARMACOL TOXICOL, V92, P246, DOI 10.1034/j.1600-0773.2003.920508.x.
   FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   FRIVAS S, 1988, J CHEM RES, V84, P515.
   HASHIMOTO Y, 1982, J AM CHEM SOC, V104, P7636, DOI 10.1021/ja00390a040.
   HIROSE M, 1995, JPN J CANCER RES, V86, P516.
   JOHANSSON MAE, 1994, CARCINOGENESIS, V15, P1511, DOI 10.1093/carcin/15.8.1511.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   Majer BJ, 2004, J CHROMATOGR B, V802, P167, DOI 10.1016/j.jchromb.2003.10.042.
   MATSUMOTO T, 1981, CANCER LETT, V12, P105, DOI 10.1016/0304-3835(81)90045-8.
   MOLLER L, 1993, CARCINOGENESIS, V14, P1343, DOI 10.1093/carcin/14.7.1343.
   Nagao M, 1999, MUTAT RES-FUND MOL M, V431, P3, DOI 10.1016/S0027-5107(99)00154-2.
   Nagao M, 1997, MUTAT RES-FUND MOL M, V376, P161, DOI 10.1016/S0027-5107(97)00039-0.
   Ohe T, 1997, MUTAT RES-GEN TOX EN, V393, P73, DOI 10.1016/S1383-5718(97)00087-9.
   OHGAKI H, 1984, CARCINOGENESIS, V5, P815, DOI 10.1093/carcin/5.6.815.
   Pfau W, 1997, CHEM RES TOXICOL, V10, P1192, DOI 10.1021/tx9701182.
   POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0.
   Raza H, 1996, DRUG METAB DISPOS, V24, P395.
   ROHRMANN S, 2002, EUROPEAN J CLIN NUTR, V12, P1216.
   Totsuka Y, 1996, CARCINOGENESIS, V17, P1029, DOI 10.1093/carcin/17.5.1029.
   Turesky RJ, 2004, J CHROMATOGR B, V802, P155, DOI 10.1016/j.jchromb.2003.10.053.
   Turesky RJ, 2002, DRUG METAB REV, V34, P625, DOI 10.1081/DMR-120005665.
   Turteltaub KW, 1997, MUTAT RES-FUND MOL M, V376, P243, DOI 10.1016/S0027-5107(97)00049-3.
   Wakabayashi K, 1995, Princess Takamatsu Symp, V23, P39.
   Wohlin P, 1996, CHEM RES TOXICOL, V9, P1050, DOI 10.1021/tx960050a.
   YAMASHITA K, 1986, P JPN ACAD B-PHYS, V62, P45, DOI 10.2183/pjab.62.45.
   YOSHIDA D, 1978, BIOCHEM BIOPH RES CO, V83, P915, DOI 10.1016/0006-291X(78)91482-1.
   ZEISIG M, 1995, CARCINOGENESIS, V16, P1, DOI 10.1093/carcin/16.1.1.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{9}},
Journal-ISO = {{Biomarkers}},
Doc-Delivery-Number = {{881JP}},
Wos-Id = {{ISI:000225863700002}},
}

@article{ ISI:000220121200028,
Author = {Sentellas, S and Moyano, E and Puignou, L and Galceran, MT},
Title = {{Optimization of a clean-up procedure for the determination of
   heterocyclic aromatic amines in urine by field-amplified sample
   injection-capillary electrophoresis-mass spectrometry}},
Journal = {{JOURNAL OF CHROMATOGRAPHY A}},
Year = {{2004}},
Volume = {{1032}},
Number = {{1-2}},
Pages = {{193-201}},
Month = {{APR 2}},
Abstract = {{Heterocyclic amines (HAs), generated when proteinaceous food is cooked,
   are of special interest since they can be carcinogenic for humans. In
   this paper, the optimization of a clean-up procedure for the isolation
   and preconcentration of 15 heterocyclic amines in urine samples is
   described. The method proposed combines liquid extraction on a solid
   support of diatomaceous earth with solid-phase extraction in cartridges.
   Tests were performed on several cartridges containing graphitic carbon
   or mixed phases, i.e., combining reversed-phase and cation-exchange
   mechanism, and the best results were obtained with Oasis MCX. The
   optimized purification method was applied to the quantification of
   heterocyclic amines in hydrolyzed spiked human urine. The method was
   carried out by capillary electrophoresis (CE) coupled to mass
   spectrometry (MS) and applying field-amplified sample injection (FASI)
   as in-line preconcentration procedure. We obtained detection limits down
   to 0.3 ng/ml of urine and errors lower than 17\%. (C) 2003 Elsevier B.V.
   All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Galceran, MT (Reprint Author), Univ Barcelona, Dept Analyt Chem, Diagonal 647, Barcelona 08028, Spain.
   Univ Barcelona, Dept Analyt Chem, Barcelona 08028, Spain.}},
DOI = {{10.1016/j.chroma.2003.11.011}},
ISSN = {{0021-9673}},
Keywords = {{sample preparation; field-enhanced sample stacking; amines, heterocyclic
   aromatic}},
Keywords-Plus = {{ORTHOGONAL ARRAY DESIGN; ZONE-ELECTROPHORESIS;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO(4,5-B)PYRIDINE PHIP; MUTAGENIC AMINES;
   BEEF EXTRACTS; MEAT EXTRACTS; FRIED MEAT; EXCRETION; CONSUMPTION;
   METABOLITES}},
Research-Areas = {{Biochemistry \& Molecular Biology; Chemistry}},
Web-of-Science-Categories  = {{Biochemical Research Methods; Chemistry, Analytical}},
Author-Email = {{galceran@apolo.qui.ub.es}},
Cited-References = {{Britt C, 1998, J AGR FOOD CHEM, V46, P4891, DOI 10.1021/jf980233y.
   Dietrich CG, 2001, CARCINOGENESIS, V22, P805, DOI 10.1093/carcin/22.5.805.
   Frandsen H, 2002, FOOD CHEM TOXICOL, V40, P1125, DOI 10.1016/S0278-6915(02)00033-9.
   Friesen MD, 2001, CANCER LETT, V173, P43, DOI 10.1016/S0304-3835(01)00672-3.
   Galceran MT, 1996, J CHROMATOGR A, V719, P203, DOI 10.1016/0021-9673(95)00420-3.
   GROSS GA, 1990, CARCINOGENESIS, V11, P1597, DOI 10.1093/carcin/11.9.1597.
   JAGERSTAD M, 1991, MUTAT RES, V259, P219, DOI 10.1016/0165-1218(91)90119-7.
   Kidd LCR, 1999, CANCER EPIDEM BIOMAR, V8, P439.
   Knize MG, 1998, J AGR FOOD CHEM, V46, P4648, DOI 10.1021/jf980639a.
   Knize MG, 2001, J CHROMATOGR A, V914, P95, DOI 10.1016/S0021-9673(01)00522-2.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   Mardones C, 1998, CHROMATOGRAPHIA, V48, P700, DOI 10.1007/BF02467602.
   Murkovic M, 1998, Z LEBENSM UNTERS F A, V207, P477, DOI 10.1007/s002170050364.
   MURRAY S, 1988, CARCINOGENESIS, V9, P321, DOI 10.1093/carcin/9.2.321.
   MURRAY S, 1993, J CHROMATOGR-BIOMED, V616, P211, DOI 10.1016/0378-4347(93)80388-K.
   OLSSON JC, 1997, J CHROMATOGR A, V765, P321.
   Pais P, 1997, J CHROMATOGR A, V778, P207, DOI 10.1016/S0021-9673(97)00219-7.
   Puignou L, 1997, J CHROMATOGR A, V769, P293, DOI 10.1016/S0021-9673(97)00033-2.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   Sentellas S, 2003, ELECTROPHORESIS, V24, P3075, DOI 10.1002/elps.200305523.
   Skog K, 1998, J CHROMATOGR A, V803, P227, DOI 10.1016/S0021-9673(97)01266-1.
   SKOG K, 1992, MUTAT RES, V268, P191, DOI 10.1016/0027-5107(92)90224-P.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   Strickland PT, 2002, MUTAT RES-FUND MOL M, V506, P163, DOI 10.1016/S0027-5107(02)00163-X.
   SUGIMURA T, 1995, P 23 INT S PRINC TAK, P214.
   Toribio F, 2002, J CHROMATOGR A, V948, P267, DOI 10.1016/S0021-9673(01)01476-5.
   Toribio F, 2000, J CHROMATOGR A, V869, P307, DOI 10.1016/S0021-9673(99)01091-2.
   VANDERLAAN M, 1993, ENVIRON HEALTH PERSP, V99, P285, DOI 10.2307/3431502.
   WU J, 1995, J CHROMATOGR SCI, V33, P712.
   Wu J, 1996, J CHROMATOGR SCI, V34, P139.
   WU J, 1995, J CHROMATOGR A, V709, P351, DOI 10.1016/0021-9673(95)00459-Z.
   Zhao YI, 1998, ELECTROPHORESIS, V19, P2213, DOI 10.1002/elps.1150191228.}},
Number-of-Cited-References = {{32}},
Times-Cited = {{35}},
Journal-ISO = {{J. Chromatogr. A}},
Doc-Delivery-Number = {{801UQ}},
Wos-Id = {{ISI:000220121200028}},
}

@article{ ISI:000189248700013,
Author = {Gerbl, U and Cichna, M and Zsivkovits, M and Knasmuller, S and Sontag, G},
Title = {{Determination of heterocyclic aromatic amines in beef extract, cooked
   meat and rat urine by liquid chromatography with coulometric electrode
   array detection}},
Journal = {{JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
   AND LIFE SCIENCES}},
Year = {{2004}},
Volume = {{802}},
Number = {{1}},
Pages = {{107-113}},
Month = {{MAR 25}},
Abstract = {{This paper describes a method for the determination of heterocyclic
   aromatic amines (HAs; DMIP, IQ, MeIQ, MeIQx, 4,8-DiMeIQx, 7,8-DiMeIQx,
   AalphaC, PhIP) by high-performance liquid chromatography (HPLC) with
   coulometric electrode array detection. The compounds are separated on
   reversed phase columns (LiChroCart Superspher 60 RP-select B, 250 mm x 2
   mm, 4 mum and LiChrospher 60 RP-select B, 250 turn x 4 mm, 5 mum) using
   mobile phases consisting of acetonitrile/buffer/distilled water and
   detected at eight working electrodes at potentials between +190 and +680
   mV against modified palladium electrodes. In the context of an
   EU-interlaboratory exercise, the method was applied to analyse a
   standardised test solution and-after isolation of the analytes by
   several clean-up steps-for the analysis of standardised beef extract and
   grilled meat. Further, the method could be applied for the analysis of
   HAs in suspensions of bacteria and rat urine without any sample
   preparation step beyond sample dilution. The data obtained show that
   HPLC with coulometric electrode array detection gives accurate results.
   (C) 2003 Elsevier B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Sontag, G (Reprint Author), Univ Vienna, Inst Analyt Chem, Waehringer Str 38, A-1090 Vienna, Austria.
   Univ Vienna, Inst Analyt Chem, A-1090 Vienna, Austria.
   Inst Canc Res, A-1090 Vienna, Austria.}},
DOI = {{10.1016/j.jchromb.2003.10.063}},
ISSN = {{1570-0232}},
Keywords = {{heterocyclic aromatic amines; coulometric electrode array detection;
   food analysis}},
Keywords-Plus = {{MODEL SYSTEMS; ELECTROCHEMICAL DETECTION; VARYING DEGREES;
   DAIRY-PRODUCTS; FOOD-PRODUCTS; PAN RESIDUES; CARCINOGENS; DRIPPINGS;
   DONENESS; BACTERIA}},
Research-Areas = {{Biochemistry \& Molecular Biology; Chemistry}},
Web-of-Science-Categories  = {{Biochemical Research Methods; Chemistry, Analytical}},
Author-Email = {{gerhard.sontag@univie.ac.at}},
Cited-References = {{Bast E, 1999, MIKROBIOLOGISCHE MET.
   Bolognani F, 1997, FOOD CHEM TOXICOL, V35, P535, DOI 10.1016/S0278-6915(97)00029-X.
   Borgen E, 2001, FOOD CHEM, V74, P11, DOI 10.1016/S0308-8146(00)00333-2.
   Bross C, 1997, DEUT LEBENSM-RUNDSCH, V93, P384.
   GALCERAN MT, 1993, J CHROMATOGR A, V655, P101, DOI 10.1016/0021-9673(93)87017-G.
   GERTEN B, 1993, OXOID HDB, V5.
   GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B.
   Jagerstad M, 1998, Z LEBENSM UNTERS F A, V207, P419, DOI 10.1007/s002170050355.
   Johansson MAE, 1995, FOOD CHEM TOXICOL, V33, P993, DOI 10.1016/0278-6915(95)00074-7.
   Keating GA, 2001, FOOD CHEM TOXICOL, V39, P29, DOI 10.1016/S0278-6915(00)00115-0.
   Knasmuller S, 2001, MUTAT RES-FUND MOL M, V480, P129, DOI 10.1016/S0027-5107(01)00176-2.
   Knize MG, 1997, J CHROMATOGR A, V763, P179, DOI 10.1016/S0021-9673(96)00720-0.
   Knize MG, 1998, J AGR FOOD CHEM, V46, P4648, DOI 10.1021/jf980639a.
   KNIZE MG, 1995, FOOD CHEM TOXICOL, V33, P545, DOI 10.1016/0278-6915(95)00025-W.
   Krach C, 2000, ANAL CHIM ACTA, V417, P77, DOI 10.1016/S0003-2670(00)00923-5.
   Murkovic M, 1999, FOOD CHEM, V65, P233, DOI 10.1016/S0308-8146(98)00214-3.
   Murkovic M, 1997, Z LEBENSM UNTERS F A, V205, P347, DOI 10.1007/s002170050178.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   Pais P, 1999, J AGR FOOD CHEM, V47, P1098, DOI 10.1021/jf980644e.
   Pais P, 2000, J CHROMATOGR B, V747, P139, DOI 10.1016/S0378-4347(00)00118-3.
   Richling E, 1996, CHROMATOGRAPHIA, V42, P7, DOI 10.1007/BF02271047.
   Santos FJ, 2004, J CHROMATOGR B, V802, P69, DOI 10.1016/j.jchromb.2003.09.030.
   SCHWARZENBACH R, 1992, J CHROMATOGR, V624, P491, DOI 10.1016/0021-9673(92)85698-S.
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P289, DOI 10.1016/S0278-6915(97)00159-2.
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P279, DOI 10.1016/S0278-6915(97)00162-2.
   Skog K, 1997, FOOD CHEM TOXICOL, V35, P555, DOI 10.1016/S0278-6915(97)00021-5.
   Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1.
   Tavan E, 2002, CARCINOGENESIS, V23, P477, DOI 10.1093/carcin/23.3.477.
   Toribio F, 2000, J CHROMATOGR B, V747, P171, DOI 10.1016/S0378-4347(00)00154-7.
   VANDYCK MMC, 1995, J CHROMATOGR A, V697, P377, DOI 10.1016/0021-9673(94)00837-Y.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   ZHANG XB, 1991, J DAIRY SCI, V74, P752.
   Zimmerli B, 2001, FOOD ADDIT CONTAM, V18, P533, DOI 10.1080/02652030110035084.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{8}},
Journal-ISO = {{J. Chromatogr. B}},
Doc-Delivery-Number = {{778NY}},
Wos-Id = {{ISI:000189248700013}},
}

@article{ ISI:000189248700017,
Author = {Kulp, KS and Knize, MG and Fowler, ND and Salmon, CP and Felton, JS},
Title = {{PhIP metabolites in human urine after consumption of well-cooked chicken}},
Journal = {{JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
   AND LIFE SCIENCES}},
Year = {{2004}},
Volume = {{802}},
Number = {{1}},
Pages = {{143-153}},
Month = {{MAR 25}},
Abstract = {{We devised an assay to quantify the metabolites of
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) in human urine
   following a single exposure to well-cooked meat. Our method uses
   LC/MS/MS to detect four metabolites and four deuterated internal
   standard peaks in a single chromatographic run.
   N-2-OH-PhIP-N-2-glucuronide was the most abundant urinary metabolite
   excreted by the 12 individuals who participated in our study. N-2-PhIP
   glucuronide was the second most abundant metabolite for 8 of the 12
   volunteers. The stability of PhIP metabolism over time was studied in
   three of the volunteers who repeated the assay eight times over a 2.5
   year-period. PhIP metabolite excretion varied in each subject over time,
   although the rate of excretion was more constant. Our results suggest
   that quantifying PhIP metabolites should make future studies of
   individual susceptibility and dietary interventions possible. (C) 2003
   Elsevier B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kulp, KS (Reprint Author), Lawrence Livermore Natl Lab, Biol \& Biotechnol Res Program, POB 808,7000 East Ave,L-452, Livermore, CA 94551 USA.
   Lawrence Livermore Natl Lab, Biol \& Biotechnol Res Program, Livermore, CA 94551 USA.}},
DOI = {{10.1016/j.jchromb.2003.09.032}},
ISSN = {{1570-0232}},
Keywords = {{food analysis; metabolism;
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine; heterocyclic aromatic
   amine}},
Keywords-Plus = {{HETEROCYCLIC AMINE CONTENT; BREAST-CANCER RISK; FRIED GROUND-BEEF; DONE
   MEAT INTAKE; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP;
   COLORECTAL ADENOMAS; UNITED-STATES; SALMONELLA MUTAGENICITY;
   LIQUID-CHROMATOGRAPHY; LIVER-MICROSOMES}},
Research-Areas = {{Biochemistry \& Molecular Biology; Chemistry}},
Web-of-Science-Categories  = {{Biochemical Research Methods; Chemistry, Analytical}},
Author-Email = {{kulp2@llnl.gov}},
Cited-References = {{ALEXANDER J, 1991, CARCINOGENESIS, V12, P2239, DOI 10.1093/carcin/12.12.2239.
   Augustsson K, 1999, LANCET, V353, P703, DOI 10.1016/S0140-6736(98)06099-1.
   Barrett JH, 2003, CARCINOGENESIS, V24, P275, DOI 10.1093/carcin/24.2.275.
   Bogen KT, 2001, J EXPO ANAL ENV EPID, V11, P155, DOI 10.1038/sj.jea.7500158.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   BUONARATI MH, 1992, CARCINOGENESIS, V15, P2429.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   Dai Q, 2002, CANCER EPIDEM BIOMAR, V11, P801.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P2091, DOI 10.1093/carcin/14.10.2091.
   Delfino RJ, 2000, CARCINOGENESIS, V21, P607, DOI 10.1093/carcin/21.4.607.
   Dingley KH, 1999, CANCER EPIDEM BIOMAR, V8, P507.
   Dubuisson JG, 1998, NUTRITION, V14, P683, DOI 10.1016/S0899-9007(98)00106-3.
   EDWARDS RJ, 1994, CARCINOGENESIS, V15, P829, DOI 10.1093/carcin/15.5.829.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   Friesen MD, 2001, CANCER LETT, V173, P43, DOI 10.1016/S0304-3835(01)00672-3.
   Galijatovic A, 2001, PHARMACEUT RES, V18, P374, DOI 10.1023/A:1011019417236.
   Garner RC, 1999, CANCER LETT, V143, P161, DOI 10.1016/S0304-3835(99)00118-4.
   Gertig DM, 1999, INT J CANCER, V80, P13, DOI 10.1002/(SICI)1097-0215(19990105)80:1<13::AID-IJC3>3.0.CO;2-W.
   Hein DW, 2002, ENVIRON MOL MUTAGEN, V40, P161, DOI 10.1002/em.10103.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1695, DOI 10.1093/carcin/15.8.1695.
   Keating GA, 2000, CANCER CAUSE CONTROL, V11, P731, DOI 10.1023/A:1008935407971.
   Kidd LCR, 1999, CANCER EPIDEM BIOMAR, V8, P439.
   Knize MG, 2002, MUTAT RES-FUND MOL M, V506, P153, DOI 10.1016/S0027-5107(02)00162-8.
   Knize MG, 1998, J AGR FOOD CHEM, V46, P4648, DOI 10.1021/jf980639a.
   KNIZE MG, 1995, FOOD CHEM TOXICOL, V33, P545, DOI 10.1016/0278-6915(95)00025-W.
   KNIZE MG, 1985, FOOD CHEM TOXICOL, V23, P1035, DOI 10.1016/0278-6915(85)90049-3.
   KNIZE MG, 1994, FOOD CHEM TOXICOL, V32, P595, DOI 10.1016/0278-6915(94)90002-7.
   Knize MG, 2001, J CHROMATOGR A, V914, P95, DOI 10.1016/S0021-9673(01)00522-2.
   Kulp KS, 2000, CARCINOGENESIS, V21, P2065, DOI 10.1093/carcin/21.11.2065.
   KULP KS, IN PRESS FOOD CHEM T.
   Lang NP, 1999, CANCER LETT, V143, P135, DOI 10.1016/S0304-3835(99)00142-1.
   Langouet S, 2002, CARCINOGENESIS, V23, P115, DOI 10.1093/carcin/23.1.115.
   Lawson T, 2002, CANCER LETT, V175, P141, DOI 10.1016/S0304-3835(01)00732-7.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   Lynch AM, 1998, MUTAGENESIS, V13, P601, DOI 10.1093/mutage/13.6.601.
   MALFATTI MA, 1995, MUTAGENESIS, V10, P425, DOI 10.1093/mutage/10.5.425.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   Nelson CP, 2001, CANCER RES, V61, P103.
   Norrish AE, 1999, J NATL CANCER I, V91, P2038, DOI 10.1093/jnci/91.23.2038.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   OZAWA S, 1994, JPN J CANCER RES, V85, P1220.
   Pais P, 1999, J AGR FOOD CHEM, V47, P1098, DOI 10.1021/jf980644e.
   ProbstHensch NM, 1997, CANCER CAUSE CONTROL, V8, P175, DOI 10.1023/A:1018416128894.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   Sachse C, 2002, CARCINOGENESIS, V23, P1839, DOI 10.1093/carcin/23.11.1839.
   SCHUT HAJ, 1988, CARCINOGENIC MUTAGEN, P265.
   Shirai T, 1997, CANCER RES, V57, P195.
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P289, DOI 10.1016/S0278-6915(97)00159-2.
   SINHA R, 1995, CANCER RES, V55, P4516.
   Sinha R, 1998, CANCER CAUSE CONTROL, V9, P621, DOI 10.1023/A:1008805525525.
   Sinha R, 2001, CANCER EPIDEM BIOMAR, V10, P559.
   SINHA R, 1997, TOXICOLOGY, V36, P279.
   Sinha R, 1999, CANCER RES, V59, P4320.
   SKOG K, 1993, FOOD CHEM TOXICOL, V31, P655, DOI 10.1016/0278-6915(93)90049-5.
   SKOG K, 1995, CARCINOGENESIS, V16, P861, DOI 10.1093/carcin/16.4.861.
   SNYDERWINE EG, 1994, CARCINOGENESIS, V15, P2757, DOI 10.1093/carcin/15.12.2757.
   Stillwell WG, 2002, CARCINOGENESIS, V23, P831, DOI 10.1093/carcin/23.5.831.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   Strickland PT, 2002, MUTAT RES-FUND MOL M, V506, P163, DOI 10.1016/S0027-5107(02)00163-X.
   Strickland PT, 2001, BIOMARKERS, V6, P313.
   STYCZYNSKI PB, 1993, CHEM RES TOXICOL, V6, P846, DOI 10.1021/tx00036a014.
   Tanga MJ, 2001, J LABELLED COMPD RAD, V44, P405, DOI 10.1002/jlcr.468.
   THOMPSON LH, 1987, MUTAGENESIS, V2, P483, DOI 10.1093/mutage/2.6.483.
   THOMPSON LH, 1983, MUTAT RES, V117, P243, DOI 10.1016/0165-1218(83)90125-8.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P1843.
   Winsten J. A., 1977, ORIGINS HUMAN CANC, P1561.
   WU RW, 1995, CARCINOGENESIS, V16, P1207, DOI 10.1093/carcin/16.5.1207.
   Zheng W, 1998, J NATL CANCER I, V90, P1724, DOI 10.1093/jnci/90.22.1724.
   Zheng W, 2001, CANCER EPIDEM BIOMAR, V10, P89.
   Zheng W, 2002, BREAST CANCER RES TR, V74, P9, DOI 10.1023/A:1016005100958.}},
Number-of-Cited-References = {{72}},
Times-Cited = {{28}},
Journal-ISO = {{J. Chromatogr. B}},
Doc-Delivery-Number = {{778NY}},
Wos-Id = {{ISI:000189248700017}},
}

@article{ ISI:000189248700018,
Author = {Turesky, RJ and Vouros, P},
Title = {{Formation and analysis of heterocyclic aromatic amine-DNA adducts in
   vitro and in vivo}},
Journal = {{JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
   AND LIFE SCIENCES}},
Year = {{2004}},
Volume = {{802}},
Number = {{1}},
Pages = {{155-166}},
Month = {{MAR 25}},
Abstract = {{The detection and quantification of heterocyclic aromatic amine
   (HAA)-DNA adducts, critical biomarkers in interspecies extrapolation of
   toxicity data for human risk assessment, remains a challenging
   analytical problem. The two main analytical methods currently in use to
   screen for HAA-DNA adducts are the P-32-postlabeling assay and mass
   spectrometry, using either accelerated mass spectrometry (AMS) or liquid
   chromatography and electrospray ionization mass spectrometry
   (LC-ESI-MS). In this review, the principal methods to synthesize and
   characterize DNA adducts, and the methods applied to measure HAA-DNA
   adduct in vitro and vivo are discussed. (C) 2003 Elsevier B.V. All
   rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Turesky, RJ (Reprint Author), Natl Ctr Toxicol Res, Div Chem, 3900 NCTR Rd, Jefferson, AR 72079 USA.
   Natl Ctr Toxicol Res, Div Chem, Jefferson, AR 72079 USA.
   Northeastern Univ, Dept Chem, Boston, MA 02115 USA.
   Northeastern Univ, Barnett Inst, Boston, MA 02115 USA.}},
DOI = {{10.1016/j.jchromb.2003.10.053}},
ISSN = {{1570-0232}},
Keywords = {{reviews; heterocyclic aromatic amine-DNA adducts; DNA}},
Keywords-Plus = {{CHROMATOGRAPHY/MICROELECTROSPRAY MASS-SPECTROMETRY; MAMMARY
   EPITHELIAL-CELLS; FOOD-BORNE CARCINOGEN; P-32 POSTLABELING METHOD;
   POST-LABELING ANALYSIS; N-ACETOXY DERIVATIVES; MEA-ALPHA-C;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP;
   ELECTROSPRAY-IONIZATION; METABOLIC-ACTIVATION}},
Research-Areas = {{Biochemistry \& Molecular Biology; Chemistry}},
Web-of-Science-Categories  = {{Biochemical Research Methods; Chemistry, Analytical}},
Author-Email = {{rturesky@nctr.fda.gov}},
Cited-References = {{BEACH AC, 1992, CARCINOGENESIS, V13, P1053, DOI 10.1093/carcin/13.7.1053.
   BELAND FA, 1985, ENVIRON HEALTH PERSP, V62, P19, DOI 10.2307/3430089.
   BOOBIS AR, 1995, HETEROCYCLIC AMINES, P134.
   Boobis AR, 1996, ARCH TOX S, V18, P286.
   Brown K, 2001, NUCLEIC ACIDS RES, V29, P1951, DOI 10.1093/nar/29.9.1951.
   BUTLER MA, 1989, P NATL ACAD SCI USA, V86, P7696, DOI 10.1073/pnas.86.20.7696.
   Crofts FG, 1998, CARCINOGENESIS, V19, P1969, DOI 10.1093/carcin/19.11.1969.
   Crosbie SJ, 2000, J CHROMATOGR B, V744, P55, DOI 10.1016/S0378-4347(00)00227-9.
   CUMMINGS DA, 1994, CARCINOGENESIS, V15, P2623, DOI 10.1093/carcin/15.11.2623.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P2091, DOI 10.1093/carcin/14.10.2091.
   Dingley KH, 1999, CANCER EPIDEM BIOMAR, V8, P507.
   Doerge DR, 1999, CARCINOGENESIS, V20, P1055, DOI 10.1093/carcin/20.6.1055.
   Esmans EL, 1998, J CHROMATOGR A, V794, P109, DOI 10.1016/S0021-9673(97)00902-3.
   FAN LJ, 1995, CARCINOGENESIS, V16, P775, DOI 10.1093/carcin/16.4.775.
   FARMER PB, 1995, J MASS SPECTROM, V30, P1369, DOI 10.1002/jms.1190301002.
   Felton J. S., 2000, Food borne carcinogens: heterocyclic amines., P31.
   Felton J.S., 1990, HDB EXPT PHARM, P471.
   FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315.
   FRANDSEN H, 1994, CARCINOGENESIS, V15, P2553, DOI 10.1093/carcin/15.11.2553.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   Friesen MD, 1996, CARCINOGENESIS, V17, P67, DOI 10.1093/carcin/17.1.67.
   FUKUTOME K, 1994, JPN J CANCER RES, V85, P113.
   Gangl ET, 1999, CHEM RES TOXICOL, V12, P1019, DOI 10.1021/tx990060m.
   Gangl ET, 2001, ANAL CHEM, V73, P2397, DOI 10.1021/ac0100401.
   GHOSHAL A, 1995, CARCINOGENESIS, V16, P2725, DOI 10.1093/carcin/16.11.2725.
   Goldman R, 2000, CHEM-BIOL INTERACT, V126, P171, DOI 10.1016/S0009-2797(00)00160-5.
   GRIVAS S, 1988, J CHEM RES-S, P84.
   Guengerich FP, 1997, CHEM-BIOL INTERACT, V106, P161, DOI 10.1016/S0009-2797(97)00068-9.
   GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081.
   Andrews CL, 1999, J CHROMATOGR A, V856, P515, DOI 10.1016/S0021-9673(99)00779-7.
   HASHIMOTO Y, 1982, MUTAT RES, V105, P9, DOI 10.1016/0165-7992(82)90200-7.
   HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007.
   HIROSE M, 1995, JPN J CANCER RES, V86, P516.
   Josephy PD, 1996, MUTAGENESIS, V11, P3, DOI 10.1093/mutage/11.1.3.
   KADERLIK KR, 1995, PHARMACOGENETICS, V5, pS108, DOI 10.1097/00008571-199512001-00011.
   King R.S., 2000, FOOD BORNE CARCINOGE, P90.
   Lawson T, 2002, CANCER LETT, V175, P141, DOI 10.1016/S0304-3835(01)00732-7.
   Lightfoot TJ, 2000, MUTAT RES-GEN TOX EN, V472, P119, DOI 10.1016/S1383-5718(00)00134-0.
   LIN DX, 1994, ENVIRON HEALTH PERSP, V102, P11, DOI 10.2307/3432144.
   LIN DX, 1994, CANCER RES, V54, P4920.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MILLER EC, 1978, CANCER RES, V38, P1479.
   NAGAO M, 1993, MUTAT RES, V290, P43, DOI 10.1016/0027-5107(93)90031-A.
   Nagao M., 2000, Food borne carcinogens: heterocyclic amines., P163.
   Nelson CP, 2001, CANCER RES, V61, P103.
   NORDHOFF E, 1994, NUCLEIC ACIDS RES, V22, P2460, DOI 10.1093/nar/22.13.2460.
   OCHIAI M, 1993, CARCINOGENESIS, V14, P2165, DOI 10.1093/carcin/14.10.2165.
   Ochiai M, 1999, MUTAGENESIS, V14, P239, DOI 10.1093/mutage/14.2.239.
   Paehler A, 2002, CHEM RES TOXICOL, V15, P551, DOI 10.1021/tx010178e.
   Pfau W, 1997, MUTAT RES-FUND MOL M, V378, P13, DOI 10.1016/S0027-5107(97)00093-6.
   Pfau W, 1996, CARCINOGENESIS, V17, P2727, DOI 10.1093/carcin/17.12.2727.
   Pfau W, 1997, CHEM RES TOXICOL, V10, P1192, DOI 10.1021/tx9701182.
   PFAU W, 1992, CARCINOGENESIS, V13, P907, DOI 10.1093/carcin/13.5.907.
   PFAU W, 1994, CARCINOGENESIS, V15, P877, DOI 10.1093/carcin/15.5.877.
   Phillips DH, 1997, MUTAT RES-FUND MOL M, V378, P1, DOI 10.1016/S0027-5107(97)00092-4.
   Phillips DH, 2000, ENVIRON MOL MUTAGEN, V35, P222, DOI 10.1002/(SICI)1098-2280(2000)35:3<222::AID-EM9>3.0.CO;2-E.
   Phillips DH, 1999, MUTAGENESIS, V14, P301, DOI 10.1093/mutage/14.3.301.
   POIRIER MC, 1992, CHEM RES TOXICOL, V5, P749, DOI 10.1021/tx00030a003.
   RANDERATH K, 1985, ENVIRON HEALTH PERSP, V62, P57, DOI 10.2307/3430093.
   RINDGEN D, 1995, CHEM RES TOXICOL, V8, P1005, DOI 10.1021/tx00050a003.
   Sadrieh N, 1996, CANCER RES, V56, P2683.
   SANTELLA RM, 1983, ENVIRON HEALTH PERSP, V49, P107, DOI 10.2307/3429587.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   SCHUT HAJ, 1994, CARCINOGENESIS, V15, P1467, DOI 10.1093/carcin/15.7.1467.
   SCHUT HAJ, 1991, CARCINOGENESIS, V12, P931, DOI 10.1093/carcin/12.5.931.
   Shibutani S, 1999, J BIOL CHEM, V274, P27433, DOI 10.1074/jbc.274.39.27433.
   Shimada T, 1996, CANCER RES, V56, P2979.
   SHIMADA T, 1989, CANCER RES, V49, P3218.
   Shirai T, 1997, CANCER RES, V57, P195.
   Shirai T, 2002, TOXICOLOGY, V181, P89, DOI 10.1016/S0300-483X(02)00260-3.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1061, DOI 10.1093/carcin/9.6.1061.
   Snyderwine EG, 1998, RECENT RES CANCER, V152, P3.
   Snyderwine EG, 2002, FOOD CHEM TOXICOL, V40, P1529, DOI 10.1016/S0278-6915(02)00110-2.
   Snyderwine E. G., 2000, Food borne carcinogens: heterocyclic amines., P131.
   Soglia JR, 2001, ANAL CHEM, V73, P2819, DOI 10.1021/ac010218j.
   STONE JG, 1995, CANCER RES, V55, P1267.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   TADA A, 1994, CARCINOGENESIS, V15, P1275, DOI 10.1093/carcin/15.6.1275.
   THORGEIRSSON SS, 1995, HETEROCYCLIC AMINES, P85.
   Totsuka Y, 1996, CARCINOGENESIS, V17, P1029, DOI 10.1093/carcin/17.5.1029.
   Turesky RJ, 1996, CHEM RES TOXICOL, V9, P403, DOI 10.1021/tx950132j.
   Turesky RJ, 1997, MUTAT RES-FUND MOL M, V376, P235, DOI 10.1016/S0027-5107(97)00048-1.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P925, DOI 10.1021/tx980022n.
   TURESKY RJ, 1994, DNA ADDUCTS IDENTIFI, P217.
   Turesky RJ, 1996, CHEM RES TOXICOL, V9, P397, DOI 10.1021/tx950131r.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005.
   Turesky RJ, 1999, CANCER LETT, V143, P109, DOI 10.1016/S0304-3835(99)00137-8.
   TURESKY RJ, 1994, CHEM RES TOXICOL, V7, P752, DOI 10.1021/tx00042a007.
   Turteltaub KW, 1997, MUTAT RES-FUND MOL M, V376, P243, DOI 10.1016/S0027-5107(97)00049-3.
   TURTELTAUB KW, 1990, P NATL ACAD SCI USA, V87, P5288, DOI 10.1073/pnas.87.14.5288.
   Vanhoutte K, 1997, ANAL CHEM, V69, P3161, DOI 10.1021/ac970121q.
   Wang ZW, 2001, ORG LETT, V3, P565, DOI 10.1021/ol006968h.
   WESTRA JG, 1981, CARCINOGENESIS, V2, P355, DOI 10.1093/carcin/2.4.355.
   WILD D, 1989, CARCINOGENESIS, V10, P335, DOI 10.1093/carcin/10.2.335.
   WILD D, 1991, CARCINOGENESIS, V12, P1091, DOI 10.1093/carcin/12.6.1091.
   Williams JA, 1998, PHARMACOGENETICS, V8, P519, DOI 10.1097/00008571-199812000-00009.
   Williams JA, 2000, MUTAGENESIS, V15, P149, DOI 10.1093/mutage/15.2.149.
   WOLF SM, 1994, CHEM RES TOXICOL, V7, P82, DOI 10.1021/tx00037a013.
   Yamazoe Y., 2000, FOOD BORNE CARCINOGE, P74.
   ZU HX, 1991, CANCER RES, V51, P5636.}},
Number-of-Cited-References = {{102}},
Times-Cited = {{57}},
Journal-ISO = {{J. Chromatogr. B}},
Doc-Delivery-Number = {{778NY}},
Wos-Id = {{ISI:000189248700018}},
}

@article{ ISI:000186619300002,
Author = {Magagnotti, C and Pastorelli, R and Pozzi, S and Andreoni, B and
   Fanelli, R and Airoldi, L},
Title = {{Genetic polymorphisms and modulation of
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP)-DNA adducts in
   human lymphocytes}},
Journal = {{INTERNATIONAL JOURNAL OF CANCER}},
Year = {{2003}},
Volume = {{107}},
Number = {{6}},
Pages = {{878-884}},
Month = {{DEC 20}},
Abstract = {{2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) is the most
   abundant heterocyclic amine derived from food, possibly involved in
   human carcinogenesis. We evaluated the formation of PhIP-DNA adducts in
   lymphocytes from 76 incident colorectal cancer patients likely to be
   exposed to dietary PhIP. To address the role of the metabolic
   polymorphisms relevant to PhIP-DNA adduct formation, the patients were
   genotyped for common polymorphisms in the N-acetyl-transferase (NAT1 and
   NAT2), sulfotransferase (SULTIA1) and glutathione S-transferase (GSTM1
   and GSTA1) genes. PhIP released from adducted DNA after hydrolysis was
   quantitated by liquid chromatography-tandem mass spectrometry. Overall,
   adducts were 3.24 +/- 3.58/10(8) nucleotides (mean +/- SD); they were
   not related to sex, smoking habits or age, though levels were not
   significantly higher in smokers, young subjects and high meat consumers.
   High vegetable intake significantly reduced PhIP-DNA adducts
   (Mann-Whitney U, p = 0.044). Individuals with the GSTM1 null genotype
   showed colon cancer onset at earlier age (58.8 +/- 1.8 vs. 63.5 +/- 1.6
   years; Mann-Whitney U, p = 0.047). None of the genetic polymorphisms
   studied significantly affected PhIP-DNA adducts. However, individuals
   carrying 2 mutated GSTA1 alleles and younger than the median age had
   higher adduct levels than homozygous wild-type and heterozygous ones
   (Kruskal-Wallis p = 0.0008). In conclusion, these preliminary data
   indicate that PhIP-DNA adducts are formed in people likely to be exposed
   to this carcinogen through the diet, suggesting this biomarker may be
   useful to detect human exposure and DNA damage. Overall, the genetic
   polymorphisms considered had limited effect on PhIP-DNA levels, but
   young people with lower detoxification capacity may form a subgroup
   particularly susceptible to dietary carcinogen. (C) 2003 Wiley-Liss,
   Inc.}},
Publisher = {{WILEY-LISS}},
Address = {{DIV JOHN WILEY \& SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Airoldi, L (Reprint Author), Ist Ric Farmacol Mario Negri, Dept Environm Hlth Sci, Via Eritrea 62, I-20157 Milan, Italy.
   Ist Ric Farmacol Mario Negri, Dept Environm Hlth Sci, I-20157 Milan, Italy.
   European Inst Oncol, Div Gen Surg, Milan, Italy.
   Univ Milan, Sch Med, Milan, Italy.}},
DOI = {{10.1002/ijc.11492}},
ISSN = {{0020-7136}},
Keywords = {{PhIP; DNA adducts; genetic polymorphism; liquid chromatography-tandem
   mass spectrometry}},
Keywords-Plus = {{S-TRANSFERASE M1; CARCINOGENIC HETEROCYCLIC AMINES; FOOD-BORNE
   CARCINOGEN; COLORECTAL-CANCER; DNA-ADDUCTS; BLADDER-CANCER;
   COLON-CANCER; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP;
   IN-VITRO; VEGETABLE CONSUMPTION}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
ResearcherID-Numbers = {{pozzi, samantha/A-7617-2012}},
Cited-References = {{Airoldi L, 2002, CARCINOGENESIS, V23, P861, DOI 10.1093/carcin/23.5.861.
   BADAWI AF, 1995, CANCER RES, V55, P5230.
   Bamber DE, 2001, PHARMACOGENETICS, V11, P679, DOI 10.1097/00008571-200111000-00006.
   BELL DA, 1995, CANCER RES, V55, P3537.
   BELL DA, 1993, J NATL CANCER I, V85, P1159, DOI 10.1093/jnci/85.14.1159.
   Bruhn C, 1999, BIOCHEM PHARMACOL, V58, P1759, DOI 10.1016/S0006-2952(99)00269-5.
   Cascorbi I, 2001, CANCER RES, V61, P5051.
   Cascorbi I, 1999, DRUG METAB REV, V31, P489, DOI 10.1081/DMR-100101932.
   Chen J, 1998, CANCER RES, V58, P3307.
   CHENEVIXTRENCH G, 1995, CARCINOGENESIS, V16, P1655, DOI 10.1093/carcin/16.7.1655.
   Coles B, 2001, MUTAT RES-FUND MOL M, V482, P3, DOI 10.1016/S0027-5107(01)00187-7.
   COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605.
   Coles BF, 2001, PHARMACOGENETICS, V11, P663, DOI 10.1097/00008571-200111000-00004.
   Coughtrie MWH, 1999, BIOCHEM J, V337, P45, DOI 10.1042/0264-6021:3370045.
   Crosbie SJ, 2000, J CHROMATOGR B, V744, P55, DOI 10.1016/S0378-4347(00)00227-9.
   Dingley KH, 1999, CANCER EPIDEM BIOMAR, V8, P507.
   Frame LT, 1997, ENVIRON TOXICOL PHAR, V4, P277, DOI 10.1016/S1382-6689(97)10023-0.
   Friesen MD, 1996, CARCINOGENESIS, V17, P67, DOI 10.1093/carcin/17.1.67.
   Gertig DM, 1998, CANCER EPIDEM BIOMAR, V7, P1001.
   Gil JP, 1998, CARCINOGENESIS, V19, P37, DOI 10.1093/carcin/19.1.37.
   Hein DW, 2000, PHARMACOGENETICS, V10, P291, DOI 10.1097/00008571-200006000-00002.
   Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29.
   Hubbard AL, 1998, BRIT J CANCER, V77, P913, DOI 10.1038/bjc.1998.151.
   Hughes NC, 1998, PHARMACOGENETICS, V8, P55, DOI 10.1097/00008571-199802000-00008.
   Kampman E, 1999, CANCER EPIDEM BIOMAR, V8, P15.
   Knize MG, 2002, MUTAT RES-FUND MOL M, V506, P153, DOI 10.1016/S0027-5107(02)00162-8.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   LIN DX, 1994, CANCER RES, V54, P4920.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   Magagnotti C, 2000, INT J CANCER, V88, P1, DOI 10.1002/1097-0215(20001001)88:1<1::AID-IJC1>3.0.CO;2-D.
   Malaveille C, 1996, CARCINOGENESIS, V17, P2193, DOI 10.1093/carcin/17.10.2193.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   Murray S, 2001, CARCINOGENESIS, V22, P1413, DOI 10.1093/carcin/22.9.1413.
   NELSON HH, 1995, CARCINOGENESIS, V16, P1243, DOI 10.1093/carcin/16.5.1243.
   Okkels H, 1997, CANCER EPIDEM BIOMAR, V6, P225.
   Palli D, 2000, INT J CANCER, V87, P444, DOI 10.1002/1097-0215(20000801)87:3<444::AID-IJC21>3.0.CO;2-\#.
   Pastorelli R, 2002, INT J CANCER, V100, P9, DOI 10.1002/ijc.10463.
   Peluso M, 2000, CARCINOGENESIS, V21, P183, DOI 10.1093/carcin/21.2.183.
   Perera FP, 2002, CARCINOGENESIS, V23, P1641, DOI 10.1093/carcin/23.10.1641.
   Potter JD, 1996, IARC SCI PUBL, V139, P61.
   Potter JD, 1999, J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916.
   Raftogianis RB, 1999, BIOCHEM PHARMACOL, V58, P605, DOI 10.1016/S0006-2952(99)00145-8.
   RINDGEN D, 1995, CHEM RES TOXICOL, V8, P1005, DOI 10.1021/tx00050a003.
   Sachse C, 2002, CARCINOGENESIS, V23, P1839, DOI 10.1093/carcin/23.11.1839.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1.
   Slattery ML, 2000, CANCER CAUSE CONTROL, V11, P1, DOI 10.1023/A:1008913619957.
   SNYDERWINE EG, 1994, CARCINOGENESIS, V15, P2757, DOI 10.1093/carcin/15.12.2757.
   Stillwell WG, 2002, CARCINOGENESIS, V23, P831, DOI 10.1093/carcin/23.5.831.
   Stillwell WG, 1999, CANCER LETT, V143, P145, DOI 10.1016/S0304-3835(99)00144-5.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   Tang DL, 2001, CANCER RES, V61, P6708.
   Vineis P, 2000, INT J CANCER, V88, P325, DOI 10.1002/1097-0215(20001101)88:3<325::AID-IJC1>3.0.CO;2-K.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   Wu Q, 1995, NUCLEIC ACIDS RES, V23, P5087, DOI 10.1093/nar/23.24.5087.
   Ye Z, 2002, TERATOGEN CARCIN MUT, V22, P385, DOI 10.1002/tcm.10035.
   Zheng W, 2001, CANCER EPIDEM BIOMAR, V10, P89.
   ZHONG S, 1993, CARCINOGENESIS, V14, P1821, DOI 10.1093/carcin/14.9.1821.}},
Number-of-Cited-References = {{59}},
Times-Cited = {{29}},
Journal-ISO = {{Int. J. Cancer}},
Doc-Delivery-Number = {{744GJ}},
Wos-Id = {{ISI:000186619300002}},
}

@article{ ISI:000187219100006,
Author = {Bacon, JR and Williamson, G and Garner, RC and Lappin, G and Langouet, S
   and Bao, YP},
Title = {{Sulforaphane and quercetin modulate PhIP-DNA adduct formation in human
   HepG2 cells and hepatocytes}},
Journal = {{CARCINOGENESIS}},
Year = {{2003}},
Volume = {{24}},
Number = {{12}},
Pages = {{1903-1911}},
Month = {{DEC}},
Abstract = {{The formation of DNA adducts in human HepG2 cells and human hepatocytes
   exposed to C-14-labelled
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) was examined
   using Accelerator Mass Spectrometry (AMS). PhIP generated DNA adducts in
   a linear dose-dependent manner between 100 pM and 20 muM. Co-treatment
   with the dietary isothiocyanate, sulforaphane (SFN, 1-10 muM), or the
   flavonoid, quercetin (5-20 muM), significantly reduced the level of
   PhIP-DNA adducts in a dose-dependent manner. The degree of protection
   was dependent on PhIP concentration, i.e. after 100 pM PhIP exposure,
   SFN or quercetin reduced adduct levels to below the limit of detection
   (0.15 amol PhIP/mug DNA) but at higher PhIP exposure (10 nM and 1 muM),
   the protection was 60 and 10\%, respectively. The involvement of phase
   I, phase II and DNA repair enzymes in this protection against PhIP-DNA
   adduct formation was investigated using real-time RT-PCR and enzyme
   activity assays. In intact HepG2 cells, quercetin inhibited cytochrome
   P450 (CYP)1A2, the main phase I enzyme responsible for PhIP
   bioactivation. In contrast, SFN induced phase II detoxification enzymes,
   UDP-glucuronosyltransferase 1A1 and glutathione S-transferase A1 mRNA
   expression. SFN and quercetin showed no effect on DNA repair, neither in
   terms of the level of PhIP-DNA adducts, when cells were treated with
   phytochemicals after the carcinogen exposure, nor the regulation of mRNA
   expression of two DNA repair enzymes, apurinic endonuclease and DNA
   polymerase beta. This study indicates that dietary isothiocyanates and
   flavonoids modulate phase I and phase II enzyme expression, hence
   increasing the rate of detoxification of the dietary carcinogen PhIP in
   human HepG2 cells but do not affect the rate of PhIP-DNA adduct repair.
   The formation of PhIP-DNA adducts in human hepatocytes was also
   dose-dependent with PhIP-concentration and the levels of protection by
   SFN or quercetin were up to 60\% after 10 nM PhIP treatment, but showed
   large inter-individual variation with no observed protection in some
   individuals.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bao, YP (Reprint Author), Inst Food Res, Norwich Res Pk, Norwich NR4 7UA, Norfolk, England.
   Inst Food Res, Norwich NR4 7UA, Norfolk, England.
   Xceleron Ltd, York Bioctr, York YO10 5NY, N Yorkshire, England.
   Univ Rennes 1, Fac Pharm, INSERM, U456, F-35043 Rennes, France.}},
DOI = {{10.1093/carcin/bgg157}},
ISSN = {{0143-3334}},
Keywords-Plus = {{ACCELERATOR MASS-SPECTROMETRY; FOOD-BORNE CARCINOGEN; BASE
   EXCISION-REPAIR; FEMALE F344 RATS; HETEROCYCLIC AMINES; POLYMERASE BETA;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; CHEMOPREVENTIVE
   AGENT; APURINIC ENDONUCLEASE; GLUTATHIONE CONJUGATE}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Author-Email = {{yongping.bao@bbsrc.ac.uk}},
ResearcherID-Numbers = {{Williamson, Gary/C-9684-2010
   Bao, Yongping/A-6951-2010}},
Cited-References = {{Abalea V, 1999, FREE RADICAL BIO MED, V26, P1457, DOI 10.1016/S0891-5849(99)00010-6.
   Alexander J, 2002, FOOD CHEM TOXICOL, V40, P1131, DOI 10.1016/S0278-6915(02)00053-4.
   ALEXANDER J, 1991, CARCINOGENESIS, V12, P2239, DOI 10.1093/carcin/12.12.2239.
   Barker J, 1999, RAPID COMMUN MASS SP, V13, P285, DOI 10.1002/(SICI)1097-0231(19990228)13:4<285::AID-RCM469>3.0.CO;2-R.
   Basten GP, 2002, CARCINOGENESIS, V23, P1399, DOI 10.1093/carcin/23.8.1399.
   Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166.
   Bonnesen C, 2001, CANCER RES, V61, P6120.
   BRADFORD M, 1906, ANAL BIOCHEM, V72, P248.
   Brown K, 2001, P NATL ACAD SCI USA, V98, P8507, DOI 10.1073/pnas.151251898.
   Cabelof DC, 2002, CARCINOGENESIS, V23, P1419, DOI 10.1093/carcin/23.9.1419.
   Canitrot Y, 2000, FASEB J, V14, P1765, DOI 10.1096/fj.99-1063com.
   Dingley KH, 1998, CHEM RES TOXICOL, V11, P1217, DOI 10.1021/tx9801458.
   DONATO MT, 1993, ANAL BIOCHEM, V213, P29, DOI 10.1006/abio.1993.1381.
   DOOSTDAR H, 1988, FEBS LETT, V241, P15, DOI 10.1016/0014-5793(88)81021-4.
   FAN LJ, 1995, CARCINOGENESIS, V16, P775, DOI 10.1093/carcin/16.4.775.
   Frandsen H, 2000, CARCINOGENESIS, V21, P1197, DOI 10.1093/carcin/21.6.1197.
   Frandsen H, 1997, CARCINOGENESIS, V18, P1555, DOI 10.1093/carcin/18.8.1555.
   GHOSHAL A, 1995, CARCINOGENESIS, V16, P2725, DOI 10.1093/carcin/16.11.2725.
   GOMEZLECHON MJ, 1990, IN VITRO CELL DEV B, V26, P67.
   Gooderham NJ, 1997, MUTAT RES-FUND MOL M, V376, P53, DOI 10.1016/S0027-5107(97)00025-0.
   Grosch S, 1998, CANCER RES, V58, P4410.
   GUGUENGUILLOUZO C, 1982, CELL BIOL INT REP, V6, P625, DOI 10.1016/0309-1651(82)90187-4.
   Hammons GJ, 1999, NUTR CANCER, V33, P46.
   He YH, 2000, FOOD CHEM TOXICOL, V38, P15, DOI 10.1016/S0278-6915(99)00117-9.
   Hirose M, 1999, FOOD CHEM TOXICOL, V37, P985, DOI 10.1016/S0278-6915(99)00092-7.
   Hirose M, 2002, ENVIRON MOL MUTAGEN, V39, P271, DOI 10.1002/em.10066.
   Huber WW, 1997, MUTAT RES-FUND MOL M, V376, P115, DOI 10.1016/S0027-5107(97)00033-X.
   Klein JC, 2001, CARCINOGENESIS, V22, P619, DOI 10.1093/carcin/22.4.619.
   Knasmuller S, 1999, MUTAGENESIS, V14, P533, DOI 10.1093/mutage/14.6.533.
   Knize MG, 2002, MUTAT RES-FUND MOL M, V506, P153, DOI 10.1016/S0027-5107(02)00162-8.
   Knize MG, 1997, MUTAT RES-FUND MOL M, V376, P129, DOI 10.1016/S0027-5107(97)00035-3.
   Langouet S, 2002, CARCINOGENESIS, V23, P115, DOI 10.1093/carcin/23.1.115.
   Langouet S, 2000, CHEM RES TOXICOL, V13, P245, DOI 10.1021/tx990189w.
   Langouet S, 2001, CHEM RES TOXICOL, V14, P211, DOI 10.1021/tx000176e.
   LAPPIN G, 2003, BIOANALYTICAL SEPARA, V4, P331, DOI 10.1016/S1567-7192(03)80012-8.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   Lightfoot TJ, 2000, MUTAT RES-GEN TOX EN, V472, P119, DOI 10.1016/S1383-5718(00)00134-0.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.034858100.
   Maheo K, 1997, CANCER RES, V57, P3649.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   Murray S, 2001, CARCINOGENESIS, V22, P1413, DOI 10.1093/carcin/22.9.1413.
   Nowell SA, 1999, CARCINOGENESIS, V20, P1107, DOI 10.1093/carcin/20.6.1107.
   O'Leary KA, 2003, BIOCHEM PHARMACOL, V65, P479, DOI 10.1016/S0006-2952(02)01510-1.
   ONO K, 1990, EUR J BIOCHEM, V190, P469, DOI 10.1111/j.1432-1033.1990.tb15597.x.
   Poirier MC, 2000, CARCINOGENESIS, V21, P353, DOI 10.1093/carcin/21.3.353.
   Reid JM, 1999, CLIN CANCER RES, V5, P2192.
   Runge D, 2000, BIOCHEM BIOPH RES CO, V273, P333, DOI 10.1006/bbrc.2000.2902.
   Scalbert A, 2000, J NUTR, V130, p2073S.
   Schut HAJ, 2000, NUTR CANCER, V36, P52, DOI 10.1207/S15327914NC3601\_8.
   Shibutani S, 1999, J BIOL CHEM, V274, P27433, DOI 10.1074/jbc.274.39.27433.
   SINHA R, 1995, CANCER RES, V55, P4516.
   Sinha R, 2000, J NATL CANCER I, V92, P1352, DOI 10.1093/jnci/92.16.1352.
   Skog K, 2002, FOOD CHEM TOXICOL, V40, P1197, DOI 10.1016/S0278-6915(02)00052-2.
   Stillwell WG, 2002, CARCINOGENESIS, V23, P831, DOI 10.1093/carcin/23.5.831.
   Sugimura T, 2000, CARCINOGENESIS, V21, P387, DOI 10.1093/carcin/21.3.387.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P217, DOI 10.1021/tx9701891.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   Webster RP, 1996, CANCER LETT, V109, P185, DOI 10.1016/S0304-3835(96)04443-6.
   WU RW, 1995, CARCINOGENESIS, V16, P1207, DOI 10.1093/carcin/16.5.1207.
   Ye LX, 2002, CLIN CHIM ACTA, V316, P43, DOI 10.1016/S0009-8981(01)00727-6.}},
Number-of-Cited-References = {{61}},
Times-Cited = {{53}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{753EL}},
Wos-Id = {{ISI:000187219100006}},
}

@article{ ISI:000184635500050,
Author = {Arimoto-Kobayashi, S and Inada, N and Sato, Y and Sugiyama, C and
   Okamoto, K and Hayatsu, H and Negishi, T},
Title = {{Inhibitory effects of (-)-epigallocatechin gallate on the mutation, DNA
   strand cleavage, and DNA adduct formation by heterocyclic amines}},
Journal = {{JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY}},
Year = {{2003}},
Volume = {{51}},
Number = {{17}},
Pages = {{5150-5153}},
Month = {{AUG 13}},
Abstract = {{Green tea is known to be a potential chemopreventive agent against
   cancer. In this study, we investigated the inhibitory activities of tea
   extracts, and in particular the polyphenolic component
   (-)epigallocatechin gallate (EGCG), against heterocyclic amine-induced
   genotoxicity. The tea extracts displayed inhibition of
   2-hydroxyamino-6-methyldipyrido{[}1,2-a,3',2'-d]imidazole
   (Glu-P-1(NHOH))-induced mutagenicity. This inhibition can be accounted
   for by the presence of EGCG in the extracts. The mutagenic effect of
   Glu-P-1 (NHOH), which induces single-strand cleavage in supercoiled
   circular DNA under neutral conditions, was inhibited by EGCG. Using the
   Drosophila repair test, a test for gross DNA damage, and DNA adduct
   detection by P-32-postlabeling, we showed that EGCG prevented
   2-amino-3,8-dimethylimidazo{[}4,5-f]quinoline-induced DNA damage and
   adduct formation in insect DNA. EGCG was found to accelerate the
   degradation of Glu-P-1 (NHOH) in vitro. This observation suggested that
   the inhibition by EGCG is associated with an accelerated degradation of
   metabolically activated heterocyclic amines.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Arimoto-Kobayashi, S (Reprint Author), Okayama Univ, Fac Pharmaceut Sci, 1-1-1 Tsushima, Okayama 7008530, Japan.
   Okayama Univ, Fac Pharmaceut Sci, Okayama 7008530, Japan.}},
DOI = {{10.1021/jf0302761}},
ISSN = {{0021-8561}},
Keywords = {{green tea; epigallocatechin gallate; heterocyclic arnines; DNA strand
   break; antimutagenicity; DNA adduct; Drosophila}},
Keywords-Plus = {{GREEN TEA; F344 RATS; CARCINOGENS; SALMONELLA; MUTAGENICITIES;
   DERIVATIVES; DROSOPHILA}},
Research-Areas = {{Agriculture; Chemistry; Food Science \& Technology}},
Web-of-Science-Categories  = {{Agriculture, Multidisciplinary; Chemistry, Applied; Food Science \&
   Technology}},
Cited-References = {{ARIMOTO S, 1987, MUTAT RES, V192, P253, DOI 10.1016/0165-7992(87)90065-0.
   Arimoto-Kobayashi S, 1999, J AGR FOOD CHEM, V47, P221, DOI 10.1021/jf980685a.
   Brown M D, 1999, Altern Med Rev, V4, P360.
   BUABBAS A, 1994, MUTAGENESIS, V9, P325, DOI 10.1093/mutage/9.4.325.
   Embola CW, 2002, FOOD CHEM TOXICOL, V40, P841, DOI 10.1016/S0278-6915(02)00022-4.
   FUJIKAWA K, 1988, J FOOD HYG SOC JPN, V29, P115.
   Fujiki H, 1998, MUTAT RES-FUND MOL M, V402, P307, DOI 10.1016/S0027-5107(97)00310-2.
   HAYATSU H, 1992, PREV MED, V21, P370, DOI 10.1016/0091-7435(92)90044-I.
   Johnson MK, 2000, MUTAT RES-DNA REPAIR, V459, P211, DOI 10.1016/S0921-8777(99)00074-9.
   MARON DM, 1984, HDB MUTAGENICITY TES, P93.
   OCHIAI M, 1993, CARCINOGENESIS, V14, P2165, DOI 10.1093/carcin/14.10.2165.
   SAITO K, 1983, CARCINOGENESIS, V4, P1547, DOI 10.1093/carcin/4.12.1547.
   Santana-Rios G, 2001, MUTAT RES-GEN TOX EN, V495, P61, DOI 10.1016/S1383-5718(01)00200-5.
   Schut HAJ, 2000, NUTR CANCER, V36, P52, DOI 10.1207/S15327914NC3601\_8.
   Stoner G D, 1995, J Cell Biochem Suppl, V22, P169.
   Sugimura T, 2000, CARCINOGENESIS, V21, P387, DOI 10.1093/carcin/21.3.387.
   Sugiyama C, 1996, JPN J CANCER RES, V87, P325.
   WAKATA A, 1985, CANCER RES, V45, P5867.
   YAHAGI T, 1977, MUTAT RES, V48, P121, DOI 10.1016/0027-5107(77)90151-8.
   Yoshizawa S, 1987, PHYTOTHER RES, V1, P44, DOI 10.1002/ptr.2650010110.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{15}},
Journal-ISO = {{J. Agric. Food Chem.}},
Doc-Delivery-Number = {{709QH}},
Wos-Id = {{ISI:000184635500050}},
}

@article{ ISI:000181733900020,
Author = {Lin, DX and Thompson, PA and Teitel, C and Chen, JS and Kadlubar, FF},
Title = {{Direct reduction of N-acetoxy-PhIP by tea polyphenols: a possible
   mechanism for chemoprevention against PhIP-DNA adduct formation}},
Journal = {{MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS}},
Year = {{2003}},
Volume = {{523}},
Number = {{SI}},
Pages = {{193-200}},
Month = {{FEB-MAR}},
Note = {{Conference on Dietary and Medicinal Antimutagens and Anticarcinogens -
   Molecular Mechanisms and Chempreventive Potential, SEOUL, SOUTH KOREA,
   OCT 17-19, 2001}},
Abstract = {{The chemopreventive effect of tea against
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP)-DNA adduct
   formation and its mechanism were studied. Rats were exposed to freshly
   prepared aqueous extracts of green tea (3\% (w/v)) as the sole source of
   drinking water for 10 days prior to administration with a single dose of
   PhIP (10 mg/kg body weight) by oral gavage. PhIP-DNA adducts in the
   liver, colon, heart, and lung were measured using the P-32-postlabelling
   technique. Rats pre-treated with tea and given PhIP 20 h before
   sacrifice had significantly reduced levels of PhIP-DNA adducts as
   compared with controls given PhIP alone. The possible mechanism of
   protective effect of tea on PhIP-DNA adduct formation was then examined
   in vitro. It was found that an aqueous extract of green and black tea,
   mixtures of green and black tea polyphenols, as well as purified
   polyphenols could strongly inhibit the DNA binding of N-acetoxy-PhIP, a
   putative ultimate carcinogen of PhIP formed in vivo via metabolic
   activation. Among these, epigallocatechin gallate was exceptionally
   potent. HPLC analyses of these incubation mixtures containing
   N-acetoxy-PhIP and the tea polyphenols each revealed the production of
   the parent amine, PhIP, indicating the involvement of a redox mechanism.
   In view of the presence of relatively high levels of tea polyphenols in
   rat and human plasma after ingestion of tea, this study suggests that
   direct reduction of the ultimate carcinogen N-acetoxy-PhIP by tea
   polyphenols is likely to be involved in the mechanism of chemoprotection
   of tea against this carcinogen. Published by Elsevier Science B.V.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Kadlubar, FF (Reprint Author), Natl Ctr Toxicol Res, Div Mol Epidemiol, Jefferson, AR 72079 USA.
   Natl Ctr Toxicol Res, Div Mol Epidemiol, Jefferson, AR 72079 USA.
   Beijing Union Med Univ, Chinese Acad Med Sci, Inst Canc, Div Canc Etiol, Beijing 100021, Peoples R China.
   Chinese Acad Prevent Med, Inst Nutr \& Food Hyg, Beijing 100050, Peoples R China.}},
DOI = {{10.1016/S0027-5107(02)00335-4}},
ISSN = {{0027-5107}},
Keywords = {{chemoprevention; tea polyphenols; heterocyclic amines; foodborne
   carcinogens}},
Keywords-Plus = {{FOOD-BORNE CARCINOGEN; RAT-LIVER MICROSOMES; PHASE-II ENZYMES; GREEN
   TEA; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; BLACK TEA;
   A/J MICE; METABOLIC-ACTIVATION; HETEROCYCLIC AMINES; LUNG TUMORIGENESIS}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Author-Email = {{fkadlubar@nctr.fda.gov}},
Cited-References = {{ALEXANDER J, 1991, CARCINOGENESIS, V12, P2239, DOI 10.1093/carcin/12.12.2239.
   ALEXANDER J, 1989, CARCINOGENESIS, V10, P1543, DOI 10.1093/carcin/10.8.1543.
   BUABBAS A, 1994, CARCINOGENESIS, V15, P2575, DOI 10.1093/carcin/15.11.2575.
   BUABBAS A, 1995, FOOD CHEM TOXICOL, V33, P27, DOI 10.1016/0278-6915(95)00079-8.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   Dingley KH, 1999, CANCER EPIDEM BIOMAR, V8, P507.
   FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   Hammons GJ, 1999, NUTR CANCER, V33, P46.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1695, DOI 10.1093/carcin/15.8.1695.
   KHAN SG, 1992, CANCER RES, V52, P4050.
   LEE MJ, 1995, CANCER EPIDEM BIOMAR, V4, P393.
   LIN DX, 1995, DRUG METAB DISPOS, V23, P518.
   LIN DX, 1994, CANCER RES, V54, P4920.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   NARISAWA T, 1993, JPN J CANCER RES, V84, P1007.
   NIJIHOFF WA, 1993, INT J ONCOL, V3, P1131.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   OKUSHIO N, 1995, BIOL PHARM BULL, V19, P326.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SHI ST, 1994, CANCER RES, V54, P4641.
   SOHN OS, 1994, XENOBIOTICA, V24, P119.
   STEELE CM, 1985, CANCER RES, V45, P3573.
   STYCZYNSKI PB, 1993, CHEM RES TOXICOL, V6, P846, DOI 10.1021/tx00036a014.
   Suganuma M, 1998, CARCINOGENESIS, V19, P1771, DOI 10.1093/carcin/19.10.1771.
   TEPHLY TR, 1990, TRENDS PHARMACOL SCI, V11, P276, DOI 10.1016/0165-6147(90)90008-V.
   TURESKY RJ, 1988, CARCINOGENESIS, V9, P1043, DOI 10.1093/carcin/9.6.1043.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P941, DOI 10.1093/carcin/11.6.941.
   WANG ZY, 1995, CARCINOGENESIS, V16, P2143, DOI 10.1093/carcin/16.9.2143.
   WANG ZY, 1988, DRUG METAB DISPOS, V16, P98.
   WANG ZY, 1992, CANCER RES, V52, P1943.
   WANG ZY, 1989, CARCINOGENESIS, V10, P411, DOI 10.1093/carcin/10.2.411.
   WORTELBOER HM, 1992, FOOD CHEM TOXICOL, V30, P17, DOI 10.1016/0278-6915(92)90132-5.
   Xu M, 1996, CARCINOGENESIS, V17, P1429, DOI 10.1093/carcin/17.7.1429.
   XU Y, 1992, CANCER RES, V52, P3875.}},
Number-of-Cited-References = {{37}},
Times-Cited = {{10}},
Journal-ISO = {{Mutat. Res.-Fundam. Mol. Mech. Mutagen.}},
Doc-Delivery-Number = {{658RH}},
Wos-Id = {{ISI:000181733900020}},
}

@article{ ISI:000186980800015,
Author = {Dingley, KH and Ubick, EA and Chiarappa-Zucca, ML and Nowell, S and
   Abel, S and Ebeler, SE and Mitchell, AE and Burns, SA and Steinberg, FM
   and Clifford, AJ},
Title = {{Effect of dietary constituents with chemopreventive potential on adduct
   formation of a low dose of the heterocyclic amines PhIP and IQ and phase
   II hepatic enzymes}},
Journal = {{NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL}},
Year = {{2003}},
Volume = {{46}},
Number = {{2}},
Pages = {{212-221}},
Abstract = {{We conducted a study to evaluate dietary chemopreventive strategies to
   reduce genotoxic effects of the carcinogens
   2-amino-l-methyl-6-phenyl-imidazo{[}4,5-b]pyridine (PhIP) and
   2-amino-3-methylimidazo{[}4,5-f]quinoline (IQ). PUP and IQ are
   heterocyclic amines (HCAs) that are found in cooked meat and may be risk
   factors for cancer Typical chemoprevention studies have used carcinogen
   doses many thousand-fold higher than usual human daily intake.
   Therefore, we administered a low dose of {[}C-14] PhIP and {[}H-3]IQ and
   utilized accelerator mass spectrometry to quantify PhIP adducts in the
   liver colon,prostate, and blood plasma and IQ adducts in the liver and
   blood plasma with high sensitivity. Diets supplemented with
   phenethylisothiocyanate (PEITC), genistein, chlorophyllin, or lycopene
   were evaluated for their ability to decrease adduct formation of
   {[}C-14]PhIP and {[}H-3]IQ in rats. We also examined the effect of
   treatments on the activity of the phase II detoxification enzymes
   glutathione S-transferase (GST), UDP-glucuronyltransferase (UGT), phenol
   sulfotransferase (SULT) and quinone reductase (QR). PEITC and
   chlorophyllin significantly decreased PhIP-DNA adduct levels in all
   tissues examined, which was reflected by similar changes in PhIP binding
   to albumin in the blood. In contrast, genistein and lycopene tended to
   increase PhIP adduct levels. The treatments did not significantly alter
   the level of IQ-DNA or -protein adducts in the liver With the exception
   of lycopene, the treatments had some effect on the activity of one or
   more hepatic phase II detoxification enzymes. We conclude that PEITC and
   chlorophyllin are protective of PhIP-induced genotoxicity after a low
   exposure dose of carcinogen, possibly through modification of HCA
   metabolism.}},
Publisher = {{LAWRENCE ERLBAUM ASSOC INC}},
Address = {{10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Dingley, KH (Reprint Author), Lawrence Livermore Natl Lab, Biol \& Biotechnol Res Program, L-452, Livermore, CA 94550 USA.
   Lawrence Livermore Natl Lab, Biol \& Biotechnol Res Program, Livermore, CA 94551 USA.
   Lawrence Livermore Natl Lab, Ctr Accelerator Mass Spectrometry, Livermore, CA 94551 USA.
   Lawrence Livermore Natl Lab, Chem Biol \& Nucl Div, Chem \& Mat Sci Directorate, Livermore, CA 94551 USA.
   Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
   Univ Calif Davis, Dept Vegetable Crops, Davis, CA 95616 USA.
   Univ Calif Davis, Dept Viticulture \& Enol, Davis, CA 95616 USA.
   Univ Calif Davis, Dept Food Sci \& Technol, Davis, CA 95616 USA.
   Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA.}},
DOI = {{10.1207/S15327914NC4602\_15}},
ISSN = {{0163-5581}},
Keywords-Plus = {{GLUTATHIONE S-TRANSFERASES; INDUCED MAMMARY CARCINOGENESIS; DNA-ADDUCT;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; BREAST-CANCER;
   UDP-GLUCURONOSYLTRANSFERASES; PHENETHYL ISOTHIOCYANATE;
   METABOLIZING-ENZYMES; ANTIOXIDANT ENZYMES; COLORECTAL-CANCER}},
Research-Areas = {{Oncology; Nutrition \& Dietetics}},
Web-of-Science-Categories  = {{Oncology; Nutrition \& Dietetics}},
Cited-References = {{Astorg P, 1997, NUTR CANCER, V29, P60.
   Augustsson K, 1997, CARCINOGENESIS, V18, P1931, DOI 10.1093/carcin/18.10.1931.
   Autrup H, 2000, MUTAT RES-GEN TOX EN, V464, P65, DOI 10.1016/S1383-5718(99)00167-9.
   Breinholt V, 2000, CANCER LETT, V154, P201, DOI 10.1016/S0304-3835(00)00401-8.
   Breinholt V, 1999, XENOBIOTICA, V29, P1227.
   Chen Z, 1999, NUTR CANCER, V33, P82.
   Chiarappa-Zucca ML, 2002, ANAL CHEM, V74, P6285, DOI 10.1021/ac020295u.
   Chung FL, 2000, CARCINOGENESIS, V21, P2287, DOI 10.1093/carcin/21.12.2287.
   Clifford AJ, 1996, AM J CLIN NUTR, V64, P748.
   Coles B, 2001, MUTAT RES-FUND MOL M, V482, P3, DOI 10.1016/S0027-5107(01)00187-7.
   Dalu A, 1998, PROSTATE, V37, P36.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P2091, DOI 10.1093/carcin/14.10.2091.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P61, DOI 10.1093/carcin/14.1.61.
   De Flora S, 1994, Eur J Cancer Prev, V3, P364.
   de Kleijn MJJ, 2001, J NUTR, V131, P1826.
   DeMarini DM, 1998, MUTAT RES-FUND MOL M, V400, P457, DOI 10.1016/S0027-5107(98)00052-9.
   DeStefani E, 1997, CANCER EPIDEM BIOMAR, V6, P573.
   Dingley KH, 1999, CANCER EPIDEM BIOMAR, V8, P507.
   Dingley KH, 1998, DRUG METAB DISPOS, V26, P825.
   DRAGSTED LO, 1995, CARCINOGENESIS, V16, P2785, DOI 10.1093/carcin/16.11.2785.
   Ewings P, 1996, BRIT J CANCER, V74, P661, DOI 10.1038/bjc.1996.418.
   Frame LT, 2000, DRUG METAB DISPOS, V28, P1063.
   Futakuchi M, 1998, EUR J CANCER PREV, V7, P153.
   GHOSHAL A, 1995, CARCINOGENESIS, V16, P2725, DOI 10.1093/carcin/16.11.2725.
   Giovannucci E, 2002, J NATL CANCER I, V94, P391, DOI 10.1093/jnci/94.5.391.
   Guo Dexin, 1995, Carcinogenesis (Oxford), V16, P2931, DOI 10.1093/carcin/16.12.2931.
   GUO D, 1994, CARCINOGENESIS, V15, P763, DOI 10.1093/carcin/15.4.763.
   HABIG WH, 1974, J BIOL CHEM, V249, P7130.
   Hamilton SM, 1996, ANTICANCER RES, V16, P3597.
   HASEGAWA R, 1995, CARCINOGENESIS, V16, P2243, DOI 10.1093/carcin/16.9.2243.
   HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007.
   Hirose M, 2002, ENVIRON MOL MUTAGEN, V39, P271, DOI 10.1002/em.10066.
   Imaida K, 2001, CARCINOGENESIS, V22, P467, DOI 10.1093/carcin/22.3.467.
   IRSHAID YM, 1987, MOL PHARMACOL, V31, P27.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1695, DOI 10.1093/carcin/15.8.1695.
   KASAI H, 1981, J CHEM SOC PERK T 1, P2290, DOI 10.1039/p19810002290.
   Keating GA, 2000, CANCER CAUSE CONTROL, V11, P731, DOI 10.1023/A:1008935407971.
   KENSLER TW, 1996, J CELL BIOCHEM, V25, pS85.
   KHACHIK F, 1986, J AGR FOOD CHEM, V34, P603, DOI 10.1021/jf00070a006.
   Knasmuller S, 1996, MUTAT RES-FUND MOL M, V350, P93, DOI 10.1016/0027-5107(95)00095-X.
   KNEKT P, 1994, INT J CANCER, V59, P756, DOI 10.1002/ijc.2910590608.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   LIN DX, 1994, CANCER RES, V54, P4920.
   Malfatti MA, 2001, CARCINOGENESIS, V22, P1087, DOI 10.1093/carcin/22.7.1087.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   Mauthe RJ, 1999, INT J CANCER, V80, P539, DOI 10.1002/(SICI)1097-0215(19990209)80:4<539::AID-IJC10>3.3.CO;2-3.
   MITCHELL AE, 1995, CHEM RES TOXICOL, V8, P1054, DOI 10.1021/tx00050a009.
   Nowell S, 2000, PHARMACOGENETICS, V10, P789, DOI 10.1097/00008571-200012000-00004.
   Nowell SA, 1999, CARCINOGENESIS, V20, P1107, DOI 10.1093/carcin/20.6.1107.
   OHGAKI H, 1986, ENVIRON HEALTH PERSP, V67, P129, DOI 10.2307/3430327.
   Ohta T, 2000, CARCINOGENESIS, V21, P937, DOI 10.1093/carcin/21.5.937.
   PROCHASKA HJ, 1988, ANAL BIOCHEM, V169, P328, DOI 10.1016/0003-2697(88)90292-8.
   Rao AV, 1998, FOOD RES INT, V31, P737, DOI 10.1016/S0963-9969(99)00053-8.
   Roberts ML, 2000, NUCL INSTRUM METH B, V172, P262, DOI 10.1016/S0168-583X(00)00094-X.
   Santell RC, 2000, J NUTR, V130, P1665.
   SCHUT HAJ, 1988, CANCER LETT, V41, P345, DOI 10.1016/0304-3835(88)90296-0.
   Seow A, 1998, CANCER EPIDEM BIOMAR, V7, P775.
   Shirai T, 1997, CANCER RES, V57, P195.
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P289, DOI 10.1016/S0278-6915(97)00159-2.
   SINHA R, 1995, CANCER RES, V55, P4516.
   Sinha R, 2000, J NATL CANCER I, V92, P1352, DOI 10.1093/jnci/92.16.1352.
   SKIPPER PL, 1990, CARCINOGENESIS, V11, P507, DOI 10.1093/carcin/11.4.507.
   SKOG K, 1997, FOOD CHEM TOXICOL, V35, P355.
   STEELE VE, 1995, J NUTR, V125, pS713.
   Steinkellner H, 2001, MUTAT RES-FUND MOL M, V480, P285, DOI 10.1016/S0027-5107(01)00188-9.
   Sticha KRK, 2002, CARCINOGENESIS, V23, P1433, DOI 10.1093/carcin/23.9.1433.
   Swenberg JA, 1995, TOXICOL LETT, V82-3, P751, DOI 10.1016/0378-4274(95)03593-1.
   Talalay P, 1996, BIOCHEM SOC T, V24, P806.
   TALAMINI R, 1992, NUTR CANCER, V18, P277.
   THOMPSON LH, 1987, MUTAGENESIS, V2, P483, DOI 10.1093/mutage/2.6.483.
   Turteltaub KW, 1999, CANCER LETT, V143, P149, DOI 10.1016/S0304-3835(99)00116-0.
   Vogel JS, 1995, ANAL CHEM, V67, P353.
   Wakai K, 1999, NUTR CANCER, V33, P139, DOI 10.1207/S15327914NC330204.
   WATTENBERG LW, 1992, CANCER RES, V52, pS2085.
   Wei HC, 1998, CARCINOGENESIS, V19, P1509, DOI 10.1093/carcin/19.8.1509.
   WILD D, 1985, MUTAT RES, V156, P93, DOI 10.1016/0165-1218(85)90011-4.
   Williams JA, 2001, PHARMACOGENETICS, V11, P373, DOI 10.1097/00008571-200107000-00002.
   Xu MR, 1999, CANCER LETT, V143, P179, DOI 10.1016/S0304-3835(99)00121-4.
   Yamazoe Y, 1999, CANCER LETT, V143, P103, DOI 10.1016/S0304-3835(99)00136-6.
   Zheng W, 1998, J NATL CANCER I, V90, P1724, DOI 10.1093/jnci/90.22.1724.}},
Number-of-Cited-References = {{81}},
Times-Cited = {{55}},
Journal-ISO = {{Nutr. Cancer}},
Doc-Delivery-Number = {{750FN}},
Wos-Id = {{ISI:000186980800015}},
}

@article{ ISI:000180149000006,
Author = {Moonen, HJJ and Briede, JJ and van Maanen, JMS and Kleinjans, JCS and de
   Kok, TMCM},
Title = {{Generation of free radicals and induction of DNA adducts by activation
   of heterocyclic aromatic amines via different metabolic pathways in
   vitro}},
Journal = {{MOLECULAR CARCINOGENESIS}},
Year = {{2002}},
Volume = {{35}},
Number = {{4}},
Pages = {{196-203}},
Month = {{DEC}},
Abstract = {{Food-derived heterocyclic aromatic amines (HCAs) have proved to be
   carcinogenic in both rodents and nonhuman primates. Two different
   metabolic pathways are suggested for the metabolic activation of HCA.
   The hepatic pathway proceeds via a two-step process involving
   N-hydroxylation by cytochrome P4501A2 and subsequent O-acetylation by
   N-acetyltransferase-2. An alternative pathway may be of particular
   interest in extrahepatic tissues and proceeds via one-electron oxidation
   catalyzed by prostaglandin H synthase (PHS), rendering free-radical
   metabolites. In this study, we investigated the metabolic activation of
   two HCAs, 2-amino-3-methylimidazo{[}4,5-f]quinoline (IQ) and
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP), by two
   different enzyme systems in vitro, generating different primary and
   secondary reactive metabolites. Rat liver S9 mix and PHS were used as
   the activating system and represent the hepatic and extrahepatic
   pathways, respectively. Electron-spin resonance spectroscopy showed that
   both IQ and PhIP exerted inhibiting effects on PHS-mediated formation of
   hydroxyl radicals during the conversion of arachidonic acid to
   prostaglandins. Evidence for the formation of HCA free radicals was
   presented in an indirect way by the formation of glutathione-derived
   thiyl radicals,;with purified PHS as the activating system. Activation
   by S9 mix did not result in the formation of detectable radical
   metabolites, showing that the two metabolic routes primarily led to the
   formation of different metabolites. In all electron-spin resonance
   experiments, IQ appeared to be more effective than PhIP. In contrast,
   DNA adduct analysis by means of (32)P-postlabeling showed similar adduct
   patterns for S9 and PHS in single-stranded and double-stranded salmon
   testes DNA after incubation with PhIP, indicating the ultimate formation
   of a common reactive intermediate. For IQ, activation by PHS led to an
   additional adduct spot that was not present after S9 activation.
   Furthermore, activation of IQ resulted in higher adduct levels compared
   with PhIP for both activation pathways. Overall, adduct levels were
   higher in single-stranded DNA than double-stranded DNA. Our results
   showed that the hepatic and extrahepatic pathways resulted in different
   primary metabolites, while the ultimate formation of a similar reactive
   intermediate for PhIP, possibly an arylnitrenium ion, suggested that
   both pathways could play an important role in the onset of
   carcinogenesis. (C) 2002 Wiley-Liss, Inc.}},
Publisher = {{WILEY-BLACKWELL}},
Address = {{COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Moonen, HJJ (Reprint Author), Univ Maastricht, Dept Hlth Risk Anal \& Toxicol, POB 616, NL-6200 MD Maastricht, Netherlands.
   Univ Maastricht, Dept Hlth Risk Anal \& Toxicol, NL-6200 MD Maastricht, Netherlands.}},
DOI = {{10.1002/mc.10089}},
ISSN = {{0899-1987}},
Keywords = {{2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine;
   2-amino-3-methylimidazo{[}4,5-f]quinoline; cyclo-oxygenase;
   electron-spin resonance; (32)P-postlabeling}},
Keywords-Plus = {{PROSTAGLANDIN-H SYNTHASE; ENDOPEROXIDE SYNTHETASE; MUTAGENIC ACTIVATION;
   FOOD MUTAGEN; COOKED FOOD; IQ;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE;
   2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE; HYDROPEROXIDASE; SUBSTRATE}},
Research-Areas = {{Biochemistry \& Molecular Biology; Oncology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Oncology}},
Cited-References = {{ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433.
   DEGEN GH, 1994, METABOLIC ASPECTS CE, P95.
   de Kok TMCM, 2002, J CHROMATOGR B, V778, P345, DOI 10.1016/S0378-4347(01)00543-6.
   ELING T, 1983, DRUG METAB REV, V14, P1023, DOI 10.3109/03602538308991420.
   ELING TE, 1990, ANNU REV PHARMACOL, V30, P1.
   ELING TE, 1985, ARACHIDONIC ACID MET, P83.
   ELING TE, 1986, J BIOL CHEM, V261, P5023.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   Felton JS, 1999, CANCER LETT, V143, P127, DOI 10.1016/S0304-3835(99)00141-X.
   Halliwell B., 1985, FREE RADICALS BIOL M.
   HALLIWELL B, 1987, FASEB J, V1, P358.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   Kasprzak K.S., 1996, TOXICOLOGY METALS, P299.
   KRAUSS RS, 1985, CANCER RES, V45, P1680.
   MARKEY CM, 1987, J BIOL CHEM, V262, P6266.
   MARNETT LJ, 1992, CANCER RES, V52, P5575.
   MARNETT LJ, 1983, REV BIOCHEM TOXICOL, V5, P135.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   PETRY TW, 1989, CARCINOGENESIS, V10, P2201, DOI 10.1093/carcin/10.12.2201.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   REICHERT WL, 1992, CARCINOGENESIS, V13, P1474.
   ROBERTSON IGC, 1983, CANCER RES, V43, P476.
   SUGIMURA T, 1983, CANCER RES, V43, P2415.
   SUGIMURA T, 1977, ORIGINS HUMAN CANC, VC, P1561.
   SUGIMURA T, 1977, P JPN ACAD, V53, P58.
   SUGIMURA T, 1990, PROG CLIN BIOL RES, V347, P1.
   WILD D, 1987, CARCINOGENESIS, V8, P541, DOI 10.1093/carcin/8.4.541.
   Williams JA, 2000, MUTAGENESIS, V15, P149, DOI 10.1093/mutage/15.2.149.
   Wolz E, 2000, FOOD CHEM TOXICOL, V38, P513, DOI 10.1016/S0278-6915(00)00038-7.
   WOLZ E, 1995, ARCH TOXICOL, V69, P171, DOI 10.1007/s002040050154.}},
Number-of-Cited-References = {{31}},
Times-Cited = {{25}},
Journal-ISO = {{Mol. Carcinog.}},
Doc-Delivery-Number = {{631CE}},
Wos-Id = {{ISI:000180149000006}},
}

@article{ ISI:000177218200024,
Author = {Snyderwine, EG and Yu, M and Schut, HAJ and Knight-Jones, L and Kimura,
   S},
Title = {{Effect of CYP1A2 deficiency on heterocyclic amine DNA adduct levels in
   mice}},
Journal = {{FOOD AND CHEMICAL TOXICOLOGY}},
Year = {{2002}},
Volume = {{40}},
Number = {{10}},
Pages = {{1529-1533}},
Month = {{OCT}},
Abstract = {{The contribution of CYPIA2 to the formation of DNA adducts of the cooked
   meat-derived heterocyclic amines (HCAs)
   2-amino-3-methylimidazo{[}4,5-f]quinoline (IQ) and
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) was examined in
   CYP1A2-null (knock-out, KO) and wild-type (WT) mice. IQ (25 mg and 75
   mg/kg) and PhIP (150 mg/kg) were administered by gavage to mice and DNA
   adduct levels in liver, kidney, mammary gland and colon were examined by
   the P-32-postlabeling assay. Three hours after either dose of IQ,
   adducts levels in liver and kidney of KO mice were 20-30\% of the levels
   in WT mice, a difference that was statistically significant (Student's
   t-test, P<0.05). In the colon, adduct levels in KO mice were
   significantly lower than in the WT mice only at the lowest dose of IQ
   (1.6+/-0.6 vs 4.6+/-0.7, respectively, relative adduct labeling (RAL) x
   10(8), mean-+/-S.E.M., n = 3-5 mice). In the mammary gland, however,
   there was no difference in IQ-DNA adduct levels in KO and WT mice at
   either dose of IQ. Three hours after dosing with PhIP, PhIP-DNA adduct
   levels were statistically significantly lower in KO mice than in WT mice
   in all tissues examined. PhIP-DNA adducts in liver and kidney of WT mice
   were 9.9+/-1.1 and 22.5+/-6.9, respectively, whereas no PhIP-DNA adducts
   were detected in either organ of KO mice (limit of detection, 1.4+/-2.8
   x 10(9)). PhIP-DNA adduct levels in mammary gland and colon of WT mice
   were 47.1+/-9.5 and 58.0+/-21.7, respectively, but accordingly only
   3.8+/-0.7 and 5.4+/-0.9 in KO mice. The findings indicate that CYPIA2,
   responsible for IQ and PhIP N-hydroxylation, the first step in the
   metabolic action, significantly effects DNA adduct formation in vivo.
   However, the data raise the possibility that other cytochromes P450 as
   well as other pathways of activation potentially contribute to DNA
   adduct formation in specific organs, depending on the HCA substrate.
   Published by Elsevier Science Ltd.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Snyderwine, EG (Reprint Author), NCI, Ctr Canc Res, Chem Carcinogenesis Sect, Lab Expt Carcinogenesis, Bldg 37,Room 3C28,37 Convent Dr,MSC-4258, Bethesda, MD 20892 USA.
   NCI, Ctr Canc Res, Chem Carcinogenesis Sect, Lab Expt Carcinogenesis, Bethesda, MD 20892 USA.
   NCI, Ctr Canc Res, Lab Metab, Bethesda, MD 20892 USA.
   Med Coll Ohio, Dept Pathol, Toledo, OH 43614 USA.}},
DOI = {{10.1016/S0278-6915(02)00110-2}},
ISSN = {{0278-6915}},
Keywords = {{CYP1A2; cytochrome P450; null mice; DNA adducts; postlabelling}},
Keywords-Plus = {{HUMAN-LIVER-MICROSOMES; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE
   PHIP; 2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE IQ; MUTAGENIC ACTIVATION;
   CARCINOGENIC ARYLAMINES; METABOLIC-ACTIVATION; AROMATIC-AMINES; COOKED
   FOOD; IN-VITRO; CYTOCHROME-P-450}},
Research-Areas = {{Food Science \& Technology; Toxicology}},
Web-of-Science-Categories  = {{Food Science \& Technology; Toxicology}},
Cited-References = {{AOYAMA T, 1990, CANCER RES, V50, P2060.
   AOYAMA T, 1989, MOL CARCINOGEN, V1, P253, DOI 10.1002/mc.2940010408.
   BADAWI AF, 1996, PROG CLIN BIOL RES, V395, P109.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   Buters JTM, 1996, PHARMACOGENETICS, V6, P291, DOI 10.1097/00008571-199608000-00002.
   BUTLER MA, 1989, P NATL ACAD SCI USA, V86, P7696, DOI 10.1073/pnas.86.20.7696.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P61, DOI 10.1093/carcin/14.1.61.
   EDWARDS RJ, 1994, CARCINOGENESIS, V15, P829, DOI 10.1093/carcin/15.5.829.
   GHOSHAL A, 1995, CARCINOGENESIS, V16, P2725, DOI 10.1093/carcin/16.11.2725.
   Hammons GJ, 1997, CARCINOGENESIS, V18, P851, DOI 10.1093/carcin/18.4.851.
   HOWIE AF, 1990, CARCINOGENESIS, V11, P451, DOI 10.1093/carcin/11.3.451.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1995, PHARMACOGENETICS, V5, pS108, DOI 10.1097/00008571-199512001-00011.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1695, DOI 10.1093/carcin/15.8.1695.
   Landi MT, 1999, IARC SCI PUBL, V148, P173.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LIN DX, 1994, CANCER RES, V54, P4920.
   MCMANUS ME, 1990, CANCER RES, V50, P3367.
   Nagao M, 1999, MUTAT RES-FUND MOL M, V431, P3, DOI 10.1016/S0027-5107(99)00154-2.
   Nerurkar PV, 1996, MOL PHARMACOL, V49, P874.
   NERURKAR PV, 1995, CANCER RES, V55, P3043.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   SADRIEH N, 1995, CARCINOGENESIS, V16, P1549, DOI 10.1093/carcin/16.7.1549.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   SCHUT HAJ, 1988, CANCER LETT, V41, P345, DOI 10.1016/0304-3835(88)90296-0.
   SCHWEIKL H, 1993, PHARMACOGENETICS, V3, P239, DOI 10.1097/00008571-199310000-00003.
   Shimada T, 1996, CANCER RES, V56, P2979.
   SHIMADA T, 1989, CANCER RES, V49, P3218.
   Sinha R, 2000, J NATL CANCER I, V92, P1352, DOI 10.1093/jnci/92.16.1352.
   Sinha R, 1999, CANCER RES, V59, P4320.
   SNYDERWINE EG, 1993, FOOD CHEM TOXICOL, V31, P415, DOI 10.1016/0278-6915(93)90156-S.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   SNYDERWINE EG, 1999, WOMEN CANC, V1, P21.
   SNYDERWINE EG, 1989, J NATL CANCER I, V81, P223, DOI 10.1093/jnci/81.3.223.
   Wiese F. W., 2001, CARCINOGENESIS, V21, P5.
   YAMAZAKI H, 1995, CARCINOGENESIS, V16, P2167, DOI 10.1093/carcin/16.9.2167.
   YAMAZOE Y, 1988, JPN J CANCER RES, V79, P1159.}},
Number-of-Cited-References = {{40}},
Times-Cited = {{24}},
Journal-ISO = {{Food Chem. Toxicol.}},
Doc-Delivery-Number = {{580CZ}},
Wos-Id = {{ISI:000177218200024}},
}

@article{ ISI:000178513400018,
Author = {Strickland, PT and Qian, Z and Friesen, MD and Rothman, N and Sinha, R},
Title = {{Metabolites of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) in
   human urine after consumption of charbroiled or fried beef}},
Journal = {{MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS}},
Year = {{2002}},
Volume = {{506}},
Number = {{SI}},
Pages = {{163-173}},
Month = {{SEP 30}},
Note = {{8th International Conference on Carcinogenic/Mutagenic N-Substituted
   Aryl Compounds, WASHINGTON, D.C., NOV 12-14, 2001}},
Organization = {{NCI; US FDA, Natl Ctr Toxicol Res; Toronto Res Chem Inc; Nestle Res Ctr;
   Oregon State Univ, Linus Pauling Inst}},
Abstract = {{Heterocyclic amines (HAs) are carcinogenic combustion products formed
   during the cooking of meat at moderate to high temperatures. PhIP is the
   most common HA formed in fried, grilled or broiled meat, and is a colon,
   breast, and prostate carcinogen in rodents. The major metabolites of
   PhIP detected in human urine are N-2-OH-PhIP-N-2-glucuronide,
   PhIP-N-2-glucuronide, N-2-OH-PhIP-M-glucuronide, and 4'-PhIP-sulphate.
   We have measured the time course of PhIP in untreated and acid- or
   alkali-hydrolyzed urines from 10 healthy non-smoking subjects ingesting
   identical amounts of char-broiled beef (containing both HAs and PAHs)
   for 5 days. The morning after the first day of broiled beef consumption
   (containing 7.7 mug PhIP), urinary concentration of PhIP increased 14-
   to 38-fold above mean prefeed concentration. Following cessation of
   broiled meat consumption, urinary PhIP declined to near prefeed levels
   within 48-72 h. The ratio of alkali-labile PhIP metabolites to
   unmetabolized PhIP varied by 2.7-fold among subjects, ranging from 18:1
   to 48:1. In a subsequent study we measured PhIP in acid-hydrolyzed urine
   from 66 subjects ingesting beef pan-fried at high temperature. A
   significant correlation (r = 0.61, P < 0.0001) was observed between the
   amount of fried meat ingested and concentration of PhIP in urines
   collected between 0 and 12 h after feeding. Other investigators have
   identified 2-OH-PhIP in acid-hydrolyzed urine from these subjects, and
   also observed a significant coffelation (r = 0.52, P < 0.0001) with the
   amount of fried meat ingested. Additional studies have measured PhIP
   metabolites in subjects consuming their normal (unrestricted) diet. PhIP
   was detected in acid-hydrolyzed urine from 20 to 50\% of these subjects,
   depending on ethnic group. Taken together, these studies indicate that
   significant amounts of PhIP are bioavailable from ingestion of fried or
   char-broiled meats, and that urinary PhIP metabolites reflect recent
   (12-24b) ingestion. Furthermore, significant interindividual differences
   in the amounts of urinary PhIP metabolite excreted are observed
   following ingestion of similar amounts of PhIP. These differences do not
   correlate with interindividual differences in excretion of urinary
   pyrene metabolites in the same individuals after ingestion of
   char-broiled beef, indicating that levels of PhIP and pyrene metabolites
   in human urine are mediated by compound-specific metabolic factors. (C)
   2002 Elsevier Science B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Strickland, PT (Reprint Author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA.
   Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA.
   Int Agcy Res Canc, Unit Nutr \& Canc, F-69372 Lyon, France.
   NCI, Div Canc Epidemiol \& Genet, Bethesda, MD 20892 USA.}},
DOI = {{10.1016/S0027-5107(02)00163-X}},
ISSN = {{0027-5107}},
Keywords = {{urine metabolites; PhIP; HPLC; biomarker; heterocyclic amines; dietary
   carcinogens}},
Keywords-Plus = {{FOOD MUTAGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE;
   HETEROCYCLIC AROMATIC-AMINES; CYTOCHROME P4501A2; HYDROLYZED URINE;
   COOKED FOOD; 2-AMINO-3,8-DIMETHYLIMIDAZO<4,5-F>QUINOXALINE;
   IDENTIFICATION; CARCINOGENS; ACTIVATION; EXCRETION}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
ResearcherID-Numbers = {{Friesen, Marlin/D-7328-2012}},
Cited-References = {{ALEXANDER J, 1991, CARCINOGENESIS, V12, P2239, DOI 10.1093/carcin/12.12.2239.
   ALEXANDER J, 1989, CARCINOGENESIS, V10, P1543, DOI 10.1093/carcin/10.8.1543.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   Crofts FG, 1998, CARCINOGENESIS, V19, P1969, DOI 10.1093/carcin/19.11.1969.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FELTON JS, 1990, CHEM CARCINOGENESIS, V1, P471.
   Friesen MD, 2001, CANCER LETT, V173, P43, DOI 10.1016/S0304-3835(01)00672-3.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KANG DH, 1995, CARCINOGENESIS, V16, P1079, DOI 10.1093/carcin/16.5.1079.
   Kidd LCR, 1999, CANCER EPIDEM BIOMAR, V8, P439.
   Kulp KS, 2000, CARCINOGENESIS, V21, P2065, DOI 10.1093/carcin/21.11.2065.
   Lang NP, 1999, CANCER LETT, V143, P135, DOI 10.1016/S0304-3835(99)00142-1.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   SINHA R, 1994, CANCER RES, V54, P6154.
   SINHA R, 1995, CARCINOGENESIS, V16, P2859, DOI 10.1093/carcin/16.11.2859.
   STILLWELL WG, UNPUB EXCRETION N2 G.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   Strickland PT, 2001, BIOMARKERS, V6, P313.
   STYCZYNSKI PB, 1993, CHEM RES TOXICOL, V6, P846, DOI 10.1021/tx00036a014.
   SUGIMURA T, 1983, CANCER RES, V43, P2415.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{29}},
Journal-ISO = {{Mutat. Res.-Fundam. Mol. Mech. Mutagen.}},
Doc-Delivery-Number = {{602PJ}},
Wos-Id = {{ISI:000178513400018}},
}

@article{ ISI:000178513400019,
Author = {Nowell, S and Coles, B and Sinha, R and MacLeod, S and Ratnasinghe, DL
   and Stotts, C and Kadlubar, FF and Ambrosone, CB and Lang, NP},
Title = {{Analysis of total meat intake and exposure to individual heterocyclic
   amines in a case-control study of colorectal cancer: contribution of
   metabolic variation to risk}},
Journal = {{MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS}},
Year = {{2002}},
Volume = {{506}},
Number = {{SI}},
Pages = {{175-185}},
Month = {{SEP 30}},
Note = {{8th International Conference on Carcinogenic/Mutagenic N-Substituted
   Aryl Compounds, WASHINGTON, D.C., NOV 12-14, 2001}},
Organization = {{NCI; US FDA, Natl Ctr Toxicol Res; Toronto Res Chem Inc; Nestle Res Ctr;
   Oregon State Univ, Linus Pauling Inst}},
Abstract = {{A case-control study of colorectal cancer, consisting of 157 cases and
   380 controls matched by sex, ethnicity, decade of age and county of
   residence was performed to explore the associations between
   environmental exposure, metabolic polymorphisms and cancer risk.
   Participants were required to provide a blood sample, undergo caffeine
   phenotyping and complete an in-person interview that evaluated meat
   consumption, cooking methods and degree of doneness. A color atlas of
   foods cooked to different degrees of doneness was used to estimate food
   preparation techniques and food models were used to estimate serving
   portion sizes. Data was analyzed using a reference database of
   heterocyclic amine (HCA) exposure based on the food preferences chosen
   from the atlas. Data regarding individual food items cooked to different
   levels of doneness, as well as summary variables of foods and of food
   groups cooked to different degrees of doneness were also evaluated in a
   univariate analysis for association with colorectal cancer case status.
   Three measures of metabolic variation, hGSTA1 genotype, SULT1A1 genotype
   and the phenotype for CYP2A6 were also evaluated for possible
   association with colon cancer.
   While higher exposure to HCAs was strongly associated with colorectal
   cancer risk, increased consumption of five red meats cooked well done or
   very well done produced comparable odds ratios (OR) for colorectal
   cancer risk (OR = 4.36, 95\% CI 2.08-9.60) for the highest quartile of
   exposure. Similarly, individuals in the most rapid CYP2A6 phenotype
   quartile showed an odds ratio (OR = 4.18, 95 \% CI 2.03-8.90). The ORs
   for the low activity hGSTA1 and low activity SULT1A1 alleles were 2.0,
   95\% CI 1.0-3.7 and 0.6, 95\% CI 0.3-1.1, respectively. Individual
   measures of specific HCAs provided little improvement in risk assessment
   over the measure of meat consumption, suggesting that exposure to other
   environmental or dietary carcinogens such as nitrosamines or undefined
   HCAs may contribute to colorectal cancer risk. Published by Elsevier
   Science B.V.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Lang, NP (Reprint Author), Cent Arkansas Vet Hlth Care Syst, 4300 W 7th St, Little Rock, AR 72205 USA.
   Cent Arkansas Vet Hlth Care Syst, Little Rock, AR 72205 USA.
   Arkansas Canc Res Ctr, Little Rock, AR 72205 USA.
   Univ Arkansas Med Sci, Dept Pharmacol \& Toxicol, Little Rock, AR 72205 USA.
   Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
   NCI, Div Canc Epidemiol \& Genet, NIH, Bethesda, MD 20892 USA.
   Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA.
   Mt Sinai Sch Med, New York, NY USA.}},
DOI = {{10.1016/S0027-5107(02)00164-1}},
ISSN = {{0027-5107}},
Keywords = {{colorectal cancer; heterocyclic amines (HCA); glutathione S-transferase
   A1; sulfotransferase 1A1; cytochrome P450 2A6; genotype; caffeine
   phenotype}},
Keywords-Plus = {{GLUTATHIONE S-TRANSFERASES; CYTOCHROME P4501A2; POSSIBLE MECHANISM;
   VARYING DEGREES; UNITED-STATES; COLON-CANCER; DNA-ADDUCTS; WELL-DONE;
   RED MEAT; PHIP}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Cited-References = {{BECHER G, 1988, CARCINOGENESIS, V9, P247, DOI 10.1093/carcin/9.2.247.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   BUTLER MA, 1992, PHARMACOGENETICS, V2, P116, DOI 10.1097/00008571-199206000-00003.
   Chao A, 2000, J NATL CANCER I, V92, P1888, DOI 10.1093/jnci/92.23.1888.
   CHOU HC, 1995, CANCER RES, V55, P525.
   Coles B, 2001, MUTAT RES-FUND MOL M, V482, P3, DOI 10.1016/S0027-5107(01)00187-7.
   COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605.
   Coles BF, 2001, PHARMACOGENETICS, V11, P663, DOI 10.1097/00008571-200111000-00004.
   Coughtrie MWH, 1999, BIOCHEM J, V337, P45, DOI 10.1042/0264-6021:3370045.
   Dingley KH, 1999, CANCER EPIDEM BIOMAR, V8, P507.
   Frame LT, 2000, DRUG METAB DISPOS, V28, P1063.
   FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   Gerhardsson de Verdier M, 1991, Int J Cancer, V49, P520.
   Ghazali RA, 1999, LIFE SCI, V65, P1625, DOI 10.1016/S0024-3205(99)00423-3.
   HATCH FT, 1988, ENVIRON MOL MUTAGEN, V12, P1, DOI 10.1002/em.2860120602.
   Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491.
   HORN EP, 1995, CANCER EPIDEM BIOMAR, V4, P529.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   Kampman E, 1999, CANCER EPIDEM BIOMAR, V8, P15.
   Knekt P, 1999, INT J CANCER, V80, P852.
   KNIZE MG, 1995, FOOD CHEM TOXICOL, V33, P545, DOI 10.1016/0278-6915(95)00025-W.
   KNIZE MG, 1988, MUTAGENESIS, V3, P503, DOI 10.1093/mutage/3.6.503.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   LIN DX, 1994, CANCER RES, V54, P4920.
   LYON JL, 1988, AM J EPIDEMIOL, V128, P1000.
   MINCHIN RF, 1992, BIOCHEM BIOPH RES CO, V185, P839, DOI 10.1016/0006-291X(92)91703-S.
   MUSCAT JE, 1994, AM J PUBLIC HEALTH, V84, P856, DOI 10.2105/AJPH.84.5.856.
   NAGAO M, 1983, BIOCHEM BIOPH RES CO, V114, P626, DOI 10.1016/0006-291X(83)90826-4.
   Norat T, 2001, NUTR REV, V59, P37.
   Nowell S, 2002, CANCER EPIDEM BIOMAR, V11, P377.
   Nowell S, 2000, PHARMACOGENETICS, V10, P789, DOI 10.1097/00008571-200012000-00004.
   Ozawa S, 1998, CHEM-BIOL INTERACT, V109, P237, DOI 10.1016/S0009-2797(97)00135-X.
   PETERS RK, 1989, CANCER RES, V49, P5459.
   Potter JD, 1996, CANCER CAUSE CONTROL, V7, P127, DOI 10.1007/BF00115644.
   ProbstHensch NM, 1997, CANCER CAUSE CONTROL, V8, P175, DOI 10.1023/A:1018416128894.
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P289, DOI 10.1016/S0278-6915(97)00159-2.
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P279, DOI 10.1016/S0278-6915(97)00162-2.
   SINHA R, 1995, CANCER RES, V55, P4516.
   Sinha R, 2001, CANCER EPIDEM BIOMAR, V10, P559.
   Sinha R, 1999, CANCER RES, V59, P4320.
   Sinha R, 1997, MUTAT RES-FUND MOL M, V376, P195, DOI 10.1016/S0027-5107(97)00043-2.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.}},
Number-of-Cited-References = {{42}},
Times-Cited = {{74}},
Journal-ISO = {{Mutat. Res.-Fundam. Mol. Mech. Mutagen.}},
Doc-Delivery-Number = {{602PJ}},
Wos-Id = {{ISI:000178513400019}},
}

@article{ ISI:000177393700012,
Author = {Frandsen, H and Frederiksen, H and Alexander, J},
Title = {{2-amino-1-methyl-6-(5-hydroxy-)phenylimidazo{[}4,5-b]pyridine
   (5-OH-PhIP), a biomarker for the genotoxic dose of the heterocyclic
   amine, 2-amino-1-methyl-6-phenylimidazo{[}4, 5-b]pyridine (PhIP)}},
Journal = {{FOOD AND CHEMICAL TOXICOLOGY}},
Year = {{2002}},
Volume = {{40}},
Number = {{8}},
Pages = {{1125-1130}},
Month = {{AUG}},
Note = {{International Conference on Dietary Factors, VIENNA, AUSTRIA, FEB 14-17,
   2001}},
Abstract = {{2-Amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) is a mutagenic
   and carcinogenic heterocyclic amine formed during ordinary cooking. PhIP
   is metabolically activated by CYP P450 mediated N-hydroxylation followed
   by phase II esterification. The ultimate mutagenic metabolite reacts
   with DNA resulting in formation of adducts, and with proteins and other
   cellular constituents resulting in unstable products which are degraded
   to 5-hydroxy-PhIP. Rats were dosed orally with PhIP and urine and faeces
   were collected to 24, 48 and 72 h. Urine and faeces samples were
   hydrolysed with glucuronidase/sulfatase in order to release conjugated
   metabolites, followed by purification on C18 columns. The rats excreted
   0.88\% of the dose as 5-hydroxy-PhIP with the urine to 24 h and 0.04 and
   0.01\% to 48 and 72 h, respectively. The amounts of 5-hydroxy-PhIP found
   in faeces were 0.03, 0.1 and 0\% to 24, 48 and 72 h. Urinary excretion
   of 5-hydroxy-PhIP showed a linear dose-response relationship in rats
   dosed orally with PhIP. This shows that 5-hydroxy-PhIP is also formed in
   vivo and that 91\% is excreted with the urine in 24 h, indicating the
   possible use of 5-hydroxy-PhIP as a urinary biomarker for the bioactive
   dose of PhIP. In a preliminary study, using molecular imprinted polymer
   a specific sorbent for purification, after enzymatic hydrolysis and
   purification on a C18 column, we have identified 5-OH-PhIP in a 24-h
   urine sample from a male volunteer who had ingested a fried beef. This
   indicates that urinary 5-OH-PhIP could be used as an easily obtainable
   marker for the genotoxic dose of PhIP in human biomonitoring studies.
   (C) 2002 Elsevier Science Ltd. All rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Frandsen, H (Reprint Author), Danish Vet \& Food Adm, Inst Food Safety \& Toxicol, Morkhoj Bygade 19, DK-2600 Glostrup, Denmark.
   Danish Vet \& Food Adm, Inst Food Safety \& Toxicol, DK-2600 Glostrup, Denmark.
   Natl Inst Publ Hlth, Dept Environm Med, N-0403 Oslo, Norway.}},
DOI = {{10.1016/S0278-6915(02)00033-9}},
ISSN = {{0278-6915}},
Keywords = {{PhIP; 5-OH-PhIP; human biomonitoring; molecular imprinted polymer}},
Keywords-Plus = {{ADDUCT FORMATION; FOOD MUTAGEN; IDENTIFICATION; DNA; 2'-DEOXYGUANOSINE;
   ACTIVATION; METABOLISM; HUMANS}},
Research-Areas = {{Food Science \& Technology; Toxicology}},
Web-of-Science-Categories  = {{Food Science \& Technology; Toxicology}},
Cited-References = {{Alexander J, 1997, MUTAT RES-FUND MOL M, V376, P7, DOI 10.1016/S0027-5107(97)00019-5.
   Andersson LI, 2000, J CHROMATOGR B, V745, P3, DOI 10.1016/S0378-4347(00)00135-3.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312.
   FRANCISCUS RG, 1992, B MEM SOC ANTHRO PAR, V4, P5, DOI 10.3406/bmsap.1992.2300.
   Frandsen H, 2000, CARCINOGENESIS, V21, P1197, DOI 10.1093/carcin/21.6.1197.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   Haupt K, 1998, ANAL CHEM, V70, P628, DOI 10.1021/ac9711549.
   Ito N, 1997, MUTAT RES-FUND MOL M, V376, P107, DOI 10.1016/S0027-5107(97)00032-8.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MacLeod S, 1997, MUTAT RES-FUND MOL M, V376, P135, DOI 10.1016/S0027-5107(97)00036-5.
   NAGAOKA H, 1992, JPN J CANCER RES, V83, P1025.
   REISTAD R, 1994, CARCINOGENESIS, V15, P2547, DOI 10.1093/carcin/15.11.2547.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P217, DOI 10.1021/tx9701891.
   TURTELTAUB KW, 1993, ENVIRON HEALTH PERSP, V99, P183, DOI 10.2307/3431477.
   Turteltaub KW, 1999, CANCER LETT, V143, P149, DOI 10.1016/S0304-3835(99)00116-0.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{32}},
Journal-ISO = {{Food Chem. Toxicol.}},
Doc-Delivery-Number = {{583EM}},
Wos-Id = {{ISI:000177393700012}},
}

@article{ ISI:000177393700013,
Author = {Alexander, J and Reistad, R and Hegstad, S and Frandsen, H and
   Ingebrigtsen, K and Paulsen, JE and Becher, G},
Title = {{Biomarkers of exposure to heterocyclic amines: approaches to improve the
   exposure assessment}},
Journal = {{FOOD AND CHEMICAL TOXICOLOGY}},
Year = {{2002}},
Volume = {{40}},
Number = {{8}},
Pages = {{1131-1137}},
Month = {{AUG}},
Note = {{International Conference on Dietary Factors, VIENNA, AUSTRIA, FEB 14-17,
   2001}},
Abstract = {{Various methods of exposure assessment, such as questionnaires,
   sometimes combined with pictures of cooked meat, have been employed in
   investigations on the relationship between heterocyclic amines (HA) and
   health effects. However, as the content of heterocyclic amines vary
   greatly with cooking conditions, it is difficult to obtain an accurate
   estimate of the exposure. To improve the exposure assessment, the use of
   biomarkers has been investigated. The metabolism of
   2-amino-3,8-dimethylinlidazo{[}4,5-f]quinoxaline (MeIQx) and
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) is well
   characterised. In humans, the major part of the dose is excreted in
   urine within 24-48 h following a meal. A few percent is excreted as
   parent compounds, whereas the major part is metabolites. Urinary level
   of parent HA reflects only recent exposure. However, the pattern of
   excreted metabolites might indicate the capacity to activate or detoxify
   HAs. The excretion of glucuronide conjugates of N-hydroxy-PhIP and
   N-hydroxy-MeIQx could be a marker for the N-hydroxylation capacity and
   the dose of the proximate metabolites. Recently, we proposed 5-OH-PhIP
   as a marker for the ultimate reactive metabolite of PhIP, since it is
   formed from this compound as a by-product along with the formation of
   PhIP-DNA adducts. In a search for biomarkers reflecting exposure over
   some time, blood protein adducts with a longer lifespan have been
   investigated, and PhIP adducts of serum albumin and haemoglobin from
   meat-consuming humans were recently reported. Many compounds, like
   drugs, nicotine and narcotics, bind to melanin in hair and give
   information on exposure for longer time periods. In mice, PhIP is
   irreversibly incorporated in a dose-dependent manner into hair, and in
   humans exposed to an ordinary diet, it was found. to vary from <50 to
   5000 pg PhIP/g hair. The incorporation is also dependent on the content
   of eumelanin. The use of PhIP in hair as a biomarker of exposure is
   promising, but needs validation, using other methods of exposure
   assessment. (C) 2002 Elsevier Science Ltd. All rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Alexander, J (Reprint Author), Norwegian Inst Publ Hlth, Div Environm Med, POB 4404 Nydalen, NO-0403 Oslo, Norway.
   Norwegian Inst Publ Hlth, Div Environm Med, NO-0403 Oslo, Norway.
   Danish Vet \& Food Directorate, Inst Food Safety \& Toxicol, DK-2600 Glostrup, Denmark.
   Norwegian Sch Vet Sci, Dept Pharmacol Microbiol \& Food Hyg, NO-0033 Oslo, Norway.}},
DOI = {{10.1016/S0278-6915(02)00053-4}},
ISSN = {{0278-6915}},
Keywords = {{heterocyclic amines; PhIP; MeIQx; biomarker; urine; protein adduct; hair}},
Keywords-Plus = {{FOOD MUTAGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE; DONE RED
   MEAT; WELL-DONE; URINARY-EXCRETION; BREAST-CANCER; COOKED FOODS;
   2-AMINO-3,8-DIMETHYLIMIDAZO<4,5-F>QUINOXALINE MEIQX; COLORECTAL
   ADENOMAS; CYTOCHROME P4501A2; AROMATIC-AMINES}},
Research-Areas = {{Food Science \& Technology; Toxicology}},
Web-of-Science-Categories  = {{Food Science \& Technology; Toxicology}},
Cited-References = {{Adamson RH, 1996, ARCH TOX S, V18, P303.
   Alexander J, 1996, ARCH TOX S, V18, P275.
   ALEXANDER J, 1991, MUTAGENS FOOD DETECT, P143.
   Alexander J, 1997, MUTAT RES-FUND MOL M, V376, P7, DOI 10.1016/S0027-5107(97)00019-5.
   Augustsson K, 1997, CARCINOGENESIS, V18, P1931, DOI 10.1093/carcin/18.10.1931.
   Augustsson K, 1999, LANCET, V353, P703, DOI 10.1016/S0140-6736(98)06099-1.
   BERGMAN K, 1985, CANCER RES, V45, P1351.
   BRANDT I, 1989, CARCINOGENESIS, V10, P1529, DOI 10.1093/carcin/10.8.1529.
   BRANDT I, 1983, CARCINOGENESIS, V4, P1291, DOI 10.1093/carcin/4.10.1291.
   BRITTEBO EB, 1992, CARCINOGENESIS, V13, P2263, DOI 10.1093/carcin/13.12.2263.
   DAVIES DS, 1995, HETEROCYCLIC AMINES, P190.
   Delfino RJ, 2000, CARCINOGENESIS, V21, P607, DOI 10.1093/carcin/21.4.607.
   Dragsted LO, 1996, ARCH TOX S, V18, P259.
   DUPONT RL, 1995, FORENSIC SCI INT, V70, P63, DOI 10.1016/0379-0738(94)01625-F.
   Frandsen H, 2000, CARCINOGENESIS, V21, P1197, DOI 10.1093/carcin/21.6.1197.
   FRANDSEN H, 2002, FOOD CHEM TOXICOLOGY, V40.
   Friesen MD, 2001, CANCER LETT, V173, P43, DOI 10.1016/S0304-3835(01)00672-3.
   GERSTENBERG B, 1995, DRUG METAB DISPOS, V23, P143.
   Gertig DM, 1999, INT J CANCER, V80, P13, DOI 10.1002/(SICI)1097-0215(19990105)80:1<13::AID-IJC3>3.0.CO;2-W.
   Hegstad S, 2000, CHROMATOGRAPHIA, V52, P499, DOI 10.1007/BF02535726.
   Hegstad S, 2000, BIOMARKERS, V5, P24.
   HEGSTAD S, 2002, IN PRESS PHARM TOXIC.
   Ito N, 1997, MUTAT RES-FUND MOL M, V376, P107, DOI 10.1016/S0027-5107(97)00032-8.
   JI IL, 1994, CANC EPIDEMIOLOGY BI, V3, P407.
   Johansen HR, 1996, ENVIRON HEALTH PERSP, V104, P756, DOI 10.2307/3433222.
   Joseph RE, 1996, J ANAL TOXICOL, V20, P338.
   Kidd LCR, 1999, CANCER EPIDEM BIOMAR, V8, P439.
   Knize MG, 1997, MUTAT RES-FUND MOL M, V376, P129, DOI 10.1016/S0027-5107(97)00035-3.
   Kulp KS, 2000, CARCINOGENESIS, V21, P2065, DOI 10.1093/carcin/21.11.2065.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   Lang NP, 1999, CANCER LETT, V143, P135, DOI 10.1016/S0304-3835(99)00142-1.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   LYNCH AM, 1993, CARCINOGENESIS, V14, P191, DOI 10.1093/carcin/14.2.191.
   LYNCH AM, 1991, CARCINOGENESIS, V12, P1067, DOI 10.1093/carcin/12.6.1067.
   LYON JL, 1988, AM J EPIDEMIOL, V128, P1000.
   Magagnotti C, 2000, INT J CANCER, V88, P1, DOI 10.1002/1097-0215(20001001)88:1<1::AID-IJC1>3.0.CO;2-D.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   MURRAY S, 1989, CARCINOGENESIS, V10, P763, DOI 10.1093/carcin/10.4.763.
   MUSCAT JE, 1994, AM J PUBLIC HEALTH, V84, P856, DOI 10.2105/AJPH.84.5.856.
   Norrish AE, 1999, J NATL CANCER I, V91, P2038, DOI 10.1093/jnci/91.23.2038.
   Paulsen JE, 1999, CARCINOGENESIS, V20, P1277, DOI 10.1093/carcin/20.7.1277.
   ProbstHensch NM, 1997, CANCER CAUSE CONTROL, V8, P175, DOI 10.1023/A:1018416128894.
   REISTAD R, 1994, CARCINOGENESIS, V15, P2547, DOI 10.1093/carcin/15.11.2547.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   Reistad R, 1999, BIOMARKERS, V4, P263.
   Shirai T, 1997, CANCER RES, V57, P195.
   Sinha R, 1998, CANCER CAUSE CONTROL, V9, P621, DOI 10.1023/A:1008805525525.
   Sinha R, 1999, CANCER RES, V59, P4320.
   SKIPPER PL, 1994, ENVIRON HEALTH PERSP, V102, P17, DOI 10.2307/3432145.
   SKOG K, 2002, IN PRESS FOOD CHEM T.
   Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1.
   STILLWELL WG, 1994, CANCER EPIDEM BIOMAR, V3, P399.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   Stillwell WG, 1999, CANCER RES, V59, P5154.
   TANNENBAUM SR, 1995, HETEROCYCLIC AMINES, P197.
   TJOTTA K, 1992, CARCINOGENESIS, V13, P779, DOI 10.1093/carcin/13.5.779.
   TURESKY RJ, 1987, CARCINOGENESIS, V8, P1537, DOI 10.1093/carcin/8.10.1537.
   Turteltaub KW, 1999, CANCER LETT, V143, P149, DOI 10.1016/S0304-3835(99)00116-0.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   VANDERLAAN M, 1991, CARCINOGENESIS, V12, P349, DOI 10.1093/carcin/12.2.349.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   World Cancer Research Fund, 1997, FOOD NUTR PREV CANC.
   Zheng W, 1998, J NATL CANCER I, V90, P1724, DOI 10.1093/jnci/90.22.1724.}},
Number-of-Cited-References = {{64}},
Times-Cited = {{34}},
Journal-ISO = {{Food Chem. Toxicol.}},
Doc-Delivery-Number = {{583EM}},
Wos-Id = {{ISI:000177393700013}},
}

@article{ ISI:000175879000023,
Author = {Murata, M and Kawanishi, S},
Title = {{Oxidation of 5 `-site guanine at GG and GGG sequences induced by a
   metabolite of carcinogenic heterocyclic amine PhIP in the presence of
   Cu(II) and NADH}},
Journal = {{CARCINOGENESIS}},
Year = {{2002}},
Volume = {{23}},
Number = {{5}},
Pages = {{855-860}},
Month = {{MAY}},
Abstract = {{Adduct formation has been considered to be a major causal factor of DNA
   damage by carcinogenic heterocyclic amines. By means of experiments with
   an electrochemical detector coupled to a high-performance liquid
   chromatograph, we revealed that N-hydroxy metabolite of
   2-amino-1-methyl-6-phenylimidazo {[}4,5-b] pyridine (PhIP) induced the
   formation of 8-hydroxy-2'-deoxyguanosine (8-OH-dG) in the presence of
   Cu(II). Addition of an endogenous reductant NADH enhanced the 8-OH-dG
   formation. Experiments with P-32-labeled DNA fragments showed that this
   metabolite {[}PhIP(NHOH)] caused 8-hydroxylation of guanines in the
   presence of Cu(II) and NADH, and subsequent treatment with
   formamidopyrimidine-DNA glycosylase led to chain cleavages at the
   5'-site guanine of GG and GGG sequences. Interestingly, antioxidant
   enzyme SOD enhanced the intensity of DNA damage, and thymine residues
   were appended to its guanine-predominant cleavage sites. Catalase and
   bathocuproine, a Cu(I)-specific chelator, inhibited the DNA damage,
   suggesting the involvement of H2O2 and Cu(I). A UV-visible spectroscopic
   study indicated that Cu(II) and SOD catalyze the autoxidation of
   PhIP(NHOH). These results suggest that Cu(II) -dependent autooxidation
   of PhIP(NHOH) coupled with NADH-mediated reduction of its oxidized
   product form redox cycle, resulting in oxidative DNA damage by low
   concentrations of PhIP(NHOH). We conclude that in addition to DNA adduct
   formation, oxidative DNA damage may be involved in the carcinogenic
   process of PhIP.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kawanishi, S (Reprint Author), Mie Univ, Sch Med, Dept Hyg, 2-174 Edobashi, Tsu, Mie 5148507, Japan.
   Mie Univ, Sch Med, Dept Hyg, Tsu, Mie 5148507, Japan.}},
DOI = {{10.1093/carcin/23.5.855}},
ISSN = {{0143-3334}},
Keywords-Plus = {{N-HYDROXY METABOLITE; DNA-DAMAGE;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; SITE-SPECIFICITY;
   FOOD MUTAGEN; COOKED FOOD; COPPER-ION; MODULATION; INDUCTION; PEROXIDE}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{ARUOMA OI, 1991, BIOCHEM J, V273, P601.
   CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0.
   Chen F, 1998, FREE RADICAL RES, V29, P197, DOI 10.1080/10715769800300231.
   CHUMAKOV P, 1990, EMBL DATA LIBR.
   Crofts FG, 1998, CARCINOGENESIS, V19, P1969, DOI 10.1093/carcin/19.11.1969.
   David-Cordonnier MH, 2000, J BIOL CHEM, V275, P11865, DOI 10.1074/jbc.275.16.11865.
   El-Bayoumy K, 2000, CANCER LETT, V151, P7, DOI 10.1016/S0304-3835(99)00391-2.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FRANCIK WB, 1990, GARBAGE-PRACT J ENV, V2, P4.
   Fretland AJ, 2001, TOXICOL SCI, V59, P226, DOI 10.1093/toxsci/59.2.226.
   FUJII H, 1994, FREE RADICAL RES, V21, P235, DOI 10.3109/10715769409056575.
   Hiraku Y, 1996, CANCER RES, V56, P5172.
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840.
   IARC, 1993, IARC MON EV CARC RIS, V56, P229.
   ITO K, 1993, J BIOL CHEM, V268, P13221.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KAKIUCHI H, 1995, P NATL ACAD SCI USA, V92, P910, DOI 10.1073/pnas.92.3.910.
   Leipold MD, 2000, BIOCHEMISTRY-US, V39, P14984, DOI 10.1021/bi0017982.
   LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0.
   Lewis AJ, 1998, CARCINOGENESIS, V19, P2049, DOI 10.1093/carcin/19.11.2049.
   Li YB, 1996, MOL PHARMACOL, V49, P412.
   Martin FL, 2000, CARCINOGENESIS, V21, P799, DOI 10.1093/carcin/21.4.799.
   Maxam A M, 1980, Methods Enzymol, V65, P499.
   Midorikawa K, 2001, FEBS LETT, V495, P187, DOI 10.1016/S0014-5793(01)02383-3.
   Murata M, 2001, FREE RADICAL BIO MED, V30, P765, DOI 10.1016/S0891-5849(01)00463-4.
   Murata M, 1998, FREE RADICAL BIO MED, V25, P586, DOI 10.1016/S0891-5849(98)00091-4.
   Murata M, 1999, BIOCHEM PHARMACOL, V57, P881, DOI 10.1016/S0006-2952(98)00370-0.
   MURATA M, 1999, JPN J CANCER RES, V90, P272.
   Nagao M, 1999, MUTAT RES-FUND MOL M, V431, P3, DOI 10.1016/S0027-5107(99)00154-2.
   Ohkuma Y, 1999, ARCH BIOCHEM BIOPHYS, V372, P97, DOI 10.1006/abbi.1999.1461.
   Ohkuma Y, 2001, ARCH BIOCHEM BIOPHYS, V389, P49, DOI 10.1006/abbi.2001.2302.
   Ohnishi S, 2001, BIOCHEM BIOPH RES CO, V280, P48, DOI 10.1006/bbrc.2000.4095.
   Ohnishi S, 2001, MUTAT RES-GEN TOX EN, V494, P63, DOI 10.1016/S1383-5718(01)00177-2.
   Ohnishi S, 2001, JPN J CANCER RES, V92, P23.
   Ohta T, 2000, CARCINOGENESIS, V21, P937, DOI 10.1093/carcin/21.5.937.
   Oikawa S, 2001, CARCINOGENESIS, V22, P1239, DOI 10.1093/carcin/22.8.1239.
   Oikawa S, 1996, BIOCHEMISTRY-US, V35, P4584, DOI 10.1021/bi9527000.
   Poulsen HE, 1998, EUR J CANCER PREV, V7, P9.
   PRYOR WA, 1978, BIOCHEM BIOPH RES CO, V81, P498, DOI 10.1016/0006-291X(78)91562-0.
   Ross MK, 2000, TOXICOL SCI, V53, P224, DOI 10.1093/toxsci/53.2.224.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   STOEWE R, 1987, FREE RADICAL BIO MED, V3, P97, DOI 10.1016/S0891-5849(87)80003-5.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   Takahashi S, 1998, CANCER RES, V58, P4307.
   Toyota M, 1996, CANCER, V77, P1593, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1593::AID-CNCR2>3.0.CO;2-F.
   Wakabayashi K, 1998, J NUTR BIOCHEM, V9, P604, DOI 10.1016/S0955-2863(98)00057-6.
   WAKATA A, 1985, CANCER RES, V45, P5867.
   WATAYA Y, 1988, JPN J CANCER RES, V79, P576.
   Weisburger JH, 1998, MUTAT RES-GEN TOX EN, V416, P125, DOI 10.1016/S1383-5718(98)00083-7.
   Williams JA, 2000, CARCINOGENESIS, V21, P1683, DOI 10.1093/carcin/21.9.1683.
   YAMAMOTO K, 1989, J BIOL CHEM, V264, P15435.
   Yamashita N, 1998, MUTAT RES-FUND MOL M, V397, P191, DOI 10.1016/S0027-5107(97)00210-8.
   YOUNGMAN RJ, 1981, FEBS LETT, V129, P265, DOI 10.1016/0014-5793(81)80180-9.}},
Number-of-Cited-References = {{53}},
Times-Cited = {{11}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{556ZB}},
Wos-Id = {{ISI:000175879000023}},
}

@article{ ISI:000177743100013,
Author = {Turesky, RJ},
Title = {{Heterocyclic aromatic amine metabolism, DNA adduct formation,
   mutagenesis, and carcinogenesis}},
Journal = {{DRUG METABOLISM REVIEWS}},
Year = {{2002}},
Volume = {{34}},
Number = {{3}},
Pages = {{625-650}},
Note = {{5th International Symposium on the Biological Oxidation of Nitrogen in
   Organic Molecules, MUNICH, GERMANY, OCT 04-06, 2001}},
Abstract = {{Heterocyclic aromatic amines (HAAs) are carcinogenic compounds formed in
   meats, fish, and poultry prepared under common household cooking
   practices. Some HAAs are also formed in tobacco smoke condensate.
   Because of the widespread occurrence of HAAs in these daily staples,
   health concerns have been raised regarding the potential role of HAAs in
   the etiology of some human cancers associated with frequent consumption
   of these products. In this review, the metabolism of HAAs to
   biologically active metabolites that bind to DNA and provoke mutations
   and cancer in various biological systems is discussed. Some of the
   current analytical and molecular methods that are used to measure
   biomarkers of HAA exposure and genetic damage in experimental animal
   models and humans are also presented. These biochemical data combined
   may help to better assess the role that HAAs may have in the development
   of some common forms of human cancers.}},
Publisher = {{MARCEL DEKKER INC}},
Address = {{270 MADISON AVE, NEW YORK, NY 10016 USA}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Turesky, RJ (Reprint Author), Natl Ctr Toxicol Res, Div Chem, 3900 NCTR Rd, Jefferson, AR 72079 USA.
   Natl Ctr Toxicol Res, Div Chem, Jefferson, AR 72079 USA.}},
DOI = {{10.1081/DMR-120005665}},
ISSN = {{0360-2532}},
Keywords-Plus = {{CHROMATOGRAPHY/MICROELECTROSPRAY MASS-SPECTROMETRY; SISTER-CHROMATID
   EXCHANGES; HUMAN LYMPHOBLASTOID-CELLS; HUMAN CYTOCHROME-P450 1A2; P-32
   POSTLABELING ASSAY; N-ACETOXY DERIVATIVES; SALMONELLA-TYPHIMURIUM;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; NONHUMAN-PRIMATES;
   ESCHERICHIA-COLI}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Cited-References = {{ADAMSON RH, 2000, FOOD BORNE CARCINOGE, P229.
   AESCHBACHER HU, 1991, MUTAT RES, V259, P235, DOI 10.1016/0165-1218(91)90120-B.
   AESCHBACHER HU, 1995, HETEROCYCLIC AMINES.
   AESCHBACHER HU, 1991, POTENTIAL CARCINOGEN.
   AESCHBACHER HU, 1997, MUTAGENIC CARCINOGEN.
   AESCHBACHER HU, 1999, 7 INT C CARC MUT N S.
   AESCHBACHER HU, 1989, CARCINOGENESIS, V10, P429, DOI 10.1093/carcin/10.3.429.
   AESCHBACHER HU, 2000, FOOD BORNE CARCINOGE.
   Andreassen A, 2001, MUTAGENESIS, V16, P309, DOI 10.1093/mutage/16.4.309.
   BEACH AC, 1992, CARCINOGENESIS, V13, P1053, DOI 10.1093/carcin/13.7.1053.
   BELAND FA, 1985, ENVIRON HEALTH PERSP, V62, P19, DOI 10.2307/3430089.
   BICHARA M, 1985, J MOL BIOL, V183, P341, DOI 10.1016/0022-2836(85)90005-1.
   Bol SAM, 2000, CARCINOGENESIS, V21, P1, DOI 10.1093/carcin/21.1.1.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   BROOKS RA, 1994, CANCER RES, V54, P1665.
   Brown K, 2001, P NATL ACAD SCI USA, V98, P8507, DOI 10.1073/pnas.151251898.
   Burnouf DY, 2001, CARCINOGENESIS, V22, P329, DOI 10.1093/carcin/22.2.329.
   CAROTHRS AM, 1994, CHEM RES TOXICOL, V7, P209, DOI 10.1021/tx00038a015.
   Crosbie SJ, 2000, J CHROMATOGR B, V744, P55, DOI 10.1016/S0378-4347(00)00227-9.
   DASHWOOD R, 1995, HETEROCYCLIC AMINES, P181.
   Dashwood RH, 1998, CANCER RES, V58, P1127.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P2091, DOI 10.1093/carcin/14.10.2091.
   Davis CD, 1996, MUTAT RES-FUND MOL M, V356, P287, DOI 10.1016/0027-5107(96)00074-7.
   Dingley KH, 1999, CANCER EPIDEM BIOMAR, V8, P507.
   Dingley KH, 1998, DRUG METAB DISPOS, V26, P825.
   Felton J. S., 2000, Food borne carcinogens: heterocyclic amines., P31.
   Felton J.S., 1990, HDB EXPT PHARM, P471.
   FELTON JS, 1994, ENVIRON HEALTH PERSP, V102, P201, DOI 10.2307/3432178.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   TURTELTAUB KW, 1992, CANCER RES, V52, P4682.
   FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   FUJIMOTO Y, 1994, JPN J CANCER RES, V85, P506.
   FUSCOE JC, 1988, MUTAT RES, V201, P241, DOI 10.1016/0027-5107(88)90131-5.
   Gangl ET, 2001, ANAL CHEM, V73, P2397, DOI 10.1021/ac0100401.
   GARCIA A, 1993, P NATL ACAD SCI USA, V90, P5989, DOI 10.1073/pnas.90.13.5989.
   GAYLOR DW, 1991, MUTAGENS FOOD DETECT, P229.
   Guengerich FP, 1997, CHEM-BIOL INTERACT, V106, P161, DOI 10.1016/S0009-2797(97)00068-9.
   Hasegawa R, 1996, JPN J CANCER RES, V87, P1125.
   HASEGAWA R, 1994, CARCINOGENESIS, V15, P2567, DOI 10.1093/carcin/15.11.2567.
   HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007.
   JAGERSTAD M, 1991, MUTAT RES, V259, P219, DOI 10.1016/0165-1218(91)90119-7.
   Josephy PD, 1996, MUTAGENESIS, V11, P3, DOI 10.1093/mutage/11.1.3.
   Josephy PD, 1997, MUTAT RES-REV MUTAT, V386, P1.
   Josephy PD, 1998, CHEM RES TOXICOL, V11, P70, DOI 10.1021/tx970171q.
   KAKIUCHI H, 1995, P NATL ACAD SCI USA, V92, P910, DOI 10.1073/pnas.92.3.910.
   KATO R, 1987, JPN J CANCER RES, V78, P297.
   King R.S., 2000, FOOD BORNE CARCINOGE, P90.
   KOSAKARN P, 1993, CARCINOGENESIS, V14, P511, DOI 10.1093/carcin/14.3.511.
   LAMBERT IB, 1992, P NATL ACAD SCI USA, V89, P1310, DOI 10.1073/pnas.89.4.1310.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   Langouet S, 2001, CHEM RES TOXICOL, V14, P211, DOI 10.1021/tx000176e.
   Leclercq L, 1997, ANAL CHEM, V69, P1952, DOI 10.1021/ac9607673.
   Leong-Morgenthaler PM, 1998, CARCINOGENESIS, V19, P1749, DOI 10.1093/carcin/19.10.1749.
   LIN DX, 1994, CANCER RES, V54, P4920.
   LUTZ WK, 1992, CARCINOGENESIS, V13, P2211, DOI 10.1093/carcin/13.12.2211.
   MacLeod S.L., 2000, FOOD BORNE CARCINOGE, P112.
   MANABE S, 1993, CARCINOGENESIS, V14, P899, DOI 10.1093/carcin/14.5.899.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   MCCOY EC, 1983, MUTAT RES, V121, P17, DOI 10.1016/0165-7992(83)90081-7.
   MILLER EC, 1978, CANCER RES, V38, P1479.
   MORGENTHALER PML, 1995, CARCINOGENESIS, V16, P713, DOI 10.1093/carcin/16.4.713.
   NAGAO M, 1993, MUTAT RES, V290, P43, DOI 10.1016/0027-5107(93)90031-A.
   Nagao M, 1997, MUTAT RES-FUND MOL M, V376, P161, DOI 10.1016/S0027-5107(97)00039-0.
   Nagao M, 2001, MUTAT RES-FUND MOL M, V477, P119, DOI 10.1016/S0027-5107(01)00113-0.
   Nagao M, 1996, ENVIRON HEALTH PERSP, V104, P497, DOI 10.2307/3432812.
   OCHIAI M, 1993, CARCINOGENESIS, V14, P2165, DOI 10.1093/carcin/14.10.2165.
   ODA Y, 1995, MUTAT RES-ENVIR MUTA, V334, P145, DOI 10.1016/0165-1161(95)90005-5.
   Oda Y, 2001, MUTAT RES-GEN TOX EN, V492, P81, DOI 10.1016/S1383-5718(01)00154-1.
   Okochi E, 1999, CARCINOGENESIS, V20, P1933, DOI 10.1093/carcin/20.10.1933.
   Okonogi H, 1997, MUTAT RES-GEN TOX EN, V395, P93, DOI 10.1016/S1383-5718(97)00146-0.
   Okonogi H, 1997, CARCINOGENESIS, V18, P745, DOI 10.1093/carcin/18.4.745.
   Paehler A, 2002, CHEM RES TOXICOL, V15, P551, DOI 10.1021/tx010178e.
   PFAU W, 1994, CARCINOGENESIS, V15, P877, DOI 10.1093/carcin/15.5.877.
   Phillips DH, 1997, MUTAT RES-FUND MOL M, V378, P1, DOI 10.1016/S0027-5107(97)00092-4.
   POIRIER MC, 1992, CHEM RES TOXICOL, V5, P749, DOI 10.1021/tx00030a003.
   Potter JD, 1996, CANCER CAUSE CONTROL, V7, P127, DOI 10.1007/BF00115644.
   POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0.
   REDDY BS, 1993, CANCER RES, V53, P3914.
   RINDGEN D, 1995, CHEM RES TOXICOL, V8, P1005, DOI 10.1021/tx00050a003.
   Ronco A, 1996, INT J CANCER, V65, P328, DOI 10.1002/(SICI)1097-0215(19960126)65:3<328::AID-IJC9>3.0.CO;2-1.
   SANTELLA RM, 1983, ENVIRON HEALTH PERSP, V49, P107, DOI 10.2307/3429587.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   Shibutani S, 1999, J BIOL CHEM, V274, P27433, DOI 10.1074/jbc.274.39.27433.
   Shimada T, 1996, CANCER RES, V56, P2979.
   Shirai T, 1997, CANCER RES, V57, P195.
   Singh G, 2000, ANAL CHEM, V72, P3007, DOI 10.1021/ac000374a.
   SINHA R, 1994, CANCER RES, V54, P6154.
   SINHA R, 1995, CANCER RES, V55, P4516.
   SKIPPER PL, 1990, CARCINOGENESIS, V11, P507, DOI 10.1093/carcin/11.4.507.
   SNYDERWINE EG, 1994, CANCER, V74, P1070, DOI 10.1002/1097-0142(19940801)74:3+<1070::AID-CNCR2820741515>3.0.CO;2-7.
   Snyderwine EG, 1997, MUTAT RES-FUND MOL M, V376, P203, DOI 10.1016/S0027-5107(97)00044-4.
   SNYDERWINE EG, 2000, FOOD BORNE CARCINOGE, P241.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1061, DOI 10.1093/carcin/9.6.1061.
   Soglia JR, 2001, ANAL CHEM, V73, P2819, DOI 10.1021/ac010218j.
   Solomon MS, 1996, J BIOL CHEM, V271, P18368.
   Stuart GR, 2000, CANCER RES, V60, P266.
   SUGIMURA T, 1983, CANCER RES, V43, P2415.
   SUGIMURA T, 1986, ENV HLTH PERSPECT, P5.
   Sugimura T, 2000, MUTAT RES-FUND MOL M, V447, P15, DOI 10.1016/S0027-5107(99)00196-7.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   THOMPSON LH, 1987, MUTAGENESIS, V2, P483, DOI 10.1093/mutage/2.6.483.
   THOMPSON LH, 1983, MUTAT RES, V117, P243, DOI 10.1016/0165-1218(83)90125-8.
   Thorgeirsson SS, 2000, TOXICOL LETT, V112, P553, DOI 10.1016/S0378-4274(99)00224-6.
   TOHDA H, 1980, MUTAT RES, V77, P65, DOI 10.1016/0165-1218(80)90121-4.
   Turesky RJ, 1996, CHEM RES TOXICOL, V9, P403, DOI 10.1021/tx950132j.
   Turesky RJ, 1997, MUTAT RES-FUND MOL M, V376, P235, DOI 10.1016/S0027-5107(97)00048-1.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P925, DOI 10.1021/tx980022n.
   TURESKY RJ, 1994, DNA ADDUCTS IDENTIFI, P217.
   TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005.
   TURESKY RJ, 1994, CHEM RES TOXICOL, V7, P752, DOI 10.1021/tx00042a007.
   Turteltaub KW, 1997, MUTAT RES-FUND MOL M, V376, P243, DOI 10.1016/S0027-5107(97)00049-3.
   TURTELTAUB KW, 1990, P NATL ACAD SCI USA, V87, P5288, DOI 10.1073/pnas.87.14.5288.
   USHIJIMA T, 1994, MOL CARCINOGEN, V10, P38, DOI 10.1002/mc.2940100107.
   Vogel JS, 1995, ANAL CHEM, V67, P353.
   WATANABE M, 1990, MUTAT RES, V234, P337, DOI 10.1016/0165-1161(90)90044-O.
   WATANABE M, 1993, CARCINOGENESIS, V14, P1149, DOI 10.1093/carcin/14.6.1149.
   Wattenberg LW, 1997, P SOC EXP BIOL MED, V216, P133.
   WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404.
   Willett WC, 1995, ENVIRON HEALTH PERSP, V103, P165, DOI 10.2307/3432305.
   Winsten J. A., 1977, ORIGINS HUMAN CANC, P1561.
   WU RW, 1995, CARCINOGENESIS, V16, P1207, DOI 10.1093/carcin/16.5.1207.
   YadollahiFarsani M, 1996, CARCINOGENESIS, V17, P617, DOI 10.1093/carcin/17.4.617.}},
Number-of-Cited-References = {{122}},
Times-Cited = {{72}},
Journal-ISO = {{Drug Metab. Rev.}},
Doc-Delivery-Number = {{589DN}},
Wos-Id = {{ISI:000177743100013}},
}

@article{ ISI:000174494000007,
Author = {Felton, JS and Knize, MG and Salmon, CP and Malfatti, MA and Kulp, KS},
Title = {{Human exposure to heterocyclic amine food mutagens/carcinogens:
   Relevance to breast cancer}},
Journal = {{ENVIRONMENTAL AND MOLECULAR MUTAGENESIS}},
Year = {{2002}},
Volume = {{39}},
Number = {{2-3}},
Pages = {{112-118}},
Note = {{Conference on Breast Cancer and Environmental Mutagens, RES TRIANGLE PK,
   NORTH CAROLINA, SEP 22-25, 2001}},
Organization = {{Environm Mutagen Soc}},
Abstract = {{Heterocyclic amines produced from overcooked foods are extremely
   mutagenic in numerous in vitro and in vivo test systems. One of these
   mutagens, 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP),
   induces breast tumors in rats and has been implicated in dietary
   epidemiology studies as raising the risk of breast cancer in humans.
   Efforts in our laboratory and others have centered on defining the
   exposure to PhIP and other dietary mutagens derived from cooked food. We
   accomplish this by analyzing the foods with a series of solid-phase
   extractions and HPLC. We have developed an LC/MS/MS method to analyze
   the four major human PhIP metabolites (sulfates and glucuronides)
   following a single meal containing 27 mug of cooking-produced PhIP in
   200 g of grilled meat. Although the intake of PhIP was similar for each
   of eight women, the total amount excreted in the urine and the
   metabolite profiles differed among the subjects. It appears that
   adsorption (digestion) from the meat matrix, other foods in the diet,
   and genetic differences in metabolism may contribute to the variation.
   The four major metabolites that can be routinely assayed in the urine
   are N-2-OH-PhIP-N-2-glucuronide, PhIP-N-2-glucuronide,
   4'-PhIP-glucuronide, and N-2-OH-PhIP-N3-glucuronide. This work is suited
   to investigate individual exposure and risk, especially for breast
   cancer, from these potent dietary mutagens. Published 2002 Wiley-Liss,
   Inc.}},
Publisher = {{WILEY-LISS}},
Address = {{DIV JOHN WILEY \& SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Felton, JS (Reprint Author), Lawrence Livermore Natl Lab, Mol \& Struct Biol Div, L-452, Livermore, CA 94551 USA.
   Lawrence Livermore Natl Lab, Mol \& Struct Biol Div, Livermore, CA 94551 USA.}},
DOI = {{10.1002/em.10070}},
ISSN = {{0893-6692}},
Keywords = {{dietary mutagen; heterocyclic aromatic amines; glucuronide; PhIP;
   tumorigenicity; chemoprevention}},
Keywords-Plus = {{FRIED GROUND-BEEF; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP;
   COOKED FOODS; NONHUMAN-PRIMATES; LIVER-MICROSOMES; COLON-CANCER;
   MUTAGEN; GLUCURONIDATION; IDENTIFICATION; CHICKEN}},
Research-Areas = {{Environmental Sciences \& Ecology; Genetics \& Heredity; Toxicology}},
Web-of-Science-Categories  = {{Environmental Sciences; Genetics \& Heredity; Toxicology}},
Cited-References = {{ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   ADAMSON RH, 1994, ENVIRON HEALTH PERSP, V102, P190, DOI 10.2307/3431610.
   ALINK GM, 1988, MUTAT RES, V206, P387, DOI 10.1016/0165-1218(88)90125-5.
   Bjeldanes L. F., 1982, FOOD CHEM TOXICOL, V20, P57.
   BJELDANES LF, 1982, MUTAT RES, V105, P43, DOI 10.1016/0165-7992(82)90206-8.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   DEVERDIER MG, 1991, INT J CANCER, V49, P1.
   EDWARDS RJ, 1994, CARCINOGENESIS, V15, P829, DOI 10.1093/carcin/15.5.829.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FELTON JS, 1984, CARCINOGENESIS, V5, P95, DOI 10.1093/carcin/5.1.95.
   FELTON JS, 1994, J NATL CANCER I, V86, P1041, DOI 10.1093/jnci/86.14.1041.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   FENNEMA O, 1990, TOXICOL FORUM   0716.
   GAYLOR DW, 1991, MUTAGENS FOOD DETECT, P229.
   GOLDBOHM RA, 1994, CANCER RES, V54, P718.
   Green MD, 1998, DRUG METAB DISPOS, V26, P860.
   GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1695, DOI 10.1093/carcin/15.8.1695.
   KASAI H, 1981, CHEM LETT, P485, DOI 10.1246/cl.1981.485.
   King CD, 1996, ARCH BIOCHEM BIOPHYS, V332, P92, DOI 10.1006/abbi.1996.0320.
   KNIZE MG, 1992, J CHROMATOGR, V624, P253, DOI 10.1016/0021-9673(92)85683-K.
   Knize MG, 1998, J AGR FOOD CHEM, V46, P4648, DOI 10.1021/jf980639a.
   KNIZE MG, 1989, CARCINOGENESIS, V10, P1479, DOI 10.1093/carcin/10.8.1479.
   KNIZE MG, 1994, FOOD CHEM TOXICOL, V32, P55, DOI 10.1016/0278-6915(84)90037-1.
   KNIZE MG, 1985, FOOD CHEM TOXICOL, V23, P1035, DOI 10.1016/0278-6915(85)90049-3.
   KNIZE MG, 1988, MUTAGENESIS, V3, P503, DOI 10.1093/mutage/3.6.503.
   Kulp KS, 2000, CARCINOGENESIS, V21, P2065, DOI 10.1093/carcin/21.11.2065.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001.
   Malfatti MA, 2001, CARCINOGENESIS, V22, P1087, DOI 10.1093/carcin/22.7.1087.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   MANABE S, 1993, CARCINOGENESIS, V14, P899, DOI 10.1093/carcin/14.5.899.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   Nowell SA, 1999, CARCINOGENESIS, V20, P1107, DOI 10.1093/carcin/20.6.1107.
   OHGAKI H, 1987, CARCINOGENESIS, V8, P665, DOI 10.1093/carcin/8.5.665.
   OZAWA S, 1994, JPN J CANCER RES, V85, P1220.
   SCHIFFMAN MH, 1990, AM J EPIDEMIOL, V131, P376.
   Shirai T, 1997, CANCER RES, V57, P195.
   SINHA R, 1995, CANCER RES, V55, P4516.
   SINHA R, 2000, P AM ASSOC CANC RES, V41, P804.
   Steineck G, 1993, Eur J Cancer Prev, V2, P293, DOI 10.1097/00008469-199307000-00002.
   Strassburg CP, 1998, MOL PHARMACOL, V54, P647.
   STYCZYNSKI PB, 1993, CHEM RES TOXICOL, V6, P846, DOI 10.1021/tx00036a014.
   SUGIMURA T, 1988, CHEM INDUCTION CANC, P681.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   TURTELTAUB KW, 1989, FOOD CHEM TOXICOL, V27, P667, DOI 10.1016/0278-6915(89)90121-X.
   TURTLETAUB KW, 1988, P AM ASSOC CANC RES, V29, P120.
   VISVANATHAN K, 2000, P AM ASSOC CANC RES, V41, P805.
   Winsten J. A., 1977, ORIGINS HUMAN CANC, P1561.
   Wu RW, 1997, MUTAT RES-GEN TOX EN, V390, P93, DOI 10.1016/S0165-1218(97)00005-0.
   Wu RW, 2000, ENVIRON MOL MUTAGEN, V35, P57, DOI 10.1002/(SICI)1098-2280(2000)35:1<57::AID-EM8>3.0.CO;2-7.
   ZHENG W, 2000, P AM ASSOC CANC RES, V41, P805.}},
Number-of-Cited-References = {{55}},
Times-Cited = {{37}},
Journal-ISO = {{Environ. Mol. Mutagen.}},
Doc-Delivery-Number = {{532UT}},
Wos-Id = {{ISI:000174494000007}},
}

@article{ ISI:000171579300007,
Author = {Friesen, MD and Rothman, N and Strickland, PT},
Title = {{Concentration of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP)
   in urine and alkali-hydrolyzed urine after consumption of charbroiled
   beef}},
Journal = {{CANCER LETTERS}},
Year = {{2001}},
Volume = {{173}},
Number = {{1}},
Pages = {{43-51}},
Month = {{NOV 8}},
Abstract = {{Heterocyclic amines (HAs) and polycyclic aromatic hydrocarbons are
   carcinogenic products formed during the cooking of meat at moderate to
   high temperatures. We have previously shown that the urinary
   concentration of 1-hydroxypyrene-glucuronide, a metabolite of pyrene,
   increased significantly in ten subjects who had ingested charbroiled
   ground beef. We now report the time course and interindividual variation
   of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) concentration
   in the urine samples from these ten subjects. PhIP concentration was
   determined in both untreated and alkali-hydrolyzed urine to obtain
   estimates of the proportion of conjugated PhIP metabolites in each
   subject. PhIP was measured by gas chromatography-negative ion chemical
   ionization-mass spectrometry after derivatization with pentafluorobenzyl
   bromide. Ten healthy nonsmoking males consumed identical amounts of
   broiled beef on five consecutive days. The morning after the first day
   of broiled beef consumption, urinary concentration of PhIP increased
   14-38 fold above mean pre-feed concentration of PhIP in individual
   alkali-hydrolyzed urine samples. Following cessation of broiled beef
   consumption, urinary PhIP concentration declined to near pre-feed levels
   within 48-72 hrs. The ratio of total alkali-labile PhIP metabolites to
   unmetabolized PhIP varied by about 2.7-fold among subjects, ranging from
   18:1 to 48:1, suggesting that interindividual differences in PhIP
   metabolism occur and can be detected by this method. This study of
   urinary PhIP following ingestion of meat cooked by charbroiling, that
   contains both HAs and polycyclic aromatic hydrocarbons, extends previous
   studies of ingestion of pan-fried meat that contains primarily HAs. The
   results indicate that significant amounts of PhIP are bioavailable from
   ingestion of charbroiled ground beef and that measurement of proportions
   of alkali-labile PhIP metabolites and parent PhIP in human urine may
   yield information on individual metabolism of ingested PhIP. (C) 2001
   Elsevier Science Ireland Ltd. All rights reserved.}},
Publisher = {{ELSEVIER SCI IRELAND LTD}},
Address = {{CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Strickland, PT (Reprint Author), 615 N Wolfe St, Baltimore, MD 21205 USA.
   Int Agcy Res Canc, Unit Gene Environm Interact, F-69372 Lyon, France.
   NCI, Div Canc Epidemiol \& Genet, Bethesda, MD 20892 USA.
   Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA.}},
DOI = {{10.1016/S0304-3835(01)00672-3}},
ISSN = {{0304-3835}},
Keywords = {{heterocyclic aromatic amine; broiled meat; carcinogen; PhIP; urine
   metabolites}},
Keywords-Plus = {{FOOD MUTAGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE;
   HETEROCYCLIC AMINES; COLORECTAL-CANCER; CYTOCHROME P4501A2;
   COLON-CANCER; COOKED FOOD; WELL-DONE; RED MEAT; HUMANS; IDENTIFICATION}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
ResearcherID-Numbers = {{Friesen, Marlin/D-7328-2012}},
Cited-References = {{ALEXANDER J, 1991, CARCINOGENESIS, V12, P2239, DOI 10.1093/carcin/12.12.2239.
   ALEXANDER J, 1989, CARCINOGENESIS, V10, P1543, DOI 10.1093/carcin/10.8.1543.
   AUGUSTSSON K, 1999, LANCET, V353, P686.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   CONNEY AH, 1982, CANCER RES, V42, P4875.
   Crofts FG, 1998, CARCINOGENESIS, V19, P1969, DOI 10.1093/carcin/19.11.1969.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FELTON JS, 1990, CHEM CARCINOGENESIS, V1, P471.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   Friedman JM, 1996, PENN CTR N, V5, P67.
   Gerhardsson de Verdier M, 1991, Int J Cancer, V49, P520.
   GIOVANNUCCI E, 1994, CANCER RES, V54, P2390.
   Greenberg A., 1993, Polycyclic Aromatic Compounds, V3, P101, DOI 10.1080/10406639308047862.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KANG DH, 1995, CARCINOGENESIS, V16, P1079, DOI 10.1093/carcin/16.5.1079.
   Kidd LCR, 1999, CANCER EPIDEM BIOMAR, V8, P439.
   Kulp KS, 2000, CARCINOGENESIS, V21, P2065, DOI 10.1093/carcin/21.11.2065.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   MUSCAT JE, 1994, AM J PUBLIC HEALTH, V84, P856, DOI 10.2105/AJPH.84.5.856.
   PETERS RK, 1989, CANCER RES, V49, P5459.
   Potter JD, 1999, J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916.
   ProbstHensch NM, 1997, CANCER CAUSE CONTROL, V8, P175, DOI 10.1023/A:1018416128894.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   SCHIFFMAN MH, 1990, AM J EPIDEMIOL, V131, P376.
   SINHA R, 1995, CARCINOGENESIS, V16, P2859, DOI 10.1093/carcin/16.11.2859.
   Sinha R, 1999, CANCER RES, V59, P4320.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   STRICKLAND PT, 2001, IN PRESS BIOMARKERS, V6.
   STYCZYNSKI PB, 1993, CHEM RES TOXICOL, V6, P846, DOI 10.1021/tx00036a014.
   SUGIMURA T, 1988, CHEM INDUCTION CANC, P681.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   {*}AM I RES CANC WOR, 1997, FOOD NUTR PREV CANC.}},
Number-of-Cited-References = {{38}},
Times-Cited = {{23}},
Journal-ISO = {{Cancer Lett.}},
Doc-Delivery-Number = {{482ME}},
Wos-Id = {{ISI:000171579300007}},
}

@article{ ISI:000171083800002,
Author = {Coles, B and Nowell, SA and MacLeod, SL and Sweeney, C and Lang, NP and
   Kadlubar, FF},
Title = {{The role of human glutathione S-transferases (hGSTs) in the
   detoxification of the food-derived carcinogen metabolite N-acetoxy-PhIP,
   and the effect of a polymorphism in hGSTA1 on colorectal cancer risk}},
Journal = {{MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS}},
Year = {{2001}},
Volume = {{482}},
Number = {{1-2, SI}},
Pages = {{3-10}},
Month = {{OCT 1}},
Abstract = {{Food-derived heterocyclic amines (HCAs), particularly
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP), are implicated
   in the etiology of human colorectal cancer (CRC) via a process of
   N-oxidation followed by O-acetylation or O-sulfation to form
   electrophilic metabolites that react with DNA. Glutathione
   S-transferases (GSTs) detoxify activated carcinogen metabolites by
   catalysis of their reaction with GSH. However, among HCAs, only
   N-acetoxy-PhIP has been shown to be a substrate for the GSTs. By using a
   competitive DNA-binding assay, we confirm that hGSTA1-1 is an efficient
   catalyst of the detoxification of N-acetoxy-PhIP. Further, we show that
   hGSTs A2-2, P1-1, M1-1, T1-1 and T2-2 appear to have low activity
   towards N-acetoxy-PhIP, and that hGSTs A4-4, M2-2, M4-4 and Z1-1 appear
   to have no activity towards N-acetoxy-PhIP. A genetic polymorphism in
   the 5 ` -regulatory sequence of hGSTA1 has been shown to correlate with
   the relative and absolute levels of expression of GSTA1/GSTA2 in human
   liver. Examination of hGSTA1 allele frequency in 100 Caucasian CRC
   patients and 226 Caucasian controls demonstrated a significant
   over-representation of the homozygous hGSTA1{*}B genotype among cases
   compared to controls (24.0 and 13.7\%, respectively, P = 0.04). This
   corresponds to an odds ratio for risk of CRC of 2.0 (95\% Cl 1.0-3.7)
   when comparing homozygous hGSTA1{*}B individuals with all other
   genotypes. Thus. individuals who are homozygous hGSTA1{*}B, and who
   would be predicted to have the lowest levels of hGSTA1 expression in
   their livers, appear to be at risk of developing CRC, possibly as a
   result of inefficient hepatic detoxification of N-acetoxy-PhIP. (C) 2001
   Elsevier Science B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Coles, B (Reprint Author), Natl Ctr Toxicol Res, Div Mol Epidemiol, HFT 100,3900 NCTR Rd, Jefferson, AR 72079 USA.
   Natl Ctr Toxicol Res, Div Mol Epidemiol, Jefferson, AR 72079 USA.
   Univ Arkansas Med Sci, Div Surg Oncol, Dept Surg, Little Rock, AR 72205 USA.
   Cent Arkansas Vet Healthcare Syst, Surg Serv, Little Rock, AR 72205 USA.}},
DOI = {{10.1016/S0027-5107(01)00187-7}},
ISSN = {{0027-5107}},
Keywords = {{human glutathione S-transferases; hGSTA1 genetic polymorphism;
   colorectal cancer; PhIP; detoxification}},
Keywords-Plus = {{MUTAGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP;
   HETEROCYCLIC AMINE CARCINOGENS; ALPHA-CLASS; TISSUE DISTRIBUTION;
   LIVER-MICROSOMES; COLON-CANCER; DNA-ADDUCTS; IN-VITRO; RAT;
   IDENTIFICATION}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
ResearcherID-Numbers = {{yang, min/G-3030-2011}},
Cited-References = {{ALEXANDER J, 1989, CARCINOGENESIS, V10, P1543, DOI 10.1093/carcin/10.8.1543.
   Board PG, 1997, BIOCHEM J, V328, P929.
   Board PG, 1998, BIOCHEM J, V330, P827.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   CHOU HC, 1995, CANCER RES, V55, P525.
   Coleman MD, 2000, ENVIRON TOXICOL PHAR, V8, P167, DOI 10.1016/S1382-6689(00)00037-5.
   COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605.
   COLES BF, 2001, IN PRESS PHARMACOGEN.
   Coles BF, 2000, CANCER RES, V60, P573.
   Cotton SC, 2000, AM J EPIDEMIOL, V151, P7.
   de Bruin WCC, 1999, CARCINOGENESIS, V20, P1453, DOI 10.1093/carcin/20.8.1453.
   de Bruin WCC, 2000, JPN J CANCER RES, V91, P310.
   Dingley KH, 1999, CANCER EPIDEM BIOMAR, V8, P507.
   Felton J.S., 1990, HDB EXPT PHARM, P471.
   Gertig DM, 1998, CANCER EPIDEM BIOMAR, V7, P1001.
   Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491.
   Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29.
   HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007.
   Hengstler JG, 1998, CANCER LETT, V128, P105, DOI 10.1016/S0304-3835(98)00059-7.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   Hubatsch I, 1998, BIOCHEM J, V330, P175.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1695, DOI 10.1093/carcin/15.8.1695.
   King RS, 1999, CANCER LETT, V143, P167, DOI 10.1016/S0304-3835(99)00119-6.
   Kiss I, 2000, ANTICANCER RES, V20, P519.
   LANDI MT, 1999, METABOLIC POLYMORPHI, V148, P173.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LIN DX, 1994, CANCER RES, V54, P4920.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   Liu SX, 1998, ARCH BIOCHEM BIOPHYS, V352, P306, DOI 10.1006/abbi.1998.0608.
   LUKS HJ, 1989, CANCER RES, V49, P4407.
   MEYER DJ, 1991, BIOCHEM J, V274, P409.
   MEYER DJ, 1995, METHOD ENZYMOL, V252, P53.
   MINCHIN RF, 1992, BIOCHEM BIOPH RES CO, V185, P839, DOI 10.1016/0006-291X(92)91703-S.
   Nagao M, 1999, MUTAT RES-FUND MOL M, V431, P3, DOI 10.1016/S0027-5107(99)00154-2.
   POTTER JD, 1993, EPIDEMIOL REV, V15, P499.
   Rebbeck TR, 1997, CANCER EPIDEM BIOMAR, V6, P733.
   Roberts-Thomson IC, 1999, EUR J CANCER PREV, V8, P207, DOI 10.1097/00008469-199906000-00008.
   Rowe JD, 1997, BIOCHEM J, V325, P481.
   Sherratt PJ, 1997, BIOCHEM J, V326, P837.
   SJODIN P, 1989, CARCINOGENESIS, V10, P1269, DOI 10.1093/carcin/10.7.1269.
   SUNDBERG AGM, 1993, PHARMACOL TOXICOL, V72, P321.
   THOMPSON LH, 1987, MUTAGENESIS, V2, P483, DOI 10.1093/mutage/2.6.483.
   TURESKY RJ, 1988, CARCINOGENESIS, V9, P1043, DOI 10.1093/carcin/9.6.1043.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P941, DOI 10.1093/carcin/11.6.941.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WALLIN H, 1989, CARCINOGENESIS, V10, P1277, DOI 10.1093/carcin/10.7.1277.
   Zhang H, 1999, INT J CANCER, V84, P135, DOI 10.1002/(SICI)1097-0215(19990420)84:2<135::AID-IJC7>3.0.CO;2-C.}},
Number-of-Cited-References = {{51}},
Times-Cited = {{61}},
Journal-ISO = {{Mutat. Res.-Fundam. Mol. Mech. Mutagen.}},
Doc-Delivery-Number = {{474BE}},
Wos-Id = {{ISI:000171083800002}},
}

@article{ ISI:000170235200002,
Author = {Strickland, PT and Qian, Z and Friesen, MD and Rothman, N and Sinha, R},
Title = {{Measurement of 2-amino-1-methyl-6-phenylimidazo(4,5-b) pyridine (PhIP)
   in acid-hydrolyzed urine by high-performance liquid chromatography with
   fluorescence detection}},
Journal = {{BIOMARKERS}},
Year = {{2001}},
Volume = {{6}},
Number = {{5}},
Pages = {{313-325}},
Month = {{SEP}},
Abstract = {{Heterocyclic aromatic amines are carcinogenic combustion products formed
   during the cooking of meat at moderate to high temperatures. The authors
   have developed a simplified method to measure the commonly formed
   heterocyclic amine, 2-amino-1-methyl-6-phenylimidazo( 4,5-b) pyridine
   (PhIP), in acid-hydrolyzed human urine by HPLC with fluorescence
   detection after immuno-affinity chromatography. The method was compared
   with a previously validated method using gas chromatography/mass
   spectrometry after chemical derivatization. The comparison was performed
   using 100 urine samples from a study of 10 subjects before, during and
   after ingesting identical amounts of charbroiled (grilled) meat on 5
   consecutive days. The overall correlation between the two assays was r =
   0.87 (p < 0.0001). The HPLC method was then used to measure PhIP in
   acid-hydrolyzed urine collected from 66 subjects participating in a
   study of fried meat ingestion. Fried meat cooked at high temperature was
   fed to subjects based on body weight; urines were collected before
   feeding and 0-12 and 12-24 h after feeding. In a subset of six subjects,
   urinary PhIP concentration was 3-13-fold higher in the 0-12-h urine than
   in the 12-24-h urine. In the total study population, a significant
   correlation (r = 0.61, p < 0.0001) between the amount of fried meat
   ingested and urinary PhIP was observed. These results indicate that
   measurement of urinary PhIP by HPLC after immuno-affinity chromatography
   is a useful alternative to mass spectrometry methods for assessing
   recent exposure in subjects ingesting moderate to high levels of PhIP.}},
Publisher = {{TAYLOR \& FRANCIS LTD}},
Address = {{11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Strickland, PT (Reprint Author), Johns Hopkins Univ, Sch Hyg \& Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Sch Hyg \& Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA.
   Int Agcy Res Canc, Div Gene Environm Interact, F-69372 Lyon, France.
   NCI, Div Canc Epidemiol \& Genet, Bethesda, MD 20892 USA.}},
ISSN = {{1354-750X}},
Keywords = {{urine metabolites; PhIP; HPLC; biomarker; heterocyclic amines; dietary
   carcinogens}},
Keywords-Plus = {{HETEROCYCLIC AROMATIC-AMINES; FOOD MUTAGEN
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE; CYTOCHROME P4501A2;
   COLORECTAL-CANCER; BORNE CARCINOGEN; COLON-CANCER; COOKED FOOD; DNA
   ADDUCTS; FRIED MEAT; HUMANS}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Toxicology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Toxicology}},
ResearcherID-Numbers = {{Friesen, Marlin/D-7328-2012}},
Cited-References = {{ALEXANDER J, 1991, CARCINOGENESIS, V12, P2239, DOI 10.1093/carcin/12.12.2239.
   ALEXANDER J, 1989, CARCINOGENESIS, V10, P1543, DOI 10.1093/carcin/10.8.1543.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   Crofts FG, 1998, CARCINOGENESIS, V19, P1969, DOI 10.1093/carcin/19.11.1969.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FELTON JS, 1990, CHEM CARCINOGENESIS, V1, P471.
   FISHER LD, 1993, BIOSTATISTICS METHOD, P369.
   Friesen MD, 1996, CARCINOGENESIS, V17, P67, DOI 10.1093/carcin/17.1.67.
   Gerhardsson de Verdier M, 1991, Int J Cancer, V49, P520.
   GIOVANNUCCI E, 1994, CANCER RES, V54, P2390.
   GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KANG DH, 1995, CARCINOGENESIS, V16, P1079, DOI 10.1093/carcin/16.5.1079.
   Kidd LCR, 1999, CANCER EPIDEM BIOMAR, V8, P439.
   KULP KS, 2000, P AM ASSOC CANC RES, V41, P596.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   Potter JD, 1999, J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   SCHIFFMAN MH, 1990, AM J EPIDEMIOL, V131, P376.
   SINHA R, 1994, CANCER RES, V54, P6154.
   SINHA R, 1995, CARCINOGENESIS, V16, P2859, DOI 10.1093/carcin/16.11.2859.
   Sinha R, 1999, CANCER RES, V59, P4320.
   SKOG K., 1995, HETEROCYCLIC AMINES, P9.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   STYCZYNSKI PB, 1993, CHEM RES TOXICOL, V6, P846, DOI 10.1021/tx00036a014.
   SUGIMURA T, 1983, CANCER RES, V43, P2415.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{15}},
Journal-ISO = {{Biomarkers}},
Doc-Delivery-Number = {{459DF}},
Wos-Id = {{ISI:000170235200002}},
}

@article{ ISI:000171047100004,
Author = {Dubuisson, JG and Murph, WS and Griffin, SR and Gaubatz, JW},
Title = {{Cytosolic enzymes from rat tissues that activate the cooked meat mutagen
   metabolite N-Hydroxyamino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine
   (N-OH-PhIP)}},
Journal = {{JOURNAL OF NUTRITIONAL BIOCHEMISTRY}},
Year = {{2001}},
Volume = {{12}},
Number = {{9}},
Pages = {{518-528}},
Month = {{SEP}},
Abstract = {{Heterocyclic amines are formed during the cooking of foods rich in
   protein and can be metabolically converted into cytotoxic and mutagenic
   compounds. These ``cooked-food mutagens{''} constitute a potential
   health hazard because DNA damage arising from dietary exposure to
   heterocyclic amines can modify cell genomes and thereby affect future
   organ function. To determine enzymes responsible for heterocyclic amine
   processing in mammalian tissues, we performed studies to measure
   genotoxic activation of the N-hydroxy form of
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP)-a common
   dietary mutagen. O-Acetyltransferase, sulfotransferase, kinase, and
   amino-acyl synthetase activities were assayed using substrate-specific
   reactions and cytosolic enzymes from newborn and adult rat heart, liver,
   spleen, kidney, brain, lung, and skeletal muscle. The resultant
   enzyme-specific DNA adduct formation was quantified via 32P-postlabeling
   techniques. In biochemical assays with rat tissue cytosolic proteins,
   O-acetyltransferases were the enzymes most responsible for
   N-hydroxy-PhIP (N-OH-PhIP) activation. Compared to O-acetyltransferase
   activation, there was significantly less kinase activity and even lesser
   amounts of sulfotransferase activity. Proyl-tRNA synthetase activation
   of N-OH-PhIP was not detected. Comparing newborn rat tissues, the
   highest level of O-acetyltransferase mutagen activation was observed for
   neonatal heart tissue with activities ranked in the order of heart >
   kidney > lung > liver > skeletal muscle > brain > spleen. Enzymes from
   cultured neonatal myocytes displayed high O-acetyltransferase
   activities, similar to that observed for whole newborn heart. This
   tissue specificity suggests that neonatal cardiac myocytes might be at
   greater risk for damage from dietary heterocyclic amine mutagens than
   some other cell types. However, cytosolic enzymes from adult rat tissues
   exhibited a different O-acetyltransferase activation profile, such that
   liver > muscle > spleen > kidney > lung > brain > heart. These results
   demonstrated that enzymes involved in catalyzing PhIP-DNA adduct
   formation varied substantially in activity between tissues and in some
   tissues, changed significantly during development and aging. The results
   further suggest that O-acetyltransferases are the primary activators of
   N-OH-PhIP in rat tissues. (C) 2001 Elsevier Science Inc. All rights
   reserved.}},
Publisher = {{ELSEVIER SCIENCE INC}},
Address = {{655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Gaubatz, JW (Reprint Author), Univ S Alabama, Coll Med, Dept Biochem \& Mol Biol, Mobile, AL 36688 USA.
   Univ S Alabama, Coll Med, Dept Biochem \& Mol Biol, Mobile, AL 36688 USA.}},
DOI = {{10.1016/S0955-2863(01)00168-1}},
ISSN = {{0955-2863}},
Keywords = {{cooked meat mutagens; heterocyclic amines; PhIP; DNA damage; rat
   tissues; phase II activation; carcinogen metabolism}},
Keywords-Plus = {{FOOD-BORNE CARCINOGEN; DNA-ADDUCTS; HETEROCYCLIC AMINE;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; POSTLABELING
   ANALYSIS; CULTURED MYOCYTES; MOUSE MYOCARDIUM; HEART-DISEASE; HUMAN
   LIVER; CANCER}},
Research-Areas = {{Biochemistry \& Molecular Biology; Nutrition \& Dietetics}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Nutrition \& Dietetics}},
Cited-References = {{BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   CUMMINGS DA, 1994, CARCINOGENESIS, V15, P2523.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P2091, DOI 10.1093/carcin/14.10.2091.
   DAVIS CD, 1995, FOOD CHEM TOXICOL, V33, P641, DOI 10.1016/0278-6915(95)00033-X.
   DAVIS CD, 1994, J NATL CANCER I, V86, P1065, DOI 10.1093/jnci/86.14.1065.
   DAVIS CD, 1994, TOXICOL APPL PHARM, V124, P201, DOI 10.1006/taap.1994.1024.
   DRAGSTED LO, 1995, CARCINOGENESIS, V16, P2785, DOI 10.1093/carcin/16.11.2785.
   Dubuisson JG, 1998, NUTRITION, V14, P683, DOI 10.1016/S0899-9007(98)00106-3.
   FELTON JS, 1994, ENVIRON HEALTH PERSP, V102, P138, DOI 10.2307/3431598.
   FELTON JS, 1990, CHEM CARCINOGENESIS, V1, P471.
   FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   FUKUTOME K, 1994, JPN J CANCER RES, V85, P113.
   Gaubatz JW, 1997, J NUTR BIOCHEM, V8, P490, DOI 10.1016/S0955-2863(97)00080-6.
   GAUBATZ JW, 1995, FASEB J, V10, pA967.
   GAUBATZ JW, 1986, J MOL CELL CARDIOL, V18, P1317, DOI 10.1016/S0022-2828(86)80435-7.
   Gaubatz JW, 1995, MOL BASIS AGING, VCRC Press, P71.
   GAUBATZ JW, 1989, ARCH GERONTOL GERIAT, V8, P47, DOI 10.1016/0167-4943(89)90069-1.
   GORDON T, 1981, CIRCULATION, V63, P500.
   HASEGAWA R, 1993, CARCINOGENESIS, V14, P2553, DOI 10.1093/carcin/14.12.2553.
   He YH, 1999, J BIOCHEM MOL TOXIC, V13, P239, DOI 10.1002/(SICI)1099-0461(1999)13:5<239::AID-JBT3>3.0.CO;2-P.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERIK KR, 1994, CARCINOGENESIS, V15, P711.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LIN DX, 1995, DRUG METAB DISPOS, V23, P518.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   NAGAO M, 1993, MUTAT RES, V290, P43, DOI 10.1016/0027-5107(93)90031-A.
   Nerurkar PV, 1996, MOL PHARMACOL, V49, P874.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   OVERVIK E, 1991, MUTAT RES, V256, P37, DOI 10.1016/0921-8734(91)90031-6.
   OVERVIK E, 1990, MUTAGENESIS, V5, P437, DOI 10.1093/mutage/5.5.437.
   OVERVIK E, 1987, MUTAT RES, V187, P47, DOI 10.1016/0165-1218(87)90117-0.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   SHIMADA T, 1991, CANCER RES, V51, P5284.
   Shirai T, 1997, CANCER RES, V57, P195.
   SHIRAI T, HETEROCYCLIC AMINES, P185.
   SIMPSON P, 1982, CIRC RES, V50, P101.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   SNYDERWINE EG, 1992, CANCER RES, V52, pS2099.
   SPERELAKIS N, 1978, ENVIRON HEALTH PERSP, V26, P243, DOI 10.2307/3428847.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TAKAYAMA S, 1987, P JPN ACAD B-PHYS, V63, P161, DOI 10.2183/pjab.63.161.
   THOROGOOD M, 1994, BRIT MED J, V308, P1667.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WAKABAYASHI K, 1990, MUTAT RES, V239, P181, DOI 10.1016/0165-1110(90)90005-V.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   YAMAZOE Y, 1989, CARCINOGENESIS, V10, P1675, DOI 10.1093/carcin/10.9.1675.}},
Number-of-Cited-References = {{52}},
Times-Cited = {{4}},
Journal-ISO = {{J. Nutr. Biochem.}},
Doc-Delivery-Number = {{473MC}},
Wos-Id = {{ISI:000171047100004}},
}

@article{ ISI:000169660100010,
Author = {Soglia, JR and Turesky, RJ and Paehler, A and Vouros, P},
Title = {{Quantification of the heterocyclic aromatic amine DNA adduct
   N-(deoxyguanosin-8-yl)-2-amino-3-methylimidazo{[}4,5-f]quinoline in
   livers of rats using capillary liquid chromatography/microelectrospray
   mass spectrometry: a dose-response study}},
Journal = {{ANALYTICAL CHEMISTRY}},
Year = {{2001}},
Volume = {{73}},
Number = {{13}},
Pages = {{2819-2827}},
Month = {{JUL 1}},
Abstract = {{Capillary liquid chromatography/microelectrospray-mass spectrometry
   (capillary LC/mu ESI-MS) was used to quantify DNA adducts of the
   heterocyclic aromatic amine 2-amino-3-methylimidazo{[}4,5-f]quinoline
   (IQ) in livers of male Fischer-344 rats. Animals received a single oral
   dose of either 0.05, 0.50, 1.0, or 10 mg/kg IQ and were sacrificed 24 h
   following treatment. The major lesion identified at all doses was
   N-(deoxyguanosine-8-yl)-2-amino-3-methylimidazo{[}4,5-f]quinoline
   (dG-C8-IQ), The capillary LC/mu ESI-MS method provided the means for
   quantifying 17.5 fmol of dG-C8-IQ (2.0 adducts in 10(8) nucleosides)
   (S/N 10) in 300 mug of liver DNA with an intra- and interday precision
   of 3.5 and 6.6\% (RSD), respectively, dG-C8-IQ was quantified with a
   mean intra-and interday accuracy of 105 +/- 26 and 106 +/- 28 (SD) based
   on back-calculated adduct masses from five standard curves analyzed over
   a four-week period. This is the first report on development of a
   capillary LC/mu ESI-MS method to quantify dG-CS-IQ adducts in liver DNA
   of rats following dosing with IQ at different levels. Furthermore, the
   ability to accurately and precisely quantify dG-C8-IQ at a level of 2.0
   adducts in 108 nucleosides in vivo makes this method well suited for use
   in future studies relating carcinogen exposure to risk in humans.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Vouros, P (Reprint Author), Northeastern Univ, Barnett Inst, Boston, MA 02115 USA.
   Northeastern Univ, Barnett Inst, Boston, MA 02115 USA.
   Northeastern Univ, Dept Chem, Boston, MA 02115 USA.
   Natl Ctr Toxicol Res, Div Chem, Jefferson, AR 72079 USA.
   Nestec Ltd, Nestle Res Ctr, CH-1000 Lausanne 26, Switzerland.}},
DOI = {{10.1021/ac010218j}},
ISSN = {{0003-2700}},
Keywords-Plus = {{FOOD MUTAGEN 2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE; P-32 POSTLABELING
   ASSAY; NONHUMAN-PRIMATES; CARCINOGEN
   2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE; ENVIRONMENTAL CARCINOGENS;
   CHEMICAL CARCINOGENESIS; BORNE CARCINOGEN; N-2 ATOMS; IDENTIFICATION;
   CHROMATOGRAPHY}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Analytical}},
Cited-References = {{ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   ADAMSON RH, 1994, ENVIRON HEALTH PERSP, V102, P190, DOI 10.2307/3431610.
   AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258.
   BATTULA N, 1991, MOL CARCINOGEN, V4, P407, DOI 10.1002/mc.2940040513.
   BEACH AC, 1992, CARCINOGENESIS, V13, P1053, DOI 10.1093/carcin/13.7.1053.
   Beland FA, 1999, CHEM RES TOXICOL, V12, P68, DOI 10.1021/tx980172y.
   DEWIT JSM, 1987, ANAL CHEM, V59, P2400, DOI 10.1021/ac00146a017.
   DOLL R, 1981, J NATL CANCER I, V66, P1191.
   FELTON JS, 1990, HDB EXPT PHARM, V94, P471.
   FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312.
   Gangl ET, 1999, CHEM RES TOXICOL, V12, P1019, DOI 10.1021/tx990060m.
   GANGL ET, 2001, ANAL CHEM, V72, P2397.
   GRIVAS S, 1988, J CHEM RES-S, P84.
   GROOPMAN JD, 1993, CHEM RES TOXICOL, V6, P764, DOI 10.1021/tx00036a004.
   GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P391, DOI 10.1021/tx00022a001.
   GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081.
   HASHIMOTO Y, 1980, BIOCHEM BIOPH RES CO, V96, P355, DOI 10.1016/0006-291X(80)91222-X.
   HASHIMOTO Y, 1982, J AM CHEM SOC, V104, P7635.
   HEFLICH RH, 1986, MUTAGENESIS, V1, P201, DOI 10.1093/mutage/1.3.201.
   Jeanville PM, 2000, J PHARMACEUT BIOMED, V23, P897, DOI 10.1016/S0731-7085(00)00362-9.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   NAGAO M, 1993, MUTAT RES, V290, P43, DOI 10.1016/0027-5107(93)90031-A.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   PARKER CE, 1993, J CHROMATOGR-BIOMED, V616, P45, DOI 10.1016/0378-4347(93)80470-O.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   RANDERATH K, 1985, ENVIRON HEALTH PERSP, V62, P57, DOI 10.2307/3430093.
   RANDERATH K, 1981, P NATL ACAD SCI-BIOL, V78, P6126, DOI 10.1073/pnas.78.10.6126.
   Robins RH, 1997, RAPID COMMUN MASS SP, V11, P1661, DOI 10.1002/(SICI)1097-0231(19971015)11:15<1661::AID-RCM57>3.0.CO;2-W.
   SCHUT HAJ, 1988, CANCER LETT, V41, P345, DOI 10.1016/0304-3835(88)90296-0.
   SCHUT HAJ, 1994, ENVIRON HEALTH PERSP, V102, P57, DOI 10.2307/3432153.
   SHIELDS PG, 1993, MUTAGENESIS, V8, P121, DOI 10.1093/mutage/8.2.121.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1061, DOI 10.1093/carcin/9.6.1061.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P411, DOI 10.1093/carcin/9.3.411.
   SUGIMURA T, 1986, SCIENCE, V233, P312, DOI 10.1126/science.3088728.
   SUGIMURA T, 1982, CANCER, V49, P1970, DOI 10.1002/1097-0142(19820515)49:10<1970::AID-CNCR2820491005>3.0.CO;2-F.
   SUGIMURA T, 1988, CHEM INDUCTION CAN C, V3, P681.
   SUGIMURA T, 1988, TRENDS PHARMACOL SCI, V9, P205.
   SUGIMURA T, 1988, MUTAT RES, V205, P33, DOI 10.1016/0165-1218(88)90006-7.
   TANAKA T, 1985, JPN J CANCER RES, V76, P570.
   THORGEIRSSON UP, 1994, REGUL TOXICOL PHARM, V19, P130, DOI 10.1006/rtph.1994.1013.
   Turesky RJ, 1996, CHEM RES TOXICOL, V9, P403, DOI 10.1021/tx950132j.
   Turesky RJ, 1997, MUTAT RES-FUND MOL M, V376, P235, DOI 10.1016/S0027-5107(97)00048-1.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P925, DOI 10.1021/tx980022n.
   TURESKY RJ, 1990, CHEM RES TOXICOL, V3, P524, DOI 10.1021/tx00018a006.
   Turesky RJ, 1996, CHEM RES TOXICOL, V9, P397, DOI 10.1021/tx950131r.
   TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005.
   TURESKY RJ, 1994, CHEM RES TOXICOL, V7, P752, DOI 10.1021/tx00042a007.
   TURESKY RJ, 1995, CARCINOGENESIS, V16, P2275, DOI 10.1093/carcin/16.9.2275.
   VALASKOVIC GA, 1995, ANAL CHEM, V67, P3802, DOI 10.1021/ac00116a030.
   Vanhoutte K, 1997, ANAL CHEM, V69, P3161, DOI 10.1021/ac970121q.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WEISBURGER JH, 1987, ISI ATLAS-PHARMACOL, V1, P162.
   ZHAO JJ, 2000, J PHARM BIOMED ANAL, V9, P1133.}},
Number-of-Cited-References = {{54}},
Times-Cited = {{32}},
Journal-ISO = {{Anal. Chem.}},
Doc-Delivery-Number = {{448ZP}},
Wos-Id = {{ISI:000169660100010}},
}

@article{ ISI:000168640800017,
Author = {Dietrich, CG and de Waart, DR and Ottenhoff, R and Bootsma, AH and van
   Gennip, AH and Elferink, RPJO},
Title = {{Mrp2-deficiency in the rat impairs biliary and intestinal excretion and
   influences metabolism and disposition of the food-derived carcinogen
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP)}},
Journal = {{CARCINOGENESIS}},
Year = {{2001}},
Volume = {{22}},
Number = {{5}},
Pages = {{805-811}},
Month = {{MAY}},
Abstract = {{While metabolism of 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine
   (PhIP), the most abundant food-derived heterocyclic amine and
   carcinogen, has been studied extensively in several species, transport
   of this compound and its metabolites has not been defined yet. Therefore
   we studied metabolism and disposition of PhIP in Wistar and
   Mrp2-deficient TR- rats to determine the role of Mrp2 in the defence
   against this compound. In the first 2 h after intravenous dosing, total
   excretion of PhIP and its metabolites in bile was >4-fold reduced in TR-
   rats compared with Wistar rats, while excretion in the urine of the TR-
   rat was 1.8-fold higher. This difference was the result of an almost
   complete absence of secretion of glucuronidated metabolites but also a
   reduced level of secretion of unchanged PhIP into bile of the TR- rat.
   Direct intestinal excretion of unmetabolized PhIP was 3-fold higher in
   Wistar versus TR- rats. As a consequence, PhIP tissue levels in the
   liver were 1.7-fold higher in TR- rats, and tissue binding of PhIP,
   determined after ethanol extraction, was elevated by a similar
   magnitude. Mrp2-mediated transport of the parent compound PhIP is
   glutathione (GSH)-dependent, because GSH depletion by
   L-buthionine{[}S,R]-sulfoximine (BSO) treatment in Wistar rats reduced
   intestinal secretion to the same level as that in TR- rats. TR- rats
   produced less glucuronides and 4'-OH-PhIP in the 2 h following PhIP
   administration, We conclude that Mrp2 protects against the carcinogen
   PhIP by biliary excretion of the parent compound and all major phase-II
   metabolites, but, more importantly, also by direct extrusion of the
   parent compound from the gut mucosa.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Elferink, RPJO (Reprint Author), Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol, Lab Expt Hepatol, F0-116,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol, Lab Expt Hepatol, NL-1105 AZ Amsterdam, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Dept Genet Metab Dis, NL-1105 AZ Amsterdam, Netherlands.}},
DOI = {{10.1093/carcin/22.5.805}},
ISSN = {{0143-3334}},
Keywords-Plus = {{MULTIDRUG-RESISTANCE PROTEIN-2; MUTAGEN
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE; GLUTATHIONE DEPLETION;
   HETEROCYCLIC AMINES; LIVER-MICROSOMES; COOKED-FOOD; BUTHIONINE
   SULFOXIMINE; REDUCED GLUTATHIONE; BORNE CARCINOGEN; IN-VIVO}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
ResearcherID-Numbers = {{yang, min/G-3030-2011}},
Cited-References = {{ADAMSON RH, 1995, ADV EXP MED BIOL, V369, P211.
   Alexander J, 1995, Princess Takamatsu Symp, V23, P113.
   ALEXANDER J, 1991, CARCINOGENESIS, V12, P2239, DOI 10.1093/carcin/12.12.2239.
   ALEXANDER J, 1989, CARCINOGENESIS, V10, P1543, DOI 10.1093/carcin/10.8.1543.
   BUONARATI MH, 1992, CARCINOGENESIS, V13, P621, DOI 10.1093/carcin/13.4.621.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   Crofts FG, 1997, CARCINOGENESIS, V18, P1793, DOI 10.1093/carcin/18.9.1793.
   Crofts FG, 1998, CARCINOGENESIS, V19, P1969, DOI 10.1093/carcin/19.11.1969.
   DREW R, 1984, BIOCHEM PHARMACOL, V33, P2989, DOI 10.1016/0006-2952(84)90598-7.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   Gotoh Y, 2000, J PHARMACOL EXP THER, V292, P433.
   Hirohashi T, 1998, MOL PHARMACOL, V53, P1068.
   Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   JANSEN PLM, 1985, HEPATOLOGY, V5, P573, DOI 10.1002/hep.1840050408.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1695, DOI 10.1093/carcin/15.8.1695.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1711, DOI 10.1093/carcin/15.8.1711.
   Kadlubar F, 1995, Princess Takamatsu Symp, V23, P207.
   Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914.
   Lang NP, 1999, CANCER LETT, V143, P135, DOI 10.1016/S0304-3835(99)00142-1.
   LIN DX, 1995, DRUG METAB DISPOS, V23, P518.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   Loe DW, 1998, CANCER RES, V58, P5130.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   Malfatti MA, 1996, CANCER RES, V56, P2550.
   MCMANUS ME, 1989, CARCINOGENESIS, V10, P357, DOI 10.1093/carcin/10.2.357.
   MINCHINTON AI, 1984, INT J RADIAT ONCOL, V10, P1261.
   Morrow CS, 2000, MOL CARCINOGEN, V29, P170, DOI 10.1002/1098-2744(200011)29:3<170::AID-MC6>3.0.CO;2-W.
   Mottino AD, 2000, J PHARMACOL EXP THER, V293, P717.
   Ortiz DF, 1999, AM J PHYSIOL-GASTR L, V276, pG1493.
   ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215.
   Paulusma CC, 2000, HEPATOLOGY, V31, P684, DOI 10.1002/hep.510310319.
   Paulusma CC, 1999, BIOCHEM J, V338, P393, DOI 10.1042/0264-6021:3380393.
   Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126.
   Schaub TP, 1997, J AM SOC NEPHROL, V8, P1213.
   Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1.
   STYCZYNSKI PB, 1993, CHEM RES TOXICOL, V6, P846, DOI 10.1021/tx00036a014.
   TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5.
   Walle UK, 1999, CARCINOGENESIS, V20, P2153, DOI 10.1093/carcin/20.11.2153.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P1073, DOI 10.1093/carcin/12.6.1073.}},
Number-of-Cited-References = {{42}},
Times-Cited = {{50}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{431PY}},
Wos-Id = {{ISI:000168640800017}},
}

@article{ ISI:000170077100001,
Author = {Bogen, KT and Keating, GA},
Title = {{US dietary exposures to heterocyclic amines}},
Journal = {{JOURNAL OF EXPOSURE ANALYSIS AND ENVIRONMENTAL EPIDEMIOLOGY}},
Year = {{2001}},
Volume = {{11}},
Number = {{3}},
Pages = {{155-168}},
Month = {{MAY-JUN}},
Abstract = {{Heterocyclic amines (HAs) formed in fried, broiled or grilled meats are
   potent mutagens that increase rates of colon, mammary, prostate and
   other cancers in bioassay rodents. Studies of how human dietary HA
   exposures may affect cancer risks have so far relied on fairly crudely
   defined HA - exposure categories. Recently, an integrated, quantitative
   approach to HA-exposure assessment (HAEA) was developed to estimate
   compound-specific intakes for particular individuals based on
   corresponding HA-concentration estimates that reflect their meat-type,
   intake-rate, cooking-method and meat-doneness preferences. This method
   was applied in the present study to U.S. national Continuing Survey of
   Food Intakes by Individuals (CSFII) data on meats consumed and cooking
   methods used by > 25,000 people, after adjusting for underreported
   energy intake and conditional on meat-doneness preferences estimated
   from additional survey data. The U.S. population average lifetime
   time-weighted average of total HAs consumed was estimated to be similar
   to9 ng/kg/day, with 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine
   (PhIP) estimated to comprise about two thirds of this intake. Pan-fried
   meats were the largest source of HA in the diet and chicken the largest
   source of HAs among different meat types. Estimated total HA intakes by
   male vs. female children were generally similar, with those by (0- to
   15-year-old) children -25\% greater than those by (16+-year-old) adults.
   Race-, age- and sex-specific mean HA intakes were estimated to be
   greatest for African American males, who were estimated to consume
   similar to2- and similar to3- fold more PhIP than white males at ages <
   16 and 30+ years, respectively, after considering a relatively greater
   preference for more well-done items among African Americans based on
   national survey data. This difference in PhIP intakes may at least
   partly explain why prostate cancer (PC) kills similar to2- fold more
   African American than white men, in view of experimental data indicating
   that PhIP mutates prostate DNA and causes prostate tumors in rats.}},
Publisher = {{NATURE PUBLISHING GROUP}},
Address = {{75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bogen, KT (Reprint Author), Lawrence Livermore Natl Lab, Hlth \& Ecol Assessment Div L 396, 7000 East Ave, Livermore, CA 94550 USA.
   Lawrence Livermore Natl Lab, Hlth \& Ecol Assessment Div L 396, Livermore, CA 94550 USA.}},
DOI = {{10.1038/sj.jea.7500158}},
ISSN = {{1053-4245}},
Keywords = {{age; cancer; cooked-food mutagens; energy; meat; prostate; race; sex;
   variability}},
Keywords-Plus = {{DONE MEAT INTAKE; PROSTATE-CANCER; UNITED-STATES; COOKED FOODS;
   WELL-DONE; DNA-ADDUCTS; RED MEAT; GENETIC SUSCEPTIBILITY;
   METABOLIC-ACTIVATION; MUTAGENIC ACTIVATION}},
Research-Areas = {{Environmental Sciences \& Ecology; Public, Environmental \& Occupational
   Health; Toxicology}},
Web-of-Science-Categories  = {{Environmental Sciences; Public, Environmental \& Occupational Health;
   Toxicology}},
Author-Email = {{bogen@LLNL.gov}},
Cited-References = {{ARMITAGE P, 1957, BRIT J CANCER, V11, P161, DOI 10.1038/bjc.1957.22.
   Augustsson K, 1997, CARCINOGENESIS, V18, P1931, DOI 10.1093/carcin/18.10.1931.
   Augustsson K, 1999, LANCET, V353, P703, DOI 10.1016/S0140-6736(98)06099-1.
   BOGEN KT, 2000, UCRLMA110232 LLNL.
   BOGEN KT, 1994, FOOD CHEM TOXICOL, V32, P505, DOI 10.1016/0278-6915(94)90106-6.
   Briefel RR, 1997, AM J CLIN NUTR, V65, pS1203.
   Byrne C, 1998, CANCER EPIDEM BIOMAR, V7, P523.
   Cox RJ, 1997, MEAT SCI, V45, P75, DOI 10.1016/S0309-1740(96)00080-0.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P61, DOI 10.1093/carcin/14.1.61.
   DEVERDIER MG, 1991, INT J CANCER, V40, P1.
   Djavan B, 1999, Tech Urol, V5, P139.
   DOLL R, 1981, J NATL CANCER I, V66, P1191.
   DRAPER NR, 1981, APPL REGRESISON ANAL.
   ELBAYOUMY K, 1995, CARCINOGENESIS, V16, P431, DOI 10.1093/carcin/16.2.431.
   FELTON JS, 1990, PROG CLIN BIOL RES, V347, P19.
   FELTON JS, 1990, HDB EXPT PHARM, V94, P471.
   FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312.
   FELTON JS, 1984, CARCINOGENESIS, V5, P95, DOI 10.1093/carcin/5.1.95.
   GHOSHAL A, 1994, CARCINOGENESIS, V15, P2429, DOI 10.1093/carcin/15.11.2429.
   HATCH ET, 1986, ENV MUTAGEN, V8, P467.
   Hayes RB, 1999, CANCER EPIDEM BIOMAR, V8, P25.
   Hsing AW, 2000, INT J CANCER, V85, P60, DOI 10.1002/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.3.CO;2-2.
   Ito N, 1997, MUTAT RES-FUND MOL M, V376, P107, DOI 10.1016/S0027-5107(97)00032-8.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1711, DOI 10.1093/carcin/15.8.1711.
   Kampman E, 1999, CANCER EPIDEM BIOMAR, V8, P15.
   KATO R, 1987, JPN J CANC RES GANN, V81, P10.
   KATO T, 1986, J AGR FOOD CHEM, V34, P810, DOI 10.1021/jf00071a010.
   Keating GA, 1999, MUTAT RES-GEN TOX EN, V443, P149, DOI 10.1016/S1383-5742(99)00017-4.
   Keating GA, 2000, CANCER CAUSE CONTROL, V11, P731, DOI 10.1023/A:1008935407971.
   Keating GA, 2001, FOOD CHEM TOXICOL, V39, P29, DOI 10.1016/S0278-6915(00)00115-0.
   KENDALL M, 1979, ADV THEORY STAT, V2, P159.
   Kidd LCR, 1999, CANCER EPIDEM BIOMAR, V8, P439.
   KNIZE MG, 1995, FOOD CHEM TOXICOL, V33, P545, DOI 10.1016/0278-6915(95)00025-W.
   KNIZE MG, 1994, FOOD CHEM TOXICOL, V32, P595, DOI 10.1016/0278-6915(94)90002-7.
   Kolonel LN, 1999, J NATL CANCER I, V91, P414, DOI 10.1093/jnci/91.5.414.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   LAYTON DW, 1993, HEALTH PHYS, V64, P23.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201.
   LYON JL, 1988, AM J EPIDEMIOL, V128, P1000.
   Macintosh CA, 1998, CANCER RES, V58, P23.
   MCMANUS ME, 1990, CANCER RES, V50, P3367.
   Miller B. A., 1996, NIH PUBL.
   MUSCAT JE, 1994, AM J PUBLIC HEALTH, V84, P856, DOI 10.2105/AJPH.84.5.856.
   Norrish AE, 1999, J NATL CANCER I, V91, P2038, DOI 10.1093/jnci/91.23.2038.
   NRC, 1986, NUTR AD ASS US FOOD.
   OCHIAI M, 1991, JPN J CANCER RES, V82, P363.
   OHGAKI H, 1986, ENVIRON HEALTH PERSP, V67, P129, DOI 10.2307/3430327.
   PETTAWAY CA, 1999, J NATL MED ASSOC, V91, P652.
   ProbstHensch NM, 1997, CANCER CAUSE CONTROL, V8, P175, DOI 10.1023/A:1018416128894.
   REAGAN JO, 1995, BEEF CUSTOMER SATISF.
   Robbins AS, 1998, J NATL CANCER I, V90, P986, DOI 10.1093/jnci/90.13.986.
   ROSENKRANZ H S, 1985, Journal of Environmental Science and Health Part C Environmental Carcinogenesis Reviews, V3, P221, DOI 10.1080/10590508509373334.
   Ross RK, 1998, CANCER RES, V58, P4497.
   Ruijter ET, 1996, J PATHOL, V180, P295.
   SATO S, 1986, ENVIRON HEALTH PERSP, V67, P105, DOI 10.2307/3430323.
   Schofield WN, 1985, HUM NUTR CLIN N C S1, V39C, P1.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   Selvin S, 1995, PRACTICAL BIOSTATIST.
   SHIFFMAN MH, 1990, AM J EPIDEMIOL, V131, P376.
   Shirai T, 1997, CANCER RES, V57, P195.
   Shirai T, 1999, CANCER LETT, V143, P217, DOI 10.1016/S0304-3835(99)00128-7.
   Signorello LB, 1999, J NATL CANCER I, V91, P1965, DOI 10.1093/jnci/91.22.1965.
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P289, DOI 10.1016/S0278-6915(97)00159-2.
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P279, DOI 10.1016/S0278-6915(97)00162-2.
   SINHA R, 1995, CANCER RES, V55, P4516.
   Sinha R, 1998, CANCER CAUSE CONTROL, V9, P621, DOI 10.1023/A:1008805525525.
   Sinha R, 1999, CANCER RES, V59, P4320.
   SKOG K, 1995, CARCINOGENESIS, V16, P861, DOI 10.1093/carcin/16.4.861.
   SNYDERWINE EG, 1989, J NATL CANCER I, V81, P223, DOI 10.1093/jnci/81.3.223.
   SUGIMURA T, 1986, GENETIC TOXICOLOGY D, P85.
   SUGIMURA T, 1988, CHEM INDUCTION CANC, P681.
   Takahashi S, 1998, CANCER RES, V58, P4307.
   Thomson BM, 1996, P NUT SOC N, V21, P106.
   THORGEIRSSON SS, 1984, BIOCH BASIS CHEM CAR, P47.
   THORGIRSSON SS, 1983, REV BIOCH TOXICITY, V6, P349.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   US Department of Agriculture (USDA), 1998, 1994 96 CONT SURV FO.
   Ward MH, 1997, INT J CANCER, V71, P14, DOI 10.1002/(SICI)1097-0215(19970328)71:1<14::AID-IJC4>3.0.CO;2-6.
   WHITTEMORE AS, 1995, J NATL CANCER I, V87, P652, DOI 10.1093/jnci/87.9.652.
   Wolfram S., 1999, MATH BOOK.
   Yang S, 1998, MMWR CDC Surveill Summ, V47, P33.
   Zheng W, 1998, J NATL CANCER I, V90, P1724, DOI 10.1093/jnci/90.22.1724.
   Zheng W, 1999, CANCER EPIDEM BIOMAR, V8, P233.
   {*}ICRP, 1975, 25 ICRP.
   {*}USDA, 1997, US MEAT THERM INT EL.
   {*}USDA, 1993, 1989 91 CONT SURV FO.
   {*}USDHHS, 1998, SER US DHHS, V11.}},
Number-of-Cited-References = {{90}},
Times-Cited = {{47}},
Journal-ISO = {{J. Expo. Anal. Environ. Epidemiol.}},
Doc-Delivery-Number = {{456HM}},
Wos-Id = {{ISI:000170077100001}},
}

@article{ ISI:000166638300006,
Author = {Fretland, AJ and Devanaboyina, US and Feng, Y and Leff, MA and Xiao, GH
   and Webb, SJ and Hein, DW},
Title = {{Oral administration of 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine
   (PhIP) yields PhIP-DNA adducts but not tumors in male syrian hamsters
   congenic at the n-acetyltransferase 2 (NAT2) locus}},
Journal = {{TOXICOLOGICAL SCIENCES}},
Year = {{2001}},
Volume = {{59}},
Number = {{2}},
Pages = {{226-230}},
Month = {{FEB}},
Abstract = {{2-Amino-1-methyl-6-phenyIimidazo{[}4,5-b] pyridine (PhIP) is a
   heterocyclic amine carcinogen present in well-done meat. PhIP must
   undergo host-mediated bioactivation to exert its mutagenic and
   carcinogenic effects. Following N-hydroxylation, N-acetyltransferases
   catalyze the O-acetylation (activation) of N-hydroxy-PhIP to an
   electrophile causing DNA damage. A well-defined genetic polymorphism in
   N-acetyltransferase 2 (NAT2) activity exists in humans and the Syrian
   hamster. Since some human epidemiological studies suggest an association
   between acetylator genotype and cancer susceptibility in individuals who
   consume well done meats, this study was designed to investigate the
   specific role of acetylator genotype in PhIP-induced tumors using a
   Syrian hamster model congenic at the NAT2 locus. Following oral
   administration of PhIP to male rapid and slow acetylator Syrian
   hamsters, DNA adducts were identified in each tissue examined with
   levels in the relative order: pancreas > heart and urinary bladder >
   prostate, small intestine and transverse colon > ascending colon, liver,
   cecum, descending colon, and rectum. However, no tumors were observed in
   male rapid and slow acetylator congenic hamsters administered 11 oral
   doses of PhIP (75 mg/kg) and maintained on a high fat diet for one year.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hein, DW (Reprint Author), Univ Louisville, Sch Med, Dept Pharmacol \& Toxicol, Louisville, KY 40292 USA.
   Univ Louisville, Sch Med, Dept Pharmacol \& Toxicol, Louisville, KY 40292 USA.
   Univ N Dakota, Sch Med \& Hlth Sci, Dept Pharmacol \& Toxicol, Grand Forks, ND 58202 USA.}},
DOI = {{10.1093/toxsci/59.2.226}},
ISSN = {{1096-6080}},
Keywords = {{N-acetyltransferase 2 (NAT2);
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine; PhIP; acetylator
   genotype; DNA adducts; Syrian hamster}},
Keywords-Plus = {{HETEROCYCLIC AMINE CARCINOGENS; RECOMBINANT HUMAN NAT1; FOOD-BORNE
   CARCINOGEN; SPRAGUE-DAWLEY RATS; METABOLIC-ACTIVATION; ACETYLATOR
   GENOTYPE; ARYLAMINE CARCINOGENS; <4,5-B>PYRIDINE PHIP; NONTARGET ORGANS;
   URINARY-BLADDER}},
Research-Areas = {{Toxicology}},
Web-of-Science-Categories  = {{Toxicology}},
ResearcherID-Numbers = {{Hein, David/A-9707-2008}},
Cited-References = {{ALEXANDER J, 1994, ENVIRON HEALTH PERSP, V102, P109, DOI 10.2307/3432162.
   Archer CL, 2000, CANCER LETT, V155, P55, DOI 10.1016/S0304-3835(00)00413-4.
   Augustsson K, 1999, LANCET, V353, P703, DOI 10.1016/S0140-6736(98)06099-1.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   CHOU HC, 1995, CANCER RES, V55, P525.
   Feng Y, 1996, TOXICOL APPL PHARM, V141, P248, DOI 10.1006/taap.1996.0281.
   Feng Y, 1996, TOXICOL APPL PHARM, V140, P315, DOI 10.1006/taap.1996.0226.
   FENG Y, 1994, TOXICOL APPL PHARM, V124, P10, DOI 10.1006/taap.1994.1002.
   Feng Y, 1996, CANCER RES, V56, P527.
   Feng Y, 1999, TOXICOL METHOD, V9, P91.
   Ferguson RJ, 1996, PHARMACOGENETICS, V6, P55, DOI 10.1097/00008571-199602000-00004.
   FERGUSON RJ, 1994, GENE, V140, P247, DOI 10.1016/0378-1119(94)90552-5.
   FERGUSON RJ, 1994, PHARMACOGENETICS, V4, P82, DOI 10.1097/00008571-199404000-00005.
   FRETLAND AJ, IN PRESS J BIOCH MOL.
   Fretland A J, 1997, Proc West Pharmacol Soc, V40, P9.
   Friesen MD, 1996, CARCINOGENESIS, V17, P67, DOI 10.1093/carcin/17.1.67.
   GHOSHAL A, 1994, CARCINOGENESIS, V15, P2429, DOI 10.1093/carcin/15.11.2429.
   HASEGAWA R, 1993, CARCINOGENESIS, V14, P2553, DOI 10.1093/carcin/14.12.2553.
   HEIN DW, 1994, TOXICOL APPL PHARM, V124, P16, DOI 10.1006/taap.1994.1003.
   HEIN DW, 1994, ARCH TOXICOL, V68, P129, DOI 10.1007/s002040050045.
   HEIN DW, 1993, CARCINOGENESIS, V14, P1633, DOI 10.1093/carcin/14.8.1633.
   HEIN DW, 1991, TOXICOL METHOD, V1, P44, DOI 10.3109/15376519109036524.
   Hein DW, 1997, MUTAT RES-FUND MOL M, V376, P101, DOI 10.1016/S0027-5107(97)00031-6.
   Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1711, DOI 10.1093/carcin/15.8.1711.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   Leff MA, 1999, J PHARMACOL EXP THER, V290, P182.
   LIN DX, 1994, CANCER RES, V54, P4920.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MINCHIN RF, 1992, BIOCHEM BIOPH RES CO, V185, P839, DOI 10.1016/0006-291X(92)91703-S.
   Norrish AE, 1999, J NATL CANCER I, V91, P2038, DOI 10.1093/jnci/91.23.2038.
   Paulsen JE, 1996, CARCINOGENESIS, V17, P459, DOI 10.1093/carcin/17.3.459.
   Pfau W, 1997, MUTAT RES-FUND MOL M, V378, P13, DOI 10.1016/S0027-5107(97)00093-6.
   Purewal M, 2000, CANCER LETT, V149, P53, DOI 10.1016/S0304-3835(99)00346-8.
   Purewal M, 2000, CANCER EPIDEM BIOMAR, V9, P529.
   Shirai T, 1997, CANCER RES, V57, P195.
   Shirai T, 1999, CANCER LETT, V143, P217, DOI 10.1016/S0304-3835(99)00128-7.
   Sinha R, 2000, J NATL CANCER I, V92, P1352, DOI 10.1093/jnci/92.16.1352.
   Sinha R, 1999, CANCER RES, V59, P4320.
   Snyderwine EG, 1998, NUTR CANCER, V31, P160.
   SO BT, 1972, J NATL CANCER I, V48, P1733.
   Steffensen IL, 2000, PHARMACOL TOXICOL, V86, P257, DOI 10.1111/j.0901-9928.2000.860603.x.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   WILLIAMS GM, 1981, J NATL CANCER I, V67, P481.
   Wu RW, 2000, ENVIRON MOL MUTAGEN, V35, P57, DOI 10.1002/(SICI)1098-2280(2000)35:1<57::AID-EM8>3.0.CO;2-7.
   Yoshimoto M, 1999, CANCER LETT, V143, P235, DOI 10.1016/S0304-3835(99)00131-7.
   Zheng W, 1998, J NATL CANCER I, V90, P1724, DOI 10.1093/jnci/90.22.1724.}},
Number-of-Cited-References = {{49}},
Times-Cited = {{6}},
Journal-ISO = {{Toxicol. Sci.}},
Doc-Delivery-Number = {{396LR}},
Wos-Id = {{ISI:000166638300006}},
}

@article{ ISI:000089062000001,
Author = {Magagnotti, C and Orsi, F and Bagnati, R and Celli, N and Rotilio, D and
   Fanelli, R and Airoldi, L},
Title = {{Effect of diet on serum albumin and hemoglobin adducts of
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) in humans}},
Journal = {{INTERNATIONAL JOURNAL OF CANCER}},
Year = {{2000}},
Volume = {{88}},
Number = {{1}},
Pages = {{1-6}},
Month = {{OCT 1}},
Abstract = {{2-Amino-1-methyl-6-phenylimidazo {[}4,5-b]pyridine (PhIP) is the most
   abundant heterocyclic amine formed in meat and fish during cooking and
   can be used as a model compound for this class of chemicals possibly
   involved in human carcinogenesis. Knowing the exposure to heterocyclic
   amines is important for establishing their role in human diseases. Serum
   albumin (SA) and globin (Gb) adducts were first tested as biomarkers of
   exposure to PhIP in male Fischer 344 rats given oral doses of 0.1, 0.5,
   1 and 10 mg/kg. Blood samples were collected 24 hr after treatment and
   PhIP released from SA and Gb after acidic hydrolysis was analyzed by gas
   chromatography-mass spectrometry or liquid chromatography-tandem mass
   spectrometry. PhIP-SA and Gb adducts increased linearly with the dose.
   Studies on 35 volunteers with different dietary habits exhibited that
   diet was a major determinant in the formation of both adducts. PhIP-SA
   adducts were significantly higher in meat consumers than in vegetarians
   (6.7 +/- 1.6 and 0.7 +/- 0.3 fmol/mg SA; respectively, mean +/- SE; p =
   0.04, Mann-Whitney U test). The Cb adduct pattern was quantitatively
   lower but paralleled SA (3 +/- 0.8 in meat consumers and 0.3 +/- 0.1 in
   vegetarians). PhIP-SA adducts were no different in smokers and in
   non-smokers. The results show for the first time that PhIP-blood protein
   adducts are present: in humans not given the synthetic compound. Both
   biomarkers appear to be suitable for assessing dietary exposure and
   internal PhIP dose and may be promising tools for studying the role of
   heterocyclic amines in the etiology of colon cancer and other diseases.
   (C) 2000 Wiley-Liss, Inc.}},
Publisher = {{WILEY-LISS}},
Address = {{DIV JOHN WILEY \& SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Airoldi, L (Reprint Author), Mario Negri Inst Pharmacol Res, Dept Environm Hlth Sci, Via Eritrea 62, I-20157 Milan, Italy.
   Mario Negri Inst Pharmacol Res, Dept Environm Hlth Sci, I-20157 Milan, Italy.
   Consorzio Mario Negri Sud, Ctr Environm Hlth G Paone, Santa Maria Imbaro, Chieti, Italy.}},
DOI = {{10.1002/1097-0215(20001001)88:1<1::AID-IJC1>3.0.CO;2-D}},
ISSN = {{0020-7136}},
Keywords-Plus = {{HETEROCYCLIC AROMATIC-AMINES; FOOD-BORNE CARCINOGEN; PROTEIN ADDUCTS;
   CYTOCHROME-P450 ENZYMES; MOLECULAR DOSIMETRY; MASS-SPECTROMETRY;
   URINARY-EXCRETION; UNITED-STATES; COOKED FOODS; CANCER}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{Alexander J, 1997, MUTAT RES-FUND MOL M, V376, P7, DOI 10.1016/S0027-5107(97)00019-5.
   Augustsson K, 1997, CARCINOGENESIS, V18, P1931, DOI 10.1093/carcin/18.10.1931.
   Augustsson K, 1999, LANCET, V353, P703, DOI 10.1016/S0140-6736(98)06099-1.
   Baker H.J., 1979, LAB RAT.
   BONFANTI M, 1990, CANCER RES, V50, P6870.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   Byrne C, 1998, CANCER EPIDEM BIOMAR, V7, P523.
   Crofts FG, 1997, CARCINOGENESIS, V18, P1793, DOI 10.1093/carcin/18.9.1793.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P2091, DOI 10.1093/carcin/14.10.2091.
   Dingley KH, 1999, CANCER EPIDEM BIOMAR, V8, P507.
   Dingley KH, 1998, DRUG METAB DISPOS, V26, P825.
   DOLL R, 1981, J NATL CANCER I, V66, P1191.
   ENGLARD S, 1990, GUIDE PROTEIN PURIFI, P285.
   Gooderham NJ, 1997, MUTAT RES-FUND MOL M, V376, P53, DOI 10.1016/S0027-5107(97)00025-0.
   Hammons GJ, 1997, CARCINOGENESIS, V18, P851, DOI 10.1093/carcin/18.4.851.
   Kidd LCR, 1999, CANCER EPIDEM BIOMAR, V8, P439.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LIN DX, 1995, DRUG METAB DISPOS, V23, P518.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   LYNCH AM, 1993, CARCINOGENESIS, V14, P191, DOI 10.1093/carcin/14.2.191.
   LYNCH AM, 1991, CARCINOGENESIS, V12, P1067, DOI 10.1093/carcin/12.6.1067.
   MANABE S, 1993, CARCINOGENESIS, V14, P899, DOI 10.1093/carcin/14.5.899.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   Pastorelli R, 1996, CARCINOGENESIS, V17, P2389, DOI 10.1093/carcin/17.11.2389.
   Pastorelli R, 1998, CANCER EPIDEM BIOMAR, V7, P703.
   Potter JD, 1996, CANCER CAUSE CONTROL, V7, P127, DOI 10.1007/BF00115644.
   ProbstHensch NM, 1997, CANCER CAUSE CONTROL, V8, P175, DOI 10.1023/A:1018416128894.
   Reistad R., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P151.
   REISTAD R, 1994, CARCINOGENESIS, V15, P2547, DOI 10.1093/carcin/15.11.2547.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   Richling E, 1997, J CHROMATOGR A, V791, P71, DOI 10.1016/S0021-9673(97)00842-X.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   SKIPPER PL, 1990, CARCINOGENESIS, V11, P507, DOI 10.1093/carcin/11.4.507.
   Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   TURESKY RJ, 1987, CARCINOGENESIS, V8, P1537, DOI 10.1093/carcin/8.10.1537.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P925, DOI 10.1021/tx980022n.
   Vineis P, 1996, CANCER CAUSE CONTROL, V7, P479, DOI 10.1007/BF00052675.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P2291, DOI 10.1093/carcin/12.12.2291.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P1073, DOI 10.1093/carcin/12.6.1073.
   {*}WHO, 1993, IARC MON EV CARC RIS, V56, P229.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{34}},
Journal-ISO = {{Int. J. Cancer}},
Doc-Delivery-Number = {{349TQ}},
Wos-Id = {{ISI:000089062000001}},
}

@article{ ISI:000087942800003,
Author = {Dunstan, PO},
Title = {{Thermochemistry of adducts of manganese(II) and copper(II)
   pentane-2,4-dionate with heterocyclic amines}},
Journal = {{THERMOCHIMICA ACTA}},
Year = {{2000}},
Volume = {{356}},
Number = {{1-2}},
Pages = {{19-25}},
Month = {{AUG 7}},
Abstract = {{The compounds {[}M(pd)(2)(L)] (where M is manganese(II) or copper(II);
   pd is pentane-2,4-dionate; and L is piperazine (pipz), 4-cyanopyridine
   (4-cyanopy), quinoline (quin) or 2,2'-bipyridine (bipy)) were
   synthesized and characterized by elemental analysis, melting points,
   thermal studies and electronic and IR spectroscopy. The enthalpies of
   dissolution of adducts, metal pentane-2,4-dionate and ligands in a 1:3
   (v/v) mixture of aqueous HCl 1.2 M and methanol were measured and by
   using thermochemical cycles the following thermochemical parameters for
   the adducts have been determined: the standard enthalpies for the Lewis
   acid/base reaction (Delta(r)H(theta)), the standard enthalpies of
   formation (Delta(f)H(theta)), the standard enthalpies of decomposition
   (Delta(D)H(theta)), the lattice standard enthalpies (Delta(M)H(theta))
   and the standard enthalpies of the Lewis acid/base reaction in the
   gaseous phase (Delta(r)H(theta)(g)). The mean standard bond dissociation
   enthalpies of the manganese-nitrogen and copper-nitrogen bonds have been
   determined. (C) 2000 Elsevier Science B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Dunstan, PO (Reprint Author), Univ Estadual Campinas, Inst Quim, CP 6154, BR-13083970 Campinas, SP, Brazil.
   Univ Estadual Campinas, Inst Quim, BR-13083970 Campinas, SP, Brazil.}},
DOI = {{10.1016/S0040-6031(00)00496-2}},
ISSN = {{0040-6031}},
Keywords = {{Mn-N and Cu-N bonds; manganese(II) and copper(II) pentane-2,4-dionate;
   Mn(IT) and Cu(II) adducts; thermochemical parameters; thermochemistry}},
Keywords-Plus = {{ACETYLACETONATE CHELATE; ARSENIC TRIHALIDES; BASES; COMPLEXES}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Analytical; Chemistry, Physical}},
Cited-References = {{AHUJA IS, 1971, INORG NUCL CHEM LETT, V7, P937, DOI 10.1016/0020-1650(71)80005-3.
   Ahuja IS, 1969, INORG CHIM ACTA, V3, P110, DOI 10.1016/S0020-1693(00)92459-9.
   AIROLDI C, 1986, J CHEM SOC DALTON, P1913, DOI 10.1039/dt9860001913.
   BENNKE GT, 1967, INORG CHEM, V6, P443.
   BOLSTER MWG, 1972, THESIS LEIDEN, P98.
   CASEY RJ, 1967, J INORG NUCL CHEM, V29, P1301, DOI 10.1016/0022-1902(67)80373-7.
   CHARLES RG, 1958, J PHYS CHEM-US, V62, P440, DOI 10.1021/j150562a017.
   CHARLES RG, 1960, INORG SYN, V6, P164, DOI 10.1002/9780470132371.ch51.
   DUNSTAN PO, 1989, THERMOCHIM ACTA, V156, P163, DOI 10.1016/0040-6031(89)87182-5.
   Dunstan PO, 1999, J CHEM ENG DATA, V44, P243, DOI 10.1021/je980113m.
   DUNSTAN PO, 1992, THERMOCHIM ACTA, V197, P201, DOI 10.1016/0040-6031(92)87051-B.
   Dunstan PO, 1997, THERMOCHIM ACTA, V303, P209, DOI 10.1016/S0040-6031(97)00280-3.
   Dunstan PO, 1998, THERMOCHIM ACTA, V317, P165, DOI 10.1016/S0040-6031(98)00382-7.
   DUNSTAN PO, 2000, THERMOCHIM ACTA, V345, P17.
   Dunstan PO, 1996, J CHEM ENG DATA, V41, P1450, DOI 10.1021/je960164o.
   FAROUR M, 1985, J CHEM SOC P2, P811.
   FLASCHKA HA, 1964, EDTA TITRATIONS INTR, P104.
   GALLAGHER MJ, 1978, THERMOCHIM ACTA, V27, P269, DOI 10.1016/0040-6031(78)85042-4.
   GILL NS, 1961, J INORG NUCL CHEM, V18, P79, DOI 10.1016/0022-1902(61)80372-2.
   GILL NS, 1966, AUST J CHEM, V19, P2197.
   GRADDON DP, 1965, AUST J CHEM, V18, P507, DOI 10.1071/CH9650507.
   GRADDON DP, 1974, AUST J CHEM, V27, P741.
   GRADDON DP, 1965, AUST J CHEM, V18, P1731.
   GRADDON DP, 1961, J INORG NUCL CHEM, V21, P49, DOI 10.1016/0022-1902(61)80412-0.
   Henrigton E. F, 1974, PURE APPL CHEM, V40, P391.
   HILL JO, 1993, REV INORG CHEM, V13, P157.
   HILL JO, 1993, REV INORG CHEM, V13, P125.
   KAKOLOWICZ W, 1983, J CHEM THERMODYN, V15, P203.
   MISRA MK, 1969, J INORG NUCL CHEM, V31, P3875, DOI 10.1016/0022-1902(69)80313-1.
   MOHAPATRA BK, 1970, INORG CHIM ACTA, V4, P404, DOI 10.1016/S0020-1693(00)93314-0.
   OLSZEWSK.EJ, 1965, J INORG NUCL CHEM, V27, P1043, DOI 10.1016/0022-1902(65)80414-6.
   PEDLEY JB, 1970, SUSSEX NPL COMPUTER.
   PINCHAS S, 1967, J CHEM PHYS, V46, P1506, DOI 10.1063/1.1840881.
   SINHA SP, 1964, SPECTROCHIM ACTA, V20, P879, DOI 10.1016/0371-1951(64)80086-2.
   SKINNER HA, 1963, Q REV CHEM SOC, V17, P264, DOI 10.1039/qr9631700264.
   STEELE WV, 1988, J CHEM THERMODYN, V20, P1233, DOI 10.1016/0021-9614(88)90161-9.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{7}},
Journal-ISO = {{Thermochim. Acta}},
Doc-Delivery-Number = {{330BK}},
Wos-Id = {{ISI:000087942800003}},
}

@article{ ISI:000088680300007,
Author = {Crosbie, SJ and Murray, S and Boobis, AR and Gooderham, NJ},
Title = {{Mass spectrometric detection and measurement of N-2-(2
   `-deoxyguanosin-8-yl)PhIP adducts in DNA}},
Journal = {{JOURNAL OF CHROMATOGRAPHY B}},
Year = {{2000}},
Volume = {{744}},
Number = {{1}},
Pages = {{55-64}},
Month = {{JUL 7}},
Abstract = {{Capillary column gas chromatography-electron-capture mass spectrometry
   (GC-MS) and microbore liquid chromatography-positive ion electrospray
   mass spectrometry (LC-MS) have been used to measure the carcinogenic,
   food-derived, heterocyclic amine 2-amino-1-methyl-6-phenylimidazo{[}4,
   5-b]pyridine (PhIP) adducted at C-8 of deoxyguanosine in DNA. For CC-MS
   analysis, PhIP was released from adducted DNA by alkaline hydrolysis and
   analysed as the di(3,5-bistrifluoromethylbenzyl) derivative, while for
   LC-MS analysis, the nucleoside N-2-(2'-deoxyguanosin-8-yl)PhIP was
   generated by enzymic digestion of DNA and analysed intact. A deuterated
   analogue of N-2-(2'-deoxyguanosin-8-yl)PhIP was used as an internal
   standard in both assays, which each had a limit of quantification of 200
   pg/500 mu g DNA. The two methods were used to analyse DNA extracted from
   h1A2v2 cells and HCT116 cells that had been exposed to PhIP. (C) 2000
   Elsevier Science BN. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Murray, S (Reprint Author), Univ London Imperial Coll Sci Technol \& Med, Hammersmith Hosp, Div Med, Sect Clin Pharmacol, Du Cane Rd, London W12 0NN, England.
   Univ London Imperial Coll Sci Technol \& Med, Hammersmith Hosp, Div Med, Sect Clin Pharmacol, London W12 0NN, England.}},
DOI = {{10.1016/S0378-4347(00)00227-9}},
ISSN = {{0378-4347}},
Keywords = {{DNA; 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine}},
Keywords-Plus = {{FOOD-BORNE CARCINOGEN; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE
   PHIP; COOKED BEEF; IN-VITRO; IDENTIFICATION; EXPOSURE; RATS; VALIDATION;
   METABOLISM; MUTAGENS}},
Research-Areas = {{Biochemistry \& Molecular Biology; Chemistry}},
Web-of-Science-Categories  = {{Biochemical Research Methods; Chemistry, Analytical}},
Cited-References = {{DAVIS CD, 1994, CARCINOGENESIS, V15, P641, DOI 10.1093/carcin/15.4.641.
   Dingley KH, 1999, CANCER EPIDEM BIOMAR, V8, P507.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   Friesen MD, 1996, CARCINOGENESIS, V17, P67, DOI 10.1093/carcin/17.1.67.
   GIESE RW, 1991, HUMAN CARCINOGEN EXP, P247.
   Gooderham NJ, 1996, BRIT J CLIN PHARMACO, V42, P91, DOI 10.1046/j.1365-2125.1996.37513.x.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   MURRAY S, 1993, J CHROMATOGR-BIOMED, V616, P211, DOI 10.1016/0378-4347(93)80388-K.
   RINDGEN D, 1995, CHEM RES TOXICOL, V8, P1005, DOI 10.1021/tx00050a003.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   Turteltaub K W, 1995, Princess Takamatsu Symp, V23, P93.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P2291, DOI 10.1093/carcin/12.12.2291.
   YadollahiFarsani M, 1996, CARCINOGENESIS, V17, P617, DOI 10.1093/carcin/17.4.617.
   ZHAO K, 1994, CARCINOGENESIS, V15, P1285, DOI 10.1093/carcin/15.6.1285.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{18}},
Journal-ISO = {{J. Chromatogr. B}},
Doc-Delivery-Number = {{343AV}},
Wos-Id = {{ISI:000088680300007}},
}

@article{ ISI:000088030600003,
Author = {Steffensen, IL and Fretland, AJ and Paulsen, JE and Feng, Y and Eide, TJ
   and Devanaboyina, US and Hein, DW and Alexander, J},
Title = {{DNA adduct levels and intestinal lesions in congenic rapid and slow
   acetylator Syrian hamsters administered the food mutagens
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) or
   2-amino-3-methylimidazo{[}4,5-f]quinoline (IQ)}},
Journal = {{PHARMACOLOGY \& TOXICOLOGY}},
Year = {{2000}},
Volume = {{86}},
Number = {{6}},
Pages = {{257-263}},
Month = {{JUN}},
Abstract = {{Epidemiological studies indicate that rapid acetylators with a high
   intake of well-done red meat have an increased risk of colorectal
   cancer. Arylamine N-acetyltransferase enzymes (E.C. 2.3.1.5) activate
   carcinogenic heterocyclic amines found in the crust of fried meat via
   O-acetylation of their N-hydroxylamines to reactive intermediates that
   bind covalently to DNA and produce mutations. Syrian hamsters as well as
   humans express two N-acetyltransferase isozymes (NAT1 and NAT2) which
   differ in substrate specificity and genetic control. Nucleic acid
   substitutions in the NAT2 gene segregate individuals into rapid,
   intermediate and slow acetylator phenotypes. In the present paper, Ne
   examined the role of the polymorphic NAT2 acetylator genotype in
   carcinogenesis induced by the food mutagens
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) or
   2-amino-3-methylimidazo{[}4,5-f]quinoline (IQ) by comparing Syrian
   hamster lines congenic at the NAT2 locus. No differences were found
   between rapid and slow acetylator congenic hamsters in levels of
   intestinal PhIP-DNA adducts. In contrast to previous studies in rats, no
   carcinogen-related induction of the preneoplastic lesions aberrant crypt
   foci or tumors was found in the intestines of rapid and slow acetylator
   congenic Syrian hamsters administered PhIP or IQ.}},
Publisher = {{MUNKSGAARD INT PUBL LTD}},
Address = {{35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Steffensen, IL (Reprint Author), Natl Inst Publ Hlth, Dept Environm Med, POB 4404 Torshov, N-0403 Oslo, Norway.
   Natl Inst Publ Hlth, Dept Environm Med, N-0403 Oslo, Norway.
   Univ N Dakota, Sch Med \& Hlth Sci, Dept Pharmacol \& Toxicol, Grand Forks, ND 58202 USA.
   Univ Louisville, Sch Med, Dept Pharmacol \& Toxicol, Louisville, KY 40292 USA.
   Natl Hosp Norway, Dept Pathol, N-0027 Oslo, Norway.}},
DOI = {{10.1111/j.0901-9928.2000.860603.x}},
ISSN = {{0901-9928}},
Keywords-Plus = {{ABERRANT CRYPT FOCI; ARYLAMINE N-ACETYLTRANSFERASES; COLORECTAL-CANCER;
   METABOLIC-ACTIVATION; ARYLHYDROXAMIC ACIDS; HETEROCYCLIC AMINES; COLON
   CARCINOGEN; BORNE CARCINOGEN; BROILED SARDINE; BEEF EXTRACT}},
Research-Areas = {{Pharmacology \& Pharmacy; Toxicology}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy; Toxicology}},
ResearcherID-Numbers = {{Hein, David/A-9707-2008}},
Cited-References = {{ALEXANDER J, 1994, ENVIRON HEALTH PERSP, V102, P109, DOI 10.2307/3432162.
   ALEXANDER J, 1991, MUTAGENS FOOD DETECT, P143.
   BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1.
   BLUM M, 1990, DNA CELL BIOL, V9, P193, DOI 10.1089/dna.1990.9.193.
   Chen J, 1998, CANCER RES, V58, P3307.
   Delclos K. B., 1997, COMPREHENSIVE TOXICO, V12, P141.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   EVANS DAP, 1989, PHARMACOL THERAPEUT, V42, P157.
   Feng Y, 1997, TOXICOL APPL PHARM, V147, P56, DOI 10.1006/taap.1997.8259.
   Feng Y, 1996, TOXICOL APPL PHARM, V140, P315, DOI 10.1006/taap.1996.0226.
   Feng Y, 1996, CANCER RES, V56, P527.
   Ferguson RJ, 1996, PHARMACOGENETICS, V6, P55, DOI 10.1097/00008571-199602000-00004.
   FERGUSON RJ, 1994, GENE, V140, P247, DOI 10.1016/0378-1119(94)90552-5.
   FERGUSON RJ, 1994, PHARMACOGENETICS, V4, P82, DOI 10.1097/00008571-199404000-00005.
   FIALA ES, 1981, CARCINOGENESIS, V2, P965, DOI 10.1093/carcin/2.10.965.
   GRANT DM, 1993, PHARMACOGENETICS, V3, P45, DOI 10.1097/00008571-199302000-00005.
   GRANT DM, 1991, MOL PHARMACOL, V39, P184.
   Hanna P E, 1994, Adv Pharmacol, V27, P401, DOI 10.1016/S1054-3589(08)61041-8.
   HASEGAWA R, 1993, CARCINOGENESIS, V14, P2553, DOI 10.1093/carcin/14.12.2553.
   HEIN DW, 1994, TOXICOL APPL PHARM, V124, P16, DOI 10.1006/taap.1994.1003.
   HEIN DW, 1985, J PHARMACOL EXP THER, V234, P358.
   HEIN DW, 1988, BIOCHIM BIOPHYS ACTA, V948, P37, DOI 10.1016/0304-419X(88)90004-2.
   HEIN DW, 1993, CARCINOGENESIS, V14, P1633, DOI 10.1093/carcin/14.8.1633.
   HEIN DW, 1991, TOXICOL METHOD, V1, P44, DOI 10.3109/15376519109036524.
   Hein DW, 1997, ARCH TOXICOL, V71, P306, DOI 10.1007/s002040050391.
   Hein DW, 1997, MUTAT RES-FUND MOL M, V376, P101, DOI 10.1016/S0027-5107(97)00031-6.
   HEIN DW, 1993, CANCER RES, V53, P509.
   Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   Jiang W, 1999, TOXICOL APPL PHARM, V156, P187, DOI 10.1006/taap.1998.8621.
   Jones RF, 1996, CARCINOGENESIS, V17, P1729, DOI 10.1093/carcin/17.8.1729.
   KADLUBAR FF, 1992, ENVIRON HEALTH PERSP, V98, P69, DOI 10.2307/3431249.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   Leff MA, 1999, J PHARMACOL EXP THER, V290, P182.
   LIN DX, 1995, DRUG METAB DISPOS, V23, P518.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   NAGAO M, 1993, MUTAT RES, V290, P43, DOI 10.1016/0027-5107(93)90031-A.
   NUSSBAUM M, 1983, ENVIRON HEALTH PERSP, V49, P223, DOI 10.2307/3429601.
   OCHIAI M, 1991, JPN J CANCER RES, V82, P363.
   OHGAKI H, 1984, CARCINOGENESIS, V5, P921, DOI 10.1093/carcin/5.7.921.
   ORMHOUDT LW, 1999, CRIT REV TOXICOL, V29, P59.
   OZAWA S, 1990, CARCINOGENESIS, V11, P2137, DOI 10.1093/carcin/11.12.2137.
   Paulsen JE, 1996, CARCINOGENESIS, V17, P459, DOI 10.1093/carcin/17.3.459.
   PUREWAL M, 2000, IN PRESS CANC EPIDEM, V9.
   Purewal M, 2000, CANCER LETT, V149, P53, DOI 10.1016/S0304-3835(99)00346-8.
   RobertsThomson IC, 1996, LANCET, V347, P1372, DOI 10.1016/S0140-6736(96)91012-0.
   SMITH TJ, 1986, CARCINOGENESIS, V7, P697, DOI 10.1093/carcin/7.5.697.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   Steffensen IL, 1997, CARCINOGENESIS, V18, P1049, DOI 10.1093/carcin/18.5.1049.
   Steffensen IL, 1995, CARCINOGENESIS, V16, P2981, DOI 10.1093/carcin/16.12.2981.
   TAKAHASHI S, 1991, JPN J CANCER RES, V82, P135.
   TAKAYAMA S, 1984, GANN, V75, P467.
   TANAKA T, 1985, JPN J CANCER RES, V76, P570.
   TUDEK B, 1989, CANCER RES, V49, P1236.
   VATSIS K, 1997, COMPREHENSIVE TOXICO, P385.
   Ware JA, 1996, BIOCHEM PHARMACOL, V52, P1613, DOI 10.1016/S0006-2952(96)00567-9.
   WEBER WW, 1985, PHARMACOL REV, V37, P25.
   WEISBURGER JH, 1994, J NATL CANCER I, V86, P25, DOI 10.1093/jnci/86.1.25.
   Welfare MR, 1997, CARCINOGENESIS, V18, P1351, DOI 10.1093/carcin/18.7.1351.
   Xu M, 1996, CARCINOGENESIS, V17, P1429, DOI 10.1093/carcin/17.7.1429.}},
Number-of-Cited-References = {{61}},
Times-Cited = {{10}},
Journal-ISO = {{Pharmacol. Toxicol.}},
Doc-Delivery-Number = {{331QW}},
Wos-Id = {{ISI:000088030600003}},
}

@article{ ISI:000085745600008,
Author = {Imaida, K and Ogawa, K and Takahashi, S and Ito, T and Yamaguchi, T and
   Totsuka, Y and Wakabayashi, K and Tanaka, K and Ito, N and Shirai, T},
Title = {{Delay of DNA-adduct repair and severe toxicity in xeroderma pigmentosum
   group A gene (XPA) deficient mice treated with
   2-amino-1-methyl-6-phenyl-imidazo {[}4,5-b] pyridine (PhIP)}},
Journal = {{CANCER LETTERS}},
Year = {{2000}},
Volume = {{150}},
Number = {{1}},
Pages = {{63-69}},
Month = {{MAR 13}},
Abstract = {{Group-A xeroderma pigmentosum (XPA) gene-deficient mice are defective in
   nucleotide-excision repair and highly susceptible to ultraviolet-B-, and
   9,10-dimethyl-1,2-benz{[}a]anthracene (DMBA)-induced skin carcinogenesis
   {[}1]. In this study, changes of
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b] pyridine (PhIP)-DNA adduct
   formations in the liver, colon and lung, as assessed by the
   P-32-postlabeling method and immunohistochemical analysis, and
   carcinogenic and/or toxic susceptibility of both sexes of XPA-deficient
   mice (XPA(-/-)) to PhIP, which is a carcinogenic heterocyclic amine, was
   examined. Levels of PhIP-DNA adduct formations in the liver, colon and
   lung, were almost twice as high in XPA(-/-) as in wild type mice
   (XPA(+/+)) mice, 7 days after a single i.g. administration of PhIP, and
   their delay in recovery was observed in XPA(-/-) mice. For the longterm
   experiment, XPA(-/-) and XPA(+/+) type mice were treated with 80 ppm
   PhIP in the diet for the first 4 weeks followed by 40 ppm after a 2-week
   recovery period (long-term experiment I), or 40 ppm PhIP throughout the
   experiment (long-term experiment II). Severe toxicity; as evidenced by
   body weight retardation and poor survival, was observed in the PhIP
   treated XPA(-/-). mice of both sexes, but not in the XPA(+/+). At week
   40 the experiments were terminated and histopathological examinations
   were performed after complete autopsy. Only lymphomas/leukemias were
   observed as neoplastic lesions, but no significant differences were
   observed between the groups. As non-neoplastic :lesions, degenerating
   changes, for example in the pancreatic acinar cells, were observed with
   XPA(-/-) mice tending to be more sensitive than XPA(+/+) mice. The
   present study demonstrated that PhIP-DNA adduct formations in the liver,
   colon and lung of XPA(-/-) mice were demonstrated and their recovery
   rate was more delayed than XPA(+/+) mice, and furthermore, more severe
   toxicity to PhIP in XPA-deficient mice was observed, but they were not
   susceptible to PhIP carcinogenicity under the conditions of the
   experiment. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.}},
Publisher = {{ELSEVIER SCI IRELAND LTD}},
Address = {{CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Imaida, K (Reprint Author), Nagoya City Univ, Sch Med, Dept Pathol 1, Nagoya, Aichi 4678601, Japan.
   Nagoya City Univ, Sch Med, Dept Pathol 1, Nagoya, Aichi 4678601, Japan.
   Natl Canc Ctr, Canc Prevent Div, Inst Res, Tokyo 104, Japan.
   Osaka Univ, Inst Mol \& Cell Biol, Osaka 565, Japan.}},
DOI = {{10.1016/S0304-3835(99)00377-8}},
ISSN = {{0304-3835}},
Keywords = {{xeroderma pigmentosum; XPA deficient transgenic mouse; heterocyclic
   amine; PhIP; PhIP-DNA adduct; bioassay; genotoxic carcinogen}},
Keywords-Plus = {{SPRAGUE-DAWLEY RATS; HA-RAS GENE;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; TRANSGENIC MOUSE;
   MUTAGENIC COMPOUND; CARCINOGENICITY; FOOD; BIOASSAYS; INDUCTION;
   LYMPHOMA}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{Aboussekhra Abdelilah, 1994, Current Opinion in Genetics and Development, V4, P212, DOI 10.1016/S0959-437X(05)80047-4.
   Berg RJW, 1997, CANCER RES, V57, P581.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FUKUTOME K, 1994, JPN J CANCER RES, V85, P113.
   HASEGAWA R, 1992, FOOD CHEM TOXICOL, V30, P979, DOI 10.1016/0278-6915(92)90184-M.
   HASEGAWA R, 1995, CANCER RES, V55, P4333.
   HASEGAWA R, 1993, CARCINOGENESIS, V14, P2553, DOI 10.1093/carcin/14.12.2553.
   Holden HE, 1998, J APPL TOXICOL, V18, P19, DOI 10.1002/(SICI)1099-1263(199801/02)18:1<19::AID-JAT464>3.3.CO;2-H.
   Imaida K, 1996, JPN J CANCER RES, V87, P1116.
   ISHIKAWA T, 1997, P JPN CANC ASS, V56, P68.
   Ito N, 1995, CRIT REV ONCOL HEMAT, V21, P105, DOI 10.1016/1040-8428(94)00169-3.
   Ito N, 1997, MUTAT RES-FUND MOL M, V376, P107, DOI 10.1016/S0027-5107(97)00032-8.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   Ito N, 1996, EXP TOXICOL PATHOL, V48, P113.
   Mitsumori K, 1998, CANCER LETT, V129, P181, DOI 10.1016/S0304-3835(98)00095-0.
   NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0.
   Rao CV, 1996, CANCER RES, V56, P3395.
   Shirai T, 1997, CANCER RES, V57, P195.
   Takahashi S, 1998, CANCER RES, V58, P4307.
   Takahashi S, 1996, TOXICOL PATHOL, V24, P273.
   TAKAYAMA S, 1985, JPN J CANCER RES, V76, P815.
   TAMANO S, 1994, CARCINOGENESIS, V15, P2009, DOI 10.1093/carcin/15.9.2009.
   TENNANT RW, 1995, ENVIRON HEALTH PERSP, V103, P942, DOI 10.2307/3432740.
   Tennant RW, 1996, MUTAT RES-REV GENET, V365, P119, DOI 10.1016/S0165-1110(96)90016-0.
   Yamamoto S, 1998, ENVIRON HEALTH PERSP, V106, P57, DOI 10.2307/3433912.
   {*}ICH STEER COMM, 1997, ICH4 4 INT C HARM CA.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{8}},
Journal-ISO = {{Cancer Lett.}},
Doc-Delivery-Number = {{291PQ}},
Wos-Id = {{ISI:000085745600008}},
}

@article{ ISI:000086073400010,
Author = {Williams, JA and Stone, EM and Millar, BC and Hewer, A and Phillips, DH},
Title = {{Pathways of heterocyclic amine activation in the breast: DNA adducts of
   2-amino-3-methylimidazo{[}4,5-f]quinoline (IQ) formed by peroxidases and
   in human mammary epithelial cells and fibroblasts}},
Journal = {{MUTAGENESIS}},
Year = {{2000}},
Volume = {{15}},
Number = {{2}},
Pages = {{149-154}},
Month = {{MAR}},
Abstract = {{Most human mammary carcinomas originate in the epithelial cells of the
   breast ducts; A potential role of heterocyclic amines (HAs) in the
   aetiology of this disease has led us to investigate peroxidase-catalysed
   and stromal (non-epithelial) activation of the HA.
   2-amino-3-methylimidazo {[}4,5-f]quinoline (IQ), which may subsequently
   lead to DNA damage in the adjacent human mammary epithelial cells
   (HMECs). HAs are formed when proteinaceous foods are cooked at high
   temperature and some, but not all, can cause mammary tumours in rats.
   Myeloperoxidase (MPO) and lactoperoxidase (LPO) are peroxidase enzymes
   present in breast secretions. P-32-post-labelling analysis showed that
   IQ-DNA adducts were formed after co-incubation of IQ (500 mu M) with
   calf thymus DNA, hydrogen peroxide and either bovine LPO or horseradish
   peroxidase (HRP), The major HRP-mediated IQ-DNA adduct co-migrated on
   TLC and HPLC with the major adduct formed in HMECs, suggesting a common
   reactive intermediate (nitrenium ion). IQ-DNA adducts were also formed
   in extracellular DNA when phorbol myristate acetate-stimulated
   neutrophils (which activate IQ via MPO) were co-incubated with IQ (500
   mu M) and extracellular plasmid (4 +/- 1 adducts/10(8) nucleotides) or
   calf thymus DNA (6 +/- 2), Mean adduct formation was five to seven times
   greater in neutrophil DNA (31 +/- 20), Primary cultures of human mammary
   fibroblasts or epithelial cells isolated from reduction mammoplasty
   tissues (n = 4 individuals) were incubated with IQ (500 mu M) and formed
   2.5 and 14.8 adducts/10(8) nucleotides (mean values), respectively. Our
   results indicate the possible contribution of stromal cells and breast
   peroxidases to the metabolic activation of carcinogens in the mammary
   gland.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Williams, JA (Reprint Author), Inst Canc Res, Haddow Labs, Cotswold Rd, Sutton SM2 5NG, Surrey, England.
   Inst Canc Res, Haddow Labs, Sutton SM2 5NG, Surrey, England.}},
DOI = {{10.1093/mutage/15.2.149}},
ISSN = {{0267-8357}},
Keywords-Plus = {{CANCER RISK; METABOLIC-ACTIVATION; GENETIC POLYMORPHISMS;
   CIGARETTE-SMOKING; EXPRESSION;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE; EPIDEMIOLOGY;
   CARCINOGENS; RECEPTOR; ALLERGY}},
Research-Areas = {{Genetics \& Heredity; Toxicology}},
Web-of-Science-Categories  = {{Genetics \& Heredity; Toxicology}},
Author-Email = {{andyw@icr.ac.uk}},
Cited-References = {{Ambrosone CB, 1996, JAMA-J AM MED ASSOC, V276, P1494, DOI 10.1001/jama.276.18.1494.
   Ambrosone CB, 1998, INT J CANCER, V75, P825, DOI 10.1002/(SICI)1097-0215(19980316)75:6<825::AID-IJC2>3.0.CO;2-X.
   ANDERSON WA, 1979, PROG HISTOCHEM CYTOC, V11, P1.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   BOTEJU LW, 1994, CHEM RES TOXICOL, V7, P684, DOI 10.1021/tx00041a014.
   CLARKE C, 1994, EPITHELIAL CELL BIOL, V3, P38.
   Crofts FG, 1998, CARCINOGENESIS, V19, P1969, DOI 10.1093/carcin/19.11.1969.
   DeBruin LS, 1999, CHEM RES TOXICOL, V12, P78, DOI 10.1021/tx980168m.
   DOLL R, 1981, J NATL CANCER I, V66, P1191.
   Eltom SE, 1998, CARCINOGENESIS, V19, P1437, DOI 10.1093/carcin/19.8.1437.
   ENDO H, 1994, CANCER RES, V54, P3745.
   ERIKSSON NE, 1995, ALLERGY, V50, P718, DOI 10.1111/j.1398-9995.1995.tb01212.x.
   Goldman AS, 1998, PEDIATR RES, V43, P155, DOI 10.1203/00006450-199802000-00001.
   GUPTA RC, 1985, CANCER RES, V45, P5656.
   Guzman RC, 1999, P NATL ACAD SCI USA, V96, P2520, DOI 10.1073/pnas.96.5.2520.
   HALL M, 1990, CARCINOGENESIS, V11, P1005, DOI 10.1093/carcin/11.6.1005.
   Hellmold H, 1998, J CLIN ENDOCR METAB, V83, P886, DOI 10.1210/jc.83.3.886.
   Hunter DJ, 1996, CANCER CAUSE CONTROL, V7, P56, DOI 10.1007/BF00115638.
   Ishibe N, 1998, CANCER RES, V58, P667.
   Josephy PD, 1996, MUTAGENESIS, V11, P3, DOI 10.1093/mutage/11.1.3.
   Josephy PD, 1998, CAN J PHYSIOL PHARM, V76, P693, DOI 10.1139/cjpp-76-7-8-693.
   Kelsey JL, 1996, ANNU REV PUBL HEALTH, V17, P47, DOI 10.1146/annurev.publhealth.17.1.47.
   KING EB, 1975, AM J CLIN PATHOL, V64, P728.
   Larsen MC, 1998, CANCER RES, V58, P2366.
   Lewis AJ, 1998, CARCINOGENESIS, V19, P2049, DOI 10.1093/carcin/19.11.2049.
   London SJ, 1997, CANCER RES, V57, P5001.
   Malfatti MA, 1999, CARCINOGENESIS, V20, P705, DOI 10.1093/carcin/20.4.705.
   Martin FL, 1996, CANCER RES, V56, P5342.
   Martin FL, 1999, BIOCHEM BIOPH RES CO, V257, P319, DOI 10.1006/bbrc.1999.0421.
   MILLS PK, 1992, AM J EPIDEMIOL, V136, P287.
   NAGAO M, 1994, CANCER, V74, P1063, DOI 10.1002/1097-0142(19940801)74:3+<1063::AID-CNCR2820741514>3.0.CO;2-2.
   Ochiai M, 1999, MUTAGENESIS, V14, P239, DOI 10.1093/mutage/14.2.239.
   PETRAKIS NL, 1993, CANCER EPIDEM BIOMAR, V2, P3.
   Phillips DH, 1999, MUTAT RES-GEN TOX EN, V443, P139, DOI 10.1016/S1383-5742(99)00016-2.
   Sadrieh N, 1996, CANCER RES, V56, P2683.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   SKIPPER PL, 1994, ENVIRON HEALTH PERSP, V102, P17, DOI 10.2307/3432145.
   Stone EM, 1998, CARCINOGENESIS, V19, P873, DOI 10.1093/carcin/19.5.873.
   STONE EM, 1999, MUTAGENESIS, V14, P652.
   TRUSH MA, 1985, P NATL ACAD SCI USA, V82, P5194, DOI 10.1073/pnas.82.15.5194.
   TSURUTA Y, 1985, CHEM-BIOL INTERACT, V54, P143, DOI 10.1016/S0009-2797(85)80159-9.
   TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005.
   Ueda T, 1997, EUR J BIOCHEM, V243, P32, DOI 10.1111/j.1432-1033.1997.0032a.x.
   Willett WC, 1995, ENVIRON HEALTH PERSP, V103, P165, DOI 10.2307/3432305.
   Williams JA, 1998, PHARMACOGENETICS, V8, P519, DOI 10.1097/00008571-199812000-00009.
   YU MC, 1981, BRIT J CANCER, V43, P826, DOI 10.1038/bjc.1981.121.
   Zheng W, 1998, J NATL CANCER I, V90, P1724, DOI 10.1093/jnci/90.22.1724.
   Zheng W, 1999, CANCER EPIDEM BIOMAR, V8, P233.}},
Number-of-Cited-References = {{48}},
Times-Cited = {{24}},
Journal-ISO = {{Mutagenesis}},
Doc-Delivery-Number = {{297GG}},
Wos-Id = {{ISI:000086073400010}},
}

@article{ ISI:000085712200008,
Author = {Purewal, M and Fretland, AJ and Schut, HAJ and Hein, DW and Wargovich,
   MJ},
Title = {{Association between acetylator genotype and
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) DNA adduct
   formation in colon and prostate of inbred Fischer 344 and Wistar Kyoto
   rats}},
Journal = {{CANCER LETTERS}},
Year = {{2000}},
Volume = {{149}},
Number = {{1-2}},
Pages = {{53-60}},
Month = {{FEB 28}},
Abstract = {{2-Amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP), a heterocyclic
   amine (HCA) found in cooked meats, causes colon and prostate tumors in
   male rats. Polymorphic N-acetyltransferase metabolizes N-hydroxy-PhIP to
   a DNA-reactive form. Liver, colon, and prostate PhIP-DNA adduct levels
   were compared in male rapid-acetylator Fischer 344 (F344) and
   slow-acetylator Wistar-Kyoto (WKY) rats fed 0.01 or 0.04\% PhIP. Liver
   PhIP-DNA adduct levels at both PhIP doses, and colon PhIP-DNA adduct
   levels at the 0.01\% PhIP dose were unaffected by acetylator genotype.
   However, in rats fed 0.04\% PhIP, colon PhIP-DNA adduct levels were
   higher in rapid acetylator F344 rats (P < 0.05). Similarly, prostate
   PhIP-DNA adduct levels were higher in rapid acetylator F344 rats at both
   PhIP doses (P < 0.05). The combination of the high-PhIP dose and
   rapid-acetylator genotype resulted in the highest level of PhIP-DNA
   adducts in rat colon and prostate. (C) 2000 Elsevier Science Ireland
   Ltd. All rights reserved.}},
Publisher = {{ELSEVIER SCI IRELAND LTD}},
Address = {{CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hein, DW (Reprint Author), Univ Louisville, Sch Med, Dept Pharmacol \& Toxicol, Louisville, KY 40292 USA.
   Univ Louisville, Sch Med, Dept Pharmacol \& Toxicol, Louisville, KY 40292 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol \& Digest Dis, Houston, TX 77030 USA.
   Med Coll Ohio, Dept Pathol, Toledo, OH 43699 USA.
   S Carolina Canc Ctr, Dept Pathol, Columbia, SC USA.}},
DOI = {{10.1016/S0304-3835(99)00346-8}},
ISSN = {{0304-3835}},
Keywords = {{heterocyclic amines; 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine
   (PhIP); DNA adducts; inbred rats; N-acetyltransferase}},
Keywords-Plus = {{ARYLAMINE N-ACETYLTRANSFERASE; HETEROCYCLIC AMINE CARCINOGENS;
   RECOMBINANT HUMAN NAT1; METABOLIC-ACTIVATION; COOKED FOODS; EXPRESSION;
   HYDROXYARYLAMINES; IDENTIFICATION; POLYMORPHISM; CYTOSOLS}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
ResearcherID-Numbers = {{Hein, David/A-9707-2008}},
Cited-References = {{CHOU HC, 1995, CANCER RES, V55, P525.
   CROFTS FG, 1997, CARCINOGENESIS, V18, P193.
   CUMMINGS DA, 1994, CARCINOGENESIS, V15, P2623, DOI 10.1093/carcin/15.11.2623.
   DOLL MA, 1995, PHARMACOGENETICS, V5, P247, DOI 10.1097/00008571-199508000-00009.
   Doll MA, 1997, BIOCHEM BIOPH RES CO, V233, P584, DOI 10.1006/bbrc.1997.6501.
   Feng Y, 1997, TOXICOL APPL PHARM, V147, P56, DOI 10.1006/taap.1997.8259.
   FRETLAND AJ, 1998, TOXICOL SCI, V42, P281.
   Fretland A J, 1997, Proc West Pharmacol Soc, V40, P9.
   Grant DM, 1997, MUTAT RES-FUND MOL M, V376, P61, DOI 10.1016/S0027-5107(97)00026-2.
   HASEGAWA R, 1993, CARCINOGENESIS, V14, P2553, DOI 10.1093/carcin/14.12.2553.
   HEIN DW, 1994, ARCH TOXICOL, V68, P129, DOI 10.1007/s002040050045.
   HEIN DW, 1993, CARCINOGENESIS, V14, P1633, DOI 10.1093/carcin/14.8.1633.
   HEIN DW, 1987, CARCINOGENESIS, V8, P1767, DOI 10.1093/carcin/8.12.1767.
   Hein DW, 1997, MUTAT RES-FUND MOL M, V376, P101, DOI 10.1016/S0027-5107(97)00031-6.
   HEIN DW, 1991, J PHARMACOL EXP THER, V258, P232.
   HEIN DW, 1999, IN PRESS TOXICOL LET.
   HEIN DW, 1993, CANCER RES, V53, P509.
   HEIN DW, 1991, DRUG METAB DISPOS, V19, P933.
   Imaida K, 1996, JPN J CANCER RES, V87, P1116.
   Ito N, 1997, MUTAT RES-FUND MOL M, V376, P107, DOI 10.1016/S0027-5107(97)00032-8.
   JOHANSSON MAE, 1994, CARCINOGENESIS, V15, P1511, DOI 10.1093/carcin/15.8.1511.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LIN DX, 1994, CANCER RES, V54, P4920.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215.
   MINCHIN RF, 1992, BIOCHEM BIOPH RES CO, V185, P839, DOI 10.1016/0006-291X(92)91703-S.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   REMER H, 1967, METHOD ENZYMOL, V10, P703.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SESARDIC D, 1990, BIOCHEM PHARMACOL, V39, P489, DOI 10.1016/0006-2952(90)90055-P.
   Shirai T, 1997, CANCER RES, V57, P195.
   Takahashi S, 1998, CANCER RES, V58, P4307.
   TRINIDAD A, 1990, CANCER RES, V50, P7942.}},
Number-of-Cited-References = {{35}},
Times-Cited = {{19}},
Journal-ISO = {{Cancer Lett.}},
Doc-Delivery-Number = {{291BD}},
Wos-Id = {{ISI:000085712200008}},
}

@article{ ISI:000085617900003,
Author = {He, YH and Friesen, MD and Ruch, RJ and Schut, HAJ},
Title = {{Indole-3-carbinol as a chemopreventive agent in
   2-amino-1-methyl-6-phenylimidazo{[}4, 5-b]pyridine (PhIP)
   carcinogenesis: Inhibition of PhIP-DNA adduct formation, acceleration of
   PhIP metabolism, and induction of cytochrome P450 in female F344 rats}},
Journal = {{FOOD AND CHEMICAL TOXICOLOGY}},
Year = {{2000}},
Volume = {{38}},
Number = {{1}},
Pages = {{15-23}},
Month = {{JAN}},
Abstract = {{The chemopreventive properties of dietary indole-3-carbinol (I3C) were
   evaluated by assessing its effect on DNA adduct formation and metabolism
   of the dietary carcinogen,
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP), and the
   induction of cytochromes P450 1A1 and -1A2 in female F344 rats. In
   experiment 1, animals on I3C diets (0, 0.02\% or 0.1\%, w/w) were
   treated by gavage with 1 mg/kg/day of PhIP for 23 days, On days 2, 9, 16
   and 23, their 24-hr urine was collected and unmetabolized PhIP was
   measured by GC/MS. On day 24, the animals sere sacrificed, and DNA from
   pancreas, spleen, white blood cells (WBCs), lung, colon, kidney, mammary
   epithelial cells, caecum, heart, small intestine, liver and stomach was
   isolated for determination of PhIP-DNA adduct levels by
   P-32-postlabelling assays, Except in the mammary gland, I3C diets
   significantly inhibited PhIP-DNA adduct formation in WBCs and in all
   organs, ranging from 34.7 to 67.7\% with the 0.02\% I3C diet to 68.4 to
   95.3\% with the 0.1\% I3C diet. I3C diets also significantly decreased
   the concentration of urinary unmetabolized PhIP to 29.5-38.4\% (0.02\%
   I3C) and 12.8-17.8\% (0.1\% I3C) of values obtained with;he I3C-free
   diet. In experiment 2, animals were either treated by intubation of I3C
   at 100 or 200 mg/kg for 2 consecutive days or given an I3C-containing
   diet (0.02\% or 0.1\%, w/w) for 2 weeks. The expression and activity of
   cytochromes P450 1A1 and -1A2 were studied by Northern blots, Western
   blots, and in,vitro enzyme determinations, Both the expression and
   activity of these cytochromes mere induced by all of the I3C treatments.
   It is concluded that, in the female F344 rat, dietary I3C inhibits
   PhIP-DNA adduct formation and accelerates PhIP metabolism, probably
   through induction of cytochromes P450 1A1 and -1A2. The chemopreventive
   properties of I3C in PhIP-induced carcinogenesis are probably mediated
   through enhancement of PhIP detoxification pathways. (C) 2000 Elsevier
   Science Ltd. All rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{He, YH (Reprint Author), Med Coll Ohio, Dept Pathol, Hlth Educ Bldg,Room 202,3055 Arlington Ave, Toledo, OH 43614 USA.
   Med Coll Ohio, Dept Pathol, Toledo, OH 43614 USA.
   Int Agcy Res Canc, Unit Gene Environm Interact, F-69372 Lyon, France.}},
DOI = {{10.1016/S0278-6915(99)00117-9}},
ISSN = {{0278-6915}},
Keywords = {{heterocyclic amines; food mutagens; PhIP; DNA adducts; chemoprevention;
   indole-3-carbinol}},
Keywords-Plus = {{FOOD-BORNE CARCINOGEN; HETEROCYCLIC AMINES; EPITHELIAL-CELLS; AFLATOXIN
   B-1; COOKED FOODS; IN-VITRO; LIVER; MICE; ACTIVATION; COLON}},
Research-Areas = {{Food Science \& Technology; Toxicology}},
Web-of-Science-Categories  = {{Food Science \& Technology; Toxicology}},
ResearcherID-Numbers = {{Friesen, Marlin/D-7328-2012}},
Cited-References = {{BRADLOW HL, 1994, CANCER EPIDEM BIOMAR, V3, P591.
   BURKE MD, 1994, BIOCHEM PHARMACOL, V48, P923, DOI 10.1016/0006-2952(94)90363-8.
   CUMMINGS DA, 1995, CARCINOGENESIS, V16, P2523, DOI 10.1093/carcin/16.10.2523.
   CUMMINGS DA, 1994, CARCINOGENESIS, V15, P2623, DOI 10.1093/carcin/15.11.2623.
   DASHWOOD RH, 1988, CARCINOGENESIS, V9, P427, DOI 10.1093/carcin/9.3.427.
   DEFLORA S, 1994, MUTAGENESIS, V9, P39, DOI 10.1093/mutage/9.1.39.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   Friesen MD, 1996, CARCINOGENESIS, V17, P67, DOI 10.1093/carcin/17.1.67.
   GHOSHAL A, 1995, CARCINOGENESIS, V16, P2725, DOI 10.1093/carcin/16.11.2725.
   GRUBBS CJ, 1995, ANTICANCER RES, V15, P709.
   Guo Dexin, 1995, Carcinogenesis (Oxford), V16, P2931, DOI 10.1093/carcin/16.12.2931.
   He Y H, 1997, J Cell Biochem Suppl, V27, P42.
   HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   JONGEN WMF, 1989, TOXICOL IN VITRO, V3, P207, DOI 10.1016/0887-2333(89)90007-6.
   JONGEN WMF, 1989, MUTAT RES, V222, P263, DOI 10.1016/0165-1218(89)90142-0.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1711, DOI 10.1093/carcin/15.8.1711.
   Kim DJ, 1997, CARCINOGENESIS, V18, P377, DOI 10.1093/carcin/18.2.377.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MCDANELL R, 1988, FOOD CHEM TOXICOL, V26, P59, DOI 10.1016/0278-6915(88)90042-7.
   MORSE MA, 1990, CANCER RES, V50, P2613.
   PARK JY, 1992, CHEM-BIOL INTERACT, V83, P235, DOI 10.1016/0009-2797(92)90100-Y.
   PENCE BC, 1986, J NATL CANCER I, V77, P269.
   PFAU W, 1994, CARCINOGENESIS, V15, P877, DOI 10.1093/carcin/15.5.877.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   Rao CV, 1996, CANCER RES, V56, P3395.
   RINDGEN D, 1995, CHEM RES TOXICOL, V8, P1005, DOI 10.1021/tx00050a003.
   RUCH RJ, 1994, CARCINOGENESIS, V15, P301, DOI 10.1093/carcin/15.2.301.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   Schut HAJ, 1997, MUTAT RES-FUND MOL M, V376, P185, DOI 10.1016/S0027-5107(97)00042-0.
   SHARMA S, 1994, CANCER RES, V54, P5848.
   SHERTZER HG, 1991, FOOD CHEM TOXICOL, V29, P237, DOI 10.1016/0278-6915(91)90020-8.
   Shirai T, 1997, CANCER RES, V57, P195.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   Steele V E, 1994, J Cell Biochem Suppl, V20, P32.
   STRESSER DM, 1994, DRUG METAB DISPOS, V22, P392.
   STRESSER DM, 1994, DRUG METAB DISPOS, V22, P383.
   Sugimura T, 1997, MUTAT RES-FUND MOL M, V376, P211, DOI 10.1016/S0027-5107(97)00045-6.
   SUTO A, 1993, BREAST CANCER RES TR, V27, P193, DOI 10.1007/BF00665689.
   Taioli E, 1997, CANCER EPIDEM BIOMAR, V6, P517.
   TANAKA T, 1990, CARCINOGENESIS, V11, P1403, DOI 10.1093/carcin/11.8.1403.
   VANG O, 1990, CARCINOGENESIS, V11, P1259, DOI 10.1093/carcin/11.8.1259.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   Wang XY, 1997, CYTOKINES CELL MOL T, V3, P3.
   WATTENBERG LW, 1978, CANCER RES, V38, P1410.
   Xu M, 1996, CARCINOGENESIS, V17, P1429, DOI 10.1093/carcin/17.7.1429.
   Xu MR, 1997, CARCINOGENESIS, V18, P2149, DOI 10.1093/carcin/18.11.2149.}},
Number-of-Cited-References = {{50}},
Times-Cited = {{36}},
Journal-ISO = {{Food Chem. Toxicol.}},
Doc-Delivery-Number = {{289JR}},
Wos-Id = {{ISI:000085617900003}},
}

@article{ ISI:000085257600007,
Author = {Cui, L and Takahashi, S and Tada, M and Kato, K and Yamada, Y and Kohri,
   K and Shirai, T},
Title = {{Immunohistochemical detection of carcinogen-DNA adducts in normal human
   prostate tissues transplanted into the subcutis of athymic nude mice:
   Results with 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP)
   and 3,2 `-dimethyl-4-aminobiphenyl (DMAB) and relation to cytochrome
   P450s and N-acetyltransferase activity}},
Journal = {{JAPANESE JOURNAL OF CANCER RESEARCH}},
Year = {{2000}},
Volume = {{91}},
Number = {{1}},
Pages = {{52-58}},
Month = {{JAN}},
Abstract = {{Human prostate tissue transplanted into nude mice was examined
   immunohistochemically for DNA adducts formed after administration of
   3,2'-dimethyl-4-aminobiphenyl (DMAB) or
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP). Positive
   staining for DMAB- or PhIP-DNA adducts was evident in 70-95\% of both
   epithelial and stromal cells in human prostate xenografts. Reverse
   transcription-polymerase chain reaction (RT-PCR) analysis revealed a
   normal human prostate epithelial cell line (PrEC) to express both
   cytochrome P450 IA2 (CYP1A2) and N-acetyltransferase 2 (NAT2) mRNA,
   while a normal human prostate fibroblast cell line (NHPF) expressed
   NAT2, but not CYP1A2 mRNA. In addition, NAT2 and to a lesser extent
   CYP1A2 mRNAs were also found in four cases of normal human prostate
   tissues. The results suggest that initial activation of chemicals by
   liver CYP1A2 and subsequent metabolism by prostate NAT2 is a major
   pathway of DNA adduct formation in human prostate cells. Thus, the data
   suggest that human prostate has the potential to be targeted by
   environmental carcinogens.}},
Publisher = {{ELSEVIER SCI IRELAND LTD}},
Address = {{CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Cui, L (Reprint Author), Nagoya City Univ, Sch Med, Dept Pathol 1, Mizuho Ku, Nagoya, Aichi 4678601, Japan.
   Nagoya City Univ, Sch Med, Dept Pathol 1, Mizuho Ku, Nagoya, Aichi 4678601, Japan.
   Nagoya City Univ, Sch Med, Dept Urol, Mizuho Ku, Nagoya, Aichi 4678601, Japan.
   Aichi Shukutoku Univ, Fac Literature, Aichi 4801100, Japan.}},
ISSN = {{0910-5050}},
Keywords = {{PhIP; DMAB; DNA adducts; human prostate; immunohistochemistry}},
Keywords-Plus = {{HETEROCYCLIC AMINES; HUMAN LIVER; FOOD; IDENTIFICATION; MUTAGEN;
   METABOLISM; ACTIVATION; EXPRESSION; SEQUENCE; CYP1A2}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{BOOBIS AR, 1994, CANCER RES, V54, P89.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   DOLL R, 1988, J CANCER RES CLIN, V114, P447, DOI 10.1007/BF00391491.
   DOOLEY KL, 1992, CANCER LETT, V62, P205, DOI 10.1016/0304-3835(92)90097-F.
   EDWARDS RJ, 1994, CARCINOGENESIS, V15, P829, DOI 10.1093/carcin/15.5.829.
   ERCOLANI L, 1988, J BIOL CHEM, V263, P15335.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   GUENGERICH FP, 1988, CANCER RES, V48, P2946.
   Hansen Larry G., 1994, P49.
   IKEYA K, 1989, MOL ENDOCRINOL, V3, P1399.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MANABE S, 1993, CARCINOGENESIS, V14, P899, DOI 10.1093/carcin/14.5.899.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   MURRAY JC, 1993, COOPERATIVE HUM LINK, V1, P1.
   NAGARAJAIAH S, 1992, 1992 P PRESS VESS PI, V2, P83.
   OHSAKO S, 1990, J BIOL CHEM, V265, P4630.
   PELUSO M, 1991, CARCINOGENESIS, V12, P713, DOI 10.1093/carcin/12.4.713.
   Shirai T, 1997, CANCER RES, V57, P195.
   Shirai Tomoyuki, 1998, Toxicology Letters (Shannon), V102-103, P441, DOI 10.1016/S0378-4274(98)00366-X.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   SUGIMURA T, 1986, SCIENCE, V233, P312, DOI 10.1126/science.3088728.
   TADA M, 1989, CARCINOGENESIS, V10, P1397, DOI 10.1093/carcin/10.8.1397.
   Takahashi S, 1998, CANCER RES, V58, P4307.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   Yamada Y, 1998, PROSTATE, V37, P109, DOI 10.1002/(SICI)1097-0045(19981001)37:2<109::AID-PROS7>3.0.CO;2-B.
   ZHAO K, 1994, CARCINOGENESIS, V15, P1285, DOI 10.1093/carcin/15.6.1285.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{19}},
Journal-ISO = {{Jpn. J. Cancer Res.}},
Doc-Delivery-Number = {{283CB}},
Wos-Id = {{ISI:000085257600007}},
}

@article{ ISI:000086699500008,
Author = {Schut, HAJ and Yao, RS},
Title = {{Tea as a potential chemopreventive agent in PhIP carcinogenesis: Effects
   of green tea and black tea on PhIP-DNA adduct formation in female F-344
   rats}},
Journal = {{NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL}},
Year = {{2000}},
Volume = {{36}},
Number = {{1}},
Pages = {{52-58}},
Abstract = {{The heterocyclic amine 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine
   (PhIP) is formed during the cooking of proteinaceous animal foods (meat,
   chicken, and fish). PhIP is a carcinogen in the Fischer 344 (F-344) rat;
   it induces mammary tumors in female rats and lymphomas and colon and
   prostate rumors in male rats. In F-344 rats, PhIP forms DNA adducts in
   various organs, including the target organs. Inhibition of PhIP-DNA
   adduct formation is likely to lead to inhibition of PhIP tumorigenicity.
   We have examined the chemopreventive properties of green tea and black
   tea in PhIP carcinogenesis by evaluating their effects on PhIP-DNA
   adduct formation in the female F-344 rat. Young adult animals were
   maintained on powdered AIN-76A diet while receiving regular drinking
   water or 2\% (wt/vol) infusions of green tea or black tea for a total of
   six weeks. During Weeks 3, 4, and 5, all animals received PhIP by gavage
   (1 mg/kg/day). Three rats per group were euthanized on Days 1 and 8
   after termination of PhIP exposure. DNA was isolated from a number of
   organs and analyzed for PhIP-DNA adducts by P-32-postlabeling assays.
   Compared with animals on regular drinking wafer, PhIP-DMA adduct
   formation was inhibited in small intestine, colon, liver, and mammary
   epithelial cells (MECS) of animals receiving green tea or black tea as
   the sole source of drinking fluid. Green tea inhibited adduct formation
   in colon, liver, and MECs (33.3-80.0\%) on both days, but only on Day 8
   (54.4\%) in small intestine. Black tea inhibited adduct formation on
   both days in liver (71.4-80.0\%), on Day 1 in colon (40.0\%), and on Day
   8 in small intestine (81.8\%); it had no effect on MEC adducts. Neither
   green tea nor black tea had an effect on adduct levels in pancreas:
   lungs, white blood cells, heart, kidneys, spleen, cecum, or stomach.
   Similarly, these teas did not affect the rate of adduct removal (percent
   change from Day 1 to Day 8) in any organ. It is concluded that green tea
   and black tea are potential chemopreventive agents in PhIP-induced
   tumorigenesis in the F-344 rat.}},
Publisher = {{LAWRENCE ERLBAUM ASSOC INC}},
Address = {{10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Schut, HAJ (Reprint Author), Med Coll Ohio, Dept Pathol, Hlth Educ Bldg,Rm 202,3055 Arlington Ave, Toledo, OH 43614 USA.
   Med Coll Ohio, Dept Pathol, Toledo, OH 43614 USA.}},
DOI = {{10.1207/S15327914NC3601\_8}},
ISSN = {{0163-5581}},
Keywords-Plus = {{MAMMARY-GLAND CARCINOGENESIS; MUTAGEN
   2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE IQ; NATURALLY-OCCURRING
   ANTIOXIDANTS; HETEROCYCLIC AROMATIC-AMINES; INDUCED COLON
   CARCINOGENESIS; FOOD-BORNE CARCINOGEN; SPRAGUE-DAWLEY RATS;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP;
   METABOLIC-ACTIVATION; CYTOCHROME P4501A2}},
Research-Areas = {{Oncology; Nutrition \& Dietetics}},
Web-of-Science-Categories  = {{Oncology; Nutrition \& Dietetics}},
Cited-References = {{Apostolides Z, 1997, MUTAT RES-GEN TOX EN, V389, P167, DOI 10.1016/S1383-5718(96)00143-X.
   Apostolides Z, 1996, MUTAT RES-ENVIR MUTA, V359, P159, DOI 10.1016/S0165-1161(96)90262-9.
   APOSTOLIDES Z, 1995, MUTAT RES-FUND MOL M, V326, P219, DOI 10.1016/0027-5107(94)00175-5.
   BUABBAS A, 1994, CARCINOGENESIS, V15, P2575, DOI 10.1093/carcin/15.11.2575.
   Chen LS, 1996, DRUG METAB DISPOS, V24, P529.
   CUMMINGS DA, 1995, CARCINOGENESIS, V16, P2523, DOI 10.1093/carcin/16.10.2523.
   CUMMINGS DA, 1994, CARCINOGENESIS, V15, P2623, DOI 10.1093/carcin/15.11.2623.
   Dingley KH, 1999, CANCER EPIDEM BIOMAR, V8, P507.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   Friedman JM, 1996, PENN CTR N, V5, P67.
   GHOSHAL A, 1995, CARCINOGENESIS, V16, P2725, DOI 10.1093/carcin/16.11.2725.
   GRAHAM HN, 1992, PREV MED, V21, P334, DOI 10.1016/0091-7435(92)90041-F.
   Guo Dexin, 1995, Carcinogenesis (Oxford), V16, P2931, DOI 10.1093/carcin/16.12.2931.
   Hammons GJ, 1999, NUTR CANCER, V33, P46.
   Hasaniya N, 1997, JPN J CANCER RES, V88, P553.
   He YH, 2000, FOOD CHEM TOXICOL, V38, P15, DOI 10.1016/S0278-6915(99)00117-9.
   He YH, 1999, J BIOCHEM MOL TOXIC, V13, P239, DOI 10.1002/(SICI)1099-0461(1999)13:5<239::AID-JBT3>3.0.CO;2-P.
   HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007.
   HIROSE M, 1993, CARCINOGENESIS, V14, P1549, DOI 10.1093/carcin/14.8.1549.
   HIROSE M, 1995, CARCINOGENESIS, V16, P217, DOI 10.1093/carcin/16.2.217.
   Hirose M, 1995, CARCINOGENESIS, V16, P3049, DOI 10.1093/carcin/16.12.3049.
   HIROSE M, 1994, CANCER LETT, V83, P149, DOI 10.1016/0304-3835(94)90312-3.
   Hirose M, 1998, EUR J CANCER PREV, V7, P61.
   HO CT, 1992, PREV MED, V21, P520, DOI 10.1016/0091-7435(92)90059-Q.
   Huber WW, 1997, MUTAT RES-FUND MOL M, V376, P115, DOI 10.1016/S0027-5107(97)00033-X.
   ITO N, 1997, J TOXICOL PATHOL, V10, P1.
   Josyula S, 1999, FOOD CHEM TOXICOL, V37, P287, DOI 10.1016/S0278-6915(99)00018-6.
   Josyula S, 1998, NUTR CANCER, V32, P132.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KATIYAR SK, 1993, CARCINOGENESIS, V14, P849, DOI 10.1093/carcin/14.5.849.
   Katiyar SK, 1996, INT J ONCOL, V8, P221.
   KHAN SG, 1992, CANCER RES, V52, P4050.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   Lu YP, 1997, CARCINOGENESIS, V18, P2163, DOI 10.1093/carcin/18.11.2163.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   Malfatti MA, 1996, CANCER RES, V56, P2550.
   Moore MA, 1999, TOXICOL PATHOL, V27, P237, DOI 10.1177/019262339902700211.
   MUKHTAR H, 1992, PREV MED, V21, P351, DOI 10.1016/0091-7435(92)90042-G.
   NARISAWA T, 1993, JPN J CANCER RES, V84, P1007.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9.
   Rogers AE, 1998, CARCINOGENESIS, V19, P1269, DOI 10.1093/carcin/19.7.1269.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   SCHUT HAJ, 1997, MUTAT RES, V376, P187.
   Schut HAJ, 1997, MUTAT RES-FUND MOL M, V378, P23, DOI 10.1016/S0027-5107(97)00094-8.
   SCHUT HAJ, 1993, ANTICANCER RES, V13, P1517.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   SOHN OS, 1994, XENOBIOTICA, V24, P119.
   Stavric B, 1996, FOOD CHEM TOXICOL, V34, P515, DOI 10.1016/0278-6915(96)00014-2.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   Takahashi S, 1998, CANCER RES, V58, P4307.
   TSUDA H, 1994, JPN J CANCER RES, V85, P1214.
   VALSIC S, 1999, CHEM RES TOXICOL, V12, P382.
   Weisburger JH, 1997, CANCER LETT, V114, P323, DOI 10.1016/S0304-3835(97)04693-4.
   Xu M, 1996, CARCINOGENESIS, V17, P1429, DOI 10.1093/carcin/17.7.1429.
   YAMANE T, 1991, JPN J CANCER RES, V82, P1336.
   YAMANE T, 1995, CANCER RES, V55, P2081.
   YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038.
   YIN PZ, 1994, CANCER LETT, V79, P33.}},
Number-of-Cited-References = {{62}},
Times-Cited = {{40}},
Journal-ISO = {{Nutr. Cancer}},
Doc-Delivery-Number = {{308FH}},
Wos-Id = {{ISI:000086699500008}},
}

@article{ ISI:000082495500010,
Author = {Stillwell, WG and Turesky, RJ and Sinha, R and Skipper, PL and
   Tannenbaum, SR},
Title = {{Biomonitoring of heterocyclic aromatic amine metabolites in human urine}},
Journal = {{CANCER LETTERS}},
Year = {{1999}},
Volume = {{143}},
Number = {{2}},
Pages = {{145-148}},
Month = {{SEP 1}},
Note = {{7th International Conference on Carcinogenic and Mutagenic N-Substituted
   Aryl Compounds, NAGOYA, JAPAN, NOV 04-06, 1998}},
Abstract = {{Human exposure to heterocyclic aromatic amines such as MeIQx
   (2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline) may be monitored by
   measuring the levels of the heterocyclic aromatic amine in urine. In
   order to investigate the contribution of N-oxidation to the metabolism
   of MeIQx in vivo, we developed a biomonitoring procedure for the
   analysis and quantification of the N-2-glucuronide conjugate of
   2-hydroxyamino-3,8-dimethylimidazo{[}4,5-f]quinoxaline in human urine.
   Subjects (n = 66) in the dietary study ingested a uniform diet of cooked
   meat containing known amounts of MeIQx, and urine was collected after
   consumption of the test meal. A method based on solid-phase extraction
   and immunoaffinity separation was used to isolate
   N-2-(beta-1-glucosiduronyl)-2-hydroxyamino-3,8-dimethylimidazo{[}4,5-f]q
   uinoxaline and its stable isotope-labeled internal standard from urine.
   The isolated conjugate was converted to the deaminated product
   2-hydroxy-3,8-dimethylimidazo{[}4,5-f]quinoxaline by treatment with
   acetic acid under moderate heating.
   2-Hydroxy-3,8-dimethylimidazo{[}4,5-f]quinoxaline and the
   {[}H-2(3)]methyl analog were derivatized to form the corresponding
   3,5-bis(trifluoromethyl)benzyl ether derivatives and quantified by
   capillary gas chromatography-negative ion chemical ionization mass
   spectrometry employing selected ion monitoring procedures. The amounts
   of
   N-2-(beta-1-glucosiduronyl)-2-hydroxyamino-3,8-dimethylimidazo{[}4,5-f]q
   uinoxaline recovered in urine collected 0-12 h after the test meal
   accounted for 2.2-17.1\% of the ingested dose, with a median value of
   9.5\%. The variability in the proportion of the dose excreted among the
   subjects may be reflective of several factors, including interindividual
   variation in the enzymic activity of CYP1A2 and/or conjugation reactions
   of the N-hydroxylamine metabolite with N-glucuronosyltransferase(s). (C)
   1999 Elsevier Science Ireland Ltd. All rights reserved.}},
Publisher = {{ELSEVIER SCI IRELAND LTD}},
Address = {{CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Tannenbaum, SR (Reprint Author), MIT, Div Bioengn \& Environm Hlth, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   MIT, Div Bioengn \& Environm Hlth, Cambridge, MA 02139 USA.
   Nestec Ltd, Nestle Res Ctr, CH-1000 Lausanne 26, Switzerland.
   NCI, Div Canc Epidemiol \& Genet, Bethesda, MD 20892 USA.
   MIT, Dept Chem, Cambridge, MA 02139 USA.}},
DOI = {{10.1016/S0304-3835(99)00144-5}},
ISSN = {{0304-3835}},
Keywords = {{biomonitoring; human urine; heterocyclic aromatic amines; food mutagens;
   biotransformation}},
Keywords-Plus = {{CYTOCHROME P4501A2; FRIED MEAT;
   2-AMINO-3,8-DIMETHYLIMIDAZO<4,5-F>QUINOXALINE; EXCRETION;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE; EXPOSURE; MEIQX}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{JI H, 1994, CANCER EPIDEM BIOMAR, V3, P407.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   MURRAY S, 1989, CARCINOGENESIS, V10, P763, DOI 10.1093/carcin/10.4.763.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   SINHA R, 1994, CANCER RES, V54, P6154.
   SINHA R, 1995, CARCINOGENESIS, V16, P2859, DOI 10.1093/carcin/16.11.2859.
   STILLWELL WG, 1994, CANCER EPIDEM BIOMAR, V3, P399.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   TURESKY RJ, 1989, CARCINOGENESIS, V10, P151, DOI 10.1093/carcin/10.1.151.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P217, DOI 10.1021/tx9701891.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1847, DOI 10.1093/carcin/12.10.1847.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   Wakabayashi K, 1997, MUTAT RES-FUND MOL M, V376, P253, DOI 10.1016/S0027-5107(97)00050-X.}},
Number-of-Cited-References = {{14}},
Times-Cited = {{26}},
Journal-ISO = {{Cancer Lett.}},
Doc-Delivery-Number = {{234QH}},
Wos-Id = {{ISI:000082495500010}},
}

@article{ ISI:000082495500011,
Author = {Turteltaub, KW and Dingley, KH and Curtis, KD and Malfatti, MA and
   Turesky, RJ and Garner, RC and Felton, JS and Lang, NP},
Title = {{Macromolecular adduct formation and metabolism of heterocyclic amines in
   humans and rodents at low doses}},
Journal = {{CANCER LETTERS}},
Year = {{1999}},
Volume = {{143}},
Number = {{2}},
Pages = {{149-155}},
Month = {{SEP 1}},
Note = {{7th International Conference on Carcinogenic and Mutagenic N-Substituted
   Aryl Compounds, NAGOYA, JAPAN, NOV 04-06, 1998}},
Abstract = {{2-Amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline (MeIQx) and
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) are
   heterocyclic amines formed during the cooking of meat and fish. Both are
   genotoxic in a number of test systems and are carcinogenic in rats and
   mice. Human exposure to these compounds via dietary sources has been
   estimated to be under 1 mu g/kg body wt. per day, although most
   laboratory animal studies have been conducted at doses in excess of 10
   mg/kg body wt. per day. We are using accelerator mass spectrometry
   (AMS), a tool for measuring isotopes with attomole sensitivity, to study
   the dosimetry of protein and DNA adduct formation by low doses of MeIQx
   and PhIP in rodents and comparing the adduct levels to those formed in
   humans. The results of these studies show: 1, protein and DNA adduct
   levels in rodents are dose-dependent; 2, adduct levels in human tissues
   and blood are generally greater than ill rodents administered equivalent
   doses; and 3, metabolite profiles differ substantially between humans
   and rodents for both MeIQx and PhIP, with more N-hydroxylation
   (bioactivation) and less ring oxidation (detoxification) in humans.
   These data suggest that rodent models do not accurately represent the
   human response to heterocyclic amine exposure. (C) 1999 Published by
   Elsevier Science Ireland Ltd.}},
Publisher = {{ELSEVIER SCI IRELAND LTD}},
Address = {{CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Turteltaub, KW (Reprint Author), Univ Calif Lawrence Livermore Natl Lab, Livermore, CA 94550 USA.
   Univ Calif Lawrence Livermore Natl Lab, Livermore, CA 94550 USA.
   Nestec Ltd, Nestle Res Ctr, CH-1000 Lausanne 26, Switzerland.
   Univ York, Jack Birch Unit Environm Carcinogenesis, York YO1 5DD, N Yorkshire, England.
   Univ Arkansas Med Sci, Little Rock, AR 72205 USA.}},
DOI = {{10.1016/S0304-3835(99)00116-0}},
ISSN = {{0304-3835}},
Keywords = {{2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine;
   2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline; accelerator mass
   spectrometry; human; rodent; dosimetry}},
Keywords-Plus = {{BREAST-CANCER; MUTAGEN 2-AMINO-3,8-DIMETHYLIMIDAZO<4,5-F>QUINOXALINE;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; COLORECTAL-CANCER;
   COVALENT BINDING; FOOD MUTAGEN; RAT-LIVER; RISK; DNA; MEAT}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{Ambrosone CB, 1998, INT J CANCER, V75, P825, DOI 10.1002/(SICI)1097-0215(19980316)75:6<825::AID-IJC2>3.0.CO;2-X.
   BOOBIS AR, 1995, P 23 INT S PRINC TAK, P134.
   CHOU HC, 1995, CANCER RES, V55, P525.
   CONNORS MS, 1995, CHEM-BIOL INTERACT, V96, P185, DOI 10.1016/0009-2797(94)03595-Y.
   DeStefani E, 1997, CANCER EPIDEM BIOMAR, V6, P573.
   Dingley KH, 1998, DRUG METAB DISPOS, V26, P825.
   Dingley K. H., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P635.
   Felton JS, 1997, MUTAT RES-FUND MOL M, V376, P37, DOI 10.1016/S0027-5107(97)00023-7.
   FRANTZ CE, 1995, CARCINOGENESIS, V16, P367, DOI 10.1093/carcin/16.2.367.
   TURTELTAUB KW, 1992, CANCER RES, V52, P4682.
   Gerhardsson de Verdier M, 1991, Int J Cancer, V49, P520.
   HAYATSU H, 1987, CANCER RES, V47, P791.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   Kadlubar F, 1995, Princess Takamatsu Symp, V23, P207.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   MALFATTI MA, IN PRESS CARCINOGENE.
   MAUTHE RJ, IN PRESS INT J CANC.
   MUSCAT JE, 1994, AM J PUBLIC HEALTH, V84, P856, DOI 10.2105/AJPH.84.5.856.
   Ronco A, 1996, INT J CANCER, V65, P328, DOI 10.1002/(SICI)1097-0215(19960126)65:3<328::AID-IJC9>3.0.CO;2-1.
   SCHIFFMAN MH, 1990, AM J EPIDEMIOL, V131, P376.
   SJODIN P, 1989, CARCINOGENESIS, V10, P1269, DOI 10.1093/carcin/10.7.1269.
   TADA A, 1994, CARCINOGENESIS, V15, P1275, DOI 10.1093/carcin/15.6.1275.
   Tannenbaum S R, 1995, Princess Takamatsu Symp, V23, P197.
   TURESKY RJ, 1988, CARCINOGENESIS, V9, P1043, DOI 10.1093/carcin/9.6.1043.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P217, DOI 10.1021/tx9701891.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   Turteltaub KW, 1997, MUTAT RES-FUND MOL M, V376, P243, DOI 10.1016/S0027-5107(97)00049-3.
   TURTELTAUB KW, 1990, P NATL ACAD SCI USA, V87, P5288, DOI 10.1073/pnas.87.14.5288.
   TURTELTAUB KW, 1989, FOOD CHEM TOXICOL, V27, P667, DOI 10.1016/0278-6915(89)90121-X.
   TURTELTAUB KW, 1996, MASS SPECTROMETRY BI, P477.
   Vogel JS, 1995, ANAL CHEM, V67, P353.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   Winsten J. A., 1977, ORIGINS HUMAN CANC, P1561.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{54}},
Journal-ISO = {{Cancer Lett.}},
Doc-Delivery-Number = {{234QH}},
Wos-Id = {{ISI:000082495500011}},
}

@article{ ISI:000081670800003,
Author = {Reistad, R and Nyholm, SH and Haug, LS and Becher, G and Alexander, J},
Title = {{2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) in human hair
   as biomarker for dietary exposure}},
Journal = {{BIOMARKERS}},
Year = {{1999}},
Volume = {{4}},
Number = {{4}},
Pages = {{263-271}},
Month = {{JUL-AUG}},
Abstract = {{Heterocyclic aromatic amines (HAAs), formed during cooking of meat, are
   multipotent rodent carcinogens and are suspected to cause cancer in
   humans. In a search for suitable biomarkers for human dietary exposure
   to HAAs, we have investigated the concentration of a common fried food
   mutagen, 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP), in
   human hair. Fourteen volunteers participated in the study, each
   contributing hair from a regular haircut, and completing a questionnaire
   about consumption of fried/grilled meat and smoking habits. Hair samples
   were treated with 1 N NaOH at 100 degrees C, and the HAAs extracted
   under alkaline and acidic conditions, derivatized and analysed by gas
   chromatography-mass spectrometry: PhIP was found in 12 out of 14 hair
   samples, in amounts from approx. 50 to 5000 pg g(-1) hair, while two
   samples were below the detection limit (<50 pg g(-1) hair). Grey/white
   hair straws from subjects with a mixture of coloured and grey/white hair
   had about a 50\% reduction in PhIP concentration as compared with the
   natural hair mixture from the same person. This demonstrates that
   melanin, responsible for hair colour and spectrophotometrically
   characterized in the samples, participates in PhIP binding. Thus, when
   HAA binding components of the hair are taken into account, hair seems
   like an interesting object of further investigation as a biomarker for
   human exposure to dietary PhIP.}},
Publisher = {{TAYLOR \& FRANCIS LTD}},
Address = {{ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Reistad, R (Reprint Author), Natl Inst Publ Hlth, POB 4404 Torshov, N-0403 Oslo, Norway.
   Natl Inst Publ Hlth, N-0403 Oslo, Norway.
   Natl Inst Consumer Res, N-1324 Lysaker, Norway.}},
ISSN = {{1354-750X}},
Keywords = {{PhIP; biomarker; hair; melanin; diet}},
Keywords-Plus = {{HETEROCYCLIC AMINE CONTENT; AROMATIC-AMINES; VARYING DEGREES;
   HUMAN-URINE; MEAT MEAL; MICE; BEEF;
   2-AMINO-3,8-DIMETHYLIMIDAZO<4,5-F>QUINOXALINE; TEMPERATURE; CARCINOGEN}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Toxicology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Toxicology}},
Cited-References = {{Augustsson K, 1997, CARCINOGENESIS, V18, P1931, DOI 10.1093/carcin/18.10.1931.
   BERGMAN K, 1985, CANCER RES, V45, P1351.
   BRANDT I, 1989, CARCINOGENESIS, V10, P1529, DOI 10.1093/carcin/10.8.1529.
   BRANDT I, 1983, CARCINOGENESIS, V4, P1291, DOI 10.1093/carcin/4.10.1291.
   BRITTEBO EB, 1992, CARCINOGENESIS, V13, P2263, DOI 10.1093/carcin/13.12.2263.
   DUPONT RL, 1995, FORENSIC SCI INT, V70, P63, DOI 10.1016/0379-0738(94)01625-F.
   GERSTENBERG B, 1995, DRUG METAB DISPOS, V23, P143.
   Green ST, 1996, J ANAL TOXICOL, V20, P121.
   JI H, 1994, CANCER EPIDEM BIOMAR, V3, P407.
   Joseph RE, 1996, J ANAL TOXICOL, V20, P338.
   KNIZE MG, 1994, FOOD CHEM TOXICOL, V32, P595, DOI 10.1016/0278-6915(94)90002-7.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   MURRAY S, 1989, CARCINOGENESIS, V10, P763, DOI 10.1093/carcin/10.4.763.
   NAKAHARA Y, 1995, BIOL PHARM BULL, V18, P1223.
   ORTONNE JP, 1993, J INVEST DERMATOL, V101, pS82, DOI 10.1111/1523-1747.ep12362884.
   Ozeki H, 1996, PIGM CELL RES, V9, P265, DOI 10.1111/j.1600-0749.1996.tb00116.x.
   Poirier MC, 1997, ENVIRON HEALTH PERSP, V105, P907, DOI 10.2307/3433302.
   Potsch L, 1997, FORENSIC SCI INT, V84, P25, DOI 10.1016/S0379-0738(96)02045-2.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P289, DOI 10.1016/S0278-6915(97)00159-2.
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P279, DOI 10.1016/S0278-6915(97)00162-2.
   SINHA R, 1995, CANCER RES, V55, P4516.
   SKOG K, 1995, CARCINOGENESIS, V16, P861, DOI 10.1093/carcin/16.4.861.
   Tikkanen LM, 1996, FOOD CHEM TOXICOL, V34, P725, DOI 10.1016/0278-6915(96)00036-1.
   TJOTTA K, 1992, CARCINOGENESIS, V13, P779, DOI 10.1093/carcin/13.5.779.
   TURESKY RJ, 1994, ENVIRON HEALTH PERSP, V102, P47, DOI 10.2307/3432151.
   UEMATSU T, 1992, J PHARM SCI-US, V81, P45, DOI 10.1002/jps.2600810109.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{26}},
Journal-ISO = {{Biomarkers}},
Doc-Delivery-Number = {{220MY}},
Wos-Id = {{ISI:000081670800003}},
}

@article{ ISI:000080300400007,
Author = {Kidd, LCR and Stillwell, WG and Yu, MC and Wishnok, JS and Skipper, PL
   and Ross, RK and Henderson, BE and Tannenbaum, SR},
Title = {{Urinary excretion of 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine
   (PhIP) in white, African-American, and Asian-American men in Los Angeles
   County}},
Journal = {{CANCER EPIDEMIOLOGY BIOMARKERS \& PREVENTION}},
Year = {{1999}},
Volume = {{8}},
Number = {{5}},
Pages = {{439-445}},
Month = {{MAY}},
Abstract = {{Meats, such as beef, pork, poultry, and fish, cooked at high
   temperatures produce heterocyclic aromatic amines, which have been
   implicated indirectly as etiological agents involved in colorectal and
   other cancers in humans, This study examined the urinary excretion of a
   mutagenic/carcinogenic heterocyclic aromatic amine,
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP), among 45
   African-American, 42 Asian-American (Chinese or Japanese), and 42
   non-Hispanic white male residents of Los Angeles who consumed an
   unrestricted diet, Total PhIP (free and conjugated) was isolated from
   overnight urine collections, purified by immunoaffinity chromatography,
   and then quantified by high-pressure liquid chromatography combined with
   electrospray ionization mass spectrometry, Geometric mean levels of PhIP
   in Asian-Americans and African-Americans were approximately 2.8-fold
   higher than in whites. The urinary excretion levels of PhIP were not
   associated with intake frequencies of any cooked meat based on a
   self-administered dietary questionnaire, in contrast to our earlier
   finding (Ji et al,, Cancer Epidemiol, Biomark, Prev., 3: 407-411, 1994)
   of a positive and statistically significant association between bacon
   intake and the urinary level of
   2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline (MeIQx) among this same
   group of study subjects, Although there is a statistically significant
   association between urinary levels of PhIP and MeIQx (2-sided P =
   0.001), 10 subjects (8\%) displayed extreme discordance between urinary
   PhIP and MeIQx levels. Several factors, including variable contents of
   heterocyclic aromatic amines in food, enzymic and interindividual
   metabolic differences, and analytical methodology determine the degree
   of concordance between the urinary excretion levels of PhIP and MeIQx,
   Accordingly, urinary excretion levels of a single heterocyclic aromatic
   amine can only serve as an approximate measure of another in estimating
   exposure to these compounds in humans consuming unrestricted diets.}},
Publisher = {{AMER ASSOC CANCER RESEARCH}},
Address = {{PO BOX 11806, BIRMINGHAM, AL 35202 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Tannenbaum, SR (Reprint Author), MIT, Div Bioengn \& Environm Hlth, 77 Massachusetts Ave,Bldg 56-731, Cambridge, MA 02139 USA.
   MIT, Div Bioengn \& Environm Hlth, Cambridge, MA 02139 USA.
   MIT, Dept Chem, Cambridge, MA 02139 USA.
   Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA.}},
ISSN = {{1055-9965}},
Keywords-Plus = {{HETEROCYCLIC AMINES; COLORECTAL-CANCER; COLON-CANCER; CYTOCHROME
   P4501A2; MASS-SPECTROMETRY; MEAT-PRODUCTS; FRIED FOODS; RISK;
   2-AMINO-3,8-DIMETHYLIMIDAZO<4,5-F>QUINOXALINE; CARCINOGENS}},
Research-Areas = {{Oncology; Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Oncology; Public, Environmental \& Occupational Health}},
ResearcherID-Numbers = {{Wishnok, John/A-3173-2009}},
Cited-References = {{ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411.
   Bernstein L, 1991, CANC LOS ANGELES COU.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   BRESLOW NE, 1980, IEARC SCI PUBL, V32.
   DEVERDIER MG, 1991, INT J CANCER, V49, P520, DOI 10.1002/ijc.2910490408.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   Farooq S, 1997, J CHROMATOGR B, V702, P49, DOI 10.1016/S0378-4347(97)00364-2.
   Felton J.S., 1990, HDB EXPT PHARM, P471.
   FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   GROSS GA, 1993, CARCINOGENESIS, V14, P2313, DOI 10.1093/carcin/14.11.2313.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   JI H, 1994, CANCER EPIDEM BIOMAR, V3, P407.
   Knize MG, 1997, MUTAT RES-FUND MOL M, V376, P129, DOI 10.1016/S0027-5107(97)00035-3.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   LYON JL, 1988, AM J EPIDEMIOL, V128, P1000.
   MURRAY S, 1989, CARCINOGENESIS, V10, P763, DOI 10.1093/carcin/10.4.763.
   MUSCAT JE, 1994, AM J PUBLIC HEALTH, V84, P856, DOI 10.2105/AJPH.84.5.856.
   POTTER JD, 1993, EPIDEMIOL REV, V15, P499.
   Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9.
   Salmon CP, 1997, FOOD CHEM TOXICOL, V35, P433, DOI 10.1016/S0278-6915(97)00020-3.
   SCHIFFMAN MH, 1990, AM J EPIDEMIOL, V131, P376.
   Shirai T, 1997, CANCER RES, V57, P195.
   SINHA R, 1995, CANCER RES, V55, P4516.
   SKOG K, 1993, FOOD CHEM TOXICOL, V31, P655, DOI 10.1016/0278-6915(93)90049-5.
   SKOG K, 1995, CARCINOGENESIS, V16, P861, DOI 10.1093/carcin/16.4.861.
   Snedecor G. W., 1967, STAT METHODS.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P2517, DOI 10.1093/carcin/14.12.2517.
   STILLWELL WG, 1994, CANCER EPIDEM BIOMAR, V3, P399.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   TURESKY RJ, 1989, CARCINOGENESIS, V10, P151, DOI 10.1093/carcin/10.1.151.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   Wakabayashi K, 1997, MUTAT RES-FUND MOL M, V376, P253, DOI 10.1016/S0027-5107(97)00050-X.
   YU MC, 1994, J NATL CANCER I, V86, P712, DOI 10.1093/jnci/86.9.712.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{53}},
Journal-ISO = {{Cancer Epidemiol. Biomarkers Prev.}},
Doc-Delivery-Number = {{196GJ}},
Wos-Id = {{ISI:000080300400007}},
}

@article{ ISI:000081122300002,
Author = {Josyula, S and Schut, HAJ},
Title = {{Dietary omega-3 fatty acids as potential inhibitors of carcinogenesis:
   Effect on DNA adduct formation of
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) in mice and
   rats}},
Journal = {{FOOD AND CHEMICAL TOXICOLOGY}},
Year = {{1999}},
Volume = {{37}},
Number = {{4}},
Pages = {{287-296}},
Month = {{APR}},
Abstract = {{The heterocyclic amine 2-amino-1-methyl-6-phenylimidazo{[}4-5-b]pyridine
   (PhIP) is carcinogenic in the CDF, mouse, causing lymphomas (spleen and
   lymph nodes) and in the F344 rat, causing mammary rumours in the female
   and colon rumours in the male. Dietary Fish oil, a rich sourer of
   omega-3 fatty acids, exhibits chemopreventive properties in several
   rodent tumour models. The potential chemopreventive properties of
   dietary omega-3 fatty acid ethyl ester concentrate (O3C) were tested by
   evaluating its effects on the formation and removal of PhIP DNA adducts.
   In the First experiment. a powdered AIN-76A diet containing 4.0\% (w/w)
   O3C inhibited PhIP-DNA adduct formation in various organs of the CDF,
   mouse, but not in those of the F344 rat. In a subsequent, second
   experiment, groups of male CDF1 mice were maintained for 43 days on
   AIN-76A diets containing the following percentages (w/w) of corn oil
   ethyl esters and O3C: 7.0 and 0, 5.5 and 1.5, 4.0 and 3.0, and 1.0 and
   6.0, respectively. All animals received 0.04\% (w/w) PhIP in the diet
   during weeks 3 and 4. Using P-32-postlabelling assays, PhIP-DNA adducts
   Here analysed in various organs and white blood cells (WBC) on days 1, 8
   and 15 after removal of PhIP From the dirt. In the liver, O3C-containing
   diets inhibited adduct formation at all three time points (40.3-60.0\%,
   53.9-75.7\% and 43.3-64.3\% on days 1, 8 and 15, respectively). In the
   spleen, inhibition a as evident only on days 8 (35.4-38.8\%) and 15
   (38.4-56.5\%). O3C diets inhibited adduct formation in the stomach,
   small intestine and caecum at all three time points (except in the
   stomach and caecum on day 15) amounting to 18.5-31.5\% decreases in the
   stomach, 40.0 60.3\% decreases in the small intestine and 24.4-31.4\%
   decreases in the caecum. The extant of inhibition was not related to O3C
   concentration In the colon and WBC, adduct levels were independent of
   the type of diet. In all organs, adduct levels decreased significantly
   over time, with day 15 levels bring 6.3-31.6\% of those on day 1. Rate
   of adduct removal was independent of the type of diet. It is concluded
   that dietary O3C inhibits PhIP DNA adduct formation in a target organ
   (spleen) as well as in non-target organs (liver and gastrointestinal
   tract) of the CDF1 mouse, but that the rate of adduct removal is
   independent of the O3C content of the diet. (C) 1999 Elsevier Science
   Ltd. All rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Schut, HAJ (Reprint Author), Med Coll Ohio, Dept Pathol, HE202,3055 Arlington Ave, Toledo, OH 43614 USA.
   Med Coll Ohio, Dept Pathol, Toledo, OH 43614 USA.}},
DOI = {{10.1016/S0278-6915(99)00018-6}},
ISSN = {{0278-6915}},
Keywords = {{PhIP; heterocyclic amines; food mutagens; chemoprevention; omega-3-fatty
   acids; DNA adducts}},
Keywords-Plus = {{MUTAGEN 2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE IQ; CIGARETTE-SMOKE
   CONDENSATE; SPRAGUE-DAWLEY RATS; FOOD MUTAGEN; CDF1 MICE;
   DOCOSAHEXAENOIC ACID; HETEROCYCLIC AMINES; EICOSAPENTAENOIC ACID; COLON
   CARCINOGENESIS; FISCHER-344 RATS}},
Research-Areas = {{Food Science \& Technology; Toxicology}},
Web-of-Science-Categories  = {{Food Science \& Technology; Toxicology}},
Cited-References = {{ANDERSON KE, 1991, ANNU REV NUTR, V11, P141, DOI 10.1146/annurev.nutr.11.1.141.
   BANG HO, 1976, ACTA MED SCAND, V200, P69.
   BEACH AC, 1992, CARCINOGENESIS, V13, P1053, DOI 10.1093/carcin/13.7.1053.
   BEGIN ME, 1986, J NATL CANCER I, V77, P1053.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   BOREK C, 1994, WORLD REV NUTR DIET, V76, P66.
   BOURRE JM, 1992, ADV EXP MED BIOL, V318, P211.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   CUMMINGS DA, 1995, CARCINOGENESIS, V16, P2523, DOI 10.1093/carcin/16.10.2523.
   CUMMINGS DA, 1994, CARCINOGENESIS, V15, P2623, DOI 10.1093/carcin/15.11.2623.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P2091, DOI 10.1093/carcin/14.10.2091.
   DEBRAVO MG, 1991, LIPIDS, V26, P866.
   DOOLEY KL, 1992, CANCER LETT, V62, P205, DOI 10.1016/0304-3835(92)90097-F.
   ELBAYOUMY K, 1995, CARCINOGENESIS, V16, P431, DOI 10.1093/carcin/16.2.431.
   ElSohemy A, 1997, CANCER RES, V57, P3685.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   FLAMMANG TJ, 1989, CANCER RES, V49, P1977.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   FUKUTOME K, 1994, JPN J CANCER RES, V85, P113.
   GHOSHAL A, 1994, CARCINOGENESIS, V15, P2429, DOI 10.1093/carcin/15.11.2429.
   He Y H, 1997, J Cell Biochem Suppl, V27, P42.
   HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007.
   HIROSE M, 1995, CARCINOGENESIS, V16, P217, DOI 10.1093/carcin/16.2.217.
   HIROSE M, 1993, CARCINOGENESIS, V14, P2359, DOI 10.1093/carcin/14.11.2359.
   Hirose M, 1995, CARCINOGENESIS, V16, P3049, DOI 10.1093/carcin/16.12.3049.
   HIROSE M, 1993, BASIC LIFE SCI, V61, P181.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   ITO N, 1990, BASIC LIFE SCI, V52, P183.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KARMALI RA, 1987, ANTICANCER RES, V7, P1173.
   KINSELLA JE, 1990, J NUTR BIOCHEM, V1, P123, DOI 10.1016/0955-2863(90)90011-9.
   Kozumbo W J, 1986, Basic Life Sci, V39, P491.
   KROKAN HE, 1993, BIOCHIM BIOPHYS ACTA, V1168, P59, DOI 10.1016/0005-2760(93)90266-C.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MALASANOS TH, 1991, DIABETES CARE, V14, P1160, DOI 10.2337/diacare.14.12.1160.
   MANABE S, 1993, CARCINOGENESIS, V14, P899, DOI 10.1093/carcin/14.5.899.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   MORGENTHALER PML, 1995, CARCINOGENESIS, V16, P713, DOI 10.1093/carcin/16.4.713.
   NORDOY A, 1991, AM J CLIN NUTR, V53, P1185.
   PFAU W, 1994, CARCINOGENESIS, V15, P877, DOI 10.1093/carcin/15.5.877.
   POISSON JP, 1990, BIBLIO NUTRITIO DIET, V46, P70.
   Rao CV, 1996, CANCER RES, V56, P3395.
   REDDY BS, 1991, CANCER RES, V51, P487.
   ROSE DP, 1993, J NATL CANCER I, V85, P1743, DOI 10.1093/jnci/85.21.1743.
   SCHMIDT EB, 1994, DRUGS, V47, P405.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353.
   Schut HAJ, 1997, MUTAT RES-FUND MOL M, V378, P23, DOI 10.1016/S0027-5107(97)00094-8.
   SCHUT HAJ, 1993, ANTICANCER RES, V13, P1517.
   Shapiro JA, 1996, EPIDEMIOLOGY, V7, P256, DOI 10.1097/00001648-199605000-00007.
   SHIMADA T, 1991, CANCER RES, V51, P5284.
   Shirai T, 1997, CANCER RES, V57, P195.
   Singh J, 1997, CANCER RES, V57, P3465.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   SNYDERWINE EG, 1994, CARCINOGENESIS, V15, P2757, DOI 10.1093/carcin/15.12.2757.
   TAKAHASHI M, 1992, CANCER RES, V52, P154.
   Takahashi M, 1997, CARCINOGENESIS, V18, P1337, DOI 10.1093/carcin/18.7.1337.
   TAKATA T, 1990, CARCINOGENESIS, V11, P2015, DOI 10.1093/carcin/11.11.2015.
   THOMPSON LH, 1987, MUTAGENESIS, V2, P483, DOI 10.1093/mutage/2.6.483.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P941, DOI 10.1093/carcin/11.6.941.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WILD D, 1987, CARCINOGENESIS, V8, P541, DOI 10.1093/carcin/8.4.541.
   YANG CS, 1992, FASEB J, V6, P737.
   ZU HX, 1991, CARCINOGENESIS, V12, P2163, DOI 10.1093/carcin/12.11.2163.}},
Number-of-Cited-References = {{69}},
Times-Cited = {{15}},
Journal-ISO = {{Food Chem. Toxicol.}},
Doc-Delivery-Number = {{210UD}},
Wos-Id = {{ISI:000081122300002}},
}

@article{ ISI:000079066400001,
Author = {Schut, HAJ and Snyderwine, EG},
Title = {{DNA adducts of heterocyclic amine food mutagens: implications for
   mutagenesis and carcinogenesis}},
Journal = {{CARCINOGENESIS}},
Year = {{1999}},
Volume = {{20}},
Number = {{3}},
Pages = {{353-368}},
Month = {{MAR}},
Abstract = {{The heterocyclic amines (HCAs) are a family of mutagenic/carcinogenic
   compounds produced during the pyrolysis of creatine, amino acids and
   proteins. The major subclass of HCAs found in the human diet comprise
   the amino-imidazoazaarenes (AIAs)
   2-amino-3-methylimidazo{[}4,5-f]quinoline (IQ),
   2-amino-3,4-dimethylimidazo{[}4,5-f]quinoline (MeIQ),
   2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline (MeIQx),
   2-amino-3,4,8-trimethylimidazo{[}4,5-f]quinoxaline (DiMeIQx) and
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP). All, except
   DiMeIQx, have been shown to be carcinogenic in animals. These compounds
   are present in cooked muscle meats at the p.p.b. level. Since the
   discovery of the HCAs in the late 1970s, many studies have examined the
   DNA adducts of these compounds. This review compiles the literature on
   AIA-DNA adducts including their identification and characterization,
   pathways of formation, mutagenesis in vitro and in vivo, and their
   association with carcinogenesis in animal models. It is now known that
   metabolic activation leading to the formation of DNA adducts is critical
   for mutagenicity and carcinogenicity of these compounds. All of the AIAs
   studied adduct to the guanine base, the major adduct being formed at the
   C8 position, Two AIAs, IQ and MeIQx, also form minor adducts at the NZ
   position of guanine, A growing body of literature has reported on the
   mutation spectra induced by AIA-guanine adducts, Studies of animal
   tumors induced by AIAs have begun to relate AIA-DNA adduct-induced
   mutagenic events with the mutations found in critical genes associated
   with oncogenesis. Several studies have demonstrated the feasibility of
   chemoprevention of AIA tumorigenesis, Only a few studies have reported
   on the detection of AZA-DNA adducts in human tissues; difficulties
   persist in the routine detection of ALA-DNA adducts in humans for the
   purpose of biomonitoring of exposure to AIAs, The AIAs are nevertheless
   regarded as possible human carcinogens, and future research on AIA-DNA
   adducts is likely to help address the role of AIAs in human cancer.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Snyderwine, EG (Reprint Author), NCI, Chem Carcinogenesis Sect, Expt Carcinogenesis Lab, Div Basic Sci, Bldg 37,Room 3C28,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.
   NCI, Chem Carcinogenesis Sect, Expt Carcinogenesis Lab, Div Basic Sci, Bethesda, MD 20892 USA.
   Med Coll Ohio, Dept Pathol, Toledo, OH 43614 USA.}},
DOI = {{10.1093/carcin/20.3.353}},
ISSN = {{0143-3334}},
Keywords-Plus = {{HUMAN-LIVER-MICROSOMES; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B> PYRIDINE
   PHIP; 2-AMINO-3-METHYLIMIDAZO<4,5-F> QUINOLINE IQ; MAMMARY
   EPITHELIAL-CELLS; CULTURED MAMMALIAN-CELLS; MOUSE FORESTOMACH TUMORS;
   P-32 POSTLABELING METHOD; COLONIC ABERRANT CRYPTS; N-ACETOXY
   DERIVATIVES; CHINESE-HAMSTER CELLS}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Author-Email = {{elizabeth\_snyderwine@nih.gov}},
Cited-References = {{ADAMSON RH, 1991, XENOBIOTICS AND CANCER, P289.
   ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   ADAMSON RH, 1994, ENVIRON HEALTH PERSP, V102, P190, DOI 10.2307/3431610.
   AESCHBACHER HU, 1991, MUTAT RES, V259, P235, DOI 10.1016/0165-1218(91)90120-B.
   AESCHBACHER HU, 1989, CARCINOGENESIS, V10, P429, DOI 10.1093/carcin/10.3.429.
   ALLDRICK AJ, 1986, MUTAT RES, V163, P109, DOI 10.1016/0027-5107(86)90041-2.
   GOLD LS, 1994, CANCER LETT, V83, P21.
   Anari MR, 1997, EUR J DRUG METAB PH, V22, P305.
   Anari MR, 1997, CHEM RES TOXICOL, V10, P582, DOI 10.1021/tx960144k.
   Anderson KE, 1997, CARCINOGENESIS, V18, P1085, DOI 10.1093/carcin/18.5.1085.
   AOYAMA T, 1990, CANCER RES, V50, P2060.
   AOYAMA T, 1989, MOL CARCINOGEN, V1, P253, DOI 10.1002/mc.2940010408.
   ASAN E, 1987, CARCINOGENESIS, V8, P1589, DOI 10.1093/carcin/8.11.1589.
   Augustsson K, 1997, CARCINOGENESIS, V18, P1931, DOI 10.1093/carcin/18.10.1931.
   AUNE T, 1986, CARCINOGENESIS, V7, P273, DOI 10.1093/carcin/7.2.273.
   BATTULA N, 1991, MOL CARCINOGEN, V4, P407, DOI 10.1002/mc.2940040513.
   Bird R P, 1986, Nutr Cancer, V8, P93.
   BIRD RP, 1984, J NATL CANCER I, V73, P237.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   Boobis AR, 1996, ARCH TOX S, V18, P286.
   Breneman JW, 1996, FOOD CHEM TOXICOL, V34, P717, DOI 10.1016/0278-6915(96)00043-9.
   BROOKMAN KW, 1985, MUTAT RES, V149, P249, DOI 10.1016/0027-5107(85)90031-4.
   BROOKS RA, 1994, CANCER RES, V54, P1665.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   BUONARATI MH, 1991, MUTAGENESIS, V6, P253, DOI 10.1093/mutage/6.4.253.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   Butcher NJ, 1996, CARCINOGENESIS, V17, P889, DOI 10.1093/carcin/17.4.889.
   BUTLER MA, 1989, P NATL ACAD SCI USA, V86, P7696, DOI 10.1073/pnas.86.20.7696.
   Carmichael PL, 1996, CARCINOGENESIS, V17, P1769, DOI 10.1093/carcin/17.8.1769.
   CAROTHRS AM, 1994, CHEM RES TOXICOL, V7, P209, DOI 10.1021/tx00038a015.
   CHOU HC, 1995, CANCER RES, V55, P525.
   COMMONER B, 1978, SCIENCE, V201, P913, DOI 10.1126/science.567374.
   Crofts FG, 1997, CARCINOGENESIS, V18, P1793, DOI 10.1093/carcin/18.9.1793.
   CUMMINGS DA, 1995, CARCINOGENESIS, V16, P2523, DOI 10.1093/carcin/16.10.2523.
   CUMMINGS DA, 1994, CARCINOGENESIS, V15, P2623, DOI 10.1093/carcin/15.11.2623.
   DASHWOOD R, 1992, CARCINOGENESIS, V13, P1121, DOI 10.1093/carcin/13.7.1121.
   Dashwood RH, 1998, CANCER RES, V58, P1127.
   DASHWOOD RH, 1992, CARCINOGENESIS, V13, P113, DOI 10.1093/carcin/13.1.113.
   Davies DS, 1996, ARCH TOX S, V18, P251.
   DAVIS CD, 1994, CANCER LETT, V84, P67, DOI 10.1016/0304-3835(94)90359-X.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P2091, DOI 10.1093/carcin/14.10.2091.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P61, DOI 10.1093/carcin/14.1.61.
   DAVIS CD, 1994, CARCINOGENESIS, V15, P641, DOI 10.1093/carcin/15.4.641.
   DAVIS CD, 1995, FOOD CHEM TOXICOL, V33, P641, DOI 10.1016/0278-6915(95)00033-X.
   Davis CD, 1996, MUTAT RES-FUND MOL M, V356, P287, DOI 10.1016/0027-5107(96)00074-7.
   DAVIS CD, 1994, TOXICOL APPL PHARM, V124, P201, DOI 10.1006/taap.1994.1024.
   DEVERDIER MG, 1991, INT J CANCER, V49, P1.
   Director AE, 1996, MUTAT RES-ENVIR MUTA, V359, P53, DOI 10.1016/S0165-1161(96)90009-6.
   DIRR A, 1988, MUTAGENESIS, V3, P147, DOI 10.1093/mutage/3.2.147.
   DOLARA P, 1986, MUTAT RES, V175, P255, DOI 10.1016/0165-7992(86)90063-1.
   DOOLEY KL, 1992, CANCER LETT, V62, P205, DOI 10.1016/0304-3835(92)90097-F.
   EDWARDS RJ, 1994, CARCINOGENESIS, V15, P829, DOI 10.1093/carcin/15.5.829.
   ELBAYOUMY K, 1995, CARCINOGENESIS, V16, P431, DOI 10.1093/carcin/16.2.431.
   ENDO H, 1995, MOL CARCINOGEN, V14, P198, DOI 10.1002/mc.2940140309.
   ENDO H, 1994, CANCER RES, V54, P3745.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FAN L, 1994, MOL CARCINOGEN, V10, P30, DOI 10.1002/mc.2940100106.
   FELTON JS, 1990, HDB EXPT PHARM, V94, P471.
   FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FELTON JS, 1994, ENVIRON HEALTH PERSP, V102, P201, DOI 10.2307/3432178.
   FLAMMANG TJ, 1989, CANCER RES, V49, P1977.
   FORD GP, 1992, CHEM-BIOL INTERACT, V81, P19, DOI 10.1016/0009-2797(92)90024-F.
   FRANCIK WB, 1990, GARBAGE-PRACT J ENV, V2, P4.
   FRANDSEN H, 1994, MUTAGENESIS, V9, P59, DOI 10.1093/mutage/9.1.59.
   FRANDSEN H, 1994, CARCINOGENESIS, V15, P2553, DOI 10.1093/carcin/15.11.2553.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   FRANKEL Y, 1995, IEEE PERS COMMUN, V2, P16, DOI 10.1109/98.403454.
   TURTELTAUB KW, 1992, CANCER RES, V52, P4682.
   FRIEDLANDER L, 1995, IEEE MULTIMEDIA, V2, P6, DOI 10.1109/93.368594.
   FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   FUJIMOTO Y, 1994, JPN J CANCER RES, V85, P506.
   FUKUTOME K, 1994, JPN J CANCER RES, V85, P113.
   FUSCOE JC, 1988, MUTAT RES, V201, P241, DOI 10.1016/0027-5107(88)90131-5.
   GHOSHAL A, 1994, CARCINOGENESIS, V15, P2429, DOI 10.1093/carcin/15.11.2429.
   GHOSHAL A, 1995, CARCINOGENESIS, V16, P2725, DOI 10.1093/carcin/16.11.2725.
   GIOVANNUCCI E, 1992, J NATL CANCER I, V84, P91, DOI 10.1093/jnci/84.2.91.
   GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B.
   Guo Dexin, 1995, Carcinogenesis (Oxford), V16, P2931, DOI 10.1093/carcin/16.12.2931.
   GUO D, 1994, CARCINOGENESIS, V15, P763, DOI 10.1093/carcin/15.4.763.
   GUO DX, 1995, CANCER LETT, V95, P161, DOI 10.1016/0304-3835(95)03882-W.
   GUPTA RC, 1988, CARCINOGENESIS, V9, P1687, DOI 10.1093/carcin/9.9.1687.
   HALL M, 1990, CARCINOGENESIS, V11, P1005, DOI 10.1093/carcin/11.6.1005.
   HASEGAWA R, 1993, CARCINOGENESIS, V14, P2553, DOI 10.1093/carcin/14.12.2553.
   HASEGAWA R, 1995, CARCINOGENESIS, V16, P2243, DOI 10.1093/carcin/16.9.2243.
   Hatch FT, 1997, MUTAT RES-FUND MOL M, V376, P87, DOI 10.1016/S0027-5107(97)00029-8.
   HAYASHI S, 1985, JPN J CANCER RES, V76, P835.
   HAYATSU H, 1993, BASIC LIFE SCI, V61, P387.
   He Y H, 1997, J Cell Biochem Suppl, V27, P42.
   HEIN DW, 1994, ARCH TOXICOL, V68, P129, DOI 10.1007/s002040050045.
   HELLMOLD H, 1993, CARCINOGENESIS, V14, P1751, DOI 10.1093/carcin/14.9.1751.
   Hellmold H, 1998, MOL PHARMACOL, V53, P475.
   HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007.
   Hernaez J, 1997, ENVIRON MOL MUTAGEN, V30, P468, DOI 10.1002/(SICI)1098-2280(1997)30:4<468::AID-EM12>3.0.CO;2-B.
   HERZOG CR, 1993, MOL CARCINOGEN, V3, P202.
   HIROSE M, 1995, CARCINOGENESIS, V16, P217, DOI 10.1093/carcin/16.2.217.
   HIROSE M, 1995, JPN J CANCER RES, V86, P516.
   Hirose M, 1995, CARCINOGENESIS, V16, P3049, DOI 10.1093/carcin/16.12.3049.
   HOLME JA, 1987, CELL BIOL TOXICOL, V3, P51, DOI 10.1007/BF00117825.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   HOLME JA, 1987, MUTAT RES, V187, P181, DOI 10.1016/0165-1218(87)90035-8.
   HOWES AJ, 1986, FOOD CHEM TOXICOL, V24, P383, DOI 10.1016/0278-6915(86)90202-4.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   JAGERSTAD M, 1991, MUTAT RES, V259, P219, DOI 10.1016/0165-1218(91)90119-7.
   JI H, 1994, CANCER EPIDEM BIOMAR, V3, P407.
   JOSEPHY PD, 1995, CANCER RES, V55, P799.
   JOSYULA S, 1999, IN PRESS FOOD CHEM T.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1711, DOI 10.1093/carcin/15.8.1711.
   KADLUBAR FF, 1985, ACS SYM SER, V283, P341.
   KAJIKAWA A, 1995, CANCER RES, V55, P2769.
   KAKIUCHI H, 1993, MOL CARCINOGEN, V8, P44, DOI 10.1002/mc.2940080110.
   KAKIUCHI H, 1995, P NATL ACAD SCI USA, V92, P910, DOI 10.1073/pnas.92.3.910.
   KATO R, 1987, JPN J CANCER RES, V78, P297.
   KATO R, 1986, CRIT REV TOXICOL, V16, P307, DOI 10.3109/10408448609037466.
   KATO T, 1988, CARCINOGENESIS, V9, P71, DOI 10.1093/carcin/9.1.71.
   Kato T, 1996, JPN J CANCER RES, V87, P127.
   KATO T, 1989, CARCINOGENESIS, V10, P601, DOI 10.1093/carcin/10.3.601.
   KERDAR RS, 1993, TOXICOL LETT, V67, P73, DOI 10.1016/0378-4274(93)90047-2.
   Kim DJ, 1997, CARCINOGENESIS, V18, P377, DOI 10.1093/carcin/18.2.377.
   KITAZAWA T, 1994, MOL CARCINOGEN, V9, P67, DOI 10.1002/mc.2940090203.
   Knasmuller S, 1996, MUTAT RES-FUND MOL M, V350, P93, DOI 10.1016/0027-5107(95)00095-X.
   KNASMULLER S, 1992, MUTAGENESIS, V7, P235, DOI 10.1093/mutage/7.4.235.
   KNEKT P, 1994, INT J CANCER, V59, P756, DOI 10.1002/ijc.2910590608.
   Koch WH, 1998, ENVIRON MOL MUTAGEN, V31, P327, DOI 10.1002/(SICI)1098-2280(1998)31:4<327::AID-EM4>3.0.CO;2-F.
   KOSAKARN P, 1993, CARCINOGENESIS, V14, P511, DOI 10.1093/carcin/14.3.511.
   KUDO M, 1991, MOL CARCINOGEN, V4, P36, DOI 10.1002/mc.2940040107.
   KUSHIDA H, 1994, CANCER LETT, V83, P31, DOI 10.1016/0304-3835(94)90295-X.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   LAWSON T, 1994, MUTAT RES LETT, V325, P125, DOI 10.1016/0165-7992(94)90074-4.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LEE H, 1995, MOL CARCINOGEN, V13, P122, DOI 10.1002/mc.2940130209.
   Liew C, 1995, CARCINOGENESIS, V16, P3037, DOI 10.1093/carcin/16.12.3037.
   LIN DX, 1995, DRUG METAB DISPOS, V23, P518.
   LIN DX, 1994, CANCER RES, V54, P4920.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   Lynch AM, 1995, CRIT REV ONCOL HEMAT, V21, P19, DOI 10.1016/1040-8428(95)00178-6.
   Lynch AM, 1996, MUTAGENESIS, V11, P505, DOI 10.1093/mutage/11.5.505.
   MAEDA H, 1995, HETEROCYCLIC AMINES, P103.
   MAKINO H, 1992, CANCER LETT, V62, P115, DOI 10.1016/0304-3835(92)90181-T.
   MAKINO H, 1992, P NATL ACAD SCI USA, V89, P4850, DOI 10.1073/pnas.89.11.4850.
   MAKINO H, 1994, JPN J CANCER RES, V85, P510.
   MALAVEILLE C, 1992, CARCINOGENESIS, V13, P2317, DOI 10.1093/carcin/13.12.2317.
   MALFATTI MA, 1995, MUTAGENESIS, V10, P425, DOI 10.1093/mutage/10.5.425.
   Malfatti MA, 1996, CANCER RES, V56, P2550.
   MARSCH GA, 1995, CHEM RES TOXICOL, V8, P659, DOI 10.1021/tx00047a005.
   Mauthe RJ, 1998, CARCINOGENESIS, V19, P919, DOI 10.1093/carcin/19.5.919.
   Mauthe R. J., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P466.
   MCKINNON RA, 1992, CANCER RES, V52, pS2108.
   MCMANUS ME, 1989, CARCINOGENESIS, V10, P357, DOI 10.1093/carcin/10.2.357.
   MCMANUS ME, 1988, CANCER RES, V48, P4513.
   MCMANUS ME, 1990, CANCER RES, V50, P3367.
   MINCHIN RF, 1992, BIOCHEM BIOPH RES CO, V185, P839, DOI 10.1016/0006-291X(92)91703-S.
   MINKLER JL, 1984, MUTAT RES, V140, P49, DOI 10.1016/0165-7992(84)90041-1.
   MORGENTHALER PML, 1995, CARCINOGENESIS, V16, P713, DOI 10.1093/carcin/16.4.713.
   MORRISON LD, 1993, MUTAT RES, V302, P45, DOI 10.1016/0165-7992(93)90089-E.
   MURRAY S, 1989, CARCINOGENESIS, V10, P763, DOI 10.1093/carcin/10.4.763.
   Nagao M, 1997, MUTAT RES-FUND MOL M, V376, P161, DOI 10.1016/S0027-5107(97)00039-0.
   Nagao M, 1996, ENVIRON HEALTH PERSP, V104, P497, DOI 10.2307/3432812.
   NAGAO M, 1994, CANCER, V74, P1063, DOI 10.1002/1097-0142(19940801)74:3+<1063::AID-CNCR2820741514>3.0.CO;2-2.
   NAGOAKA H, 1992, JPN J CANC RES, V83, P1025.
   NELSON RL, 1992, ANTICANCER RES, V12, P737.
   Nerurkar PV, 1996, MOL PHARMACOL, V49, P874.
   NERURKAR PV, 1995, CANCER RES, V55, P3043.
   Ochiai M, 1996, CARCINOGENESIS, V17, P95, DOI 10.1093/carcin/17.1.95.
   OCHIAI M, 1993, CARCINOGENESIS, V14, P2165, DOI 10.1093/carcin/14.10.2165.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   OHGAKI H, 1984, CARCINOGENESIS, V5, P921, DOI 10.1093/carcin/5.7.921.
   OHGAKI H, 1986, CARCINOGENESIS, V7, P1889, DOI 10.1093/carcin/7.11.1889.
   OHGAKI H, 1987, CARCINOGENESIS, V8, P665, DOI 10.1093/carcin/8.5.665.
   OKAMOTO T, 1981, CHEM PHARM BULL, V29, P590.
   Okonogi H, 1997, CARCINOGENESIS, V18, P745, DOI 10.1093/carcin/18.4.745.
   Otsuka C, 1996, MUTAT RES-GENET TOX, V371, P23, DOI 10.1016/S0165-1218(96)90091-9.
   Otsuka C, 1996, MUTAT RES-GENET TOX, V367, P115, DOI 10.1016/0165-1218(95)00082-8.
   OVERVIK E, 1991, MUTAT RES, V256, P37, DOI 10.1016/0921-8734(91)90031-6.
   OZAWA S, 1994, JPN J CANCER RES, V85, P1220.
   PENCE BC, 1986, J NATL CANCER I, V77, P269.
   PETRY TW, 1989, CARCINOGENESIS, V10, P2201, DOI 10.1093/carcin/10.12.2201.
   PFAU W, 1992, CARCINOGENESIS, V13, P907, DOI 10.1093/carcin/13.5.907.
   PFAU W, 1994, CARCINOGENESIS, V15, P877, DOI 10.1093/carcin/15.5.877.
   PROBST MR, 1992, CARCINOGENESIS, V13, P1713, DOI 10.1093/carcin/13.10.1713.
   ProbstHensch NM, 1997, CANCER CAUSE CONTROL, V8, P175, DOI 10.1023/A:1018416128894.
   Rao CV, 1996, CANCER RES, V56, P3395.
   REDDY BS, 1993, CANCER RES, V53, P3914.
   REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543.
   RICH KJ, 1992, CARCINOGENESIS, V13, P2221, DOI 10.1093/carcin/13.12.2221.
   Roberts-Thomson SJ, 1997, MOL CARCINOGEN, V20, P348, DOI 10.1002/(SICI)1098-2744(199712)20:4<348::AID-MC4>3.0.CO;2-F.
   RODRIGUES AS, 1994, MUTAT RES-GENET TOX, V341, P93, DOI 10.1016/0165-1218(94)90091-4.
   Ryu D.-Y., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P633.
   SABBIONI G, 1992, CARCINOGENESIS, V13, P709, DOI 10.1093/carcin/13.4.709.
   Sadrieh N, 1996, CANCER RES, V56, P2683.
   SADRIEH N, 1995, CARCINOGENESIS, V16, P1549, DOI 10.1093/carcin/16.7.1549.
   SAITO K, 1985, ARCH BIOCHEM BIOPHYS, V239, P286, DOI 10.1016/0003-9861(85)90838-0.
   Santoni-Rugiu E, 1998, CANCER RES, V58, P123.
   SCHUT HAJ, 1992, FASEB J, V6, P2942.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SCHUT HAJ, 1997, MUTAT RES, V376, P187.
   Schut HAJ, 1997, MUTAT RES-FUND MOL M, V378, P23, DOI 10.1016/S0027-5107(97)00094-8.
   SCHUT HAJ, 1988, CANCER LETT, V41, P345, DOI 10.1016/0304-3835(88)90296-0.
   SCHUT HAJ, 1993, ANTICANCER RES, V13, P1517.
   SCHUT HAJ, 1994, CARCINOGENESIS, V15, P1467, DOI 10.1093/carcin/15.7.1467.
   SCHUT HAJ, 1991, CARCINOGENESIS, V12, P931, DOI 10.1093/carcin/12.5.931.
   SENGSTAG C, 1994, CARCINOGENESIS, V15, P837, DOI 10.1093/carcin/15.5.837.
   SHIBUTANI S, 1998, P INT WORKSH HET AR, P23.
   SHIMADA T, 1989, CANCER RES, V49, P3218.
   SHIMADA T, 1991, CANCER RES, V51, P5284.
   Shirai T, 1997, CANCER RES, V57, P195.
   SINHA R, 1995, CANCER RES, V55, P4516.
   Sinha R., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P365.
   SINHA R, 1995, CARCINOGENESIS, V16, P2859, DOI 10.1093/carcin/16.11.2859.
   SNYDERWINE EG, 1994, CANCER, V74, P1070, DOI 10.1002/1097-0142(19940801)74:3+<1070::AID-CNCR2820741515>3.0.CO;2-7.
   SNYDERWINE EG, 1993, FOOD CHEM TOXICOL, V31, P415, DOI 10.1016/0278-6915(93)90156-S.
   SNYDERWINE EG, 1987, CARCINOGENESIS, V8, P1017, DOI 10.1093/carcin/8.7.1017.
   Snyderwine EG, 1998, CARCINOGENESIS, V19, P1209, DOI 10.1093/carcin/19.7.1209.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   SNYDERWINE EG, 1994, CARCINOGENESIS, V15, P2757, DOI 10.1093/carcin/15.12.2757.
   SNYDERWINE EG, 1995, CARCINOGENESIS, V16, P1377, DOI 10.1093/carcin/16.6.1377.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1739, DOI 10.1093/carcin/9.10.1739.
   SNYDERWINE EG, 1989, J NATL CANCER I, V81, P223, DOI 10.1093/jnci/81.3.223.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1061, DOI 10.1093/carcin/9.6.1061.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P411, DOI 10.1093/carcin/9.3.411.
   Solomon MS, 1996, J BIOL CHEM, V271, P18368.
   STAVRIC B, 1994, FOOD CHEM TOXICOL, V32, P977, DOI 10.1016/0278-6915(94)90093-0.
   Steineck G, 1993, Eur J Cancer Prev, V2, P293, DOI 10.1097/00008469-199307000-00002.
   STILLWELL WG, 1994, CANCER EPIDEM BIOMAR, V3, P399.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   SUGIMURA T, 1982, CANCER, V49, P1970, DOI 10.1002/1097-0142(19820515)49:10<1970::AID-CNCR2820491005>3.0.CO;2-F.
   Sugimura T, 1996, ENVIRON HEALTH PERSP, V104, P429, DOI 10.2307/3432798.
   Suzuki A, 1998, CANCER RES, V58, P1833.
   Suzuki T, 1996, MUTAT RES-GENET TOX, V369, P45, DOI 10.1016/S0165-1218(96)90046-4.
   TACHINO N, 1995, MOL CARCINOGEN, V12, P187, DOI 10.1002/mc.2940120402.
   TADA A, 1994, CARCINOGENESIS, V15, P1275, DOI 10.1093/carcin/15.6.1275.
   Takahashi S, 1996, TOXICOL PATHOL, V24, P273.
   TAKAMIYA O, 1993, HUM MOL GENET, V2, P1355, DOI 10.1093/hmg/2.9.1355.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TAKAYAMA S, 1984, GANN, V75, P467.
   TANAKA T, 1985, JPN J CANCER RES, V76, P570.
   THOMPSON LH, 1987, MUTAGENESIS, V2, P483, DOI 10.1093/mutage/2.6.483.
   THOMPSON LH, 1991, P NATL ACAD SCI USA, V88, P3827, DOI 10.1073/pnas.88.9.3827.
   THOMPSON LH, 1983, MUTAT RES, V117, P243, DOI 10.1016/0165-1218(83)90125-8.
   THORGEIRSSON SS, 1995, HETEROCYCLIC AMINES, P85.
   THORGEIRSSON UP, 1994, ENVIRON HEALTH PERSP, V102, P194, DOI 10.2307/3431611.
   Totsuka Y, 1996, CARCINOGENESIS, V17, P1029, DOI 10.1093/carcin/17.5.1029.
   Toyota M, 1996, CANCER, V77, P1593, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1593::AID-CNCR2>3.0.CO;2-F.
   TROTTIER Y, 1992, MUTAT RES, V281, P39, DOI 10.1016/0165-7992(92)90034-F.
   TSUDA H, 1994, JPN J CANCER RES, V85, P1214.
   TUCKER JD, 1989, MUTAT RES, V224, P105, DOI 10.1016/0165-1218(89)90009-8.
   Turesky RJ, 1996, CHEM RES TOXICOL, V9, P403, DOI 10.1021/tx950132j.
   Turesky RJ, 1998, CHEM RES TOXICOL, V11, P925, DOI 10.1021/tx980022n.
   TURESKY RJ, 1990, CHEM RES TOXICOL, V3, P524, DOI 10.1021/tx00018a006.
   Turesky RJ, 1996, CHEM RES TOXICOL, V9, P397, DOI 10.1021/tx950131r.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005.
   TURESKY RJ, 1994, CHEM RES TOXICOL, V7, P752, DOI 10.1021/tx00042a007.
   Turteltaub K W, 1993, J Cell Biochem Suppl, V17F, P138.
   TURTELTAUB KW, 1995, HETEROCYCLIC AMINES, P93.
   TURTELTAUB KW, 1990, P NATL ACAD SCI USA, V87, P5288, DOI 10.1073/pnas.87.14.5288.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P941, DOI 10.1093/carcin/11.6.941.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P43, DOI 10.1093/carcin/11.1.43.
   USHIJIMA T, 1995, MOL CARCINOGEN, V12, P23, DOI 10.1002/mc.2940120105.
   USHIJIMA T, 1994, MOL CARCINOGEN, V10, P38, DOI 10.1002/mc.2940100107.
   USHIJIMA T, 1994, CARCINOGENESIS, V15, P2805, DOI 10.1093/carcin/15.12.2805.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   Ward MH, 1997, INT J CANCER, V71, P14, DOI 10.1002/(SICI)1097-0215(19970328)71:1<14::AID-IJC4>3.0.CO;2-6.
   WATANABE J, 1982, BIOCHEM BIOPH RES CO, V104, P193, DOI 10.1016/0006-291X(82)91958-1.
   WATANABE M, 1993, CARCINOGENESIS, V14, P1149, DOI 10.1093/carcin/14.6.1149.
   WEISBURGER JH, 1994, P SOC EXP BIOL MED, V205, P347.
   WILD D, 1995, CARCINOGENESIS, V16, P643, DOI 10.1093/carcin/16.3.643.
   WILD D, 1988, CARCINOGENESIS, V9, P869, DOI 10.1093/carcin/9.5.869.
   WILD D, 1989, CARCINOGENESIS, V10, P335, DOI 10.1093/carcin/10.2.335.
   WILD D, 1987, CARCINOGENESIS, V8, P541, DOI 10.1093/carcin/8.4.541.
   WILD D, 1989, MUTAGENESIS, V4, P446, DOI 10.1093/mutage/4.6.446.
   WILD D, 1991, CARCINOGENESIS, V12, P1091, DOI 10.1093/carcin/12.6.1091.
   WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404.
   Winsten J. A., 1977, ORIGINS HUMAN CANC, P1561.
   WINTON DJ, 1990, CANCER RES, V50, P7992.
   Wohlin P, 1996, CHEM RES TOXICOL, V9, P1050, DOI 10.1021/tx960050a.
   WU RW, 1995, CARCINOGENESIS, V16, P1207, DOI 10.1093/carcin/16.5.1207.
   Xu M, 1996, CARCINOGENESIS, V17, P1429, DOI 10.1093/carcin/17.7.1429.
   Xu MR, 1997, CARCINOGENESIS, V18, P2149, DOI 10.1093/carcin/18.11.2149.
   YadollahiFarsani M, 1996, CARCINOGENESIS, V17, P617, DOI 10.1093/carcin/17.4.617.
   YAMASHITA K, 1988, NUCLEIC ACIDS RES S, V19, P111.
   YAMASHITA K, 1990, JPN J CANCER RES, V81, P470.
   YAMAZAKI H, 1995, CARCINOGENESIS, V16, P2167, DOI 10.1093/carcin/16.9.2167.
   YAMAZOE Y, 1988, JPN J CANCER RES, V79, P1159.
   YAMAZOE Y, 1988, CARCINOGENESIS, V9, P105, DOI 10.1093/carcin/9.1.105.
   YAMAZOE Y, 1983, CANCER RES, V43, P5768.
   YANAGAWA Y, 1994, CANCER RES, V54, P3422.
   YANAGISAWA H, 1986, BIOCHEM BIOPH RES CO, V138, P1084, DOI 10.1016/S0006-291X(86)80393-X.
   YOSHIMI N, 1988, ENVIRON MOL MUTAGEN, V12, P53, DOI 10.1002/em.2860120108.
   YUN CH, 1995, CARCINOGENESIS, V16, P1437, DOI 10.1093/carcin/16.6.1437.
   Zhang XB, 1996, CARCINOGENESIS, V17, P2259, DOI 10.1093/carcin/17.10.2259.
   ZHAO K, 1994, CARCINOGENESIS, V15, P1285, DOI 10.1093/carcin/15.6.1285.
   ZU HX, 1991, CARCINOGENESIS, V12, P2163, DOI 10.1093/carcin/12.11.2163.
   ZU HX, 1992, FOOD CHEM TOXICOL, V30, P9, DOI 10.1016/0278-6915(92)90131-4.
   ZU HX, 1991, CANCER RES, V51, P5636.}},
Number-of-Cited-References = {{300}},
Times-Cited = {{238}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{174ZL}},
Wos-Id = {{ISI:000079066400001}},
}

@article{ ISI:000079225200017,
Author = {Dunstan, PO},
Title = {{Thermochemistry of adducts of bis(2,4-pentanedionato)zinc with
   heterocyclic amines}},
Journal = {{JOURNAL OF CHEMICAL AND ENGINEERING DATA}},
Year = {{1999}},
Volume = {{44}},
Number = {{2}},
Pages = {{243-247}},
Month = {{MAR-APR}},
Abstract = {{The adducts Zn(AcAc)(2). nL {[}where L = piperazine (pipz), morpholine
   (morph), piperidine (pipd), pyridine (py), 3-methylpyridine (beta-pico),
   4-methylpyridine (gamma-pico), 3-cyanopyridine (3-cyanopy),
   4-cyanopyridine (4-cyanopy), 2,2'-bipyridine (bipy), or quinoline
   (quin); n = 1 or 3/2; AcAc = acetylacetonate] were synthesized and
   characterized by melting points, elemental analysis, thermal studies,
   and infrared spectroscopy. From calorimetric studies in solution, the
   mean standard enthalpies of the zinc-nitrogen bonds were determined.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Dunstan, PO (Reprint Author), Univ Estadual Campinas, Inst Quim, CP 6154, BR-13083970 Campinas, SP, Brazil.
   Univ Estadual Campinas, Inst Quim, BR-13083970 Campinas, SP, Brazil.}},
DOI = {{10.1021/je980113m}},
ISSN = {{0021-9568}},
Keywords-Plus = {{ARSENIC TRIHALIDES; COMPLEXES; LIGANDS; BASES}},
Research-Areas = {{Chemistry; Engineering}},
Web-of-Science-Categories  = {{Chemistry, Multidisciplinary; Engineering, Chemical}},
Cited-References = {{AHUJA IS, 1971, INORG NUCL CHEM LETT, V7, P937, DOI 10.1016/0020-1650(71)80005-3.
   Ahuja IS, 1969, INORG CHIM ACTA, V3, P110, DOI 10.1016/S0020-1693(00)92459-9.
   AIROLDI C, 1986, J CHEM SOC DALTON, P1913, DOI 10.1039/dt9860001913.
   BEHNKE GT, 1967, INORG CHEM, V6, P440, DOI 10.1021/ic50049a002.
   DUNSTAN PO, 1994, THERMOCHIM ACTA, V240, P91, DOI 10.1016/0040-6031(94)87031-4.
   DUNSTAN PO, 1989, THERMOCHIM ACTA, V156, P163, DOI 10.1016/0040-6031(89)87182-5.
   DUNSTAN PO, 1992, THERMOCHIM ACTA, V197, P201, DOI 10.1016/0040-6031(92)87051-B.
   Dunstan PO, 1997, THERMOCHIM ACTA, V303, P209, DOI 10.1016/S0040-6031(97)00280-3.
   Dunstan PO, 1996, J CHEM ENG DATA, V41, P1450, DOI 10.1021/je960164o.
   Fackler J. P., 1966, PROGR INORG CHEM, P361, DOI 10.1002/9780470166086.ch6.
   FAVOUR M, 1985, J CHEM SOC P2, P811.
   Flaschka HA, 1964, EDTA TITRATIONS INTR.
   GALLAGHER MJ, 1978, THERMOCHIM ACTA, V27, P269, DOI 10.1016/0040-6031(78)85042-4.
   GILL NS, 1961, J INORG NUCL CHEM, V18, P79, DOI 10.1016/0022-1902(61)80372-2.
   GILL NS, 1966, AUST J CHEM, V19, P2197.
   GRADDON DP, 1965, AUST J CHEM, V18, P507, DOI 10.1071/CH9650507.
   GRADDON DP, 1965, AUST J CHEM, V18, P1731.
   HENRIGTON EF, 1974, PURE APPL CHEM, V40, P399.
   Kakalowicz W., 1983, J CHEM THERMODYN, V15, P203.
   LIPPINCOTT ER, 1952, J CHEM PHYS, V20, P536, DOI 10.1063/1.1700478.
   MOHAPATRA BK, 1970, INORG CHIM ACTA, V4, P404, DOI 10.1016/S0020-1693(00)93314-0.
   PEDLEY JB, 1970, N P L COMPUTER ANAL.
   PELLACAN.GC, 1973, J INORG NUCL CHEM, V35, P2243, DOI 10.1016/0022-1902(73)80287-8.
   PINCHAS S, 1967, J CHEM PHYS, V46, P1506, DOI 10.1063/1.1840881.
   Rudolph G., 1967, INORG SYNTH, V10, P74, DOI 10.1002/9780470132418.ch14.
   SARIEGO R, 1971, J INORG NUCL CHEM, V33, P1528, DOI 10.1016/0022-1902(71)80454-2.
   SINHA SP, 1964, SPECTROCHIM ACTA, V20, P879, DOI 10.1016/0371-1951(64)80086-2.
   STEELE WV, 1988, J CHEM THERMODYN, V20, P1233, DOI 10.1016/0021-9614(88)90161-9.
   WEST R, 1958, J INORG NUCL CHEM, V5, P295, DOI 10.1016/0022-1902(58)80007-X.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{6}},
Journal-ISO = {{J. Chem. Eng. Data}},
Doc-Delivery-Number = {{177RQ}},
Wos-Id = {{ISI:000079225200017}},
}

@article{ ISI:000078319100007,
Author = {Cortes, F and Deschaseaux, F and Uchida, N and Labastie, MC and Friera,
   AM and He, DP and Charbord, P and Peault, B},
Title = {{HCA, an immunoglobulin-like adhesion molecule present on the earliest
   human hematopoietic precursor cells, is also expressed by stromal cells
   in blood-forming tissues}},
Journal = {{BLOOD}},
Year = {{1999}},
Volume = {{93}},
Number = {{3}},
Pages = {{826-837}},
Month = {{FEB 1}},
Abstract = {{We have previously shown that the HCA/ALCAM (CD166) glycoprotein, a
   member of the immunoglobulin family that mediates both homophilic and
   heterophilic cell-cell adhesion, via the CD6 ligand, is expressed at the
   surface of all of the most primitive CD38(-/lo), Thy-1(+), rho123(lo),
   CD34(+) hematopoietic cells in human fetal liver and fetal and adult
   bone marrow. In the present report we show that HCA is also expressed by
   subsets of stromal cells in the primary hematopoietic sites that
   sequentially develop in the human embryo and fetus, ie, the paraaortic
   mesoderm, liver, thymus, and bone marrow. Adult bone marrow stromal
   cells established in vitro, including those derived from Stro-1(+)
   progenitors and cells from immortalized cell lines, express HCA. In
   contrast, no HCA expression could be detected in peripheral lymphoid
   tissues, fetal spleen, and lymph nodes. HCA membrane molecules purified
   from marrow stromal cells interact with intact marrow stromal cells,
   CD34(+) CD38(-) hematopoietic precursors, and CD3(+) CD6(+) peripheral
   blood lymphocytes. Finally, low but significant levels of CD6 are here
   for the first time detected at the surface of CD34(+) rho123(med/lo)
   progenitors in the bone marrow and in mobilized blood from healthy
   individuals. Altogether, these results indicate that the HCA/ALCAM
   surface molecule is involved in homophilic or heterophilic (with CD6)
   adhesive interactions between early hematopoietic progenitors and
   associated stromal cells in primary blood-forming organs. (C) 1999 by
   The American Society of Hematology.}},
Publisher = {{AMER SOC HEMATOLOGY}},
Address = {{1200 19TH ST, NW, STE 300, WASHINGTON, DC 20036-2422 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Peault, B (Reprint Author), CNRS, Inst Embryol Cellulaire \& Mol, UPR 9064, 49bis,Ave Belle Gabrielle, F-94736 Nogent Sur Marne, France.
   CNRS, Inst Embryol Cellulaire \& Mol, UPR 9064, F-94736 Nogent Sur Marne, France.
   Etab Transfus Sanguine, Besancon, France.
   SyStemix Inc, Palo Alto, CA USA.}},
ISSN = {{0006-4971}},
Keywords-Plus = {{HUMAN-BONE-MARROW; YOLK-SAC ENDODERM; PROGENITOR CELLS; STEM-CELLS;
   PHENOTYPIC CHARACTERIZATION; DIFFERENTIATION PATHWAY; THYMIC
   MICROENVIRONMENT; LYMPHOCYTE PRECURSORS; SURFACE PROTEIN; ADHERENT CELLS}},
Research-Areas = {{Hematology}},
Web-of-Science-Categories  = {{Hematology}},
Author-Email = {{peault@infobiogen.fr}},
Cited-References = {{Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111.
   ANDREONI C, 1990, EXP HEMATOL, V18, P431.
   Arroyo AG, 1996, CELL, V85, P997, DOI 10.1016/S0092-8674(00)81301-X.
   BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804.
   BERTONCELLO I, 1985, EXP HEMATOL, V13, P999.
   Bielinska M, 1996, BLOOD, V88, P3720.
   Bloom W, 1940, AM J ANAT, V67, P21, DOI 10.1002/aja.1000670103.
   Bowen MA, 1997, EUR J IMMUNOL, V27, P1469, DOI 10.1002/eji.1830270625.
   BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213.
   Bruder SP, 1998, J BONE MINER RES, V13, P655, DOI 10.1359/jbmr.1998.13.4.655.
   BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3.
   CHARBORD P, 1991, BLOOD, V78, P1230.
   Charbord P, 1996, BLOOD, V87, P4109.
   CHARBORD P, IN PRESS KEYST S HEM.
   CHEDOTAL A, 1995, EUR J NEUROSCI, V7, P198, DOI 10.1111/j.1460-9568.1995.tb01056.x.
   CLAPP DW, 1995, BLOOD, V86, P2113.
   COOMBE DR, 1994, BLOOD, V84, P739.
   Corbel C, 1996, P NATL ACAD SCI USA, V93, P2844, DOI 10.1073/pnas.93.7.2844.
   Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X.
   Degen WGJ, 1998, AM J PATHOL, V152, P805.
   Dieterlen-Lievre F., 1984, DEV COMP IMMUNOL S, V3, P75.
   Dieterlen-Lievre F, 1993, SEMIN DEV BIOL, V4, P325, DOI 10.1006/sedb.1993.1036.
   DORSHKIND K, 1990, ANNU REV IMMUNOL, V8, P111, DOI 10.1146/annurev.immunol.8.1.111.
   DZIERZAK E, 1998, IMMUNOL TODAY, V11, P359.
   FONTAINEPERUS JC, 1981, J IMMUNOL, V126, P2310.
   FRANTZ CN, 1986, HYBRIDOMA, V5, P297, DOI 10.1089/hyb.1986.5.297.
   GALMICHE MC, 1993, BLOOD, V82, P66.
   GARCIAPORRERO JA, 1995, ANAT EMBRYOL, V192, P427.
   HARIGAYA K, 1985, P NATL ACAD SCI USA, V82, P3477, DOI 10.1073/pnas.82.10.3477.
   HAYNES BF, 1984, ADV IMMUNOL, V36, P87, DOI 10.1016/S0065-2776(08)60900-1.
   HAYNES BF, 1995, J EXP MED, V181, P1445, DOI 10.1084/jem.181.4.1445.
   HAYNES BF, 1988, J EXP MED, V168, P1061, DOI 10.1084/jem.168.3.1061.
   HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0.
   Hirsch E, 1996, NATURE, V380, P171, DOI 10.1038/380171a0.
   HJELMELAND LM, 1990, METHOD ENZYMOL, V182, P253.
   Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774.
   HUYHN A, 1995, BLOOD, V86, P4474.
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S.
   Jacobsen K, 1996, BLOOD, V87, P73.
   JOTEREAU F, 1987, J IMMUNOL, V138, P1026.
   JOTEREAU FV, 1982, J IMMUNOL, V129, P1869.
   Karagogeos D, 1997, J COMP NEUROL, V379, P415, DOI 10.1002/(SICI)1096-9861(19970317)379:3<415::AID-CNE7>3.0.CO;2-6.
   KESSEL J, 1986, DEV BIOL, V116, P319, DOI 10.1016/0012-1606(86)90135-1.
   LAESSING U, 1994, DIFFERENTIATION, V56, P21, DOI 10.1046/j.1432-0436.1994.56120021.x.
   LERAT H, 1993, BLOOD, V82, P1480.
   LI J, 1995, EXP HEMATOL, V23, P133.
   Li J, 1997, EXP HEMATOL, V25, P582.
   Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8.
   MIGLIACCIO G, 1986, J CLIN INVEST, V78, P51, DOI 10.1172/JCI112572.
   MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557.
   MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599.
   PALIS J, 1995, BLOOD, V86, P156.
   PAPAYANNOPOULOU T, 1995, P NATL ACAD SCI USA, V92, P9647, DOI 10.1073/pnas.92.21.9647.
   PATEL DD, 1995, J EXP MED, V181, P1563, DOI 10.1084/jem.181.4.1563.
   PAUL SR, 1991, BLOOD, V77, P1723.
   Péault B, 1996, J Hematother, V5, P369, DOI 10.1089/scd.1.1996.5.369.
   PEDUZZI JD, 1994, BRAIN RES, V640, P296, DOI 10.1016/0006-8993(94)91885-6.
   POURQUIE O, 1990, DEVELOPMENT, V109, P743.
   PRINCE JT, 1992, DEV BRAIN RES, V68, P193, DOI 10.1016/0165-3806(92)90061-Z.
   REZA JN, 1994, DEV IMMUNOL, V4, P55, DOI 10.1155/1994/49301.
   ROECKLEIN BA, 1995, BLOOD, V85, P997.
   RONNOVJESSEN L, 1992, J HISTOCHEM CYTOCHEM, V40, P475.
   RYAN DH, 1991, J CLIN INVEST, V88, P995, DOI 10.1172/JCI115403.
   SAELAND S, 1992, EXP HEMATOL, V20, P24.
   SENSEBE L, 1995, EXP HEMATOL, V23, P507.
   SIMMONS PJ, 1992, BLOOD, V80, P388.
   SIMMONS PJ, 1991, BLOOD, V78, P55.
   TAKASHINA T, 1987, J ANAT, V151, P125.
   TAMAYO E, 1994, STEM CELLS, V12, P304.
   TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8.
   Tavian M, 1996, BLOOD, V87, P67.
   TEIXIDO J, 1992, J CLIN INVEST, V90, P358, DOI 10.1172/JCI115870.
   TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218.
   THALMEIER K, 1994, BLOOD, V83, P1799.
   Tjonnfjord GE, 1996, EXP HEMATOL, V24, P875.
   Uchida N, 1997, BLOOD, V89, P2706.
   Uchida N, 1996, BLOOD, V88, P1297.
   UCHIDA N, 1993, CURR OPIN IMMUNOL, V5, P177, DOI 10.1016/0952-7915(93)90002-A.
   UDOMSAKDI C, 1991, EXP HEMATOL, V19, P338.
   WATT SM, 1993, BLOOD, V82, P2649.
   Wood HB, 1997, BLOOD, V90, P2300.
   YODER MC, 1994, BLOOD, V83, P2436.}},
Number-of-Cited-References = {{82}},
Times-Cited = {{50}},
Journal-ISO = {{Blood}},
Doc-Delivery-Number = {{161YX}},
Wos-Id = {{ISI:000078319100007}},
}

@article{ ISI:000076219100021,
Author = {Takahashi, S and Tamano, S and Hirose, M and Kimoto, N and Ikeda, Y and
   Sakakibara, M and Tada, M and Kadlubar, FF and Ito, N and Shirai, T},
Title = {{Immunohistochemical demonstration of carcinogen-DNA adducts in tissues
   of rats given 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP):
   Detection in paraffin-embedded sections and tissue distribution}},
Journal = {{CANCER RESEARCH}},
Year = {{1998}},
Volume = {{58}},
Number = {{19}},
Pages = {{4307-4313}},
Month = {{OCT 1}},
Abstract = {{A polyclonal antibody against
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP)-DNA adducts was
   raised for their immunohistochemical demonstration in paraffin-embedded
   sections. Specificity of this antibody was confirmed by competitive
   ELISA, Positive signals were immunohistochemically detected in
   acetone-fixed but not in formalin- or ethanol-fixed sections from F344
   rats treated by gavage with a single dose of PhIP at 37.5-300 mg/kg and
   killed at 1, 2, and 7 days thereafter. Dose-dependent positive staining
   was observed in almost all organs of both sexes, including the colon,
   prostate, and mammary gland but largely independent of the tumor
   response. Repair activity, judged by disappearance of adducts with time,
   differed according to the organ or cell type. One exception was
   hepatocytes, the liver incidentally being a nontarget organ. The results
   suggest that the generated antibody is applicable for detection of cells
   targeted by PhIP in paraffin-embedded sections and also for the
   investigation of the mechanisms of PhIP-carcinogenesis.}},
Publisher = {{AMER ASSOC CANCER RESEARCH}},
Address = {{PO BOX 11806, BIRMINGHAM, AL 35202 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Takahashi, S (Reprint Author), 1 Kawasumi,Mizuho Cho,Mizuho Ku, Nagoya, Aichi 4678601, Japan.
   Nagoya City Univ, Sch Med, Dept Pathol 1, Mizuho Ku, Nagoya, Aichi 4678601, Japan.
   Daiyukai Inst Med Sci, Ichinomiya 4910113, Japan.
   Aichi Shukutoku Univ, Aichi 4801100, Japan.
   Natl Ctr Toxicol Res, Res Off, Jefferson, AR 72079 USA.}},
ISSN = {{0008-5472}},
Keywords-Plus = {{FOOD MUTAGENS; HETEROCYCLIC AMINES; COOKED-FOOD; IDENTIFICATION;
   ANTIBODIES; CHROMATOGRAPHY; LYMPHOMA; EXPOSURE; PROSTATE; SMOKERS}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{Curigliano G, 1996, CARCINOGENESIS, V17, P911, DOI 10.1093/carcin/17.5.911.
   DAVIS CD, 1994, TOXICOL APPL PHARM, V124, P201, DOI 10.1006/taap.1994.1024.
   DOLL R, 1988, J CANCER RES CLIN, V114, P447, DOI 10.1007/BF00391491.
   DOOLEY KL, 1992, CANCER LETT, V62, P205, DOI 10.1016/0304-3835(92)90097-F.
   DRAGSTED LO, 1995, CARCINOGENESIS, V16, P2795, DOI 10.1093/carcin/16.11.2795.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   FUKUTOME K, 1994, JPN J CANCER RES, V85, P113.
   HASEGAWA R, 1995, CANCER RES, V55, P4333.
   HASEGAWA R, 1993, CARCINOGENESIS, V14, P2553, DOI 10.1093/carcin/14.12.2553.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   Malfatti MA, 1996, CANCER RES, V56, P2550.
   MANABE S, 1993, CARCINOGENESIS, V14, P899, DOI 10.1093/carcin/14.5.899.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   MILLER AB, 1985, J NUTR GROWTH CANCER, V2, P159.
   NAKAGAWA K, 1988, J NATL CANCER I, V80, P419, DOI 10.1093/jnci/80.6.419.
   PELUSO M, 1991, CARCINOGENESIS, V12, P713, DOI 10.1093/carcin/12.4.713.
   Rao CV, 1996, CANCER RES, V56, P3395.
   Shirai T, 1997, CANCER RES, V57, P195.
   SHIRAI T, 1990, CARCINOGENESIS, V11, P653, DOI 10.1093/carcin/11.4.653.
   Stillwell WG, 1997, CANCER RES, V57, P3457.
   SUGIMURA T, 1986, SCIENCE, V233, P312, DOI 10.1126/science.3088728.
   TADA M, 1989, CARCINOGENESIS, V10, P1397, DOI 10.1093/carcin/10.8.1397.
   Takahashi S, 1996, TOXICOL PATHOL, V24, P273.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   VANDERLAAN M, 1989, CARCINOGENESIS, V10, P2215, DOI 10.1093/carcin/10.12.2215.
   VANDERLAAN M, 1991, CARCINOGENESIS, V12, P349, DOI 10.1093/carcin/12.2.349.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{38}},
Journal-ISO = {{Cancer Res.}},
Doc-Delivery-Number = {{125CD}},
Wos-Id = {{ISI:000076219100021}},
}

@article{ ISI:000076131400006,
Author = {Annas, A and Brittebo, EB},
Title = {{Localization of cytochrome P4501A1 and covalent binding of a mutagenic
   heterocyclic amine in blood vessel endothelia of rodents}},
Journal = {{TOXICOLOGY}},
Year = {{1998}},
Volume = {{129}},
Number = {{2-3}},
Pages = {{145-156}},
Month = {{AUG 21}},
Abstract = {{Immunohistochemistry was used to examine the cellular localization of
   cytochrome P4501A1 (CYP1A1) in various types of endothelial linings in
   muscle tissues of rats and mice treated with the Ah receptor agonist
   beta-naphthoflavone (BNF). In addition, light microscopic
   autoradiography was used to localize sites of metabolic activation of
   H-3-labeled Trp-P-1 (3-amino-1,4-dimethyl-5H-pyrido{[}4,3-b]indole), a
   heterocyclic amine known to be metabolized by CYP1A1, in rodent tissue
   slices. The results showed a colocalization of CYP1A1 immunoreactivity
   and covalent binding of H-3-Trp-P-1 in endothelial linings of
   capillaries and veins of heart, skeletal muscle, and uterus in
   BNF-treated rodents, indicating the presence of catalytically active
   CYP1A1 at these sites. The immunohistochemical staining and covalent
   binding of H-3-Trp-P-1 in endothelia of arteries and arterioles was
   generally weak with the exception of uterine arterioles. In lymph nodes
   of BNF-treated rats, there was an intense CYP1A1 staining of high
   endothelial venules. The results suggest that endothelial linings of
   capillaries and veins in muscle tissues but also uterine arterioles and
   high endothelial venules in lymph nodes may be targets for
   CYP1A1-mediated metabolic products of endogenous and exogenous
   substances following exposure to CYP1A1 inducing agents. (C) 1998
   Elsevier Science Ireland Ltd. All rights reserved.}},
Publisher = {{ELSEVIER SCI IRELAND LTD}},
Address = {{CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Brittebo, EB (Reprint Author), Uppsala Univ, Dept Pharmaceut Biosci, Div Toxicol, Box 594, SE-75124 Uppsala, Sweden.
   Uppsala Univ, Dept Pharmaceut Biosci, Div Toxicol, SE-75124 Uppsala, Sweden.}},
DOI = {{10.1016/S0300-483X(98)00087-0}},
ISSN = {{0300-483X}},
Keywords = {{CYP1A1; endothelium; food mutagen; heart; immunohistochemistry; lymph
   node; muscle; uterus}},
Keywords-Plus = {{LUNG-CANCER PATIENTS; SMOOTH-MUSCLE CELLS; ARACHIDONIC-ACID;
   METABOLIC-ACTIVATION; DEPENDENT HYPERPOLARIZATION; MESENTERIC-ARTERY;
   CYTOCHROME-P-450-DEPENDENT MONOOXYGENASE; IMMUNOHISTOCHEMICAL
   LOCALIZATION; MONOCLONAL-ANTIBODY; RABBIT AORTA}},
Research-Areas = {{Pharmacology \& Pharmacy; Toxicology}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy; Toxicology}},
Cited-References = {{ABRAHAM NG, 1985, HYPERTENSION, V7, P899.
   ABRAHAM NG, 1987, J MOL CELL CARDIOL, V19, P73, DOI 10.1016/S0022-2828(87)80546-1.
   Adeagbo ASO, 1997, AM J HYPERTENS, V10, P763, DOI 10.1016/S0895-7061(97)00057-5.
   ANDERSON LM, 1987, CANCER RES, V47, P6079.
   ANNAS A, 1998, ARCH TOXICOL, V72, P411.
   ANTTILA S, 1991, INT J CANCER, V47, P681, DOI 10.1002/ijc.2910470509.
   ANTTILA S, 1992, ENVIRON HEALTH PERSP, V98, P179, DOI 10.2307/3431265.
   BOND JA, 1979, LIFE SCI, V25, P425, DOI 10.1016/0024-3205(79)90574-5.
   Brittebo EB, 1997, TOXICOL IN VITRO, V11, P417, DOI 10.1016/S0887-2333(97)00047-7.
   BRITTEBO EB, 1994, CARCINOGENESIS, V15, P667, DOI 10.1093/carcin/15.4.667.
   BRITTEBO EB, 1994, CANCER RES, V54, P2887.
   BRITTEBO EB, 1987, CANCER RES, V47, P1449.
   Celander M, 1997, BIOCHEM BIOPH RES CO, V232, P749, DOI 10.1006/bbrc.1997.6366.
   Chen GF, 1996, CIRC RES, V79, P827.
   COCEANI F, 1994, CAN J PHYSIOL PHARM, V72, P217.
   Crosbie SJ, 1997, HUM EXP TOXICOL, V16, P138.
   EDWARDS RJ, 1995, BIOCHEM PHARMACOL, V49, P39, DOI 10.1016/0006-2952(94)00395-3.
   FALCK JR, 1990, J BIOL CHEM, V265, P10244.
   FARIN FM, 1994, TOXICOL APPL PHARM, V124, P1, DOI 10.1006/taap.1994.1001.
   Feletou M, 1996, CLIN EXP PHARMACOL P, V23, P1082, DOI 10.1111/j.1440-1681.1996.tb01174.x.
   Forkert PG, 1996, CARCINOGENESIS, V17, P127, DOI 10.1093/carcin/17.1.127.
   FORKERT PG, 1989, DRUG METAB DISPOS, V17, P551.
   FOSTER JR, 1986, BIOCHEM PHARMACOL, V35, P4543, DOI 10.1016/0006-2952(86)90777-X.
   Fukao M, 1997, BRIT J PHARMACOL, V120, P439, DOI 10.1038/sj.bjp.0700932.
   FULTON D, 1995, BRIT J PHARMACOL, V114, P99.
   Germolec DR, 1996, TOXICOL APPL PHARM, V137, P57, DOI 10.1006/taap.1996.0057.
   GIACHELLI CM, 1991, J BIOL CHEM, V266, P3981.
   GILBERTSON M, 1991, J TOXICOL ENV HEALTH, V33, P455.
   GUENGERICH FP, 1979, MOL PHARMACOL, V15, P154.
   Guiney PD, 1997, TOXICOL APPL PHARM, V143, P256, DOI 10.1006/taap.1996.8051.
   HAZINSKI TA, 1995, J CLIN INVEST, V96, P2083, DOI 10.1172/JCI118257.
   Henry TR, 1997, TOXICOL APPL PHARM, V142, P56, DOI 10.1006/taap.1996.8024.
   HUSOY AM, 1994, TOXICOL APPL PHARM, V129, P294, DOI 10.1006/taap.1994.1254.
   JUCHAU MR, 1976, P NATL ACAD SCI USA, V73, P3723, DOI 10.1073/pnas.73.10.3723.
   KEITH IM, 1987, CANCER RES, V47, P1878.
   Leaver M. J., 1993, Molecular Marine Biology and Biotechnology, V2, P338.
   MANABE S, 1991, J TOXICOL SCI S, V1, P63.
   MCCALLUM GP, 1993, CAN J PHYSIOL PHARM, V71, P151.
   OVERBY LH, 1992, MOL PHARMACOL, V41, P1039.
   OYEKAN AO, 1991, CIRC RES, V68, P958.
   OYEKAN AO, 1994, J PHARMACOL EXP THER, V268, P262.
   Pinkerton KE, 1996, INHAL TOXICOL, V8, P927, DOI 10.3109/08958379609034271.
   PINTO A, 1986, J PHARMACOL EXP THER, V236, P445.
   Popp R, 1996, J PHYSIOL-LONDON, V497, P699.
   PYYKKO K, 1994, INT J CANCER, V56, P140.
   RIFKIND AB, 1983, NATURE, V303, P524, DOI 10.1038/303524a0.
   SERABJITSINGH CJ, 1985, MOL PHARMACOL, V28, P72.
   Shimada T, 1996, CANCER RES, V56, P2979.
   SHIMADA T, 1992, MOL PHARMACOL, V41, P856.
   Shimada T, 1996, DRUG METAB DISPOS, V24, P515.
   SMOLOWITZ RM, 1992, CARCINOGENESIS, V13, P2395, DOI 10.1093/carcin/13.12.2395.
   STEGEMAN JJ, 1989, MOL PHARMACOL, V36, P723.
   STEGEMAN JJ, 1995, MOL PHARMACOL, V47, P296.
   STEGEMAN JJ, 1991, TOXICOL APPL PHARM, V110, P486, DOI 10.1016/0041-008X(91)90049-K.
   SUGIMURA T, 1985, MUTAT RES, V150, P33, DOI 10.1016/0027-5107(85)90098-3.
   Vanheel B, 1997, J PHYSIOL-LONDON, V501, P331, DOI 10.1111/j.1469-7793.1997.331bn.x.}},
Number-of-Cited-References = {{56}},
Times-Cited = {{18}},
Journal-ISO = {{Toxicology}},
Doc-Delivery-Number = {{123NN}},
Wos-Id = {{ISI:000076131400006}},
}

@article{ ISI:000078511000002,
Author = {Josyula, S and He, YH and Ruch, RJ and Schut, HAJ},
Title = {{Inhibition of DNA adduct formation of PhIP in female F344 rats by
   dietary conjugated linoleic acid}},
Journal = {{NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL}},
Year = {{1998}},
Volume = {{32}},
Number = {{3}},
Pages = {{132-138}},
Abstract = {{The dietary mutagen 2-amino-1-methyl-6-phenyl-imidazo{[}4,5-b]pyridine
   (PhIP) is a mammary carcinogen in the female Fischer (F344) rat and a
   colon carcinogen in the male F344 rat. To exert its carcinogenicity, it
   is believed that PhIP needs to form adducts with DNA, a process
   requiring N-hydroxylation of PhIP by cytochromes P-450 1A1 and/or 1A2
   (CYP 1A1 and/or 1A2), as well as further esterification of the
   hydroxylamine thus formed. Dietary congregated linoleic acid (CLA)
   inhibits chemical carcinogenesis in various experimental models. We have
   examined the effect of dietary CLA on PhIP-DNA adduct formation in
   female F344 rats. Four-week-old animals were maintained on AIN-76A diet
   without or with CLA (1\%, 0.5\%, and 0.1\% wt/wt) for 57 days. PhIP was
   added to the diets (0.04\% wt/wt) from Days 14-42. Animals were killed
   (4/group) on Days 43, 50, and 57 DNA isolated from liver, mammary
   epithelial cells (MEC), colon, and white blood cells (WBC) was analyzed
   for PhIP-DNA adducts by P-32-postlabeling assays. On Day 43, CLA
   inhibited adduct formation in the liver (up to 58\%) in a dose-dependent
   manner. CLA also inhibited hepatic adduct levels (29-39\%) on Day 50 (at
   1.0\% and 0.5\% CLA) and on Day 57 (53\% at 0.5\% CLA). CLA
   significantly reduced adduct levels in the WBC on Day 50 (63-70\%).
   Adducts in MEC and the colon were not affected by dietary CLA. On Day 57
   adduct levels in MEG, liver, colon, and WBC were 0-30.3\%, 8.6-41.7\%,
   21.5-50.7\%, and 75-11.8\%, respectively, of those on Day 43. Northern
   blot analysis of liver RNA showed that dietary CLA did not affect
   steady-state levels of CYP 1A1 or 1A2 mRNA. It is concluded that dietary
   CLA inhibits PhIP-DNA adduct formation in liver and WBC hut that those
   in MEC and the colon are unaffected when a low-level dietary regimen of
   carcinogen and inhibitor was used. In inhibiting PhIP-DNA adduct
   formation, CLA does not appear to act by inhibiting CYP 1A1 or 1A2
   expression.}},
Publisher = {{LAWRENCE ERLBAUM ASSOC INC}},
Address = {{10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Med Coll Ohio, Dept Pathol, Toledo, OH 43614 USA.}},
ISSN = {{0163-5581}},
Keywords-Plus = {{MAMMARY-CANCER PREVENTION; HEAT-ALTERED DERIVATIVES; FRIED GROUND-BEEF;
   HETEROCYCLIC AMINES; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE
   PHIP; COOKED FOOD; DIENOIC DERIVATIVES; CDF1 MICE;
   2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE IQ; FISCHER-344 RATS}},
Research-Areas = {{Oncology; Nutrition \& Dietetics}},
Web-of-Science-Categories  = {{Oncology; Nutrition \& Dietetics}},
Cited-References = {{BARTLET JC, 1961, J AGR FOOD CHEM, V9, P50, DOI 10.1021/jf60113a015.
   Belury MA, 1996, NUTR CANCER, V26, P149.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   Booth RG, 1935, BIOCHEM J, V29, P133.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   CAWOOD P, 1983, FEBS LETT, V162, P239, DOI 10.1016/0014-5793(83)80763-7.
   CHIN SF, 1994, J NUTR, V124, P694.
   Chomczynski P., 1987, ANAL BIOCHEM, V162, P156.
   CUMMINGS DA, 1994, CARCINOGENESIS, V15, P2623, DOI 10.1093/carcin/15.11.2623.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P2091, DOI 10.1093/carcin/14.10.2091.
   DOLL R, 1981, J NATL CANCER I, V66, P1191.
   DOOLEY KL, 1992, CANCER LETT, V62, P205, DOI 10.1016/0304-3835(92)90097-F.
   ELBAYOUMY K, 1995, CARCINOGENESIS, V16, P431, DOI 10.1093/carcin/16.2.431.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   FLAMMANG TJ, 1989, CANCER RES, V49, P1977.
   FUKUTOME K, 1994, JPN J CANCER RES, V85, P113.
   GHOSHAL A, 1995, CARCINOGENESIS, V16, P2725, DOI 10.1093/carcin/16.11.2725.
   GOSHAL A, 1994, CARCINOGENESIS, V15, P2429.
   HA YL, 1989, J AGR FOOD CHEM, V37, P75, DOI 10.1021/jf00085a018.
   HA YL, 1990, CANCER RES, V50, P1097.
   HA YL, 1987, CARCINOGENESIS, V8, P1881, DOI 10.1093/carcin/8.12.1881.
   He Y H, 1997, J Cell Biochem Suppl, V27, P42.
   HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007.
   IP C, 1994, CANCER RES, V54, P1212.
   IP C, 1991, CANCER RES, V51, P6118.
   IP C, 1995, NUTR CANCER, V24, P241.
   Ip C, 1996, CARCINOGENESIS, V17, P1045, DOI 10.1093/carcin/17.5.1045.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   Liew C, 1995, CARCINOGENESIS, V16, P3037, DOI 10.1093/carcin/16.12.3037.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MANABE S, 1993, CARCINOGENESIS, V14, P899, DOI 10.1093/carcin/14.5.899.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   Miller ES, 1939, P SOC EXP BIOL MED, V41, P485.
   PARIZA MW, 1985, CARCINOGENESIS, V6, P591, DOI 10.1093/carcin/6.4.591.
   PARIZA MW, 1983, CANCER RES, V43, P2444.
   PFAU W, 1994, CARCINOGENESIS, V15, P877, DOI 10.1093/carcin/15.5.877.
   REISER R, 1950, P SOC EXP BIOL MED, V74, P666.
   RobbanaBarnat S, 1996, ENVIRON HEALTH PERSP, V104, P280, DOI 10.2307/3432886.
   RUCH RJ, 1994, CARCINOGENESIS, V15, P301, DOI 10.1093/carcin/15.2.301.
   SCHONBERG S, 1995, ANTICANCER RES, V15, P1241.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SCHUT HAJ, 1993, ANTICANCER RES, V13, P1517.
   Schut HAJ, 1997, MUTAT RES-FUND MOL M, V376, P185, DOI 10.1016/S0027-5107(97)00042-0.
   Shirai T, 1997, CANCER RES, V57, P195.
   SHULTZ TD, 1992, CANCER LETT, V63, P125, DOI 10.1016/0304-3835(92)90062-Z.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   SUGIMURA T, 1983, CANCER RES, V43, P2415.
   THOMPSON LH, 1987, MUTAGENESIS, V2, P483, DOI 10.1093/mutage/2.6.483.
   TUCKER JD, 1989, MUTAT RES, V224, P105, DOI 10.1016/0165-1218(89)90009-8.
   WILD D, 1987, CARCINOGENESIS, V8, P541, DOI 10.1093/carcin/8.4.541.
   ZU HX, 1991, CARCINOGENESIS, V12, P2163, DOI 10.1093/carcin/12.11.2163.
   ZU HX, 1992, FOOD CHEM TOXICOL, V30, P9, DOI 10.1016/0278-6915(92)90131-4.}},
Number-of-Cited-References = {{55}},
Times-Cited = {{20}},
Journal-ISO = {{Nutr. Cancer}},
Doc-Delivery-Number = {{165FX}},
Wos-Id = {{ISI:000078511000002}},
}

@article{ ISI:000078511000003,
Author = {Josyula, S and Schut, HAJ},
Title = {{Effects of dietary conjugated linoleic acid on DNA adduct formation of
   PhIP and IQ after bolus administration to female F344 rats}},
Journal = {{NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL}},
Year = {{1998}},
Volume = {{32}},
Number = {{3}},
Pages = {{139-145}},
Abstract = {{Meats cooked at high temperatures contain mutagenic heterocyclic amines
   such as 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) and
   2-amino-3-methylimidazo{[}4,5-f]quinoline (Ie). In female Fischer 344
   rats, IQ is a multiorgan carcinogen, whereas PhIP induces mammary
   adenocarcinomas. For IQ and PhIP, N-hydroxylation, catalyzed by
   microsomal cytochrome P-450 1A1 and/or 1A2, and then esterification,
   especially O-acetylation, are the principal steps leading to DNA adduct
   formation. Conjugated linoleic acid (CLA) is a mixture of conjugated
   linoleic acid isomers found in various meat and dairy products. We have
   examined the effect of dietary CLA on DNA adduct formation by PhIP and
   Ie in female Fischer 344 rats. Four-week-old animals were maintained on
   AIN-76A diet without or with CLA (4\% wt/wt) and treated with IQ or PhIP
   (50 mg/kg by gavage) after two weeks. Animals were killed (4/group) one,
   four, and eight days later. DNA isolated from mammary epithelial cells,
   liver, colon, and white blood cells was analyzed for carcinogen-DNA
   adducts by P-32-postlabeling assays. On Day I, dietary CLA significantly
   inhibited adduct formation (82.0\%) in mammary epithelial cells in
   IQ-but not in PhIP-treated rats. In the colon, dietary CLA significantly
   inhibited PhIP-DNA adduct formation (18.7\%) on Day 8 but increased
   IQ-DNA adduct formation (30.5\%) on Day 8. Dietary CLA had no effect on
   adduct levels in liver or white blood cells. Calf thymus DNA was
   incubated with N-hydroxy-PhIP or -IQ in the presence of acetyl-CoA.
   Enzymatic activation was catalyzed by liver or mammary cytosol. A
   two-week pretreatment with 2\% (wt/wt) dietary CLA had no effect on
   O-acetyltransferase-catalyzed IQ- or PhIP-DNA adduct formation. It is
   concluded, under certain conditions, that dietary CLA can lower IQ- and
   PhIP-DNA adduct formation. Overall, however, the major mode of action of
   CLA is probably by a mechanism other than the inhibition of the
   N-hydroxylation and subsequent O-acetylation of PhIP or IQ.}},
Publisher = {{LAWRENCE ERLBAUM ASSOC INC}},
Address = {{10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Med Coll Ohio, Dept Pathol, Toledo, OH 43614 USA.}},
ISSN = {{0163-5581}},
Keywords-Plus = {{HETEROCYCLIC AROMATIC-AMINES; MALE FISCHER-344 RATS; SPRAGUE-DAWLEY
   RATS; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; DIENOIC
   DERIVATIVES; CARCINOGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE;
   MUTAGENIC ACTIVATION; BROILED SARDINE; MAMMARY-GLAND; FOOD MUTAGEN}},
Research-Areas = {{Oncology; Nutrition \& Dietetics}},
Web-of-Science-Categories  = {{Oncology; Nutrition \& Dietetics}},
Cited-References = {{AESCHBACHER HU, 1991, MUTAT RES, V259, P235, DOI 10.1016/0165-1218(91)90120-B.
   AOYAMA T, 1990, CANCER RES, V50, P2060.
   BARTLET JC, 1961, J AGR FOOD CHEM, V9, P50, DOI 10.1021/jf60113a015.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   CUMMINGS DA, 1994, CARCINOGENESIS, V15, P2623, DOI 10.1093/carcin/15.11.2623.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P2091, DOI 10.1093/carcin/14.10.2091.
   DEGAWA M, 1992, JPN J CANCER RES, V83, P1047.
   DOOLEY KL, 1992, CANCER LETT, V62, P205, DOI 10.1016/0304-3835(92)90097-F.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FLAMMANG TJ, 1989, CANCER RES, V49, P1977.
   FUKUTOME K, 1994, JPN J CANCER RES, V85, P113.
   GHOSHAL A, 1994, CARCINOGENESIS, V15, P2429, DOI 10.1093/carcin/15.11.2429.
   GHOSHAL A, 1995, CARCINOGENESIS, V16, P2725, DOI 10.1093/carcin/16.11.2725.
   HA YL, 1989, J AGR FOOD CHEM, V37, P75, DOI 10.1021/jf00085a018.
   HA YL, 1990, CANCER RES, V50, P1097.
   He Y H, 1997, J Cell Biochem Suppl, V27, P42.
   HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007.
   IP C, 1994, CANCER RES, V54, P1212.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   Josyula S, 1998, NUTR CANCER, V32, P132.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   Liew C, 1995, CARCINOGENESIS, V16, P3037, DOI 10.1093/carcin/16.12.3037.
   OHGAKI H, 1984, CARCINOGENESIS, V5, P921, DOI 10.1093/carcin/5.7.921.
   PARIZA MW, 1985, CARCINOGENESIS, V6, P591, DOI 10.1093/carcin/6.4.591.
   PARIZA MW, 1983, CANCER RES, V43, P2444.
   PFAU W, 1994, CARCINOGENESIS, V15, P877, DOI 10.1093/carcin/15.5.877.
   RODRIGUES AD, 1989, EUR J BIOCHEM, V181, P627, DOI 10.1111/j.1432-1033.1989.tb14769.x.
   SCHONBERG S, 1995, ANTICANCER RES, V15, P1241.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SCHUT HAJ, 1991, CARCINOGENESIS, V12, P931, DOI 10.1093/carcin/12.5.931.
   Shirai T, 1997, CANCER RES, V57, P195.
   SHULTZ TD, 1992, CANCER LETT, V63, P125, DOI 10.1016/0304-3835(92)90062-Z.
   SNYDERWINE EG, 1993, FOOD CHEM TOXICOL, V31, P415, DOI 10.1016/0278-6915(93)90156-S.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P411, DOI 10.1093/carcin/9.3.411.
   TAKAYAMA S, 1984, GANN, V75, P467.
   TANAKA T, 1985, JPN J CANCER RES, V76, P570.
   TURESKY RJ, 1994, CHEM RES TOXICOL, V7, P752, DOI 10.1021/tx00042a007.
   WILD D, 1987, CARCINOGENESIS, V8, P541, DOI 10.1093/carcin/8.4.541.
   ZU HX, 1992, FOOD CHEM TOXICOL, V30, P9, DOI 10.1016/0278-6915(92)90131-4.
   ZU HX, 1991, CANCER RES, V51, P5636.}},
Number-of-Cited-References = {{42}},
Times-Cited = {{16}},
Journal-ISO = {{Nutr. Cancer}},
Doc-Delivery-Number = {{165FX}},
Wos-Id = {{ISI:000078511000003}},
}

@article{ ISI:000074123900010,
Author = {Shen, CL and Purewal, M and San Francisco, S and Pence, BC},
Title = {{Absence of PhIP adducts, p53 and Apc mutations, in rats fed a cooked
   beef diet containing a high level of heterocyclic amines}},
Journal = {{NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL}},
Year = {{1998}},
Volume = {{30}},
Number = {{3}},
Pages = {{227-231}},
Abstract = {{Meat cooked at high temperatures contains mutagens and carcinogens known
   as heterocyclic amines (HCA). Cooking temperature and time determine the
   amount of HCA produced. The present study examined the DNA of liver,
   colon, and stomach from rats fed a high level of HCA for 27 weeks. Male
   Sprague-Dawley rats were fed a high-fat AIN-76A-based diet containing
   60\% by weight cooked beef containing a high level of HCA, especially
   2-amino-1-mefhyl-6-phenylimidazo{[}4, 5-b]pyridine (PhIP, 72 ng/g cooked
   beef), the most abundant HCA in cooked meat products. At the end of 27
   weeks the rats were terminated, and small portions of liver colon, and
   stomach were quick-frozen in liquid nitrogen. The DNA was isolated from
   the thawed tissue by phenol-chloroform extraction, and the genomic DNA
   was analyzed for the presence of PhIP adducts by P-32-postlabeling
   analysis. The DNA was also used in polymerase chain reactions to amplify
   the rat p53 and Ape genes, then direct dye-terminator DNA sequencing was
   carried out. Results showed no PhIP adducts in any tissue. In addition,
   no signature p53 or Ape gene mutations were seen in colon or stomach
   DNA. These results indicate that the high level of HCA present in a diet
   of well-cooked meat does not cause 1) persistent PhIP adducts similar to
   those produced by feeding pure PhIP at high doses or 2) p53 and Ape gene
   mutations in nontumor tissue.}},
Publisher = {{LAWRENCE ERLBAUM ASSOC INC}},
Address = {{10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Pence, BC (Reprint Author), Texas Tech Univ, Hlth Sci Ctr, Dept Pathol, 3601 4th St, Lubbock, TX 79430 USA.
   Texas Tech Univ, Hlth Sci Ctr, Dept Pathol, Lubbock, TX 79430 USA.
   Texas Tech Univ, Inst Biotechnol, Lubbock, TX 79430 USA.
   Md Anderson Canc Ctr, Houston, TX 77030 USA.}},
ISSN = {{0163-5581}},
Keywords-Plus = {{2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; DNA ADDUCTS;
   KI-RAS; TUMORS; COLON; GENE; CARCINOGEN; TUMORIGENESIS; CANCERS; OCCUR}},
Research-Areas = {{Oncology; Nutrition \& Dietetics}},
Web-of-Science-Categories  = {{Oncology; Nutrition \& Dietetics}},
Cited-References = {{CHOZICK BS, 1994, CANCER, V73, P406, DOI 10.1002/1097-0142(19940115)73:2<406::AID-CNCR2820730228>3.0.CO;2-S.
   DEVERDIER MG, 1991, INT J CANCER, V49, P520, DOI 10.1002/ijc.2910490408.
   Friesen MD, 1996, CARCINOGENESIS, V17, P67, DOI 10.1093/carcin/17.1.67.
   GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943.
   Hecker KH, 1996, BIOTECHNIQUES, V20, P478.
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KAKIUCHI H, 1993, MOL CARCINOGEN, V8, P44, DOI 10.1002/mc.2940080110.
   KAKIUCHI H, 1995, P NATL ACAD SCI USA, V92, P910, DOI 10.1073/pnas.92.3.910.
   LU JJW, 1986, CANCER RES, V46, P3046.
   MAKINO H, 1994, JPN J CANCER RES, V85, P510.
   NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0.
   Ouhtit A, 1997, CANCER EPIDEM BIOMAR, V6, P433.
   Pence BC, 1998, NUTR CANCER, V30, P220.
   POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SUGIMURA T, 1994, J NATL CANCER I, V86, P2, DOI 10.1093/jnci/86.1.2.
   SUZUI M, 1995, MOL CARCINOGEN, V12, P193, DOI 10.1002/mc.2940120403.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   Ward M. H., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P282.
   WEGHORST CM, 1994, CANCER RES, V54, P215.}},
Number-of-Cited-References = {{22}},
Times-Cited = {{2}},
Journal-ISO = {{Nutr. Cancer}},
Doc-Delivery-Number = {{ZT770}},
Wos-Id = {{ISI:000074123900010}},
}

@article{ ISI:000071519900002,
Author = {Reistad, R and Rossland, OJ and Latva-Kala, KJ and Rasmussen, T and
   Vikse, R and Becher, G and Alexander, J},
Title = {{Heterocyclic aromatic amines in human urine following a fried meat meal}},
Journal = {{FOOD AND CHEMICAL TOXICOLOGY}},
Year = {{1997}},
Volume = {{35}},
Number = {{10-11}},
Pages = {{945-955}},
Month = {{OCT-NOV}},
Abstract = {{In a search for suitable biomarkers for human dietary exposure to
   heterocyclic aromatic amines (HAAs), we have investigated the
   concentrations of three common fried food mutagens in food and urine
   after consumption of a fried meat meal. In this connection we developed
   a method for the determination of HAAs and have investigated the common
   fried red meat HAAs 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine
   (PhIP), 2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline (MeIQx) and
   2-amino-3,4,8-trimethylimidazo{[}4,5-f]quinoxaline (DiMeIQx). Eight
   volunteers participated in the study, each consuming a meal of fried
   minced beef patties (295 g), boiled potatoes, and a green salad. Urine
   was collected for two 12-hr periods prior to and following the meal.
   HAAs were determined in cooked meat and in untreated and acid hydrolysed
   urine by a series of liquid/liquid extractions, followed by Blue cotton
   adsorption and finally by a novel derivatization technique for gas
   chromatography-mass spectrometry (GC-MS). The primary amino groups were
   derivatized by acylation with heptafluorobutyric acid anhydride, and the
   resulting amide methylated using diazomethane. Phenolic hydroxyl groups
   were also methylated by this procedure, making it possible to detect
   hydroxylated HAAs, possible metabolites or constituents of the fried
   meat. 4'-Hydroxy-PhIP
   \{2-amino-1-methyl-6-(4-hydroxyphenyl)imidazo{[}4,5-b]pyridine\}
   (4'-OH-PhIP) was indeed found in meat as well as in urine. The contents
   of PhIP, MeIQx and DiMeIQx in meat were 4.0 +/- 2.6, 3.5 +/- 0.9 and 0.3
   +/- 0.1 ng g(-1) (mean +/- SD, n = 4), from which the mean amounts
   ingested were calculated to be 1180, 1030 and 90 ng, respectively. Total
   amounts of HAAs in the 0-24-hr post-meal untreated urine (and percent of
   ingested dose) were 6-23 ng PhIP (0.5-2\%) and 10-63 ng MeIQx (1-6\%).
   In hydrolysed urine, the levels of HAAs were higher, totalling 24-100 ng
   PhIP (2-8.5\%) and 133-329 ng of MeIQx (13-32\%). DiMeIQx was below
   detection limit in all urine samples. Judged from our study, there were
   rather large inter-individual variations in the amounts of excreted
   HAAs, possibly caused by variations in the activities of enzymes taking
   part in HAA metabolism. (C) 1997 Elsevier Science Ltd. All rights
   reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Reistad, R (Reprint Author), Natl Inst Publ Hlth, POB 4404, N-0403 Oslo, Norway.
   Natl Inst Publ Hlth, N-0403 Oslo, Norway.
   Natl Inst Consumer Res, N-1324 Lysaker, Norway.
   VTT, Biotechnol \& Food Res, FIN-02044 Espoo, Finland.
   Akershus Coll, N-1340 Bekkestua, Norway.}},
DOI = {{10.1016/S0278-6915(97)00112-9}},
ISSN = {{0278-6915}},
Keywords-Plus = {{FOOD MUTAGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE; CARCINOGEN
   2-AMINO-3,8-DIMETHYLIMIDAZO<4,5-F>QUINOXALINE; PROTEIN ADDUCTS; PHIP;
   METABOLISM; MEIQX; BEEF; RAT; ACTIVATION; EXPOSURE}},
Research-Areas = {{Food Science \& Technology; Toxicology}},
Web-of-Science-Categories  = {{Food Science \& Technology; Toxicology}},
Cited-References = {{ALEXANDER J, 1991, CARCINOGENESIS, V12, P2239, DOI 10.1093/carcin/12.12.2239.
   Alexander J, 1997, MUTAT RES-FUND MOL M, V376, P7, DOI 10.1016/S0027-5107(97)00019-5.
   ALEXANDER J, 1989, CARCINOGENESIS, V10, P1543, DOI 10.1093/carcin/10.8.1543.
   Black T. H., 1983, ALDRICHIM ACTA, V16, P3.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   Boobis AR, 1996, ARCH TOX S, V18, P286.
   EDWARDS RJ, 1994, CARCINOGENESIS, V15, P829, DOI 10.1093/carcin/15.5.829.
   Friesen MD, 1996, CARCINOGENESIS, V17, P67, DOI 10.1093/carcin/17.1.67.
   JI H, 1994, CANCER EPIDEM BIOMAR, V3, P407.
   KNIZE MG, 1994, FOOD CHEM TOXICOL, V32, P595, DOI 10.1016/0278-6915(94)90002-7.
   KUROSAKA R, 1992, JPN J CANCER RES, V83, P919.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   LYNCH AM, 1993, CARCINOGENESIS, V14, P191, DOI 10.1093/carcin/14.2.191.
   MANABE S, 1993, CARCINOGENESIS, V14, P899, DOI 10.1093/carcin/14.5.899.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   MURRAY S, 1988, CARCINOGENESIS, V9, P321, DOI 10.1093/carcin/9.2.321.
   MURRAY S, 1989, CARCINOGENESIS, V10, P763, DOI 10.1093/carcin/10.4.763.
   REISTAD R, 1994, CARCINOGENESIS, V15, P2547, DOI 10.1093/carcin/15.11.2547.
   SINHA R, 1995, CARCINOGENESIS, V16, P2859, DOI 10.1093/carcin/16.11.2859.
   SNYDERWINE EG, 1995, CARCINOGENESIS, V16, P1377, DOI 10.1093/carcin/16.6.1377.
   SNYDERWINE EG, 1995, HETEROCYCLIC AMINES, P69.
   TANNENBAUM SR, 1993, ENVIRON HEALTH PERSP, V99, P51, DOI 10.2307/3431457.
   TURESKY RJ, 1988, CARCINOGENESIS, V9, P1043, DOI 10.1093/carcin/9.6.1043.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WAKABAYASHI K, 1995, HETEROCYCLIC AMINES, P39.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   ZHAO K, 1994, CARCINOGENESIS, V15, P1285, DOI 10.1093/carcin/15.6.1285.}},
Number-of-Cited-References = {{27}},
Times-Cited = {{81}},
Journal-ISO = {{Food Chem. Toxicol.}},
Doc-Delivery-Number = {{YR684}},
Wos-Id = {{ISI:000071519900002}},
}

@article{ ISI:A1997XQ87800018,
Author = {Frandsen, H},
Title = {{Excretion of DNA adducts of
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine and
   2-amino-3,4,8-trimethylimidazo{[}4,5-f]quinoxaline, PhIP-dG, PhIP-DNA
   and DiMeIQx-DNA from the rat.}},
Journal = {{CARCINOGENESIS}},
Year = {{1997}},
Volume = {{18}},
Number = {{8}},
Pages = {{1555-1560}},
Month = {{AUG}},
Abstract = {{The heterocyclic aromatic amines,
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) and
   2-amino-3,4,8-trimethylimidazo{[}4,5-f]quinoxaline (il,8-DiMeIQx) are
   formed during frying of meat. PhIP and 4,8-DiMeIQx have, after metabolic
   activation, been shown to form adducts with DNA at the C8 of guanine
   both in vitro and in vivo. In order to investigate possible urinary
   biomarkers for estimation of the genotoxic dose of PhIP and 4,8-DiMeIQx,
   {[}H-3]PhIP-dG, {[}H-3]PhIP-DNA and {[}C-14]4,8-DiMeIQx-DNA were
   injected i.p. to rats and the excretion of radioactivity in urine and
   faeces were measured. For all three {[}H-3]PhIP-dG, {[}H-3]PhIP-DNA and
   {[}C-14]4,8-DiMeIQx-DNA 15-20\% of the dose were excreted in the urine
   and 80-85\% of the dose were excreted in the faeces, Urinary excretion
   showed maximum to 24 h (90\%) with a rapid decline, 10\% to 48 h and 0\%
   to 72 h. Faecal excretion also showed maximum to 24 h (60\%) with a
   slower decline, 30\% to 48 h and 10\% to 72 h. HPLC analysis of samples
   of urine and extracts from faeces, from rats dosed with {[}H-3]PhIP-dG,
   showed that similar to 90\% of the radioactivity co-eluted with PhIP-dG,
   indicating that PhIP-dG is excreted unmetabolized. HPLC analysis of
   samples of urine and extracts from faeces, from rats dosed with
   {[}H-3]PhIP-DNA, showed that similar to 85\% of the radioactivity
   co-eluted with PhIP-dG, indicating that PhIP-DNA adducts is mainly
   excreted as nucleoside adducts. similar to 5\% of the radioactivity
   excreted in the urine co-eluted with PhIP-G, indicating loss of
   deoxyribose. HPLC analysis of samples of urine and extracts from faeces,
   from rats dosed with {[}C-14]4,8-DiMeIQx-DNA, showed that similar to
   90\% of the radioactivity co-eluted with 4,8-DiMeIQx-dG, indicating that
   4,8-DiMeIQx-DNA adducts is mainly excreted as nucleoside adducts. Man is
   able to eliminate compounds of a higher mel. wt in the urine than the
   rat, the percentage of PhIP-dG and 4,8-DiMeIQx eliminated in the urine
   of man would therefore be expected to be higher than in the rat.
   Measurement of urinary nucleoside adducts of PhIP and 4,8-DiMeIQx could
   therefore provide a basis for the development of a biomonitoring
   strategy for the genotoxic dose of these food derived HAA.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Frandsen, H (Reprint Author), NATL FOOD AGCY,INST TOXICOL,MORKHOJ BYGADE 19,DK-2860 SOBORG,DENMARK.}},
DOI = {{10.1093/carcin/18.8.1555}},
ISSN = {{0143-3334}},
Keywords-Plus = {{IDENTIFICATION; 4,8-DIMEIQX; CARCINOGEN; BEEF}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312.
   FRANDSEN H, 1994, CARCINOGENESIS, V15, P2553, DOI 10.1093/carcin/15.11.2553.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   GROOPMAN JD, 1994, CANC RES S, V54.
   HARRIS CC, 1991, MOL DOSIMETRY HUMAN, P15.
   HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007.
   KLAASSEN CD, 1981, PROGR DRUG METABOLIS, V6, P1.
   La DK, 1996, MUTAT RES-REV GENET, V365, P129, DOI 10.1016/S0165-1110(96)90017-2.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MCCONNELL IF, 1995, BIOMARKERS FOOD CHEM, P56.
   Nestmann ER, 1996, REGUL TOXICOL PHARM, V24, P9, DOI 10.1006/rtph.1996.0059.
   ROGAN EG, 1990, CHEM RES TOXICOL, V3, P441, DOI 10.1021/tx00017a009.
   SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120.
   SHUKER DEG, 1992, CHEM RES TOXICOL, V5, P450, DOI 10.1021/tx00028a001.
   SHUKER DEG, 1987, RELEVANCE N NITROSO, P407.
   SHUKER DEG, 1993, ENVIRON HEALTH PERSP, V101, P151, DOI 10.2307/3431717.
   SHUKER DEG, 1987, RELEVANCE N NITROSO, P187.
   STRICKLAND PT, 1995, AM J CLIN NUTR S, V61.
   TAKAHASHI M, 1985, CARCINOGENESIS, V6, P1537, DOI 10.1093/carcin/6.10.1537.
   TURESKY RJ, 1995, BIOMARKERS FOOD CHEM, P56.
   WAKABAYASHI K, 1992, CANC RES S, V52.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{4}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{XQ878}},
Wos-Id = {{ISI:A1997XQ87800018}},
}

@article{ ISI:A1997XR48200002,
Author = {Pfau, W and Brockstedt, U and Shirai, T and Ito, N and Marquardt, H},
Title = {{Pancreatic DNA adducts formed in vitro and in vivo by the food mutagens
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) and
   2-amino-3-methyl-9H-pyrido{[}2,3-b]indol (MeA alpha C)}},
Journal = {{MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS}},
Year = {{1997}},
Volume = {{378}},
Number = {{1-2}},
Pages = {{13-22}},
Month = {{AUG 1}},
Abstract = {{Genotoxic heterocyclic amines have been detected in grilled or fried
   meat and tobacco smoke. Among these,
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) and
   2-amino-3-methyl-9H-pyrido{[}2,3-b]indole (MeA alpha C) have been shown
   to induce tumours in rodents in several organs. Here we report on the
   DNA adduct formation by PhIP and MeA alpha C in vitro and in vivo, both
   in rat hepatic and rat pancreatic tissues or cells. Using
   P-32-postlabelling analysis both compounds were shown to induce a
   dose-dependent DNA modification in primary rat hepatocytes that was
   correlated with cytotoxicity in these cells, In explanted rat pancreas
   maintained in dynamic short-term organ culture MeA alpha C was shown to
   induce covalent DNA adducts, No DNA adducts were observed with PhIP in
   this assay. DNA adducts were observed in the liver and the pancreas of
   F344 rats treated with PhIP, with a 36-times higher level of adducts in
   the pancreas, confirming data reported earlier. DNA adduct levels
   induced by feeding 32, 160 or 800 ppm MeA alpha C in the diet were
   dose-dependent and higher in the liver compared with other organs
   including pancreas. While for PhIP the
   N-2-(desoxyguanin-8-yl)-derivative was accounting for more than 90\% of
   DNA adducts detected, in the case of MeA alpha C the
   N-2-(desoxyguanin-8-yl) adduct was predominant in vitro and determined
   in vivo as one of up to 5 DNA adducts. MeA alpha C had been reported to
   induce preneoplastic foci and rumours in the liver and tumours and
   atrophy in the pancreas. In the case of MeA alpha C, the DNA adduct
   formation and cytotoxicity observed by us in vitro and in vivo correlate
   with the organ specificity of the reported pathological lesions. In the
   case of PhIP our in vitro data in pancreas and liver and the low adduct
   levels in liver in vivo also reflect the reported lack of pathological
   effects in these organs, In contrast, in pancreas, in vivo
   extraordinarily high adduct levels induced by PhIP were observed
   confirming studies published earlier, in spite of the fact that this
   compound does not cause pancreatic lesions. This enigmatic observation
   is discussed and the relevant literature is reviewed. (C) 1997 Elsevier
   Science B.V.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Pfau, W (Reprint Author), FRAUNHOFER SOC,DEPT TOXICOL \& ENVIRONM MED,GRINDELALLEE 117,D-20146 HAMBURG,GERMANY.
   UNIV HAMBURG,SCH MED,DEPT TOXICOL,D-20146 HAMBURG,GERMANY.
   NAGOYA CITY UNIV,SCH MED,DEPT PATHOL,NAGOYA,AICHI 467,JAPAN.}},
DOI = {{10.1016/S0027-5107(97)00093-6}},
ISSN = {{0027-5107}},
Keywords = {{DNA adduct; food mutagen; heterocyclic amine; MeA alpha C;
   2-amino-3-methyl-9H-pyrido{[}2,3-b]indole; pancreas; PhIP;
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine; P-32-postlabeling}},
Keywords-Plus = {{5 HETEROCYCLIC AMINES; COOKED-FOOD; RAT-LIVER; IN-VITRO;
   2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE IQ; P-32-POSTLABELING ANALYSIS;
   FOCI DEVELOPMENT; INVITRO REACTION; SALIVARY-GLANDS; CDF1 MICE}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Cited-References = {{AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772.
   ANDERSON KE, 1992, P AM ASSOC CANC RES, V33, P920.
   BELAND FA, 1990, HDB EXPT PHARM, V94.
   CONNORS MS, 1995, CHEM-BIOL INTERACT, V96, P185, DOI 10.1016/0009-2797(94)03595-Y.
   EISENBRAND G, 1993, TOXICOLOGY, V84, P1, DOI 10.1016/0300-483X(93)90109-6.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   FRANDSEN H, 1994, CARCINOGENESIS, V15, P2553, DOI 10.1093/carcin/15.11.2553.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   Friesen MD, 1996, CARCINOGENESIS, V17, P67, DOI 10.1093/carcin/17.1.67.
   FUKUTOME K, 1994, JPN J CANCER RES, V85, P113.
   GUPTA RC, 1985, CANCER RES, V45, P5656.
   GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943.
   HALL M, 1990, CARCINOGENESIS, V11, P1005, DOI 10.1093/carcin/11.6.1005.
   HASEGAWA R, 1991, JPN J CANCER RES, V82, P1378.
   HASEGAWA R, 1992, CARCINOGENESIS, V13, P1427, DOI 10.1093/carcin/13.8.1427.
   IARC, 1990, IARC SCI PUBL, V100.
   ITO N, 1991, CARCINOGENESIS, V12, P767, DOI 10.1093/carcin/12.5.767.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   LAWSON T, 1994, MUTAT RES, V325, P124.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LIN D, 1992, CHEM RES TOXICOL, V5, P692.
   MATSUMOTO T, 1982, CANC LETT, V12, P105.
   NAGAOKA H, 1992, JPN J CANCER RES, V83, P1025.
   NORELL SE, 1986, AM J EPIDEMIOL, V124, P894.
   OHGAKI H, 1984, CARCINOGENESIS, V5, P815, DOI 10.1093/carcin/5.6.815.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   Pfau W, 1996, CARCINOGENESIS, V17, P2727, DOI 10.1093/carcin/17.12.2727.
   PFAU W, 1991, J CHROMATOGR-BIOMED, V570, P65, DOI 10.1016/0378-4347(91)80201-M.
   PFAU W, 1994, CARCINOGENESIS, V15, P877, DOI 10.1093/carcin/15.5.877.
   RANDERATH K, 1994, DRUG METAB REV, V26, P67, DOI 10.3109/03602539409029785.
   RANDERATH K, 1981, P NATL ACAD SCI-BIOL, V78, P6126, DOI 10.1073/pnas.78.10.6126.
   Raza H, 1996, DRUG METAB DISPOS, V24, P395.
   REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   SNYDERWINE EG, 1994, CARCINOGENESIS, V15, P2757, DOI 10.1093/carcin/15.12.2757.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1061, DOI 10.1093/carcin/9.6.1061.
   SUGIMURA T, 1983, CANCER RES, V43, P2415.
   SUGIMURA T, 1985, MUTAT RES, V150, P33, DOI 10.1016/0027-5107(85)90098-3.
   TADA A, 1994, CARCINOGENESIS, V15, P1275, DOI 10.1093/carcin/15.6.1275.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TAKAYAMA S, 1985, P JPN ACAD B-PHYS, V61, P277.
   TAMANO S, 1994, CARCINOGENESIS, V15, P2009, DOI 10.1093/carcin/15.9.2009.
   Totsuka Y, 1996, CARCINOGENESIS, V17, P1029, DOI 10.1093/carcin/17.5.1029.
   Turesky RJ, 1996, CHEM RES TOXICOL, V9, P403, DOI 10.1021/tx950132j.
   TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005.
   Turesky R.J., 1994, IARC SCI PUBL, V125, P217.
   WAKABAYASHI K, 1992, CANC RES S, V52, pS2093.
   WEISBURGER JH, 1993, CANCER RES, V53, P2422.
   WEISBURGER JH, 1994, J NATL CANCER I, V8, P25.
   WILLIAMS GM, 1977, CANCER RES, V37, P1845.
   WYNDER EL, 1977, J NATL CANCER I, V58, P825.
   YAMASHITA K, 1986, P JPN ACAD B-PHYS, V62, P45, DOI 10.2183/pjab.62.45.
   YAMASHITA K, 1988, MUTAGENESIS, V3, P515, DOI 10.1093/mutage/3.6.515.
   YAMASHITA K, 1988, NUCL ACID RES S SERI, V19, P11.
   YOSHIDA D, 1980, CANCER LETT, V10, P141, DOI 10.1016/0304-3835(80)90037-3.
   ZU HX, 1991, CARCINOGENESIS, V12, P2163, DOI 10.1093/carcin/12.11.2163.}},
Number-of-Cited-References = {{60}},
Times-Cited = {{13}},
Journal-ISO = {{Mutat. Res.-Fundam. Mol. Mech. Mutagen.}},
Doc-Delivery-Number = {{XR482}},
Wos-Id = {{ISI:A1997XR48200002}},
}

@article{ ISI:A1997XN53300006,
Author = {Sinha, R and Caporaso, N},
Title = {{Heterocyclic amines, cytochrome P4501A2, and N-acetyltransferase: Issues
   involved in incorporating putative genetic susceptibility markers into
   epidemiological studies}},
Journal = {{ANNALS OF EPIDEMIOLOGY}},
Year = {{1997}},
Volume = {{7}},
Number = {{5}},
Pages = {{350-356}},
Month = {{JUL}},
Note = {{Annual Meeting of the American-College-of-Epidemiology on Molecular
   Epidemiology in the 1990s and the Interface between Epidemiology and
   Behavioral Science, ST LOUIS, MO, SEP 10-12, 1995}},
Organization = {{Amer Coll Epidemiol}},
Abstract = {{PURPOSE: Heterocyclic amines (HCAs), which are found mainly in
   well-cooked meat, require metabolic activation to function as mutagens
   and animal carcinogens. Enzymes such as cytochrome P4501A2 (CYP1A2) and
   N-acetyltransferase (NAT2) perform this task and are subject to
   interindividual variation. The source of this variation may be genetic,
   as in the case of NAT2, or both genetic and environmental as with
   CYP1A2. The present study examined the effect of HCAs on the NAT2 and
   CYP1A2 phenotypes in 33 males and 33 females.
   METHODS: The subjects consumed a low HCA-containing dirt for 1 week
   followed by a high HCA diet for the subsequent week. The subjects were
   phenotyped for CYP1A2 and NAT2 at the time of entry into the study
   (free-living), 1 week later (end of low-HCA or low-induction diet) and 2
   weeks later (end of high-HCA or high-induction diet).
   RESULTS: Consistent with genetic sources oi variability, NAT2 showed
   little effect of a high-HCA diet and exhibited high intraindividual
   correlation. CYP1A2, in contrast, was induced by a high-HCA diet and
   exhibited a more modest intraindividual correlation.
   CONCLUSIONS: Incorporating putative genetic susceptibility makers in
   population studies requires consideration of issues of induction and
   inhibition of metabolizing enzymes, and effects of covariates. Published
   by Elsevier Science Inc.}},
Publisher = {{ELSEVIER SCIENCE INC}},
Address = {{655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{NCI,DIV CANC EPIDEMIOL \& GENET,NIH,ROCKVILLE,MD 20892.}},
DOI = {{10.1016/S1047-2797(97)00027-6}},
ISSN = {{1047-2797}},
Keywords = {{heterocyclic amines; cytochrome P4501A2; N-acetyltransferase MelQx;
   genotype; phenotype; inducible enzymes}},
Keywords-Plus = {{POLYCYCLIC AROMATIC-HYDROCARBONS; DATA SUGGESTING POLYMORPHISMS;
   CAFFEINE URINARY METABOLITES; FREQUENCY-DISTRIBUTIONS; DRUG-METABOLISM;
   CARCINOGENS; INDUCTION; ENZYMES; CYP1A2; HUMANS}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Cited-References = {{BOOBIS AR, 1994, CANCER RES, V54, P89.
   BUTLER MA, 1992, PHARMACOGENETICS, V2, P116, DOI 10.1097/00008571-199206000-00003.
   CAPORASO N, 1991, PHARMACOGENETICS, V1, P4, DOI 10.1097/00008571-199110000-00003.
   CONNEY AH, 1982, CANCER RES, V42, P4875.
   CONNEY AH, 1976, CLIN PHARMACOL THER, V20, P633.
   DALY AK, 1993, PHARMACOL THERAPEUT, V57, P129, DOI 10.1016/0163-7258(93)90053-G.
   DEGAWA M, 1989, CARCINOGENESIS, V10, P1119, DOI 10.1093/carcin/10.6.1119.
   DELEO JM, 1993, RECEIVER OPERATING C.
   dErrico A, 1996, BIOMARKERS, V1, P149, DOI 10.3109/13547509609079352.
   EVANS DAP, 1980, J MED GENET, V17, P102, DOI 10.1136/jmg.17.2.102.
   FUHR U, 1994, PHARMACOGENETICS, V4, P109, DOI 10.1097/00008571-199406000-00001.
   GIRRE C, 1994, BIOCHEM PHARMACOL, V47, P1503, DOI 10.1016/0006-2952(94)90524-X.
   GONZALEZ FJ, 1992, TRENDS PHARMACOL SCI, V13, P346, DOI 10.1016/0165-6147(92)90107-H.
   GUENGERICH FP, 1993, AM SCI, V81, P440.
   GUENGERICH FP, 1992, LIFE SCI, V50, P1471.
   HORN EP, 1995, CANCER EPIDEM BIOMAR, V4, P529.
   JACKSON PR, 1989, BRIT J CLIN PHARMACO, V28, P655.
   JACKSON PR, 1989, BRIT J CLIN PHARMACO, V28, P647.
   JOHANSSON I, 1993, P NATL ACAD SCI USA, V90, P11825, DOI 10.1073/pnas.90.24.11825.
   KADLUBAR FF, 1996, CANC EPIDEMIOLOGY BI, V5, P231.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   LeMarchand L, 1996, CANCER EPIDEM BIOMAR, V5, P449.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   NAKAJIMA M, 1994, CANCER EPIDEM BIOMAR, V3, P413.
   NERURKAR PV, 1993, J BIOCHEM TOXICOL, V8, P175, DOI 10.1002/jbt.2570080403.
   SINHA R, 1994, CANCER RES, V54, P6154.
   SINHA R, 1995, CANCER RES, V55, P4516.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   VATSIS KP, 1995, PHARMACOGENETICS, V5, P1, DOI 10.1097/00008571-199502000-00001.
   WEBER WW, 1985, PHARMACOL REV, V37, P25.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{11}},
Journal-ISO = {{Ann. Epidemiol.}},
Doc-Delivery-Number = {{XN533}},
Wos-Id = {{ISI:A1997XN53300006}},
}

@article{ ISI:A1997XE48900017,
Author = {Huber, WW and McDaniel, LP and Kaderlik, KR and Teitel, CH and Lang, NP
   and Kadlubar, FF},
Title = {{Chemoprotection against the formation of colon DNA adducts from the
   food-borne carcinogen 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine
   (PhIP) in the rat}},
Journal = {{MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS}},
Year = {{1997}},
Volume = {{376}},
Number = {{1-2}},
Pages = {{115-122}},
Month = {{MAY 12}},
Note = {{6th International Conference on Carcinogenic and Mutagenic N-Substituted
   Aryl Compounds, MONTEREY, CA, NOV 04-08, 1995}},
Organization = {{Flavor \& Extract Manufacturers Assoc US; Int Flavors \& Fragrances Inc;
   Lawrence Livermore Natl Lab, Biol \& Biotechnol Res Program; US FDA,
   Natl Ctr Toxicol Res; NCI; NIEHS; Nestle S A; Toronto Res Chem Inc}},
Abstract = {{The mutagenic heterocyclic aromatic amine,
   2-amina-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP), is a pyrolysis
   product in cooked foods that has been shown to be a rat colon carcinogen
   and has been implicated in the etiology of human colon cancer. In order
   to identify chemoprotection strategies that could be carried out in
   humans, a pilot study was conducted in which PhIP-DNA-adduct levels were
   quantified in the colons of male F344 rats that had been subjected to 16
   different putative chemoprotection regimens, followed by a gavage of
   PhIP (50 mg/kg) and sacrifice 24 h later. The 16 treatments (Oltipraz,
   benzylisothiocyanate, diallyl sulfide, garlic powder, ethoxyquin,
   butylated hydroxyanisole, glutathione, indole-3-carbinol,
   alpha-angelicalactone, kahweol/cafestol palmitates, quercetin, green
   tea, black tea, tannic acid, amylase-resistant starch, and physical
   exercise) comprised sulfur-containing compounds, antioxidants,
   flavonoids, diterpenes, polyphenols, high dietary fiber, etc. The
   strongest inhibition of PhIP-DNA adduct formation in the colon was
   observed upon pretreatment with black. tea, benzylisothiocyanate, and a
   mixture (1:1) of kahweol:cafestol palmitates, which resulted in 67, 66,
   and 54\% decreases in colon PhIP-DNA adduct levels, as compared with
   controls. Preliminary studies on their mechanism of action indicated
   that only kahweol:cafestol caused a substantial induction of glutathione
   S-transferase isozymes (GSTs) that are thought to be important in the
   detoxification of PhIP. Notably, this induction occurred in the liver
   rather than in the colon.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Huber, WW (Reprint Author), NATL CTR TOXICOL RES,DIV MOL EPIDEMIOL HFT100,JEFFERSON,AR 72079, USA.
   ARKANSAS CANC RES CTR,LITTLE ROCK,AR 72205.}},
DOI = {{10.1016/S0027-5107(97)00033-X}},
ISSN = {{0027-5107}},
Keywords = {{2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP);
   chemoprotection; food-borne carcinogen; rat}},
Keywords-Plus = {{GLUTATHIONE S-TRANSFERASES; HETEROCYCLIC AROMATIC-AMINES; DIETARY
   BUTYLATED HYDROXYANISOLE; METABOLIC-ACTIVATION; LIVER-MICROSOMES;
   MUTAGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE; COOKED FOODS;
   METHYLAZOXYMETHANOL ACETATE; CHEMOPREVENTIVE AGENTS; ORGANOSULFUR
   COMPOUNDS}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Cited-References = {{ALEXANDER J, 1991, CARCINOGENESIS, V12, P2239, DOI 10.1093/carcin/12.12.2239.
   ALEXANDER J, 1989, CARCINOGENESIS, V10, P1543, DOI 10.1093/carcin/10.8.1543.
   BENSON AM, 1985, CANCER RES, V45, P4219.
   BOCK KW, 1992, TRENDS PHARMACOL SCI, V13, P223, DOI 10.1016/0165-6147(92)90068-H.
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   DEGAWA M, 1994, CANCER RES, V54, P4915.
   DESCHNER EE, 1991, CARCINOGENESIS, V12, P1193, DOI 10.1093/carcin/12.7.1193.
   DISIMPLICIO P, 1989, BIOCHEM J, V263, P679.
   FARRANTS AKO, 1987, BIOCHEM J, V245, P423.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FELTON JS, 1994, ENVIRON HEALTH PERSP, V102, P201, DOI 10.2307/3432178.
   GHOSHAL A, 1994, CARCINOGENESIS, V15, P2429, DOI 10.1093/carcin/15.11.2429.
   GROSS GA, 1990, CARCINOGENESIS, V11, P1597, DOI 10.1093/carcin/11.9.1597.
   GUENGERICH FP, 1995, AM J CLIN NUTR, V61, pS651.
   Guo Dexin, 1995, Carcinogenesis (Oxford), V16, P2931, DOI 10.1093/carcin/16.12.2931.
   GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081.
   HABIG WH, 1974, J BIOL CHEM, V249, P7130.
   HALPERT JR, 1994, TOXICOL APPL PHARM, V125, P163, DOI 10.1006/taap.1994.1061.
   HASEGAWA R, 1993, CARCINOGENESIS, V14, P2553, DOI 10.1093/carcin/14.12.2553.
   ITO N, 1992, TERATOGEN CARCIN MUT, V12, P79, DOI 10.1002/tcm.1770120205.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1695, DOI 10.1093/carcin/15.8.1695.
   Katiyar SK, 1996, INT J ONCOL, V8, P221.
   KENSLER TW, 1985, CARCINOGENESIS, V6, P759, DOI 10.1093/carcin/6.5.759.
   KENSLER TW, 1987, CANCER RES, V47, P4271.
   LAM LKT, 1991, CARCINOGENESIS, V12, P2311, DOI 10.1093/carcin/12.12.2311.
   LAM LKT, 1982, CANCER RES, V42, P1193.
   LAM LKT, 1987, J MED CHEM, V30, P1399, DOI 10.1021/jm00391a022.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   LIN DX, 1995, DRUG METAB DISPOS, V23, P518.
   LIN DX, 1994, ENVIRON HEALTH PERSP, V102, P11, DOI 10.2307/3432144.
   LIN DX, 1994, CANCER RES, V54, P4920.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   LIU JZ, 1992, CARCINOGENESIS, V13, P1847, DOI 10.1093/carcin/13.10.1847.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   MCMANUS ME, 1989, CARCINOGENESIS, V10, P357, DOI 10.1093/carcin/10.2.357.
   MILLER EG, 1991, NUTR CANCER, V15, P41.
   NAGAO M, 1994, CANCER, V74, P1063, DOI 10.1002/1097-0142(19940801)74:3+<1063::AID-CNCR2820741514>3.0.CO;2-2.
   NARISAWA T, 1993, JPN J CANCER RES, V84, P1007.
   NIJHOFF WA, 1995, CARCINOGENESIS, V16, P607, DOI 10.1093/carcin/16.3.607.
   NIJHOFF WA, 1992, BIOCHEM PHARMACOL, V44, P596, DOI 10.1016/0006-2952(92)90456-S.
   OLSEN J, 1993, INT J EPIDEMIOL, V22, P398, DOI 10.1093/ije/22.3.398.
   REDDY BS, 1993, CANCER RES, V53, P3493.
   REDDY BS, 1984, J NATL CANCER I, V72, P1181.
   SCHIFFMAN MH, 1989, CANCER RES, V49, P3420.
   SHIMADA T, 1992, MOL PHARMACOL, V41, P856.
   SINHA R, 1994, CANCER RES, V54, P6154.
   SPARNINS PL, 1982, J NATL CANCER I, V68, P493.
   Stoner G D, 1995, J Cell Biochem Suppl, V22, P169.
   STYCZYNSKI PB, 1993, CHEM RES TOXICOL, V6, P846, DOI 10.1021/tx00036a014.
   SUGIE S, 1994, CARCINOGENESIS, V15, P1555, DOI 10.1093/carcin/15.8.1555.
   SUGIMURA T, 1991, ADV EXP MED BIOL, V283, P569.
   SUGIMURA T, 1994, J NATL CANCER I, V86, P2, DOI 10.1093/jnci/86.1.2.
   SUMIYOSHI H, 1990, CANCER RES, V50, P5084.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P941, DOI 10.1093/carcin/11.6.941.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   WARGOVICH MJ, 1987, CARCINOGENESIS, V8, P487, DOI 10.1093/carcin/8.3.487.
   WATTENBERG LW, 1979, CANCER RES, V39, P1651.
   YAMANE T, 1991, JPN J CANCER RES, V82, P1336.
   YIN PZ, 1994, CANCER LETT, V79, P33.
   ZHANG K, 1994, BIOCHEM PHARMACOL, V47, P2063, DOI 10.1016/0006-2952(94)90082-5.}},
Number-of-Cited-References = {{67}},
Times-Cited = {{78}},
Journal-ISO = {{Mutat. Res.-Fundam. Mol. Mech. Mutagen.}},
Doc-Delivery-Number = {{XE489}},
Wos-Id = {{ISI:A1997XE48900017}},
}

@article{ ISI:A1997XE48900026,
Author = {Schut, HAJ and Cummings, DA and Smale, MHE and Josyula, S and Friesen,
   MD},
Title = {{DNA adducts of heterocyclic amines: Formation, removal and inhibition by
   dietary components}},
Journal = {{MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS}},
Year = {{1997}},
Volume = {{376}},
Number = {{1-2}},
Pages = {{185-194}},
Month = {{MAY 12}},
Note = {{6th International Conference on Carcinogenic and Mutagenic N-Substituted
   Aryl Compounds, MONTEREY, CA, NOV 04-08, 1995}},
Organization = {{Flavor \& Extract Manufacturers Assoc US; Int Flavors \& Fragrances Inc;
   Lawrence Livermore Natl Lab, Biol \& Biotechnol Res Program; US FDA,
   Natl Ctr Toxicol Res; NCI; NIEHS; Nestle S A; Toronto Res Chem Inc}},
Abstract = {{The dietary mutagens 2-amino-3-methylimidazo{[}4,5-f]quinoline (IQ) and
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) are
   carcinogenic in rodents. In F344 rats PhIP induces mammary tumors in
   females and colon tumors in males, while IQ induces tumors principally
   in the liver, Zymbal gland and intestines. In CDF1 mice, IQ induces
   liver, lung and forestomach tumors. We have evaluated the dynamics of
   formation, removal and inhibition of PhIP- and IQ-DNA adducts in these
   rodents. After bolus doses (50 mg/kg, by gavage) of IQ or PhIP, both IQ-
   and PhIP-DNA adducts were removed rapidly from both target and nontarget
   organs, while after 3-4 weeks of feeding IQ or PhIP (0.01-0.04\%) adduct
   removal was much slower. Gavaging of male F344 rats with PhIP (0.1-1000
   mu g/kg/day) for 23 days resulted in accumulation of PhIP-DNA adducts in
   various organs, but adducts were detectable only at 100 or 1000 mu
   g/kg/day. Urinary excretion of unchanged PhIP was a constant proportion
   (1.6-2.1\%) of the daily dose over the entire dose range and was
   independent of duration of exposure. When weanling female F344 rats were
   exposed to dietary PhIP (0.01-0.04\%) for 1-4 weeks, the presence of
   either conjugated linoleic acid (CLA; 0.1-1.0\%) or indole-3-carbinol
   (I3C; 0.1\%) in the diet inhibited PhIP-DNA adduct formation (58-99\%)
   in various organs, including the mammary gland and the colon. Similarly,
   the inclusion of 0.075\% 4-ipomeanol (IPO) in the diet of male CDF1 mice
   exposed for 3 weeks to dietary IQ (0.01\%) resulted in inhibition of
   IQ-DNA adduct formation (30-59\%) in the target organs (liver, lungs,
   stomach) but not in a number of other organs. It is concluded that (1)
   the rate of PhIP- and IQ-DNA adduct removal depends on the dose and
   frequency of administration, (2) urinary PhIP may be a good biomarker of
   recent PhIP exposure and (3) CLA, I3C and LPO are potential
   chemopreventive agents against PhIP- or IQ-induced tumors in rodents.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Schut, HAJ (Reprint Author), MED COLL OHIO,DEPT PATHOL,HE 202,3000 ARLINGTON AVE,TOLEDO,OH 43614, USA.
   INT AGCY RES CANC,UNIT ENVIRONM CARCINOGENESIS,F-69372 LYON 08,FRANCE.}},
DOI = {{10.1016/S0027-5107(97)00042-0}},
ISSN = {{0027-5107}},
Keywords = {{heterocyclic amine; food mutagen; IQ; PhIP; DNA adduct; chemoprevention}},
Keywords-Plus = {{FOOD CARCINOGEN 2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE; HEAT-ALTERED
   DERIVATIVES; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP;
   LINOLEIC-ACID; CDF1 MICE; FISCHER-344 RATS; MAMMARY-TUMORS; IQ;
   INDOLE-3-CARBINOL; 4-IPOMEANOL}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
ResearcherID-Numbers = {{Friesen, Marlin/D-7328-2012}},
Cited-References = {{GOLD LS, 1994, CANCER LETT, V83, P21.
   BRADLOW HL, 1994, CANCER EPIDEM BIOMAR, V3, P591.
   CHRISTIAN MC, 1989, J NATL CANCER I, V81, P1133, DOI 10.1093/jnci/81.15.1133.
   CUMMINGS DA, 1995, CARCINOGENESIS, V16, P2523, DOI 10.1093/carcin/16.10.2523.
   CUMMINGS DA, 1994, CARCINOGENESIS, V15, P2623, DOI 10.1093/carcin/15.11.2623.
   CZERWINSKI M, 1991, CANCER RES, V51, P4636.
   DASHWOOD RH, 1994, CANCER RES, V54, P3617.
   DAVIS CD, 1994, TOXICOL APPL PHARM, V124, P201, DOI 10.1006/taap.1994.1024.
   FONG AT, 1990, BIOCHEM PHARMACOL, V39, P19, DOI 10.1016/0006-2952(90)90643-Y.
   FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   Friesen MD, 1996, CARCINOGENESIS, V17, P67, DOI 10.1093/carcin/17.1.67.
   FUKUTOME K, 1994, JPN J CANCER RES, V85, P113.
   GHOSHAL A, 1995, CARCINOGENESIS, V16, P2725, DOI 10.1093/carcin/16.11.2725.
   Guo Dexin, 1995, Carcinogenesis (Oxford), V16, P2931, DOI 10.1093/carcin/16.12.2931.
   HA YL, 1989, J AGR FOOD CHEM, V37, P75, DOI 10.1021/jf00085a018.
   HA YL, 1987, CARCINOGENESIS, V8, P1881, DOI 10.1093/carcin/8.12.1881.
   HARTMAN PE, 1990, ENVIRON MOL MUTAGEN, V15, P145, DOI 10.1002/em.2850150305.
   HAYATSU H, 1988, MUTAT RES, V202, P429, DOI 10.1016/0027-5107(88)90204-7.
   HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007.
   IP C, 1991, CANCER RES, V51, P6118.
   KELLOFF GJ, 1994, CANCER EPIDEM BIOMAR, V3, P85.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LIN JM, 1992, CHEM RES TOXICOL, V5, P674, DOI 10.1021/tx00029a013.
   LIU JZ, 1992, CARCINOGENESIS, V13, P1847, DOI 10.1093/carcin/13.10.1847.
   LIU JZ, 1991, CANCER RES, V51, P4613.
   MCDANELL R, 1988, FOOD CHEM TOXICOL, V26, P59, DOI 10.1016/0278-6915(88)90042-7.
   MORSE MA, 1990, CANCER RES, V50, P2613.
   OVERVIK E, 1991, MUTAT RES, V256, P37, DOI 10.1016/0921-8734(91)90031-6.
   PFAU W, 1994, CARCINOGENESIS, V15, P877, DOI 10.1093/carcin/15.5.877.
   SCHUT HAJ, 1996, IN PRESS CARCINOGENE.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SCHUT HAJ, 1984, DRUG METAB REV, V15, P753, DOI 10.3109/03602538409041079.
   Schut HAJ, 1995, ANN NY ACAD SCI, V768, P210, DOI 10.1111/j.1749-6632.1995.tb12124.x.
   SCHUT HAJ, 1988, CANCER LETT, V41, P345, DOI 10.1016/0304-3835(88)90296-0.
   SCHUT HAJ, 1993, ANTICANCER RES, V13, P1517.
   SCHUT HAJ, 1991, CARCINOGENESIS, V12, P931, DOI 10.1093/carcin/12.5.931.
   SINGLETARY KW, 1991, CANCER LETT, V60, P169, DOI 10.1016/0304-3835(91)90224-6.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   SNYDERWINE EG, 1994, CARCINOGENESIS, V15, P2757, DOI 10.1093/carcin/15.12.2757.
   TAKAYAMA K, 1989, JPN J CANC RES, V80, P145.
   THORGEIRSSON UP, 1994, ENVIRON HEALTH PERSP, V102, P194, DOI 10.2307/3431611.
   TURESKY RJ, 1994, CHEM RES TOXICOL, V7, P752, DOI 10.1021/tx00042a007.
   TURESKY RJ, 1995, CARCINOGENESIS, V16, P2275, DOI 10.1093/carcin/16.9.2275.
   ZU HX, 1991, CARCINOGENESIS, V12, P2163, DOI 10.1093/carcin/12.11.2163.
   ZU HX, 1992, FOOD CHEM TOXICOL, V30, P9, DOI 10.1016/0278-6915(92)90131-4.}},
Number-of-Cited-References = {{45}},
Times-Cited = {{33}},
Journal-ISO = {{Mutat. Res.-Fundam. Mol. Mech. Mutagen.}},
Doc-Delivery-Number = {{XE489}},
Wos-Id = {{ISI:A1997XE48900026}},
}

@article{ ISI:A1997XE48900033,
Author = {Wakabayashi, K and Totsuka, Y and Fukutome, K and Oguri, A and Ushiyama,
   H and Sugimura, T},
Title = {{Human exposure to mutagenic/carcinogenic heterocyclic amines and
   comutagenic beta-carbolines}},
Journal = {{MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS}},
Year = {{1997}},
Volume = {{376}},
Number = {{1-2}},
Pages = {{253-259}},
Month = {{MAY 12}},
Note = {{6th International Conference on Carcinogenic and Mutagenic N-Substituted
   Aryl Compounds, MONTEREY, CA, NOV 04-08, 1995}},
Organization = {{Flavor \& Extract Manufacturers Assoc US; Int Flavors \& Fragrances Inc;
   Lawrence Livermore Natl Lab, Biol \& Biotechnol Res Program; US FDA,
   Natl Ctr Toxicol Res; NCI; NIEHS; Nestle S A; Toronto Res Chem Inc}},
Abstract = {{Various kinds of mutagenic and carcinogenic heterocyclic amines (HCAs)
   are produced by heating protein-rich foods, such as meat and fish. To
   evaluate the risk of these HCAs in terms of human cancer development,
   exposure levels must be measured. We therefore analyzed their amounts in
   various kinds of cooked foods and in urine samples of healthy volunteers
   living in Tokyo. Based on the obtained quantitative data, daily exposure
   levels to 2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline (MeIQx) and
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) were calculated
   to be 0.3-3.9 and 0.005-0.3 mu g per person, respectively, Moreover,
   human DNA samples were analyzed with the P-32-postlabeling method, and
   colon, rectum and kidney tissues were found to contain an adduct spot
   corresponding to the standard 5'-pdG-C8-MeIQx by TLC and HPLC, at levels
   of 14, 18 and 1.8 per 10(10) nucleotides, respectively. The
   beta-carboline compound, norharman, is produced by heating L-tryptophan,
   and is known to be present in cooked foods and in cigarette smoke at
   higher levels than mutagenic and carcinogenic HCAs. While norharman is
   not itself mutagenic to Salmonella, it does become mutagenic to S.
   typhimurium TA98 with S9 mix in the presence of non-mutagenic aromatic
   amines like aniline and o-toluidine. When we examined whether DNA
   adducts are formed in the DNA of S. typhimurium TA98 by treatment with
   norharman and aromatic amines using P-32-postlabeling analysis, DNA
   adduct formation by norharman with aromatic amines was found to be
   related to the appearance of mutagenicity by norharman with aromatic
   amines.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Wakabayashi, K (Reprint Author), NATL CANC CTR,RES INST,DIV BIOCHEM,CHUO KU,1-1 TSUKIJI 5 CHOME,TOKYO 104,JAPAN.
   TOKYO METROPOLITAN RES LAB PUBL HLTH,DIV FOOD HYG,SHINJUKU KU,TOKYO 169,JAPAN.}},
DOI = {{10.1016/S0027-5107(97)00050-X}},
ISSN = {{0027-5107}},
Keywords = {{heterocyclic amine; comutagen; norharman; human exposure; DNA adduct}},
Keywords-Plus = {{COLORECTAL-CANCER; CASE-REFERENT; FRIED FOODS; CARCINOGENS; STOCKHOLM;
   NORHARMAN; MUTAGENS; ADDUCT; URINE; RISK}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Cited-References = {{ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   DEVERDIER MG, 1991, INT J CANCER, V49, P520, DOI 10.1002/ijc.2910490408.
   FUKUTOME K, 1994, JPN J CANCER RES, V85, P113.
   IKEDA M, 1983, JPN J CANCER RES, V74, P640.
   JAGERSTAD M, 1991, MUTAT RES, V259, P219, DOI 10.1016/0165-1218(91)90119-7.
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   MORI M, 1996, CARCINOGENESIS, V17, P1029.
   NAGAO M, 1977, P JPN ACAD B-PHYS, V53, P34, DOI 10.2183/pjab.53.34.
   NAGAO M, 1978, BIOCHEM BIOPH RES CO, V83, P373, DOI 10.1016/0006-291X(78)91000-8.
   NORELL SE, 1986, AM J EPIDEMIOL, V124, P894.
   POINDEXTER EH, 1962, PHYTOCHEMISTRY, V1, P215, DOI 10.1016/S0031-9422(00)82825-3.
   SCHIFFMAN MH, 1990, AM J EPIDEMIOL, V131, P376.
   STEINECK G, 1990, INT J CANCER, V45, P1006, DOI 10.1002/ijc.2910450604.
   SUGIMURA T, 1992, SCIENCE, V258, P603, DOI 10.1126/science.1411570.
   SUGIMURA T, 1977, P JPN ACAD, V53, P58.
   TADA A, 1994, CARCINOGENESIS, V15, P1275, DOI 10.1093/carcin/15.6.1275.
   TOTSUKA Y, 1996, IN PRESS CARCINOGENE.
   USHIYAMA H, 1995, P JPN ACAD B-PHYS, V71, P57, DOI 10.2183/pjab.71.57.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   YASUDA T, 1978, MED GCMS SOC, V3, P97.
   YOSHIDA D, 1979, AGR BIOL CHEM TOKYO, V43, P1155.
   {*}INT AG RES CANC, 1982, IARC MON EV CARC RIS, V27, P39.
   {*}INT AG RES CANC, 1982, IARC MON EV CARC RIS, V27, P155.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{63}},
Journal-ISO = {{Mutat. Res.-Fundam. Mol. Mech. Mutagen.}},
Doc-Delivery-Number = {{XE489}},
Wos-Id = {{ISI:A1997XE48900033}},
}

@article{ ISI:000073559800009,
Author = {He, YH and Smale, MHE and Schut, HAJ},
Title = {{Chemopreventive properties of indole-3-carbinol (I3C): Inhibition of DNA
   adduct formation of the dietary carcinogen,
   2-amino-1-methyl-6-phenylimidazo {[}4,5-b]pyridine (PhIP), in female
   F344 rats}},
Journal = {{JOURNAL OF CELLULAR BIOCHEMISTRY}},
Year = {{1997}},
Number = {{27}},
Pages = {{42-51}},
Note = {{International Cancer Chemoprevention Conference, BEIJING, PEOPLES R
   CHINA, OCT 13-16, 1996}},
Abstract = {{Indole-3-carbinol (13C), a naturally occurring inhibitor of experimental
   carcinogenesis, was evaluated for its possible inhibitory effect on
   DNA-adduct formation of
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhlP), a dietary
   mutagen, in female F344 rats. PhlP is a mammary carcinogen in female
   F344 rats and a colon carcinogen in male F344 rats. Four-week-old
   animals (4/group) were maintained on powdered AIN-76A diet with or
   without 13C (0.02\% or 0.1\%, w/w) for 58 days. PhlP (0.04\%, w/w) was
   added to the diet from days 15 through 42. Animals were killed on days
   43 and 58. DNA isolated from mammary epithelial cells (MECs), colon,
   liver, and white blood cells (WBCs) was analyzed for PhlP-DNA adducts by
   P-32-postlabeling assays. On day 43, adduct levels of the group
   receiving 0.1\% dietary 13C decreased in MECs (91.9\%), colon (67.2\%),
   liver (69.2\%), and WBCs (82.3\%). On day 58, DNA adduct formation was
   inhibited in the colon (81.3-82.2\%) at both dietary 13C concentrations,
   and in liver (46.8\%) only in the animals fed 0.1\% 13C. When
   incorporated in the diet after exposure to dietary PhlP (0.04\% for 2
   weeks), 13C (0.1\%) had no effect on the rate of removal of PhlP-DNA
   adducts over the next 28 days. It is concluded that dietary 13C inhibits
   PhlP-DNA adduct formation in the female F344 rat but does not affect
   adduct removal. 13C may be a promising chemopreventive agent in
   PhlP-induced carcinogenesis in rats. (C) 1998 Wiley-Liss, Inc.}},
Publisher = {{WILEY-LISS}},
Address = {{DIV JOHN WILEY \& SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Schut, HAJ (Reprint Author), Med Coll Ohio, Dept Pathol, HE 202,3055 Arlington Ave, Toledo, OH 43614 USA.
   Med Coll Ohio, Dept Pathol, Toledo, OH 43614 USA.}},
ISSN = {{0730-2312}},
Keywords = {{food mutagens; indole-3-carbinol; chemoprevention; DNA adducts; PhIP;
   heterocyclic amines}},
Keywords-Plus = {{MUTAGEN 2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE IQ; CIGARETTE-SMOKE
   CONDENSATE; HUMAN-LIVER-MICROSOMES; POST-LABELING ANALYSIS; FOOD-BORNE
   CARCINOGEN; SPRAGUE-DAWLEY RATS; HETEROCYCLIC AMINES; MAMMARY-TUMORS;
   IN-VIVO; FISCHER-344 RATS}},
Research-Areas = {{Biochemistry \& Molecular Biology; Cell Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Cell Biology}},
Cited-References = {{BRADFIELD CA, 1984, FOOD CHEM TOXICOL, V22, P977, DOI 10.1016/0278-6915(84)90147-9.
   BRADLOW HL, 1994, CANCER EPIDEM BIOMAR, V3, P591.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   Christensen JG, 1996, CANCER RES, V56, P574.
   CUMMINGS DA, 1995, CARCINOGENESIS, V16, P2523, DOI 10.1093/carcin/16.10.2523.
   CUMMINGS DA, 1994, CARCINOGENESIS, V15, P2623, DOI 10.1093/carcin/15.11.2623.
   DOOLEY KL, 1992, CANCER LETT, V62, P205, DOI 10.1016/0304-3835(92)90097-F.
   ELBAYOUMY K, 1995, CARCINOGENESIS, V16, P431, DOI 10.1093/carcin/16.2.431.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   Friesen MD, 1996, CARCINOGENESIS, V17, P67, DOI 10.1093/carcin/17.1.67.
   FUKUTOME K, 1994, JPN J CANCER RES, V85, P113.
   GHOSHAL A, 1994, CARCINOGENESIS, V15, P2429, DOI 10.1093/carcin/15.11.2429.
   GHOSHAL A, 1995, CARCINOGENESIS, V16, P2725, DOI 10.1093/carcin/16.11.2725.
   GRUBBS CJ, 1995, ANTICANCER RES, V15, P709.
   Guo Dexin, 1995, Carcinogenesis (Oxford), V16, P2931, DOI 10.1093/carcin/16.12.2931.
   GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081.
   HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   Kim DJ, 1997, CARCINOGENESIS, V18, P377, DOI 10.1093/carcin/18.2.377.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   LIU JZ, 1992, CARCINOGENESIS, V13, P1847, DOI 10.1093/carcin/13.10.1847.
   LIU JZ, 1991, CANCER RES, V51, P4613.
   MANABE S, 1993, CARCINOGENESIS, V14, P899, DOI 10.1093/carcin/14.5.899.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   MCDANELL R, 1988, FOOD CHEM TOXICOL, V26, P59, DOI 10.1016/0278-6915(88)90042-7.
   MCMANUS ME, 1989, CARCINOGENESIS, V10, P357, DOI 10.1093/carcin/10.2.357.
   MORSE MA, 1990, CANCER RES, V50, P2613.
   PENCE BC, 1986, J NATL CANCER I, V77, P269.
   PFAU W, 1994, CARCINOGENESIS, V15, P877, DOI 10.1093/carcin/15.5.877.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   Schut HAJ, 1995, ANN NY ACAD SCI, V768, P210, DOI 10.1111/j.1749-6632.1995.tb12124.x.
   SCHUT HAJ, 1993, ANTICANCER RES, V13, P1517.
   Schut HAJ, 1997, MUTAT RES-FUND MOL M, V376, P185, DOI 10.1016/S0027-5107(97)00042-0.
   SHIMADA T, 1991, CANCER RES, V51, P5284.
   Shirai T, 1997, CANCER RES, V57, P195.
   SINGLETARY KW, 1991, CANCER LETT, V60, P169, DOI 10.1016/0304-3835(91)90224-6.
   SINHA R, 1995, CANCER RES, V55, P4516.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   SNYDERWINE EG, 1994, CARCINOGENESIS, V15, P2757, DOI 10.1093/carcin/15.12.2757.
   SPARNINS PL, 1982, J NATL CANCER I, V68, P493.
   STRESSER DM, 1994, DRUG METAB DISPOS, V22, P392.
   Taioli E, 1997, CANCER EPIDEM BIOMAR, V6, P517.
   TAKAHASHI N, 1995, FOOD CHEM TOXICOL, V33, P111, DOI 10.1016/0278-6915(94)00117-7.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TANAKA T, 1990, CARCINOGENESIS, V11, P1403, DOI 10.1093/carcin/11.8.1403.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P941, DOI 10.1093/carcin/11.6.941.
   VANG O, 1990, CARCINOGENESIS, V11, P1259, DOI 10.1093/carcin/11.8.1259.
   WATTENBERG LW, 1978, CANCER RES, V38, P1410.
   WORTELBOER HM, 1992, FOOD CHEM TOXICOL, V30, P589, DOI 10.1016/0278-6915(92)90193-O.
   Xu M, 1996, CARCINOGENESIS, V17, P1429, DOI 10.1093/carcin/17.7.1429.}},
Number-of-Cited-References = {{55}},
Times-Cited = {{2}},
Journal-ISO = {{J. Cell. Biochem.}},
Doc-Delivery-Number = {{ZM634}},
Wos-Id = {{ISI:000073559800009}},
}

@article{ ISI:A1996VJ55900022,
Author = {Davis, CD and Dacquel, EJ and Schut, HAJ and Thorgeirsson, SS and
   Snyderwine, EG},
Title = {{In vivo mutagenicity and DNA adduct levels of heterocyclic amines in
   Muta(TM) Mice and c-myc/lacZ double transgenic mice}},
Journal = {{MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS}},
Year = {{1996}},
Volume = {{356}},
Number = {{2}},
Pages = {{287-296}},
Month = {{SEP 23}},
Abstract = {{The cooked meat derived heterocyclic amines (HCAs)
   2-amino-3-methylimidazo{[}4,5-f]quinoline (IQ),
   2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline (MeIQx), and
   2-amino-9H-pyrido{[}2,3-b]indole (A alpha C) are established mutagens in
   the Salmonella assay and hepatocarcinogens in mice. The current study
   uses transgenic mice to examine hepatic HCA-DNA adduct formation and
   mutagenesis in vivo and the impact of hepatic overexpression of the
   c-myc oncogene on HCA-induced mutagenesis. C57B1/lacZ and c-myc/lacZ
   mice strains, produced by crossbreeding Muta(TM)Mice (carrying the lacZ
   mutation target gene) with either C57B1 control or c-myc transgenic
   mice, respectively, were treated with 10 daily doses of IQ, MeIQx or A
   alpha C (20 mu g/g, p.o.). Four weeks after dosing, the frequency of
   mutations in the lacZ gene in liver of either C57B1/lacZ or c-myc/lacZ
   mice was significantly higher in mice treated with any one of the three
   HCAs than in mice given vehicle only. In addition, all three HCAs formed
   hepatic DNA adducts, as measured by the P-32-postlabeling analysis 24 h
   after dosing. In both strains of mice, hepatic DNA adduct levels were
   2-3-fold higher with A alpha C than with either IQ or MeIQx, although
   the mutant frequencies in the lacZ gene were 30-40\% lower in mice dosed
   with A alpha C. These results suggest that A alpha C-DNA adducts may be
   less mutagenic in vivo than either IQ- or MeIQx-DNA adducts. The lacZ
   mutant frequencies observed with all three HCAs appeared to be
   influenced by c-myc transgene expression: after HCA treatment,
   transgenic mice carrying the c-myc gene showed a 30-40\% higher lacZ
   mutant frequency than mice not carrying this transgene. Notably, lacZ
   mutant frequencies were not different among C57B1/lacZ and c-myc/lacZ
   mice that received vehicle control. DNA adduct studies showed that the
   levels of IQ- and MeIQx-DNA adducts were 2-3-fold higher in c-myc/lacZ
   mice than in C57B1/lacZ mice; however, A alpha C-DNA adducts were not
   statistically different between the two strains. In addition, phase I
   metabolic activation of these HCAs, as assessed by hepatic microsomal
   mutagenic activation, was also similar in both strains of mice. These
   results support the notion that overexpression of the c-myc oncogene
   cooperates with the HCAs to enhance in vivo mutagenicity. Further
   studies are needed to assess the mechanisms of this cooperative effect.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{NCI,EXPT CARCINOGENESIS LAB,BETHESDA,MD 20892.
   MED COLL OHIO,DEPT PATHOL,TOLEDO,OH 43614.}},
DOI = {{10.1016/0027-5107(96)00074-7}},
ISSN = {{0027-5107}},
Keywords = {{2-amino-3-methylimidazo{[}4,5-f]quinoline;
   2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline;
   2-amino-9H-pyrido{[}2,3-b]indole; P-32-postlabeling; in vivo
   mutagenicity}},
Keywords-Plus = {{CYNOMOLGUS MONKEYS; ESCHERICHIA-COLI; IN-VIVO; LIVER; GENE; FOOD; RAT;
   2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE; ACTIVATION; IQ}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity; Toxicology}},
Cited-References = {{AMES BN, 1975, MUTAT RES, V31, P347, DOI 10.1016/0165-1161(75)90046-1.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P61, DOI 10.1093/carcin/14.1.61.
   DAVIS CD, 1993, CANCER LETT, V73, P95, DOI 10.1016/0304-3835(93)90250-D.
   DEAN SW, 1994, MUTAGENESIS, V9, P183, DOI 10.1093/mutage/9.3.183.
   DOLL R, 1981, J NATL CANCER I, V66, P1191.
   ENDO H, 1995, MOL CARCINOGEN, V14, P198, DOI 10.1002/mc.2940140309.
   ENDO H, 1994, CANCER RES, V54, P3745.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   GOSSEN JA, 1989, P NATL ACAD SCI USA, V86, P7971, DOI 10.1073/pnas.86.20.7971.
   GOSSEN JA, 1992, NUCLEIC ACIDS RES, V20, P3254, DOI 10.1093/nar/20.12.3254.
   GOSSEN JA, 1993, BIOTECHNIQUES, V14, P324.
   GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B.
   HARRIS CC, 1991, CANCER RES, V51, pS5023.
   KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958.
   LOWRY OH, 1951, J BIOL CHEM, V193, P265.
   MIENTJES EJ, 1994, TRANSGENIC RES, V3, P67, DOI 10.1007/BF01976029.
   MURAKAMI H, 1993, CANCER RES, V53, P1719.
   OGHAKI H, 1984, CRCINOGENESIS, V5, P921.
   OGHAKI H, 1984, CARCINOGENESIS, V5, P815.
   OGHAKI H, 1987, CARCINOGENESIS, V8, P665.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   SCHUT HA, 1978, MOL PHARMACOL, V14, P682.
   SCHUT HAJ, 1988, CANCER LETT, V41, P345, DOI 10.1016/0304-3835(88)90296-0.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   SUGIMURA T, 1982, CANCER, V49, P1970, DOI 10.1002/1097-0142(19820515)49:10<1970::AID-CNCR2820491005>3.0.CO;2-F.
   SUGIMURA T, 1985, MUTAT RES, V150, P33, DOI 10.1016/0027-5107(85)90098-3.
   TINWELL H, 1994, MUTAT RES, V307, P169, DOI 10.1016/0027-5107(94)90289-5.
   TURESKY RJ, 1995, CARCINOGENESIS, V16, P2275, DOI 10.1093/carcin/16.9.2275.
   USHIJIMA T, 1994, CARCINOGENESIS, V15, P2805, DOI 10.1093/carcin/15.12.2805.
   WATANABE M, 1993, CARCINOGENESIS, V14, P1149, DOI 10.1093/carcin/14.6.1149.
   YAMASHITA K, 1990, JPN J CANCER RES, V81, P470.
   {*}SAS I, 1989, SAS STAT US GUID VER, P891.}},
Number-of-Cited-References = {{32}},
Times-Cited = {{30}},
Journal-ISO = {{Mutat. Res.-Fundam. Mol. Mech. Mutagen.}},
Doc-Delivery-Number = {{VJ559}},
Wos-Id = {{ISI:A1996VJ55900022}},
}

@article{ ISI:A1996VG66600012,
Author = {Lynch, AM and Gooderham, NJ and Boobis, AR},
Title = {{Organ distinctive mutagenicity in muta(TM)mouse after short-term
   exposure to PhIP}},
Journal = {{MUTAGENESIS}},
Year = {{1996}},
Volume = {{11}},
Number = {{5}},
Pages = {{505-509}},
Month = {{SEP}},
Abstract = {{We have investigated PhIP-induced mutagenicity in various tissues
   (kidney, liver, large and small intestine) using a transgenic mouse
   model (Muta(TM)Mouse), In addition to tissue specific mutagenesis, we
   measured the binding of {[}C-14]PhIP to Muta(TM)Mouse mice blood
   proteins (haemoglobin and albumin), to obtain a quantitative estimate of
   carcinogen exposure and activation and their relationship to
   mutagenesis, Short-term (4 days) treatment of Muta(TM)Mouse mice with
   {[}C-14]PhIP by oral gavage resulted in the dose-dependent accumulation
   of radiolabelled material bound to haemoglobin and serum albumin, PhIP,
   at the highest dose (20 mg/kg), caused a 5.9-fold increase in the
   mutation frequency in the large intestine, a 4.2-fold increase in the
   mutation frequency in the small intestine but only a marginal 1.6-fold
   increase in the liver, However, there was no significant increase in
   mutations in the kidney at this dose. In contrast, there were no
   significant differences in any of these tissues between the vehicle
   control and the two lower doses (2.0 and 0.2 mg/kg respectively), These
   results are discussed in relationship to those previously reported for
   PhIP at the Dlb-1 locus.}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Lynch, AM (Reprint Author), ROYAL POSTGRAD MED SCH,DEPT CLIN PHARMACOL,DUCANE RD,LONDON W12 0NN,ENGLAND.}},
DOI = {{10.1093/mutage/11.5.505}},
ISSN = {{0267-8357}},
Keywords-Plus = {{TRANSGENIC MOUSE MODEL; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE
   PHIP; HETEROCYCLIC AMINES; METABOLIC-ACTIVATION; MUTATIONS INVIVO; GENE
   MUTATION; COOKED BEEF; DNA-ADDUCTS; IN-VITRO; CARCINOGENS}},
Research-Areas = {{Genetics \& Heredity; Toxicology}},
Web-of-Science-Categories  = {{Genetics \& Heredity; Toxicology}},
Cited-References = {{BLAKEY DH, 1995, MUTAGENESIS, V10, P145, DOI 10.1093/mutage/10.2.145.
   BOOBIS AR, 1995, P 23 INT S PRINC TAK, P134.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   BROOKS RA, 1994, CANCER RES, V54, P1665.
   BROOKS TM, 1995, MUTAGENESIS, V10, P149, DOI 10.1093/mutage/10.2.149.
   BUONARATI MH, 1992, CARCINOGENESIS, V13, P621, DOI 10.1093/carcin/13.4.621.
   BUONARATI MH, 1991, MUTAGENESIS, V6, P253, DOI 10.1093/mutage/6.4.253.
   CAROTHRS AM, 1994, CHEM RES TOXICOL, V7, P209, DOI 10.1021/tx00038a015.
   DEAN SW, 1994, MUTAGENESIS, V9, P183, DOI 10.1093/mutage/9.3.183.
   DRAGSTED LO, 1995, CARCINOGENESIS, V11, P2785.
   FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312.
   FELTON JS, 1995, P 23 INT S PRINC TAK, P50.
   Gerhardsson de Verdier M, 1991, Int J Cancer, V49, P520.
   GOSSEN JA, 1989, P NATL ACAD SCI USA, V86, P7971, DOI 10.1073/pnas.86.20.7971.
   HARRIS AL, 1991, NATURE, V350, P377, DOI 10.1038/350377a0.
   HOORN AJW, 1993, MUTAGENESIS, V8, P7, DOI 10.1093/mutage/8.1.7.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KADLUBAR FF, 1992, ENVIRON HEALTH PERSP, V98, P69, DOI 10.2307/3431249.
   KAKIUCHI H, 1995, P NATL ACAD SCI USA, V92, P910, DOI 10.1073/pnas.92.3.910.
   LIN DX, 1994, CANCER RES, V54, P4920.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   LYNCH AM, 1993, CARCINOGENESIS, V14, P191, DOI 10.1093/carcin/14.2.191.
   LYNCH AM, 1991, CARCINOGENESIS, V12, P1067, DOI 10.1093/carcin/12.6.1067.
   MIENTJES EJ, 1994, TRANSGENIC RES, V3, P67, DOI 10.1007/BF01976029.
   MORGENTHALER PML, 1995, CARCINOGENESIS, V16, P713, DOI 10.1093/carcin/16.4.713.
   MORRISON V, 1994, MUTAGENESIS, V9, P367, DOI 10.1093/mutage/9.4.367.
   MURRAY S, 1993, J CHROMATOGR-BIOMED, V616, P211, DOI 10.1016/0378-4347(93)80388-K.
   MYHR BC, 1991, ENVIRON MOL MUTAGEN, V18, P308, DOI 10.1002/em.2850180420.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0.
   REISTAD R, 1994, CARCINOGENESIS, V15, P2547, DOI 10.1093/carcin/15.11.2547.
   SKOG K, 1993, FOOD CHEM TOXICOL, V31, P655, DOI 10.1016/0278-6915(93)90049-5.
   SUGIMURA T, 1983, CANCER RES, V43, P2415.
   TAO KS, 1993, P NATL ACAD SCI USA, V90, P10681, DOI 10.1073/pnas.90.22.10681.
   TIMBRELL JA, 1992, PRINCIPLES BIOCH TOX, P73.
   TURESKY RJ, 1987, CARCINOGENESIS, V8, P1537, DOI 10.1093/carcin/8.10.1537.
   UMEMOTO A, 1992, CARCINOGENESIS, V13, P1025, DOI 10.1093/carcin/13.6.1025.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   YadollahiFarsani M, 1996, CARCINOGENESIS, V17, P617, DOI 10.1093/carcin/17.4.617.}},
Number-of-Cited-References = {{39}},
Times-Cited = {{17}},
Journal-ISO = {{Mutagenesis}},
Doc-Delivery-Number = {{VG666}},
Wos-Id = {{ISI:A1996VG66600012}},
}

@article{ ISI:A1996UQ08400018,
Author = {Nagao, M and Wakabayashi, K and Ushijima, T and Toyota, M and Totsuka, Y
   and Sugimura, T},
Title = {{Human exposure to carcinogenic heterocyclic amines and their mutational
   fingerprints in experimental animals}},
Journal = {{ENVIRONMENTAL HEALTH PERSPECTIVES}},
Year = {{1996}},
Volume = {{104}},
Number = {{3}},
Pages = {{497-501}},
Month = {{MAY}},
Note = {{2nd International Conference on Environmental Mutagens in Human
   Populations, PRAGUE, CZECH REPUBLIC, AUG 20-25, 1995}},
Organization = {{Prague Inst Adv Studies, Prague, Czech Republic; Reg Inst Hygiene Cent
   Bohemia, Prague, Czech Republic; Univ Tex Med Branch}},
Abstract = {{Heterocyclic amines (HCAs) are mutagens/carcinogens to which humans are
   exposed on almost a daily basis.
   2-Amino-1-melhyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) is the most
   abundant of the various carcinogenic HCAs (present at a level of 0.56 to
   69.2 ng/g of cooked meat or fish), with
   2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline (MeIQx) following it at
   0.64 to 6.44 ng/g. HCAs have been found in the urine of healthy people
   who consume ordinary diets, while patients receiving parenteral
   alimentation lack, for example, PhIP and MeIOx in their urine. Based on
   the concentrations of PhIP and MeIOx in urine samples from 10 healthy
   volunteers, daily intake of MeIQx in Japanese was calculated to be 0.3
   to 3.9 mu g/person, while that of PhIP was 0.005 to 0.3 mu g. The
   Japanese consume more MeIQx than Americans, whereas Japanese intake of
   PhIP was about one-third that of Americans. MeIQx-DNA adducts have also
   been detected in Japanese kidney, colon, and rectum samples using the
   P-32-postlabeling method followed by identification using
   high-performance liquid chromatography (HPLC) analysis; the levels were
   0.18, 1.8, and 1.4 per 10(9) nucleotides, respectively. In addition, we
   elucidated the mutational fingerprints of PhIP by analyzing Apc
   mutations in rat colon cancers induced by this carcinogen. Four of eight
   tumors had a total of five mutations in the Apc gene, four of which
   featured a guanine deletion from 5'-GTGGGAT-3' sequences. This specific
   mutation spectrum may be used as a fingerprint of PhIP in evaluating its
   risk potential for human colon carcinogenesis. Mutations were not found
   in similar 2-amino-3-methylimidazo{[}4,5-f]quinoline-induced colon
   lesions. Microsatellite instability was detected in both colon and
   mammary tumors induced by PhIP. The mechanisms involved in this
   development of microsatellite instability in PhIP-induced cancers remain
   to be elucidated.}},
Publisher = {{NATL INST ENVIRON HEALTH SCI}},
Address = {{PO BOX 12233, RES TRIANGLE PK, NC 27709}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Nagao, M (Reprint Author), NATL CANC CTR,RES INST,DIV CARCINOGENESIS,CHUO KU,1-1 TSUKIJI 5 CHOME,TOKYO 104,JAPAN.
   NATL CANC CTR,RES INST,DIV BIOCHEM,TOKYO 104,JAPAN.}},
DOI = {{10.2307/3432812}},
ISSN = {{0091-6765}},
Keywords = {{HCA; DNA adducts in human tissues; mutational fingerprint; Apc; MI}},
Keywords-Plus = {{2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; COOKED FOOD; DNA
   ADDUCTS; 2'-DEOXYGUANOSINE; COLON}},
Research-Areas = {{Environmental Sciences \& Ecology; Public, Environmental \& Occupational
   Health}},
Web-of-Science-Categories  = {{Environmental Sciences; Public, Environmental \& Occupational Health}},
Cited-References = {{CANZIAN F, 1994, CANCER RES, V54, P6315.
   DAMS E, 1995, CANCER RES, V55, P1547.
   FOILES PG, 1991, CHEM RES TOXICOL, V4, P364, DOI 10.1021/tx00021a017.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   Gerhardsson de Verdier M, 1991, Int J Cancer, V49, P520.
   GREENBLATT MS, 1994, CANCER RES, V54, P4855.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KAKIUCHI H, 1993, MOL CARCINOGEN, V8, P44, DOI 10.1002/mc.2940080110.
   KAKIUCHI H, 1995, P NATL ACAD SCI USA, V92, P910, DOI 10.1073/pnas.92.3.910.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LIN DX, 1994, ENVIRON HEALTH PERSP, V102, P11, DOI 10.2307/3432144.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   MAKINO H, 1994, JPN J CANCER RES, V85, P510.
   MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122.
   Nagao M., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P159.
   NAGAOKA H, 1992, JPN J CANCER RES, V83, P1025.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266.
   POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0.
   SKOG K, 1995, CARCINOGENESIS, V16, P861, DOI 10.1093/carcin/16.4.861.
   Steineck G, 1993, Eur J Cancer Prev, V2, P293, DOI 10.1097/00008469-199307000-00002.
   TADA A, 1994, CARCINOGENESIS, V15, P1275, DOI 10.1093/carcin/15.6.1275.
   TOTSUKA Y, IN PRESS CARCINOGENE.
   TOYOTA M, IN PRESS MAMMAL GENO.
   TURESKY RJ, 1994, CHEM RES TOXICOL, V7, P752, DOI 10.1021/tx00042a007.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   VANSCHOOTEN FJ, 1990, CARCINOGENESIS, V11, P1677, DOI 10.1093/carcin/11.9.1677.
   WAKABAYASHI K, 1995, HETEROCYCLIC AMINES, P39.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   Zhang X. B., 1995, Environmental and Molecular Mutagenesis, V25, P60.}},
Number-of-Cited-References = {{31}},
Times-Cited = {{33}},
Journal-ISO = {{Environ. Health Perspect.}},
Doc-Delivery-Number = {{UQ084}},
Wos-Id = {{ISI:A1996UQ08400018}},
}

@article{ ISI:A1996UG81400040,
Author = {Butcher, NJ and Minchin, RF and Kadlubar, FF and Ilett, KF},
Title = {{Uptake of the food-derived heterocyclic amine carcinogen
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine and its N-hydroxy
   metabolite into rat pancreatic acini and hepatocytes in vitro}},
Journal = {{CARCINOGENESIS}},
Year = {{1996}},
Volume = {{17}},
Number = {{4}},
Pages = {{889-892}},
Month = {{APR}},
Abstract = {{Since DNA adducts of 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine
   (PhIP) are formed at relatively high levels in the fat pancreas but not
   liver, we examined the uptake of PhIP and its N-hydroxy metabolite
   (N-OH-PhIP) into pancreatic acini and hepatocytes to determine if
   differential tissue uptake was a factor modulating the formation of
   PhIP-DNA adducts, Pn addition, since the precursors of PhIP formation
   are two amino acids and since various amino acid transporters have been
   identified in the pancreas, the possible involvement of these
   transporters in the uptake of PhIP and N-OH-PhIP was investigated. The
   uptake of both heterocyclic compounds into both tissue preparations was
   rapid, with maximal uptake occurring within 1-2 min, However, PhIP
   uptake into pancreatic acini was significantly (2-way ANOVA, P < 0.05)
   greater than uptake of N-OH-PhIP into pancreatic acini and the uptake of
   both PhIP and N-OH-PhIP into hepatocytes. Although uptake was rapid,
   efflux of both compounds from both tissue preparations was also rapid.
   However, the efflux rate constant (1.86 +/- 0.6/min, mean +/- SEM) for
   PhIP was significantly lower (Student's t-test, P < 0.05) than that for
   N-OH-PhIP (4.14 +/- 0.04/min) from pancreatic acini. This, combined with
   the increased uptake of PhIP into pancreatic acini, suggests that there
   is substantial but reversible binding of PhIP in the pancreas, The
   uptake of both PhIP and N-OH-PhIP into pancreatic acini acid hepatocytes
   was not affected by the presence of various amino acids in the
   incubation buffer, indicating that amino acid transporters are not
   involved in uptake of these compounds, Furthermore, uptake of both
   compounds did not appear to be dependent on metabolic energy supply. The
   above data, together with the high octanol:buffer partition coefficients
   (logP = 1.322 and 1.301 for PhIP and N-OH-PhIP respectively) suggest
   that both uptake and efflux of PhIP and N-OH-PhIP are consistent with a
   process of passive diffusion, The tissue binding characteristics for
   PhIP in the pancreas may create conditions whereby pancreatic cytochrome
   P450 1A1 can catalyse the formation of N-OH-PhIP. While N-OH-PhIP is not
   the ultimate reactive DNA binding species, it has been shown to directly
   bind to and form DNA adducts, Therefore, it is possible that the
   apparent selective accumulation of PhIP may contribute to the high level
   of PhIP-DNA adducts formed in the rat pancreas.}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{UNIV WESTERN AUSTRALIA,DEPT PHARMACOL,NEDLANDS,WA 6907,AUSTRALIA.
   NATL CTR TOXICOL RES,DIV MOLEC EPIDEMIOL,JEFFERSON,AR 72079.
   WESTERN AUSTRALIA INST PATHOL \& MED RES,CLIN PHARMACOL \& TOXICOL LAB,NEDLANDS,WA 6907,AUSTRALIA.}},
DOI = {{10.1093/carcin/17.4.889}},
ISSN = {{0143-3334}},
Keywords-Plus = {{EXOCRINE PANCREAS; PHIP; PHENYLALANINE; ACTIVATION; TRANSPORT; MUTAGENS;
   PROTEIN; CANCER; INFLUX; CELLS}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{AMSTERDA.A, 1974, J CELL BIOL, V63, P1037, DOI 10.1083/jcb.63.3.1037.
   Baron J, 1986, Adv Exp Med Biol, V197, P119.
   BIEGER W, 1977, CELL TISSUE RES, V180, P45, DOI 10.1007/BF00227029.
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   CHRISTEN.HN, 1969, J BIOL CHEM, V244, P1510.
   DURBEC JP, 1983, BRIT J CANCER, V47, P467.
   FAN LJ, 1995, CARCINOGENESIS, V16, P775, DOI 10.1093/carcin/16.4.775.
   FELTON JS, 1990, HDB EXPT PHARM, V94, P471.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   GRIVAS S, 1988, J CHEM RES, V5, P84.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KAWABATA TT, 1984, CANCER RES, V44, P215.
   MACK TM, 1986, J NATL CANCER I, V76, P49.
   MANN GE, 1986, BIOCHIM BIOPHYS ACTA, V858, P263, DOI 10.1016/0005-2736(86)90331-7.
   MARSCH GA, 1994, NUCLEIC ACIDS RES, V22, P5408, DOI 10.1093/nar/22.24.5408.
   MCMANUS ME, 1990, CANCER RES, V50, P3367.
   MILLER JA, 1970, CANCER RES, V30, P559.
   NORELL SE, 1986, AM J EPIDEMIOL, V124, P894.
   POTTER JD, 1990, CANC PREVENTION VITA.
   SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1.
   SHIOYA M, 1987, MUTAT RES, V191, P133, DOI 10.1016/0165-7992(87)90143-6.
   SWEIRY JH, 1991, BIOCHIM BIOPHYS ACTA, V1070, P135, DOI 10.1016/0005-2736(91)90155-2.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WEINSTEIN IB, 1981, J SUPRAMOL STR CELL, V17, P99, DOI 10.1002/jsscb.380170202.
   WESTRA JG, 1981, CARCINOGENESIS, V2, P355, DOI 10.1093/carcin/2.4.355.}},
Number-of-Cited-References = {{27}},
Times-Cited = {{10}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{UG814}},
Wos-Id = {{ISI:A1996UG81400040}},
}

@article{ ISI:A1996UC14800011,
Author = {Friesen, MD and Cummings, DA and Garren, L and Butler, R and Bartsch, H
   and Schut, HAJ},
Title = {{Validation in rats of two biomarkers of exposure to the food-borne
   carcinogen 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP):
   PhIP-DNA adducts and urinary PhIP}},
Journal = {{CARCINOGENESIS}},
Year = {{1996}},
Volume = {{17}},
Number = {{1}},
Pages = {{67-72}},
Month = {{JAN}},
Abstract = {{2-Amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP)-DNA adducts in
   white blood cells and tissues and unmetabolized PhIP in urine were
   validated as biomarkers of exposure in male Fischer-344 rats treated
   with daily PhIP doses ranging from 1 to 0.0001 mg/kg, At the end of the
   23 day treatment period all rats were killed and their blood and 10
   tissues were collected for isolation of DNA and analysis of PhIP-DNA
   adducts by P-32-postlabeling and alkaline hydrolysis with GC/MS,
   PhIP-DNA adducts could be detected only in animals receiving 1 or 0.1
   mg/kg/day, with highest adduct levels in the pancreas, heart and
   kidneys, There was a good correlation (r = 0.77, P < 0.005) between the
   two methods of analysis, with average adduct levels determined by
   P-32-postlabeling similar to 1.4 times higher than those determined by
   alkaline hydrolysis with GC/MS, PhIP-DNA adducts accumulated in most
   tissues, especially in the liver, kidneys, heart and pancreas, with
   lower levels in the white blood cells, small intestine, stomach, colon
   and cecum, Using GC/MS levels of unmetabolized PhIP were measurable in
   four weekly 24 h urine samples even at 0.0001 mg/kg/day, a dose
   comparable with reported human dietary exposure. A linear dose-response
   was obtained for excretion of unmetabolized PhIP across the range of
   doses, with similar to 1.8\% of the dose excreted daily, largely
   independent of the number of doses, No PhIP was detected in the urine of
   untreated rats, If it can be shown that a constant percentage of PhIP is
   excreted unchanged in human urine, irrespective of dose, as has been
   found with the rat, measurement of urinary PhIP could be used as an
   accurate measure of dietary exposure to this amine in man.}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Friesen, MD (Reprint Author), INT AGCY RES CANC,150 COURS ALBERT THOMAS,F-69372 LYON,FRANCE.
   MED COLL OHIO,DEPT PATHOL,TOLEDO,OH 43614.
   WOMENS \& CHILDRENS HOSP,ADELAIDE,SA,AUSTRALIA.}},
DOI = {{10.1093/carcin/17.1.67}},
ISSN = {{0143-3334}},
Keywords-Plus = {{MUTAGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE; HETEROCYCLIC
   AMINES; MASS-SPECTROMETRY; LIVER-MICROSOMES; COOKED FOOD; ACTIVATION;
   BEEF; IDENTIFICATION; RABBIT; ASSAY}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
ResearcherID-Numbers = {{Friesen, Marlin/D-7328-2012}},
Cited-References = {{BOOBIS AR, 1994, CANCER RES, V54, P89.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   CUMMINGS DA, 1995, CARCINOGENESIS, V16, P2523, DOI 10.1093/carcin/16.10.2523.
   CUMMINGS DA, 1994, CARCINOGENESIS, V15, P2623, DOI 10.1093/carcin/15.11.2623.
   DAVIS CD, 1994, TOXICOL APPL PHARM, V124, P201, DOI 10.1006/taap.1994.1024.
   FELTON JS, 1990, HDB EXPT PHARM, V94, P471.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   FRANDSEN H, 1990, MUTAGENESIS, V6, P93.
   FRIESEN MD, 1994, CHEM RES TOXICOL, V7, P733, DOI 10.1021/tx00042a004.
   FRIESEN MD, 1993, ENVIRON HEALTH PERSP, V99, P179, DOI 10.2307/3431476.
   Gerhardsson de Verdier M, 1991, Int J Cancer, V49, P520.
   GIOVANNUCCI E, 1994, CANCER RES, V54, P2390.
   GROSS GA, 1993, CARCINOGENESIS, V14, P2313, DOI 10.1093/carcin/14.11.2313.
   GROSS GA, 1990, CARCINOGENESIS, V11, P1597, DOI 10.1093/carcin/11.9.1597.
   GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081.
   HASEGAWA R, 1993, CARCINOGENESIS, V14, P2553, DOI 10.1093/carcin/14.12.2553.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   LU LJW, 1986, CANCER RES, V46, P3046.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   MCMANUS ME, 1989, CARCINOGENESIS, V10, P357, DOI 10.1093/carcin/10.2.357.
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215.
   MURRAY S, 1993, J CHROMATOGR-BIOMED, V616, P211, DOI 10.1016/0378-4347(93)80388-K.
   MURRAY S, 1989, CARCINOGENESIS, V10, P763, DOI 10.1093/carcin/10.4.763.
   OVERVIK E, 1991, MUTAT RES, V256, P37, DOI 10.1016/0921-8734(91)90031-6.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   SCHIFFMAN MH, 1990, PROG CLIN BIOL RES, V340, P205.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SHIOYA M, 1987, MUTAT RES, V191, P133, DOI 10.1016/0165-7992(87)90143-6.
   SNYDERWINE EG, 1994, CARCINOGENESIS, V15, P2757, DOI 10.1093/carcin/15.12.2757.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P2517, DOI 10.1093/carcin/14.12.2517.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   THORGEIRSSON UP, 1994, ENVIRON HEALTH PERSP, V102, P194, DOI 10.2307/3431611.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P941, DOI 10.1093/carcin/11.6.941.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P1073, DOI 10.1093/carcin/12.6.1073.
   WILD D, 1991, CARCINOGENESIS, V12, P1091, DOI 10.1093/carcin/12.6.1091.
   ZHAO K, 1994, CARCINOGENESIS, V15, P1285, DOI 10.1093/carcin/15.6.1285.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{22}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{UC148}},
Wos-Id = {{ISI:A1996UC14800011}},
}

@article{ ISI:A1996UC14800015,
Author = {Ochiai, M and Watanabe, M and Kushida, H and Wakabayashi, K and
   Sugimura, T and Nagao, M},
Title = {{DNA adduct formation, cell proliferation and aberrant crypt focus
   formation induced by PhIP in male and female rat colon with relevance to
   carcinogenesis}},
Journal = {{CARCINOGENESIS}},
Year = {{1996}},
Volume = {{17}},
Number = {{1}},
Pages = {{95-98}},
Month = {{JAN}},
Abstract = {{2-Amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) induces colon
   tumors in male, but not female, F344 rats, We investigated the
   mechanisms leading to this difference by measuring the level of PhIP-DNA
   adducts, the enhancement of cell proliferation and aberrant crypt focus
   (ACF) formation in colon mucosa. PhIP was administered in the diet at a
   level of 0.04\% to both male and female F344 rats for 1-8 weeks. The
   level of DNA adducts in the colon mucosa was measured using the
   P-32-postlabeling method. Four major PhIP-DNA adducts were detected in
   fairly constant proportions in all the animals examined, The level of
   PhIP-DNA adducts in male and female rats was the same, indicating no
   direct correlation between adduct levels and carcinogenesis, Labeling
   indices (LIs) were determined by measuring BrdU incorporation in rats
   after feeding with a PhIP diet for 4, 8 and 12 weeks, After 8 weeks
   administration the LI had increased 1.5-fold in the colon of the male
   rats, but no increase was observed in the female rats. ACF formation was
   examined after feeding with a PhIP diet for 14 weeks, The number of
   aberrant crypt foci was 6.6 +/- 1.5 per rat in males and 1.9 +/- 0.5 per
   rat in females. Thus differences in colon tumor development in male and
   female rats takes place at an early stage(s). Our results suggest that,
   in addition to DNA adduct formation, enhanced proliferation contributes
   to the formation of ACFs, which are premalignant lesions of the colon.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{NATL CANC CTR, RES INST, DIV CARCINOGENESIS, CHUO KU, TOKYO 104, JAPAN.}},
DOI = {{10.1093/carcin/17.1.95}},
ISSN = {{0143-3334}},
Keywords-Plus = {{HETEROCYCLIC AROMATIC-AMINES;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; LARGE BOWEL; FOOD;
   IDENTIFICATION; MUCOSA; 2'-DEOXYGUANOSINE; QUANTIFICATION; INDOMETHACIN;
   ACTIVATION}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{BELAND FA, 1992, PROG CLIN BIOL RES, V374, P79.
   BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   FUKUTOME K, 1994, JPN J CANCER RES, V85, P113.
   GROSS GA, 1990, CARCINOGENESIS, V11, P1597, DOI 10.1093/carcin/11.9.1597.
   HASEGAWA R, 1993, CARCINOGENESIS, V14, P2553, DOI 10.1093/carcin/14.12.2553.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1711, DOI 10.1093/carcin/15.8.1711.
   KADLUBAR FF, 1993, HETEROCYCLIC AMINES, P207.
   KITAZAWA T, 1994, MOL CARCINOGEN, V9, P67, DOI 10.1002/mc.2940090203.
   KUDO T, 1980, GANN, V71, P260.
   LIN DX, 1994, CANCER RES, V54, P4920.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MARNETT LJ, 1992, CANCER RES, V52, P5575.
   MCDONNELL TJ, 1993, MOL CARCINOGEN, V8, P209, DOI 10.1002/mc.2940080402.
   MURRAY S, 1993, J CHROMATOGR-BIOMED, V616, P211, DOI 10.1016/0378-4347(93)80388-K.
   NAGAOKA H, 1992, JPN J CANCER RES, V83, P1025.
   OHGAKI H, 1988, CANCER RES, V48, P5275.
   POLLARD M, 1980, CANCER TREAT REP, V64, P1323.
   PRETLOW TP, 1991, CANCER RES, V51, P1564.
   SATO Y, 1986, AM J PATHOL, V125, P431.
   SCHIEFERSTEIN GJ, 1985, EUR J CANCER CLIN ON, V21, P865, DOI 10.1016/0277-5379(85)90227-5.
   SIMANOWSKI UA, 1989, COLORECTAL CANC PATH, P225.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   SUNTER JP, 1981, BRIT J CANCER, V44, P35, DOI 10.1038/bjc.1981.144.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   THOMPSON LH, 1987, MUTAGENESIS, V2, P483, DOI 10.1093/mutage/2.6.483.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.}},
Number-of-Cited-References = {{31}},
Times-Cited = {{55}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{UC148}},
Wos-Id = {{ISI:A1996UC14800015}},
}

@article{ ISI:A1995TL66800007,
Author = {Herman, DG and Schut, HAJ and Davis, CD and Snyderwine, EG and Bailey,
   GS and Dashwood, RH},
Title = {{Protection by chlorophyllin and indole-3-carbinol against
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP)-induced DNA
   adducts and colonic aberrant crypts in the F344 rat}},
Journal = {{CARCINOGENESIS}},
Year = {{1995}},
Volume = {{16}},
Number = {{12}},
Pages = {{2931-2937}},
Month = {{DEC}},
Abstract = {{The most abundant heterocyclic amine in fried ground beef,
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP), induces colon
   carcinomas in the male F344 rat, The potential chemopreventive effects
   of two compounds, namely, the `interceptor molecule' chlorophyllin (CHL)
   and a modulator of carcinogen activation, indole-3-carbinol (I3C), were
   examined in a PhIP colon carcinogenesis model, During weeks 3 and 4 of a
   16-week study, F344 rats were given PhIP by oral gavage (50 mg/kg body
   weight, alternating days), Inhibitors were given either before and
   during PhIP exposure, after PhIP treatment, or continuously for 16
   weeks, Treatment of rats with 0.1\% CHL in the drinking water inhibited
   the formation of aberrant crypt foci (ACF) with greater than or equal to
   4 crypts/focus, from 1.4 +/- 0.9 in controls to 0.7 +/- 0.3 following
   post-initiation CHL treatment, and to 0.3 +/- 0.5 in rats given CHL
   continuously for 16 weeks (mean +/- SD; P < 0.05), Potent inhibition of
   PhIP-induced ACF occurred following initiation, postinitiation and
   continuous exposure to 0.1\% I3C in the diet, Using the initiation
   protocol, I3C completely inhibited the induction of ACF with greater
   than or equal to 4 crypts/focus, In a separate experiment, rats were
   given 0.1\% CHL in the drinking water or 0.1\% I3C in the diet for 4
   weeks, At the end of week 3, animals received 50 mg PhIP/kg body weight
   by single oral gavage and PhIP-DNA adducts were quantified in the colon
   and several other tissues by P-32-postlabeling analysis, In addition,
   the urine and feces were collected to study the effects of inhibitor
   treatment on PhIP metabolism and excretion, No significant protection
   against PhIP-DNA adduct formation was detected in the colon after CHL
   dosing, nor was a consistent pattern of CHL inhibition observed in
   several other tissues, In contrast, I3C shifted the time-course of
   adducts in all tissue; compared with controls, adducts were increased by
   I3C at 6 h but decreased at 24 h and 7 days following PhIP treatment,
   Analysis of urine metabolites revealed that I3C and CHL decreased the
   excretion of unmetabolized PhIP and 4'-hydroxy-much less than PhIP but
   increased the phase II detoxification products PhIP-4'-O-glucuronide and
   PhIP-4'-sulfate, In the feces, the elimination of unmetabolized PhIP was
   increased from 54,5\% in controls to similar to 67\% in CHL-treated rats
   and decreased to 28\% in rats given I3C (P < 0.05), These results
   support a protective role for CHL and I3C against PhIP-induced colon
   carcinogenesis through mechanisms which alter the uptake or metabolism
   of the carcinogen, and by suppression in the post-initiation phase.}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{UNIV HAWAII,DEPT ENVIRONM BIOCHEM,HONOLULU,HI 96822.
   MED COLL OHIO,DEPT PATHOL,TOLEDO,OH 43614.
   NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892.
   OREGON STATE UNIV,DEPT FOOD SCI \& TECHNOL,CORVALLIS,OR 97331.}},
ISSN = {{0143-3334}},
Keywords-Plus = {{2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE IQ; METABOLIC-ACTIVATION;
   FISCHER-344 RATS; CARCINOGENESIS; FOCI; BINDING; PHIP; AZOXYMETHANE;
   INHIBITION; MUTAGEN}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
ResearcherID-Numbers = {{Dashwood, Roderick/E-9090-2011}},
Cited-References = {{ARIMOTO S, 1993, MUTAT RES, V287, P293, DOI 10.1016/0027-5107(93)90022-8.
   BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1.
   BREINHOLT V, 1995, CANCER RES, V55, P57.
   BREINHOLT V, 1995, CHEM RES TOXICOL, V8, P506, DOI 10.1021/tx00046a004.
   BUONARATI MH, 1992, CARCINOGENESIS, V13, P1621.
   CUMMINGS DA, 1994, CARCINOGENESIS, V15, P2623, DOI 10.1093/carcin/15.11.2623.
   DASHWOOD R, 1992, ENVIRON MOL MUTAGEN, V20, P199, DOI 10.1002/em.2850200308.
   DASHWOOD R, 1993, ENVIRON MOL MUTAGEN, V22, P164, DOI 10.1002/em.2850220309.
   DASHWOOD R, 1992, CARCINOGENESIS, V13, P1121, DOI 10.1093/carcin/13.7.1121.
   DASHWOOD RH, 1991, CANCER RES, V51, P2362.
   DASHWOOD RH, 1994, CANCER RES, V54, P3617.
   DASHWOOD RH, 1989, CARCINOGENESIS, V10, P175, DOI 10.1093/carcin/10.1.175.
   DASHWOOD RH, 1992, CARCINOGENESIS, V13, P113, DOI 10.1093/carcin/13.1.113.
   DOLL R, 1981, J NATL CANCER I, V66, P1191.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   FONG AT, 1990, BIOCHEM PHARMACOL, V39, P19, DOI 10.1016/0006-2952(90)90643-Y.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   FUKUTOME K, 1994, JPN J CANCER RES, V85, P113.
   GUO D, 1994, CARCINOGENESIS, V15, P763, DOI 10.1093/carcin/15.4.763.
   GUO DX, 1995, CANCER LETT, V95, P161, DOI 10.1016/0304-3835(95)03882-W.
   HASEGAWA R, 1995, CARCINOGENESIS, V16, P2243, DOI 10.1093/carcin/16.9.2243.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   LAM LKT, 1991, CARCINOGENESIS, V12, P2311, DOI 10.1093/carcin/12.12.2311.
   LIN D, 1992, CHEM RES TOXICOL, V5, P687.
   MORSE MA, 1990, CANCER RES, V50, P2613.
   NEGISHI T, 1989, CARCINOGENESIS, V10, P145, DOI 10.1093/carcin/10.1.145.
   NELSON RL, 1992, ANTICANCER RES, V12, P737.
   PENCE BC, 1986, J NATL CANCER I, V77, P269.
   PRETLOW TP, 1992, CARCINOGENESIS, V13, P1509, DOI 10.1093/carcin/13.9.1509.
   PRETLOW TP, 1991, CANCER RES, V51, P1564.
   RAO CV, 1993, CANCER RES, V53, P4182.
   SATO M, 1986, CHEM PHARM BULL, V34, P2428.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SHIVAPURKAR N, 1992, CARCINOGENESIS, V13, P887, DOI 10.1093/carcin/13.5.887.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P2517, DOI 10.1093/carcin/14.12.2517.
   STOPERA SA, 1992, CARCINOGENESIS, V13, P573, DOI 10.1093/carcin/13.4.573.
   STOPERA SA, 1992, CARCINOGENESIS, V13, P1863, DOI 10.1093/carcin/13.10.1863.
   STRESSER DM, 1994, DRUG METAB DISPOS, V22, P392.
   TACHINO N, 1994, MUTAT RES, V308, P191, DOI 10.1016/0027-5107(94)90154-6.
   TACHINO N, 1995, MOL CARCINOGEN, V12, P187, DOI 10.1002/mc.2940120402.
   TAKAHASHI N, 1995, FOOD CHEM TOXICOL, V33, P111, DOI 10.1016/0278-6915(94)00117-7.
   TAKAHASHI S, 1991, JPN J CANCER RES, V82, P135.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TANAKA T, 1992, JPN J CANCER RES, V83, P835.
   TANAKA T, 1990, CARCINOGENESIS, V11, P1403, DOI 10.1093/carcin/11.8.1403.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   VIVONA AA, 1993, CARCINOGENESIS, V14, P1777, DOI 10.1093/carcin/14.9.1777.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P1073, DOI 10.1093/carcin/12.6.1073.
   WATTENBERG LW, 1992, CANCER RES, V52, pS2085.
   WEISBURGER JH, 1977, CANCER, V40, P2414, DOI 10.1002/1097-0142(197711)40:5+<2414::AID-CNCR2820400904>3.0.CO;2-D.
   WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404.
   WORTELBOER HM, 1992, FOOD CHEM TOXICOL, V30, P589, DOI 10.1016/0278-6915(92)90193-O.
   1990, 1989 CANCER FACTS FI.}},
Number-of-Cited-References = {{55}},
Times-Cited = {{0}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{TL668}},
Wos-Id = {{ISI:A1995TL66800007}},
}

@article{ ISI:A1995TG19400019,
Author = {GHOSHAL, A and DAVIS, CD and SCHUT, HAJ and SNYDERWINE, EG},
Title = {{POSSIBLE MECHANISMS FOR PHIP-DNA ADDUCT FORMATION IN THE MAMMARY-GLAND
   OF FEMALE SPRAGUE-DAWLEY RATS}},
Journal = {{CARCINOGENESIS}},
Year = {{1995}},
Volume = {{16}},
Number = {{11}},
Pages = {{2725-2731}},
Month = {{NOV}},
Abstract = {{2-Amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP), the most
   abundant heterocyclic amine in fried beef, is a mammary gland carcinogen
   in rats. Using the P-32-postlabeling method, PhIP-DNA adduct levels were
   measured in mammary epithelial cells isolated from female Sprague-Dawely
   rats given 10 daily doses of PhIP (75 mg/ kg, p.o.) according to a
   protocol previously shown to induce mammary gland cancer. At 24 h, 48 h,
   1 week and 5 weeks after the last dose of PhIP, PhIP-DNA adduct levels
   {[}relative adduct labeling (RAL) x 10(7), mean +/- SD] were 10.2 +/-
   0.7, 7.9 +/- 2.7, 2.2 +/- 0.6 and 0.9 +/- 0.03 respectively, When
   isolated rat mammary epithelial cells (from untreated rats) were
   incubated in vitro with N-hydroxy-PhIP (45 mu M, 1 h, 37 degrees C),
   PhIP-DNA adducts were detected in cell DNA (RAL = similar to 97 x
   10(7)); however, no adducts were detected in cells incubated with PhIP
   (200 mu M, 15 h, 37 degrees C), Incubating cells with pentachlorophenol,
   an inhibitor of acetyltransferase, or incubating cells at 0-4 degrees C,
   reduced N-hydroxy-PhIP adduct levels by 45 and 75\% respectively,
   indicating that formation of N-hydroxy-PhIP adducts was largely due to
   metabolic activation, Further studies showed that rat mammary gland
   microsomes had little capacity to N-hydroxylate PhIP, as assayed by the
   mutagenic activation of PhIP in the Ames Salmonella assay, In contrast,
   N-hydroxy-PhIP was metabolically activated by rat mammary gland
   O-acetyltransferase, as assayed by cytosol-catalyzed PhIP-DNA adduct
   formation to calf thymus DNA incubated in vitro with N-hydroxy-PhIP (2
   mu M) in the presence of acetyl CoA, Notably, mammary cytosolic
   O-acetyltransferase activation of N-hydroxy-PhIP was similar to 16- to
   17-fold higher than that observed with hepatic cytosol and at least
   two-fold higher than the mammary O-acetyltransferase activation of
   N-hydroxy-IQ or N-hydroxy-MeIQx, All three N-hydroxylamines were
   activated via cytosolic proline aminoacyl-tRNA synthetase and
   phosphorylase, although the activities of these enzymes were similar to
   100-fold lower than O-acetyltransferase. No mammary cytosolic
   sulfotransferase activation could be detected with any of the
   N-hydroxylamines, Our results are consistent with the notion that
   PhIP-DNA adduct formation and initiation of carcinogenesis in the rat
   mammary gland may be associated with N-hydroxylation of PhIP outside the
   mammary gland, transport of the N-hydroxylamine to the mammary gland and
   subsequent in situ O-acetyltransferase-catalyzed activation of
   N-hydroxy-PhIP.}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892.
   MED COLL OHIO,DEPT PATHOL,TOLEDO,OH 43614.}},
DOI = {{10.1093/carcin/16.11.2725}},
ISSN = {{0143-3334}},
Keywords-Plus = {{METABOLIC-ACTIVATION; HETEROCYCLIC AMINES;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; ENVIRONMENTAL
   FACTORS; COVALENT BINDING; AROMATIC-AMINES; COOKED FOOD; MUTAGENICITY;
   CARCINOGEN; CANCER}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{AESCHBACHER HU, 1991, MUTAT RES, V259, P235, DOI 10.1016/0165-1218(91)90120-B.
   ALLABEN WT, 1985, CARCINOGENESIS, V3, P233.
   AMES BN, 1975, MUTAT RES, V32, P347.
   ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411.
   BARTSCH H, 1973, BIOCHIM BIOPHYS ACTA, V304, P42, DOI 10.1016/0304-4165(73)90113-X.
   BUELL P, 1974, J NATL CANCER I, V51, P1479.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   CARROLL KK, 1975, CANCER RES, V35, P3374.
   DAVIS CD, 1994, CANCER LETT, V84, P67, DOI 10.1016/0304-3835(94)90359-X.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P2091, DOI 10.1093/carcin/14.10.2091.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P61, DOI 10.1093/carcin/14.1.61.
   DRASAR BS, 1973, BRIT J CANCER, V27, P167, DOI 10.1038/bjc.1973.20.
   ELBAYOUMY K, 1992, CHEM RES TOXICOL, V5, P585, DOI 10.1021/tx00029a001.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   FLAMMANG TJ, 1986, CARCINOGENESIS, V7, P919, DOI 10.1093/carcin/7.6.919.
   FLAMMANG TJ, 1985, MICROSOMES DRUG OXID, P190.
   FLINT DJ, 1982, MOL CELL ENDOCRINOL, V26, P281, DOI 10.1016/0303-7207(82)90117-4.
   GHOSHAL A, 1994, CARCINOGENESIS, V15, P2429, DOI 10.1093/carcin/15.11.2429.
   GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943.
   HASEGAWA R, 1993, CARCINOGENESIS, V14, P2553, DOI 10.1093/carcin/14.12.2553.
   HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007.
   IRVING CC, 1971, CANCER RES, V31, P387.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KADLUBAR FF, 1992, ENVIRON HEALTH PERSP, V98, P69, DOI 10.2307/3431249.
   KATO R, 1987, JPN J CANCER RES, V78, P297.
   KATO R, 1986, CRIT REV TOXICOL, V16, P307, DOI 10.3109/10408448609037466.
   KATO T, 1989, CARCINOGENESIS, V10, P601, DOI 10.1093/carcin/10.3.601.
   KING CM, 1979, CANCER RES, V39, P3369.
   KING CM, 1969, J BIOL CHEM, V244, P6209.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   LOWRY OH, 1951, J BIOL CHEM, V14, P682.
   MALEJKAGIGANTI D, 1983, ENVIRON HEALTH PERSP, V49, P175, DOI 10.2307/3429596.
   MALFATTI MA, 1994, CHEM RES TOXICOL, V7, P139, DOI 10.1021/tx00038a005.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   RUSSO J, 1983, AM J PATHOL, V113, P50.
   Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718.
   RUSSO J, 1990, LAB INVEST, V62, P244.
   SAITO K, 1985, ARCH BIOCHEM BIOPHYS, V239, P286, DOI 10.1016/0003-9861(85)90838-0.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SCHUT HAJ, 1978, MOL PHARMACOL, V14, P1145.
   SCHUT HAJ, 1988, CANCER LETT, V41, P345, DOI 10.1016/0304-3835(88)90296-0.
   SHIRAI T, 1981, CANCER RES, V41, P4346.
   SNYDERWINE EG, 1994, CANCER, V74, P1070, DOI 10.1002/1097-0142(19940801)74:3+<1070::AID-CNCR2820741515>3.0.CO;2-7.
   SNYDERWINE EG, 1987, CARCINOGENESIS, V8, P1017, DOI 10.1093/carcin/8.7.1017.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P411, DOI 10.1093/carcin/9.3.411.
   SNYDERWINE EG, 1992, CANCER RES, V52, pS2099.
   TANAKA T, 1985, JPN J CANCER RES, V76, P570.
   THOMPSON LH, 1987, MUTAGENESIS, V2, P483, DOI 10.1093/mutage/2.6.483.
   TURESKY RJ, 1993, CHEM RES TOXICOL, V3, P525.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   WEISBURGER JH, 1994, P SOC EXP BIOL MED, V205, P347.
   YAMAZOE Y, 1981, BIOCHEM BIOPH RES CO, V102, P432, DOI 10.1016/0006-291X(81)91539-4.
   YAMAZOE Y, 1985, CANCER RES, V45, P2495.
   1989, SAS USERS GUIDE STAT, P891.}},
Number-of-Cited-References = {{57}},
Times-Cited = {{51}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{TG194}},
Wos-Id = {{ISI:A1995TG19400019}},
}

@article{ ISI:A1995TT70700002,
Author = {Lynch, AM and Murray, S and Gooderham, NJ and Boobis, AR},
Title = {{Exposure to and activation of dietary heterocyclic amines in humans}},
Journal = {{CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY}},
Year = {{1995}},
Volume = {{21}},
Number = {{1-3}},
Pages = {{19-31}},
Month = {{NOV}},
Publisher = {{ELSEVIER SCIENCE INC}},
Address = {{655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Lynch, AM (Reprint Author), ROYAL POSTGRAD MED SCH,DEPT CLIN PHARMACOL,DUCANE RD,LONDON W12 0NN,ENGLAND.}},
DOI = {{10.1016/1040-8428(95)00178-6}},
ISSN = {{1040-8428}},
Keywords-Plus = {{FOOD-BORNE CARCINOGEN; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE
   PHIP; COOKED-FOOD; HUMAN-LIVER; MUTAGENIC ACTIVATION; MASS-SPECTROMETRY;
   ADDUCT FORMATION; AROMATIC-AMINES; DNA ADDUCTS;
   2-AMINO-3,8-DIMETHYLIMIDAZO<4,5-F>QUINOXALINE MEIQX}},
Research-Areas = {{Oncology; Hematology}},
Web-of-Science-Categories  = {{Oncology; Hematology}},
Cited-References = {{ADAMSON RH, 1990, CANC PREVENTION, P1.
   ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   ADAMSON RH, 1990, INT S PRINCESS TAKAM, V21, P289.
   AESCHBACHER HU, 1989, CARCINOGENESIS, V10, P429, DOI 10.1093/carcin/10.3.429.
   AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586.
   AOYAMA T, 1990, CANCER RES, V50, P2060.
   BAILEY E, 1988, ARCH TOXICOL, V62, P247, DOI 10.1007/BF00332482.
   BOOBIS AR, 1994, CANCER RES, V54, P89.
   BOOBIS AR, 1990, XENOBIOTICA, V20, P1139.
   BOOBIS AR, 1992, 23RD INT S PRINC TAK.
   BROOKS RA, 1994, CANCER RES, V54, P1665.
   BRYANT MS, 1987, CANCER RS, V8, P665.
   BUONARATI MH, 1991, MUTAGENESIS, V6, P253, DOI 10.1093/mutage/6.4.253.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   COMMONER B, 1978, SCIENCE, V201, P913, DOI 10.1126/science.567374.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P61, DOI 10.1093/carcin/14.1.61.
   DEVERDIER MG, 1991, INT J CANCER, V49, P520, DOI 10.1002/ijc.2910490408.
   DOLL R, 1992, CANCER RES, V52, pS2024.
   DOLL R, 1981, CAUSES CANC, P1226.
   DOOLEY KL, 1992, CANCER LETT, V62, P205, DOI 10.1016/0304-3835(92)90097-F.
   EDWARDS RJ, 1994, CARCINOGENESIS, V15, P829, DOI 10.1093/carcin/15.5.829.
   Farmer P B, 1989, Arch Toxicol Suppl, V13, P83.
   FEARON ER, 1990, SCIENCE, V247, P79.
   FELTON JS, 1990, PROG CLIN BIOL RES, V347, P19.
   FELTON JS, 1990, HDB EXPT PHARM, V94, P471.
   FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312.
   FELTON JS, 1992, CANCER RES, V52, pS2103.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   FENECH M, 1993, FOOD CHEM TOXICOL, V31, P337, DOI 10.1016/0278-6915(93)90188-5.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   TURTELTAUB KW, 1992, CANCER RES, V52, P4682.
   GARNER RC, 1991, HUMAN CARCINOGEN EXP.
   GOODERHAM NJ, 1987, BIOCHEM BIOPH RES CO, V148, P1377, DOI 10.1016/S0006-291X(87)80284-X.
   GRIVAS S, 1985, ACTA CHEM SCAND B, V39, P31, DOI 10.3891/acta.chem.scand.39b-0031.
   GROSE KR, 1986, J AGR FOOD CHEM, V34, P201, DOI 10.1021/jf00068a012.
   GROSS GA, 1993, CARCINOGENESIS, V14, P2313, DOI 10.1093/carcin/14.11.2313.
   GROSS GA, 1990, CARCINOGENESIS, V11, P1597, DOI 10.1093/carcin/11.9.1597.
   HARRIS CC, 1987, ENVIRON HEALTH PERSP, V75, P109, DOI 10.2307/3430584.
   HATCH FT, 1988, ENVIRON MOL MUTAGEN, V12, P1, DOI 10.1002/em.2860120602.
   HATCH FT, 1988, PHARMACOLOGY, P222.
   HAYATSU H, 1992, J CHROMATOGR, V597, P37, DOI 10.1016/0021-9673(92)80095-C.
   HENDERSON MM, 1992, CANCER RES S, V252, pS2030.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   HOWES AJ, 1986, FOOD CHEM TOXICOL, V24, P383, DOI 10.1016/0278-6915(86)90202-4.
   JAGERSTAD M, 1990, PROG CLIN BIOL RES, V347, P71.
   JAGERSTAD M, 1991, MUTAT RES, V259, P219, DOI 10.1016/0165-1218(91)90119-7.
   KADLUBAR FF, 1992, 23RD P INT S PRINC T.
   KADLUBAR FF, 1992, ENVIRON HEALTH PERSP, V98, P69, DOI 10.2307/3431249.
   KATO T, 1988, CARCINOGENESIS, V9, P71, DOI 10.1093/carcin/9.1.71.
   KNIZE MG, 1992, J CHROMATOGR, V624, P253, DOI 10.1016/0021-9673(92)85683-K.
   KNIZE MG, 1991, MUTAT RES, V260, P313, DOI 10.1016/0165-1218(91)90016-F.
   KOOREY DJ, 1993, J GASTROEN HEPATOL, V8, P174, DOI 10.1111/j.1440-1746.1993.tb01511.x.
   LEMARCHAND L, 1993, NOV JOINT AACR IARC.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   LYNCH AM, 1993, CARCINOGENESIS, V14, P191, DOI 10.1093/carcin/14.2.191.
   LYNCH AM, 1991, CARCINOGENESIS, V12, P1067, DOI 10.1093/carcin/12.6.1067.
   MANABE S, 1987, MUTAT RES, V179, P33, DOI 10.1016/0027-5107(87)90038-8.
   MANABE S, 1987, CANCER RES, V47, P6150.
   MANABE S, 1993, CARCINOGENESIS, V14, P899, DOI 10.1093/carcin/14.5.899.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   MINCHIN RF, 1992, BIOCHEM BIOPH RES CO, V185, P839, DOI 10.1016/0006-291X(92)91703-S.
   MURRAY BP, 1993, CARCINOGENESIS, V14, P585, DOI 10.1093/carcin/14.4.585.
   MURRAY BP, 1988, BIOCHEM SOC T, V12, P620.
   MURRAY S, 1988, CARCINOGENESIS, V9, P321, DOI 10.1093/carcin/9.2.321.
   MURRAY S, 1987, CARCINOGENESIS, V8, P937, DOI 10.1093/carcin/8.7.937.
   MURRAY S, 1993, J CHROMATOGR-BIOMED, V616, P211, DOI 10.1016/0378-4347(93)80388-K.
   MURRAY S, 1989, CARCINOGENESIS, V10, P763, DOI 10.1093/carcin/10.4.763.
   NAGAOKA H, 1992, JPN J CANCER RES, V83, P1025.
   NAKAMURA Y, 1992, TOHOKU J EXP MED, V168, P141, DOI 10.1620/tjem.168.141.
   NEUMANN HG, 1984, ARCH TOXICOL, V56, P1, DOI 10.1007/BF00316343.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   RICH KJ, 1992, TOXICOL LETT S, P304.
   RICH KJ, 1992, CARCINOGENESIS, V13, P2221, DOI 10.1093/carcin/13.12.2221.
   SCHIFFMAN MH, 1990, AM J EPIDEMIOL, V131, P376.
   SCHUT HAJ, 1991, CARCINOGENESIS, V12, P931, DOI 10.1093/carcin/12.5.931.
   SESARDIC D, 1990, CARCINOGENESIS, V11, P1183, DOI 10.1093/carcin/11.7.1183.
   SESARDIC D, 1990, BRIT J CLIN PHARMACO, V29, P651.
   SESARDIC D, 1990, BIOCHEM PHARMACOL, V39, P489, DOI 10.1016/0006-2952(90)90055-P.
   SHIMADA T, 1989, CANCER RES, V49, P3218.
   SJODIN P, 1989, CARCINOGENESIS, V10, P1269, DOI 10.1093/carcin/10.7.1269.
   SKOG K, 1992, MUTAT RES, V268, P191, DOI 10.1016/0027-5107(92)90224-P.
   SKOG K, 1993, FOOD CHEM TOXICOL, V31, P655, DOI 10.1016/0278-6915(93)90049-5.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1739, DOI 10.1093/carcin/9.10.1739.
   STILLWELL W G, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P158.
   STILLWELL WG, 1987, BIOMED ENVIRON MASS, V14, P221, DOI 10.1002/bms.1200140505.
   SUGIMURA T, 1983, CANCER RES, V43, P2415.
   SUGIMURA T, 1991, ADV EXP MED BIOL, V283, P569.
   SUGIMURA T, 1988, CHEM INDUCTION CANC, P681.
   TANNENBAUM SR, 1986, MECHANISMS DNA DAMAG, V38, P473.
   TARRUS E, 1987, BRIT J CLIN PHARMACO, V23, P9.
   THOMPSON LH, 1987, MUTAGENESIS, V2, P483, DOI 10.1093/mutage/2.6.483.
   TURESKY RJ, 1988, CARCINOGENESIS, V9, P1043, DOI 10.1093/carcin/9.6.1043.
   TURESKY RJ, 1989, CARCINOGENESIS, V10, P151, DOI 10.1093/carcin/10.1.151.
   TURESKY RJ, 1987, CARCINOGENESIS, V8, P1537, DOI 10.1093/carcin/8.10.1537.
   TURESKY RJ, 1993, ENVIRON HEALTH PERSP, V99, P123, DOI 10.2307/3431467.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1847, DOI 10.1093/carcin/12.10.1847.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005.
   Turteltaub K. W., 1993, IARC SCI PUBL, V124, P293.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P43, DOI 10.1093/carcin/11.1.43.
   TURTELTAUB KW, 1989, FOOD CHEM TOXICOL, V27, P667, DOI 10.1016/0278-6915(89)90121-X.
   UMEMOTO A, 1992, CARCINOGENESIS, V13, P1025, DOI 10.1093/carcin/13.6.1025.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   VANDERLAAN M, 1988, CARCINOGENESIS, V9, P153, DOI 10.1093/carcin/9.1.153.
   VANRENSBURG SJ, 1985, BRIT J CANCER, V51, P713, DOI 10.1038/bjc.1985.107.
   WAKABAYASHI K, 1991, GENETIC TOXICOLOGY, P303.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WALLIN H, 1992, PHARMACOL TOXICOL, V70, P220.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P2291, DOI 10.1093/carcin/12.12.2291.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P1073, DOI 10.1093/carcin/12.6.1073.
   WATTENBERG LW, 1992, CANCER RES, V52, pS2085.
   WILLIAMS AC, 1993, SEMIN CANCER BIOL, V4, P153.
   Winsten J. A., 1977, ORIGINS HUMAN CANC, P1561.
   WINTON DJ, 1990, CANCER RES, V50, P7992.
   WOHLLEB JC, 1990, INT J CANCER, V46, P22, DOI 10.1002/ijc.2910460107.
   YANAGAWA Y, 1994, CANCER RES, V54, P3442.
   YANAGISAWA H, 1986, BIOCHEM BIOPH RES CO, V138, P1084, DOI 10.1016/S0006-291X(86)80393-X.
   YEH FS, 1989, CANCER RES, V49, P2506.
   YOSHIMI N, 1988, ENVIRON MOL MUTAGEN, V12, P53, DOI 10.1002/em.2860120108.
   ZHAO K, 1994, CARCINOGENESIS, V15, P1285, DOI 10.1093/carcin/15.6.1285.
   1989, MONOGRAPH EUROPEAN C, V13.}},
Number-of-Cited-References = {{123}},
Times-Cited = {{10}},
Journal-ISO = {{Crit. Rev. Oncol./Hematol.}},
Doc-Delivery-Number = {{TT707}},
Wos-Id = {{ISI:A1995TT70700002}},
}

@article{ ISI:A1995RX11400026,
Author = {HASEGAWA, R and KIMURA, J and YAONO, M and TAKAHASHI, S and KATO, T and
   FUTAKUCHI, M and FUKUTAKE, M and FUKUTOME, K and WAKABAYASHI, K and
   SUGIMURA, T and ITO, N and SHIRAI, T},
Title = {{INCREASED RISK OF MAMMARY-CARCINOMA DEVELOPMENT FOLLOWING TRANSPLACENTAL
   AND TRANS-BREAST MILK EXPOSURE TO A FOOD-DERIVED CARCINOGEN,
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO{[}4,5-B]PYRIDINE (PHIP), IN
   SPRAGUE-DAWLEY RATS}},
Journal = {{CANCER RESEARCH}},
Year = {{1995}},
Volume = {{55}},
Number = {{19}},
Pages = {{4333-4338}},
Month = {{OCT 1}},
Abstract = {{Effects of transplacental and trans-breast milk exposure to a
   food-derived mammary and colon carcinogen,
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP), were
   investigated in rats, Female Sprague-Dawley rats were administered PhIP
   in the diet (100 ppm) for 4 weeks before mating with nontreated males
   and also during gestation and lactation, As controls, additional females
   were maintained on the basal diet without PhIP and mated as with the
   treated animals, The offspring of both groups were subdivided for each
   sex at weaning into three dietary groups receiving 100, 25, and 0 ppm
   and were killed at 47 weeks of age. Effects of the transplacental and
   neonatal exposure to PhIP on mammary carcinogenesis were most evident in
   females administered 25 ppm PhIP after weaning; the incidence and
   multiplicity of adenocarcinomas in offspring from the PhIP fed dams
   (42.9\%, 0.62/rat) was significantly higher than the value for offspring
   from nontreated dams (4.8\%, 0.05/rat), Furthermore, in the basal diet
   groups, the incidence of adenocarcinomas in females was higher, albeit
   not significantly, in offspring of the PhIP-treated than the nontreated
   dams (16.7\%, 0.22/rat as compared with 3.3\%, 0.07/rat). Although the
   highest incidence of mammary adenocarcinomas was found in the female
   progeny given 100 ppm PhIP from PhIP-treated dams (70.0\%, 1.55/rat),
   this was only slightly higher than the 61.9\% and 0.90/rat of the same
   dose group from the nontreated dams. In males, no apparent effects of
   transplacental and neonatal exposures were evident. In a separate
   experiment, excretion of PhIP into breast milk and transfer of PhIP to
   fetuses and neonates with resultant hepatic PhIP-DNA adduct formation
   were demonstrated. Thus, maternal exposure to this food-derived
   carcinogen may be a critical risk factor for generation of mammary
   carcinomas.}},
Publisher = {{AMER ASSOC CANCER RESEARCH}},
Address = {{PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W.,
   PHILADELPHIA, PA 19106}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{HASEGAWA, R (Reprint Author), NAGOYA CITY UNIV,SCH MED,DEPT PATHOL 1,MIZUHO KU,NAGOYA,AICHI 467,JAPAN.
   NATL CANC CTR,RES INST,DIV BIOCHEM,CHUO KU,TOKYO 104,JAPAN.}},
ISSN = {{0008-5472}},
Keywords-Plus = {{5 HETEROCYCLIC AMINES; COOKED FOOD; CALORIC RESTRICTION; FOCI
   DEVELOPMENT; DNA-ADDUCTS; CANCER; COLON; IDENTIFICATION; ENHANCEMENT;
   LIVER}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{BRITTEBO EB, 1994, FOOD CHEM TOXICOL, V32, P717.
   DAVIS CD, 1994, CANCER LETT, V84, P67, DOI 10.1016/0304-3835(94)90359-X.
   DAVIS CD, 1994, J NATL CANCER I, V86, P1065, DOI 10.1093/jnci/86.14.1065.
   DEVERDIER MG, 1991, INT J CANCER, V49, P520, DOI 10.1002/ijc.2910490408.
   DOLL R, 1988, J CANCER RES CLIN, V114, P447, DOI 10.1007/BF00391491.
   DOLL R, 1981, J NATL CANCER I, V66, P1191.
   DOOLEY KL, 1992, CANCER LETT, V62, P205, DOI 10.1016/0304-3835(92)90097-F.
   DUNNICK JK, 1995, CARCINOGENESIS, V16, P173, DOI 10.1093/carcin/16.2.173.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   FUKUTOME K, 1994, JPN J CANCER RES, V85, P113.
   GHOSHAL A, 1994, CARCINOGENESIS, V15, P2429, DOI 10.1093/carcin/15.11.2429.
   GHOSHAL A, 1993, CARCINOGENESIS, V14, P2199, DOI 10.1093/carcin/14.11.2199.
   GROSS GA, 1993, CARCINOGENESIS, V14, P2313, DOI 10.1093/carcin/14.11.2313.
   HAGIWARA A, 1993, 52ND P JPN CANC ASS, P77.
   HASEGAWA R, 1994, CARCINOGENESIS, V15, P1037, DOI 10.1093/carcin/15.5.1037.
   HASEGAWA R, 1995, IN PRESS CARCINOGENE.
   HASEGAWA R, 1991, JPN J CANCER RES, V82, P1378.
   HASEGAWA R, 1992, CARCINOGENESIS, V13, P1427, DOI 10.1093/carcin/13.8.1427.
   HASEGAWA R, 1994, CARCINOGENESIS, V15, P2567, DOI 10.1093/carcin/15.11.2567.
   HASEGAWA R, 1993, CARCINOGENESIS, V14, P2553, DOI 10.1093/carcin/14.12.2553.
   HIROSE M, 1995, CARCINOGENESIS, V16, P217, DOI 10.1093/carcin/16.2.217.
   ITO N, 1991, CARCINOGENESIS, V12, P767, DOI 10.1093/carcin/12.5.767.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KHAN N, 1994, CARCINOGENESIS, V15, P2645, DOI 10.1093/carcin/15.11.2645.
   KLURFELD DM, 1987, CANCER RES, V47, P2759.
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   ROSE DP, 1986, CANCER, V58, P2363, DOI 10.1002/1097-0142(19861201)58:11<2363::AID-CNCR2820581102>3.0.CO;2-\#.
   RUGGERI BA, 1989, CANCER RES, V49, P4130.
   Russo J, 1990, IARC SCI PUBL, V99, P47.
   SCHIFFMAN MH, 1990, AM J EPIDEMIOL, V131, P376.
   SUGIMURA T, 1983, CANCER RES, V43, P2415.
   SUGIMURA T, 1992, SCIENCE, V258, P603, DOI 10.1126/science.1411570.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   WEISBURGER JH, 1993, CANCER RES, V53, P2422.
   ZIEGLER RG, 1993, J NATL CANCER I, V85, P1819, DOI 10.1093/jnci/85.22.1819.}},
Number-of-Cited-References = {{39}},
Times-Cited = {{34}},
Journal-ISO = {{Cancer Res.}},
Doc-Delivery-Number = {{RX114}},
Wos-Id = {{ISI:A1995RX11400026}},
}

@inproceedings{ ISI:A1995BE92E00021,
Author = {Schut, HAJ and Dashwood, RH},
Editor = {{Bradlow, HL and Osborne, MP and Veronesi, U}},
Title = {{Inhibition of DNA adduct formation of
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) by dietary
   indole-3-carbinol (I3C) in the mammary gland, colon, and liver of the
   female F-344 rat}},
Booktitle = {{CANCER PREVENTION: FROM THE LABORATORY TO THE CLINIC: IMPLICATIONS OF
   GENETIC, MOLECULAR, AND PREVENTIVE RESEARCH}},
Series = {{ANNALS OF THE NEW YORK ACADEMY OF SCIENCES}},
Year = {{1995}},
Volume = {{768}},
Pages = {{210-214}},
Note = {{International Conference on Cancer Prevention - From the Laboratory to
   the Clinic: Implications to Genetic, Molecular, and Preventive Research,
   NEW YORK, NY, SEP 22-24, 1994}},
Organization = {{Strang Canc Prevent Ctr; European Sch Oncol; Cornell Univ Med Coll}},
Publisher = {{NEW YORK ACAD SCIENCES}},
Address = {{2 EAST 63RD ST, NEW YORK, NY 10021}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Schut, HAJ (Reprint Author), MED COLL OHIO,DEPT PATHOL,TOLEDO,OH 43614, USA.
   UNIV HAWAII,DEPT ENVIRONM BIOCHEM,HONOLULU,HI 96822.}},
DOI = {{10.1111/j.1749-6632.1995.tb12124.x}},
ISSN = {{0077-8923}},
ISBN = {{0-89766-947-9}},
Keywords-Plus = {{MUTAGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE; HETEROCYCLIC
   AMINES; COOKED FOOD; ACTIVATION; MONKEYS; MEIQX; IQ}},
Research-Areas = {{Oncology; Science \& Technology - Other Topics}},
Web-of-Science-Categories  = {{Oncology; Multidisciplinary Sciences}},
ResearcherID-Numbers = {{Dashwood, Roderick/E-9090-2011}},
Cited-References = {{BRADLOW HL, 1994, CANCER EPIDEM BIOMAR, V3, P591.
   BRADLOW HL, 1991, CARCINOGENESIS, V12, P1571, DOI 10.1093/carcin/12.9.1571.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   CUMMINGS DA, 1994, CARCINOGENESIS, V15, P2623, DOI 10.1093/carcin/15.11.2623.
   DASHWOOD RH, 1994, CANCER RES, V54, P3617.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P2091, DOI 10.1093/carcin/14.10.2091.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FONG AT, 1990, BIOCHEM PHARMACOL, V39, P19, DOI 10.1016/0006-2952(90)90643-Y.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   MCDANELL R, 1988, FOOD CHEM TOXICOL, V26, P59, DOI 10.1016/0278-6915(88)90042-7.
   MCMANUS ME, 1989, CARCINOGENESIS, V10, P357, DOI 10.1093/carcin/10.2.357.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   WATTENBERG LW, 1978, CANCER RES, V38, P1410.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{12}},
Journal-ISO = {{Ann.NY Acad.Sci.}},
Doc-Delivery-Number = {{BE92E}},
Wos-Id = {{ISI:A1995BE92E00021}},
}

@article{ ISI:A1994PW57000007,
Author = {LANG, NP and BUTLER, MA and MASSENGILL, J and LAWSON, M and STOTTS, RC
   and HAUERJENSEN, M and KADLUBAR, FF},
Title = {{RAPID METABOLIC PHENOTYPES FOR ACETYLTRANSFERASE AND CYTOCHROME P4501A2
   AND PUTATIVE EXPOSURE TO FOOD-BORNE HETEROCYCLIC AMINES INCREASE THE
   RISK FOR COLORECTAL-CANCER OR POLYPS}},
Journal = {{CANCER EPIDEMIOLOGY BIOMARKERS \& PREVENTION}},
Year = {{1994}},
Volume = {{3}},
Number = {{8}},
Pages = {{675-682}},
Month = {{DEC}},
Abstract = {{The metabolic activation of food-borne heterocyclic amines to colon
   carcinogens in humans is hypothesized to occur via N-oxidation followed
   by O-acetylation to form the N-acetoxy arylamine that binds to DNA to
   give carcinogen-DNA adducts. These steps are catalyzed by hepatic
   cytochrome P4501A2 (CYP1A2) and acetyltransferase-2 (NAT-2),
   respectively, which are known to be polymorphic in humans. On the basis
   of this proposed metabolic activation pathway, patients at greatest risk
   to develop colorectal cancer or nonfamilial polyps should be those who
   possess both the rapid NAT-2 and rapid CYP1A2 phenotypes and are exposed
   to high dietary levels of carcinogenic heterocyclic amines. Using a
   method that involves caffeine administration and high pressure liquid
   chromatographic analysis of urinary metabolites, we have determined the
   CYP1A2 and NAT-2 phenotypes of 205 controls and 75 cancer/polyp cases.
   Exposure information was obtained using a dietary and health habits
   questionnaire.
   Both the rapid CYP1A2 and rapid NAT2 phenotypes were each slightly more
   prevalent in cases versus controls (57\% and 52\% verses 41\% and 45\%,
   respectively). However, the combined rapid CYP1A2-rapid NAT-2 phenotype
   was found in 35\% of cases and only 16\% of the controls, giving an odds
   ratio of 2.79 (P = 0.002). Univariate analysis of the questionnaire
   indicated that age, rapid-rapid phenotype, and consumption of well done
   red meat were associated with increased risk of colorectal neoplasia.
   Furthermore, a logistic regression model that included age (as a
   continuous variable), consumption of well done red meat, and rapid-rapid
   phenotype as independent covariates gave odds ratios of 1.08, 2.08, and
   2.91, respectively. The odds ratios for cooked meat preference and
   phenotype combinations ranged from 1.00 for rare/medium preference with
   slow/slow phenotype to 6.45 for well done preference with rapid-rapid
   NAT-2/CYP1A2 phenotype. This study indicates that metabolic phenotype
   combined with a measure of exposure to food-borne heterocyclic amine
   carcinogens are important risk factors in human colorectal cancer.}},
Publisher = {{AMER ASSOC CANCER RESEARCH}},
Address = {{PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W.,
   PHILADELPHIA, PA 19106}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{LANG, NP (Reprint Author), UNIV ARKANSAS MED SCI HOSP,ARKANSAS CANC RES CTR,DEPT SURG,4301 W MARKHAM,SLOT 725,LITTLE ROCK,AR 72205, USA.
   JL MCCLELLAN VET AFFAIRS MED CTR,LITTLE ROCK,AR 72205.
   NATL CTR TOXICOL RES,JEFFERSON,AR 72079.
   UNIV ARKANSAS MED SCI HOSP,COLL NURSING,LITTLE ROCK,AR 72205.}},
ISSN = {{1055-9965}},
Keywords-Plus = {{COLON CANCER; THEOPHYLLINE METABOLISM; CAFFEINE; EPIDEMIOLOGY;
   CARCINOMA; CYP1A2; FIBER}},
Research-Areas = {{Oncology; Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Oncology; Public, Environmental \& Occupational Health}},
Cited-References = {{BARSOUM GH, 1992, BRIT J SURG, V79, P581, DOI 10.1002/bjs.1800790639.
   BELL DA, 1993, CARCINOGENESIS, V14, P1689, DOI 10.1093/carcin/14.8.1689.
   BLOCK G, 1986, AM J EPIDEMIOL, V124, P543.
   BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7.
   BURKITT DP, 1969, LANCET, V2, P1229.
   BUTLER MA, 1992, PHARMACOGENETICS, V2, P116, DOI 10.1097/00008571-199206000-00003.
   CAMPBELL ME, 1987, CLIN PHARMACOL THER, V42, P157.
   CORMAN ML, 1993, COLON RECTAL SURG, P436.
   CORMAN ML, 1979, DIS COLON RECTUM, V22, P477, DOI 10.1007/BF02586935.
   CUMMINGS JH, 1983, LANCET, V1, P1206.
   FELTON JS, 1992, CANCER RES, V52, pS2103.
   Gerhardsson de Verdier M, 1991, Int J Cancer, V49, P520.
   GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P192, DOI 10.1093/jnci/86.3.192.
   GROSS GA, 1993, CARCINOGENESIS, V14, P2313, DOI 10.1093/carcin/14.11.2313.
   HAENSZEL W, 1973, J NATL CANCER I, V51, P1765.
   Hosmer Jr DW, 1989, APPL LOGISTIC REGRES, P307.
   ILETT KF, 1994, BIOCHEM PHARMACOL, V47, P914, DOI 10.1016/0006-2952(94)90493-6.
   ILETT KF, 1987, CANCER RES, V47, P1466.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KADLUBAR FF, 1994, HETEROCYCLIC AMINES.
   KADLUBAR FF, 1990, MUTATION ENV B, P107.
   KADLUBAR FF, 1994, DRUG METAB REV, V26, P37, DOI 10.3109/03602539409029783.
   KALOW W, 1991, CLIN PHARMACOL THER, V50, P508.
   LANG NP, 1986, ARCH SURG-CHICAGO, V121, P1259, DOI 10.1001/archsurg.121.11.1259.
   LIN DX, 1994, CANCER RES, V54, P4920.
   McMichael A J, 1985, Natl Cancer Inst Monogr, V69, P223.
   MCMICHAEL AJ, 1980, J NATL CANCER I, V65, P1201.
   MILLER CA, 1985, J CLIN INVEST, V75, P1415, DOI 10.1172/JCI111843.
   NAKAJIMA M, 1994, BIOMARKERS PREV, V3, P413.
   PEINADO MA, 1993, INT J ONCOL, V2, P123.
   POTTER JD, 1986, J NATL CANCER I, V76, P557.
   POTTER JD, 1992, JAMA-J AM MED ASSOC, V268, P1573, DOI 10.1001/jama.268.12.1573.
   SCHIFFMAN MH, 1990, AM J EPIDEMIOL, V131, P376.
   SHAHIDI NT, 1968, ANN NY ACAD SCI, V151, P822, DOI 10.1111/j.1749-6632.1968.tb48266.x.
   STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672.
   STEPHEN AM, 1980, NATURE, V284, P283, DOI 10.1038/284283a0.
   SUGIMURA T, 1983, CANCER RES, V43, P2415.
   SUGIMURA T, 1985, MUTAT RES, V150, P33, DOI 10.1016/0027-5107(85)90098-3.
   TANG BK, 1994, PHARMACOGENETICS, V4, P117, DOI 10.1097/00008571-199406000-00002.
   TANG BK, 1983, DRUG METAB DISPOS, V11, P218.
   TANNENBAUM SR, 1994, IN PRESS ENV HLTH PE.
   TEUNISSEN MWE, 1985, J PHARMACOL EXP THER, V233, P770.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   WEBER WW, 1985, PHARMACOL REV, V37, P25.
   WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404.
   WILLETT WC, 1990, NUTRITIONAL EPIDEMIO, P3.
   WOHLLEB JC, 1990, INT J CANCER, V46, P22, DOI 10.1002/ijc.2910460107.
   ZAHM SH, 1991, AM J PUBLIC HEALTH, V81, P846, DOI 10.2105/AJPH.81.7.846.}},
Number-of-Cited-References = {{48}},
Times-Cited = {{350}},
Journal-ISO = {{Cancer Epidemiol. Biomarkers Prev.}},
Doc-Delivery-Number = {{PW570}},
Wos-Id = {{ISI:A1994PW57000007}},
}

@article{ ISI:A1994PZ53900012,
Author = {SNYDERWINE, EG and SCHUT, HAJ and SUGIMURA, T and NAGAO, M and ADAMSON,
   RH},
Title = {{DNA ADDUCT LEVELS OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO{[}4,5-B]PYRIDINE
   (PHIP) IN TISSUES OF CYNOMOLGUS MONKEYS AFTER SINGLE OR MULTIPLE DOSING}},
Journal = {{CARCINOGENESIS}},
Year = {{1994}},
Volume = {{15}},
Number = {{12}},
Pages = {{2757-2761}},
Month = {{DEC}},
Abstract = {{DNA adducts of 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]-pyridine
   (PhIP), a heterocyclic amine derived from cooked meat, were measured by
   the P-32-postlabeling method in tissues of cynomolgus monkeys given
   PhIP, Monkeys received either a single dose of PhIP (20 mg/kg orally) or
   nine daily doses of PhIP (20 mg/kg orally, days 1-5 and 8-11) and tissue
   samples were obtained 24 h after the last dose, Over 28 different
   tissues were examined for PhIP-DNA adducts, Adducts were detected in all
   tissues examined except the fat and bone marrow, After a single dose,
   adduct levels (mean value/10(7) nucleotides, n = 2 monkeys) were highest
   in the liver (2.1), followed by the lung (1.7), gall bladder (1.7) and
   pancreas (0.9), Low adduct levels were detected in the brain and aorta
   (0.06 and 0.02 respectively), Following multiple doses of PhIP, adduct
   levels (mean value/10(7) nucleotides +/- SE, n = 3 monkeys) were highest
   in the heart (5.7 +/- 2.0) followed by the liver (3.8 +/- 0.8),
   submandibular gland (2.7 +/- 1.8) and pancreas (2.2 +/- 0.5), Comparison
   of the adduct levels after a single dose with those found after multiple
   doses indicates that accumulation of PhIP-DNA adducts occurred in
   certain tissues, Adduct levels in liver, pancreas, kidney, small
   intestine and colon increased about 1.5- to 2.4-fold, PhIP-DNA adduct
   levels in submandibular gland and brain increased 4- to 5-fold, Adduct
   levels in heart increased 10-fold and levels in the aorta increased
   31-fold, Adducts in white blood cell DNA increased with daily dosing for
   9 days. No apparent changes in adduct levels were seen in the lung,
   stomach, bladder, muscle and spleen, The wide distribution of PhIP-DNA
   adducts and their presence in ,white blood cells suggests that there is
   transport of reactive metabolites from the liver to extrahepatic
   tissues, The relatively high adduct levels in the gall bladder in
   comparison with the liver suggests biliary excretion and possible
   reabsorption of reactive metabolites, The presence of DNA adducts in
   tissues implicates PhIP as a potential carcinogen in non-human primates,
   The possibility that PhIP-DNA adducts in tissues such as the heart and
   aorta may have toxicological consequences is discussed.}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{SNYDERWINE, EG (Reprint Author), NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892, USA.
   NCI,DIV CANC ETIOL,OFF DIRECTOR,BETHESDA,MD 20892.
   MED COLL OHIO,DEPT PATHOL,TOLEDO,OH 43614.
   NATL CANC CTR,RES INST,TOKYO,JAPAN.}},
DOI = {{10.1093/carcin/15.12.2757}},
ISSN = {{0143-3334}},
Keywords-Plus = {{METHYL-ALPHA-CARBOLINE; P-32-POSTLABELING METHOD; HETEROCYCLIC AMINES;
   SALIVARY-GLANDS; COOKED BEEF; RATS; CARCINOGEN; MEIQX; FOOD; IQ}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{ADAMSON RH, 1991, XENOBIOTICS AND CANCER, P289.
   ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   ADAMSON RH, 1994, ENVIRON HEALTH PERSP, V102, P190, DOI 10.2307/3431610.
   BROOKS RA, 1994, CANCER RES, V54, P1665.
   CAROTHRS AM, 1994, CHEM RES TOXICOL, V7, P209, DOI 10.1021/tx00038a015.
   CUMMINGS DA, 1994, IN PRESS CARCINOGENE.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P2091, DOI 10.1093/carcin/14.10.2091.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P61, DOI 10.1093/carcin/14.1.61.
   DAVIS CD, 1994, TOXICOL APPL PHARM, V124, P201, DOI 10.1006/taap.1994.1024.
   ENDO H, 1994, CANCER RES, V54, P3745.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FAN L, 1994, MOL CARCINOGEN, V10, P30, DOI 10.1002/mc.2940100106.
   FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312.
   FUKUTOME K, 1994, JPN J CANCER RES, V85, P113.
   GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943.
   HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KLEMAN M, 1990, CARCINOGENESIS, V11, P2185, DOI 10.1093/carcin/11.12.2185.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MCKINNON RA, 1992, CANCER RES, V52, pS2108.
   OVERVIK E, 1991, MUTAT RES, V256, P37, DOI 10.1016/0921-8734(91)90031-6.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1739, DOI 10.1093/carcin/9.10.1739.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P2517, DOI 10.1093/carcin/14.12.2517.
   SNYDERWINE EG, 1992, CANCER RES, V52, pS2099.
   STROMSTEDT M, 1990, BIOCHEM SOC T, V18, P28.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TAKAYAMA S, 1985, P JPN ACAD B-PHYS, V61, P277.
   TAKAYAMA S, 1987, P JPN ACAD B-PHYS, V63, P161, DOI 10.2183/pjab.63.161.
   THOMPSON LH, 1987, MUTAGENESIS, V2, P483, DOI 10.1093/mutage/2.6.483.
   THORGEIRSSON UP, 1994, ENVIRON HEALTH PERSP, V102, P194, DOI 10.2307/3431611.
   WAKABAYASHI K, 1990, MUTAT RES, V239, P181, DOI 10.1016/0165-1110(90)90005-V.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   YAMASHITA K, 1986, P JPN ACAD B-PHYS, V62, P45, DOI 10.2183/pjab.62.45.}},
Number-of-Cited-References = {{37}},
Times-Cited = {{33}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{PZ539}},
Wos-Id = {{ISI:A1994PZ53900012}},
}

@article{ ISI:A1994PT04100022,
Author = {REISTAD, R and FRANDSEN, H and GRIVAS, S and ALEXANDER, J},
Title = {{IN-VITRO FORMATION AND DEGRADATION OF
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO{[}4,5-B]PYRIDINE (PHIP) PROTEIN ADDUCTS}},
Journal = {{CARCINOGENESIS}},
Year = {{1994}},
Volume = {{15}},
Number = {{11}},
Pages = {{2547-2552}},
Month = {{NOV}},
Abstract = {{Adduct formation between the food mutagen
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) and rat serum
   albumin (RSA) was studied in vitro using hepatic microsomes isolated
   from polychlorinated biphenyl-induced rats. With
   1-methyl-2-nitro-6-phenylimidazo{[}4,5-b]pyridine (2-nitro-PhIP) as
   starting material, four main products were formed. Pretreatment of RSA
   with beta-mercaptoethanol markedly increased the yield of one of them.
   In this adduct, the C-2 of PhIP was linked to cysteine of RSA at
   position 34 in a C-S linkage. With N-2-acetoxy-PhIP as starting
   material, unstable conjugates were formed with RSA as well as with
   glutathione (GSH) and cysteine. The suggested structures of the GSH and
   cysteine conjugates, GSH-S-N-2-PhIP and cysteine-S-N-2-PhIP
   respectively, are based on mass spectra and UV spectra. The degradation
   of the conjugates of GSH and cysteine as well as of the protein adduct
   were monitored. They all resulted in the same degradation product,
   identified as 2-amino-5
   hydroxy-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (5-hydroxy-PhIP).}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{REISTAD, R (Reprint Author), NATL INST CONSUMER RES,POB 173,N-1324 LYSAKER,NORWAY.
   NATL INST PUBL HLTH,DEPT ENVIRONM MED,N-0462 OSLO,NORWAY.
   DANISH NATL FOOD AGCY,INST TOXICOL,DK-2860 SOBORG,DENMARK.
   SWEDISH UNIV AGR SCI,S-75007 UPPSALA,SWEDEN.}},
DOI = {{10.1093/carcin/15.11.2547}},
ISSN = {{0143-3334}},
Keywords-Plus = {{FOOD MUTAGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE; MOLECULAR
   DOSIMETRY; RAT; IDENTIFICATION; GLUTATHIONE; HEMOGLOBIN; ACTIVATION;
   GENOTOXICITY; DETOXICATION; CARCINOGENS}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{ALEXANDER J, 1991, CARCINOGENESIS, V12, P2239, DOI 10.1093/carcin/12.12.2239.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   DRAGSTED LO, 1993, PHARMACOL TOXICOL, V72, P388.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   FURST P, 1990, J CHROMATOGR, V499, P557, DOI 10.1016/S0021-9673(00)97000-6.
   GRIVAS S, 1988, J CHEM RES S, V84.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   LYNCH AM, 1993, CARCINOGENESIS, V14, P191, DOI 10.1093/carcin/14.2.191.
   LYNCH AM, 1991, CARCINOGENESIS, V12, P1067, DOI 10.1093/carcin/12.6.1067.
   MEERMAN JHN, 1982, CHEM-BIOL INTERACT, V39, P149, DOI 10.1016/0009-2797(82)90118-1.
   MIKALSEN A, 1989, CHEM-BIOL INTERACT, V69, P175, DOI 10.1016/0009-2797(89)90076-8.
   SAITO K, 1983, CARCINOGENESIS, V4, P1551, DOI 10.1093/carcin/4.12.1551.
   SKIPPER PL, 1990, CARCINOGENESIS, V11, P507, DOI 10.1093/carcin/11.4.507.
   SUGIMURA T, 1990, MUTAGENS CARCINOGENS, P1.
   TANNENBAUM SR, 1993, ENVIRON HEALTH PERSP, V99, P51, DOI 10.2307/3431457.
   THOMPSON LH, 1987, MUTAGENESIS, V2, P483, DOI 10.1093/mutage/2.6.483.
   TURESKY RJ, 1987, CARCINOGENESIS, V8, P1537, DOI 10.1093/carcin/8.10.1537.
   TURESKY RJ, 1993, ENVIRON HEALTH PERSP, V99, P123, DOI 10.2307/3431467.
   UMEMOTO A, 1988, CHEM-BIOL INTERACT, V68, P57, DOI 10.1016/0009-2797(88)90006-3.
   UMEMOTO A, 1988, BIOCHEM BIOPH RES CO, V151, P1326, DOI 10.1016/S0006-291X(88)80507-2.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   WILD D, 1986, GENETIC TOXICOLOGY D, P145.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{32}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{PT041}},
Wos-Id = {{ISI:A1994PT04100022}},
}

@article{ ISI:A1994PT04100034,
Author = {CUMMINGS, DA and SCHUT, HAJ},
Title = {{REMOVAL OF DNA-ADDUCTS OF
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO{[}4,5-B]PYRIDINE (PHIP) IN THE MALE
   FISCHER-344 RAT}},
Journal = {{CARCINOGENESIS}},
Year = {{1994}},
Volume = {{15}},
Number = {{11}},
Pages = {{2623-2628}},
Month = {{NOV}},
Abstract = {{The food mutagen 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine
   (PhIP) is carcinogenic in the male Fischer-344 rat, affecting
   principally the colon. PhIP-DNA adducts may play a role in the
   initiation of the carcinogenic process. We have evaluated the formation
   and persistence of PhIP - DNA adducts in the colon, circulating white
   blood cells (WBC) and several other non-target organs of the male
   Fischer-344 rat. Young adult male animals were given a single dose of
   PhIP (50 mg/kg) by gavage. Animals were killed 1, 2, 6, 12, 16 or 20
   days after dosing (4 animals/ time point) and their liver, lungs,
   stomach, small intestine, cecum, colon, kidneys, WBC, heart and spleen
   were removed for isolation of DNA and assay of PhIP-DNA adducts by
   (32)p-postlabeling. For interorgan comparisons of cell turnover, rats
   were given a single i.p. dose of {[}methyl-H-3]thymidine, after which
   DNA was isolated at the same time intervals as for adduct analysis and
   its sp. act. (d.p.m. H-3/100 mu g) was determined. In all organs up to
   three adducts could be isolated and the adduct pattern was the same in
   each case. On day 1, total adduct levels were highest in the colon (the
   target organ), followed by the spleen, cecum, small intestine, stomach,
   liver, kidneys, lungs, WBC and heart. Rates of adduct removal were
   similar in the colon, spleen, cecum, liver, lungs, stomach and small
   intestine, with day 16 and day 20 levels falling to <16\% of those on
   day 1; rates of removal were slower in the heart and kidneys (52.0 and
   30.3\% of day 1 values remaining on day 16 respectively). Adducts in WBC
   increased at first (day 2) and decreased thereafter to virtually
   non-detectable levels on days 16 and 20. Heart adducts on days 2-12
   increased slightly or remained as high as those on day 1, then decreased
   to lower levels on days 16 and 20 (53.0 and 28.7\% of day 1 levels
   respectively). There was no preferential removal or persistence of any
   individual adduct in WBC or in any of the organs. On days 1 and 2, the
   sp. act. of intestinal DNA (small intestine, cecum and colon) was
   >30-fold higher than that in several other organs, including the liver.
   These sp. act. decreased to the low sp. act, of the liver on day 20. It
   is concluded that the rates of adduct removal from the intestines are
   more likely to be related to cell turnover of epithelial cells than to
   enzymatic repair. Factors other than rate of adduct repair may
   contribute to the striking single organ target of PhIP in the male
   Fischer-344 rat.}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{MED COLL OHIO,DEPT PATHOL,TOLEDO,OH 43699.}},
DOI = {{10.1093/carcin/15.11.2623}},
ISSN = {{0143-3334}},
Keywords-Plus = {{FOOD MUTAGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE;
   HETEROCYCLIC AROMATIC-AMINES; COOKED FOOD; METABOLIC-ACTIVATION;
   LIVER-MICROSOMES; CARCINOGEN; IDENTIFICATION; IQ; MEIQX; COLON}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{ADAMSON RH, 1991, XENOBIOTICS AND CANCER, P289.
   AESCHBACHER HU, 1991, MUTAT RES, V259, P235, DOI 10.1016/0165-1218(91)90120-B.
   ALEXANDER J, 1991, CARCINOGENESIS, V12, P2239, DOI 10.1093/carcin/12.12.2239.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P2091, DOI 10.1093/carcin/14.10.2091.
   DAVIS CD, 1994, TOXICOL APPL PHARM, V124, P201, DOI 10.1006/taap.1994.1024.
   DOLL R, 1981, J NATL CANCER I, V66, P1191.
   DOOLEY KL, 1992, CANCER LETT, V62, P205, DOI 10.1016/0304-3835(92)90097-F.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   FURIHATA C, 1986, ANNU REV NUTR, V6, P67, DOI 10.1146/annurev.nutr.6.1.67.
   GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081.
   HASEGAWA R, 1993, CARCINOGENESIS, V14, P2553, DOI 10.1093/carcin/14.12.2553.
   HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   INAMASU T, 1989, FOOD CHEM TOXICOL, V27, P369, DOI 10.1016/0278-6915(89)90142-7.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1703, DOI 10.1093/carcin/15.8.1703.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1695, DOI 10.1093/carcin/15.8.1695.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MANABE S, 1993, CARCINOGENESIS, V14, P899, DOI 10.1093/carcin/14.5.899.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   MCKINNON RA, 1993, MUTAT RES, V290, P27, DOI 10.1016/0027-5107(93)90029-F.
   MCMANUS ME, 1989, CARCINOGENESIS, V10, P357, DOI 10.1093/carcin/10.2.357.
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215.
   MURRAY BP, 1993, CARCINOGENESIS, V14, P585, DOI 10.1093/carcin/14.4.585.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   OVERVIK E, 1991, MUTAT RES, V256, P37, DOI 10.1016/0921-8734(91)90031-6.
   PELUSO M, 1991, CARCINOGENESIS, V12, P713, DOI 10.1093/carcin/12.4.713.
   PFAU W, 1994, CARCINOGENESIS, V15, P877, DOI 10.1093/carcin/15.5.877.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SCHUT HAJ, 1984, DRUG METAB REV, V15, P753, DOI 10.3109/03602538409041079.
   SCHUT HAJ, 1993, ANTICANCER RES, V13, P1517.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TAKAYAMA S, 1987, P JPN ACAD B-PHYS, V63, P161, DOI 10.2183/pjab.63.161.
   TUCKER JD, 1989, MUTAT RES, V224, P105, DOI 10.1016/0165-1218(89)90009-8.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P941, DOI 10.1093/carcin/11.6.941.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P2291, DOI 10.1093/carcin/12.12.2291.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P1073, DOI 10.1093/carcin/12.6.1073.
   WESTRA JG, 1985, CARCINOGENESIS, V6, P37, DOI 10.1093/carcin/6.1.37.
   YAMASHITA K, 1988, NUCLEIC ACIDS RES S, V19, P111.
   ZU HX, 1991, CANCER RES, V51, P5636.}},
Number-of-Cited-References = {{49}},
Times-Cited = {{32}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{PT041}},
Wos-Id = {{ISI:A1994PT04100034}},
}

@article{ ISI:A1994PT12000009,
Author = {TURESKY, RJ and GROSS, GA and STILLWELL, WG and SKIPPER, PL and
   TANNENBAUM, SR},
Title = {{SPECIES-DIFFERENCES IN METABOLISM OF HETEROCYCLIC AROMATIC-AMINES, HUMAN
   EXPOSURE, AND BIOMONITORING}},
Journal = {{ENVIRONMENTAL HEALTH PERSPECTIVES}},
Year = {{1994}},
Volume = {{102}},
Number = {{6}},
Pages = {{47-51}},
Month = {{OCT}},
Note = {{5th International Conference on Carcinogenic and Mutagenic N-Substituted
   Aryl Compounds, WURZBURG, GERMANY, OCT 18-21, 1992}},
Organization = {{DEUT FORSCHUNGSGEMEINSCH; GERMAN SOC PHARM \& TOXICOL; NATL CTR TOXOL
   RES, JEFFERSON, ARKANSAS; UNIV WURZBURG}},
Abstract = {{Heterocyclic aromatic amines (HAAs) are animal carcinogens and suspected
   human carcinogens which are formed in cooked foods at the low parts per
   billion level. HAAs in cooked meats were purified by either
   immunoaffinity chromatography or solid phase tandem extraction, which
   allowed for the simultaneous analysis of 11 HAAs by HPLC. The metabolism
   of two prominent HAAs, 2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxafine
   (MelQx) and 2-amino-3-methylimidazo{[}4,5-f]quinoline (IQ), was
   investigated in animal models and in vitro with human tissues to develop
   strategies for human biomonitoring. MelQx and IQ are rapidly absorbed
   from the gastrointestinal tract of rodents and transformed into several
   detoxification products which are excreted in urine and feces.
   Metabolites result from cytochrome P450-mediated ring oxidation at the
   C-5 position followed by conjugation to sulfate or beta-glucuronic acid.
   Other major metabolites include the phase II conjugates, N-2-glucuronide
   and N-2-sulfamate. A metastable N-2-glucuronide conjugate of the
   genotoxic metabolite of N-hydroxy-MelQx was also detected in urine and
   bile. The binding of both carcinogens to blood proteins was low and
   suggests that human biomonitoring through protein adducts may be
   difficult. These metabolic pathways exist in nonhuman primates and
   several of these pathways also occur in vitro with human liver. The
   urinary excretion of MelQx in seven human subjects following consumption
   of cooked beef or fish ranged between 2 and 22 ng in 12 hr when
   determined by negative ion chemical ionization GC-MS. After acid
   hydrolysis of urine, the amount of MelQx increased 4- to 10-fold in 6 of
   the 7 subjects. These acid labile metabolites were identified as the
   N-2-sulfamate and N-2-glucuronide following column chromatography and
   HPLC purification. Thus, amine sulfamation and N-2-glucuronidation are
   important routes of detoxification of MelQx in rodents, nonhuman
   primates, and humans.}},
Publisher = {{NATL INST ENVIRON HEALTH SCI}},
Address = {{PO BOX 12233, RES TRIANGLE PK, NC 27709}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{TURESKY, RJ (Reprint Author), NESTEC LTD,NESTLE RES CTR,VERS CHEZ LES BLANC,CH-1000 LAUSANNE,SWITZERLAND.
   MIT,DIV TOXICOL,CAMBRIDGE,MA 02139.
   MIT,DEPT CHEM,CAMBRIDGE,MA 02139.}},
DOI = {{10.2307/3432151}},
ISSN = {{0091-6765}},
Keywords = {{FOOD MUTAGENS; HETEROCYCLIC AROMATIC AMINES; METABOLISM; HUMAN
   BIOMONITORING}},
Keywords-Plus = {{BORNE CARCINOGEN 2-AMINO-3,8-DIMETHYLIMIDAZO<4,5-F>QUINOXALINE;
   HUMAN-LIVER; NONHUMAN-PRIMATES; FOOD-PRODUCTS; N-OXIDATION;
   2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE; RAT; DOSIMETRY; ACTIVATION;
   MEIQX}},
Research-Areas = {{Environmental Sciences \& Ecology; Public, Environmental \& Occupational
   Health}},
Web-of-Science-Categories  = {{Environmental Sciences; Public, Environmental \& Occupational Health}},
Cited-References = {{ABUZEID M, 1992, CARCINOGENESIS, V13, P1307, DOI 10.1093/carcin/13.8.1307.
   ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   ALEXANDER J, 1991, MUTAGENS FOOD DETECT, P143.
   BUTLER MA, 1989, P NATL ACAD SCI USA, V86, P7696, DOI 10.1073/pnas.86.20.7696.
   FELTON JS, 1990, HDB EXPT PHARM, V94, P471.
   FELTON JS, 1991, P AM ASSOC CANC RES, V32, P98.
   GRANT DM, 1984, BRIT J CLIN PHARMACO, V17, P459.
   GROSS GA, 1990, CARCINOGENESIS, V11, P1597, DOI 10.1093/carcin/11.9.1597.
   GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B.
   HERNANDEZ JS, 1991, DRUG METAB DISPOS, V19, P1071.
   KADERLIK K, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P119.
   KADLUBAR FF, 1991, IMPLICATIONS CHEM CA, V21, P329.
   KADLUBAR FF, 1994, IN PRESS ENV HLTH PE.
   KATO R, 1986, CRIT REV TOXICOL, V16, P307, DOI 10.3109/10408448609037466.
   LUKS HJ, 1989, CANCER RES, V49, P4407.
   LYNCH AM, 1991, CARCINOGENESIS, V12, P1067, DOI 10.1093/carcin/12.6.1067.
   MURRAY S, 1989, CARCINOGENESIS, V10, P763, DOI 10.1093/carcin/10.4.763.
   OVERVIK E, 1987, MUTAT RES, V187, P47, DOI 10.1016/0165-1218(87)90117-0.
   SHIMADA T, 1989, CANCER RES, V49, P3218.
   SKIPPER PL, 1990, CARCINOGENESIS, V11, P507, DOI 10.1093/carcin/11.4.507.
   SNYDERWINE EG, 1993, IN PRESS P PRINCESS.
   SNYDERWINE EG, 1992, CHEM RES TOXICOL, V5, P843, DOI 10.1021/tx00030a018.
   STILLWELL WG, 1992, 40TH P ASMS C MASS S, P1563.
   TURESKY RJ, 1988, CARCINOGENESIS, V9, P1043, DOI 10.1093/carcin/9.6.1043.
   TURESKY RJ, 1989, CARCINOGENESIS, V10, P151, DOI 10.1093/carcin/10.1.151.
   TURESKY RJ, 1987, CARCINOGENESIS, V8, P1537, DOI 10.1093/carcin/8.10.1537.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1847, DOI 10.1093/carcin/12.10.1847.
   TURESKY RJ, 1986, CARCINOGENESIS, V7, P1483, DOI 10.1093/carcin/7.9.1483.
   TURESKY RJ, 1990, CHEM RES TOXICOL, V3, P524, DOI 10.1021/tx00018a006.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WEINSHILBOUM R, 1990, PHARMACOL THERAPEUT, V45, P93, DOI 10.1016/0163-7258(90)90010-Y.
   WOGAN GN, 1985, ENVIRON HEALTH PERSP, V62, P5, DOI 10.2307/3430088.
   YAMAZOE Y, 1988, JPN J CANCER RES, V79, P1159.}},
Number-of-Cited-References = {{34}},
Times-Cited = {{16}},
Journal-ISO = {{Environ. Health Perspect.}},
Doc-Delivery-Number = {{PT120}},
Wos-Id = {{ISI:A1994PT12000009}},
}

@article{ ISI:A1994PP63100010,
Author = {STAVRIC, B},
Title = {{BIOLOGICAL SIGNIFICANCE OF TRACE LEVELS OF MUTAGENIC HETEROCYCLIC
   AROMATIC-AMINES IN HUMAN DIET - A CRITICAL-REVIEW}},
Journal = {{FOOD AND CHEMICAL TOXICOLOGY}},
Year = {{1994}},
Volume = {{32}},
Number = {{10}},
Pages = {{977-994}},
Month = {{OCT}},
Abstract = {{Cooking of protein-rich foods may induce the formation of a series of
   heterocyclic aromatic amines (HAAs) that have been found to be mutagens
   and carcinogens. Despite very potent mutagenic activity found in the
   Salmonella/microsomal assay, this test cannot predict carcinogenic
   potency of HAAs in rodents and monkeys. Doses used in the feeding
   studies with animals exceeded by several orders of magnitude the levels
   of HAAs found in human diet, being approximately 500,000-3,000,000-fold
   higher than the human dietary levels. A comparison of these levels and
   their relevance for humans is presented. Differences in metabolic fate
   of different HAAs due to species and sex of the animals are discussed.
   These differences could account for the variable cancer-producing
   potential in different species. A number of still unresolved variables
   (such as the levels of HAAs in foods, bioavailability, possible
   synergistic effect from mixtures of HAAs, and metabolic fate and
   detoxification) preclude reliable assessment of the potential health
   hazard from HAAs in foods. The difference in the ability of human and
   animal liver microsomes to bioactivate HAAs and to form DNA adducts
   causes further uncertainty. The differences due to the hepatic
   cytochrome P-450-mediated activation of HAA among rats, monkeys and
   humans may influence susceptibility to cancer from these agents. HAAs
   occur only in traces in the human diet; however, they are present in
   many foods consumed daily. The levels of
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) are
   approximately 100-fold higher than the levels of
   2-amino-3-methylimidazo{[}4,5-f]quinoline (IQ) and
   2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline (MeIQx). However, their
   mutagenic potential in the Ames Salmonella assay is reversed. Other in
   vitro tests, however, indicate similar genotoxicity between IQ, MeIQx
   and PhIP. Although most feeding studies with HAAs have been conducted
   with IQ and MeIQ, evidence obtained from a variety of studies indicates
   the possibility that PhIP may have an active role in the aetiology of
   human cancer and, therefore, its role as such should be evaluated. The
   influence of trace levels of HAAs on human health remains to be
   confirmed.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{STAVRIC, B (Reprint Author), HLTH \& WELF CANADA,HLTH PROTECT BRANCH,FOOD DIRECTORATE,DIV FOOD RES,OTTAWA K1A 0L2,ON,CANADA.}},
DOI = {{10.1016/0278-6915(94)90093-0}},
ISSN = {{0278-6915}},
Keywords-Plus = {{CHROMATOGRAPHY MASS-SPECTROMETRY; FOOD-BORNE CARCINOGEN; HAMSTER
   LUNG-CELLS; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; COOKED
   FOODS; 2-AMINO-3,8-DIMETHYLIMIDAZO<4,5-F>QUINOXALINE MEIQX; HUMAN-LIVER;
   LIQUID-CHROMATOGRAPHY; NONHUMAN-PRIMATES; BACON MEALS}},
Research-Areas = {{Food Science \& Technology; Toxicology}},
Web-of-Science-Categories  = {{Food Science \& Technology; Toxicology}},
Cited-References = {{ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   ADAMSSON RH, 1990, CANCER PREV, V1, P1.
   ALEXANDER J, 1989, CARCINOGENESIS, V10, P1543, DOI 10.1093/carcin/10.8.1543.
   AOYAMA T, 1990, CANCER RES, V50, P2060.
   BAKER R, 1982, CANCER LETT, V16, P81, DOI 10.1016/0304-3835(82)90094-5.
   BAKER RSU, 1986, ENVIRON HEALTH PERSP, V67, P147, DOI 10.2307/3430330.
   BERGMAN K, 1985, CANCER RES, V45, P1351.
   BONSER GM, 1952, BRIT J CANCER, V6, P412, DOI 10.1038/bjc.1952.47.
   BRITTEBO EB, 1992, CARCINOGENESIS, V13, P2263, DOI 10.1093/carcin/13.12.2263.
   BUONARATI MH, 1992, CARCINOGENESIS, V13, P621, DOI 10.1093/carcin/13.4.621.
   BUONARATI MH, 1991, MUTAGENESIS, V6, P253, DOI 10.1093/mutage/6.4.253.
   BUTLER MA, 1989, P NATL ACAD SCI USA, V86, P7696, DOI 10.1073/pnas.86.20.7696.
   BUTLER WH, 1968, FOOD COSMET TOXICOL, V6, P135, DOI 10.1016/0015-6264(68)90194-6.
   CARTWRIGHT RA, 1983, ENVIRON HEALTH PERSP, V49, P13, DOI 10.2307/3429575.
   CASE RAM, 1954, BRIT J IND MED, V11, P75.
   CUTHBERT.WF, 1967, BRIT J NUTR, V21, P893, DOI 10.1079/BJN19670089.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P61, DOI 10.1093/carcin/14.1.61.
   DEO MG, 1970, J PATHOL, V101, P47, DOI 10.1002/path.1711010106.
   DESERRES FJ, 1986, ENVIRON HEALTH PERSP, V67, P153, DOI 10.2307/3430331.
   DOLARA P, 1984, CANCER LETT, V22, P275, DOI 10.1016/0304-3835(84)90163-0.
   DOLL R, 1981, CAUSES CANC, P1226.
   DOOLEY KL, 1992, CANCER LETT, V62, P205, DOI 10.1016/0304-3835(92)90097-F.
   EDMONDS CG, 1986, ENVIRON HEALTH PERSP, V67, P35, DOI 10.2307/3430315.
   EISENBRAND G, 1993, TOXICOLOGY, V84, P1, DOI 10.1016/0300-483X(93)90109-6.
   EPSTEIN SM, 1969, CANCER RES, V29, P1045.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FELTON JS, 1992, CANCER RES, V52, pS2103.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   TURTELTAUB KW, 1992, CANCER RES, V52, P4682.
   FRIESEN MD, 1993, ENVIRON HEALTH PERSP, V99, P179, DOI 10.2307/3431476.
   GAYLOR DW, 1991, MUTAGENS FOOD DETECT, P229.
   GOLD LS, 1984, ENVIRON HEALTH PERSP, V58, P9, DOI 10.2307/3429857.
   GOODERHAM NJ, 1989, DRUG METAB REV, V20, P285, DOI 10.3109/03602538909103544.
   GROSS GA, 1989, CARCINOGENESIS, V10, P1175, DOI 10.1093/carcin/10.7.1175.
   GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B.
   GRY J, 1986, PUBL MINISTRY ENV NA, V139.
   HATCH FT, 1986, ENVIRON HEALTH PERSP, V67, P93, DOI 10.2307/3430322.
   INGS RMJ, 1984, DRUG METAB REV, V15, P1183, DOI 10.3109/03602538409033561.
   ITO N, 1991, CARCINOGENESIS, V12, P767, DOI 10.1093/carcin/12.5.767.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KATO T, 1986, J AGR FOOD CHEM, V34, P810, DOI 10.1021/jf00071a010.
   KATO T, 1988, CARCINOGENESIS, V9, P71, DOI 10.1093/carcin/9.1.71.
   KLEMAN M, 1989, CARCINOGENESIS, V9, P1696.
   KNASMULLER S, 1992, MUTAGENESIS, V7, P235, DOI 10.1093/mutage/7.4.235.
   KNIZE MG, 1992, J CHROMATOGR, V624, P253, DOI 10.1016/0021-9673(92)85683-K.
   KRONE CA, 1986, ENVIRON HEALTH PERSP, V67, P75, DOI 10.2307/3430320.
   LEE H, 1991, FOOD CHEM TOXICOL, V29, P517, DOI 10.1016/0278-6915(91)90043-7.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   MANABE S, 1993, CARCINOGENESIS, V14, P899, DOI 10.1093/carcin/14.5.899.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   MCMANUS ME, 1990, CANCER RES, V50, P3367.
   MUNRO IC, 1993, REGUL TOXICOL PHARM, V17, pS1.
   MURRAY S, 1993, J CHROMATOGR-BIOMED, V616, P211, DOI 10.1016/0378-4347(93)80388-K.
   MURRAY S, 1989, CARCINOGENESIS, V10, P763, DOI 10.1093/carcin/10.4.763.
   NAKAYASU M, 1983, MUTAT RES, V118, P91, DOI 10.1016/0165-1218(83)90119-2.
   NEAL J, 1967, TEX REP BIOL MED, V25, P553.
   OCHIAI M, 1991, JPN J CANCER RES, V82, P363.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   OHGAKI H, 1986, ENVIRON HEALTH PERSP, V67, P129, DOI 10.2307/3430327.
   RICH KJ, 1992, CARCINOGENESIS, V13, P2221, DOI 10.1093/carcin/13.12.2221.
   RIGDON R H, 1969, Proceedings of the Society for Experimental Biology and Medicine, V130, P146.
   SAFFIOTTI U, 1967, BLADDER CANCER S, P129.
   SHIMADA T, 1989, CANCER RES, V49, P3218.
   SJODIN P, 1984, FOOD CHEM TOXICOL, V22, P207, DOI 10.1016/0278-6915(84)90128-5.
   SNYDERWINE EG, 1992, CHEM RES TOXICOL, V5, P843, DOI 10.1021/tx00030a018.
   SNYDERWINE EG, 1992, CANCER RES, V52, pS2099.
   SONE H, 1992, CARCINOGENESIS, V13, P793, DOI 10.1093/carcin/13.5.793.
   STAVRIC B, 1992, LIPID SOLUBLE ANTIOX, P274.
   STAVRIC B, 1979, J ASSOC OFF ANA CHEM, V62, P1020.
   SUGIMURA T, 1986, ENVIRON HEALTH PERSP, V67, P5, DOI 10.2307/3430310.
   SUGIMURA T, 1990, MUTAGENS CARCINOGENS, P1.
   SUGIMURA T, 1992, SCIENCE, V258, P603, DOI 10.1126/science.1411570.
   SUGIMURA T, 1985, MUTAT RES, V150, P33, DOI 10.1016/0027-5107(85)90098-3.
   SUGIMURA T, 1989, FOOD TOXICOLOGY PERS, P31.
   SUGIMURA T, 1990, IARC SCI PUBL, V104, P399.
   TAKAHASHI M, 1983, JPN J CANCER RES, V74, P633.
   TAKAHASHI M, 1986, JPN J CANCER RES, V77, P509.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TAKAYAMA S, 1984, GANN, V75, P467.
   TAKAYAMA S, 1987, JPN J CANCER RES, V78, P1068.
   TERADA M, 1986, ENVIRON HEALTH PERSP, V67, P117, DOI 10.2307/3430325.
   THOMPSON LH, 1987, MUTAGENESIS, V2, P483, DOI 10.1093/mutage/2.6.483.
   TIKKANEN LM, 1993, FOOD CHEM TOXICOL, V31, P717, DOI 10.1016/0278-6915(93)90142-L.
   TJOTTA K, 1992, CARCINOGENESIS, V13, P779, DOI 10.1093/carcin/13.5.779.
   TSUDA H, 1988, JPN J CANCER RES, V79, P691.
   TURESKY RJ, 1993, ENVIRON HEALTH PERSP, V99, P123, DOI 10.2307/3431467.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1847, DOI 10.1093/carcin/12.10.1847.
   TURESKY RJ, 1988, FOOD CHEM TOXICOL, V26, P501, DOI 10.1016/0278-6915(88)90002-6.
   TURTELTAUB KW, 1989, FOOD CHEM TOXICOL, V27, P667, DOI 10.1016/0278-6915(89)90121-X.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P2291, DOI 10.1093/carcin/12.12.2291.
   WEISBURGER JH, 1993, CANCER RES, V53, P2422.
   WOGAN GN, 1969, PROG EXP TUMOR RES, V11, P134.
   WOGAN GN, 1967, CANCER RES, V27, P2370.
   YAMAIZUMI Z, 1980, CANCER LETT, V9, P75, DOI 10.1016/0304-3835(80)90110-X.
   YAMASHITA K, 1990, JPN J CANCER RES, V81, P470.
   ZHANG XM, 1988, MUTAT RES, V201, P181, DOI 10.1016/0027-5107(88)90124-8.
   1974, MONOGRAPHS EVALUATIO, V4, P101.
   1993, MONOGRAPHS EVALUATIO, V56, P163.
   1973, MONOGRAPHS EVALUATIO, V3, P91.}},
Number-of-Cited-References = {{105}},
Times-Cited = {{58}},
Journal-ISO = {{Food Chem. Toxicol.}},
Doc-Delivery-Number = {{PP631}},
Wos-Id = {{ISI:A1994PP63100010}},
}

@article{ ISI:A1994PC32500036,
Author = {KADERLIK, KR and MINCHIN, RF and MULDER, GJ and ILETT, KF and
   DAUGAARDJENSON, M and TEITEL, CH and KADLUBAR, FF},
Title = {{METABOLIC-ACTIVATION PATHWAY FOR THE FORMATION OF DNA-ADDUCTS OF THE
   CARCINOGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO{[}4,5-B]PYRIDINE (PHIP) IN
   RAT EXTRAHEPATIC TISSUES}},
Journal = {{CARCINOGENESIS}},
Year = {{1994}},
Volume = {{15}},
Number = {{8}},
Pages = {{1703-1709}},
Month = {{AUG}},
Abstract = {{The food-borne mutagen 2-amino-1-methyl-6-phenylimidazo{[}4,5b]pyridine
   (PhIP) induces tumors in colon of male rats and has been implicated in
   the etiology of human cancers, particularly colorectal cancer. This
   study was conducted to examine: (1) the biliary and/or circulatory
   transport of N-hydroxy-PhIP and its N-glucuronides, N-sulfonyloxy-PhIP
   and N-acetoxy-PhIP; (2) their role as proximate and ultimate
   carcinogenic metabolites of PhIP; (3) the potential role of glutathione
   in modulating PhIP-DNA adduct formation. PhIP-DNA adducts, measured by
   the P-32-postlabeling method, were highest in the pancreas (361
   adducts/10(8) nucleotides or 100\%), followed by colon (56\%), lung
   (28\%), heart (27\%) and liver (2\%), at 24 h after a single oral dose
   of PhIP (220 mu mol/kg) to male rats. In each tissue examined, we
   observed two major adducts, each of which accounted for 35-45\% of the
   total, and one minor adduct, which represented about 10-20\% of the
   total. One of the major adducts was identified as
   N-(deoxyguanosin-8-yl)-2-amino-1-methyl-6-phenylimidazo{[}4,5-b]
   pyridine by chromatographic comparisons with an authentic standard. The
   major urinary metabolites of PhIP in these rats were 4'-hydroxy-PhIP and
   its glucuronide and sulfate conjugates, followed by N-hydroxy-PhIP
   N3-glucuronide, N-hydroxy-PhIP N-2-glucuronide and unchanged PhIP. In
   bile duct-ligated rats, the urinary excretion of the N-OH-PhIP
   N3-glucuronide was increased two-fold, but there was no effect on
   PhIP-DNA adduct formation in the colon, heart, lung, pancreas or liver.
   2,6-Dichloro-4-nitrophenol, which strongly inhibits
   arylsulfotransferase-mediated DNA binding in vivo, had no effect on
   PhIP-DNA adduct levels in liver or in extrahepatic tissues. Pretreatment
   of rats with buthionine sulfoximine, which results in hepatic
   glutathione depletion, caused a five-fold increase in adduct formation
   in the liver. Intravenous administration (10 mu mol/kg) of
   N-hydroxy-PhIP and N-acetoxy-PhIP each led to high levels of PhIP-DNA
   adducts in each of the extrahepatic tissues examined. Adduct levels
   ranged from two- to six-fold higher (for N-hydroxy-PhIP and four- to
   28-fold higher (for N-acetoxy-PhIP) as compared to that after an i.v.
   dose of the parent compound, indicating that these two bioactivated
   derivatives of PhIP are sufficiently stable to be transported through
   the circulation to extrahepatic tissues. Analyses of whole blood
   obtained at 2-8 h after oral administration of {[}H-3]PNP failed to
   detect N-hydroxy-PhIP (<0.1\% of the radioactivity), however, a
   decomposition product of N-acetoxy-PhIP was found to account for about
   80\% of the total radioactivity in the blood. These results suggest that
   transport of N-acetoxy-PhIP, and perhaps N-hydroxy-PhIP, via the
   bloodstream and not biliary transport and deconjugation of
   N-hydroxy-PhIP N-glucuronides is primarily responsible for PhIP-DNA
   adduct formation in rat colon and other extrahepatic tissues.}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{KADERLIK, KR (Reprint Author), NATL CTR TOXICOL RES,HFT 100,JEFFERSON,AR 72079, USA.
   UNIV WESTERN AUSTRALIA,QUEEN ELIZABETH II MED CTR,DEPT PHARMACOL,NEDLANDS,WA 6009,AUSTRALIA.
   LEIDEN UNIV,SYLVIUS LABS,CTR BIOPHARMACEUT SCI,DIV TOXICOL,2300 PA LEIDEN,NETHERLANDS.}},
DOI = {{10.1093/carcin/15.8.1703}},
ISSN = {{0143-3334}},
Keywords-Plus = {{FOOD MUTAGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE;
   HETEROCYCLIC AROMATIC-AMINES; CHEMICAL CARCINOGENESIS; LIVER-MICROSOMES;
   IDENTIFICATION; ACETYLATION; SULFATION; COLON; 2'-DEOXYGUANOSINE;
   GLUCURONIDATION}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{ALEXANDER J, 1991, CARCINOGENESIS, V12, P2239, DOI 10.1093/carcin/12.12.2239.
   BOCK KW, 1991, CRIT REV BIOCHEM MOL, V26, P129, DOI 10.3109/10409239109081125.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   CHOU HC, 1983, P AM ASSOC CANC RES, V34, P973.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312.
   FELTON JS, 1988, CARCINOGENIC MUTAGEN, P73.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558.
   GRIVAS S, 1988, J CHEM RES, V5, P84.
   GROSS GA, 1990, CARCINOGENESIS, V11, P1597, DOI 10.1093/carcin/11.9.1597.
   GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1695, DOI 10.1093/carcin/15.8.1695.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1711, DOI 10.1093/carcin/15.8.1711.
   KADLUBAR FF, 1992, P AM ASSOC CANC RES, V33, P950.
   KADLUBAR FF, 1991, XENOBIOTICS AND CANCER, P329.
   KADLUBAR FF, 1977, CANCER RES, V37, P805.
   LIN D, 1993, IN PRESS CANCER RES.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   MCMANUS ME, 1989, CARCINOGENESIS, V10, P357, DOI 10.1093/carcin/10.2.357.
   MINCHIN RF, 1992, BIOCHEM BIOPH RES CO, V185, P839, DOI 10.1016/0006-291X(92)91703-S.
   MULDER GJ, 1983, ENVIRON HEALTH PERSP, V49, P27, DOI 10.2307/3429577.
   NAGAOKA H, 1992, JPN J CANCER RES, V83, P1025.
   PELUSO M, 1991, CARCINOGENESIS, V12, P713, DOI 10.1093/carcin/12.4.713.
   SCHIFFMAN MH, 1990, AM J EPIDEMIOL, V131, P376.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SUGIMURA T, 1983, CANCER RES, V43, P2415.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P941, DOI 10.1093/carcin/11.6.941.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   WEISBURGER JH, 1979, CANCER, V43, P1987, DOI 10.1002/1097-0142(197905)43:5+<1987::AID-CNCR2820430706>3.0.CO;2-\#.
   WESTRA JG, 1981, CARCINOGENESIS, V2, P355, DOI 10.1093/carcin/2.4.355.
   WOHLLEB JC, 1990, INT J CANCER, V46, P22, DOI 10.1002/ijc.2910460107.
   YAMAZOE Y, 1989, CARCINOGENESIS, V10, P1675, DOI 10.1093/carcin/10.9.1675.}},
Number-of-Cited-References = {{41}},
Times-Cited = {{136}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{PC325}},
Wos-Id = {{ISI:A1994PC32500036}},
}

@article{ ISI:A1994PC32500037,
Author = {KADERLIK, KR and MULDER, GJ and SHADDOCK, JG and CASCIANO, DA and
   TEITEL, CH and KADLUBAR, FF},
Title = {{EFFECT OF GLUTATHIONE DEPLETION AND INHIBITION OF GLUCURONIDATION AND
   SULFATION ON 2-AMINO-1-METHYL-6-PHENYLIMIDAZO {[}4,5-B]PYRIDINE (PHIP)
   METABOLISM, PHIP-DNA ADDUCT FORMATION AND UNSCHEDULED DNA-SYNTHESIS IN
   PRIMARY RAT HEPATOCYTES}},
Journal = {{CARCINOGENESIS}},
Year = {{1994}},
Volume = {{15}},
Number = {{8}},
Pages = {{1711-1716}},
Month = {{AUG}},
Abstract = {{The potent rat colon carcinogen
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP), unlike other
   food-borne heterocyclic amines, does not induce tumors in rat liver.
   This correlates with an extremely low level of PhIP-DNA adducts formed
   in this tissue, and together these observations suggest that PhLP is
   efficiently detoxified in the liver. In order to identify possible
   detoxification mechanisms, we assessed the effect of inhibition of
   glucuronidation, glutathione (GSH) conjugation and sulfation on PhIP
   metabolism and PhTP-induced DNA damage in rat hepatocytes. Hepatocytes
   isolated from rats pretreated with Aroclor 1254 metabolized PhIP to the
   same products found in vivo. N-Hydroxy-PhIP N3-glucuronide and
   N-hydroxy-PhIP N-2-glucuronide were major and minor metabolites
   respectively. P-32-Postlabeling analysis of DNA from the PhIP-treated
   hepatocytes indicated the presence of two major adducts, one of which
   was identified as N-(deoxyguanosin-8-yl)-PhIP, and one minor adduct.
   There was no unscheduled DNA synthesis (UDS) in these cells. However,
   pretreatment of the hepatocytes with 1-bromoheptane and buthionine
   sulfoximine, which depletes GSH and prevents its resynthesis, resulted
   in a 15-fold increase in the formation of PhIP-DNA adducts, as well as
   ire a high level of UDS. GSH depletion had no effect on the formation of
   detectable PhIP metabolites. Hepatocyte pretreatment with
   D-galactosamine, which inhibits glucuronidation, increased the formation
   of DNA adducts two-fold and UDS was increased similarly. D-Galactosamine
   decreased the formation of the two N-glucuronides of N-hydroxy-PhIP by
   50-60\%, but had no effect on other metabolites. Pentachlorophenol,
   which strongly inhibits sulfotransferases, decreased adduct formation
   slightly, but had essentially no effect on UDS or on the formation of
   PhIP metabolites. These results indicate that metabolic conjugation
   pathways involving GSH and glucuronidation may play an important role in
   protecting rat liver against PhIP carcinogenesis.}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{KADERLIK, KR (Reprint Author), NATL CTR TOXICOL RES,HFT 100,JEFFERSON,AR 72079, USA.
   LEIDEN UNIV,SYLVIUS LABS,CTR BIOPHARMACEUT SCI,DIV TOXICOL,2300 RA LEIDEN,NETHERLANDS.}},
DOI = {{10.1093/carcin/15.8.1711}},
ISSN = {{0143-3334}},
Keywords-Plus = {{FOOD MUTAGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE; BORNE
   CARCINOGEN 2-AMINO-3,8-DIMETHYLIMIDAZO<4,5-F>QUINOXALINE; HETEROCYCLIC
   AROMATIC-AMINES; LIVER; ACTIVATION; IDENTIFICATION; BINDING; COLON;
   N-HYDROXY-2-ACETYLAMINOFLUORENE; ACETYLTRANSFERASE}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{ABUZEID M, 1990, JPN J CANCER RES, V81, P653.
   ALEXANDER J, 1991, CARCINOGENESIS, V12, P2239, DOI 10.1093/carcin/12.12.2239.
   ALEXANDER J, 1989, CARCINOGENESIS, V10, P1543, DOI 10.1093/carcin/10.8.1543.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   DEWAZIERS I, 1984, MUTAT RES, V139, P15, DOI 10.1016/0165-7992(84)90115-5.
   FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312.
   FELTON JS, 1988, CARCINOGENIC MUTAGEN, P73.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   FRANDSEN H, 1990, MUTAGENESIS, V6, P93.
   GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558.
   GRIVAS S, 1988, J CHEM RES, V5, P84.
   GROSS GA, 1990, CARCINOGENESIS, V11, P1597, DOI 10.1093/carcin/11.9.1597.
   GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK KR, 1993, CARCINOGENESIS, V15, P1701.
   KADERLIK KR, 1994, CARCINOGENESIS, V15, P1695, DOI 10.1093/carcin/15.8.1695.
   KADERLIK RK, 1993, P AM ASSOC CANC RES, V34, P907.
   KAHN S, 1991, BIOCHEM BIOPH RES CO, V179, P436.
   LIN D, 1994, IN PRESS CANCER RES.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   LORETZ LJ, 1984, CARCINOGENESIS, V5, P895, DOI 10.1093/carcin/5.7.895.
   LOWRY OH, 1951, J BIOL CHEM, V193, P265.
   LYNCH AM, 1992, CANCER RES, V52, P6216.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   MCMANUS ME, 1989, CARCINOGENESIS, V10, P1357.
   MEERMAN JHN, 1980, CANCER RES, V40, P3772.
   OVERVIK E, 1991, MUTAT RES, V256, P37, DOI 10.1016/0921-8734(91)90031-6.
   SAITO K, 1983, CARCINOGENESIS, V4, P1551, DOI 10.1093/carcin/4.12.1551.
   SCHIFFMAN MH, 1990, AM J EPIDEMIOL, V131, P376.
   SHADDOCK JG, 1990, MUTAGENESIS, V5, P387, DOI 10.1093/mutage/5.4.387.
   SINGH J, 1981, BIOCHEM PHARMACOL, V30, P3252, DOI 10.1016/0006-2952(81)90528-1.
   SUGIMURA T, 1983, CANCER RES, V43, P2415.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1847, DOI 10.1093/carcin/12.10.1847.
   TURESKY RJ, 1990, CHEM RES TOXICOL, V3, P524, DOI 10.1021/tx00018a006.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P941, DOI 10.1093/carcin/11.6.941.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   WESTRA JG, 1981, CARCINOGENESIS, V2, P355, DOI 10.1093/carcin/2.4.355.
   WOHLLEB JC, 1990, INT J CANCER, V46, P22, DOI 10.1002/ijc.2910460107.
   YAMASHITA K, 1990, JPN J CANCER RES, V81, P470.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{55}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{PC325}},
Wos-Id = {{ISI:A1994PC32500037}},
}

@article{ ISI:A1994PE34700004,
Author = {BRITTEBO, EB and KARLSSON, AA and SKOG, KI and JAGERSTAD, IM},
Title = {{TRANSFER OF THE FOOD MUTAGEN PHIP TO FETUSES AND NEWBORN MICE FOLLOWING
   MATERNAL EXPOSURE}},
Journal = {{FOOD AND CHEMICAL TOXICOLOGY}},
Year = {{1994}},
Volume = {{32}},
Number = {{8}},
Pages = {{717-726}},
Month = {{AUG}},
Abstract = {{The food mutagen PhIP
   (2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine) is a liver
   carcinogen in neonatal mice. In this study the transfer of PhIP to
   foetuses and neonates following a single ip dose (4.7-5.2 mg/kg body
   weight) to pregnant or lactating C57B1/6 mice was studied by tissue
   extraction and HPLC analysis. A transplacental transfer of unchanged
   {[}H-3]PhIP to foetuses was demonstrated; the highest foetal levels were
   observed at late gestation. Autoradiography of mice injected iv with
   {[}2(-14)C]PhIP (1.4 mg/kg) during late gestation showed a high and
   selective localization of radioactivity in the pigmented parts of the
   foetal eye and a moderate level of radioactivity in the foetal liver,
   gastro-intestinal contents, urine and in the uterine fluid. HPLC
   analysis of stomach contents and tissues of newborn mice exposed for 4
   hr to lactating darns dosed ip with {[}H-3]PhIP (5.2 mg/kg) showed the
   presence of unchanged PhIP suggesting excretion of PhIP in the milk of
   the dams. The results in this study raise concern that exposure to PhIP
   during pregnancy and nursing may result in a transfer of this food
   mutagen to foetuses and infants.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{BRITTEBO, EB (Reprint Author), LUND UNIV,CTR CHEM,DEPT PHARMACOL,SOLVEGATAN 10,S-22362 LUND,SWEDEN.
   LUND UNIV,CTR CHEM,DEPT APPL NUTR \& FOOD CHEM,LUND,SWEDEN.}},
ISSN = {{0278-6915}},
Keywords-Plus = {{METHYL SULFONE METABOLITES;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP;
   BETA-NAPHTHOFLAVONE; PREGNANT MICE; COOKED FOOD; FETAL; ACTIVATION;
   CARCINOGEN; INDUCTION; MOUSE}},
Research-Areas = {{Food Science \& Technology; Toxicology}},
Web-of-Science-Categories  = {{Food Science \& Technology; Toxicology}},
Cited-References = {{ALTHOFF J, 1979, NATL CANCER I MONOGR, V51, P251.
   BERGMAN K, 1985, CANCER RES, V45, P1351.
   BRANDT I, 1988, INTERMEDIARY XENOBIO, P295.
   BRANDT I, 1982, CHEM-BIOL INTERACT, V40, P45, DOI 10.1016/0009-2797(82)90027-8.
   BRANDT I, 1983, CARCINOGENESIS, V4, P1291, DOI 10.1093/carcin/4.10.1291.
   BRITTEBO EB, 1981, ACTA PHARMACOL TOX, V48, P355.
   BRITTEBO EB, 1992, CARCINOGENESIS, V13, P2263, DOI 10.1093/carcin/13.12.2263.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   BUONARATI MH, 1992, CARCINOGENESIS, V13, P621, DOI 10.1093/carcin/13.4.621.
   DARNERUD PO, 1986, XENOBIOTICA, V16, P295.
   DOOLEY KL, 1992, CANCER LETT, V62, P205, DOI 10.1016/0304-3835(92)90097-F.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1082.
   GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   JOHANSSONBRITTEBO E, 1979, ACTA PHARMACOL TOX, V45, P73.
   JONSSON CJ, 1992, REPROD TOXICOL, V6, P233, DOI 10.1016/0890-6238(92)90178-V.
   MANABE S, 1992, CARCINOGENESIS, V13, P827, DOI 10.1093/carcin/13.5.827.
   MANABE S, 1993, CARCINOGENESIS, V14, P899, DOI 10.1093/carcin/14.5.899.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   MCMANUS ME, 1989, CARCINOGENESIS, V10, P357, DOI 10.1093/carcin/10.2.357.
   MILLER MS, 1989, CARCINOGENESIS, V10, P875.
   OCHIAI M, 1991, JPN J CANCER RES, V82, P363.
   PELUSO M, 1991, CARCINOGENESIS, V12, P713, DOI 10.1093/carcin/12.4.713.
   SHIOYA M, 1987, MUTAT RES, V191, P133, DOI 10.1016/0165-7992(87)90143-6.
   SKOG K, 1993, FOOD CHEM TOXICOL, V31, P655, DOI 10.1016/0278-6915(93)90049-5.
   SKOG K, 1991, CARCINOGENESIS, V12, P2297, DOI 10.1093/carcin/12.12.2297.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TURTELTAUB KW, 1989, FOOD CHEM TOXICOL, V27, P667, DOI 10.1016/0278-6915(89)90121-X.
   ULLBERG S, 1977, SCI TOOLS LKB INSTRU, P1.
   WADDELL WJ, 1971, TERATOLOGY, V4, P355, DOI 10.1002/tera.1420040311.
   WADDELL WJ, 1971, TERATOLOGY, V5, P219.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P2291, DOI 10.1093/carcin/12.12.2291.
   YANG HYL, 1989, BIOCHEM PHARMACOL, V38, P4027, DOI 10.1016/0006-2952(89)90683-7.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{22}},
Journal-ISO = {{Food Chem. Toxicol.}},
Doc-Delivery-Number = {{PE347}},
Wos-Id = {{ISI:A1994PE34700004}},
}

@article{ ISI:A1994NP07200015,
Author = {PFAU, W and BROCKSTEDT, U and SOHREN, KD and MARQUARDT, H},
Title = {{P-32 POST-LABELING ANALYSIS OF DNA-ADDUCTS FORMED BY FOOD-DERIVED
   HETEROCYCLIC AMINES - EVIDENCE FOR INCOMPLETE HYDROLYSIS AND A PROCEDURE
   FOR ADDUCT PATTERN SIMPLIFICATION}},
Journal = {{CARCINOGENESIS}},
Year = {{1994}},
Volume = {{15}},
Number = {{5}},
Pages = {{877-882}},
Month = {{MAY}},
Abstract = {{Food-derived aminoimidazoazarenes have been shown to be mutagenic and
   carcinogenic and to form covalent DNA adducts. P-32-Post-labelling
   analysis of DNA modified with these heterocyclic amines (HA), including
   2-amino-3-methylimidazo{[}4,5-f]quinoline (IQ),
   2-amino-1-methyl-6-phenylimidazo {[}4,5-b] pyridine (PhIP),
   2-amino-3,4-dimethylimidazo {[}4,5-f]quinoline (MeIQ),
   2-amino-3,4,8-trimethylimidazo {[}4,5-f]quinoxaline (4,8-DiMeIQx),
   2-amino-3,7,8-trimethylimidazo{[}4,5-f]quinoxaline (7,8-DiMeIQx) and
   2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline (MeIQx) has resulted in
   considerable interlaboratory variation in the characteristic patterns of
   DNA adduct spots, with up to six being detected for each compound.
   Similar complex patterns were observed when azido-derivatives of HA were
   photoreacted with calf thymus DNA. When deoxyguanosine 3'-monophosphate
   was modified with the azido derivatives and analysed using the
   P-32-post-labelling procedure, one major spot was observed for IQ,
   4,8-DiMeIQx, 7,8-DiMeIQx or PhIP and two major spots for MeIQ or MeIQx.
   In each case, these adducts were chromatographically indistinguishable
   from the major adducts formed with DNA. No major adduct spots were
   observed when 3'-phosphate derivatives of deoxyadenosine, deoxycytidine
   or thymidine were reacted with the azido-derivatives of HA. In an
   attempt to identify the additional spots, azido derivatives of PhIP or
   IQ were reacted with the synthetic homopolymer poly(dG) poly(dC), the
   alternating copolymer poly(dC-dG) or a synthetic oligonucleotide
   (TTT-GTTTTTTCTTTCCCT): in each case a reduced number of adduct spots
   were detected. The introduction of an additional nuclease P1 hydrolysis
   step following the labelling reaction further reduced the number of
   adduct spots to only one or two major spots. Reversed-phase HPLC
   analysis showed that the number of peaks of radioactivity was also
   reduced to one or two, presumably corresponding to the
   {[}P-32]-5'-monophosphate deoxyguanosine adducts. We suggest that many
   of the additional spots commonly observed in conventional
   P-32-post-labelling analysis of HA-modified DNA are adducted
   oligonucleotides that are partly resistant to hydrolysis by micrococcal
   nuclease and spleen phosphodiesterase but are susceptible to hydrolysis
   by nuclease p1.}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{PFAU, W (Reprint Author), UNIV HAMBURG,SCH MED,DEPT TOXICOL,GRINDELALLEE 117,D-20146 HAMBURG,GERMANY.}},
DOI = {{10.1093/carcin/15.5.877}},
ISSN = {{0143-3334}},
Keywords-Plus = {{SNAKE-VENOM PHOSPHODIESTERASE;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP;
   2-AMINO-3,4-DIMETHYLIMIDAZO<4,5-F>QUINOLINE MEIQ;
   2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE IQ; P-32-POSTLABELING ANALYSIS;
   DEOXYADENOSINE ADDUCTS; COOKED FOOD; HEPATIC DNA; IDENTIFICATION; RATS}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{ASAN E, 1987, CARCINOGENESIS, V8, P1589, DOI 10.1093/carcin/8.11.1589.
   BEACH AC, 1992, CARCINOGENESIS, V13, P1053, DOI 10.1093/carcin/13.7.1053.
   BELAND FA, 1990, HDB EXPT PHARM, V94, P517.
   CHEH AM, 1990, CHEM RES TOXICOL, V3, P545, DOI 10.1021/tx00018a009.
   DIPPLE AJ, 1987, CARCINOGENESIS, V8, P491, DOI 10.1093/carcin/8.3.491.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   GORELICK NJ, 1989, CARCINOGENESIS, V10, P1567, DOI 10.1093/carcin/10.9.1567.
   GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943.
   HALL M, 1990, CARCINOGENESIS, V11, P1005, DOI 10.1093/carcin/11.6.1005.
   LIN D, 1992, CHEM RES TOXICOL, V5, P692.
   OCHIAI M, 1993, CARCINOGENESIS, V14, P2165, DOI 10.1093/carcin/14.10.2165.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   OVERVIK E, 1991, MUTAT RES, V256, P37, DOI 10.1016/0921-8734(91)90031-6.
   PELUSO M, 1991, CARCINOGENESIS, V12, P713, DOI 10.1093/carcin/12.4.713.
   PFAN W, 1991, J CHROMATOGR, V570, P65.
   PFAU W, 1992, CARCINOGENESIS, V13, P907, DOI 10.1093/carcin/13.5.907.
   RANDERATH K, 1993, BIOCHEM BIOPH RES CO, V192, P61, DOI 10.1006/bbrc.1993.1381.
   RANDERATH K, 1989, CARCINOGENESIS, V10, P1231, DOI 10.1093/carcin/10.7.1231.
   RANDERATH K, 1981, P NATL ACAD SCI-BIOL, V78, P6126, DOI 10.1073/pnas.78.10.6126.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SCHUT HAJ, 1988, CANCER LETT, V41, P345, DOI 10.1016/0304-3835(88)90296-0.
   SCHUT HAJ, 1991, CARCINOGENESIS, V12, P931, DOI 10.1093/carcin/12.5.931.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1061, DOI 10.1093/carcin/9.6.1061.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005.
   WAKABAYASHI K, 1992, CANC RES S, V52, pS2093.
   WATSON WP, 1989, MUTAGENESIS, V4, P75, DOI 10.1093/mutage/4.1.75.
   WILD D, 1988, CARCINOGENESIS, V9, P869, DOI 10.1093/carcin/9.5.869.
   WILD D, 1989, CARCINOGENESIS, V10, P335, DOI 10.1093/carcin/10.2.335.
   YAMASHITA K, 1988, NUCL ACID RES S SERI, V19, P11.}},
Number-of-Cited-References = {{31}},
Times-Cited = {{52}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{NP072}},
Wos-Id = {{ISI:A1994NP07200015}},
}

@article{ ISI:A1994NE66500013,
Author = {DAVIS, CD and SCHUT, HAJ and SNYDERWINE, EG},
Title = {{ADDUCTION OF THE HETEROCYCLIC AMINE FOOD MUTAGENS IQ AND PHIP TO
   MITOCHONDRIAL AND NUCLEAR-DNA IN THE LIVER OF FISCHER-344 RATS}},
Journal = {{CARCINOGENESIS}},
Year = {{1994}},
Volume = {{15}},
Number = {{4}},
Pages = {{641-645}},
Month = {{APR}},
Abstract = {{The heterocyclic amines 2-amino-3-methylimidazo{[}4,5-f]quinoline (IQ)
   and 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) are
   carcinogens that form DNA adducts. In the present study, we used the
   P-32-postlabeling method to measure the levels of IQ and PhIP adducts in
   hepatic nuclear and mitochondrial DNA of Fischer-344 rats given a single
   dose (100 mg/kg, p.o.) or 10 doses of either carcinogen. After a single
   dose of IQ, adduct levels were > 2-fold higher in hepatic nuclear than
   in mitochondrial DNA; however, after repeated IQ exposure, the levels of
   adducts in nuclear and mitochondrial DNA were not significantly
   different. In contrast, after a single dose of PhIP, there were no
   significant differences in adduct levels in nuclear and mitochondrial
   DNA; however, after multiple doses of PhIP, adduct levels were
   significantly higher in mitochondrial DNA than in nuclear DNA. The
   percentages of individual IQ or PhIP adducts were different between
   nuclear DNA and mitochondrial DNA, particularly after 10 doses. With IQ,
   the C8-guanine adduct accounted for 72\% of the total IQ adduct levels
   in nuclear DNA but only 40\% of total adduct levels in mitochondrial
   DNA. After 10 doses of PhIP, the C8-guanine adduct accounted for 48\%
   and 15\% of total adduct levels in nuclear DNA and mitochondrial DNA
   respectively. In addition, the percentage of an uncharacterized PhIP
   adduct was 14\% in nuclear DNA but <1\% in mitochondrial DNA. The
   percentages of individual adducts were approximately the same 3, 24, 120
   and 240 h after a single dose of either compound, though total IQ and
   PhIP adduct levels appeared to decline over time in both organelles. The
   significance of IQ and PhIP mitochondrial DNA adduction and the
   influence of distinct heterocyclic amine adducts on carcinogenesis merit
   further investigation.}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{DAVIS, CD (Reprint Author), NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892, USA.
   MED COLL OHIO,DEPT PATHOL,TOLEDO,OH 43614.}},
DOI = {{10.1093/carcin/15.4.641}},
ISSN = {{0143-3334}},
Keywords-Plus = {{COOKED FOOD; CARCINOGEN; REPAIR; CELLS; BINDING;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE;
   2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE; IDENTIFICATION; AFLATOXIN-B1;
   MUTATIONS}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{ADAMSON RH, 1991, XENOBIOTICS AND CANCER, P289.
   ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   ALLEN JA, 1980, NATURE, V287, P244, DOI 10.1038/287244a0.
   ARRAND JE, 1982, NUCLEIC ACIDS RES, V10, P1547, DOI 10.1093/nar/10.5.1547.
   BACKER JM, 1982, CANCER RES, V42, P2764.
   BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9.
   BARANYIFURLONG BL, 1984, CHEM-BIOL INTERACT, V48, P15, DOI 10.1016/0009-2797(84)90003-6.
   BERKOWITZ EML, 1981, CANCER LETT, V12, P311, DOI 10.1016/0304-3835(81)90173-7.
   BOHR VA, 1987, CANCER RES, V47, P6426.
   BOLES TC, 1984, P NATL ACAD SCI-BIOL, V81, P5623, DOI 10.1073/pnas.81.18.5623.
   BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967.
   DAVIS CD, 1994, TOXICOL APPL PHARM, V124, P201, DOI 10.1006/taap.1994.1024.
   DOLL R, 1981, J NATL CANCER I, V66, P1191.
   DUAN JM, 1989, MOL CELL BIOCHEM, V90, P47.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943.
   HADLER HI, 1973, CANCER RES, V33, P117.
   HEMMINKI K, 1983, ARCH TOXICOL, V52, P249, DOI 10.1007/BF00316495.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KOOTSTRA A, 1986, NUCLEIC ACIDS RES, V14, P9897, DOI 10.1093/nar/14.24.9897.
   LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967.
   MYERS KA, 1988, CARCINOGENESIS, V9, P285, DOI 10.1093/carcin/9.2.285.
   NIRANJAN BG, 1980, BIOCHEM BIOPH RES CO, V94, P1021, DOI 10.1016/0006-291X(80)91336-4.
   NIRANJAN BG, 1982, SCIENCE, V215, P73, DOI 10.1126/science.6797067.
   Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SCHUT HAJ, 1988, CANCER LETT, V41, P345, DOI 10.1016/0304-3835(88)90296-0.
   SHAMSUDDIN AM, 1987, CARCINOGENESIS, V2, P109.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1739, DOI 10.1093/carcin/9.10.1739.
   SUGIMURA T, 1982, CANCER, V49, P1970, DOI 10.1002/1097-0142(19820515)49:10<1970::AID-CNCR2820491005>3.0.CO;2-F.
   SUGIMURA T, 1985, MUTAT RES, V150, P33, DOI 10.1016/0027-5107(85)90098-3.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TAKAYAMA S, 1984, GANN, V75, P467.
   THOMPSON LH, 1987, MUTAGENESIS, V2, P483, DOI 10.1093/mutage/2.6.483.
   WALLACE DC, 1989, TRENDS GENET, V5, P9, DOI 10.1016/0168-9525(89)90005-X.
   WILKINSON R, 1975, CHEM-BIOL INTERACT, V9, P157.
   1989, SAS USERS GUIDE STAT, P891.}},
Number-of-Cited-References = {{39}},
Times-Cited = {{21}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{NE665}},
Wos-Id = {{ISI:A1994NE66500013}},
}

@article{ ISI:A1994ND49200015,
Author = {CAROTHRS, AM and YUAN, W and HINGERTY, BE and BROYDE, S and GRUNBERGER,
   D and SNYDERWINE, EG},
Title = {{MUTATION AND REPAIR INDUCED BY THE CARCINOGEN
   2-(HYDROXYAMINO)-1-METHYL-6-PHENYLIMIDAZO{[}4,5-B]PYRIDINE (N-OH-PHIP)
   IN THE DIHYDROFOLATE-REDUCTASE GENE OF CHINESE-HAMSTER OVARY CELLS AND
   CONFORMATIONAL MODELING OF THE DG-C8-PHIP ADDUCT IN DNA}},
Journal = {{CHEMICAL RESEARCH IN TOXICOLOGY}},
Year = {{1994}},
Volume = {{7}},
Number = {{2}},
Pages = {{209-218}},
Month = {{MAR-APR}},
Abstract = {{Three experiments using 20 muM
   2-(hydroxyamino)-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (N-OH-PhIP)
   were performed to induce mutations in the dihydrofolate reductase (DHFR)
   gene of a hemizygous Chinese hamster ovary (CHO) cell line (UA21).
   Metabolized forms of this chemical primarily bind at the C-8 position of
   guanine in DNA. In total, 21 independent induced mutants were isolated
   and 20 were characterized. DNA sequencing showed that the preferred
   mutation type found in 75\% of the induced DHFR- clones was G.C --> T.A
   single and tandem double transversions. In addition to base
   substitutions, one mutant carried a -1 frameshift and another one had
   lost the entire locus by deletion. The induced changes affected purine
   targets on the nontranscribed strand of the gene in nearly all of the
   mutants sequenced (18/19). At the time that the first two experiments
   were performed, the initial adduct levels were quantitated in treated
   cells at the mutagenic dose by P-32-postlabeling. While the induced
   frequency of mutation was relatively low (approximately 5 X 10(-6)), the
   adduct levels after a 1-h exposure of UA21 cells to 20 muM N-OH-PhIP
   were relatively high (13 adducts x 10(-6) nucleotides). This latter
   method was then employed to learn if the induced mutation frequency
   correlated with rapid overall genome repair of PhIP-DNA adducts. Total
   adduct levels, determined using DNA samples from treated cells collected
   after intervals of time, were reduced by about 50\% after 6 h, and about
   70\% after 24 h. Since overall genome repair in CHO cells is relatively
   slow compared with preferential gene repair, the removal of dG-C8-PhIP
   adducts was apparently efficient. In order to better understand the
   mutational and repair results, we performed computational modeling to
   determine the lowest energy structure for the major dG-C8-PhIP adduct in
   a repetitively mutated duplex sequence opposite dA. Results of this
   analysis indicate that the PhIP-modified base resembles previous
   structural determinations of (deoxyguanosin-8-yl)-aminofluorene; the
   carcinogen is in the B-DNA minor groove and it adopts a syn conformation
   mispaired with an anti A. The implications of this conformational
   distortion in DNA structure for damage recognition by cellular repair
   enzymes are discussed.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{CAROTHRS, AM (Reprint Author), COLUMBIA UNIV,INST CANC,701 W 168TH ST,ROOM 532,NEW YORK,NY 10027, USA.
   NCI,DIV CANC ETIOL,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892.
   OAK RIDGE NATL LAB,HLTH SCI RES UNIT,OAK RIDGE,TN 37831.
   NYU,DEPT BIOL,NEW YORK,NY 10003.}},
DOI = {{10.1021/tx00038a015}},
ISSN = {{0893-228X}},
Keywords-Plus = {{FOOD MUTAGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE;
   CRYSTAL-STRUCTURE; SPLICING MUTATIONS; MAMMALIAN-CELLS; PYRIDINE PHIP;
   BASE-PAIRS;
   (+/-)-3-ALPHA,4-BETA-DIHYDROXY-1-ALPHA,2-ALPHA-EPOXY-1,2,3,4-TETRAHYDROB
   ENZO<C>.; IDENTIFICATION; SEQUENCE; GUANINE}},
Research-Areas = {{Pharmacology \& Pharmacy; Chemistry; Toxicology}},
Web-of-Science-Categories  = {{Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology}},
Cited-References = {{AKIYAMA M, 1986, J PHYS CHEM-US, V90, P1752, DOI 10.1021/j100400a005.
   ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043.
   Arnott S., 1976, HDB BIOCHEMISTRY MOL, VII, P411.
   BOHR VA, 1988, DNA REPAIR LABORATOR, V3, P347.
   BROWN T, 1989, J MOL BIOL, V207, P455, DOI 10.1016/0022-2836(89)90268-4.
   BROWN T, 1986, P NATL ACAD SCI USA, V83, P2402, DOI 10.1073/pnas.83.8.2402.
   BROWN TC, 1988, CELL, V54, P705, DOI 10.1016/S0092-8674(88)80015-1.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   CAROTHERS AM, 1992, P NATL ACAD SCI USA, V89, P11925, DOI 10.1073/pnas.89.24.11925.
   CAROTHERS AM, 1993, CARCINOGENESIS, V14, P2181, DOI 10.1093/carcin/14.10.2181.
   CAROTHERS AM, 1986, P NATL ACAD SCI USA, V83, P6519, DOI 10.1073/pnas.83.17.6519.
   CAROTHERS AM, 1993, MOL CELL BIOL, V13, P5085.
   CAROTHERS AM, 1989, BIOTECHNIQUES, V7, P494.
   CAROTHERS AM, 1990, P NATL ACAD SCI USA, V87, P5464, DOI 10.1073/pnas.87.14.5464.
   CAROTHERS AM, 1989, J MOL BIOL, V208, P417, DOI 10.1016/0022-2836(89)90506-8.
   CAROTHERS AM, 1991, P NATL ACAD SCI USA, V88, P5749, DOI 10.1073/pnas.88.13.5749.
   DREW HR, 1981, P NATL ACAD SCI-BIOL, V78, P2179, DOI 10.1073/pnas.78.4.2179.
   ESUMI H, 1991, JPN J CANCER RES, V82, P363.
   FELTON JS, 1991, MUTAGENS FOOD DETECT, P58.
   FRANDSEN H, 1991, MUTAGENESIS, V6, P93, DOI 10.1093/mutage/6.1.93.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   FREARSON PM, 1966, CANCER RES, V41, P1653.
   GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081.
   HINGERTY B, 1982, BIOCHEMISTRY-US, V21, P3243, DOI 10.1021/bi00256a034.
   HINGERTY BE, 1989, BIOPOLYMERS, V28, P1195, DOI 10.1002/bip.360280703.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   HOWARD PC, 1981, CARCINOGENESIS, V2, P97, DOI 10.1093/carcin/2.2.97.
   HUNTER WN, 1986, J BIOMOL STRUCT DYN, V4, P173.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   Kadlubar F. F., 1990, HDB EXPT PHARM CHEM, P267.
   KRIEK E, 1980, CARCINOGENESIS, V1, P459, DOI 10.1093/carcin/1.6.459.
   KRIEK E, 1967, BIOCHEMISTRY-US, V6, P177, DOI 10.1021/bi00853a029.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MAH MCM, 1991, P NATL ACAD SCI USA, V88, P10193, DOI 10.1073/pnas.88.22.10193.
   MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945.
   MELERA PW, 1984, MOL CELL BIOL, V4, P38.
   MITCHELL PJ, 1986, MOL CELL BIOL, V6, P1926.
   MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405.
   NAGAOKA H, 1992, JPN J CANCER RES, V83, P1025.
   NORMAN D, 1989, BIOCHEMISTRY-US, V28, P7462, DOI 10.1021/bi00444a046.
   OCHIAI M, 1991, JPN J CANCER RES, V82, P363.
   OHANDLEY SF, 1993, BIOCHEMISTRY-US, V32, P2481, DOI 10.1021/bi00061a005.
   ORNSTEIN RL, 1979, BIOPOLYMERS, V18, P1277, DOI 10.1002/bip.1979.360180517.
   Pfau W., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P133.
   Prive G. G., 1988, STRUCTURE EXPRESSION, V2, P27.
   PRIVE GG, 1987, SCIENCE, V238, P498, DOI 10.1126/science.3310237.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P2198, DOI 10.1021/bi00356a052.
   SHAPIRO R, 1989, J BIOMOL STRUCT DYN, V7, P493.
   SHIBUTANI S, 1990, J AM CHEM SOC, V112, P5667, DOI 10.1021/ja00170a056.
   SKELLY JV, 1993, P NATL ACAD SCI USA, V90, P804, DOI 10.1073/pnas.90.3.804.
   SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389.
   TANG MS, 1989, J BIOL CHEM, V264, P14455.
   TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P941, DOI 10.1093/carcin/11.6.941.
   URLAUB G, 1981, CANCER RES, V41, P1594.
   URLAUB G, 1983, CELL, V33, P405, DOI 10.1016/0092-8674(83)90422-1.
   VANHOUTE LPA, 1990, CARCINOGENESIS, V11, P701, DOI 10.1093/carcin/11.4.701.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   WEBSTER GD, 1990, P NATL ACAD SCI USA, V87, P6693, DOI 10.1073/pnas.87.17.6693.
   YANG JL, 1988, MOL CELL BIOL, V8, P3364.}},
Number-of-Cited-References = {{63}},
Times-Cited = {{40}},
Journal-ISO = {{Chem. Res. Toxicol.}},
Doc-Delivery-Number = {{ND492}},
Wos-Id = {{ISI:A1994ND49200015}},
}

@article{ ISI:A1993LU65600008,
Author = {TAKAHASHI, M and TOYODA, K and AZE, Y and FURUTA, K and MITSUMORI, K and
   HAYASHI, Y},
Title = {{THE RAT URINARY-BLADDER AS A NEW TARGET OF HETEROCYCLIC AMINE
   CARCINOGENICITY - TUMOR-INDUCTION BY
   3-AMINO-1-METHYL-5H-PYRIDO{[}4,3-B]INDOLE ACETATE}},
Journal = {{JAPANESE JOURNAL OF CANCER RESEARCH}},
Year = {{1993}},
Volume = {{84}},
Number = {{8}},
Pages = {{852-858}},
Month = {{AUG}},
Abstract = {{In order to examine the carcinogenicity of
   3-amino-1-methyl-5H-pyrido{[}4,3-b]indole acetate (Trp-P-2), 30 male and
   30 female F344 rats were maintained on diet containing 0, 30, or 100 ppm
   Trp-P-2 for 112 weeks. The overall mean chemical intakes in the 100 ppm
   and 30 ppm groups were 3.84 and 1.14 mg/kg/day in males, and 4.57 and
   1.34 mg/kg/day in females, respectively. Females of the 100 ppm group
   showed increased mortality in the late period of the study. In the 100
   ppm group, significant increases in the incidences of neoplastic lesions
   were found in the liver, urinary bladder and mammary gland in males, and
   in the mammary gland, hematopoietic system and clitoral gland in
   females. Histologically, tumors induced by Trp-P-2 were hepatocellular
   adenomas, transitional cell tumors (papillomas and carcinomas) of the
   urinary bladder, fibroadenomas/fibromas of the mammary gland, malignant
   lymphomas and clitoral gland tumors (adenomas and adenocarcinomas).
   These results indicate multi-target carcinogenicity of Trp-P-2 in F344
   rats and provide evidence that the urinary bladder is also a target for
   heterocyclic amine action.}},
Publisher = {{JAPANESE CANCER ASSOCIATION}},
Address = {{EDITORIAL OFFICE 7TH FLOOR, JOHKOH BLDG 2-23-11, KOISHIKAWA, TOKYO 112,
   JAPAN}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{TAKAHASHI, M (Reprint Author), NATL INST HLTH SCI,DIV PATHOL,1-18-1 KAMIYOGA,SETAGAYA KU,TOKYO 158,JAPAN.}},
ISSN = {{0910-5050}},
Keywords = {{TRP-P-2; HETEROCYCLIC AMINE; F344 RAT; CARCINOGENICITY; URINARY BLADDER
   TUMOR}},
Keywords-Plus = {{COOKED-FOOD; MOUSE SKIN; TRYPTOPHAN; MUTAGENS; TRP-P-2; ACIDS}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{COHEN SM, 1979, CANCER RES, V39, P1207.
   HASHIDA C, 1982, CANCER LETT, V17, P101, DOI 10.1016/0304-3835(82)90115-X.
   HASHIMOTO Y, 1982, MUTAT RES, V105, P9, DOI 10.1016/0165-7992(82)90200-7.
   HASHIMOTO Y, 1979, CHEM PHARM BULL, V27, P1058.
   HOSAKA S, 1981, CANCER LETT, V13, P23, DOI 10.1016/0304-3835(81)90082-3.
   ISHIDA Y, 1987, TOXICOL IN VITRO, V1, P45, DOI 10.1016/0887-2333(87)90037-3.
   ISHIKAWA T, 1979, J CANCER RES CLIN, V95, P221, DOI 10.1007/BF00410642.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   MAEKAWA A, 1983, JPN J CANCER RES, V74, P365.
   MATSUKURA N, 1981, SCIENCE, V213, P346, DOI 10.1126/science.7244619.
   NAGAO M, 1980, CARCINOGENESIS, V1, P451, DOI 10.1093/carcin/1.5.451.
   SATO H, 1987, CARCINOGENESIS, V8, P1231, DOI 10.1093/carcin/8.9.1231.
   STEINECK G, 1990, INT J CANCER, V45, P1006, DOI 10.1002/ijc.2910450604.
   SUGIMURA T, 1979, NATURALLY OCCURRING, P241.
   SUGIMURA T, 1989, FOOD TOXICOLOGY PERS, P31.
   TAKAHASHI M, 1986, JPN J CANCER RES, V77, P509.
   THOMPSON LH, 1983, MUTAT RES, V117, P243, DOI 10.1016/0165-1218(83)90125-8.
   TOHDA H, 1980, MUTAT RES, V77, P65, DOI 10.1016/0165-1218(80)90121-4.
   WAKATA A, 1985, CANCER RES, V45, P5867.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{18}},
Journal-ISO = {{Jpn. J. Cancer Res.}},
Doc-Delivery-Number = {{LU656}},
Wos-Id = {{ISI:A1993LU65600008}},
}

@article{ ISI:A1993LM97800023,
Author = {SNYDERWINE, EG and DAVIS, CD and NOUSO, K and ROLLER, PP and SCHUT, HAJ},
Title = {{P-32 POSTLABELING ANALYSIS OF IQ, MEIQX AND PHIP ADDUCTS FORMED IN-VITRO
   IN DNA AND POLYNUCLEOTIDES AND FOUND IN-VIVO IN HEPATIC DNA FROM
   IQ-TREATED, MEIQX-TREATED AND PHIP-TREATED MONKEYS}},
Journal = {{CARCINOGENESIS}},
Year = {{1993}},
Volume = {{14}},
Number = {{7}},
Pages = {{1389-1395}},
Month = {{JUL}},
Abstract = {{The P-32-postlabeling method was used to examine the adducts in DNA,
   polynucleotides, and mononucleotides reacted in vitro with the N-hydroxy
   and N-acetoxy derivatives of 2-amino-3-methylimidazo{[}4,5-f]quinoline
   (IQ), 2-amino-3, 8-dimethylimidazo{[}4,5-f]quinoxaline (MeIQx) or
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP). Adduct
   profiles were compared to those found in vivo in liver of cynomolgus
   monkeys fed IQ, MeIQx or PhIP. The N-acetoxy derivatives of IQ, MeIQx
   and PhIP (generated in situ from the corresponding N-hydroxylamine in
   the presence of acetic anhydride) each formed three principal adducts in
   DNA. Adduct 1 of IQ, MeIQx and PhIP was chromatographically identical to
   the P-32-labeled bis(phosphate) derivative of N-(deoxyguanosin-8-yl)-IQ,
   N-(deoxyguanosin-8-yl)-MeIQx, and N-(deoxyguanosin-8-yl)-PhIP
   respectively, and this adduct comprised approximately 65\% of total
   adduct levels found in DNA in vitro. The C8-guanine adduct and the two
   minor adducts were also found in poly(dG-dC).poly(dG-dC), suggesting
   that the two minor adducts of IQ, MeIQx and PhIP are also formed on the
   guanine base. The N-acetoxy derivatives of IQ, MeIQx, and to a much
   lesser extent PhIP, also formed adducts with adenine-containing
   polynucleotides including poly(dA), poly(dA).poly(dT) and
   poly(dA-dT).poly(dA-dT), but these adenine adducts were
   chromatographically different from those found in DNA. The three guanine
   adducts of N-acetoxy-IQ, -MeIQx and -PhIP found in vitro in DNA and in
   guanine-containing polynucleotides were also found in the liver of
   monkeys fed IQ, MeIQx or PhIP respectively, indicating that metabolic
   activation via N-hydroxylation and esterification occurred in vivo in
   monkeys. With each compound, the C8-guanine adduct was the predominant
   adduct found in vivo. The results indicate similarities among IQ, MeIQx
   and PhIP in the DNA adducts formed in vitro and in vivo and substantiate
   the use of the P-32-postlabeling method for comparative adduct studies.}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{SNYDERWINE, EG (Reprint Author), NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892, USA.
   NCI,MED CHEM LAB,BETHESDA,MD 20892.
   MED COLL OHIO,DEPT PATHOL,TOLEDO,OH 43699.}},
DOI = {{10.1093/carcin/14.7.1389}},
ISSN = {{0143-3334}},
Keywords-Plus = {{FOOD-BORNE CARCINOGEN; HETEROCYCLIC AMINES;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; COOKED FOOD;
   METABOLIC-ACTIVATION; URINARY MUTAGENS; BLACK TOBACCO; CDF1 MICE;
   IDENTIFICATION; BINDING}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{ADAMSON RH, 1991, XENOBIOTICS AND CANCER, P289.
   ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   ASAN E, 1987, CARCINOGENESIS, V8, P1589, DOI 10.1093/carcin/8.11.1589.
   BEACH AC, 1992, CARCINOGENESIS, V13, P1053, DOI 10.1093/carcin/13.7.1053.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   DAVIS CD, 1993, CARCINOGENESIS, V14, P61, DOI 10.1093/carcin/14.1.61.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943.
   GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081.
   HALL M, 1990, CARCINOGENESIS, V11, P1005, DOI 10.1093/carcin/11.6.1005.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KATO R, 1987, JPN J CANCER RES, V78, P297.
   KRIEK E, 1979, CHEM CARCINOGENS DNA, V2, P1.
   KRIEK E, 1971, CHEM-BIOL INTERACT, V3, P397, DOI 10.1016/0009-2797(71)90019-6.
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016.
   MENICHINI P, 1989, CARCINOGENESIS, V10, P1589, DOI 10.1093/carcin/10.9.1589.
   NAGAOKA H, 1992, JPN J CANCER RES, V83, P1025.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   OVERVIK E, 1991, MUTAT RES, V256, P37, DOI 10.1016/0921-8734(91)90031-6.
   PELUSO M, 1990, CARCINOGENESIS, V11, P1307, DOI 10.1093/carcin/11.8.1307.
   PELUSO M, 1991, CARCINOGENESIS, V12, P713, DOI 10.1093/carcin/12.4.713.
   PULKRABEK P, 1979, BIOCHEMISTRY-US, V18, P5128, DOI 10.1021/bi00590a016.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   SCHUT HAJ, 1992, CANCER LETT, V67, P117, DOI 10.1016/0304-3835(92)90134-H.
   SCHUT HAJ, 1988, CANCER LETT, V41, P345, DOI 10.1016/0304-3835(88)90296-0.
   SCHUT HAJ, 1991, CARCINOGENESIS, V12, P931, DOI 10.1093/carcin/12.5.931.
   SNYDERWINE EG, 1987, CARCINOGENESIS, V8, P1017, DOI 10.1093/carcin/8.7.1017.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1739, DOI 10.1093/carcin/9.10.1739.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1061, DOI 10.1093/carcin/9.6.1061.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P411, DOI 10.1093/carcin/9.3.411.
   SNYDERWINE EG, 1992, CANCER RES, V52, pS2099.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TANAKA T, 1985, JPN J CANCER RES, V76, P570.
   TURESKY RJ, 1990, CHEM RES TOXICOL, V3, P524, DOI 10.1021/tx00018a006.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P43, DOI 10.1093/carcin/11.1.43.
   WATANABE T, 1982, FEBS LETT, V150, P434, DOI 10.1016/0014-5793(82)80784-9.
   YAMASHITA K, 1988, NUCLEIC ACIDS RES S, V19, P111.}},
Number-of-Cited-References = {{41}},
Times-Cited = {{92}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{LM978}},
Wos-Id = {{ISI:A1993LM97800023}},
}

@article{ ISI:A1993LC43000020,
Author = {WAKABAYASHI, K and USHIYAMA, H and TAKAHASHI, M and NUKAYA, H and KIM,
   SB and HIROSE, M and OCHIAI, M and SUGIMURA, T and NAGAO, M},
Title = {{EXPOSURE TO HETEROCYCLIC AMINES}},
Journal = {{ENVIRONMENTAL HEALTH PERSPECTIVES}},
Year = {{1993}},
Volume = {{99}},
Pages = {{129-133}},
Month = {{MAR}},
Abstract = {{Many mutagenic heterocyclic amines (HAs) have been isolated from cooked
   foods and pyrolysates of amino acids and proteins, and the
   carcinogenicity of 10 of these HAs in rodents and of 1 in monkeys has
   been reported. Quantification of these carcinogenic HAs in various kinds
   of cooked foods indicated that the level of
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) was highest
   (0.56-69.2 ng/g), that of
   2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline (MeIQx) was second
   highest (0.64-6.44 ng/g), and those of other HAs were 0,03-2.50 ng/g.
   Heterocyclic amines were found in urine samples of 10 healthy volunteers
   consuming a normal diet, but HAs were not detectable in urine samples of
   three patients receiving parenteral alimentation. These results strongly
   suggest that humans are continuously exposed to HAs derived from food in
   the normal diet. Based on quantitative data on the levels of HAs in
   cooked foods and urine samples, the daily exposures to PhIP and MeIQx
   were estimated to be 0.1-13.8 mug and 0.2-2.6 mug per person,
   respectively. These levels of carcinogenic HAs are in the same range as
   those of other carcinogens such as N-nitrosodimethylamine and
   benzo{[}a]pyrene to which humans are exposed.}},
Publisher = {{US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE}},
Address = {{NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{WAKABAYASHI, K (Reprint Author), NATL CANC CTR, RES INST, DIV CARCINOGENESIS, 1-1 TSUKIJI 5-CHOME, CHUO KU, TOKYO 104, JAPAN.
   TOKYO METROPOLITAN RES LAB PUBL HLTH, SHINJUKU KU, TOKYO 169, JAPAN.
   SHIZUOKA PREFECTURAL INST PUBL HLTH \& ENVIRONM SCI, SHIUOKA 420, JAPAN.
   UNIV SHIZUOKA, SCH PHARMACEUT SCI, OYA, SHIZUOKA 422, JAPAN.}},
DOI = {{10.2307/3431468}},
ISSN = {{0091-6765}},
Keywords-Plus = {{2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; COOKED FOOD; DNA
   ADDUCTS; LIVER; MUTAGEN; 2-AMINO-3,8-DIMETHYLIMIDAZO<4,5-F>QUINOXALINE;
   2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE; INDUCTION; BEEF; IDENTIFICATION}},
Research-Areas = {{Environmental Sciences \& Ecology; Public, Environmental \& Occupational
   Health}},
Web-of-Science-Categories  = {{Environmental Sciences; Public, Environmental \& Occupational Health}},
Cited-References = {{ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   ISHIDA Y, 1987, TOXICOL IN VITRO, V1, P45, DOI 10.1016/0887-2333(87)90037-3.
   ITO N, 1991, CARCINOGENESIS, V12, P767, DOI 10.1093/carcin/12.5.767.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   JAGERSTAD M, 1984, MUTAT RES, V126, P239, DOI 10.1016/0027-5107(84)90002-2.
   KNIZE MG, 1990, CARCINOGENESIS, V11, P2259, DOI 10.1093/carcin/11.12.2259.
   MURRAY S, 1989, CARCINOGENESIS, V10, P763, DOI 10.1093/carcin/10.4.763.
   NUKAYA H, 1991, CHEM PHARM BULL, V39, P533.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   SATOH A, 1984, J FOOD HYG SOC JPN, V26, P184.
   SCANLAN RA, 1983, CANCER RES, V43, P2435.
   SHIOYA M, 1987, MUTAT RES, V191, P133, DOI 10.1016/0165-7992(87)90143-6.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1739, DOI 10.1093/carcin/9.10.1739.
   SUGIMURA T, 1986, SCIENCE, V233, P312, DOI 10.1126/science.3088728.
   SUGIMURA T, 1988, CHEM INDUCTION CAN C, V3, P681.
   SUGIMURA T, 1988, TRENDS PHARMACOL SCI, V9, P205.
   TAKAHASHI M, 1985, CARCINOGENESIS, V6, P1195, DOI 10.1093/carcin/6.8.1195.
   TAYLOR RT, 1988, ENV MUTAGEN S11, V11, P104.
   TSUDA H, 1988, JPN J CANCER RES, V79, P691.
   TURTELTAUB KW, 1990, P NATL ACAD SCI USA, V87, P5288, DOI 10.1073/pnas.87.14.5288.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901.
   WAKABAYASHI K, 1992, CANCER RES, V52, pS2092.
   YAMASHITA K, 1990, JPN J CANCER RES, V81, P470.
   YAMAZOE Y, 1988, JPN J CANCER RES, V79, P1159.
   YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252.
   ZHANG XM, 1988, MUTAT RES, V201, P181, DOI 10.1016/0027-5107(88)90124-8.
   1990, PRESENT STATUS NATIO.
   1983, IARC MONOGRAPHS EVAL, V32, P33.
   1989, ANN REPORT COMPREHEN, P70.
   1981, HLTH EFFECTS NITRATE.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{158}},
Journal-ISO = {{Environ. Health Perspect.}},
Doc-Delivery-Number = {{LC430}},
Wos-Id = {{ISI:A1993LC43000020}},
}

@article{ ISI:A1993LC43000029,
Author = {TURTELTAUB, KW and VOGEL, JS and FRANTZ, C and BUONARATI, MH and FELTON,
   JS},
Title = {{LOW-LEVEL BIOLOGICAL DOSIMETRY OF HETEROCYCLIC AMINE CARCINOGENS
   ISOLATED FROM COOKED FOOD}},
Journal = {{ENVIRONMENTAL HEALTH PERSPECTIVES}},
Year = {{1993}},
Volume = {{99}},
Pages = {{183-186}},
Month = {{MAR}},
Note = {{CONF ON BIOMONITORING AND SUSCEPTIBILITY MARKERS IN HUMAN CANCER :
   APPLICATIONS IN MOLECULAR EPIDEMIOLOGY AND RISK ASSESSMENT, KAILUA KONA,
   HI, OCT 26-NOV 01, 1991}},
Organization = {{INT AGCY RES CANC; NATL CTR TOXICOL RES; US EPA; COMMISS EUROPEAN
   COMMUNITIES; NATL CANC INST}},
Abstract = {{The bioavailability and the bioreactivity of the carcinogenic
   heterocyclic amine
   12-C-14]2-amino-1-methyl-6-phenyl-imidazo{[}4,5b]pyridine (PhIP) have
   been investigated at a dose approximating that likely from the human
   diet by accelerator mass spectrometry (AMS). 12-C-14]PhIP was
   administered to mice at a dose equivalent to the consumption of two 100
   g beef patties (41 ng/kg). The biological half-life of PhIP was 1 hr,
   with 90\% of the dose being excreted via the urine. Peak tissue PhIP
   concentrations were reached within 3 hr, with the highest levels in the
   tissues of the gastrointestinal tract, followed by the liver, kidney,
   pancreas, and thymus. Since the detection limit by AMS is dependent on
   the natural abundance of C-14, we have achieved further increases in
   sensitivity by producing mice that have 20\% of the natural abundance of
   C-14. Use of these C-14-depleted animals allows measurements to be made
   near the natural level of exposure for many environmental carcinogens.
   PhIP-DNA adduct levels have also been measured by P-32-postlabeling at
   doses of 1.0, 10, and 20 mg/kg. The highest adduct levels were found in
   the pancreas, thymus, heart, and liver and increased linearly with dose.
   The principal adducts are derived from guanine.}},
Publisher = {{NATL INST ENVIRON HEALTH SCI}},
Address = {{PO BOX 12233, RES TRIANGLE PK, NC 27709}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{TURTELTAUB, KW (Reprint Author), LAWRENCE LIVERMORE NATL LAB,DIV BIOMED SCI L452,LIVERMORE,CA 94550, USA.
   LAWRENCE LIVERMORE NATL LAB,CTR ACCELERATOR MASS SPECTROMETRY,LIVERMORE,CA 94550.}},
DOI = {{10.2307/3431477}},
ISSN = {{0091-6765}},
Keywords-Plus = {{ACCELERATOR MASS-SPECTROMETRY; BIO-MEDICAL SCIENCES; EXPOSURE; DNA}},
Research-Areas = {{Environmental Sciences \& Ecology; Public, Environmental \& Occupational
   Health}},
Web-of-Science-Categories  = {{Environmental Sciences; Public, Environmental \& Occupational Health}},
Cited-References = {{BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   DAVIS JC, 1990, NUCL INSTRUM METH B, V52, P269, DOI 10.1016/0168-583X(90)90419-U.
   FELTON JS, 1990, HDB EXPT PHARM, V94, P471.
   FELTON JS, 1990, NUCL INSTRUM METH B, V52, P517, DOI 10.1016/0168-583X(90)90469-B.
   OHGAKI H, 1991, MUTAGENS FOOD DETECT, P219.
   SCHULTE P, 1991, ENVIRON HEALTH PERSP, V90, P239, DOI 10.2307/3430874.
   TURTELTAUB KW, 1990, P NATL ACAD SCI USA, V87, P5288, DOI 10.1073/pnas.87.14.5288.
   VOGEL JS, 1989, RADIOCARBON, V31, P145.
   VOGEL JS, 1990, NUCL INSTRUM METH B, V52, P524, DOI 10.1016/0168-583X(90)90470-F.}},
Number-of-Cited-References = {{9}},
Times-Cited = {{19}},
Journal-ISO = {{Environ. Health Perspect.}},
Doc-Delivery-Number = {{LC430}},
Wos-Id = {{ISI:A1993LC43000029}},
}

@article{ ISI:A1993KJ99000011,
Author = {DAVIS, CD and SCHUT, HAJ and ADAMSON, RH and THORGEIRSSON, UP and
   THORGEIRSSON, SS and SNYDERWINE, EG},
Title = {{MUTAGENIC ACTIVATION OF IQ, PHIP AND MEIQX BY HEPATIC MICROSOMES FROM
   RAT, MONKEY AND MAN - LOW MUTAGENIC ACTIVATION OF MEIQX IN CYNOMOLGUS
   MONKEYS INVITRO REFLECTS LOW DNA ADDUCT LEVELS INVIVO}},
Journal = {{CARCINOGENESIS}},
Year = {{1993}},
Volume = {{14}},
Number = {{1}},
Pages = {{61-65}},
Month = {{JAN}},
Abstract = {{Cooked meat, poultry and fish contain a number of mutagenic and
   carcinogenic heterocyclic amines, including
   2-amino-3-methylimidazo{[}4,5-f]quinoline (IQ),
   2-amino-3,8-dimethyl-imidazo{[}4,5-f]quinoxaline (MeIQx) and
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP). In the present
   study we examined the capacity of hepatic microsomes from Fischer 344
   rats, cynomolgus monkeys and humans to metabolically activate IQ, MeIQx
   and PhIP in vitro using the Ames Salmonella mutagenicity assay. The
   mutagenic activation of IQ was similar among the three species; however,
   there were significant differences among the species in the activation
   of PhIP and MeIQx. Liver microsomes from humans showed the greatest
   capacity to activate PhIP and MeIQx, followed by rats, and then monkeys.
   The largest differences between the species were observed when MeIQx was
   used as the mutagen. MeIQx-DNA adducts formed in vivo were then compared
   among rats and monkeys given MeIQx by gavage (20 mg/kg/day, 10 doses).
   P-32-Postlabeling analysis, carried out under intensification
   conditions, was used to examine MeIQx - DNA adducts in the liver,
   kidney, heart, colon and white blood cells. MeIQx-DNA adducts were
   highest in all tissues examined from male rats, followed by female rats,
   and much lower in monkeys. In the liver, the total MeIQx - DNA adduct
   levels of monkeys were approximately 19 and approximately 10 times lower
   than in male and female rats respectively. In extrahepatic tissues, the
   differences in MeIQx-DNA adduct levels between monkeys and rats were
   even greater. The results suggest that the low level of MeIQx - DNA
   adducts found in vivo in cynomolgus monkeys reflects a low capacity to
   activate MeIQx via the hepatic cytochrome P450 monooxygenase system.}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{DAVIS, CD (Reprint Author), NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892, USA.
   NCI,DIV CANC ETIOL,OFF DIRECTOR,BETHESDA,MD 20892.
   MED COLL OHIO,DEPT PATHOL,TOLEDO,OH 43614.}},
DOI = {{10.1093/carcin/14.1.61}},
ISSN = {{0143-3334}},
Keywords-Plus = {{METABOLIC-ACTIVATION; HETEROCYCLIC AMINES; COVALENT BINDING;
   LIVER-MICROSOMES; BROILED SARDINE; BEEF EXTRACT; COOKED FOODS;
   CARCINOGENICITY; 2-AMINO-3,8-DIMETHYLIMIDAZO<4,5-F>QUINOXALINE; MICE}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{ADAMSON RH, 1991, XENOBIOTICS AND CANCER, P289.
   ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   ALLDRICK AJ, 1989, CARCINOGENESIS, V10, P1419, DOI 10.1093/carcin/10.8.1419.
   AMES BN, 1975, MUTAT RES, V31, P347, DOI 10.1016/0165-1161(75)90046-1.
   AOYAMA T, 1990, CANCER RES, V50, P2060.
   DEVERDIER MG, 1991, INT J CANCER, V49, P520, DOI 10.1002/ijc.2910490408.
   DOLL R, 1981, J NATL CANCER I, V66, P1191.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1991, MUTAT RES, V259, P2005.
   GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADLUBAR FF, 1985, ACS SYM SER, V283, P341.
   KATO R, 1987, JPN J CANCER RES, V78, P297.
   KATO T, 1988, CARCINOGENESIS, V9, P71, DOI 10.1093/carcin/9.1.71.
   LOWRY OH, 1951, J BIOL CHEM, V193, P265.
   MCMANUS ME, 1990, CANCER RES, V50, P3367.
   MURRAY S, 1989, CARCINOGENESIS, V10, P763, DOI 10.1093/carcin/10.4.763.
   NEGISHI C, 1989, MUTAT RES, V210, P127, DOI 10.1016/0027-5107(89)90051-1.
   OHGAKI H, 1984, CARCINOGENESIS, V5, P921, DOI 10.1093/carcin/5.7.921.
   OHGAKI H, 1987, CARCINOGENESIS, V8, P665, DOI 10.1093/carcin/8.5.665.
   OHTA K, 1989, MUTAT RES, V226, P163, DOI 10.1016/0165-7992(89)90014-6.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   SCHUT HA, 1978, MOL PHARMACOL, V14, P682.
   SCHUT HAJ, 1988, CANCER LETT, V41, P345, DOI 10.1016/0304-3835(88)90296-0.
   SCHUT HAJ, 1991, CARCINOGENESIS, V12, P931, DOI 10.1093/carcin/12.5.931.
   SESARDIC D, 1990, BIOCHEM PHARMACOL, V39, P499, DOI 10.1016/0006-2952(90)90056-Q.
   SESARDIC D, 1989, BR J CLIN PHARM, V526, P363.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1739, DOI 10.1093/carcin/9.10.1739.
   SNYDERWINE EG, 1989, J NATL CANCER I, V81, P223, DOI 10.1093/jnci/81.3.223.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P411, DOI 10.1093/carcin/9.3.411.
   STILLWELL W G, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P158.
   SUGIMURA T, 1982, CANCER, V49, P1970, DOI 10.1002/1097-0142(19820515)49:10<1970::AID-CNCR2820491005>3.0.CO;2-F.
   SUGIMURA T, 1985, MUTAT RES, V150, P33, DOI 10.1016/0027-5107(85)90098-3.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TAKAYAMA S, 1984, GANN, V75, P467.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P43, DOI 10.1093/carcin/11.1.43.
   WILKINSON L, 1990, SYSTAT SYSTEM STATIS.
   YAMASHITA K, 1990, JPN J CANCER RES, V81, P470.
   YAMAZOE Y, 1988, CARCINOGENESIS, V9, P105, DOI 10.1093/carcin/9.1.105.}},
Number-of-Cited-References = {{39}},
Times-Cited = {{69}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{KJ990}},
Wos-Id = {{ISI:A1993KJ99000011}},
}

@article{ ISI:A1992KH44300004,
Author = {SCHUT, HAJ and HERZOG, CR},
Title = {{FORMATION OF DNA ADDUCTS OF
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO{[}4,5-B]PYRIDINE (PHIP) IN MALE
   FISCHER-344 RATS}},
Journal = {{CANCER LETTERS}},
Year = {{1992}},
Volume = {{67}},
Number = {{2-3}},
Pages = {{117-124}},
Month = {{DEC 24}},
Abstract = {{2-Amino-1-methyl-6-phenylimidazo{[}4,5-b]-pyridine (PhIP) is known to
   induce colon tumors in male Fischer-344 rats. Using P-32-postlabeling
   assays, we have examined PhIP-DNA adduct formation in various organs and
   white blood cells (WBCs) of the male Fischer-344 344 rat 24 h after a
   single oral dose of 0, 0.5, 5 or 50 mg PhIP/kg. Three PhIP-DNA adducts
   were detected in WBCs and in all organs, except in the liver and stomach
   which had only two adducts. The extent of adduct formation was
   dose-related, but at 0.5 mg/kg no adducts could be detected in any of
   the organs. At 50 mg/kg, adduct levels, expressed as relative adduct
   labeling values (RAL X 10(7), or adducts per 10(7) nucleotides assuming
   complete labeling) were highest in the large intestine (5.66), followed
   by WBCs (5.04), stomach (1.44), small intestine (1.32), kidney (1.16),
   liver (0.67) and lungs (0. 52). It is concluded that orally administered
   PhIP forms high levels of specific DNA adducts in the large intestine,
   the target organ in PhIP carcinogenesis in the male Fischer-344 rat, and
   that the high level of adducts in WBCs indicates that significant
   amounts of the ultimate carcinogenic form of PhIP are present in the
   circulation.}},
Publisher = {{ELSEVIER SCI IRELAND LTD}},
Address = {{CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{MED COLL OHIO,DEPT PATHOL,TOLEDO,OH 43699.}},
DOI = {{10.1016/0304-3835(92)90134-H}},
ISSN = {{0304-3835}},
Keywords = {{2-AMINO-1-METHYL-6-PHENYLIMIDAZO{[}4,5-B]PYRIDINE; PHIP;
   P-32-POSTLABELING ANALYSIS; DNA ADDUCTS; COLON CARCINOGENESIS}},
Keywords-Plus = {{FOOD MUTAGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE;
   HETEROCYCLIC AROMATIC-AMINES; COOKED FOOD; METABOLIC-ACTIVATION;
   LIVER-MICROSOMES; CARCINOGEN; INDUCTION; IDENTIFICATION; RABBIT; CELLS}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{ADAMSON RH, 1991, XENOBIOTICS AND CANCER, P289.
   ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   AESCHBACHER HU, 1991, MUTAT RES, V259, P235, DOI 10.1016/0165-1218(91)90120-B.
   ALEXANDER J, 1991, CARCINOGENESIS, V12, P2239, DOI 10.1093/carcin/12.12.2239.
   BATTULA N, 1991, MOL CARCINOGEN, V4, P407, DOI 10.1002/mc.2940040513.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O.
   DAVIS CD, IN PRESS MUTAGENIC A.
   DEVERDIER MG, 1991, INT J CANCER, V49, P520, DOI 10.1002/ijc.2910490408.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629.
   FURIHATA C, 1986, ANNU REV NUTR, V6, P67, DOI 10.1146/annurev.nutr.6.1.67.
   GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   JAGERSTAD M, 1991, MUTAT RES, V259, P219, DOI 10.1016/0165-1218(91)90119-7.
   MCMANUS ME, 1989, CARCINOGENESIS, V10, P357, DOI 10.1093/carcin/10.2.357.
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   OVERVIK E, 1989, CARCINOGENESIS, V10, P2293, DOI 10.1093/carcin/10.12.2293.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   SCHUT H A J, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P92.
   SCHUT HAJ, 1988, CANCER LETT, V41, P345, DOI 10.1016/0304-3835(88)90296-0.
   SKOG K, 1991, CARCINOGENESIS, V12, P2297, DOI 10.1093/carcin/12.12.2297.
   SNYDERWINE EG, 1992, CANCER RES, V52, pS2099.
   TAKAHASHI S, 1991, JPN J CANCER RES, V82, P135.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TUCKER JD, 1989, MUTAT RES, V224, P105, DOI 10.1016/0165-1218(89)90009-8.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P941, DOI 10.1093/carcin/11.6.941.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P2291, DOI 10.1093/carcin/12.12.2291.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P1073, DOI 10.1093/carcin/12.6.1073.
   WILD D, 1991, CARCINOGENESIS, V12, P1091, DOI 10.1093/carcin/12.6.1091.
   YAMASHITA K, 1988, NUCLEIC ACIDS RES S, V19, P111.
   ZU HX, 1991, CANCER RES, V51, P5636.}},
Number-of-Cited-References = {{39}},
Times-Cited = {{81}},
Journal-ISO = {{Cancer Lett.}},
Doc-Delivery-Number = {{KH443}},
Wos-Id = {{ISI:A1992KH44300004}},
}

@article{ ISI:A1992KD32200020,
Author = {MALAVEILLE, C and HAUTEFEUILLE, A and BRUN, G and VINEIS, P and BARTSCH,
   H},
Title = {{SUBSTANCES IN HUMAN URINE THAT STRONGLY INHIBIT BACTERIAL MUTAGENICITY
   OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO{[}4,5-B]PYRIDINE (PHIP) AND RELATED
   HETEROCYCLIC AMINES}},
Journal = {{CARCINOGENESIS}},
Year = {{1992}},
Volume = {{13}},
Number = {{12}},
Pages = {{2317-2320}},
Month = {{DEC}},
Abstract = {{Extracts of human urine were shown to contain substances that strongly
   inhibited the liver S9-mediated mutagenicity of
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) in Salmonella
   typhimurium TA98 strain in a liquid incubation assay. The inhibitory
   effect was unrelated to cytotoxicity and was similar with urine extracts
   from smokers and non-smokers. Under similar assay conditions, the
   mutagenicity of the related amino-imidazoazaarenes,
   2-amino-3-methylimidazo{[}4,5-f]quinoline,
   2-amino-3,8-dimethylimidazo{[}4,5-f]quinoline and
   2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline was also found to be
   strongly inhibited by urine extracts. Decreased or enhanced mutagenicity
   was seen with 2-acetylaminofluorene and 2-aminoanthracene depending on
   the type of assay, and the time of incubation in liquid medium. A weak
   inhibition of the mutagenicity of 2-nitrofluorene, a direct-acting
   mutagen, was observed only after a short incubation time. Mutagenicity
   of 4-nitroquinoline N-oxide was not altered by the presence of urine
   extracts at concentrations shown to be inhibitory for the mutagenicity
   of heterocyclic aromatic amines. Our data suggest that the inhibitory
   substances in urine act through their capacity to non covalently bind
   the parent heterocyclic and aromatic amines, thus affecting their
   availability in aqueous medium for diffusion into liver microsomes where
   metabolic activation takes place.}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{MALAVEILLE, C (Reprint Author), INT AGCY RES CANC,150 COURS ALBERT THOMAS,F-69372 LYON,FRANCE.
   UNIV TURIN,CANC EPIDEMIOL UNIT,I-10126 TURIN,ITALY.}},
DOI = {{10.1093/carcin/13.12.2317}},
ISSN = {{0143-3334}},
Keywords-Plus = {{BLACK TOBACCO; METABOLISM; CAFFEINE; SMOKERS; FOOD; GENOTOXINS;
   ACTIVATION}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{AESCHBACHER HU, 1982, MUTAT RES, V103, P127, DOI 10.1016/0165-7992(82)90017-3.
   ALLDRICK AJ, 1988, MUTAGENESIS, V3, P423, DOI 10.1093/mutage/3.5.423.
   BERTHOU F, 1988, BIOCHEM PHARMACOL, V37, P3691, DOI 10.1016/0006-2952(88)90402-9.
   BUTLER MA, 1989, P NATL ACAD SCI USA, V86, P7696, DOI 10.1073/pnas.86.20.7696.
   CAMPBELL ME, 1987, CLIN PHARMACOL THER, V42, P157.
   DEMEESTER C, 1989, MUTAT RES, V221, P235, DOI 10.1016/0165-1110(89)90038-9.
   DERAAT WK, 1982, CANCER LETT, V16, P347, DOI 10.1016/0304-3835(82)90017-9.
   EINISTO P, 1990, MUTAT RES, V245, P87, DOI 10.1016/0165-7992(90)90005-5.
   FELTON JS, 1990, MUTAGENS FOOD DETECT, P57.
   HANNAN MA, 1981, CANCER LETT, V13, P203, DOI 10.1016/0304-3835(81)90019-7.
   LEFEVRE PA, 1981, CARCINOGENESIS, V2, P927, DOI 10.1093/carcin/2.9.927.
   MALAVEILLE C, 1979, MUTAT RES, V63, P245, DOI 10.1016/0027-5107(79)90057-5.
   MALAVEILLE C, 1989, CARCINOGENESIS, V10, P577, DOI 10.1093/carcin/10.3.577.
   MALAVEILLE C, 1982, CANCER RES, V42, P1446.
   MARON DM, 1983, MUTAT RES, V113, P173, DOI 10.1016/0165-1161(83)90010-9.
   MCMANUS ME, 1990, CANCER RES, V50, P3367.
   OVERVIK E, 1990, MUTAGENESIS, V5, P437, DOI 10.1093/mutage/5.5.437.
   PELUSO M, 1990, CARCINOGENESIS, V11, P1307, DOI 10.1093/carcin/11.8.1307.
   PELUSO M, 1991, CARCINOGENESIS, V12, P713, DOI 10.1093/carcin/12.4.713.
   QUILLARDET P, 1985, MUTAT RES, V147, P65, DOI 10.1016/0165-1161(85)90020-2.
   TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P941, DOI 10.1093/carcin/11.6.941.
   USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417.
   WATANABE M, 1990, MUTAT RES, V234, P377.
   YAMAZOE Y, 1988, JPN J CANCER RES, V79, P1159.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{13}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{KD322}},
Wos-Id = {{ISI:A1992KD32200020}},
}

@article{ ISI:A1992KD32200026,
Author = {ONEILL, I and OHGAKI, H and ELLUL, A and TURESKY, RJ},
Title = {{ENTRAPMENT BY MAGNETIC MICROCAPSULES OF THE PROTEIN PYROLYSATES IQ, PHIP
   AND GLU-P-1, AND ALTERATION OF IQ METABOLITE EXPOSURE WITHIN THE RAT
   GASTROINTESTINAL-TRACT BY RISK-MODULATING COMPONENTS OF THE HUAN DIET}},
Journal = {{CARCINOGENESIS}},
Year = {{1992}},
Volume = {{13}},
Number = {{12}},
Pages = {{2353-2359}},
Month = {{DEC}},
Abstract = {{The entrapment of heterocyclic aromatic amine gastrointestinal (GI)
   carcinogens (HAAs), by retrievable semipermeable magnetic
   polyethylenimine (PEI) microcapsules was investigated in vitro and in
   vivo as an approach for human biomonitoring. Previous studies showed
   that PEI microcapsules successfully entrapped benzo{[}a]pyrene (B{[}a]P)
   and its metabolites in the GI tract of rodents. In this study, we have
   shown that C-14-labelled 2-amino-3-methylimidazo{[}4,5f] quinoline (IQ),
   2-amino-1-methylphenylimidazo{[}4,5-b] pyridine (PhIP) and
   2-amino-6-methyldipyrido]1,2-a:3'2'-d] imidazole (Glu-P-1) are adsorbed
   to PEI microcapsules in vitro and can be desorbed by treatment with
   ammoniac methanol. Binding of HAAs to PEI microcapsules containing
   copper phthalocyanine (TCPTS), a moiety which reversibly binds chemicals
   with aromatic planar structures, was 2- to 4-fold higher than with
   unmodified PEI microcapsules. PEI microcapsules also acted as a
   nucleophile and trapped the proximate carcinogenic metabolite of IQ,
   2-hydroxy-amino-3-methyl-. imidazo{[}4,5f]quinoline (N-hydroxy-IQ). The
   entrapment of C-14-labelled IQ and PhIP by microcapsules was
   investigated in vivo in male F344 rats fed a conventional chow diet or a
   human diet with varying amounts of fat and beef intake typically
   consumed in the UK. Animals were adapted to human diets which were
   either high (H) or low (L) in fat (F), beef protein (B) and dietary
   fibre non-starch polysaccharide (NSP). Microcapsule entrapment of IQ and
   metabolites was 0.5-2.0\% of the dose and 4-fold higher in rats
   consuming a HF/HB/LNSP than those consuming a LF/LB/HNSP diet, these
   being respectively putative high- and low-risk-associated diets. In the
   HF/HB/LNSP diet group, a higher amount of IQ metabolites were detected
   in the microcapsules; a lower proportion of covalently bound metabolites
   could be removed by acid hydrolysis. Urinary excretion was 2-fold
   greater and analysis of the urinary metabolites showed there to be lower
   sulfotransferase activity than in the LF/LB/HNSP group. The amount of
   C-14-labelled PhIP entrapped by PEI microcapsules was 1.5\% of the dose
   in rodents fed a LF/HB/LNSP human diet and binding was 7-fold higher
   than in rodents fed a semi-purified diet. These results demonstrate that
   microcapsules can entrap IQ and PhIP and their metabolites within the GI
   tract of rodents. The amounts entrapped by microcapsules in the rodent
   model suggests that this approach may be feasible for human
   biomonitoring of HAAs and for non-invasively studying dietary:
   modulations of carcinogen exposure within a potential HAA target organ
   at high risk from as-yet unidentified causes.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{ONEILL, I (Reprint Author), INT AGCY RES CANC, 150 COURS ALBERT THOMAS, F-69372 LYON, FRANCE.
   NATL CANC CTR, RES INST, DIV BIOCHEM, CHUO KU, TOKYO 104, JAPAN.
   NESTEC LTD, NESTLE RES CTR, CH-1000 LAUSANNE 26, SWITZERLAND.}},
DOI = {{10.1093/carcin/13.12.2353}},
ISSN = {{0143-3334}},
Keywords-Plus = {{POLYETHYLENEIMINE MICROCAPSULES;
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; BENZO<A>PYRENE
   METABOLITES; COPPER-PHTHALOCYANINE; CHEMICAL CARCINOGENS; HETEROCYCLIC
   AMINES; COOKED FOOD; F344 RATS; FIBER; BEEF}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   ALEXAKIS T, 1992, IN PRESS BIOM ARTIF.
   ALEXANDER J, 1991, CARCINOGENESIS, V12, P2239, DOI 10.1093/carcin/12.12.2239.
   BINGHAM SA, 1992, CARCINOGENESIS, V13, P683, DOI 10.1093/carcin/13.4.683.
   CONNEY AH, 1982, CANCER RES, V42, P4875.
   DOLL R, 1981, J NATL CANCER I, V66, P1191.
   ELLUL A, 1990, CARCINOGENESIS, V11, P1577, DOI 10.1093/carcin/11.9.1577.
   FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312.
   FELTON JS, 1986, ENV HLTH PERSPECT, V67, P12.
   FRIESEN MD, 1992, IN PRESS ENV HLTH PE, V99.
   GIOVANNUCCI E, 1992, J NATL CANCER I, V84, P91, DOI 10.1093/jnci/84.2.91.
   HAYATSU H, 1983, MUTAT RES, V119, P233, DOI 10.1016/0165-7992(83)90166-5.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KADERLIK K, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P119.
   KADLUBAR FF, 1977, CANCER RES, V37, P805.
   LINDESKOG P, 1988, MUTAT RES, V204, P553, DOI 10.1016/0165-1218(88)90058-4.
   MUIR C, 1987, IARC SCI PUBLICAT 88, V5.
   OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E.
   ONEILL IK, 1991, CARCINOGENESIS, V12, P175, DOI 10.1093/carcin/12.2.175.
   ONEILL IK, 1992, IN PRESS ENV HLTH PE, V99.
   ONEILL IK, 1990, CARCINOGENESIS, V11, P599, DOI 10.1093/carcin/11.4.599.
   ONEILL IK, 1987, CARCINOGENESIS, V8, P1469, DOI 10.1093/carcin/8.10.1469.
   ONEILL IK, 1990, CARCINOGENESIS, V11, P609, DOI 10.1093/carcin/11.4.609.
   POVEY AC, 1990, CARCINOGENESIS, V11, P1989, DOI 10.1093/carcin/11.11.1989.
   POVEY AC, 1987, J PHARM SCI, V76, P194, DOI 10.1002/jps.2600760303.
   POVEY AC, 1986, J PHARM SCI, V75, P831, DOI 10.1002/jps.2600750902.
   POVEY AC, 1987, CARCINOGENESIS, V8, P825, DOI 10.1093/carcin/8.6.825.
   SNYDERWINE E G, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P121.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1739, DOI 10.1093/carcin/9.10.1739.
   SUGIMURA T, 1989, IFT BAS SYM, P31.
   TAKAYAMA S, 1984, GANN, V75, P467.
   TOMATIS L, 1990, BIOCH CHEM CARCINOGE, P1.
   TURESKY RJ, 1990, CHEM RES TOXICOL, V3, P524, DOI 10.1021/tx00018a006.
   TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839.
   WEISBURGER JH, 1987, ISI ATLAS-PHARMACOL, V1, P162.
   WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404.
   ZHANG XM, 1988, MUTAT RES, V201, P181, DOI 10.1016/0027-5107(88)90124-8.}},
Number-of-Cited-References = {{37}},
Times-Cited = {{4}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{KD322}},
Wos-Id = {{ISI:A1992KD32200026}},
}

@article{ ISI:A1992JH65200020,
Author = {HASEGAWA, R and TAKAHASHI, S and SHIRAI, T and IWASAKI, S and KIM, DJ
   and OCHIAI, M and NAGAO, M and SUGIMURA, T and ITO, N},
Title = {{DOSE-DEPENDENT FORMATION OF PRENEOPLASTIC FOCI AND DNA ADDUCTS IN
   RAT-LIVER WITH 2-AMINO-3-METHYL-9H-PYRIDO{[}2,3-B]INDOLE (MEA-ALPHA-C)
   AND 2-AMINO-1-METHYL-6-PHENYLIMIDAZO{[}4,5-B]PYRIDINE (PHIP)}},
Journal = {{CARCINOGENESIS}},
Year = {{1992}},
Volume = {{13}},
Number = {{8}},
Pages = {{1427-1431}},
Month = {{AUG}},
Abstract = {{Dose responses to two heterocyclic amines,
   2-amino-3-methyl-9H-pyrido{[}2,3-b]indole (MeA-alpha-C) and
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP), in induction
   of glutathione S-transferase placental form positive liver cell foci
   (GST-P+ foci) and DNA adduct formation in the liver were examined in
   male F344 rats. Beginning 2 weeks after a single diethylnitrosamine
   (DEN) injection (200 mg/kg, i.p.), rats received MeA-alpha-C or PhIP in
   the diet at various doses foe (6 weeks. All rats were subjected to
   two-thirds partial hepatectomy ( PH) 1 week after the test agents were
   added to the diet and were killed 8 weeks after DEN initiation.
   MeA-alpha-C (100, 200, 400 and 800 p.p.m.) significantly increased
   numbers and areas of GST-P+ foci over control levels in all dose groups
   with a clear dose-response. In contrast, PhIP (50, 100, 200 and 400
   p.p.m.) only equivocally increased foci development in the highest dose
   group and rather was associated with decrease in the lower dose groups.
   DNA adduct formation assessed by P-32-postlabeling demonstrated a
   dose-dependent increase with both chemicals, the levels being much
   higher with MeA-alpha-C. Thus, two highly mutagenic heterocyclic amines
   that are produced in broiled foodstuffs exerted different influence on
   GST-P+ foci development and DNA adduct formation; these findings are
   consistent with liver carcinogenicity in rats and/or mice.}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{HASEGAWA, R (Reprint Author), NAGOYA CITY UNIV,SCH MED,DEPT PATHOL 1,1 KAWASUMI,MIZUHO KU,NAGOYA,AICHI 467,JAPAN.
   NATL CANC CTR,RES INST,DIV CARCINOGENESIS,TOKYO 104,JAPAN.}},
DOI = {{10.1093/carcin/13.8.1427}},
ISSN = {{0143-3334}},
Keywords-Plus = {{GLUTATHIONE S-TRANSFERASE; FOOD MUTAGEN
   2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE; COOKED FOODS;
   P-32-POSTLABELING ANALYSIS; HETEROCYCLIC AMINES; SOYBEAN GLOBULIN;
   SALIVARY-GLANDS; MICE; CARCINOGENICITY; INDUCTION}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{ALEXANDER J, 1989, CARCINOGENESIS, V10, P1543, DOI 10.1093/carcin/10.8.1543.
   BUONARATI MH, 1990, CARCINOGENESIS, V11, P1133, DOI 10.1093/carcin/11.7.1133.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   Farber E, 1984, Biochim Biophys Acta, V738, P171.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   GUPTA RC, 1985, CANCER RES, V45, P5656.
   HERBERT R, 1990, IARC SCI PUBL, V104, P205.
   ITO N, 1989, CRIT REV TOXICOL, V19, P385, DOI 10.3109/10408448909029328.
   ITO N, 1988, CARCINOGENESIS, V9, P387, DOI 10.1093/carcin/9.3.387.
   ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503.
   KATO T, 1988, CARCINOGENESIS, V9, P71, DOI 10.1093/carcin/9.1.71.
   KATO T, 1989, CARCINOGENESIS, V10, P601, DOI 10.1093/carcin/10.3.601.
   LUKS HJ, 1989, CANCER RES, V49, P4407.
   MATSUKURA N, 1981, SCIENCE, V213, P346, DOI 10.1126/science.7244619.
   OCHIAI M, 1991, JPN J CANCER RES, V82, P363.
   OHGAKI H, 1984, CARCINOGENESIS, V5, P815, DOI 10.1093/carcin/5.6.815.
   OHGAKI H, 1986, CARCINOGENESIS, V7, P1889, DOI 10.1093/carcin/7.11.1889.
   OHGAKI H, 1986, ENVIRON HEALTH PERSP, V67, P129, DOI 10.2307/3430327.
   OHGAKI H, 1987, CARCINOGENESIS, V8, P665, DOI 10.1093/carcin/8.5.665.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   RANDERATH K, 1986, CARCINOGENESIS, V7, P1615, DOI 10.1093/carcin/7.9.1615.
   SANTELLA RM, 1988, MUTAT RES, V205, P271, DOI 10.1016/0165-1218(88)90022-5.
   SUGIMURA T, 1986, SCIENCE, V233, P312, DOI 10.1126/science.3088728.
   SUGIMURA T, 1986, ENVIRON HEALTH PERSP, V67, P5, DOI 10.2307/3430310.
   SUGIMURA T, 1983, CANCER RES, V43, P2415.
   SUGIMURA T, 1985, MUTAT RES, V150, P33, DOI 10.1016/0027-5107(85)90098-3.
   SYNDERWINE EG, 1988, CARCINOGENESIS, V9, P1739.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TAKAYAMA S, 1985, P JPN ACAD B-PHYS, V61, P277.
   TATEMATSU M, 1988, CARCINOGENESIS, V9, P221, DOI 10.1093/carcin/9.2.221.
   TATEMATSU M, 1985, CARCINOGENESIS, V6, P1621, DOI 10.1093/carcin/6.11.1621.
   TIWAWECH D, 1991, CARCINOGENESIS, V12, P985, DOI 10.1093/carcin/12.6.985.
   TURESKY RJ, 1988, CARCINOGENESIS, V9, P1043, DOI 10.1093/carcin/9.6.1043.
   TURESKY RJ, 1986, CARCINOGENESIS, V7, P1483, DOI 10.1093/carcin/7.9.1483.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P1073, DOI 10.1093/carcin/12.6.1073.
   WATSON WP, 1987, MUTAGENESIS, V2, P319, DOI 10.1093/mutage/2.5.319.
   YAMASHITA K, 1986, P JPN ACAD B-PHYS, V62, P45, DOI 10.2183/pjab.62.45.
   YOSHIDA D, 1978, BIOCHEM BIOPH RES CO, V83, P915, DOI 10.1016/0006-291X(78)91482-1.}},
Number-of-Cited-References = {{39}},
Times-Cited = {{31}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{JH652}},
Wos-Id = {{ISI:A1992JH65200020}},
}

@article{ ISI:A1992HL80800017,
Author = {FELTON, JS and KNIZE, MG and ROPER, M and FULTZ, E and SHEN, NH and
   TURTELTAUB, KW},
Title = {{CHEMICAL-ANALYSIS, PREVENTION, AND LOW-LEVEL DOSIMETRY OF HETEROCYCLIC
   AMINES FROM COOKED FOOD}},
Journal = {{CANCER RESEARCH}},
Year = {{1992}},
Volume = {{52}},
Number = {{7, S}},
Pages = {{S2103-S2107}},
Month = {{APR 1}},
Note = {{CONF ON NUTRITION AND CANCER, ATLANTA, GA, APR 17-19, 1991}},
Organization = {{AMER CANC SOC; CTR DIS CONTROL; EMORY UNIV; NCI}},
Abstract = {{Potent mutagenic and carcinogenic heterocyclic amines are produced from
   heated food derived from muscle. These compounds are present at
   part-per-billion levels and consist primarily of the
   amino-imidazoazaarene class of chemicals. Additional mutagens present in
   the meat are not as clearly characterized. Commercial fried-beef patties
   (hamburgers) have low levels of
   2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline (MeIQx) and
   2-amino-3,4,8-trimethylimidazo{[}4,5-f]quinoxaline (4,8-DiMeIQx),
   0.1-0.68 ng/g meat for MeIQx and slightly lower for 4,8-DiMeIQx. The
   formation of these heterocyclic amines can be reduced by microwave
   pretreatment of meat, with the resulting liquid being poured off before
   frying. The Ames/Salmonella mutagenic activity was reduced to 5-10\% of
   that of non-microwave-treated samples. MeIQx and DiMeIQx concentrations
   were reduced to 12\% and 50\% of levels in the non-microwave-treated
   samples, respectively. MeIQx adducts, as measured by accelerator mass
   spectrometry, were found to be linear with doses from 5 mg/kg to 500
   ng/kg. Linear DNA binding at low doses is important for assuming linear
   risk estimation from the high animal-feeding doses causing cancer to the
   low human-dietary exposures. Extrapolating from the rodent TD50 dose to
   humans gives a maximum credible risk from consumption of heterocyclic
   amines of approximately 1/1000 exposed individuals.}},
Publisher = {{AMER ASSOC CANCER RESEARCH}},
Address = {{PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W.,
   PHILADELPHIA, PA 19106}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{FELTON, JS (Reprint Author), UNIV CALIF LAWRENCE LIVERMORE NATL LAB,DIV BIOMED SCI,POB 5507,LIVERMORE,CA 94550, USA.}},
ISSN = {{0008-5472}},
Keywords-Plus = {{FRIED GROUND-BEEF; MUTAGENIC ACTIVITY; COOKING;
   2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE; IDENTIFICATION; MEAT; DNA}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{ADAMSON RH, 1990, CANC PREVENTION, P1.
   ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   AESCHBACHER HU, 1987, CANCER LETT, V38, P87, DOI 10.1016/0304-3835(87)90203-5.
   ALINK GM, 1988, MUTAT RES, V206, P387, DOI 10.1016/0165-1218(88)90125-5.
   BARNES WS, 1983, J AGR FOOD CHEM, V31, P883, DOI 10.1021/jf00118a053.
   BARRINGTON PJ, 1990, FOOD CHEM TOXICOL, V28, P141, DOI 10.1016/0278-6915(90)90002-5.
   BECHER G, 1988, CARCINOGENESIS, V9, P247, DOI 10.1093/carcin/9.2.247.
   BJELDANES LF, 1982, FOOD CHEM TOXICOL, V20, P357, DOI 10.1016/S0278-6915(82)80099-9.
   COMMONER B, 1978, SCIENCE, V201, P913, DOI 10.1126/science.567374.
   DOOLITTLE DJ, 1989, FOOD CHEM TOXICOL, V27, P657, DOI 10.1016/0278-6915(89)90120-8.
   FELTON JS, 1990, PROG CLIN BIOL RES, V347, P19.
   FELTON JS, 1990, HDB EXPT PHARM, V94, P471.
   FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312.
   FELTON JS, 1984, CARCINOGENESIS, V5, P95, DOI 10.1093/carcin/5.1.95.
   GAYLOR DW, 1991, MUTAGENS FOOD DETECT, P229.
   GROSS GA, 1990, CARCINOGENESIS, V11, P1597, DOI 10.1093/carcin/11.9.1597.
   HATCH FT, 1991, ENVIRON MOL MUTAGEN, V17, P4, DOI 10.1002/em.2850170103.
   JONES RC, 1988, MUTAT RES, V206, P343, DOI 10.1016/0165-1218(88)90120-6.
   KASAI H, 1980, CHEM LETT, V11, P1391.
   KASAI H, 1981, J CHEM SOC PERK T 1, P2290, DOI 10.1039/p19810002290.
   KNIZE MG, 1991, MUTAT RES, V260, P313, DOI 10.1016/0165-1218(91)90016-F.
   KNIZE MG, 1985, FOOD CHEM TOXICOL, V23, P1035, DOI 10.1016/0278-6915(85)90049-3.
   KNIZE MG, 1990, CARCINOGENESIS, V11, P2259, DOI 10.1093/carcin/11.12.2259.
   KNIZE MG, 1988, MUTAGENESIS, V3, P503, DOI 10.1093/mutage/3.6.503.
   OHGAKI H, 1991, MUTAGENS FOOD DETECT, P219.
   OVERVIK E, 1990, MUTAGENESIS, V5, P437, DOI 10.1093/mutage/5.5.437.
   PELUSO M, 1991, CARCINOGENESIS, V12, P713, DOI 10.1093/carcin/12.4.713.
   SUGIMURA T, 1988, CHEM INDUCTION CAN C, V3, P681.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TAYLOR RT, 1986, ENVIRON MOL MUTAGEN, V8, P84.
   TURTELTAUB KW, 1990, P NATL ACAD SCI USA, V87, P5288, DOI 10.1073/pnas.87.14.5288.
   VAHL M, 1988, MUTAT RES, V203, P239, DOI 10.1016/0165-1161(88)90189-6.
   WEILLTHEVENET N, 1982, MUTAT RES, V104, P1, DOI 10.1016/0165-7992(82)90112-9.
   WEILLTHEVENET N, 1981, MUTAT RES, V88, P355, DOI 10.1016/0165-1218(81)90027-6.
   Widmark EMP, 1939, NATURE, V143, P984, DOI 10.1038/143984a0.
   Winsten J. A., 1977, ORIGINS HUMAN CANC, P1561.
   ZHANG XM, 1988, MUTAT RES, V201, P181, DOI 10.1016/0027-5107(88)90124-8.}},
Number-of-Cited-References = {{37}},
Times-Cited = {{70}},
Journal-ISO = {{Cancer Res.}},
Doc-Delivery-Number = {{HL808}},
Wos-Id = {{ISI:A1992HL80800017}},
}

@article{ ISI:A1991GU07600008,
Author = {SOOD, CK and SOOD, A and SPIELVOGEL, BF and YOUSEF, JA and BURNHAM, B
   and HALL, IH},
Title = {{SYNTHESIS AND ANTINEOPLASTIC ACTIVITY OF SOME CYANOBORANE,
   CARBOXYBORANE, CARBOMETHOXYBORANE, AND CARBAMOYLBORANE ADDUCTS OF
   HETEROCYCLIC AMINES}},
Journal = {{JOURNAL OF PHARMACEUTICAL SCIENCES}},
Year = {{1991}},
Volume = {{80}},
Number = {{12}},
Pages = {{1133-1140}},
Month = {{DEC}},
Abstract = {{Boron analogues of piperidine, piperazine, morpholine, and imidazole
   proved to be cytotoxic against the growth of murine and human tissue
   culture cells.  Significant activity was demonstrated for single-cell
   suspensions of L1210 lymphoid leukemia, Tmolt3 lymphoblastic leukemia,
   and HeLa-S3 cervical carcinoma.  Trimethylamine-imidazole
   carbonyldihydroborane 17 demonstrated activity against solid tumor
   growth of human colorectal adenocarcinoma, KB nasopharynx, and
   osteosarcoma.  In addition, 4-methylpiperidine-carbomethoxyborane 12,
   2-methylimidazole-3-cyanoborane 16, and
   1-methylimidazole-3-(N-ethylcarbamoyl)borane 19 were active against the
   KB nasopharynx growth.  Piperidine-cyanoborane 2,
   piperidine-carboxyborane 4, and
   1-methylimidazole-3-(N-ethylcarbamoyl)borane 19 were effective in
   reducing the growth of osteosarcoma cells.  The imidazole derivatives
   13-19, as well as 4-methylpiperidine-carboxyborane 11 and
   carbomethoxyborane 12, demonstrated good activity against lung
   bronchogenic and glioma growth.  In the in vivo studies,
   N-methylmorpholine-carboxyborane 7, 4-phenylpiperidine-carboxyborane 9,
   4-phenylpiperidine-carbomethoxyborane 10,
   4-methylpiperidine-carboxyborane 11, imidazole cyanoborane 14, and
   1-methylimidazole-3-carbomethoxyborane 18 demonstrated the best activity
   against Lewis Lung growth and P388 lymphocytic leukemia growth in mice. 
   Mode of action studies in L1210 leukemia cells demonstrated that
   piperidine-carboxyborane 4 and N-methylmorpholine-carboxyborane 7
   inhibited DNA synthesis, purine synthesis at PRPP amido transferase and
   IMP dehydrogenase sites, and thymidine kinase and thymidine diphosphate
   kinase activities, while lowering d(NTP) pool levels.  Also, DNA strand
   scission was evident after incubation with these drugs.}},
Publisher = {{AMER PHARMACEUTICAL ASSN}},
Address = {{2215 CONSTITUTION AVE NW, WASHINGTON, DC 20037}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{UNIV N CAROLINA,SCH PHARM,DIV MED CHEM \& NAT PROD,CHAPEL HILL,NC 27599.
   DUKE UNIV,PAUL M GROSS CHEM LAB,DEPT CHEM,DURHAM,NC 27706.
   BORON BIOL INC,RALEIGH,NC 27607.}},
DOI = {{10.1002/jps.2600801209}},
ISSN = {{0022-3549}},
Keywords-Plus = {{ANTI-TUMOR AGENTS; BORON ANALOGS; CELL LINES; HYPOLIPIDEMIC ACTIVITY;
   PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; DNA-POLYMERASE; NUCLEIC-ACID;
   TRIPHOSPHATES; BRUCEANTIN}},
Research-Areas = {{Pharmacology \& Pharmacy; Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology \&
   Pharmacy}},
Cited-References = {{AARONSON SA, 1970, EXP CELL RES, V61, P1, DOI 10.1016/0014-4827(70)90250-8.
   ANDERSON KM, 1975, BIOCHIM BIOPHYS ACTA, V383, P56, DOI 10.1016/0005-2787(75)90245-2.
   BAGNARA AS, 1972, ANAL BIOCHEM, V45, P24, DOI 10.1016/0003-2697(72)90004-8.
   BAXTER RL, 1984, COMPREHENSIVE HETERO, V1, P83.
   BECKER JH, 1979, KLIN WORCHENSCHR, V57, P1109.
   DOLLACKER F, 1985, Z NATURFORSCH C, V40, P344.
   EAGLE H, 1955, P SOC EXP BIOL MED, V89, P362.
   EICHLER DC, 1977, J BIOL CHEM, V252, P4011.
   FIARCHIDL RG, 1983, 1ST P INT S NEUTR CA.
   Geran R. I., 1972, CANCER CHEMOTHERAPY, V3, P17.
   GERAN RI, 1972, CANCER CHEMOTHER R 3, V3, P7.
   HALL IH, 1979, J PHARM SCI, V68, P685, DOI 10.1002/jps.2600680607.
   HALL IH, 1987, J PHARM SCI, V76, P359, DOI 10.1002/jps.2600760504.
   HALL IH, 1984, J PHARM SCI, V73, P222, DOI 10.1002/jps.2600730220.
   HALL IH, 1985, J PHARM SCI, V74, P755, DOI 10.1002/jps.2600740712.
   HALL IH, 1982, J PHARM SCI, V71, P741, DOI 10.1002/jps.2600710706.
   HALL IH, 1981, J PHARM SCI, V70, P1147, DOI 10.1002/jps.2600701014.
   HALL IH, 1986, J PHARM SCI, V75, P706, DOI 10.1002/jps.2600750719.
   HALL IH, 1980, J PHARM SCI, V69, P1025, DOI 10.1002/jps.2600690912.
   HALL IH, 1981, J PHARM SCI, V70, P339, DOI 10.1002/jps.2600700333.
   HOFMANN K, 1953, CHEM HTEROCYCLIC C 1, V6.
   HUANG ES, 1972, J PHARM SCI, V61, P108.
   HUNTING D, 1981, CAN J BIOCHEM CELL B, V59, P723.
   KAMPF A, 1976, J MED CHEM, V19, P903, DOI 10.1021/jm00229a009.
   Landquist J. K., 1984, COMPREHENSIVE HETERO, V1, P144.
   LEIBOVITZ A, 1976, CANCER RES, V36, P4562.
   LIAO LL, 1976, MOL PHARMACOL, V12, P167.
   MALEY F, 1958, J BIOL CHEM, V233, P1538.
   MALONE LJ, 1967, INORG CHEM, V6, P2260, DOI 10.1021/ic50058a029.
   MINOWADA J, 1972, J NATL CANCER I, V49, P891.
   MOORE EC, 1966, J BIOL CHEM, V241, P4802.
   NELSONREES WA, 1975, INT J CANCER, V16, P74, DOI 10.1002/ijc.2910160109.
   PIANTADO.C, 1969, J PHARM SCI, V58, P821, DOI 10.1002/jps.2600580704.
   PUCK TT, 1956, J EXP MED, V103, P273, DOI 10.1084/jem.103.2.273.
   SAWADA H, 1974, CANCER RES, V34, P3341.
   SMITH HS, 1976, INT J CANCER, V17, P219, DOI 10.1002/ijc.2910170211.
   SPASSOVA MK, 1976, BIOCHEM PHARMACOL, V25, P923, DOI 10.1016/0006-2952(76)90316-6.
   SPIELVOGEL BF, 1980, BORON CHEM, P119.
   SPIELVOGEL BF, 1979, J INORG NUCL CHEM, V41, P1223, DOI 10.1016/0022-1902(79)80492-3.
   SPIELVOGEL BF, 1976, J AM CHEM SOC, V98, P5702, DOI 10.1021/ja00434a053.
   SPIELVOGEL BF, 1989, STRAHLENTHER ONKOL, V165, P123.
   SPIELVOGEL BF, 1984, INORG CHEM, V23, P4322, DOI 10.1021/ic00193a043.
   SPIELVOGEL BF, 1984, INORG CHEM, V23, P1776, DOI 10.1021/ic00180a025.
   WEIDIG C, 1974, INORG CHEM, V13, P1763, DOI 10.1021/ic50137a047.
   WILLIAMS WL, 1988, J PHARM SCI, V77, P178, DOI 10.1002/jps.2600770217.
   WISIANNEILSON P, 1978, INORG CHEM, V17, P2327, DOI 10.1021/ic50186a068.}},
Number-of-Cited-References = {{46}},
Times-Cited = {{45}},
Journal-ISO = {{J. Pharm. Sci.}},
Doc-Delivery-Number = {{GU076}},
Wos-Id = {{ISI:A1991GU07600008}},
}

@article{ ISI:A1991GT28200003,
Author = {DUVERGERVANBOGAERT, M and CRUTZENFAYT, MC and STECCA, C},
Title = {{MUTAGENICITY OF SOME HETEROCYCLIC AMINES IN SALMONELLA-TYPHIMURIUM WITH
   METABOLIC-ACTIVATION BY HUMAN RED-BLOOD-CELL CYTOSOL}},
Journal = {{MUTATION RESEARCH}},
Year = {{1991}},
Volume = {{261}},
Number = {{4}},
Pages = {{261-265}},
Month = {{DEC}},
Abstract = {{Purified human red blood cell cytosol was used to activate the
   heterocyclic amines 2-amino-3-methylimidazo{[}4,5-f]quinoline (IQ),
   2-amino-3,4-dimethylimidazo{[}4,5-f]quinoline (MeIQ),
   3-amino-1,4-dimethyl 5H-pyrido{[}4,3-b]indole (Trp-P-1) and
   3-amino-1-methyl-5H-pyrido{[}4,3-b]indole (Trp-P-2) into mutagenic
   intermediate(s) in the Salmonella test. The liquid preincubation method
   in the presence of strain TA98 was utilized. In order to understand the
   mechanism involved in this metabolic activation, some modulators were
   incorporated in the medium. The results suggest that an oxygenated
   hemoprotein, probably oxyhemoglobin, is involved in the activation into
   genotoxic intermediate(s).}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{DUVERGERVANBOGAERT, M (Reprint Author), CATHOLIC UNIV LOUVAIN,TEMU LAB 7237,AV EMM MOUNIER 72,B-1200 BRUSSELS,BELGIUM.}},
DOI = {{10.1016/0165-1218(91)90041-J}},
ISSN = {{0921-8262}},
Keywords = {{HETEROCYCLIC AMINES; MUTAGENICITY; SALMONELLA-TYPHIMURIUM; HUMAN RED
   BLOOD CELL CYTOSOL}},
Keywords-Plus = {{OXIDATION; PRODUCTS; RAT}},
Research-Areas = {{Genetics \& Heredity; Toxicology}},
Web-of-Science-Categories  = {{Genetics \& Heredity; Toxicology}},
Cited-References = {{AESCHBACHER HU, 1991, MUTAT RES, V259, P235, DOI 10.1016/0165-1218(91)90120-B.
   ASHBY J, 1982, MUTAT RES, V93, P67, DOI 10.1016/0027-5107(82)90126-9.
   BOYD JA, 1983, J BIOL CHEM, V258, P8246.
   CHIPMAN JK, 1987, MUTAT RES, V187, P105, DOI 10.1016/0165-1218(87)90076-0.
   COSSUM PA, 1988, BIOPHARM DRUG DISPOS, V9, P321, DOI 10.1002/bod.2510090402.
   GOLLY I, 1983, BIOCHIM BIOPHYS ACTA, V760, P69, DOI 10.1016/0304-4165(83)90125-3.
   HLAVICA P, 1982, CRC CR REV BIOCH MOL, V12, P39, DOI 10.3109/10409238209105850.
   HULTQUIST DE, 1980, MICROSOMES DRUG OXID, P509.
   ISHII K, 1980, CANCER RES, V40, P2596.
   KATO R, 1986, CRIT REV TOXICOL, V16, P307, DOI 10.3109/10408448609037466.
   KEILIN D, 1951, BIOCHEM J, V49, P88.
   MIEYAL JJ, 1985, REV BIOCHEM TOXICOL, P1.
   NAGAO M, 1977, CANCER LETT, V2, P335, DOI 10.1016/S0304-3835(77)80014-1.
   NETTER KJ, 1982, HEPATIC CYTOCHROME P, P741.
   RODRIGUES AD, 1987, BIOCHEM PHARMACOL, V36, P4277, DOI 10.1016/0006-2952(87)90670-8.
   SAITO K, 1983, CARCINOGENESIS, V4, P1551, DOI 10.1093/carcin/4.12.1551.
   SASS MD, 1969, CLIN CHIM ACTA, V24, P77, DOI 10.1016/0009-8981(69)90143-0.
   STECCA C, 1991, IN PRESS CHIM OGGI.
   SUGIMURA T, 1982, ENV MUTAGENS CARCINO, P3.
   SUGIMURA T, 1985, MUTAT RES, V150, P33, DOI 10.1016/0027-5107(85)90098-3.
   SUGIMURA T, 1983, CANCER RES S, V43, P24155.
   ULLRICH V, 1973, H-S Z PHYSIOL CHEM, V354, P514, DOI 10.1515/bchm2.1973.354.1.514.
   WILD D, 1987, CARCINOGENESIS, V18, P541.
   WILD D, 1989, MUTAGENESIS, V4, P446, DOI 10.1093/mutage/4.6.446.
   Winsten J. A., 1977, ORIGINS HUMAN CANC, P1561.
   YAMAZOE Y, 1983, CANCER RES, V43, P5768.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{6}},
Doc-Delivery-Number = {{GT282}},
Wos-Id = {{ISI:A1991GT28200003}},
}

@article{ ISI:A1991GA91100009,
Author = {USHIYAMA, H and WAKABAYASHI, K and HIROSE, M and ITOH, H and SUGIMURA, T
   and NAGAO, M},
Title = {{PRESENCE OF CARCINOGENIC HETEROCYCLIC AMINES IN URINE OF
   HEALTHY-VOLUNTEERS EATING NORMAL DIET, BUT NOT OF INPATIENTS RECEIVING
   PARENTERAL-ALIMENTATION}},
Journal = {{CARCINOGENESIS}},
Year = {{1991}},
Volume = {{12}},
Number = {{8}},
Pages = {{1417-1422}},
Month = {{AUG}},
Abstract = {{For estimation of human exposures to carcinogenic heterocyclic amines,
   the amounts of four compounds,
   3-amino-1,4-dimethyl-5H-pyrido{[}4,3-b]indole (Trp-P-1),
   3-amino-1-methyl-5H-pyrido{[}4,3-b]indole (Trp-P-2),
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP) and
   2-amino-3,8-dimethylimidazo {[}4,5-f]quinoxaline (MeIQx), in human urine
   were measured. Twenty-four hour urine specimens were collected from ten
   healthy volunteers eating normal diet (five males and five females) and
   three inpatients (two males and a female) receiving parenteral
   alimentation, and the levels of the four heterocyclic amines were
   measured by HPLC after partial purification by treatment with blue
   cotton and ion exchange column chromatography. Trp-P-1, Trp-P-2, PhIP
   and MeIQx were detected in the 24 h urine samples of all healthy
   volunteers at levels of 0.04-1.43 ng, 0.03-0.68 ng, 0.12-1.97 ng and
   11-47 ng respectively. As 1.8-4.9\% of an oral dose of MeIQx is reported
   to be excreted unchanged in the urine, the daily exposure of humans to
   MeIQx was estimated to be 0.2-2.6-mu-g/person. The four heterocyclic
   amines were not detected in the urine of parenterally fed inpatients.
   These results indicate that humans are continually exposed to
   carcinogenic heterocyclic amines in food, and these compounds may not be
   formed endogenously.}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{NATL CANC CTR,RES INST,DIV CARCINOGENESIS,1-1 TSUKIJI 5-CHOME,CHOU KU,TOKYO 104,JAPAN.
   TOKYO METROPOLITAN RES LAB PUBL HLTH,DIV FOOD HYG,SHINJUKU KU,TOKYO 169,JAPAN.
   KITASATO UNIV,SCH HYG SCI,SAGAMIHARA,KANAGAWA 228,JAPAN.}},
DOI = {{10.1093/carcin/12.8.1417}},
ISSN = {{0143-3334}},
Keywords-Plus = {{TRYPTOPHAN PYROLYSIS PRODUCTS; CIGARETTE-SMOKE CONDENSATE; COMMERCIAL
   BEEF EXTRACT; FRIED GROUND-BEEF; LIQUID-CHROMATOGRAPHY;
   MASS-SPECTROMETRY; COOKED FOODS; DNA ADDUCTS; MUTAGENS; IDENTIFICATION}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251.
   BECHER G, 1988, CARCINOGENESIS, V9, P247, DOI 10.1093/carcin/9.2.247.
   COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1984, CARCINOGENESIS, V5, P95, DOI 10.1093/carcin/5.1.95.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   GROSS GA, 1989, CARCINOGENESIS, V10, P1175, DOI 10.1093/carcin/10.7.1175.
   HARGRAVES WA, 1983, CANCER RES, V43, P1467.
   HAYATSU H, 1983, JPN J CANCER RES, V74, P472.
   ISHIDA Y, 1987, TOXICOL IN VITRO, V1, P45, DOI 10.1016/0887-2333(87)90037-3.
   KANAI Y, 1988, CARCINOGENESIS, V9, P2179, DOI 10.1093/carcin/9.12.2179.
   MANABE S, 1987, MUTAT RES, V179, P33, DOI 10.1016/0027-5107(87)90038-8.
   MANABE S, 1987, CANCER RES, V47, P6150.
   MANABE S, 1989, MUTAT RES, V226, P215, DOI 10.1016/0165-7992(89)90072-9.
   MANABE S, 1990, ENVIRON MOL MUTAGEN, V15, P229, DOI 10.1002/em.2850150410.
   MURRAY S, 1988, CARCINOGENESIS, V9, P321, DOI 10.1093/carcin/9.2.321.
   MURRAY S, 1989, CARCINOGENESIS, V10, P763, DOI 10.1093/carcin/10.4.763.
   NAGAO M, 1977, CANCER LETT, V2, P221, DOI 10.1016/S0304-3835(77)80025-6.
   OCHIAI M, 1991, JPN J CANCER RES, V82, P363.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1739, DOI 10.1093/carcin/9.10.1739.
   SUGIMURA T, 1986, SCIENCE, V233, P312, DOI 10.1126/science.3088728.
   SUGIMURA T, 1982, CANCER, V49, P1970, DOI 10.1002/1097-0142(19820515)49:10<1970::AID-CNCR2820491005>3.0.CO;2-F.
   SUGIMURA T, 1990, MUTAGENS CARCINOGENS, P1.
   SUGIMURA T, 1988, CHEM INDUCTION CAN C, V3, P681.
   SUGIMURA T, 1988, TRENDS PHARMACOL SCI, V9, P205.
   TAKAHASHI M, 1985, CARCINOGENESIS, V6, P1195, DOI 10.1093/carcin/6.8.1195.
   TURESKY RJ, 1983, CARCINOGENESIS, V4, P863, DOI 10.1093/carcin/4.7.863.
   TURTELTAUB KW, 1990, P NATL ACAD SCI USA, V87, P5288, DOI 10.1073/pnas.87.14.5288.
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901.
   WATKINS BE, 1991, CARCINOGENESIS, V12, P1073, DOI 10.1093/carcin/12.6.1073.
   Winsten J. A., 1977, ORIGINS HUMAN CANC, P1561.
   YAMAIZUMI Z, 1986, MUTAT RES, V173, P1, DOI 10.1016/0165-7992(86)90002-3.
   YAMASHITA K, 1990, JPN J CANCER RES, V81, P470.
   YAMASHITA M, 1986, JPN J CANCER RES, V77, P419.
   YAMAZOE Y, 1988, JPN J CANCER RES, V79, P1159.
   YANAGISAWA H, 1986, BIOCHEM BIOPH RES CO, V138, P1084, DOI 10.1016/S0006-291X(86)80393-X.
   YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252.
   YOSHIDA D, 1980, CANCER LETT, V10, P141, DOI 10.1016/0304-3835(80)90037-3.
   ZHANG XM, 1988, MUTAT RES, V201, P181, DOI 10.1016/0027-5107(88)90124-8.}},
Number-of-Cited-References = {{40}},
Times-Cited = {{180}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{GA911}},
Wos-Id = {{ISI:A1991GA91100009}},
}

@article{ ISI:A1991FG19700026,
Author = {PELUSO, M and CASTEGNARO, M and MALAVEILLE, C and FRIESEN, M and GARREN,
   L and HAUTEFEUILLE, A and VINEIS, P and KADLUBAR, F and BARTSCH, H},
Title = {{32POSTLABELLING ANALYSIS OF URINARY MUTAGENS FROM SMOKERS OF BLACK
   TOBACCO IMPLICATES 2-AMINO-1-METHYL-6-PHENYLIMIDAZO{[}4,5-B]PYRIDINE
   (PHIP) AS A MAJOR DNA-DAMAGING AGENT}},
Journal = {{CARCINOGENESIS}},
Year = {{1991}},
Volume = {{12}},
Number = {{4}},
Pages = {{713-717}},
Month = {{APR}},
Abstract = {{When mutagens extracted from the urine of two smokers of black tobacco
   were reacted with DNA in vitro in the presence of a metabolic activation
   system, several DNA adducts were detected by P-32-postlabelling
   analysis.  Some of these adducts were also visible, but only faintly, on
   the autoradiogram for a non-smoker's urine.  DNA adducts produced in
   vitro by 2-amino-3,8-dimethylimidazo{[}4,5-f]quinoxaline or
   2-amino-1-methyl-6-phenylimidazo{[}3,5-b]pyridine could not account for
   the adduct pattern produced by the urinary mutagens.  However, three or
   four 2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP)-related
   DNA adducts were present among the five or six adducts observed for
   smokers in the autoradiograms of urinary mutagen-adducted nucleotides. 
   Mutagenicity testing combined with HPLC fractionation of urinary
   extracts also supported the postlabelling data which implicates PhIP as
   a mutagen in the urine of smokers of black tobacco.}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{INT AGCY RES CANC,150 COURS ALBERT THOMAS,F-69372 LYONS,FRANCE.
   UNIV TURIN,I-10126 TURIN,ITALY.
   NATL CTR TOXICOL RES,JEFFERSON,AR 72079.}},
DOI = {{10.1093/carcin/12.4.713}},
ISSN = {{0143-3334}},
Keywords-Plus = {{HETEROCYCLIC AMINES; AROMATIC-AMINES; COOKED BEEF; ADDUCTS;
   IDENTIFICATION; PHENYLALANINE; GENOTOXICITY; ASSAY; MICE; MEAT}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{BRYANT MS, 1988, P NATL ACAD SCI USA, V85, P9788, DOI 10.1073/pnas.85.24.9788.
   Budavari S., 1989, MERCK INDEX, P2577.
   ESUMI H, 1989, JPN J CANCER RES, V80, P1176.
   FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081.
   GRIVAS S, 1988, J CHEM RES, V5, P84.
   GROSS GA, 1989, CARCINOGENESIS, V10, P1175, DOI 10.1093/carcin/10.7.1175.
   GUPTA RC, 1985, CANCER RES, V45, P5656.
   GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081.
   HAYATSU H, 1983, MUTAT RES, V119, P223.
   HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389.
   Johnson R A, 1979, Adv Cyclic Nucleotide Res, V10, P135.
   JUNG E, 1986, P NATL ACAD SCI USA, V83, P7231, DOI 10.1073/pnas.83.19.7231.
   KADLUBAR FF, 1977, CANCER RES, V37, P805.
   LU LJW, 1986, CANCER RES, V46, P3046.
   MALAVEILLE C, 1989, CARCINOGENESIS, V10, P577, DOI 10.1093/carcin/10.3.577.
   OVERVIK E, 1989, CARCINOGENESIS, V10, P2293, DOI 10.1093/carcin/10.12.2293.
   PELUSO M, 1990, CARCINOGENESIS, V11, P1307, DOI 10.1093/carcin/11.8.1307.
   RANDERATH E, 1988, CARCINOGENESIS, V9, P75, DOI 10.1093/carcin/9.1.75.
   REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543.
   SHIOYA M, 1987, MUTAT RES, V191, P133, DOI 10.1016/0165-7992(87)90143-6.
   SKOY K, 1990, MUTAT RES, V230, P263.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1739, DOI 10.1093/carcin/9.10.1739.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   THOMPSON LH, 1987, MUTAGENESIS, V2, P483, DOI 10.1093/mutage/2.6.483.
   WESTRA JG, 1981, CARCINOGENESIS, V2, P355, DOI 10.1093/carcin/2.4.355.
   YAMASAKI E, 1977, P NATL ACAD SCI USA, V74, P3555, DOI 10.1073/pnas.74.8.3555.
   ZHANG XM, 1988, MUTAT RES, V201, P181, DOI 10.1016/0027-5107(88)90124-8.
   1986, IARC MONOGRAPHS EVAL, V38.}},
Number-of-Cited-References = {{28}},
Times-Cited = {{95}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{FG197}},
Wos-Id = {{ISI:A1991FG19700026}},
}

@article{ ISI:A1991GP65400006,
Author = {OVERVIK, E and OCHIAI, M and HIROSE, M and SUGIMURA, T and NAGAO, M},
Title = {{THE FORMATION OF HEART DNA ADDUCTS IN F344 RATS FOLLOWING DIETARY
   ADMINISTRATION OF HETEROCYCLIC AMINES}},
Journal = {{MUTATION RESEARCH}},
Year = {{1991}},
Volume = {{256}},
Number = {{1}},
Pages = {{37-43}},
Month = {{JAN}},
Abstract = {{Most heterocyclic amines formed during the cooking of meat and fish have
   been shown to form adducts in the livers of rats. Recently, however,
   2-amino-1-methyl-6-phenylimidazo{[}4,5-b]pyridine (PhIP), administered
   in the diet to Fischer 344 (F344) rats for 4 weeks, was shown to produce
   the highest levels of adducts in the heart. In the present study
   2-amino-3-methylimidazo{[}4,5-f]quinoline (IQ),
   2-amino-3,8-dimethylimidazo {[}4,5-f]quinoxaline (MeIQx),
   3-amino-1,4-dimethyl-5H-pyrido{[}4,3-b]indole (Trp-P-1) and
   2-amino-6-methyldipyrido{[}1,2-a:1',2'-d]imidazole (Glu-P-1) were given
   to F344 rats at carcinogenic dose levels (IQ 0.03\%, MeIQx 0.04\%,
   Trp-P-1 0.015\%, Glu-P-1 0.05\%) in the diet for 4 weeks. DNA adducts in
   the liver and heart were analyzed by P-32-postlabeling. DNA adducts were
   demonstrated to appear in the hearts of all animals exposed to
   heterocyclic amines at the following levels: IQ, 1.8 adducts/10(7)
   nucleotides, MeIQx, 3.8/10(7) ntd, Trp-P-1, 20/10(7) ntd and Glu-P-1,
   7.2/10(7) ntd. Values for the heart were 10-20\% of the respective liver
   adduct levels. Heart adducts increased linearly throughout the observed
   period when MeIQx was administered for up to 40 weeks. When MeIQx
   feeding was discontinued after 20 weeks and the animals subsequently
   given the basal diet, the adduct level at 20 weeks did not change during
   the following 20 weeks. A possible role for heart DNA alterations caused
   by food-borne heterocyclic amines in the development of age-related
   myopathies and cardiovascular disease is not inconceivable.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{NATL CANC CTR,RES INST,DIV CARCINOGENESIS,CHOU KU,TOKYO 104,JAPAN.}},
DOI = {{10.1016/0921-8734(91)90031-6}},
ISSN = {{0921-8262}},
Keywords = {{DNA ADDUCTS; HETEROCYCLIC AMINES; FOOD; HEART; P-32-POSTLABELING; AGING;
   ATHEROSCLEROSIS}},
Keywords-Plus = {{METHYL-ALPHA-CARBOLINE; POST-LABELING ANALYSIS; METABOLIC-ACTIVATION;
   P-32-POSTLABELING METHOD; TISSUE DISTRIBUTION; MUTAGENIC COMPOUND;
   COVALENT BINDING; MOUSE MYOCARDIUM; SALIVARY-GLANDS; MICE}},
Research-Areas = {{Genetics \& Heredity; Toxicology}},
Web-of-Science-Categories  = {{Genetics \& Heredity; Toxicology}},
Cited-References = {{ADAMSON RH, 1990, JPN J CANCER RES, V81, P10.
   AUNE T, 1988, CARCINOGENESIS, V7, P273.
   BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753.
   BOND JA, 1980, TOXICOL APPL PHARM, V52, P323, DOI 10.1016/0041-008X(80)90119-2.
   BOND JA, 1979, LIFE SCI, V25, P425, DOI 10.1016/0024-3205(79)90574-5.
   BRIDGES B A, 1990, Mutation Research, V239, P143, DOI 10.1016/0165-1110(90)90002-S.
   GAUBATZ JW, 1986, J MOL CELL CARDIOL, V18, P1317, DOI 10.1016/S0022-2828(86)80435-7.
   GAUBATZ JW, 1989, ARCH GERONTOL GERIAT, V8, P47, DOI 10.1016/0167-4943(89)90069-1.
   GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081.
   HALL M, 1990, CARCINOGENESIS, V11, P1005, DOI 10.1093/carcin/11.6.1005.
   HOLME JA, 1987, CELL BIOL TOXICOL, V3, P51, DOI 10.1007/BF00117825.
   JUCHAU MR, 1976, P NATL ACAD SCI USA, V73, P3723, DOI 10.1073/pnas.73.10.3723.
   KATO R, 1987, JPN J CANCER RES, V78, P297.
   KATO T, 1988, CARCINOGENESIS, V9, P71, DOI 10.1093/carcin/9.1.71.
   KATO T, 1989, CARCINOGENESIS, V10, P601, DOI 10.1093/carcin/10.3.601.
   MCMANUS ME, 1988, CANCER RES, V48, P4513.
   OVERVIK E, 1990, MUTAGENESIS, V5, P437, DOI 10.1093/mutage/5.5.437.
   RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117.
   RANDERATH E, 1989, J NATL CANCER I, V81, P341, DOI 10.1093/jnci/81.5.341.
   RANDERATH E, 1988, CARCINOGENESIS, V9, P75, DOI 10.1093/carcin/9.1.75.
   RANDERATH K, 1986, CARCINOGENESIS, V7, P1615, DOI 10.1093/carcin/7.9.1615.
   RANDERATH K, 1984, CARCINOGENESIS, V5, P1613, DOI 10.1093/carcin/5.12.1613.
   REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543.
   REDDY MV, 1984, CARCINOGENESIS, V5, P231, DOI 10.1093/carcin/5.2.231.
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1739, DOI 10.1093/carcin/9.10.1739.
   SUGIMURA T, 1986, SCIENCE, V233, P312, DOI 10.1126/science.3088728.
   SUGIMURA T, 1988, CHEM INDUCTION CANC, P681.
   TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145.
   TAKAYAMA S, 1985, P JPN ACAD B-PHYS, V61, P277.
   TAKAYAMA S, 1987, P JPN ACAD B-PHYS, V63, P161, DOI 10.2183/pjab.63.161.
   WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489.
   YAMASHITA K, 1986, P JPN ACAD B-PHYS, V62, P45, DOI 10.2183/pjab.62.45.
   YAMASHITA K, 1988, NUCLEIC ACIDS RES S, V19, P111.
   YAMASHITA K, 1990, JPN J CANCER RES, V81, P470.
   YAMAZOE Y, 1988, CARCINOGENESIS, V9, P105, DOI 10.1093/carcin/9.1.105.}},
Number-of-Cited-References = {{35}},
Times-Cited = {{34}},
Doc-Delivery-Number = {{GP654}},
Wos-Id = {{ISI:A1991GP65400006}},
}

@article{ ISI:A1990EV61600113,
Author = {LUNK, A},
Title = {{PLASMA ACTIVATED PHYSICAL VAPOR-DEPOSITION (PAPVD) BY HOLLOW-CATHODE ARC
   (HCA)}},
Journal = {{VACUUM}},
Year = {{1990}},
Volume = {{41}},
Number = {{7-9}},
Pages = {{1965-1967}},
Note = {{11TH INTERNATIONAL VACUUM CONGRESS ( IVC-11 ) / 7TH INTERNATIONAL CONF
   ON SOLID SURFACES ( ICSS-7 ), COLOGNE, FED REP GER, SEP 25-29, 1989}},
Abstract = {{The HCA is a good adaptable plasma source for the performance of plasma
   activated deposition.  Experimental investigations of the HCA plasma
   show that the plasma consists of four components:  isotropical
   distributed ions, electrons and neutrals as well as non-isotropical
   distributed electrons-beam-like electrons.  The plasma conditions near
   the substrate are characterized by the isotropic part of the plasma. 
   The beam electrons and the anode-fall are used for the evaporation of
   materials in a water-cooled crucible.  The physical principle of HCA
   evaporating device, the energy balance, and technological aspects of its
   application will be discussed in detail.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{LUNK, A (Reprint Author), UNIV GREIFSWALD,DEPT PHYS,DOMSTR 10A,O-2200 GREIFSWALD,GERMANY.}},
DOI = {{10.1016/0042-207X(90)94146-H}},
ISSN = {{0042-207X}},
Keywords-Plus = {{MAGNETRON}},
Research-Areas = {{Materials Science; Physics}},
Web-of-Science-Categories  = {{Materials Science, Multidisciplinary; Physics, Applied}},
Cited-References = {{BAKSHT FG, 1977, 13 P INT C PHEN ION, V1, P319.
   BARDOS L, 1986, CZECH J PHYS, V36, P883, DOI 10.1007/BF01598339.
   BASNER R, 1987, THESIS GREIFSWALD.
   DELCROIX JL, 1974, ADV ELECTRON ELECTRO, V35, P87.
   Druyvesteyn MJ, 1930, Z PHYS, V64, P781, DOI 10.1007/BF01773007.
   LUCE JS, 1985, 2ND P INT C PEAC US, P305.
   LUNK A, 1985, THESIS GREIFSWALD.
   LUNK A, 1990, CONTRIB PLASM PHYS, V30, P1.
   LUNK A, 1981, VAKUUMINFORMATION, V11, P351.
   MEZENTSEV AP, 1988, J PHYS D APPL PHYS, V21, P1464, DOI 10.1088/0022-3727/21/9/024.
   MORLEY JR, 1971, Patent No. 3562141.
   ROSSNAGEL SM, 1986, J VAC SCI TECHNOL A, V4, P1822, DOI 10.1116/1.573947.
   RUTSCHER A, 1983, PLASMA TECHNOLOGY.
   Shapiro A. H., 1953, DYNAMICS THERMODYNAM, V1.}},
Number-of-Cited-References = {{14}},
Times-Cited = {{18}},
Journal-ISO = {{Vacuum}},
Doc-Delivery-Number = {{EV616}},
Wos-Id = {{ISI:A1990EV61600113}},
}

@article{ ISI:A1989U027400002,
Author = {YANAGISAWA, H and WADA, O},
Title = {{SIGNIFICANT INCREASE OF IQ-TYPE HETEROCYCLIC AMINES, DIETARY CARCINOGENS
   IN THE PLASMA OF PATIENTS WITH UREMIA JUST BEFORE INDUCTION OF
   HEMODIALYSIS-TREATMENT}},
Journal = {{NEPHRON}},
Year = {{1989}},
Volume = {{52}},
Number = {{1}},
Pages = {{6-10}},
Month = {{MAY}},
Publisher = {{KARGER}},
Address = {{ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{YANAGISAWA, H (Reprint Author), UNIV TOKYO,FAC MED,DEPT HYG \& PREVENT MED,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN.}},
DOI = {{10.1159/000185574}},
ISSN = {{0028-2766}},
Research-Areas = {{Urology \& Nephrology}},
Web-of-Science-Categories  = {{Urology \& Nephrology}},
Cited-References = {{BERGMAN K, 1985, CANCER RES, V44, P1351.
   DODSWORTH H, 1981, J CLIN PATHOL, V34, P58, DOI 10.1136/jcp.34.1.58.
   DOLL R, 1966, NATURE, V265, P589.
   DOLL R, 1981, J NATL CANCER I, V66, P1191.
   GROSE KR, 1986, J AGR FOOD CHEM, V33, P201.
   HAYATSU H, 1983, MUTAT RES, V119, P233, DOI 10.1016/0165-7992(83)90166-5.
   MANABE S, 1987, MUTAT RES, V179, P33, DOI 10.1016/0027-5107(87)90038-8.
   MANABE S, 1987, CANCER RES, V47, P6150.
   MATAS AJ, 1975, LANCET, V1, P833.
   Miach P J, 1976, Clin Nephrol, V5, P101.
   ODA Y, 1985, MUTAT RES, V147, P219, DOI 10.1016/0165-1161(85)90062-7.
   OHGAKI H, 1984, CARCINOGENESIS, V5, P921, DOI 10.1093/carcin/5.7.921.
   SJODIN P, 1984, FOOD CHEM TOXICOL, V22, P207, DOI 10.1016/0278-6915(84)90128-5.
   SUGIMURA T, 1982, CANCER, V49, P1970, DOI 10.1002/1097-0142(19820515)49:10<1970::AID-CNCR2820491005>3.0.CO;2-F.
   SUGIMURA T, 1983, CANCER RES, V43, P2415.
   SUGIMURA T, 1985, MUTAT RES, V150, P33, DOI 10.1016/0027-5107(85)90098-3.
   SUTHERLAND GA, 1977, NEPHRON, V18, P182, DOI 10.1159/000180813.
   TAKAYAMA S, 1984, GANN, V75, P467.
   YAMASHITA M, 1986, JPN J CANCER RES, V77, P419.
   YANAGISAWA H, 1988, CLIN NEPHROL, V30, P13.
   YANAGISAWA H, 1987, JPN J NEPHROL, V29, P1153.
   YANAGISAWA H, 1986, BIOCHEM BIOPH RES CO, V138, P1084, DOI 10.1016/S0006-291X(86)80393-X.}},
Number-of-Cited-References = {{22}},
Times-Cited = {{18}},
Journal-ISO = {{Nephron}},
Doc-Delivery-Number = {{U0274}},
Wos-Id = {{ISI:A1989U027400002}},
}

@article{ ISI:A1988N064600008,
Author = {DUNSTAN, PO and AIROLDI, C},
Title = {{ADDUCTS OF ARSENIC TRIHALIDES WITH HETEROCYCLIC AMINES - SYNTHESIS,
   CHARACTERIZATION, AND THERMOCHEMISTRY}},
Journal = {{JOURNAL OF CHEMICAL AND ENGINEERING DATA}},
Year = {{1988}},
Volume = {{33}},
Number = {{2}},
Pages = {{93-96}},
Month = {{APR}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{DUNSTAN, PO (Reprint Author), UNIV ESTADUAL CAMPINAS,CAIXA POSTAL 6154,BR-13083 CAMPINAS,SP,BRAZIL.}},
DOI = {{10.1021/je00052a008}},
ISSN = {{0021-9568}},
Research-Areas = {{Chemistry; Engineering}},
Web-of-Science-Categories  = {{Chemistry, Multidisciplinary; Engineering, Chemical}},
Cited-References = {{AIROLDI C, 1980, J CHEM SOC DALTON, P1823, DOI 10.1039/dt9800001823.
   AIROLDI C, 1981, INORG CHEM, V20, P998, DOI 10.1021/ic50218a010.
   ASHCROFT SJ, 1970, J CHEM SOC A, P1020, DOI 10.1039/j19700001020.
   Bailar Jr. J. C., 1939, INORG SYNTH, V1, P103, DOI 10.1002/9780470132326.ch36.
   BELLAMY LJ, 1955, J CHEM SOC, P2818, DOI 10.1039/jr9550002818.
   BURKINSHAW PM, 1983, COORDIN CHEM REV, V48, P101, DOI 10.1016/0010-8545(83)80001-0.
   BURKINSHAW PM, 1984, J CHEM SOC DALTON, P75, DOI 10.1039/dt9840000075.
   Churney K. L., 1982, J PHYS CHEM REF DA S, V11, P2.
   Dafert O, 1926, BER DTSCH CHEM GES, V59, P788, DOI 10.1002/cber.19260590436.
   DEVENEY MJ, 1970, J CHEM SOC A, P1643, DOI 10.1039/j19700001643.
   GADDON DP, 1965, AUST J CHEM, V18, P507.
   Gibson CS, 1930, J CHEM SOC, P1710.
   GIESSE R, 1982, THERMOCHIM ACTA, V54, P257, DOI 10.1016/0040-6031(82)80015-4.
   GILL NS, 1961, J INORG NUCL CHEM, V18, P79, DOI 10.1016/0022-1902(61)80372-2.
   GILL NS, 1966, AUST J CHEM, V19, P2197.
   GONCALVES AS, 1979, J CHEM SOC DALTON, P159, DOI 10.1039/dt9790000159.
   GRADDON DP, 1965, AUST J CHEM, V18, P507, DOI 10.1071/CH9650507.
   HOLMES RR, 1958, J AM CHEM SOC, V80, P2980, DOI 10.1021/ja01545a020.
   JORGE RA, 1978, J CHEM SOC DALTON, P1102, DOI 10.1039/dt9780001102.
   Karapet'yants M. Kh., 1970, THERMODYNAMIC CONSTA.
   KOLTHOFF IM, 1956, TRATADO ANAL CUANTIT.
   KONDRATENKO B, 1934, J ALLG CHEM, V4, P246.
   KROSS RD, 1956, J AM CHEM SOC, V78, P1332, DOI 10.1021/ja01588a019.
   LINDQUIST I, 1963, INORGANIC ADDUCT MOL.
   Loh RTC, 1926, J AM CHEM SOC, V48, P2956, DOI 10.1021/ja01690a031.
   MONTIGNIE E, 1935, B SOC CHIM FR, V5, P1365.
   ODDO G, 1924, GAZZ CHIM ITAL, V53, P56.
   PARKASH R, 1981, MONATSH CHEM, V112, P707, DOI 10.1007/BF00899773.
   PAUL RC, 1970, INDIAN J CHEM, V8, P1014.
   PAUL RC, 1969, J INDIAN CHEM SOC, V46, P26.
   Pedley JB, 1970, COMPUTER ANAL THERMO.
   Shirey WB, 1930, J AM CHEM SOC, V52, P1720, DOI 10.1021/ja01367a502.
   SIMONI JDA, 1980, J CHEM SOC DALTON, P156.
   Vogel A. I., 1973, TXB QUANTITATIVE INO.
   WEBSTER M, 1971, J CHEM SOC A, P836, DOI 10.1039/j19710000836.
   WILSON JW, 1969, J INORG NUCL CHEM, V31, P1357, DOI 10.1016/0022-1902(69)80248-4.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{17}},
Journal-ISO = {{J. Chem. Eng. Data}},
Doc-Delivery-Number = {{N0646}},
Wos-Id = {{ISI:A1988N064600008}},
}

@article{ ISI:A1987K609600004,
Author = {ASAN, E and FASSHAUER, I and WILD, D and HENSCHLER, D},
Title = {{HETEROCYCLIC AROMATIC AMINE-DNA-ADDUCTS IN BACTERIA AND MAMMALIAN-CELLS
   DETECTED BY P-32 POSTLABELING ANALYSIS}},
Journal = {{CARCINOGENESIS}},
Year = {{1987}},
Volume = {{8}},
Number = {{11}},
Pages = {{1589-1593}},
Month = {{NOV}},
Publisher = {{OXFORD UNIV PRESS UNITED KINGDOM}},
Address = {{WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{UNIV WURZBURG,INST PHARMACOL \& TOXICOL,D-8700 WURZBURG,FED REP GER.}},
DOI = {{10.1093/carcin/8.11.1589}},
ISSN = {{0143-3334}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{BARNES WS, 1985, CARCINOGENESIS, V6, P441, DOI 10.1093/carcin/6.3.441.
   BERANEK DT, 1982, P NATL ACAD SCI-BIOL, V79, P5175, DOI 10.1073/pnas.79.17.5175.
   BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303.
   BROOKMAN KW, 1985, MUTAT RES, V149, P249, DOI 10.1016/0027-5107(85)90031-4.
   DIRR A, UNPUB SYNTHESIS MUTA.
   FAHL WE, 1981, CANCER RES, V41, P3400.
   FLAMMANG TJ, 1986, CARCINOGENESIS, V7, P919, DOI 10.1093/carcin/7.6.919.
   GRIVAS S, 1984, MUTAT RES, V137, P29, DOI 10.1016/0165-1218(84)90108-3.
   GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081.
   GUPTA RC, 1984, CARCINOGENESIS, V5, P343, DOI 10.1093/carcin/5.3.343.
   HASHIMOTO Y, 1980, BIOCHEM BIOPH RES CO, V92, P971, DOI 10.1016/0006-291X(80)90797-4.
   HASHIMOTO Y, 1980, BIOCHEM BIOPH RES CO, V96, P355, DOI 10.1016/0006-291X(80)91222-X.
   HASHIMOTO Y, 1982, J AM CHEM SOC, V104, P7636, DOI 10.1021/ja00390a040.
   HOWARD PC, 1983, CANCER RES, V43, P2052.
   KAISER G, 1986, CHEM-BIOL INTERACT, V57, P97, DOI 10.1016/0009-2797(86)90052-9.
   KATO R, 1986, CRC CRIT REV TOXICOL, V16, P306.
   LORETZ LJ, 1984, CARCINOGENESIS, V5, P895, DOI 10.1093/carcin/5.7.895.
   LOUKAKOU B, 1985, CARCINOGENESIS, V6, P377, DOI 10.1093/carcin/6.3.377.
   Maniatis T, 1982, MOL CLONING LABORATO, P149.
   MARON DM, 1983, MUTAT RES, V113, P173, DOI 10.1016/0165-1161(83)90010-9.
   MEERMAN JHN, 1981, LIFE SCI, V28, P2361, DOI 10.1016/0024-3205(81)90501-4.
   MILLER JA, 1970, CANCER RES, V30, P559.
   NAGAO M, 1983, BIOCHEM BIOPH RES CO, V114, P626, DOI 10.1016/0006-291X(83)90826-4.
   OHGAKI H, 1984, CARCINOGENESIS, V5, P921, DOI 10.1093/carcin/5.7.921.
   OKAMOTO T, 1981, CHEM PHARM BULL, V29, P590.
   ORR JC, 1985, CHEM-BIOL INTERACT, V54, P281, DOI 10.1016/S0009-2797(85)80169-1.
   REDDY MV, 1984, CARCINOGENESIS, V5, P231, DOI 10.1093/carcin/5.2.231.
   SAITO K, 1983, BIOCHEM BIOPH RES CO, V116, P141, DOI 10.1016/0006-291X(83)90392-3.
   SCHIFFMANN D, 1984, CANCER LETT, V23, P297, DOI 10.1016/0304-3835(84)90097-1.
   SCHLEIF RF, 1982, PRACTICAL METHODS MO, P98.
   SCHOEPE KB, 1986, CARCINOGENESIS, V7, P535, DOI 10.1093/carcin/7.4.535.
   SHINOHARA A, 1985, CARCINOGENESIS, V6, P305, DOI 10.1093/carcin/6.2.305.
   SKIPPER PL, 1985, P AM ASSOC CANC RES, V26, P90.
   STARK AA, 1979, P NATL ACAD SCI USA, V76, P1343, DOI 10.1073/pnas.76.3.1343.
   SUGIMURA T, 1983, CANCER RES, V43, P2415.
   SUGIMURA T, 1986, GENETIC TOXICOLOGY D, P85.
   TAKAYAMA S, 1984, GANN, V75, P467.
   TANAKA T, 1985, JPN J CANCER RES, V76, P570.
   VUOLO LL, 1985, ENVIRON MUTAGEN, V7, P577, DOI 10.1002/em.2860070415.
   WILD D, 1986, PRIMARY CHANGES CONT, P76.
   WILD D, 1985, MUTAT RES, V156, P93, DOI 10.1016/0165-1218(85)90011-4.
   WILD D, 1987, IN PRESS CARCINOGENI.
   WILD D, 1986, GENETIC TOXICOLOGY D, P145.
   YAMAZOE Y, 1983, CANCER RES, V43, P5768.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{28}},
Journal-ISO = {{Carcinogenesis}},
Doc-Delivery-Number = {{K6096}},
Wos-Id = {{ISI:A1987K609600004}},
}

@article{ ISI:A1987L552200007,
Author = {BHASIN, CP and SRIVASTAVA, G and MEHROTRA, RC},
Title = {{HETEROCYCLIC DITERTIARY AMINE ADDUCTS OF NICKEL(II)
   O,O-ALKYLENEDITHIOPHOSPHATES}},
Journal = {{INDIAN JOURNAL OF CHEMISTRY SECTION A-INORGANIC BIO-INORGANIC PHYSICAL
   THEORETICAL \& ANALYTICAL CHEMISTRY}},
Year = {{1987}},
Volume = {{26}},
Number = {{10}},
Pages = {{834-837}},
Month = {{OCT}},
Publisher = {{COUNCIL SCIENTIFIC INDUSTRIAL RESEARCH}},
Address = {{PUBL \& INFO DIRECTORATE, NEW DELHI 110012, INDIA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{UNIV RAJASTHAN,DEPT CHEM,JAIPUR 302004,RAJASTHAN,INDIA.}},
ISSN = {{0376-4710}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Multidisciplinary}},
Cited-References = {{BHASIN CP, 1983, INORG CHIM A-LETT, V77, pL131, DOI 10.1016/S0020-1693(00)82590-6.
   BHASIN CP, 1987, INORG CHIM ACTA, V131, P195, DOI 10.1016/S0020-1693(00)96024-9.
   BHASIN CP, 1987, INORG CHIM ACTA, V128, P69, DOI 10.1016/S0020-1693(00)84697-6.
   CASON J, 1959, J ORG CHEM, V24, P247, DOI 10.1021/jo01084a624.
   CHAUHAN HPS, 1983, PHOSPHORUS SULPHUR, V15, P19.
   CORBRIDGE DEC, 1969, TOPICS PHOSPHORUS CH, V6, P235.
   EDWARD JL, 1976, INORG CHEM, V15, P2908.
   JONES RAY, 1960, J CHEM SOC, P4376, DOI 10.1039/jr9600004376.
   LIVINGST.SE, 1970, INORG CHEM, V9, P2545, DOI 10.1021/ic50093a033.
   NANJO M, 1970, J INORG NUCL CHEM, V32, P2411, DOI 10.1016/0022-1902(70)80524-3.
   WICHOLAS M, 1968, J AM CHEM SOC, V90, P6946, DOI 10.1021/ja01027a009.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{12}},
Journal-ISO = {{Indian J. Chem. Sect A-Inorg. Phys. Theor. Anal. Chem.}},
Doc-Delivery-Number = {{L5522}},
Wos-Id = {{ISI:A1987L552200007}},
}

@article{ ISI:A1987H100800024,
Author = {IFTIKHAR, K},
Title = {{MIXED-LIGAND LANTHANIDE COMPLEXES .6. ELECTRONIC SPECTRAL STUDY OF SOME
   LN(FOD)3 ADDUCTS WITH HETEROCYCLIC AMINES}},
Journal = {{INORGANICA CHIMICA ACTA}},
Year = {{1987}},
Volume = {{128}},
Number = {{2}},
Pages = {{273-275}},
Month = {{APR 22}},
Publisher = {{ELSEVIER SCIENCE SA LAUSANNE}},
Address = {{PO BOX 564, 1001 LAUSANNE 1, SWITZERLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{IFTIKHAR, K (Reprint Author), JAMIA MILLIA ISLAMIA,DEPT CHEM,JAMIA NAGAR,NEW DELHI 110025,INDIA.}},
DOI = {{10.1016/S0020-1693(00)86557-3}},
ISSN = {{0020-1693}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Inorganic \& Nuclear}},
Cited-References = {{BOUDREAUX EA, 1977, J INORG NUCL CHEM, V39, P595, DOI 10.1016/0022-1902(77)80571-X.
   Camall W.T., 1968, J CHEM PHYS, V49, P4412.
   CHOPPIN GR, 1966, INORG CHEM, V5, P1743, DOI 10.1021/ic50044a023.
   DAVIS SA, 1984, INORG CHEM, V23, P184, DOI 10.1021/ic00170a014.
   HENRIE DE, 1968, J CHEM PHYS, V49, P477, DOI 10.1063/1.1670099.
   HENRIE DE, 1976, COORDIN CHEM REV, V18, P199, DOI 10.1016/S0010-8545(00)82044-5.
   IFTIKHAR K, 1986, INORG CHIM ACTA, V118, pL53, DOI 10.1016/S0020-1693(00)81381-X.
   IFTIKHAR K, 1982, INORG CHEM, V21, P80, DOI 10.1021/ic00131a015.
   IFTIKHAR K, 1985, POLYHEDRON, V4, P333, DOI 10.1016/S0277-5387(00)84509-X.
   IFTIKHAR K, 1983, AUST J CHEM, V36, P695.
   IFTIKHAR K, 1982, B CHEM SOC JPN, V55, P2258, DOI 10.1246/bcsj.55.2258.
   IFTIKHAR K, 1985, J CHEM SOC DALTON, P2547, DOI 10.1039/dt9850002547.
   ISOBE T, 1974, B CHEM SOC JPN, V47, P281, DOI 10.1246/bcsj.47.281.
   JORGENSEN CK, 1983, J LESS-COMMON MET, V93, P107, DOI 10.1016/0022-5088(83)90454-X.
   JORGENSEN CK, 1964, MOL PHYS, V8, P281, DOI 10.1080/00268976400100321.
   Jorgensen C.K., 1971, MODERN ASPECTS LIGAN.
   KARRAKER DG, 1971, J INORG NUCL CHEM, V33, P3713, DOI 10.1016/0022-1902(71)80278-6.
   KARRAKER DG, 1968, INORG CHEM, V7, P473, DOI 10.1021/ic50061a018.
   KARRAKER DG, 1967, INORG CHEM, V6, P1863, DOI 10.1021/ic50056a022.
   KIRBY AF, 1981, INORG CHEM, V20, P1030, DOI 10.1021/ic50218a016.
   KIRBY AF, 1981, INORG CHEM, V20, P4219, DOI 10.1021/ic50226a038.
   KOTHARI A, 1983, CAN J CHEM, V61, P1778, DOI 10.1139/v83-304.
   KRUPKE WF, 1966, PHYS REV, V145, P325, DOI 10.1103/PhysRev.145.325.
   Mason S. F, 1980, STRUCT BONDING BERLI, V39, P43.
   MASON SF, 1975, MOL PHYS, V30, P1829, DOI 10.1080/00268977500103321.
   NAG K, 1976, INORG CHEM, V15, P2291, DOI 10.1021/ic50163a060.
   Peacock R. D., 1975, STRUCT BONDING BERLI, V22, P83, DOI DOI 10.1007/BFB0116556.
   SINHA SP, 1966, SPECTROCHIM ACTA, V22, P57, DOI 10.1016/0371-1951(66)80008-5.
   STEPHENS EM, 1984, INORG CHEM, V23, P4611, DOI 10.1021/ic00194a041.
   YATSIMIRSKII KB, 1979, COORDIN CHEM REV, V27, P223, DOI 10.1016/S0010-8545(00)82068-8.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{10}},
Journal-ISO = {{Inorg. Chim. Acta}},
Doc-Delivery-Number = {{H1008}},
Wos-Id = {{ISI:A1987H100800024}},
}

@article{ ISI:A1985AXN8600008,
Author = {LIU, WS and BUNTING, RK and WEST, DX},
Title = {{HETEROCYCLIC AMINE ADDUCTS OF BIS(2-THIOPYRIDINE N-OXIDE)NICKEL(II)}},
Journal = {{INORGANICA CHIMICA ACTA-ARTICLES AND LETTERS}},
Year = {{1985}},
Volume = {{105}},
Number = {{3}},
Pages = {{177-180}},
Month = {{DEC 16}},
Publisher = {{ELSEVIER SCIENCE SA LAUSANNE}},
Address = {{PO BOX 564, 1001 LAUSANNE 1, SWITZERLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{ILLINOIS STATE UNIV,DEPT CHEM,NORMAL,IL 61761.}},
DOI = {{10.1016/S0020-1693(00)85225-1}},
ISSN = {{0020-1693}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Inorganic \& Nuclear}},
Cited-References = {{ALI MA, 1977, J INORG NUCL CHEM, V39, P265.
   ARMSTRONG LG, 1978, INORG CHEM, V17, P2350, DOI 10.1021/ic50187a003.
   BERNSTEIN J, 1957, Patent No. 2809971.
   BOYD SA, 1976, J INORG NUCL CHEM, V38, P1605, DOI 10.1016/0022-1902(76)80644-6.
   BOYD SA, 1976, J INORG NUCL CHEM, V38, P607, DOI 10.1016/0022-1902(76)80321-1.
   BOYMEL PM, 1980, INORG CHEM, V19, P727, DOI 10.1021/ic50205a029.
   BROWN DR, 1981, J INORG NUCL CHEM, V43, P1017, DOI 10.1016/0022-1902(81)80167-4.
   CASELLATO U, 1984, INORG CHIM A-F-BLOCK, V95, P37, DOI 10.1016/S0020-1693(00)85966-6.
   CHARTIER LH, 1979, J INORG NUCL CHEM, V41, P657, DOI 10.1016/0022-1902(79)80350-4.
   CHARTIER LJ, 1978, J INORG NUCL CHEM, V41, P663.
   COUCOUVA.D, 1967, INORG CHEM, V6, P2047, DOI 10.1021/ic50057a026.
   DARBY WL, 1979, INORG CHIM ACTA, V36, P253, DOI 10.1016/S0020-1693(00)89401-3.
   Falk K.E., 1970, INORG CHEM, V9, P556, DOI 10.1021/ic50085a025.
   HAGLEY VS, 1977, J INORG NUCL CHEM, V39, P1959, DOI 10.1016/0022-1902(77)80524-1.
   HARTLEY RJ, 1980, J INORG NUCL CHEM, V42, P1141.
   HASHAGEN JT, 1965, J AM CHEM SOC, V87, P2821, DOI 10.1021/ja01091a008.
   HASHINO N, 1981, B CHEM SOC JPN, V54, P420.
   HEYDE TPEAD, 1981, J MOL STRUCT, V70, P121.
   Lever A. B. P., 1968, INORGANIC ELECT SPEC, P343.
   MARCOTRIGIANO G, 1979, B CHEM SOC JPN, V52, P3420, DOI 10.1246/bcsj.52.3420.
   MCMILLIN DR, 1976, J AM CHEM SOC, V98, P3120, DOI 10.1021/ja00427a010.
   RANI I, 1981, J INORG NUCL CHEM, V43, P2743, DOI 10.1016/0022-1902(81)80609-4.
   RAPER ES, 1977, J INORG NUCL CHEM, V39, P2163, DOI 10.1016/0022-1902(77)80387-4.
   ROBINSON MA, 1964, J INORG NUCL CHEM, V26, P1277, DOI 10.1016/0022-1902(64)80210-4.
   SASAKI Y, 1979, B CHEM SOC JPN, V52, P2295, DOI 10.1246/bcsj.52.2295.
   WAYLAND BB, 1974, INORG CHEM, V13, P2517, DOI 10.1021/ic50140a043.
   WEST DX, 1979, J INORG NUCL CHEM, V41, P49, DOI 10.1016/0022-1902(79)80392-9.
   WEST DX, 1983, INORG CHIM A-ARTICLE, V71, P251, DOI 10.1016/S0020-1693(00)83667-1.
   WEST DX, 1978, INORG NUCL CHEM LETT, V14, P155, DOI 10.1016/0020-1650(78)80100-7.
   1954, Patent No. 2686786.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{6}},
Doc-Delivery-Number = {{AXN86}},
Wos-Id = {{ISI:A1985AXN8600008}},
}

@article{ ISI:A1983TK21400004,
Author = {MROZINSKI, J and HEYDUK, E},
Title = {{BINUCLEAR COPPER(II) COMPLEXES WITH ALPHA,BETA-UNSATURATED
   CARBOXYLIC-ACIDS .2. ADDUCTS OF COPPER CROTONATE WITH HETEROCYCLIC
   AMINES}},
Journal = {{POLISH JOURNAL OF CHEMISTRY}},
Year = {{1983}},
Volume = {{57}},
Number = {{4-6}},
Pages = {{375-382}},
Publisher = {{POLISH CHEMICAL SOCIETY}},
Address = {{C/O POLISH ACAD SCIENCES, INST PHYSICAL CHEMISTRY, UL KASPRZAKA 44/52,
   01-224 WARSAW, POLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{MROZINSKI, J (Reprint Author), WROCLAW B BEIRUT UNIV,INST CHEM,PL-50383 WROCLAW,POLAND.}},
ISSN = {{0137-5083}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Multidisciplinary}},
Cited-References = {{BLEANEY B, 1952, PROC R SOC LON SER-A, V214, P451, DOI 10.1098/rspa.1952.0181.
   DUBICKI L, 1966, INORG CHEM, V5, P2203, DOI 10.1021/ic50046a027.
   Earnshaw A., 1968, INTRO MAGNETOCHEMIST.
   EDMONDSO.BJ, 1965, INORG CHEM, V4, P1608, DOI 10.1021/ic50033a016.
   FIGGIS BN, 1958, J CHEM SOC, P4190, DOI 10.1039/jr9580004190.
   FIGGIS BN, 1956, J CHEM SOC, P3837, DOI 10.1039/jr9560003837.
   GREGSON AK, 1971, PROC R SOC LON SER-A, V320, P473, DOI 10.1098/rspa.1971.0004.
   GUHA BC, 1951, PROC R SOC LON SER-A, V206, P353, DOI 10.1098/rspa.1951.0075.
   HANSON MV, 1978, J INORG NUCL CHEM, V40, P1684, DOI 10.1016/0022-1902(78)80354-6.
   JOTHAM RW, 1972, J CHEM SOC DALTON, P428, DOI 10.1039/dt9720000428.
   KATO M, 1964, CHEM REV, V64, P99, DOI 10.1021/cr60228a003.
   KISHITA M, 1964, INORG CHEM, V3, P237, DOI 10.1021/ic50012a021.
   KOKOT E, 1964, INORG CHEM, V3, P1306, DOI 10.1021/ic50019a024.
   Konig E., 1966, MAGNETIC PROPERTIES.
   KOTTIS P, 1963, J CHEM PHYS, V39, P393, DOI 10.1063/1.1734260.
   LEVER ABP, 1962, J CHEM SOC, P5262, DOI 10.1039/jr9620005262.
   MARSH WE, 1977, J INORG NUCL CHEM, V39, P939.
   MARTIN RL, 1958, J CHEM SOC, P1394, DOI 10.1039/jr9580001394.
   MARTIN RL, 1957, J CHEM SOC, P2545, DOI 10.1039/jr9570002545.
   MELNIK M, 1979, J MOL STRUCT, V57, P135, DOI 10.1016/0022-2860(79)80238-0.
   MELNIK M, 1982, J MOL STRUCT, V78, P91, DOI 10.1016/0022-2860(82)85314-3.
   MELNIK M, 1982, J MOL STRUCT, V78, P85, DOI 10.1016/0022-2860(82)85313-1.
   MELNIK M, 1981, INORG CHIM A-ARTICLE, V48, P77, DOI 10.1016/S0020-1693(00)90070-7.
   MELNIK M, 1980, MATERIAL SCI 4, V4, P197.
   MROZINSKI J, 1982, POL J CHEM, V56, P683.
   NEWTON WJ, 1980, J CHEM SOC DALTON, P1379, DOI 10.1039/dt9800001379.
   NEWTON WJ, 1979, J CHEM SOC DA, P1379.
   RESNIK RK, 1963, INROG CHEM, V2, P1246, DOI 10.1021/ic50010a035.
   STRADE H, 1973, J PHYS CHEM-US, V77, P424, DOI 10.1021/j100622a024.
   WASSERMAN E, 1964, J CHEM PHYS, V41, P1763, DOI 10.1063/1.1726156.
   WASSON JR, 1968, INORG CHEM, V7, P469, DOI 10.1021/ic50061a017.
   YAMADA S, 1958, B CHEM SOC JPN, V31, P303, DOI 10.1246/bcsj.31.303.
   ZELENTSOV VV, 1969, ZH STRUKT KHIM, V10, P259.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{10}},
Journal-ISO = {{Pol. J. Chem.}},
Doc-Delivery-Number = {{TK214}},
Wos-Id = {{ISI:A1983TK21400004}},
}

@article{ ISI:A1982SJ94400010,
Author = {MROZINSKI, J and HEYDUK, E},
Title = {{BINUCLEAR COPPER(II) COMPLEXES WITH ALPHA,BETA-UNSATURATED
   CARBOXYLIC-ACIDS .1. COPPER ACRYLATES WITH HETEROCYCLIC AMINE ADDUCTS}},
Journal = {{POLISH JOURNAL OF CHEMISTRY}},
Year = {{1982}},
Volume = {{56}},
Number = {{4-6}},
Pages = {{683-690}},
Publisher = {{POLISH CHEMICAL SOCIETY}},
Address = {{C/O POLISH ACAD SCIENCES, INST PHYSICAL CHEMISTRY, UL KASPRZAKA 44/52,
   01-224 WARSAW, POLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{MROZINSKI, J (Reprint Author), WROCLAW B BEIRUT UNIV,INST CHEM,PL-50383 WROCLAW,POLAND.}},
ISSN = {{0137-5083}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Multidisciplinary}},
Cited-References = {{BLEANEY B, 1952, PROC R SOC LON SER-A, V214, P451, DOI 10.1098/rspa.1952.0181.
   BOSE A, 1968, INDIAN J PHYS, V42, P55.
   De Mester P, 1973, J CHEM SOC DA, P2575, DOI 10.1039/dt9730002575.
   DOEDENS RJ, 1976, PROGR INORGANIC CHEM, V21.
   DUBICKI L, 1966, INORG CHEM, V5, P2203, DOI 10.1021/ic50046a027.
   Earnshaw A., 1968, INTRO MAGNETOCHEMIST.
   EDMONDSON BJ, 1965, INORG CHEM, V11, P1608.
   FIGGIS BN, 1958, J CHEM SOC, P4190, DOI 10.1039/jr9580004190.
   FIGGIS BN, 1956, J CHEM SOC, P3847.
   FORSTER LS, 1962, ACTA CHEM SCAND, V16, P1385, DOI 10.3891/acta.chem.scand.16-1385.
   GERGSON AK, 1971, P ROY SOC LOND A MAT, V320, P473.
   GERLOCH M, 1978, P ROY SOC LOND A MAT, V360, P211, DOI 10.1098/rspa.1978.0064.
   Goodgame D.M.L., 1969, CHEM COMMUN, P629.
   GRADDON DP, 1961, J INORG NUCL CHEM, V17, P222, DOI 10.1016/0022-1902(61)80143-7.
   GUHA BC, 1951, PROC R SOC LON SER-A, V206, P353, DOI 10.1098/rspa.1951.0075.
   HANSEN AE, 1965, T FARADAY SOC, V61, P631, DOI 10.1039/tf9656100631.
   JOTHAM RW, 1972, J CHEM SOC DALTON, P428, DOI 10.1039/dt9720000428.
   JOTHAM RW, 1969, CHEM COMMUN, P258.
   JOTHAM RW, 1969, J CHEM SOC A, P2816, DOI 10.1039/j19690002816.
   KAWAMORI A, 1978, J MAGN RESON, V31, P423, DOI 10.1016/S0022-2364(78)80008-0.
   KOKOT E, 1964, INORG CHEM, V3, P1306, DOI 10.1021/ic50019a024.
   Konig E., 1966, MAGNETIC PROPERTIES.
   KUMAGAI H, 1952, PHYS REV, V87, P385, DOI 10.1103/PhysRev.87.385.2.
   LEVER ABP, 1968, INORGANIC ELECTRONIC, P361.
   LEVER ABP, 1962, J CHEM SOC, P5262, DOI 10.1039/jr9620005262.
   LIFSCHITZ J, 1915, ELEKTROCHEM, V21, P499.
   MELNIK M, 1979, J MOL STRUCT, V57, P135, DOI 10.1016/0022-2860(79)80238-0.
   MELNIK M, 1978, J MOL STRUCT, V48, P79, DOI 10.1016/0022-2860(78)87225-1.
   MELNIK M, 1976, J MOL STRUCT, V31, P269, DOI 10.1016/0022-2860(76)80006-3.
   MITRA S, 1965, PHYSICA, V31, P362, DOI 10.1016/0031-8914(65)90041-8.
   MOOKHERJI A, 1962, NATURE, V186, P370.
   MOOKHERJI A, 1963, J PHYS SOC JPN, V18, P977, DOI 10.1143/JPSJ.18.977.
   MORELAND JA, 1978, INORG CHEM, V17, P674, DOI 10.1021/ic50181a033.
   Perrin D. D., 1965, DISSOCIATION CONSTAN.
   Polder D, 1942, PHYSICA, V9, P709, DOI 10.1016/S0031-8914(42)80037-3.
   Reimann G. W., 1965, INORG CHEM, V4, P1082.
   ABE H, 1953, PHYS REV, V90, P316, DOI 10.1103/PhysRev.90.316.
   STRADE H, 1973, J PHYS CHEM-US, V77, P424, DOI 10.1021/j100622a024.
   TONNET ML, 1964, T FARADAY SOC, V60, P840, DOI 10.1039/tf9646000840.
   VANNIEKERK JN, 1953, ACTA CRYST B, V31, P762.
   WASSERMAN E, 1964, J CHEM PHYS, V41, P1763, DOI 10.1063/1.1726156.
   WASSON JR, 1968, INORG CHEM, V7, P469, DOI 10.1021/ic50061a017.
   YAMADA S, 1957, B CHEM SOC JAPAN, V30, P935.
   YAMADA S, 1958, B CHEM SOC JPN, V31, P303, DOI 10.1246/bcsj.31.303.
   ZELENTSOV VV, 1969, ZH STRUKT KHIM, V10, P259.}},
Number-of-Cited-References = {{45}},
Times-Cited = {{12}},
Journal-ISO = {{Pol. J. Chem.}},
Doc-Delivery-Number = {{SJ944}},
Wos-Id = {{ISI:A1982SJ94400010}},
}

@article{ ISI:A1981LR08700045,
Author = {KEMAL, O and REESE, CB},
Title = {{SODIUM-BOROHYDRIDE REDUCTION OF ADDUCTS OF PRIMARY AMINES WITH ALDEHYDES
   AND P-THIOCRESOL - THE ALKYLATION OF HETEROCYCLIC AND AROMATIC
   AMINO-COMPOUNDS}},
Journal = {{JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1}},
Year = {{1981}},
Number = {{5}},
Pages = {{1569-1573}},
Publisher = {{ROYAL SOC CHEMISTRY}},
Address = {{THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON ROAD, CAMBRIDGE, CAMBS,
   ENGLAND CB4 4WF}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{UNIV LONDON KINGS COLL,DEPT CHEM,LONDON WC2R 2LS,ENGLAND.}},
DOI = {{10.1039/p19810001569}},
ISSN = {{0300-922X}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Organic}},
Cited-References = {{BERGSTROM FW, 1946, J ORG CHEM, V11, P239, DOI 10.1021/jo01173a005.
   BILLMAN JH, 1957, J ORG CHEM, V22, P1068, DOI 10.1021/jo01360a019.
   BORCH RF, 1972, J ORG CHEM, V37, P1673, DOI 10.1021/jo00975a049.
   BRIDSON PK, 1979, BIOORG CHEM, V8, P339, DOI 10.1016/0045-2068(79)90061-0.
   BROWN DJ, 1967, J CHEM SOC C, P1928, DOI 10.1039/j39670001928.
   GRILLOT GF, 1959, J ORG CHEM, V24, P1035, DOI 10.1021/jo01090a001.
   HALL R, 1971, MODIFIED NUCLEOSIDES.
   KADIN SB, 1973, J ORG CHEM, V38, P1348, DOI 10.1021/jo00947a021.
   KEMAL O, 1980, SYNTHESIS-STUTTGART, P1025.
   Moore M. L., 1949, ORG REACTIONS, V5, P301.
   POLLOCK JRA, 1965, DICT ORGANIC COMPOUN, P1407.
   TOMCUFEIK AS, 1962, PYRIDINE DERIVATIVES, P28.
   WEAST RC, 1974, HDB CHEM PHYSICS, pC111.
   WIBAUT JP, 1961, RECL TRAV CHIM PAY B, V80, P309.}},
Number-of-Cited-References = {{14}},
Times-Cited = {{20}},
Journal-ISO = {{J. Chem. Soc.-Perkin Trans. 1}},
Doc-Delivery-Number = {{LR087}},
Wos-Id = {{ISI:A1981LR08700045}},
}

@article{ ISI:A1978GU19700003,
Author = {WANG, WJ and WEI, HH},
Title = {{PROTON MAGNETIC-RESONANCE STUDIES OF HETEROCYCLIC AROMATIC AMINE ADDUCTS
   OF NICKEL(II) AND COBALT(II) ACETYLACETONATE}},
Journal = {{JOURNAL OF THE CHINESE CHEMICAL SOCIETY}},
Year = {{1978}},
Volume = {{25}},
Number = {{4}},
Pages = {{185-194}},
Publisher = {{CHINESE CHEM SOC}},
Address = {{PO BOX 609, TAIPEI 10099, TAIWAN}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{WANG, WJ (Reprint Author), TAMKANG COLL ARTS \& SCI,DEPT CHEM,TAMSUI 251,TAIWAN.}},
ISSN = {{0009-4536}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Multidisciplinary}},
Cited-References = {{BERTINI I, 1971, J CHEM SOC A, P489, DOI 10.1039/j19710000489.
   BLEOMBERGEN N, 1957, J CHEM PHYS, V27, P595.
   BLEOMBERGEN N, 1950, PHYS REV, V79, P179.
   COLLMAN JP, 1965, ANGEW CHEM INT EDIT, V4, P132, DOI 10.1002/anie.196501321.
   CRAMER RE, 1970, J AM CHEM SOC, V92, P66, DOI 10.1021/ja00704a011.
   DEBOER E, 1967, PROG NUCL MAGN RESON, V2, P112.
   DEWYER HP, 1956, J P ROY SOC NS WALES, V90, P29.
   DICKINSON WC, 1951, PHYS REV, V81, P717, DOI 10.1103/PhysRev.81.717.
   Eaton D. R., 1965, ADV MAGN RESON, V4, P103.
   ELDER RC, 1968, INORG CHEM, V7, P1117, DOI 10.1021/ic50064a013.
   HAAKE P, 1963, INORG CHEM, V2, P879, DOI 10.1021/ic50008a062.
   HAPPE JA, 1963, J CHEM PHYS, V39, P1211, DOI 10.1063/1.1734416.
   HASHAGEN JT, 1965, J AM CHEM SOC, V87, P2821, DOI 10.1021/ja01091a008.
   HOLM RH, 1966, PROGR INORG CHEM, V7, P135.
   HORROCKS WD, 1970, INORG CHEM, V9, P690, DOI 10.1021/ic50085a058.
   HORROCKS WD, 1964, J AM CHEM SOC, V86, P3031, DOI 10.1021/ja01069a013.
   HORROCKS WD, 1971, INORG CHEM, V10, P1835, DOI 10.1021/ic50102a066.
   JOLLY WL, 1968, INORGANIC SYNTHESIS, V11, P82.
   KLUIBER RW, 1965, J AM CHEM SOC, V87, P5350, DOI 10.1021/ja00951a016.
   MCCONNELL HM, 1958, J CHEM PHYS, V28, P107, DOI 10.1063/1.1744052.
   MCCONNELL HM, 1958, J CHEM PHYS, V29, P1361, DOI 10.1063/1.1744723.
   MCDONALD CC, 1963, J AM CHEM SOC, V85, P3736, DOI 10.1021/ja00906a005.
   RAKSHYS JW, 1970, INORG CHEM, V9, P1521, DOI 10.1021/ic50088a043.
   TORI K, 1973, CHEM LETT, V11.
   TSAI WF, 1974, THESIS TAMKANG COLLE.
   WEBB CA, 1970, ANNUAL REPORTS NMR S, P211.
   WICHOLAS M, 1968, J AM CHEM SOC, V90, P6946, DOI 10.1021/ja01027a009.
   WICHOLAS ML, 1968, J AM CHEM SOC, V90, P2196, DOI 10.1021/ja01010a059.
   YONEZAWA T, 1970, J AM CHEM SOC, V92, P1267, DOI 10.1021/ja00708a027.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{1}},
Journal-ISO = {{J. Chin. Chem. Soc.}},
Doc-Delivery-Number = {{GU197}},
Wos-Id = {{ISI:A1978GU19700003}},
}
